<SEC-DOCUMENT>0001213900-24-106589.txt : 20241209
<SEC-HEADER>0001213900-24-106589.hdr.sgml : 20241209
<ACCEPTANCE-DATETIME>20241209064241
ACCESSION NUMBER:		0001213900-24-106589
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20241209
DATE AS OF CHANGE:		20241209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apimeds Pharmaceuticals US, Inc.
		CENTRAL INDEX KEY:			0001894525
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851099700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282324
		FILM NUMBER:		241533801

	BUSINESS ADDRESS:	
		STREET 1:		2 EAST BROAD STREET
		STREET 2:		2ND FLOOR
		CITY:			HOPEWELL
		STATE:			NJ
		ZIP:			08525
		BUSINESS PHONE:		609-751-4485

	MAIL ADDRESS:	
		STREET 1:		2 EAST BROAD STREET
		STREET 2:		2ND FLOOR
		CITY:			HOPEWELL
		STATE:			NJ
		ZIP:			08525
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea0201124-09.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD><TITLE></TITLE></HEAD>
<BODY STYLE="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><DIV STYLE="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As filed with the Securities and Exchange Commission on </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">December </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">, 2024.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:right;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Registration No. 333-282324</FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"><P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:center;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:2pt;">&#x00a0;</FONT></P></DIV>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> UNITED STATES <BR>SECURITIES AND EXCHANGE COMMISSION <BR>Washington, D.C. 20549</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;">__________________________________________ </FONT></P>
		 <P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">AMENDMENT NO. 2<BR>TO<BR>FORM S-1<BR>REGISTRATION STATEMENT <BR>UNDER <BR>THE SECURITIES ACT OF 1933</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:0pt;margin-top:0pt;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;">__________________________________________ </FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:3pt;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:18pt;">APIMEDS PHARMACEUTICALS US, INC.<BR></FONT><FONT CLASS="CharOverride-4" STYLE="font-style:normal;font-weight:normal;">(Exact name of registrant as specified in its charter)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;">__________________________________________ </FONT></P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">Delaware</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">2834</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:10pt;">85-1099700</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;">(State or other jurisdiction of <BR>incorporation or organization)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(Primary Standard Industrial <BR>Classification Code Number)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(I.R.S.&#x00a0;Employer <BR>Identification Number)</P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc. <BR>2 East Broad Street 2</FONT><FONT CLASS="Bold-Superscript" STYLE="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">nd</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Floor <BR>Hopewell, NJ&#x00a0;08425<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">808-209-7887</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><BR></FONT><FONT CLASS="CharOverride-4" STYLE="font-style:normal;font-weight:normal;">Address, including zip code, and telephone number, including area code, of Registrant&#x2019;s principal executive offices)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;">__________________________________________ </FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Erik Emerson <BR>Chief Executive Officer<BR>Apimeds Pharmaceuticals US, Inc. <BR>65-1277 Ki Rd<BR>Kamuela, HI 96743<BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">808-209-7887</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><BR></FONT><FONT CLASS="CharOverride-7" STYLE="font-style:normal;font-weight:normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;">__________________________________________ </FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 37.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">W.&#x00a0;David Mannheim <BR>Kathryn Simons<BR>Nelson&#x00a0;Mullins&#x00a0;Riley&#x00a0;&amp;&#x00a0;Scarborough&#x00a0;LLP <BR>301 Hillsborough Street, Suite 1400 <BR>Raleigh, NC&#x00a0;27603 <BR>(919)&#x00a0;329-3800</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 30.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 30.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Brad L.&#x00a0;Shiffman <BR>Blank Rome LLP <BR>1271 Avenue of the Americas <BR>New York, NY&#x00a0;10020 <BR>(212)&#x00a0;885</FONT><FONT CLASS="nobreak"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">-5000</FONT></FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:3pt;text-align:center;margin-top:3pt;"><FONT CLASS="bold" STYLE="font-style:normal;font-weight:bold;font-size:6pt;">_________________________________________ </FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Approximate date of commencement of proposed sale to the public: </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">As soon as practicable after this Registration Statement is declared effective.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#x00a0;415 under the Securities Act&#x00a0;of&#x00a0;1933 check the following box. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#x00a0;462(b)&#x00a0;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">If this Form is a </FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">post</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-effective</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;"> amendment filed pursuant to Rule&#x00a0;462(c)&#x00a0;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">If this Form is a </FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">post</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-effective</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;"> amendment filed pursuant to Rule&#x00a0;462(d)&#x00a0;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a </FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">non</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-accelerated</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;"> filer, smaller reporting company or an emerging growth company. See the definitions of &#x201c;large, accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule&#x00a0;12b</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-2</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;"> of the Exchange&#x00a0;Act.</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 21.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Large,&#x00a0;accelerated&#x00a0;filer</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 28.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 21.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Accelerated&#x00a0;filer</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 26.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 21.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Non-accelerated&#x00a0;filer</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 28.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 21.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Smaller&#x00a0;reporting&#x00a0;company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 26.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;vertical-align:top;width: 21.35%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 28.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 21.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Emerging&#x00a0;growth&#x00a0;company</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 26.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;margin-top:2pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#x00a0;7(a)(2)(B)&#x00a0;of the Securities Act. </FONT><FONT CLASS="GrepStyle" STYLE="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;margin-top:2pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#x00a0;8(a)&#x00a0;of the Securities Act&#x00a0;of&#x00a0;1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section&#x00a0;8(a), may determine.</FONT></P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"><P CLASS="Text_ind" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;text-align:justify;margin-top:2pt;"><FONT CLASS="CharOverride-9" STYLE="font-size:8pt;">&#x00a0;</FONT></P></DIV>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>





	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><FONT CLASS="CharOverride-10" STYLE="color:#d2232a;">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;">PRELIMINARY PROSPECTUS</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:right;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;">SUBJECT TO COMPLETION</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:right;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;">DATED&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;">DECEMBER </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;">6</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;color:#d2232a;">,&#x00a0;2024</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;">3,333,334 Shares<BR>Common Stock</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;text-align:center;margin-top:6pt;"><FONT CLASS="CharOverride-11" STYLE="font-size:14pt;"><IMG ALT="" SRC="tapimeds_logo.jpg" STYLE="width:175.36px;max-width:100%;"></FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:6pt;margin-top:6pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:18pt;">Apimeds Pharmaceuticals US, Inc.</FONT></P>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="Basic-Table CellOverride-9" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
				</TR>
				<TR CLASS="Basic-Table _idGenTableRowColumn-16">
					<TD CLASS="Basic-Table CellOverride-9" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-12" STYLE="font-size:1pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">This is a firm commitment initial public offering of shares of common stock of Apimeds Pharmaceuticals US, Inc. Prior to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price of our shares will be between $3.00 and $4.00.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">We intend to apply to have our common stock listed on The New York Stock Exchange American (the &#x201c;NYSE American&#x201d;) under the symbol &#x201c;APUS.&#x201d; The closing of this offering is contingent upon the successful listing of our common stock on the NYSE American.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">We are an &#x201c;emerging growth company&#x201d; under the federal securities laws and have elected to comply with certain reduced public company reporting requirements.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">We are currently a &#x201c;controlled company&#x201d; under the corporate governance rules of the NYSE American. Inscobee Inc. (KRX: 006490) (&#x201c;Inscobee&#x201d;), a South Korean corporation, holds approximately 70.27% of our common stock, directly and through its wholly owned subsidiary Apimeds Inc. (&#x201c;Apimeds Korea&#x201d;). Upon completion of this offering Inscobee, directly and through Apimeds Korea, will hold 50.32% of our common stock, which will constitute a majority of the voting power of our stockholders. As a result, we will continue to be a &#x201c;controlled company&#x201d;. However, we do not intend to rely upon the &#x201c;controlled company&#x201d; exemption. See the section titled &#x201c;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;font-size:9pt;">Prospectus&#x00a0;Summary&#x00a0;&#x2014;&#x00a0;Controlled Company.</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">&#x201d;</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Certain of our existing stockholders have indicated an interest to purchase up to an aggregate of approximately $3.0</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;"> </FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">million of shares of our common stock in this offering at the initial public offering price (which would represent approximately 30% of the shares sold in this offering, assuming an offering price of $3.00 per share, which is the low end of the estimated price range). However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of our common stock in this offering to these entities, or these entities may determine to purchase more, fewer or no shares of our common stock in this offering. The underwriters will receive the same underwriting discounts and commissions on any shares of our common stock purchased by these entities as they will on any other shares of our common stock sold to the public in this offering. For more information regarding indications of interest by certain of our stockholders and the potential impact on their ownership of shares of our common stock, see &#x201c;</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;font-size:9pt;">Principal Stockholders</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">.&#x201d;</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Investing in our common stock involves a high degree of risk. See &#x201c;</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;font-size:9pt;font-style:normal;font-weight:bold;">Risk Factors</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">&#x201d; beginning on page&#x00a0;11.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 72.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.24%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-14" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Per Share</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-14" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 72.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Initial public offering price</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 72.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Underwriting discounts and commissions</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:6pt;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 72.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">Proceeds to us, before expenses</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.48%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;margin-top:10pt;"><FONT CLASS="CharOverride-9" STYLE="font-size:8pt;">(1)<FONT STYLE="width: 19px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Underwriting discounts and commissions do not include a </FONT><FONT CLASS="CharOverride-9" STYLE="font-size:8pt;">non</FONT><FONT CLASS="nobreak" STYLE="font-size:8pt;">-accountable</FONT><FONT CLASS="CharOverride-9" STYLE="font-size:8pt;"> expense allowance equal to 1.0% of the initial public offering price payable to the underwriters. We refer you to the section titled &#x201c;Underwriting&#x201d; beginning on page&#x00a0;116 for additional information regarding underwriters&#x2019; compensation.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">We have granted a 45</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-day</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;"> option to the underwriters to purchase up to 500,000 additional shares of common stock solely to cover </FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">over</FONT><FONT CLASS="nobreak" STYLE="font-size:9pt;">-allotments</FONT><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">, if any.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;margin-top:5pt;"><FONT CLASS="CharOverride-8" STYLE="font-size:9pt;">The underwriters expect to deliver the shares to purchasers on or about<FONT STYLE="width: 9px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>, 2024.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;text-align:center;margin-top:5pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Sole Book</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Running</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Manager</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:5pt;text-align:center;margin-top:5pt;"><IMG ALT="" SRC="tboral_logo.jpg" STYLE="width:249.6px;max-width:100%;"></P>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The date of this prospectus is<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>, 2024</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1_TOC" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"><A NAME="TOC001"></A>TABLE OF CONTENTS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Page</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T23">PROSPECTUS SUMMARY</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">1</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T22">THE OFFERING</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">8</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T21">SUMMARY FINANCIAL DATA</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">10</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T20">RISK FACTORS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">11</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T19">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">48</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T18">USE OF PROCEEDS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">51</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T99500">REVERSE STOCK SPLIT</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">52</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T17">DIVIDEND POLICY</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">52</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T16">CAPITALIZATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">53</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T15">DILUTION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">54</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T14">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS&#x00a0;OF OPERATIONS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">56</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T13">BUSINESS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">66</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T12">MANAGEMENT</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">91</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T11">EXECUTIVE COMPENSATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">98</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T10">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">104</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T9">PRINCIPAL STOCKHOLDERS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">108</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T8">DESCRIPTION OF CAPITAL STOCK</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">109</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T7">SHARES ELIGIBLE FOR FUTURE SALE</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">111</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T6">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">113</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T5">UNDERWRITING</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">116</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T4">LEGAL MATTERS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">124</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T3">EXPERTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">124</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2">WHERE YOU CAN FIND MORE INFORMATION</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">124</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="TOC_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T1">INDEX TO FINANCIAL STATEMENTS</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-1</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">You should rely only on the information contained in this prospectus. We and the underwriters have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">No action is being taken in any jurisdiction outside the United&#x00a0;States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United&#x00a0;States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>







	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T23"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections entitled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and our financial statements and the related notes included elsewhere in this prospectus, before making an investment decision.</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Unless the context otherwise indicates or requires, all references in this prospectus to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;our company&#x201d; &#x201c;the Company&#x201d; and &#x201c;Apimeds US&#x201d; refer to Apimeds Pharmaceuticals US, Inc.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">On&#x00a0;January&#x00a0;6, 2022, we effected a 1</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-for-10</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">,000 forward split of our common stock. All historical share amounts and share price information presented in this prospectus have been proportionally adjusted to reflect the impact of this forward stock split.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom<FONT CLASS="nobreak">-based</FONT> toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (&#x201c;Apimeds Korea&#x201d;) in the South Korea as &#x201c;Apitoxin.&#x201d; Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (&#x201c;OA&#x201d;) treatment for patients with knee pain who failed to respond adequately to conservative non<FONT CLASS="nobreak">-pharmacologic</FONT> therapy and simple analgesics.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In 2003, after completing successful Phase I, II, and III trials, the Korean Ministry of Food and Drug Safety (the &#x201c;MFDA&#x201d;) approved the use of Apitoxin to treat pain and mobility in patients with OA in South <FONT CLASS="nobreak">Kor</FONT>ea. Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since&#x00a0;2003. Additionally, a post<FONT CLASS="nobreak">-marketing</FONT>/approval safety study in South Korea followed 3,194 patients from 2003 through 2009, with no serious adverse events. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In 2013, the FDA authorized Apimeds Korea to conduct a preliminary Phase III to study the same indication approved in South Korea&#x00a0;&#x2014;&#x00a0;the use of Apitoxin to treat pain and inflammation in patients with OA&#x00a0;&#x2014;&#x00a0;which was completed in 2018 (the &#x201c;Apimeds Korea Phase III OA Trial&#x201d;). </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On August<FONT CLASS="nobreak"> </FONT>2, 2021, we entered into an agreement with Apimeds Korea, a principal stockholder of Apimeds US (the &#x201c;Business Agreement&#x201d;). Pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty<FONT CLASS="nobreak">-bearing</FONT> license to utilize all prior clinical development data associated with Apitoxin, Apitox, and all related names, and to advance clinical research, develop, manufacture and commercialize and sell Apitox in the United&#x00a0;States.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Based on the results from the Apimeds Korea Phase III OA Trial, which demonstrated therapeutic effect in the treatment group compared to the placebo group, but in combination with prior development by Apimeds Korea, did not meet the FDA&#x2019;s standards for approval, as the study population was too small and the methods for handling missing data were inadequate, resulting in a study that did not demonstrate a significant treatment effect. We will be pursuing a second Phase III trial to meet agreed upon FDA standards. Based on results from the Apimeds Korea Phase III OA Trial, we have evaluated the most appropriate population, defined as advanced knee OA patients, which will range from defined grade<FONT CLASS="nobreak"> </FONT>2, 3 and 4 within this treatment group, to continue to progress our own Phase&#x00a0;III trial in knee OA. Pursuant to our previous correspondence with the FDA, we have designed and will implement our Phase III trial to best address our patient population, appropriate dosing, and the most effective way to evaluate Apitox in meeting the patient population&#x2019;s needs.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea has also engaged in clinical trials to explore the therapeutic effect of Apitoxin in patients with multiple sclerosis (&#x201c;MS&#x201d;), including in 2014, submitting an Investigational New Drug Application (&#x201c;IND&#x201d;) 122804 to run a Phase III clinical trial. Pursuant to the Business Agreement, Apimeds Korea transferred sponsorship of IND 122804 to Apimeds US in October 2020. Pursuant to the written correspondence from the FDA, as of the date of this prospectus, there are no clinical holds relating to the planned clinical trials. However, we have made the strategic decision to focus our MS efforts on the early prosecution of appropriate patient populations through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies and will not be pursuing a Phase III trial for MS at this time.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Chronic diseases such as OA and MS cause considerable economic, personal, and societal burden. These diseases negatively impact quality of life and progress from the time of onset until death. We are dedicated to developing innovative therapies using Apitox that seek to restore the health and enhance the quality of life of patients suffering with these diseases.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To this date, Apimeds has generated no revenue from the sale and or distribution of Apitox in the United States. We have generated our clinical data and an opportunity to advance treatment opportunities with proceeds received from sales of our securities to prior investors and the work of our partners, Apimeds Korea and Inscobee Inc. We do not currently hold any debt as prior investments in the form of convertible notes have since been converted to equity. We believe that naturalized bee venom can provide an additive treatment, that pending clinical demonstration of success and FDA approval, could provide value to OA patients in need and the physicians treating OA patients, and potentially MS. The advancement of Apitox as a candidate and Apimeds as a company, will be dictated by the clinical data and the regulatory agencies interpretation of such data in regard to effectiveness, safety and potential benefit beyond existing treatment options.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Lead Candidate</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apitox is a purified, pharmaceutical grade bee venom of the <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Apis mellifera, </FONT>or western honeybee, which is classified by the FDA as an active pharmaceutical ingredient (&#x201c;API&#x201d;). Bee venom has been used in Asia and Europe as a therapeutic to treat pain for hundreds of&#x00a0;years. Bee venom contains the peptides apamin and adolapin. Although these peptides act as toxins, they possess&#x00a0;anti<FONT CLASS="nobreak">-inflammatory</FONT> and pain<FONT CLASS="nobreak">-relieving</FONT> properties.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">While not FDA approved in a controlled, prescription based biologic environment for defined indications, the use of bee venom has been FDA approved as an &#x201c;under the skin injection&#x201d; to reduce the allergic reactions to bee stings. Apimeds Korea has developed a proprietary method and process for turning extracted bee venom into a lyophilized powder for reconstitution prior to intradermal dose injections, which it sells in South Korea as Apitoxin. We intend to use a similar process with respect to Apitox, pursuant to the Business Agreement, which gives us a license to utilize all prior clinical development data associated with Apitoxin. The advancement of extracted bee venom for treatment of inflammatory conditions, including but not limited to advanced knee OA and MS is speculative but based on direction provided by prior clinical data.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea successfully completed Phase&#x00a0;I, Phase&#x00a0;II, and Phase III trials in South Korea in OA in 2003, at which point Apitoxin was approved by the MFDA to treat pain and mobility in patients with OA. Phase&#x00a0;I trials test to determine whether a new treatment is safe and look for the best way to give the treatment. Phase&#x00a0;II trials test to determine whether a condition or disease responds to the new treatment. Phase&#x00a0;III trials test to determine whether a new treatment is better than a standard treatment. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In 2013, the first of two required U.S. Phase&#x00a0;III clinical trials were authorized to enroll patients to study the use of Apitox for the same indication approved in South Korea in 2003. The first Phase&#x00a0;III trial (the Apimeds Korea Phase III OA Trial) (330 patients) was completed in 2018, and displayed no serious adverse events.&#x00a0;Based on the results from the Apimeds Korea Phase III OA Trial, which demonstrated therapeutic effect but did not meet the FDA&#x2019;s standards for approval, we will be pursuing a second Phase III trial to meet agreed upon FDA standards to best address our patient population, which we have defined as advanced knee OA patients, which is being designed to range from defined grade<FONT CLASS="nobreak"> </FONT>2, 3 and 4 within this treatment group. We have selected this treatment group based on the results from the Apimeds Korea Phase III OA Trial and the need for treatments for higher grade knee OA patients.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, we intend to submit a Biologics License Application (&#x201c;BLA&#x201d;) for Apitox with the Centers for Biologics and Research, in consultation with the FDA. A BLA is a request to the FDA for permission to introduce, or deliver for introduction, a biologic product into interstate commerce. Issuance of a BLA is a determination that the product, the manufacturing process and the manufacturing facilities meet applicable requirements&#x00a0;to ensure the continued safety, purity and potency of the product. The FDA provides 12<FONT CLASS="nobreak">-year</FONT> market exclusivity at the time of approval of a BLA, with the potential for a six<FONT CLASS="nobreak">-month</FONT> extension upon approval for pediatric use.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to outsource the manufacturing of Apitox to a third<FONT CLASS="nobreak">-party</FONT> manufacturer and plan to rely on the same manufacturing process as used in prior trials. The manufacturing process of Apitox entails converting natural bee venom to a liquified biologic state. Once in this state, Apitox will have completed multiple rounds of process enhancement, development and stability. The process of converting natural bee venom to therapeutic biologic delivery has been previously patented in Korea (though now expired). We believe the regulatory protections that are available through a BLA filing, along with our trade secrets, will provide adequate protection for our manufacturing process.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Market</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds US believes there is a significant market opportunity in the United&#x00a0;States for Apitox to enhance treatment of the lack of mobility and pain management symptoms associated with of OA and MS.&#x00a0;According to Precedence Research, the OA therapeutics market size in the United&#x00a0;States accounted for $8.28&#x00a0;billion in 2022 and it is expected to hit around $20.24&#x00a0;billion by 2032, expanding at a compounded annual growth rate, or &#x201c;CAGR&#x201d;, of 9.4% from 2023 to 2032. Although OA can damage any joint, the disorder most commonly affects joints in&#x00a0;hands, knees, hips and spine. OA symptoms can usually be managed, although the damage to joints cannot be reversed. Apitox may have certain anti<FONT CLASS="nobreak">-inflammatory</FONT> properties, which we believe could provide benefit in the treatment of symptoms related to certain chronic diseases that involve difficult to control pain and inflammation such as OA and MS.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">According to Pharmaceutical Technology the MS market size in the United&#x00a0;States accounted for $ 10.73&#x00a0;billion in 2022 and is expected to hit $ 24.4&#x00a0;billion by 2030, expanding at a CAGR of 10.32%. Starting in the first quarter of 2025, we intend to initiate early prosecution of appropriate MS patient populations through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Subject to FDA approval, our development of Apitox in the United&#x00a0;States will in the near term, have two distinct focuses (i)&#x00a0;the treatment of the certain symptoms of knee OA and (ii)&#x00a0;the quality of life issues surrounding OA, such as pain and lack of mobility. We also intend to continue the investigation of the use of Apitox to treat certain MS symptoms through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Living with a chronic disease is challenging, as it interferes with physical, mental, and social functions and thus greatly affects a person&#x2019;s quality of life. Indeed, chronically ill patients are facing major struggles such as higher expenditures, social isolation and loneliness, disabilities, fatigue, pain/discomfort, feelings of distress, anger, hopelessness, frustration, anxiety, and depression. There is the general assumption that symptom reduction increases a patient&#x2019;s quality of life. Our approach with Apitox centers around this concept&#x00a0;&#x2014;&#x00a0;effectively treating certain symptoms of the patient&#x2019;s disease, thus improving their overall quality of life.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Strategy</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds US aims is to impact high unmet medical needs of symptoms and quality of life issues surrounding knee OA and MS.&#x00a0;Our primary business strategy is to become a leading biopharmaceutical company through the development of Apitox. Key elements of our business strategy are as follows:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Initiate an additional Phase&#x00a0;III trial in advanced knee OA, focusing on efficacy of a shorter<FONT CLASS="nobreak">-term</FONT> treatment of patients who are eligible for knee replacement surgery. We intend the duration of the trial to be approximately eight&#x00a0;weeks of treatment.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Initiate multiple company sponsored trials in MS to determine the best path to clinical Phase&#x00a0;III success. This includes evaluating varying forms of relapse MS, the frequency with which patients have relapse and the impact of Apitox on said relapse.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Pursue potential collaboration arrangements and out<FONT CLASS="nobreak">-licensing</FONT> opportunities.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Seek non<FONT CLASS="nobreak">-dilutive</FONT> funding and grant awards to support our clinical research and product candidate development.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Through the clinical development of Apitox we intend to engage organizations with strong needs and category leadership in Apimeds US&#x2019;s clinical areas of focus, specifically anti<FONT CLASS="nobreak">-inflammatory</FONT> conditions. Numerous biotechnology and pharmaceutical companies have a presence in OA and MS, creating strong synergies for potential opportunities subsequent to demonstrated clinical success and FDA approval.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">One of the principal purposes of this offering is to fund the execution of a Phase III trial in knee OA and the early prosecution of appropriate patient populations in MS.&#x00a0;Proceeds will also fund manufacturing and expenses related to potential regulatory filings.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">The Science of Apitox</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apitox is purified honeybee (<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Apis mellifera</FONT>) venom manufactured as a lyophilized powder for reconstitution in 0.5% preservative<FONT CLASS="nobreak">-free</FONT> lidocaine (lmg/mg) prior to intradermal dose injections. The biologically active components include melittin (40<FONT CLASS="nobreak">-50</FONT>%), apamin (2<FONT CLASS="nobreak">-3</FONT>%), mast cell degranulating (MCD) peptide (Peptide 401,&#x00a0;2<FONT CLASS="nobreak">-3</FONT>%), phospholipase A2 (10<FONT CLASS="nobreak">-15</FONT>%), hyaluronidase (1.5<FONT CLASS="nobreak">-2</FONT>%) and other components in small amounts, including dopamine and norepinephrine. According to a publication entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective</FONT>&#x201d; by Shi et al., certain components of honeybee venom have been found to have both anti<FONT CLASS="nobreak">-inflammatory</FONT> and analgesic effects. The anti<FONT CLASS="nobreak">-inflammatory</FONT> and analgesic effects are attributed to the presence of Peptide 401, adolapin and other components that inhibit prostaglandin synthesis. There are several different types of prostaglandins, and they play several essential roles in regulating bodily processes, including healing and inflammation. The hormone<FONT CLASS="nobreak">-stimulating</FONT> effects are attributed to the presence of melittin, cardiopep and other components that stimulate the pituitary<FONT CLASS="nobreak">-adrenal</FONT> axis to produce cortisol. Results from an animal study entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Effect of bee venom and melittin on plasma cortisol in the unanesthetized monkey</FONT>&#x201d; published by Vick et al., indicate that melittin appears to stimulate the production of cortisol from the adrenal gland. The immune<FONT CLASS="nobreak">-modulating</FONT> effects, especially as it pertains to MS, are suggested to be mediated by CD4+CD2S+Foxp3+ regulatory T cells (Tregs) that are influenced by phospholipase A2. While the exact mechanism of action of Apitox is not fully understood, research such as the publication entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Therapeutic Use of Bee Venom and Potential Applications in Veterinary Medicine</FONT>&#x201d; by Bava et al., suggests that certain components in Apitox may ameliorate certain immune<FONT CLASS="nobreak">-inflammatory</FONT> responses associated with MS. Such studies suggested that treatments with melittin prevent inflammatory cytokine expression and produces anti<FONT CLASS="nobreak">-inflammatory</FONT> effects. As MS is a chronic inflammatory condition, we believe Apitox may be a potential treatment alternative for certain symptoms of MS.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Intellectual Property</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, Apimeds US will submit a BLA for Apitox with the Centers for Biologics and Research of the FDA.&#x00a0;A BLA is used to request permission to introduce, or deliver a biologic product into interstate commerce. The FDA provides 12<FONT CLASS="nobreak">-year</FONT> market exclusivity at the time of approval of a BLA, with the potential for a six<FONT CLASS="nobreak">-month</FONT> extension upon approval for pediatric use.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to file a United States&#x00a0;trademark application for &#x201c;Apitox.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Reverse Stock Split</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will effect a 1<FONT CLASS="nobreak">-for-2</FONT>.6 reverse stock split immediately prior to and contingent upon the completion of this offering, pursuant to which each 2.6<FONT CLASS="nobreak"> </FONT>shares of common stock held of record by the holder thereof will be reclassified into one share of common stock. No fractional shares will be issued (the &#x201c;Reverse Stock Split&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Unless otherwise indicated, and other than the consolidated financial statements and the related notes included elsewhere in this prospectus, the number of our shares of common stock presented in this prospectus is adjusted to reflect the Reverse Stock Split.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Controlled Company</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea&#x2019;s parent company, Inscobee Inc., has voting control over approximately 70.27% of our common stock, directly and through its wholly owned subsidiary Apimeds Korea, and therefore we currently meet the definition of a &#x201c;controlled company&#x201d; under the corporate governance standards for the NYSE American. Upon the closing of this offering, Inscobee Inc. will own approximately 50.32% of the voting power of our outstanding voting.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As long as Inscobee Inc. owns at least 50% of the voting power of our Company, we will be a &#x201c;controlled company&#x201d; as defined under the NYSE American. Under that definition, we are permitted to rely on certain exemptions from corporate governance rules, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an exemption from the rule that a majority of our Board must be independent directors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an exemption from the rule that the compensation of our chief executive officer must be determined or recommended solely by independent directors; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an exemption from the rule that our director nominees must be selected or recommended solely by <FONT CLASS="CharOverride-1" STYLE="">independent directors.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Although we do not intend to rely on the &#x201c;controlled company&#x201d; exemption under the NYSE American listing rules following this offering, we could elect to rely on this exemption in the future. If we elect to rely on the &#x201c;controlled company&#x201d; exemption, a majority of the members of our board of directors might not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely of independent directors.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As a result, if we elect to rely on this exemption in the future, you would not have the same protection afforded to shareholders of companies that are subject to these corporate governance requirements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Corporate Information</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds US was incorporated in Delaware on May&#x00a0;11, 2020. We are located at 2 East Broad Street, 2<FONT CLASS="CharOverride-2" STYLE="font-size:58%;vertical-align:super;">nd</FONT> Floor, Hopewell, New Jersey 08525. Our telephone number is&#x00a0;808<FONT CLASS="nobreak">-209-7887</FONT>. Our website address is <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.apimedspharmaus.com</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">. </FONT>Information contained on, or that can be accessed through, our website is not incorporated by reference in this prospectus.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risk Factors Summary</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our business is subject to a number of risks of which you should be aware of before making an investment decision. You should consider all of the information set forth in this prospectus and, in particular, the specific factors set forth under &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Risk Factors</FONT>&#x201d; in deciding whether to invest in our common stock. These risks include, without limitation, the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Clinical development has inherent risk in its process and our product candidate. Apitox, will be evaluated in a clinical environment for an indication which it has limited patient exposure which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability. Our stock is a highly speculative investment.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Even after this offering, we may require substantial additional funding to finance our operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain parts of our development programs or other operations.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The report of our independent registered public accounting firm included a &#x201c;going concern&#x201d; explanatory paragraph.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We have identified material weaknesses in our internal control over financial reporting, and the failure to remediate these material weakness may adversely affect our business, investor confidence in our company, our financial results and the market value of our common stock.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our business is substantially dependent on our relationships with Apimeds Korea. The loss of this relationship would have a material adverse effect on our business.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We are dependent on the clinical success of Apitox in the treatment of symptoms of knee OA and MS in the United&#x00a0;States.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidate we develop, our commercial opportunities will be negatively impacted. Our product candidate will, if approved, also compete with existing branded, generic and off<FONT CLASS="nobreak">-label</FONT> products.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our business could be adversely affected by the effects of health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations. Any future pandemic could materially affect our operations as well as the business or operations of our contract manufacturer organizations (&#x201c;CMOs&#x201d;) or other third parties with whom we conduct business.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Our product candidate may cause undesirable side effects or have other properties that could halt its clinical development, prevent its regulatory approval, limit its commercial potential or result in significant negative consequences. In addition, even if approved, our products may cause significant adverse events, toxicities or other undesirable side effects identified during post<FONT CLASS="nobreak">-marketing</FONT> surveillance, which could result in regulatory action or negatively affect our ability to market the product.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>We rely on principally on trade secrets and other forms of non<FONT CLASS="nobreak">-patent</FONT> intellectual property protection, which are difficult to protect.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Market and Industry Data</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Unless otherwise indicated, information contained in this prospectus concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third<FONT CLASS="nobreak">-party</FONT> sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third<FONT CLASS="nobreak">-party</FONT> sources, as well as data from our internal research, and are based on assumptions we made upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Risk Factors</FONT>&#x201d; and &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Special Note&#x00a0;Regarding </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Statements</FONT>.&#x201d; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Implications of Being an Emerging Growth Company</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We qualify as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>not being required to comply for a certain period of time with the auditor attestation requirements of Section&#x00a0;404 of the Sarbanes Oxley Act&#x00a0;of&#x00a0;2002, as amended;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>exemption from the auditor attestation requirement in the assessment of critical audit matters in the auditor&#x2019;s report on the financial statements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>exemptions from the requirements of holding a stockholder advisory vote on executive compensation and any golden parachute payments not previously approved.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will remain an emerging growth company until the earliest of (i)&#x00a0;the last&#x00a0;day of our first fiscal year in which we have total annual gross revenues of $1.235&#x00a0;billion or more; (ii)&#x00a0;the last&#x00a0;day of our fiscal year following the fifth anniversary of the completion of this offering; (iii)&#x00a0;the date on which we are deemed to be a &#x201c;large accelerated </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">filer,&#x201d; under the rules of the U.S.&#x00a0;Securities and Exchange Commission, or the SEC, which means the market value of equity securities that is held by non<FONT CLASS="nobreak">-affiliates</FONT> exceeds $700.0&#x00a0;million; and (iv)&#x00a0;the date on which we have issued more than $1.0&#x00a0;billion in non<FONT CLASS="nobreak">-convertible</FONT> debt securities during the prior three<FONT CLASS="nobreak">-year</FONT> period.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we are no longer an emerging growth company, or we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T22"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">THE OFFERING</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock offered by us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3,333,334<FONT CLASS="nobreak"> </FONT>shares</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Over-allotment option</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We have granted the underwriters an option for a period of 45&#x00a0;days from the date of this prospectus to purchase up to an additional 500,000<FONT CLASS="nobreak"> </FONT>shares of common stock at the public offering price, less the underwriting discount.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Common stock to be outstanding immediately after&#x00a0;this Offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><BR>11,526,943<FONT CLASS="nobreak"> </FONT>shares (12,026,943<FONT CLASS="nobreak"> </FONT>shares if the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT> option in full), after giving effect to the Reverse Stock Split.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Use of proceeds</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">We estimate that the net proceeds from the sale of our common stock in this offering will be approximately $8.8<FONT CLASS="nobreak"> </FONT>million or approximately $10.2&#x00a0;million if the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT> option in full), based on the assumed initial public offering price of $3.00 per share, which is the low end of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our common stock, facilitate future access to the public equity markets by us, our employees and our stockholders and increase our visibility in the marketplace. We intend to use the net proceeds we receive from this offering to fund our Phase III clinical trial in knee OA, to initiate at least one non<FONT CLASS="nobreak">-registered</FONT> company sponsored trials in MS, manufacturing costs, to repay current debt liabilities, and any remaining amounts to fund working capital and general corporate purposes. See the section entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Use of Proceeds</FONT>&#x201d; for additional information.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Risk factors</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">An investment in our securities involves a high degree of risk and could result in a loss of your entire investment. Prior to making an investment decision, you should carefully consider all of the information in this prospectus and, in particular, you should evaluate the risk factors set forth under the caption. See the section entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Risk Factors</FONT>&#x201d; for additional information.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 43.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;">Proposed trading symbol on NYSE American</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#x201c;APUS&#x201d;</P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The number of shares of common stock to be outstanding immediately after this offering is based on&#x00a0;8,190,303<FONT CLASS="nobreak"> </FONT>shares of common stock outstanding on September<FONT CLASS="nobreak"> </FONT>30, 2024, which includes approximately 286,457<FONT CLASS="nobreak"> </FONT>shares of common stock issuable upon the conversion of outstanding convertible notes plus accrued interest thereon and excludes:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="CharOverride-1" STYLE="">1,000,000</FONT><FONT CLASS="nobreak" STYLE=""> </FONT>shares of our common stock that are available for future issuance under our Equity Incentive Plan;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="CharOverride-1" STYLE="">213,692</FONT><FONT CLASS="nobreak" STYLE=""> </FONT>shares of common stock issuable upon exercise of outstanding non<FONT CLASS="nobreak">-plan</FONT> options; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="CharOverride-1" STYLE="">166,667&#x00a0;</FONT>shares of our common stock issuable upon exercise of the representative&#x2019;s warrants to purchase up to 166,667<FONT CLASS="nobreak"> </FONT>shares of our common stock at an exercise price per share equal to 100% of the initial public offering price per share or $3.00, based on an assumed initial public offering price of $3.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, that will be issued to the representative of the underwriters in connection with this offering (the &#x201c;Representative&#x2019;s Warrants&#x201d;).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Certain of our existing stockholders have indicated an interest to purchase up to an aggregate of approximately $3.0<FONT CLASS="nobreak"> </FONT>million of shares of our common stock in this offering at the initial public offering price (which would represent approximately 30% of the shares sold in this offering, assuming an offering price of $3.00 per share, which is the low end of the estimated price range). However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of our common stock in this offering to these entities, or these entities may determine to purchase more, fewer or no shares of our common stock in this offering. The underwriters will receive the same underwriting discounts and commissions on any shares of our common stock purchased by these entities as they will on any other shares of our common stock sold to the public in this offering. For more information regarding indications of interest by certain of our stockholders and the potential impact on their ownership of shares of our common stock, see &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Principal Stockholders</FONT>.&#x201d;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="BOXSTYLE" STYLE="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T21"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SUMMARY FINANCIAL DATA</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following tables set forth our summary statements of operations data for the&#x00a0;nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024 and 2023 and the years ended December&#x00a0;31, 2023 and 2022. The statements of operations data for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022 have been derived from our audited financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. You should read the following summary financial data together with the sections entitled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and our financial statements and the related notes included elsewhere in this prospectus. The summary financial data included in this section are not intended to replace the financial statements and are qualified in their entirety by our financial statements and the related notes included elsewhere in this prospectus.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Statement of Operations Data:</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-14" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> months <BR>Ended <BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> months <BR>Ended <BR></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year Ended <BR>December 31, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year Ended <BR>December 31, <BR>2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;&#x00a0;&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">98,544</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">368,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">118,372</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">648,892</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">271,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(188,365</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(747,436</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(639,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,794</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,228 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,811</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(81,669</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,591</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(38,069</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(29,137</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,078,357</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(210,728</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(777,694</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(668,666</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Selected Balance Sheet Data:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="9" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">September 30, 2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-22" STYLE="height:12pt;">
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Actual</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro Forma<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro Forma <BR>As Adjusted</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance Sheet Data:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,571</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,571 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,797,775 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,907</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,907 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,808,111 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable&#x00a0;&#x2013;&#x00a0;related party</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000 </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible note, net of discounts&#x00a0;&#x2013;&#x00a0;related party</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">321,992</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,083,393&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">761,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">918,019</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#x2019; deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,046,486</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(631,110</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">8,140,094</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P> <P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>On a pro forma basis to give effect to the conversion of an aggregate of $660,000 principal amount of convertible notes with an unamortized debt discount of $338,008, plus accrued and unpaid interest of approximately $93,384, into an aggregate of approximately 289,763 shares of our common stock.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T20"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">RISK FACTORS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this prospectus, including our financial statements and the related notes and the section of this prospectus entitled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We are in the early stages of clinical development for our product candidate Apitox, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To date, we have devoted substantially all of our resources to performing research and development, undertaking preclinical and clinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel, acquiring and developing our technology, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities. As an organization, we have not yet demonstrated an ability to conduct sales and marketing activities necessary for successful commercialization or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our current portfolio includes one product candidate and we do not expect to generate revenue from our product candidate in the near future. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our clinical candidate. We are transitioning from an early stage research and development company to late stage development company, with a focus on delivering Phase&#x00a0;III clinical data establishing Apitox as a viable commercial candidate. We may not be successful in this transition.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve profitability.</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are a clinical stage biopharmaceutical company that was formed on May&#x00a0;11, 2020. Investment in clinical stage companies is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidates will not gain regulatory approval or become commercially viable. We have not generated any revenue from product sales. As a result, we are not profitable and have incurred losses in each year since inception. Our net losses were $1,078,357 and $210,728 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024 and 2023, respectively. Our net losses were $777,694 and $668,666 for the&#x00a0;years ended December&#x00a0;31, 2023, and 2022, respectively. As of September<FONT CLASS="nobreak"> </FONT>30, 2024, we had an accumulated deficit of $4,080,291.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We expect to continue to spend significant resources to fund research and development of, and seek regulatory approvals for, our product candidate. We expect to incur substantial and increasing operating losses over the next several&#x00a0;years. As a result, our accumulated deficit will also increase significantly. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. We may never be profitable and, if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Even after this offering, we will require substantial additional funding to finance our operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of September<FONT CLASS="nobreak"> </FONT>30, 2024, we had cash of $26,571. We believe that the net proceeds from this offering, together with our existing cash as of the date of this prospectus, will fund our current operating plans through at least the next 12&#x00a0;months from the date of this offering. However, our operating plan may change as a result of many factors </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">currently unknown to us, and we may need to seek additional funds sooner than planned. We expect to finance our cash needs through public or private equity or debt financings, third<FONT CLASS="nobreak">-party</FONT> (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements or any combination of these approaches. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United&#x00a0;States and worldwide, including the trading price of common stock. Our future capital requirements will depend on many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical development and clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the outcome, timing and cost of seeking and obtaining regulatory approvals from the U.S.&#x00a0;Food and Drug Administration, or the FDA;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any product liability or other lawsuits related to our products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the expenses needed to attract, hire and retain skilled personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the identification and pursuit of additional clinical or regulatory opportunities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs of operating as a public company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of our product candidate or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations or milestones under the agreements. We could be required to seek collaborators for our product candidate at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our products in markets where we otherwise would seek to pursue development ourselves.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, including investors in this offering, restrict our operations or require us to relinquish rights to one or more of our technologies.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, intellectual property, future revenue streams, research programs or current or future product candidates or grant licenses on terms unfavorable to us and our shareholders.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The report of our independent registered public accounting firm included a &#x201c;going concern&#x201d; explanatory paragraph.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The report of our independent registered public accounting firm on our financial statements as of and for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. If we are unable to raise additional capital as and when needed, our business, financial condition and results of operations will be materially and adversely affected, and we may be forced to delay our development efforts, limit our activities and reduce research and development costs. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The inclusion of a going concern explanatory paragraph by our independent registered public accounting firm, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into licensing and collaboration arrangements or other contractual relationships with third parties and otherwise execute our development strategy.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We have identified&#x00a0;material weaknesses&#x00a0;in our internal control over financial reporting, and the failure to remediate these&#x00a0;material weakness&#x00a0;may adversely affect our business, investor confidence in our company, our financial results and the market value of our common stock.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">A&#x00a0;material weakness&#x00a0;is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The&#x00a0;material weaknesses&#x00a0;we identified were that the Company did not perform a risk assessment or map its processes to control objectives, the Company has not implemented comprehensive entity<FONT CLASS="nobreak">-level</FONT> internal controls, the Company has not implemented adequate system and manual controls, and the Company does not have sufficient segregation of duties. We have begun exploring remedial efforts to address the underlying causes of the&#x00a0;material weaknesses. There can be no assurance that any remedial efforts we take, if any, will be sufficient to remediate the control deficiencies that led to our&#x00a0;material weaknesses&#x00a0;in our internal controls over financial reporting or prevent future material weaknesses or control deficiencies from occurring.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are not currently required to comply with Section&#x00a0;404 of the&#x00a0;Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;and, therefore, are not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon completion of this offering, we will be required to comply with the requirements of Sections 302 and 404 of the&#x00a0;Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, which will require our management to certify financial and other information in our annual reports and provide an annual management report on the effectiveness of control over financial reporting. Though we will be required to disclose material changes in internal control over financial reporting on an annual basis, we will not be required to make our first annual assessment of our internal control over financial reporting pursuant to Section&#x00a0;404 until the year following our first filing of an annual report on Form&#x00a0;10<FONT CLASS="nobreak">-K</FONT>.&#x00a0;Additionally, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#x00a0;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Business and Industry</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our business is substantially dependent on our relationships with our principal stockholder, Apimeds Korea. The loss of this relationship would have a material adverse effect on our business.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are dependent on a license from our principal shareholder, Apimeds Korea, to continue our clinical trials and development of Apitox. We have entered into a license agreement with Apimeds Korea to obtain exclusive rights in the United&#x00a0;States to the principal trade secrets, know<FONT CLASS="nobreak">-how</FONT> and data relating to Apitox. If we default or fail to perform any of our obligations under this agreement, Apimeds Korea may terminate the agreement, subject to advance notice to cure such default. Any termination of this license agreement would have a materially adverse impact on our business and prospects.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">There may be conflicts of interest amongst our directors and officers and Apimeds Korea.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Conflicts may arise between our directors and officers and Apimeds Korea, as some of our directors and officers hold positions with both companies. Dr. Christopher Kim, our Chairman and Chief Medical Officer is the founder of Apimeds Korea and serves as a board member of Apimeds Korea. Mr.<FONT CLASS="nobreak"> </FONT>Jakap Koo, one of our directors, is the Chief Executive Officer of and President of Apimeds Korea and of Apimeds Korea&#x2019;s parent company, Inscobee Inc. These conflicts could discourage the parties from working collaboratively and our commercial success will be dependent, in part, upon the performance of our management. Although such officers and directors are aware of their duties and accountability to our Company and to applicable laws and policies relating to corporate opportunity and conflicts of interest, such conflicts of interest may include deciding how much time to devote to our affairs, as well as what business opportunities should be presented to us. Additionally, any dispute that may arise between us and Apimeds Korea may make it more difficult to favorably resolve such disputes.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The Company is reliant on its key supplier.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We contract directly with a United&#x00a0;States company for the supply of dried bee venom and have exclusivity in the field of pharmaceutical use, which does not include using venom for immunology, cosmetic or any other non<FONT CLASS="nobreak">-pharmaceutical</FONT> use, for a period of ten&#x00a0;years from November&#x00a0;3, 2021. The exclusivity exception is for sales of bee venom to Apimeds Korea for use outside the United&#x00a0;States. The agreement may be terminated upon mutual written consent of both parties. Termination of this agreement, variations in their terms or the failure of our key supplier to comply with its obligations under its agreement (including if our key supplier were to become insolvent) could have a material adverse effect on the Company&#x2019;s consolidated financial results and on your investment.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">As an organization, we have limited experience designing and implementing clinical trials, and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials, and we may not successfully or cost<FONT CLASS="nobreak">-effectively</FONT> design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or prevent initiation or completion of the trial, which can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third<FONT CLASS="nobreak">-party</FONT> payors. Additionally, a trial that is not well<FONT CLASS="nobreak">-designed</FONT> could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. If we select an incorrect dose or dose administration schedule, that could negatively impact the results of the trial, including if we select doses that are too low to be effective or administer doses too infrequently based on the half<FONT CLASS="nobreak">-life</FONT> of the active ingredient. We also expect to continue to rely on third parties to conduct our pivotal clinical trials. See &#x201c;&#x2014;&#x00a0;Risks&#x00a0;Related to Reliance on Manufacturing and Third Parties.&#x201d; If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize Apitox or any future product candidates we develop, and our business could be materially harmed. Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for BLA submission and the FDA approval of Apitox or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If we are unable to successfully develop, receive regulatory approval for, and commercialize our product candidate or future product candidates, our business will be harmed.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our product candidate is still in preclinical and clinical development, and we are early in our development efforts. The FDA permitted our investigational new drug application for Apitox to proceed in 2014, and we began enrolling subjects. Our product candidate will require additional preclinical and/or clinical development, regulatory approval, obtaining manufacturing supply, capacity, and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment, and significant marketing efforts, before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our ability to generate revenue from our product candidate, which we do not expect will occur for several&#x00a0;years, if ever, will depend heavily on the successful development, regulatory approval, and eventual commercialization of our product candidate. The success of our product candidate or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>timely and successful completion of preclinical studies and clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>effective INDs submitted to the FDA that allow commencement of our planned clinical trials or future clinical trials for our product candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>successful development of, or making arrangements with third<FONT CLASS="nobreak">-party</FONT> manufacturers for, our commercial manufacturing processes for any of our product candidates that receive regulatory approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>making arrangements for the manufacturing of our product candidate for our clinical trials, and manufacturing our product candidate at an acceptable cost and on a timely basis;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>receipt of timely marketing approvals from the FDA;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>launching commercial sales of products, if approved;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>acceptance of the benefits and use of our products, if approved, by patients, the medical community, and third<FONT CLASS="nobreak">-party</FONT> payors, for their approved indications;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the prevalence and severity of adverse events or other safety issues experienced with our product candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the availability, perceived advantages, cost, safety, and efficacy of alternative therapies for any product candidate, and any indications for such product candidate, that we develop;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to produce any product candidates we develop on a commercial scale;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidate and otherwise protecting our rights in our intellectual property portfolio;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>maintaining compliance with regulatory requirements, including cGMP requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining and maintaining coverage and adequate reimbursement by third<FONT CLASS="nobreak">-party</FONT> payors, including government payors, for our products, if approved by the FDA;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>maintaining a continued acceptable safety, tolerability and efficacy profile of the products following approval; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:6.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If we do not succeed with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidate we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The FDA regulatory approval process is lengthy and </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">time-consuming</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> and may lead to significant delays in the clinical development and regulatory approval of our product candidate.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The time required to obtain approval from the FDA is unpredictable but typically takes many&#x00a0;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of FDA.&#x00a0;Any delay in obtaining FDA and/or other necessary regulatory approvals in the United&#x00a0;States for any investigational new drug and failure to receive such approvals would have an adverse effect on the investigational new drug&#x2019;s potential commercial success and on our business, prospects, financial condition, and results of operations.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">We have not obtained regulatory approval for any product candidate. We have not previously submitted a BLA to the FDA.&#x00a0;It is possible that none of our current or future product candidates will ever obtain regulatory approval from the FDA.&#x00a0;The novel nature of our product candidate may create further challenges in obtaining regulatory approval. The regulatory approval pathway for our product candidate may be uncertain, complex, expensive, and lengthy, and approval may not be obtained. In addition, factors outside our control, such as government shutdowns, natural disasters, and public health emergencies, could disrupt business at the FDA, which could result in delays of reviews, approvals and communications with FDA related to our clinical trials and product candidates.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The FDA may disagree with the design or implementation of our clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may be unable to demonstrate to the satisfaction of FDA that a product candidate is safe, pure, and potent for its proposed indication;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the results of clinical trials may not meet the level of statistical significance required by FDA for approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The FDA may disagree with our interpretation of data from clinical trials or preclinical studies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the data collected from clinical trials of our product candidate may not be sufficient to support the submission of a BLA to the FDA to obtain regulatory approval in the United&#x00a0;States; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>FDA may find deficiencies with or fail to approve our manufacturing processes or facility or the manufacturing processes or facilities of third<FONT CLASS="nobreak">-party</FONT> manufacturers with which we contract for clinical and commercial supplies.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">The lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. FDA has substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from current or future clinical trials of our product candidate are promising, such data may not be sufficient to support approval by FDA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Even if we obtain approval, FDA may approve any of our product candidate for fewer or more limited indications, or a more limited patient population, than we request; may grant approval contingent on the performance of costly post<FONT CLASS="nobreak">-approval</FONT> clinical trials or other post<FONT CLASS="nobreak">-marketing</FONT> requirements; or may approve a product candidate with labeling that does not include the claims we believe are necessary or desirable for the successful commercialization of such product candidates. Moreover, if we modify Apitox, we may have to either file a supplemental BLA with FDA or receive FDA approval for a comparability protocol or obtain other regulatory approval. These requirements may be costly and time<FONT CLASS="nobreak">-consuming</FONT>, and FDA ultimately may not approve of such changes.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">FDA may also change its policies, promulgate additional regulations, revise existing regulations, or take other actions that may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in reaching a consensus with regulatory agencies on study design;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in obtaining required institutional review board (&#x201c;IRB&#x201d;), approval at each clinical study site;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>disruptions caused by any future pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in adding a sufficient number of trial sites;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to recruit suitable patients to participate in our clinical trials, which may be affected by, among other factors, patient eligibility and exclusion criteria defined in the protocol, the severity and difficulty of diagnosing the disease under investigation, the size of the patient population required for analysis of the trial&#x2019;s primary endpoints, the proximity of patients to study sites, and the design of the trial;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>failure by our CROs, other third parties or us to adhere to clinical study requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>failure to perform in accordance with the FDA&#x2019;s good clinical practice, or GCP, requirements or applicable regulatory guidelines in other jurisdictions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>patients dropping out of a study;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>occurrence of side effects associated with our product candidate that are viewed to outweigh their potential benefits;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost of clinical trials being greater than we anticipate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>clinical studies producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of drug for use in clinical studies or the inability to do any of the foregoing.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes, we may be required to or we may elect to conduct additional studies to bridge our modified products to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our products and may harm our business and results of operations.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our programs for which we intend to seek approval as biologics may face competition sooner than anticipated.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#x201c;ACA&#x201d;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#x201c;BPCIA&#x201d;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA<FONT CLASS="nobreak">-licensed</FONT> reference biological product. Under the BPCIA, an application for a highly similar or &#x201c;biosimilar&#x201d; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12<FONT CLASS="nobreak">-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well<FONT CLASS="nobreak">-controlled</FONT> clinical trials to demonstrate the safety, purity and potency of their product.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe that any of our programs approved as biologics under a BLA should qualify for the 12<FONT CLASS="nobreak">-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our programs to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non<FONT CLASS="nobreak">-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Because Apitox represents a novel approach to the treatment of symptoms for knee OA and potentially MS, there are many uncertainties regarding the development, market acceptance,&#x00a0;</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">third-party</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">&#x00a0;reimbursement coverage and commercial potential of our product candidate.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Because our candidate represents a novel approach to the treatment of the inflammation and pain management symptoms associated with knee OA and the potential treatment of MS, there are many uncertainties related to the development, marketing, reimbursement and the commercial potential for Apitox. There can be no assurance as to the length of the clinical trials, the number of patients the FDA will required to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of antibody products or that the design of or data generated in these trials will be acceptable to the FDA to support marketing approval.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, the FDA may take longer than usual to come to a decision on any BLA that we submit and may ultimately determine that there is insufficient data, information or experience with our product candidates to support an approval decision. The FDA may also require that we conduct additional post<FONT CLASS="nobreak">-marketing</FONT>&#x00a0;studies or implement risk management programs, such as risk evaluation and mitigation strategies until more experience with our product candidate is obtained. Finally, after increased usage, we may find that our product candidate does not have the intended effect or have unanticipated side effects, potentially jeopardizing initial or continuing regulatory approval and commercial prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical test and Phase&#x00a0;I and Phase&#x00a0;II clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials does not ensure that later large<FONT CLASS="nobreak">-scale</FONT> efficacy trials will </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">be successful, nor does it predict final results. For example, we may be unable to identify suitable animal disease models for our product candidates, which could delay or frustrate our ability to progress clinical studies or obtain marketing approval. Our product candidates may fail to show the desired safety and efficacy in clinical development despite having progressed through preclinical and initial clinical trials.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks, delays. and failures in late<FONT CLASS="nobreak">-stage</FONT> clinical trials even after achieving promising results in preclinical testing and earlier<FONT CLASS="nobreak">-stage</FONT> clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective. If the FDA or any regulatory authority limits the scope of our indication, or if we are unable to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected. Further, we are only permitted to promote our products for those indications that the FDA specifically approves and are restricted from making communications regarding uses not approved and described in the product&#x2019;s labeling. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to advisory or enforcement action by these authorities. In addition, our failure to follow FDA requirements or guidelines relating to promotion and advertising may cause the FDA to suspend or withdraw an approved product from the market, require a recall or institute fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As such, we are currently primarily focused on the development of Apitox for the treatment of the inflammation and pain management symptoms associated with knee OA and MS.&#x00a0;As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuation rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If any potential future product candidate is approved and our CMO fails to produce the product in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization of this product candidate or be unable to meet market demand and may lose potential revenues.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. Any termination or disruption of any current or future relationships relating to product development may materially harm our business and financial condition and frustrate any commercialization efforts for affected current or future product candidates.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any current or future CMOs we engage must comply with strictly enforced federal, state and foreign regulations, including cGMP requirements enforced by the FDA through its establishment inspection program. Despite the existence of CMO agreements and shared cGMP responsibilities our contract CMO may ignore these contractual provisions, or otherwise fail to meet the minimum standards set forth in the cGMP regulations, resulting in manufacturing non<FONT CLASS="nobreak">-compliance</FONT>. This may go unnoticed or uncorrected despite our best efforts to regulatory audit or confirm the CMOs regulatory responsibilities. Any failure to comply with applicable regulations may result in fines </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval, and would limit the availability of our product. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant consequences, including costly recalls, re<FONT CLASS="nobreak">-stocking</FONT> costs, damage to our reputation and potential for product liability claims.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If the CMOs upon which we rely to manufacture any current products, and any potential product candidates we may in<FONT CLASS="nobreak">-license</FONT> or acquire, fail to deliver the required commercial quantities on a timely basis at commercially reasonable prices, we would likely be unable to meet demand for our products and we would lose potential revenues.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As product candidates proceed through preclinical studies to late<FONT CLASS="nobreak">-stage</FONT> clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidate to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification, or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, and jeopardize our ability to commence sales and generate revenue.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our preclinical studies and clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent, delay or limit the scope of regulatory approval of our product candidates, limit their commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To obtain the requisite regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication. These trials are expensive and time consuming, and their outcomes are inherently uncertain. Failures can occur at any time during the development process. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target indication, and most product candidates that begin clinical trials are never approved.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Apitox, we must demonstrate through lengthy, complex and expensive preclinical and clinical trials that Apitox is both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, a product candidate may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude its obtaining marketing approval. The FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other data. A product candidate could be delayed in receiving, or fail to receive, regulatory approval for many reasons.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in us failing to obtain regulatory approval to market.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other regulatory authorities are inherently unpredictable. If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize Apitox in the United&#x00a0;States.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If any current or future product candidates are associated with undesirable side effects, toxicities, or other negative characteristics, we may need to abandon such products&#x2019; development or limit development to more narrow uses or subpopulations. Such side effects may affect patient recruitment or the ability of enrolled patients to complete the trial and could result in potential product liability claims. Many compounds that show initial promise in early<FONT CLASS="nobreak">-stage</FONT> testing are later found to cause side effects that prevent further development. If our clinical trials reveal severe or prevalent side effects, our trials could be suspended or terminated, we may be unable to recruit patients and enrolled patients may be unable to complete the trials, and the FDA or comparable foreign regulatory authorities could order issue a clinical hold or order us to cease further development or deny approval of the product candidate. Candidates may be harmed, which could significantly harm our business prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">All of our current and future products are subject to and will remain subject to substantial regulatory scrutiny even after receiving regulatory approval.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of our product candidate is subject to extensive regulation by the FDA and other regulatory authorities in the United&#x00a0;States and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United&#x00a0;States until we receive approval of an NDA from the FDA for such drug. We have not received an NDA approval from the FDA for Apitox. There can be no guarantees with respect to our product candidate or future product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Further, any current or future product candidates we may license or acquire will be subject to ongoing regulatory and compliance requirements and oversight by the FDA and other regulatory authorities. These requirements include labeling, packaging, storage, advertising, promotion, record<FONT CLASS="nobreak">-keeping</FONT> and submission of safety and other post<FONT CLASS="nobreak">-market</FONT> information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and other licensed medical professionals and recordkeeping of the drug.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Food and Drug Administration Amendments Act&#x00a0;of&#x00a0;2007 granted significant expanded authority to the FDA, much of which was aimed at improving the safety of drug products before and after approval. The FDA may also impose requirements for costly post<FONT CLASS="nobreak">-marketing</FONT> studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post<FONT CLASS="nobreak">-approval</FONT> marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off<FONT CLASS="nobreak">-label</FONT> use and if we do not market our products for only their approved indications, we may be subject to enforcement action for off<FONT CLASS="nobreak">-label</FONT> marketing. While physicians and other healthcare providers may choose to prescribe drugs for uses that are not described in the product&#x2019;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications that are specifically approved by the FDA.&#x00a0;These &#x201c;off<FONT CLASS="nobreak">-label</FONT>&#x201d; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the U.S.&#x00a0;generally do not regulate the practice of medicine, including the clinical behavior of physicians and other healthcare providers in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off<FONT CLASS="nobreak">-label</FONT> use.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Violations of the Federal Food, Drug and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictions on such products, operations, manufacturers or manufacturing processes;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictions on the labeling or marketing of a product;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictions on product distribution or use;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>requirements to conduct post<FONT CLASS="nobreak">-marketing</FONT> studies or clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>warning letters;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>withdrawal of the products from the market;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>refusal to approve pending applications or supplements to approved applications that we submit;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>recall of products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>fines, restitution or disgorgement of profits;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>suspension or withdrawal of marketing or regulatory approvals;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>suspension of any ongoing clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>denial of permits to import or export our products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product seizure; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>injunctions or the imposition of civil or criminal penalties.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Public concern regarding the safety of any of our current or future drug products could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to incur additional costs.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In light of widely publicized events concerning the safety risk of certain drug products, the FDA, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products, and the establishment of risk management programs. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review of data from our clinical trials. Data from clinical trials may receive greater scrutiny, particularly with respect to safety, which may make the FDA or other regulatory authorities more likely to require additional preclinical studies or clinical trials. If the FDA requires us to conduct additional preclinical studies or clinical trials prior to approving any other potential future product candidate, our ability to obtain such product candidate will be delayed. If the FDA requires us to provide additional clinical or preclinical data following the approval of any potential future product candidate, the indications for which such product candidate is approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize potential future product candidate may be otherwise adversely impacted.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product we are commercializing or product candidates we develop, our commercial opportunities will be negatively impacted. Our product candidate will, if approved, also compete with existing branded, generic and </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">off-label</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> products.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The development and commercialization of new drug products is highly competitive. Numerous companies are engaged in developing products for the treatment of MS symptoms, which we expect will compete with Apitox. We face competition with respect to our product candidate from many different sources, including major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide and existing treatments. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Our competitors also may obtain FDA approval or other regulatory authority approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, our ability to compete may be affected in many cases by insurers or other third<FONT CLASS="nobreak">-party</FONT> payers, particularly Medicare, seeking to encourage the use of generic products. Generic products are currently being used for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming&#x00a0;years.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Many of the companies against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early<FONT CLASS="nobreak">-stage</FONT> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified sales, marketing scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval of our products, the product may not gain market acceptance among regulators, advisory boards, physicians, patients, </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">third-party</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> payors and others in the medical community.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Even if our product receives marketing approval, it may fail to receive recommendations for use by regulators or advisory boards that recommend products, or gain market acceptance by physicians, patients, third<FONT CLASS="nobreak">-party</FONT> payors and others in the medical community. If our product candidate does not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product, if approved for commercial sale, will depend on a number of factors, including but not limited to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the success of any potential clinic studies during the drug development process;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>physicians, hospitals, third<FONT CLASS="nobreak">-party</FONT> payors and patients considering our products as safe and effective;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the prevalence and severity of any side effects;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product labeling or product insert requirements of the FDA or comparable foreign regulatory and advisory bodies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory and advisory bodies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the timing of market introduction of our products as well as competitive products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the cost of treatment in relation to alternative treatments;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the availability of coverage and adequate reimbursement and pricing by third<FONT CLASS="nobreak">-party</FONT> payors, including government authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the willingness of patients to pay out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> in the absence of coverage and adequate reimbursement by third<FONT CLASS="nobreak">-party</FONT> payors, including government authorities;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>relative convenience and ease of administration, including as compared to competitive products and alternative treatments; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the effectiveness of our sales and marketing efforts.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our ability to effectively promote and sell our products and any other current or future product candidates we may develop, license or acquire in the marketplace will also depend on pricing and cost effectiveness, including our ability to produce a product at a competitive price and achieve acceptance of the product onto formularies, as well as our ability to obtain sufficient third<FONT CLASS="nobreak">-party</FONT> coverage or reimbursement. Since many insurance plans are members of group purchasing organizations, which leverage the purchasing power of a group of entities to obtain discounts based on the collective buying power of the group, our ability to attract customers in the marketplace will also depend on our ability to effectively promote any current or future product candidates to group purchasing organizations. We will also need to demonstrate acceptable evidence of safety and efficacy, as well as relative convenience and ease of administration. Market acceptance could be further limited depending on the prevalence and severity of any expected </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">or unexpected adverse side effects associated with our current or any future product candidates. If any current or future product candidates are approved but do not achieve an adequate level of acceptance by physicians, health care payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third<FONT CLASS="nobreak">-party</FONT> payors on the benefits of any current or future product candidates may require significant resources and may never be successful.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Further, in both domestic and foreign markets, our any future product sales will depend in part upon the availability of coverage and reimbursement from third<FONT CLASS="nobreak">-party</FONT> payors. Such third<FONT CLASS="nobreak">-party</FONT> payors include government health programs such as Medicare, managed care providers, private health insurers and other organizations. We may need to conduct post<FONT CLASS="nobreak">-marketing</FONT> studies in order to demonstrate the cost<FONT CLASS="nobreak">-effectiveness</FONT> of any future products to the satisfaction of target customers and their third<FONT CLASS="nobreak">-party</FONT> payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our current or future products might not ultimately be considered cost<FONT CLASS="nobreak">-effective</FONT>. Adequate third<FONT CLASS="nobreak">-party</FONT> coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Adverse effects or other undesirable or unacceptable side effects caused by our product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidate. Such side effects could also affect trial recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Treatment<FONT CLASS="nobreak">-related</FONT> side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. If serious adverse or unacceptable side effects are identified during the development of any of any current or future product candidates, we may need to abandon such products&#x2019; development or limit development to more narrow uses or subpopulations.<FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> </FONT>The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious safety findings, negatively impacting a program prior to or after commercial launch. Adverse effects or other undesirable or unacceptable side effects caused by our product may cause us or the FDA to recall product or remove a product from the marketplace.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any of these occurrences may harm our business, financial condition and prospects significantly.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Upon completion of Phase&#x00a0;III clinical programs, we plan to develop a sales organization, and there is no assurance our marketing and sales organization will be successful.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If we are unable to successfully establish marketing and sales capabilities, we may not be able to generate product revenue. The development of an in<FONT CLASS="nobreak">-house</FONT> marketing organization and sales force will require significant capital expenditures, management resources and time, and we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. There can be no assurance that our in<FONT CLASS="nobreak">-house</FONT> sales and distribution capabilities will be successful.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If we are unable or decide not to successfully establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our products ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our products.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. There is currently a significant strain on our managerial, operational and financial resources. The loss of the services of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. We conduct substantially all of our operations at our facilities in the New&#x00a0;York Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Some of our key executives do&#x00a0;not devote his full business time to our operations.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our Chairman and Chief Medical Officer, Dr.&#x00a0;Christopher Kim, is involved in other businesses and does not devote all of his working time to our business.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Some of the other businesses engaged in by Dr.&#x00a0;Kim could prove more successful than ours, Dr.&#x00a0;Kim could choose to focus his attention on such businesses which could cause him to fail to devote sufficient attention to our business and our operations could suffer and our financial conditions and results of operations may be materially and adversely affected.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidate and will face an even greater risk if we commercialize any products. For example, we may be sued if our products cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>decreased demand for our products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>injury to our reputation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>withdrawal of clinical trial participants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>initiation of investigations by regulators;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>costs to defend the related litigation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a diversion of management&#x2019;s time and our resources;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>substantial monetary awards to trial participants or patients;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product recalls, withdrawals or labeling, marketing or promotional restrictions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>loss of revenue;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>exhaustion of any available insurance and our capital resources;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the inability to commercialize any products; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a decline in our share price.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several&#x00a0;years. Such volatility and disruptions have caused and may continue to cause severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our business could be adversely affected by the effects of health epidemics, such as the COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations. Any future pandemic could materially affect our operations, including at our headquarters in the New&#x00a0;York area.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Health epidemics in regions where we have concentrations of potential clinical trial sites or other business operations could adversely affect our business, including by causing significant disruption in the operations of our CMO and other third parties upon whom we rely.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We or the third parties upon whom we depend on may be adversely affected by natural disasters or acts of war, such as the conflicts in Ukraine and Israel, and our business continuity and disaster recovery plans may not adequately protect us from any such serious disaster.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man<FONT CLASS="nobreak">-made</FONT> accidents or incidents that result in us being unable to undergo clinical trials, fully utilize our facilities, or the manufacturing facilities of our third<FONT CLASS="nobreak">-party</FONT> CMOs, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidate or interruption of our business operations. Earthquakes or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event were to occur that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third<FONT CLASS="nobreak">-party</FONT> CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, governmental restrictions or as a result of labor disputes or unstable political environments. Supply chain issues, including those resulting from the COVID<FONT CLASS="nobreak">-19</FONT> pandemic and the ongoing military conflicts between Russian and Ukraine and Israel and surrounding areas and the attacks on marine vessels traversing the Red Sea, may affect our third<FONT CLASS="nobreak">-party</FONT> vendors and cause delays. As of the date of this prospectus, our CMOs and third<FONT CLASS="nobreak">-party</FONT> vendors have not experienced manufacturing difficulties or delays as a result of the military conflicts in Ukraine and Israel.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third<FONT CLASS="nobreak">-party</FONT> CMOs, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed and result in higher costs or adversely impact development of our product candidates.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violates (i)&#x00a0;the laws and regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii)&#x00a0;manufacturing standards, (iii)&#x00a0;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United&#x00a0;States, and (iv)&#x00a0;laws that require the true, complete and accurate reporting of financial information or data.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self<FONT CLASS="nobreak">-dealing</FONT> and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government<FONT CLASS="nobreak">-funded</FONT> healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Reliance on Third Parties</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We currently rely on </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">third-party</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> manufacturing and a </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">single-source</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> supplier to supply raw materials and components for, and manufacture, our product candidate. Our inability to have sufficient quantities of our product candidate manufactured, or our failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Efficient and scalable manufacturing and supply is a vital component of our business strategy. We currently do not own or operate any manufacturing facilities. We have developed, in collaboration with third parties manufacturing processes that we believe can scale to address clinical and commercial supply. However, our assumptions as to our ability and our CMOs ability to produce our product candidate at the scale needed for clinical development and commercial demand may prove to be wrong. If we encounter problems in our manufacturing processes or in our ability to scale to address commercial drug supply, our business would be materially adversely affected.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The manufacturing process for a drug is subject to FDA or comparable foreign regulatory authority review. Our suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as Current Good Manufacturing Practices, or cGMPs. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidate. Moreover, we do not control the manufacturing process at our CMOs and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We purchase the bee venom necessary to produce Apitox for our clinical trials from a single third<FONT CLASS="nobreak">-party</FONT> supplier. There are a limited number of suppliers for bee venom, and we may need to assess alternate suppliers to prevent a possible disruption of the manufacture of Apitox for our clinical trials and, if approved, ultimately for commercial sale. Any termination of our supply agreement or significant delay in the supply of bee venom for the manufacture of Apitox for an ongoing clinical trial due to the need to replace a third<FONT CLASS="nobreak">-party</FONT> supplier could considerably delay completion of our clinical trials, product testing and potential regulatory approval of Apitox.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Furthermore, if there is a disruption to our or our third<FONT CLASS="nobreak">-party</FONT> suppliers&#x2019; relevant operations, including as a result of the COVID<FONT CLASS="nobreak">-19</FONT> pandemic, we will have no other means of producing Apitox until they restore the affected facilities or we or they procure alternative facilities. Additionally, any damage to or destruction of our or our third party or suppliers&#x2019; facilities or equipment may significantly impair our ability to manufacture Apitox on a timely basis.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidate in a timely and competitive manner, or at all. Identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at&#x00a0;all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines, which would impair our ability to meet our development objectives or generate revenues from the sale of Apitox, if approved.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidate.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We currently do not have the ability to independently conduct preclinical or clinical studies that comply with the regulatory requirements known as Good Laboratory Practice and Good Clinical Practice (&#x201c;GCP&#x201d;). The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will need to negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any third parties conducting our preclinical studies and clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our products. As a result, our financial results and the commercial prospects for our products would be harmed, our costs could increase and our ability to generate revenue could be delayed.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If any of our relationships with trial sites or any CRO that we may use in the future terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If we or our </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">third-party</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> suppliers use hazardous, </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">non-hazardous</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United&#x00a0;States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business prospects, financial condition or results of operations.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We rely on honeybee colonies to supply our active pharmaceutical ingredient, or API, for Apitox, and if these colonies are damaged from pests, disease organisms or other phenomena, it could result in a negative impact on our business.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The mortality rate of honeybees has increased significantly over the last decade. Although the overall number of bee colonies in the United&#x00a0;States. appears to be relatively stable, the increased mortality rate means beekeepers need to spend more time and money dividing their surviving colonies to create new ones to replace those lost. This could result in supply delays and cost increases for the bee venom we use to make Apitox. In addition, pests such as tracheal mites, Varroa mites and wax moths can either severely damage a bee colony or entirely wipe out a colony. American foulbrood is a lethal bacterial disease affecting bee larvae and pupae. Colonies may also be subject to &#x201c;colony collapse disorder,&#x201d; a phenomenological happening wherein the worker bees from a specific beehive suddenly vanish causing the hive to die off. Although our supplier employs preventative measures, any of these risks may negatively impact the bee hives and our ability to obtain the bee venom to make Apitox, which would adversely affect our business and prospects.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our discovery, development and commercialization efforts with respect to our products and any future products that we may seek to develop. Any of these relationships may require us to incur non<FONT CLASS="nobreak">-recurring</FONT> and other charges, increase our near and long<FONT CLASS="nobreak">-term</FONT> expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time<FONT CLASS="nobreak">-consuming</FONT> and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our products because they may be deemed to be at too early of a stage of development for collaborative effort, and third parties may not view our products as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our products could delay the development and commercialization of our products in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Government Regulation</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our relationships with customers, physicians and </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">third-party</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, health information privacy and security laws and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Healthcare providers, physicians and third<FONT CLASS="nobreak">-party</FONT> payors in the United&#x00a0;States and elsewhere will play a primary role in the recommendation and prescription of any products for which we have or obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third<FONT CLASS="nobreak">-party</FONT> payors subject us to various federal and state fraud and abuse laws and other healthcare laws. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our products, if approved. Such laws include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the U.S.&#x00a0;federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S.&#x00a0;federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the U.S.&#x00a0;federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S.&#x00a0;federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S.&#x00a0;federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S.&#x00a0;federal government by engaging in impermissible marketing practices, such as the off<FONT CLASS="nobreak">-label</FONT> promotion of a product for an indication for which it has not received FDA approval. In&#x00a0;addition, the government may assert that a claim including items and services resulting from a violation of the U.S.&#x00a0;federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the Health Insurance Portability and Accountability Act&#x00a0;of&#x00a0;1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S.&#x00a0;federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule, including health plans, healthcare clearinghouses and certain healthcare providers as well as their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information for or on their behalf;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the Federal Food Drug or Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the U.S.&#x00a0;Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>analogous U.S.&#x00a0;state laws and regulations, including: state anti<FONT CLASS="nobreak">-kickback</FONT> and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third<FONT CLASS="nobreak">-party</FONT> payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S.&#x00a0;federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We may also be subject to other laws, such as the U.S.&#x00a0;Foreign Corrupt Practices Act&#x00a0;of&#x00a0;1977, as amended, which prohibit, among other things, U.S.&#x00a0;companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government<FONT CLASS="nobreak">-funded</FONT> healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace. In addition, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government<FONT CLASS="nobreak">-funded</FONT> healthcare programs.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, their ability to hire and retain key personnel and accept the payment of user fees and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#x00a0;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#x00a0;years, the U.S.&#x00a0;government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Of note, in response to the global COVID<FONT CLASS="nobreak">-19</FONT> pandemic, the FDA adopted a risk<FONT CLASS="nobreak">-based</FONT> system for the conduct of inspections of manufacturing facilities and began conducting voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites where an in<FONT CLASS="nobreak">-person</FONT> inspection would not be prioritized, deemed mission<FONT CLASS="nobreak">-critical</FONT>, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities inside and outside the United&#x00a0;States may adopt similar restrictions or other policy measures in response to any future pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We are subject to increasingly stringent and rapidly changing laws and regulations related to privacy and data security. The restrictions and costs imposed by these requirements, or our actual or perceived failure to comply with them, could harm our reputation, subject us to significant fines and liability, and adversely affect our business.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">We are subject to or affected by numerous evolving federal, state and foreign laws and regulations, as well as policies, contracts and other obligations governing the collection, use, disclosure, retention, and security of personal data. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This landscape may create uncertainty in our business, result in liability or impose additional costs on us. These laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised. The cost of compliance with these laws and regulations is high and is likely to increase in the future. Our failure or perceived failure to comply with these laws and regulations could result in negative publicity, diversion of management time and effort, an inability to process personal data or to operate in certain jurisdictions, restrictions on our operations and legal action against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">For example, HIPAA, as amended by HITECH, imposes requirements relating to the privacy and security of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare providers, and their respective contractors and their covered subcontractors that perform services for them involving individually identifiable health information. Additionally, certain states have adopted healthcare privacy and security laws and regulations comparable to HIPAA, some of which may be more stringent than HIPAA.&#x00a0;In the event we fail to properly maintain the </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">privacy and security of individually identifiable health information governed by HIPAA or comparable state laws, and significant or we are responsible for an unauthorized disclosure or security breach of such information, we could be subject to enforcement action under HIPAA or comparable state laws, civil and criminal penalties, and fines.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Domestic privacy and data security laws beyond HIPAA and other healthcare privacy laws are also changing rapidly and becoming more complex. For example, California recently enacted the CCPA, which took effect on January&#x00a0;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt<FONT CLASS="nobreak">-out</FONT> of certain personal information sharing, and receive detailed information about how their personal information is used, among others. The CCPA also requires covered businesses to provide detailed privacy notices to California residents and respond to requests from California residents to exercise their rights under the CCPA to access, delete and opt<FONT CLASS="nobreak">-out</FONT> of certain sharing of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data, the CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S.&#x00a0;As of January<FONT CLASS="nobreak"> </FONT>1, 2023, consumers have new rights in addition to those above, such as (i) the right to correct inaccurate personal information that a business has about them; and (ii) the right to limit the use and disclosure of sensitive personal information collected about them. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, further restrict the use of cross<FONT CLASS="nobreak">-contextual</FONT> advertising, establish restrictions on the retention of personal information, expand the types of data breaches subject to the CCPA&#x2019;s private right of action, provide for increased penalties for CPRA violations concerning California residents under the age of<FONT CLASS="nobreak"> </FONT>16, and establish a new California Privacy Protection Agency to implement and enforce the new law. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If our product candidates are approved for marketing and are found to have been improperly promoted for </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">off-label</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> uses, or if physicians misuse our products or use our products </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">off-label</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If our approved product, or any of our product candidates that are approved, are found to have been improperly promoted for off<FONT CLASS="nobreak">-label</FONT> uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about approved prescription drug products. In particular, while the FDA permits the dissemination of truthful and non<FONT CLASS="nobreak">-misleading</FONT> information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA.&#x00a0;If we are found to have promoted such off<FONT CLASS="nobreak">-label</FONT> uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of regulated products for off<FONT CLASS="nobreak">-label</FONT> uses and has enjoined several companies from engaging in off<FONT CLASS="nobreak">-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidate, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We are subject to new legislation, regulatory proposals and managed care initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In the United&#x00a0;States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March&#x00a0;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act&#x00a0;of&#x00a0;2010 (collectively, the &#x201c;ACA&#x201d;), was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United&#x00a0;States. By way of example, the ACA: increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non<FONT CLASS="nobreak">-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#x201c;branded prescription drugs&#x201d; to specified federal government programs; implemented a new methodology under which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded the eligibility criteria for Medicaid programs; created a new Patient<FONT CLASS="nobreak">-Centered</FONT> Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">a Center for Medicare and Medicaid Innovation (&#x201c;CMMI&#x201d;) at the Centers for Medicare&#x00a0;&amp; Medicaid Services (&#x201c;CMS&#x201d;), to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA.&#x00a0;Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA.&#x00a0;While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been enacted. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax<FONT CLASS="nobreak">-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, a process that is commonly referred to as the &#x201c;individual mandate.&#x201d; In addition, the Further Consolidated Appropriations Act, 2020 permanently eliminated, effective January&#x00a0;1, 2020, the ACA<FONT CLASS="nobreak">-mandated</FONT> &#x201c;Cadillac&#x201d; tax on high<FONT CLASS="nobreak">-cost</FONT> employer<FONT CLASS="nobreak">-sponsored</FONT> health coverage and medical device tax and, effective January&#x00a0;1, 2021, it also eliminated the health insurer tax. On December&#x00a0;14, 2018, the U.S.&#x00a0;District Court for the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&#x00a0;18, 2019, the U.S.&#x00a0;Court of Appeals for the Fifth Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#x00a0;2, 2020, the U.S.&#x00a0;Supreme Court reversed the Fifth Circuit&#x2019;s ruling, holding that the challengers lacked standing to sue and otherwise abstaining from reaching the merits of the case. There may be other efforts to challenge, repeal, or replace the ACA.&#x00a0;We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">President Biden signed an Executive Order on Strengthening Medicaid and the Affordable Care Act, stating his administration&#x2019;s intentions to reverse the actions of his predecessor and strengthen the ACA.&#x00a0;As part of this Executive Order, the Department of Health and Human Services, United&#x00a0;States Treasury, and the Department of Labor are directed to review all existing regulations, orders, guidance documents, policies and agency actions to consider if they are consistent with ensuring coverage under the ACA and making high<FONT CLASS="nobreak">-quality</FONT> healthcare affordable and accessible to Americans. We are unable to predict the likelihood of changes to the ACA or other healthcare laws which may negatively impact our profitability.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">President Biden intends, as his predecessor did, to take action against drug prices which are considered &#x201c;high.&#x201d; Such measures could be addressed in a legislative package later in 2021 or with the reauthorization of the Prescription Drug User Fee Act, or PDUFA, in 2022 as part of a package bill. Drug pricing continues to be a subject of debate at the executive and legislative levels of U.S.&#x00a0;government, and we expect to see legislation focusing on this in the coming year. The American Rescue Plan Act&#x00a0;of&#x00a0;2021 signed into law by President Biden on March&#x00a0;14, 2021 includes a provision that will eliminate the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January&#x00a0;2024. With the elimination of the rebate cap, manufacturers may be required to compensate states in an amount greater than what the state Medicaid programs pay for the drug.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April&#x00a0;1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030 with the exception of a temporary suspension implemented under various COVID<FONT CLASS="nobreak">-19</FONT> relief legislation from May&#x00a0;1, 2020 through December&#x00a0;31, 2021, unless additional congressional action is taken. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, to review the relationship between pricing and manufacturer patient assistance programs, and to reform government program reimbursement methodologies for pharmaceutical products. The Prescription Drug Pricing Reduction Act, or PDPRA, which was introduced in Congress in 2019, and again in 2020, proposed to, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts B and D faster than the rate of inflation, cap out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> expenses for Medicare Part&#x00a0;D beneficiaries, and proposes several changes to how drugs are reimbursed in Medicare Part&#x00a0;B.&#x00a0;A similar drug pricing bill, the Elijah E.&#x00a0;Cummings Lower Drug Costs Now Act proposes to enable direct price negotiations by the federal government for certain drugs (with the maximum price paid by Medicare capped based </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">on an international index), requires manufacturers to offer these negotiated prices to other payors, and restricts manufacturers from raising prices on drugs covered by Medicare Parts B and D.&#x00a0;This Act passed in the House of Representatives when it was introduced in 2019, and it has been introduced again in the 2021 term. We cannot predict whether any proposed legislation will become law and the effect of these possible changes on our business cannot be predicted at this time.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Further, the Centers for Medicare&#x00a0;&amp; Medicaid Services (&#x201c;CMS&#x201d;) has significant regulatory authority to promulgate regulations and impose other compliance requirements that may increase our compliance costs and impact our ability to attain profitability and market our product candidate. CMS sets coverage and reimbursement rates for Medicare and oversees the implementation of Medicaid at the state level. CMS could modify or impose coverage restrictions or modify reimbursement rates on our product candidate in a manner that could adversely impact our business. For example, on January&#x00a0;8, 2021, CMS approved Tennessee&#x2019;s Medicaid section 1115 demonstration application, granting the state the unprecedented ability to implement a closed drug formulary without foregoing the state&#x2019;s entitlement to rebates under the Medicaid Drug Rebate Program. Implementation of a closed formulary could mean that our products could be excluded from coverage under Medicaid. It is unclear whether the Biden Administration will reverse or modify Tennessee&#x2019;s section 1115 demonstration approval.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Within CMS, CMMI, as established by the ACA, has broad authority to design, implement, and test new health care payment models that could potentially lower health care spending while maintaining quality or increase quality without increasing spending. CMMI has considered implementing models that could have a significant adverse effect on our business. For example, on November&#x00a0;27, 2020, CMMI finalized a mandatory Medicare Part&#x00a0;B drug payment model that would have aligned payment for drugs with international reference prices, entitled the Most Favored Nation (MFN) Model. The MFN Model was enjoined by a Federal court on December&#x00a0;28, 2020 for failure to comply with rulemaking procedural requirements. It is unclear whether the Biden Administration will propose and implement the same or a similar model in future rulemaking, and we cannot predict how future regulatory actions by CMMI or any other component of CMS may impact our business.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our current or future product candidates. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Legislative and regulatory proposals have been made to expand post<FONT CLASS="nobreak">-approval</FONT> requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of any current or future product candidates, if any, may be. In addition, increased Congressional scrutiny of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post<FONT CLASS="nobreak">-marketing</FONT> testing and other requirements.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Any product candidates for which we intend to seek approval as biologic products may face biosimilar competition sooner than anticipated.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If we are successful in achieving regulatory approval to commercialize any biologic product candidate that we develop, it may face competition from biosimilar products. In the United&#x00a0;States, our product candidates are regulated by the FDA as biologic products subject to approval under the BLA pathway. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act&#x00a0;of&#x00a0;2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA<FONT CLASS="nobreak">-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#x00a0;years following the data the reference product was first licensed by the FDA.&#x00a0;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#x00a0;years from the date on which the reference product was first licensed by the FDA.&#x00a0;During this 12<FONT CLASS="nobreak">-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well<FONT CLASS="nobreak">-controlled</FONT> clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA.&#x00a0;As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intend to be implemented, BPCIA may be fully adopted by the FDA, any such processes could </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">have an adverse effect on the future commercial prospects for our biological products. There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12<FONT CLASS="nobreak">-year</FONT> period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. For example, in May&#x00a0;2021, the Biden administration expressed support for waiving intellectual property protections for COVID<FONT CLASS="nobreak">-19</FONT> vaccines amid concerns about vaccines access in foreign nations. Such waiver, if implemented, could extend to our product candidates. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any of our reference products in a way that is similar to traditional generic substitution for non<FONT CLASS="nobreak">-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our business activities will be subject to the Foreign Corrupt Practices Act, or FCPA, and similar </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">anti-bribery</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> and </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">anti-corruption</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> laws.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As we expand our business activities outside of the United&#x00a0;States, including our clinical trial efforts, we will be subject to the FCPA and similar anti<FONT CLASS="nobreak">-bribery</FONT> or anti<FONT CLASS="nobreak">-corruption</FONT> laws, regulations or rules of other countries in which we intend to operate. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non<FONT CLASS="nobreak">-United</FONT>&#x00a0;States government official in order to influence official action, or otherwise obtain or retain business. The FCPA also required public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore may involve significant interaction with public officials, including officials of non<FONT CLASS="nobreak">-United</FONT>&#x00a0;States governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government under the FCPA.&#x00a0;Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, of those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our&#x00a0;business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to Our Intellectual Property</FONT></P>
		 <P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We rely principally on trade secrets and other forms of </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">non-patent</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> intellectual property protection, which are difficult to protect.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our API is a natural, non<FONT CLASS="nobreak">-synthetic</FONT> compound that is not patentable, so we rely on trade secrets to protect our rights to Apitox, particularly the method and process of manufacturing Apitox. Trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors and other advisors may unintentionally or willfully disclose our information to competitors. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. We would expect any trade secret dispute to be governed by federal law, and in particular the Defend Trade Secrets Act (&#x201c;DTSA&#x201d;) of 2016. However, in the event we are not able to utilize the DTSA, we would then be limited to resolving such dispute in state court. State trade secret laws in the United&#x00a0;States vary, and state courts are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">knowledge, methods and know<FONT CLASS="nobreak">-how</FONT>. If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be harmed and our ability to successfully penetrate our target markets could be severely compromised.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our ability to compete depends in part on our ability to secure and maintain proprietary rights to our products</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea does not have any patent protection for Apitoxin. There could be several competitive products available in the marketplace possessing similar qualities.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea&#x2019;s patents related to Apitoxin expired in early 2023. If Apimeds does decide to apply for patent protection, there can be no assurance that any patent issued Apimeds Korea, and licensed to us, will provide competitive advantages or will not be challenged by third parties. Furthermore, there can be no assurance that others will not independently develop similar products or design around Apimeds Korea&#x2019;s previous patents. Any of the foregoing activities could have a material adverse effect on the Company. Moreover, enforcement of any patent or license rights may require substantial litigation costs.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our success depends in part on not only our ability, but that of Apimeds Korea&#x2019;s to protect the intellectual property, including our trade secrets, which can be difficult and costly and is not assured.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our success depends in part on our ability, and that of Apimeds Korea, to obtain and maintain trade secret and trademark protection of our rights to Apitox, as well as successfully defending the intellectual property against third<FONT CLASS="nobreak">-party</FONT> challenges.&#x00a0;Our ability to stop unauthorized third parties from misusing our trade secrets by making or using Apitox is dependent upon the extent to which we have rights under trade secrets that cover these activities.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third<FONT CLASS="nobreak">-party</FONT> contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of these parties to use or disclose our confidential information, including our trade secrets. The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. The intellectual property positions of biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. We cannot accurately predict future changes in the interpretation of intellectual property laws or changes to intellectual property laws which might be enacted into law. Those changes may materially affect our ability to protect our trade secrets.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Despite our efforts to protect our trade secrets, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Failure to protect our trade secrets, for any reason (or third<FONT CLASS="nobreak">-party</FONT> claims against our trade secrets or proprietary rights, or our involvement in disputes over our trade secrets or proprietary rights, including involvement in litigation), could have a substantial negative effect on our results of operations and financial condition.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We do not own the Apitox trademark, but may use the trademark pursuant to the terms of the Business Agreement with Apimeds Korea.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We do not own the trademark that we use in our business and may be unable to protect this intellectual property against infringement from third parties. We are party to the Business Agreement with Apimeds Korea pursuant to which Apimeds Korea granted us an exclusive, sublicensable, royalty<FONT CLASS="nobreak">-bearing</FONT> license to utilize all prior clinical development data associated with Apitoxin, Apitox, and all related names, advance clinical research, develop, </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">manufacture and commercialize and sell Apitox in the United States. The Business Agreement can be terminated by mutual written agreement by the parties and will automatically terminate upon the bankruptcy or dissolution of the Company. In the event that the Business Agreement is terminated, we will be required to, among other things, change the name of our product candidate. Any of these events could disrupt our recognition in the marketplace, damage any goodwill we may have generated, and otherwise have a material adverse effect on us. Furthermore, since we license the use of the name &#x201c;Apitox&#x201d; from Apimeds Korea, we are dependent on Apimeds Korea to defend against trademark infringement claims. Apimeds Korea&#x2019;s efforts to enforce or protect our rights related to the trademark &#x201c;Apitox&#x201d; may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We do not own any trademarks or tradenames, as we license the use of the name &#x201c;Apitox&#x201d; from Apimeds Korea pursuant to the Business Combination Agreement; however, in the future if we are to register and trademarks or tradenames, any registered trademarks or trade names may be challenged, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect our intellectual property rights, which could be expensive, time consuming and unsuccessful.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Competitors may infringe or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time<FONT CLASS="nobreak">-consuming</FONT>. An adverse result in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our intellectual property rights are invalid or unenforceable. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United&#x00a0;States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We expect to rely on trademarks as one means to distinguish our products from those approved for marketing from the products of our competitors. We intend to file a United&#x00a0;States trademark application for &#x201c;Apitox&#x201d; but have not yet begun the process of applying to register any trademarks for our current product candidate or any future&#x00a0;products. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks. In addition, any proprietary name we propose to use with our current or any other product candidates in the United&#x00a0;States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Furthermore, pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty<FONT CLASS="nobreak">-bearing</FONT> license to utilize all prior clinical development data associated with Apitoxin, Apitox, and all related names, and to advance clinical research, develop, manufacture and commercialize and sell Apitox in the United States. The Company does not own international rights to the name &#x201c;Apitox,&#x201d; and the Company has an exclusive license to use the name in the United States pursuant to the Business Agreement. The name &#x201c;Apitox&#x201d; may be used in different countries with respect to products that are not ours. We are aware of a Spanish company called PrismaNatural, offering an over<FONT CLASS="nobreak">-the-counter</FONT> topical ointment product called &#x201c;Apitox&#x201d; that can be purchased in the United States. This may create confusion with respect to our product candidate and our business may be adversely affected.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As mentioned above, we are dependent on Apimeds Korea to defend against trademark infringement claims because we license the use of the name &#x201c;Apitox&#x201d; pursuant to the Business Agreement. Notwithstanding Apimeds Korea&#x2019;s efforts, there can be no assurance that its efforts to protect its trademarks will be successful, even if Apimeds Korea intends to maintain and keep current all of its trademark registrations and to pay all applicable renewal fees as they become due. The right of a trademark owner to use its trademarks is based on a number of factors, including their first use in commerce, and trademark owners can lose trademark rights despite trademark registration and payment of renewal fees. We therefore believe that these proprietary rights, licensed to us, have been and will continue to be important in enabling us to compete and if for any reason Apimeds Korea is unable to maintain its trademark that it licenses to us, our business could be materially and negatively affected. Nor can there be any assurance that third<FONT CLASS="nobreak">-parties</FONT> will not assert claims against us for infringement of their intellectual proprietary rights. If an infringement claim is asserted, we may be required to obtain a license of such rights, pay royalties on a retrospective or prospective basis, or terminate our development, manufacturing and marketing of our infringing products. Litigation with respect to such matters could result in substantial costs and diversion of management and other resources and could have a material adverse effect on our business, financial condition, or operating results.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Because we expect to rely on third parties to manufacture Apitox and any future candidates, and we expect to collaborate with third parties on the development of our current and future therapeutics, we must, at times, share trade secrets with them. We also may conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third<FONT CLASS="nobreak">-party</FONT> contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know<FONT CLASS="nobreak">-how</FONT> and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Further, disputes may arise under these agreements regarding inventorship or ownership of proprietary information generated during research and development.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third<FONT CLASS="nobreak">-party</FONT> contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third<FONT CLASS="nobreak">-party</FONT> collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#x2019; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Risks Related to This Offering and Ownership of Our Common Stock</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">An active, liquid and orderly trading market may not develop for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock at or above the initial offering price, if at all.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Prior to this offering there has been no public market for shares of our common stock. An active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. The initial public offering price for our common stock will be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of the common stock after the offering. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">The price of our stock may be volatile, and you could lose all or part of your investment.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this prospectus, these factors include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the commencement, enrollment, progress or results of our planned or future preclinical studies or clinical trials of our products and those of our competitors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>delays or terminations of clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>regulatory or legal developments in the United&#x00a0;States;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>announcements by our competitors of new product candidates or technologies, or the results of clinical trials or regulatory decisions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the recruitment or departure or key personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>developments or disputes concerning patent applications, issued patents or other proprietary rights;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the level of expenses related to our products or preclinical and clinical development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the results of our efforts to develop additional products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>unanticipated serious safety concerns related to the use of any product candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>actual or anticipated changes in estimates as to financial results, development timelines or recommendations or reports by securities analysts;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the level of expenses and capital investment related to manufacturing out products;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our inability to obtain or delays in obtaining adequate supply for any approved products candidate;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>significant lawsuits, including patent or stockholder litigation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>variations in our financial results or those of companies perceived to be similar to us;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any approved medicines;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Overall performance of the equity markets;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>general economic, political and market conditions and overall fluctuations in the financial markets in the United&#x00a0;States; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>investors&#x2019; general perception of us and our business.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, the stock market in general, the NYSE American and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, which has resulted in decreased stock prices for many companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, operating results or financial condition.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We are controlled by our principal stockholders and management, which own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval, which will limit your ability to influence corporate matters.</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Prior to this offering, our executive officers, directors and 5% stockholders beneficially owned approximately 94.64% of our voting stock as of December<FONT CLASS="nobreak"> </FONT>6, 2024 and, upon the closing of this offering, that same group will continue to beneficially own approximately 66.45% of our outstanding voting stock (not including any shares that may be purchased by them in this offering). Moreover, Inscobee including through its wholly<FONT CLASS="nobreak">-owned</FONT> subsidiary, Apimeds Korea, beneficially owns 70.27% of our outstanding common stock prior to this offering. Accordingly, even after this offering, these stockholders will have the ability to control us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. They effectively have the ability to determine all corporate actions requiring stockholder approval, including the election and removal of directors, any amendment to our certificate of incorporation or bylaws, or the approval of any merger or other significant corporate transaction, including a sale of substantially all of our assets. This could have the effect of delaying or preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of the Company, which could cause the market price of our common stock to decline or prevent stockholders from realizing a premium over the market price for common stock. Their interests may conflict with our interests as a company or the interests of our other stockholders.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">You will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering. The initial public offering price is substantially higher than the pro forma as adjusted net tangible book value per share of our common stock. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the pro forma as adjusted book value of our tangible assets after subtracting our liabilities. Based on the assumed initial public offering price of $3.00 per share, which is the low end of the estimated price range set forth on the cover page of this prospectus, you will experience immediate dilution of $(2.29) per share, representing the difference between our pro forma as adjusted net tangible book value per share after this offering and the initial public offering price per share. See the section entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Dilution</FONT>&#x201d; for additional information.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Participation in this offering by our existing stockholders and/or their affiliated entities may reduce the public float for our common stock.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Certain of our existing stockholders have indicated an interest to purchase up to an aggregate of approximately $3.0<FONT CLASS="nobreak"> </FONT>million of shares of our common stock in this offering at the initial public offering price (which would represent approximately 30% of the shares sold in this offering, assuming an offering price of $3.00 per share, which is the low end of the estimated price range). However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of our common stock in this offering to these entities, or these entities may determine to purchase more, fewer or no shares of our common stock in this offering. The underwriters will receive the same underwriting discounts and commissions on any shares of our common stock purchased by these entities as they will on any other shares of our common stock sold to the public in this offering. For more information regarding indications of interest by certain of our stockholders and the potential impact on their ownership of shares of our common stock, see &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Principal Stockholders</FONT>.&#x201d;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the extent certain of our existing stockholders and their affiliated entities participate in this offering, such purchases would reduce the non<FONT CLASS="nobreak">-affiliate</FONT> public float of our shares, meaning the number of shares of our common stock that are not held by officers, directors, and controlling stockholders. A reduction in the public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be able to sell shares of common stock purchased in this offering. While certain of our existing stockholders and their affiliated entities have expressed interest in potentially participating in this offering, there are no assurances that they will participate in the offering to a material extent, or at all.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-style:italic;font-weight:bold;">We are an emerging growth company and a smaller reporting company and intend to take advantage of reduced disclosure requirements applicable to emerging growth companies, which could make the common stock less attractive to investors.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are an &#x201c;emerging growth company&#x201d; (&#x201c;EGC&#x201d;) as defined in the Jumpstart Our Business Startups Act&#x00a0;of&#x00a0;2012. We will remain an EGC until the earliest to occur of (i)&#x00a0;the last&#x00a0;day of the fiscal year in which it has total annual gross revenue of $1.235&#x00a0;billion or more; (ii)&#x00a0;the last&#x00a0;day of the fiscal year following the fifth anniversary of the date of the first sale of common stock pursuant to the registration statement; (iii)&#x00a0;the date on which it has issued more than $1.0&#x00a0;billion in non<FONT CLASS="nobreak">-convertible</FONT>&#x00a0;debt securities during the prior three<FONT CLASS="nobreak">-year</FONT>&#x00a0;period; or (iv)&#x00a0;the date it qualifies as a &#x201c;large accelerated filer&#x201d; under the rules of the SEC, which means the market value of the common stock held by non<FONT CLASS="nobreak">-affiliates</FONT>&#x00a0;exceeds $700&#x00a0;million as of the last business&#x00a0;day of its most recently completed second fiscal quarter after it has been a reporting company in the United&#x00a0;States for at least 12&#x00a0;months. For so long as we remain an EGC, it is permitted to and intends to rely upon exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include not being required to comply with the auditor attestation requirements of Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT>&#x00a0;Act (&#x201c;SOX&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We may take advantage of some, but not all, of the available exemptions available to EGCs. We cannot predict whether investors will find the common stock less attractive if it relies on these exemptions. If some investors find the common stock less attractive as a result, there may be a less active trading market for the common stock and the price of the common stock may be more volatile.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are also a smaller reporting company, as defined in Rule&#x00a0;405 promulgated under the Securities Act (&#x201c;SRC&#x201d;). As an SRC, our company intends to utilize certain reduced disclosure requirements, including publishing two&#x00a0;years of audited financial statements instead of three&#x00a0;years, as required for companies that do not qualify as an SRC.&#x00a0;Our company will remain an&#x00a0;SRC&#x00a0;until the last&#x00a0;day of the fiscal year in which it had (i)&#x00a0;a public float that exceeded $250&#x00a0;million or (ii)&#x00a0;annual revenues of more than $100&#x00a0;million and a public float that exceeded $700&#x00a0;million. To the extent our company takes advantage of such reduced disclosure obligations, it may make comparison of its financial statements to those of other public companies difficult or impossible.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After our company ceases to be an SRC, it is expected to incur additional management time and cost to comply with the more stringent reporting requirements applicable to companies that are accelerated filers or large accelerated filers, including complying with the auditor attestation requirements of Section&#x00a0;404 of SOX.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">As a public company, we will be subject to more stringent federal law requirements.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As a public company, we will be subject to the reporting requirements of the Securities Exchange&#x00a0;Act&#x00a0;of&#x00a0;1934, as amended, or the Exchange&#x00a0;Act, the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, the Dodd<FONT CLASS="nobreak">-Frank</FONT> Wall Street Reform and Consumer Protection Act, the listing requirements of the NYSE American, and other applicable securities rules and regulations. Despite reforms made possible by the JOBS Act, compliance with these rules and regulations will nonetheless increase our legal and financial compliance costs, make some activities more difficult, time<FONT CLASS="nobreak">-consuming</FONT> or costly and increase demand on our systems and resources, particularly after we are no longer an emerging growth company. The Exchange&#x00a0;Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As a result of disclosure of information in this prospectus and in filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business, results of operations, financial condition and prospects could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our brand and reputation, business, results of operations, financial condition and prospects. We also expect that being a public company and the associated rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain adequate coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, investor relations and other expenses that we did not incur as a private company. In addition, the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act and rules subsequently implemented by the SEC and the NYSE American have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of U.S.&#x00a0;government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will make some activities more time<FONT CLASS="nobreak">-consuming</FONT> and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We may not be able to satisfy listing requirements of the NYSE American or obtain or maintain a listing of our common stock on the NYSE American.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to apply to list our common stock on the NYSE American. If our common stock is listed on the NYSE American, we must meet certain financial and liquidity criteria to maintain such listing. If we violate the NYSE American listing requirements, our common stock may be delisted. If we fail to meet any of the NYSE American&#x2019;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from the NYSE American may materially impair our stockholders&#x2019; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pursuant to Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act, the requirements of being a reporting company under the Exchange&#x00a0;Act and any complex accounting rules in the future, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. To date, we have had limited financial and accounting personnel to fully execute our accounting processes and address our internal control over financial reporting. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants. If we or, if required, our auditors, are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">There can be no assurance that there will not be material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines that we have a material weakness in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline and we could be subject to sanctions or investigations by the NYSE American, the SEC or other regulatory </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well<FONT CLASS="nobreak">-conceived</FONT> and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision<FONT CLASS="nobreak">-making</FONT> can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United&#x00a0;States.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Generally accepted accounting principles in the United&#x00a0;States are subject to interpretation by the Financial Accounting Standards Board, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock<FONT CLASS="nobreak">-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on shares of common stock outstanding as of December<FONT CLASS="nobreak"> </FONT>6, 2024, upon the closing of this offering we will have a total of 11,526,943<FONT CLASS="nobreak"> </FONT>shares of common stock outstanding (12,026,943<FONT CLASS="nobreak"> </FONT>shares if the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT> option in full). Of these shares, only the 3,333,334<FONT CLASS="nobreak"> </FONT>shares of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#x2019; option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering. The underwriters, however, may, in their sole discretion, permit our officers, directors and other stockholders who are subject to these lock<FONT CLASS="nobreak">-up</FONT> agreements to sell shares prior to the expiration of the lock<FONT CLASS="nobreak">-up</FONT> agreements.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We expect that the lock<FONT CLASS="nobreak">-up</FONT> agreements pertaining to this offering will expire eight (8)&#x00a0;months from the date of this prospectus in the case of our directors and executive officers, and six (6)&#x00a0;months from the date of this prospectus in the case of our other stockholders. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our Equity Incentive Plan will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock<FONT CLASS="nobreak">-up</FONT> agreements and Rule&#x00a0;144 and Rule&#x00a0;701 under the Securities Act&#x00a0;of&#x00a0;1933, as amended, or the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Use of Proceeds</FONT>,&#x201d; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-&#x00a0;and intermediate<FONT CLASS="nobreak">-term</FONT>, interest<FONT CLASS="nobreak">-bearing</FONT> instruments, certificates of deposit or direct or guaranteed obligations of the U.S.&#x00a0;government. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Certain provisions in our governing documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Certain provisions in our bylaws (&#x201c;Bylaws&#x201d;) may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>allow the authorized number of our directors to be changed only by resolution of our board of directors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>limit the manner in which stockholders can remove directors from the board;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>prohibit our stockholders from calling a special meeting of our stockholders.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#x00a0;203 of the Delaware General Corporation Law, or DGCL, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three&#x00a0;years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">If applicable, add a risk regarding exclusive forum selection in the charter.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">third-party</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> claims against us and may reduce the amount of money available to us.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Our Charter and Bylaws that will be in effect upon the closing of this offering will provide that we will indemnify our directors and officers, in each case, to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any breach of the director&#x2019;s duty of loyalty to the corporation or its stockholders;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>unlawful payments of dividends or unlawful stock repurchases or redemptions; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any transaction from which the director derived an improper personal benefit.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Our Bylaws that will be in effect upon the closing of this offering will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our Bylaws will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">for indemnification for related expenses, including attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that these Charter and Bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">While we maintain directors&#x2019; and officers&#x2019; liability insurance, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third<FONT CLASS="nobreak">-party</FONT> claims and may adversely impact our cash position.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Our failure to maintain effective internal controls&#x00a0;over financial reporting could have an adverse impact on us</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish those controls, or any failure of those controls once established, could adversely impact our public disclosures regarding our business, financial condition or results of operations. In addition, management&#x2019;s assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting, disclosure of management&#x2019;s assessment of our internal controls over financial reporting or disclosure of our public accounting firm&#x2019;s attestation to or report on management&#x2019;s assessment of our internal controls over financial reporting may have an adverse impact on the price of our shares.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">In addition, discovery and disclosure of a material weakness in the future or our inability to cure the material weakness we previously discovered and disclosed, by definition, could have a material adverse impact on our financial statements. Such an occurrence could negatively affect our business and affect how our stock trades. This could, in turn, negatively affect our ability to access public equity or debt markets for capital.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline</FONT>.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T19"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">SPECIAL NOTE REGARDING </FONT><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">FORWARD-LOOKING</FONT><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;"> STATEMENTS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This prospectus contains forward<FONT CLASS="nobreak">-looking</FONT> statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, including our statements regarding the benefits and timing of the roll<FONT CLASS="nobreak">-out</FONT> of new technology, are forward<FONT CLASS="nobreak">-looking</FONT> statements. In some cases, you can identify forward<FONT CLASS="nobreak">-looking</FONT> statements because they contain words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will&#x201d; or &#x201c;would&#x201d; or the negative of these words or other similar terms or expressions. Forward<FONT CLASS="nobreak">-looking</FONT> statements in this prospectus include, but are not limited to, statements about:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our use of the net proceeds from this offering;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the timing of the initiation, progress and expected results of our preclinical studies, clinical trials and our research and development programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to advance our product candidate and successfully complete clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the commercialization of our product candidate, if approved;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for additional financing;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to compete effectively with existing competitors and new market entrants;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our manufacturing capabilities and the scalable nature of our manufacturing process;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>potential effects of extensive government regulation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the pricing, coverage and reimbursement of our products, if approved;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to hire and retain key personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to obtain additional financing in this or future offerings;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the volatility of the trading price of our common stock; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our expectation regarding the time during which we will be an emerging growth company under the JOBS Act.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">You should not rely on forward<FONT CLASS="nobreak">-looking</FONT> statements as predictions of future events. We have based the forward<FONT CLASS="nobreak">-looking</FONT> statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward<FONT CLASS="nobreak">-looking</FONT> statements is subject to risks, uncertainties and other factors described in the section entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Risk Factors</FONT>&#x201d; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward<FONT CLASS="nobreak">-looking</FONT> statements contained in this prospectus. The results, events and circumstances reflected in the forward<FONT CLASS="nobreak">-looking</FONT> statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward<FONT CLASS="nobreak">-looking</FONT> statements.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The forward<FONT CLASS="nobreak">-looking</FONT> statements made in this prospectus relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward<FONT CLASS="nobreak">-looking</FONT> statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward<FONT CLASS="nobreak">-looking</FONT> statements, and you should not place undue reliance on our forward<FONT CLASS="nobreak">-looking</FONT> statements. Our forward<FONT CLASS="nobreak">-looking</FONT> statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">TRADEMARKS, SERVICE MARKS AND TRADE NAMES</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We own or have rights to use a number of registered and common law trademarks, service marks and/or trade names in connection with our business in the United&#x00a0;States and/or in certain foreign jurisdictions.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">&#x00ae;</FONT>&#x00a0;and &#x2122;&#x00a0;symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#x2019; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T18"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">USE OF PROCEEDS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We estimate that we will receive net proceeds from this offering of approximately $8.8<FONT CLASS="nobreak"> </FONT>million (or approximately $10.2&#x00a0;million if the underwriters exercise their option to purchase additional shares in full), based on the assumed initial public offering price of $3.00 per share, which is the low end of the estimated price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The principal purposes of this offering are to fund our clinical trials, to increase our capitalization and financial flexibility, create a public market for our common stock, facilitate future access to the public equity markets by us, our employees and our stockholders and increase our visibility in the marketplace.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We currently intend to use the net proceeds we receive from this offering, together with our existing cash, to fund our Phase III clinical trial in knee OA, to initiate at least one non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship study in MS, manufacturing costs, and any remaining amounts to fund working capital and general corporate purposes.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This expected use of the net proceeds from this offering represents our intentions based on our current plans and business conditions, which could change in the future as our plans and business conditions evolve. Further, due to the uncertainties inherent in developing Apitox, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. We cannot specify with certainty all of the particular uses for the remaining net proceeds to us from this offering. We may also use a portion of the net proceeds for acquisitions or strategic investments in complementary businesses, products, services or technologies. However, we do not have agreements or commitments to enter into any such acquisitions or investments at this time. We will have broad discretion over how to use the net proceeds to us from this offering, and our investors will be relying on the judgment of our management regarding the application of the net proceeds of this offering. The amounts and timing of our expenditures will depend upon numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any clinical trials we may commence in the future, the timing of regulatory submissions, and the amount of cash obtained through any future collaborations.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We estimate that the net proceeds from this offering, together with our current cash, will be sufficient for us to fund our operating expenses and capital expenditure requirements through at least the next 12&#x00a0;months. The expected net proceeds from this offering, together with our cash will allow us to fund a Phase III trial in knee OA, initiate at least one non<FONT CLASS="nobreak">-registered</FONT> company sponsored trial in MS, fund our internal operations, and pay off our current debt liabilities as they come due. We believe the net proceeds from this offering will allow us to complete all of these activities within the next 24<FONT CLASS="nobreak"> </FONT>months. We anticipate that approximately $6.5<FONT CLASS="nobreak"> </FONT>million of the net proceeds will be used to fund the Phase III trial in knee OA, approximately $1.0<FONT CLASS="nobreak"> </FONT>million will be used to initiate at least one non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship study in MS, and approximately $1.0 will be used for manufacturing. In addition, approximately $0.1 and $0.2<FONT CLASS="nobreak"> </FONT>million will be used for repayment of current debt liabilities comprised of two promissory notes with our majority stockholder, Inscobee, which accrue interest at 5% and mature May<FONT CLASS="nobreak"> </FONT>19, 2025 and August<FONT CLASS="nobreak"> </FONT>19, 2025, respectively. All of the proceeds of such indebtedness is short<FONT CLASS="nobreak">-term</FONT> borrowings used for working capital. The remaining net proceeds will be used for working capital and general corporate expenses. In the event the net proceeds for this offering are less than of $10<FONT CLASS="nobreak"> </FONT>million, we will adjust our initiatives based on the amount of capital actually raised. In such instance, we intend to prioritize a Phase III trial in knee OA, costs needed to meet manufacturing and regulatory requirements for the product candidate, and funding our internal operations. In the event the net proceeds for this offering are less than of $10<FONT CLASS="nobreak"> </FONT>million, we may need to raise additional capital to complete the development of our product candidate. We expect to finance our cash needs through public or private equity or debt financings, government or other third<FONT CLASS="nobreak">-party</FONT> funding, collaborations, strategic alliances and licensing arrangements, or a combination of these sources. We have based these estimates on assumptions that may prove to be incorrect, and we could expend our available capital resources at a rate greater than we currently expect.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to invest the net proceeds to us from this offering that are not used as described above in short- and intermediate<FONT CLASS="nobreak">-term</FONT>, interest<FONT CLASS="nobreak">-bearing</FONT> obligations, investment<FONT CLASS="nobreak">-grade</FONT> instruments, certificates of deposit or direct or guaranteed obligations of the U.S.&#x00a0;government.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T99500"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">REVERSE STOCK SPLIT</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will effect the Reverse Stock Split immediately prior to and contingent upon the completion of this offering, pursuant to which each 2.6<FONT CLASS="nobreak"> </FONT>shares of common stock held of record by the holder thereof will be reclassified into one share of common stock. No fractional shares will be issued in connection with the Reverse Stock Split. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Unless otherwise indicated, and other than the consolidated financial statements and the related notes included elsewhere in this prospectus, the number of our shares of common stock presented in this prospectus is adjusted to reflect the Reverse Stock Split.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T17"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DIVIDEND POLICY</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the discretion of our board of directors and will depend on then<FONT CLASS="nobreak">-existing</FONT> conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, we may enter into agreements in the future that could contain restrictions on payments of cash dividends.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T16"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CAPITALIZATION</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">The following unaudited table sets forth our cash, total capitalization and indebtedness as of September<FONT CLASS="nobreak"> </FONT>30, 2024:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on an actual basis;</P>
		 <P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on a pro forma basis to give effect to the conversion of an aggregate of $660,000 principal amount of convertible notes, plus accrued and unpaid interest of approximately $93,384 into an aggregate of approximately 753,384<FONT CLASS="nobreak"> </FONT>shares of our common stock (on a pre<FONT CLASS="nobreak">-Reverse</FONT> Stock Split basis); and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>on a pro forma as adjusted basis to give effect to the pro forma adjustments, the Reverse Stock Split, and the sale by us of 3,333,334<FONT CLASS="nobreak"> </FONT>shares of our common stock in this offering at an assumed public offering price of $3.00 per share, which is the low end of the estimated offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and estimated offering expenses payable by us (assuming no exercise of the underwriter&#x2019;s over<FONT CLASS="nobreak">-allotment</FONT> option).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">You should read this information together with our consolidated financial statements and related notes, as well as the information set forth under the headings &#x201c;Use of Proceeds&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; appearing elsewhere in this prospectus.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="9" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> 30, 2024</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Actual</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Pro Forma</FONT><FONT CLASS="Bold-Superscript" STYLE="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Pro Forma <BR>As Adjusted</FONT><FONT CLASS="Bold-Superscript" STYLE="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,571</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,571</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,797,775</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Debt:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes payable &#x2013; related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes, net of discount &#x2013; related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">321,992</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total debt</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">571,992</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shareholders&#x2019; equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, par value $0.01; 100,000,000 shares authorized; 20,550,000, 21,303,384, and 11,526,943 issued and outstanding as of actual, pro forma and pro forma as adjusted<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">212,948</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">115,269</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,828,305</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,205,108</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,105,115</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,080,291</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,080,291</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,080,291</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total shareholders&#x2019; equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,046,486</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(631,110</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,140,094</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total capitalization</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(474,494</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(381,110</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,390,094</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P> <P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Actual and pro forma share information does not give effect to the consummation of the Reverse Stock Split to be effected immediately prior to and contingent upon the closing of this offering.</P>
		 <P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>On a pro forma basis to give effect to the conversion of an aggregate of $660,000 principal amount of convertible notes with an unamortized debt discount of $338,008, plus accrued and unpaid interest of approximately $93,384, into an aggregate of approximately 289,763 shares of our common stock.</P>
		 <P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Pro forma as adjusted share information gives effect to the consummation of the Reverse Stock Split.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">A $1.00 increase (decrease) in the assumed initial public offering price of $3.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma, as adjusted net tangible book value per share after this offering and dilution per share to investors purchasing common stock in this offering by $0.27 and ($0.27), respectively, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">The table above excludes:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>1,000,000<FONT CLASS="nobreak"> </FONT>shares of our common stock that are available for future issuance under our Equity Incentive Plan;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>213,692<FONT CLASS="nobreak"> </FONT>shares of common stock issuable upon exercise of outstanding non<FONT CLASS="nobreak">-plan</FONT> options; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>166,667<FONT CLASS="nobreak"> </FONT>shares of our common stock issuable upon exercise of the Representative&#x2019;s Warrants to purchase up to 166,667<FONT CLASS="nobreak"> </FONT>shares of our common stock at an exercise price per share equal to 100% of the initial public offering price per share or $3.00, based on an assumed initial public offering price of $3.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, that will be issued to the representative of the underwriters in connection with this offering.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T15"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DILUTION</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If you purchase shares of our common stock offered in this prospectus, your ownership interest will be diluted to the extent of the difference between the assumed initial public offering price in this offering of $3.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, and the adjusted net tangible book value per share of our common stock upon consummation of this offering. As of September<FONT CLASS="nobreak"> </FONT>30, 2024, we had a historical net tangible book value (deficit) of $(1,046,486) or $(0.13) per share of common stock. Our historical net tangible book value per share represents the book value of our total tangible assets less the book value of our total liabilities divided by the number of shares of common stock then issued and outstanding.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our pro forma net tangible book value, as of September<FONT CLASS="nobreak"> </FONT>30, 2024, was $(639,705), or $(0.08) per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the conversion of the convertible notes into 289,763<FONT CLASS="nobreak"> </FONT>shares of common stock. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding, as of September<FONT CLASS="nobreak"> </FONT>30, 2024, after giving effect to the pro forma adjustments described above.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After giving further effect to our sale of 3,333,334&#x00a0;shares of common stock in this offering, at an assumed initial public offering price of $3.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma, as adjusted net tangible book value as of September<FONT CLASS="nobreak"> </FONT>30, 2024, would have been $7,890,092 or $0.68 per share (assuming no exercise of the underwriters&#x2019; option to purchase additional shares of our common stock). This represents an immediate and substantial dilution of $(2.29) per share to new investors purchasing common stock in this offering. The following table illustrates this dilution per share:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assumed initial public offering price per share</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Historical net tangible book value (deficit) per share as of September 30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.13</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increase in as adjusted net tangible book value per share attributable to&#x00a0;new investors participating in this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.06</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma net tangible book value per share as of September 30, 2024</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.08</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Increase in pro forma, as adjusted net tangible book value per share attributable to investors purchasing shares of common stock in this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.78</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma, as adjusted net tangible book value per share after giving effect to this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.71</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dilution in as adjusted net tangible book value (deficit) per share in this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(2.29</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The dilution information discussed above is illustrative only and may change based on the actual initial public offering price and other terms of this offering.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">A $1.00 increase (decrease) in the assumed initial public offering price of $3.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma, as adjusted net tangible book value per share after this offering and dilution per share to investors purchasing common stock in this offering by $0.27 and ($0.27), respectively, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If the underwriters exercise their over<FONT CLASS="nobreak">-allotment</FONT>&#x00a0;option in full to purchase additional shares of common stock, the pro forma, as adjusted net tangible book value per share after the offering would be $0.92 per share, assuming an initial public offering price of $3.00 per share, which is the low end of the price range on the cover page of this prospectus.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes, on an pro forma as adjusted basis as of September<FONT CLASS="nobreak"> </FONT>30, 2024, the total number of shares of common stock owned by existing stockholders and to be owned by new investors, the total consideration paid, and the average price per share paid by our existing stockholders and to be paid by new investors in this offering at low end of the estimated price range set forth on the cover page of this prospectus of $3.00 per share, calculated before deduction of estimated underwriting discounts and commissions:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-19" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 27.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Shares Purchased</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total Consideration</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Average <BR>Price Per <BR>Share</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 27.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Number</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Percent</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Percent</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 27.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Existing stockholders</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,193,609</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,808,384</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.34</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 27.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">New investors participating in this offering</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,333,334</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,000,002</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.00</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-12" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 27.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,526,943</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,808,386</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.11</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If the underwriters exercise their option to purchase additional shares in full, the number of shares of common stock held by existing stockholders will be reduced to 68% of the total number of shares of common stock to be outstanding after this offering, and the number of shares of common stock held by investors participating in this offering will be further increased to 32% of the total number of shares of common stock to be outstanding after this offering.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T14"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL <BR></FONT><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CONDITION AND RESULTS OF OP</FONT><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ERATIONS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and related notes and other financial information included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> statements as a result of various factors, including those set forth under the section entitled &#x201c;Risk Factors&#x201d; and elsewhere in this prospectus. You should carefully read the &#x201c;Risk Factors&#x201d; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> statements. Please also see the section entitled &#x201c;Special Note&#x00a0;Regarding </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Forward</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Looking</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Statements.&#x201d;</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that is in the process of developing Apitox, a proprietary intradermally administered bee venom<FONT CLASS="nobreak">-based</FONT> toxin. Our primary focus is to advance Apitox in the treatment of inflammatory conditions in the United&#x00a0;States, specifically osteoarthritis (&#x201c;OA&#x201d;) and, eventually, multiple sclerosis (&#x201c;MS&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apitox, is currently marketed and sold by Apimeds, Inc. in South Korea (&#x201c;Apimeds Korea&#x201d;) as &#x201c;Apitoxin&#x201d; for the treatment of inflammation and pain management symptoms associated with OA.&#x00a0;There is an extensive history of use of bee venom, both in the United&#x00a0;States and around the world, to assist with pain management. We believe that, in addition to knee OA and MS, Apitox has the potential to help manage difficult to control pain and inflammation issues, which we will explore in the future.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Product Candidate</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our product candidate Apitox is a purified, pharmaceutical grade venom of the <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Apis mellifera</FONT>, or honeybee, which is classified by the U.S Food and Drug Administration (&#x201c;FDA&#x201d;) as an active pharmaceutical ingredient (&#x201c;API&#x201d;). Apimeds Inc. (&#x201c;Apimeds Korea&#x201d;) has developed a proprietary method and process of turning extracted bee venom into a lyophilized powder for reconstitution prior to intradermal dose injections, which they sell in Korea as South Apitoxin. Apimeds Korea has exclusively licensed to us all rights to develop, commercialize, market and sell Apitoxin as &#x201c;Apitox&#x201d; in the United&#x00a0;States in exchange for a sales royalty. See &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions&#x00a0;&#x2014;&#x00a0;Apimeds Korea Licensing Agreement</FONT>.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Recent Developments</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On November&#x00a0;9, 2023, we entered into a business development agreement (the &#x201c;Consulting Agreement&#x201d;) with Murdock Capital Partners Corp., a New&#x00a0;York corporation (the &#x201c;Advisor&#x201d;), pursuant to which the Advisor agreed to render services to the Company on as its corporate consultant and advisor. During the term of the Consulting Agreement, the Advisor shall provide advice concerning all aspects of corporate business development, such as corporate partnerships, commercial arrangements, vendor selection, management and advisor recruiting, product positioning strategy and similar functions.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Advisor is not obligated to devote any specific amount of time to providing advice and consultation to the Company. The term of the Consulting Agreement shall be from the execution of the Consulting Agreement until January&#x00a0;1, 2024 (the &#x201c;Term&#x201d;). Upon the mutual consent of both parties, the Consulting Agreement may be extended for an additional two&#x00a0;months but shall terminate no later than March&#x00a0;1, 2024. The Company shall pay the Advisor a $7,500<FONT CLASS="nobreak"> </FONT>monthly fee. The Company shall also reimburse the Advisor for out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> expenses incurred in connection with its services. To date $30,000 has been paid by the Company to the Advisor under the Consulting Agreement.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pursuant to the Consulting Agreement, we will issue to Advisor or its designees at the closing of the next equity offering in excess of $5,000,000 (the &#x201c;Next Round&#x201d;), a warrant to purchase that number of shares of common stock equal to 6% of the aggregate number of common shares sold in the Next Round. The warrants will be exercisable at any time and from time to time, in whole or in part, during the five year period from the closing date of the Next Round at a price per share equal to 100.0% of the lowest price at which common stock is sold to new investors in the Next Round. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The warrant will provide for registration rights (including a one<FONT CLASS="nobreak">-time</FONT> demand registration right and unlimited piggyback rights) and customary anti<FONT CLASS="nobreak">-dilution</FONT> provisions (for stock dividends and splits and recapitalizations). If requested by the Company, the Advisor agrees to enter into a lock<FONT CLASS="nobreak">-up</FONT> agreement at issuance for a period of 180&#x00a0;days.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In the event the Next Round is consummated within the 12&#x00a0;months of the effective date of the Consulting Agreement, we have agreed to retain the Advisor for a period of three&#x00a0;years for investor relations services. We will pay the Advisor a sum of $10,000 per month for such investor relations services.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This offering will qualify as the Next Round, and we will issue the warrants to the Advisor upon the closing of this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Results of Operations</FONT></P>
		 <P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Nine </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Months Ended </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">September</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> 30, 2024 Compared to </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Nine</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Months Ended </FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">September</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> 30, 2023</FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Results of operations for the </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">nine</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> months ended </FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> 30, 2024 and 2023</FONT></P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">) </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">118,372</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">881,110</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(188,365</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(811,117</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other (expenses) income:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,794</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,228</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">566</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(81,669</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(24,591</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(57,078</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,078,357</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(210,728</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(867,629</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">) </P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Revenues</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">For the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024 and September<FONT CLASS="nobreak"> </FONT>30, 2023, the Company had no revenue.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes the changes in research and development expenses for the periods presented:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll expenses and related taxes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Research and development expenses were $0 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, compared to $69,993 for the same period in 2023, representing a decrease of $69,993. The decrease in research and development expenses was primarily attributed to a decrease in payroll expenses. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">General and administrative expenses</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes the period<FONT CLASS="nobreak">-over-period</FONT> changes in general and administrative expenses for the period presented:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll expenses and related taxes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">297,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">297,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Professional services</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">669,923</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">66,156</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">603,767</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Office expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,144</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,645</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,499</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,415</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49,949</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(21,156</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total general and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">118,372</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">881,110</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">General and administrative expenses were $999,482 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, compared to $118,372 for the same period in 2023, representing an increase of $881,110. The increase was mostly attributable to an increase in professional services by approximately $603,767 and an increase in salaries and wages for several officers of the Company by $297,000. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Other (expense) income</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Other expense was $78,875 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, compared to $22,363 for the same period in 2023, representing an increase of $56,512. The increase was mostly attributable to accretion expenses incurred during 2024 of $55,101, as compared to $0 in the prior period, due to the fact that accretion on the notes did not commence until the end of 2023.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Net Loss</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Net loss was $1,078,357 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, compared to $210,728 in the same period of 2023, representing an increase of $867,629. The increase was mainly due to the increase of general and administrative expenses, specifically payroll expenses and professional fees associated with the S<FONT CLASS="nobreak">-1</FONT> filing and pre<FONT CLASS="nobreak">-IPO</FONT> expenses.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Year Ended December&#x00a0;31, 2023 Compared to Year Ended December&#x00a0;31, 2022</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Results of operations for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022</FONT></P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December&#x00a0;31, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December&#x00a0;31, <BR>2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">98,544</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">368,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(269,456</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">648,892</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">271,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">377,363</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(747,436</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(639,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(107,907</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,811</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,811</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(38,069</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(29,137</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,863</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">) </P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(777,694</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(668,666</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(103,959</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Revenues</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">For the years ended December&#x00a0;31, 2023 and December&#x00a0;31, 2022, the Company had no revenue.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Research and Development Expenses</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:6pt;">The following table summarizes the year<FONT CLASS="nobreak">-over</FONT><FONT CLASS="nobreak">-year</FONT> changes in research and development expenses for the periods presented:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December&#x00a0;31, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December&#x00a0;31, <BR>2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll expenses and related taxes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">86,993 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">343,438</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(256,445</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Clinical and lab expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,057</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,057</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other general</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,551</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15,505</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,954</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">98,544</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">368,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(269,456</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Research and development expenses were $98,544 for the year ended December&#x00a0;31, 2023, compared to $368,000 for the same period in 2022, representing a decrease of $269,456. The decrease in research and development expenses was primarily attributed to a decrease in payroll expenses. Certain employees of the Company were terminated during 2022, therefore leading to a decrease in payroll expenses of $256,445 for the year ended December&#x00a0;31, 2023. Additionally, consulting fees, which are included as part of the &#x201c;other general&#x201d; categorization above decreased significantly in 2022.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">General and administrative expenses</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes the year<FONT CLASS="nobreak">-over</FONT><FONT CLASS="nobreak">-year</FONT> changes in general and administrative expenses for the&#x00a0;years presented:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December&#x00a0;31, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year ended <BR>December&#x00a0;31, <BR>2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Payroll expenses and related taxes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">223,406</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(109,406</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Professional services</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">485,949 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,253</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">453,696 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Office expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33,539</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,754</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,785</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General administrative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15,404</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,116</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,288</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total general and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">648,892</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">271,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">377,363</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">General and administrative expenses were $648,892 for the year ended December&#x00a0;31, 2023, compared to $271,529 for the same period in 2022, representing an increase of $377,363. The increase was mostly attributable to an increase in professional expenses. This increase in professional expenses was slightly offset by a decrease in payroll expenses as a result of the termination of employees during 2022, which reduced payroll and related taxes by approximately $110,000. </P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Net Loss</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Net loss was $777,694 for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2023, compared to $668,666 in the same period of 2022, representing an increase of $109,028. The increase was mainly due to the increase of general and administrative expenses, specifically professional fees associated with the S<FONT CLASS="nobreak">-1</FONT> filing and pre<FONT CLASS="nobreak">-IPO</FONT> expenses.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Sources of Liquidity</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are a development stage company as we have not generated any product revenues to date and do not expect to have significant revenues until we are able to sell a product candidate after obtaining applicable regulatory approvals or we establish collaborations that provide funding, such as licensing fees, milestone payments, royalties, research funding or otherwise. To date, operations have been funded through capital contribution from shareholders, convertible note and promissory notes, and the subsequent conversion of those convertible and promissory notes. </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our objectives, when managing capital, are to ensure there are sufficient funds available to carry out our research, development and eventual commercialization programs. We do not hold any asset<FONT CLASS="nobreak">-backed</FONT> commercial paper and our cash is not subject to any external restrictions. We manage liquidity risk by frequently monitoring actual and projected cash flows. The majority of our accounts payable and accrued liabilities have maturities of less than six&#x00a0;months. We are dependent on our ability to generate revenues from our future products or secure additional financing to continue our research and development activities and meet our ongoing obligations.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company&#x2019;s management acknowledges that the current cash position does not reflect the necessary runway for a period longer than 12&#x00a0;months from financial statement issuance, that would allow the Company to continue operations without securing additional financing. As such, we believe that these conditions raise substantial doubt as to the Company&#x2019;s ability to continue as a going concern within 12&#x00a0;months of the date the Financial Statements are issued. Additional funding will be necessary to fund our research and development efforts to advance product candidates. We will seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. There is no assurance of success in obtaining such additional financing on terms acceptable to us, if at all, and there is no assurance that we will be able to enter into collaborations or other arrangements. If we are unable to obtain funding, it could force us to delay, reduce or eliminate research and development programs and product portfolio expansion. These potential delays, reductions and eliminations could adversely affect future business prospects, and the ability to continue operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Funding Requirements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidate. In addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. The timing and amount of our operating expenditures will depend largely on our ability to:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>advance development of our Apitox clinical programs;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>acquire additional product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late clinical stage manufacturing;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>seek regulatory approvals for any product candidates that successfully complete clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>hire additional clinical, quality control and scientific personnel;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development and manufacturing efforts and our operations as a public company; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtain, maintain, expand and protect our intellectual property portfolio.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">As of September<FONT CLASS="nobreak"> </FONT>30, 2024, we had cash of $26,571. We believe that the anticipated net proceeds from this offering, together with our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for the next 12&#x00a0;months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we advance our programs, seek regulatory approval of our product candidate, and pursue in<FONT CLASS="nobreak">-licenses</FONT> or acquisitions of other product candidate.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Because of the numerous risks and uncertainties associated with research and development of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs, timing and outcome of regulatory review of our product candidates;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs, timing and ability to manufacture our product candidates to supply our preclinical development efforts and our clinical trials;</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs of manufacturing commercial<FONT CLASS="nobreak">-grade</FONT> product and necessary inventory to support commercial launch, should any of our product candidates receive marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the ability to receive additional non<FONT CLASS="nobreak">-dilutive</FONT> funding, including grants from organizations and foundations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property<FONT CLASS="nobreak">-related</FONT> claims;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>our ability to establish and maintain collaborations on favorable terms, if at all; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the extent to which we acquire or in<FONT CLASS="nobreak">-license</FONT> other product candidates and technologies.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research and product development efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2022 Convertible Notes (amended from notes payable)&#x00a0;&#x2014;&#x00a0;related parties</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">On March&#x00a0;21, 2022, the Company entered into a promissory note agreement in the amount of $160,000 with Inscobee, one of its shareholders. On June&#x00a0;3, 2022, the Company received an additional $100,000 from Inscobee, as part of another promissory note agreement (together as &#x201c;2022 Convertible Notes&#x201d;). The 2022 Convertible Notes bear interest at 5% per annum and mature on the earlier of (a)&#x00a0;the closing of an equity financing with proceeds to the Company of at least $3&#x00a0;million, or (b)&#x00a0;July&#x00a0;15, 2022.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">On December&#x00a0;5, 2023, the Company amended their promissory notes to be convertible and extended the maturity date of the convertible notes with the related parties to be the earlier of (i)&#x00a0;December&#x00a0;31, 2026 or (ii)&#x00a0;consummation of a Qualified Offering (defined below). The Notes Payable are convertible at a price of $2.60 per share (the &#x201c;Conversion Price&#x201d;). As amended, the 2022 Convertible Notes will automatically convert at the Conversion Price simultaneously with the consummation of a Qualified Offering, where a &#x201c;Qualified Offering&#x201d; is an offering of common stock resulting in the listing for trading of the common stock on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing). </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">The purchase of convertible notes and cancellation of the old promissory notes was accounted for as a debt extinguishment that did not result in a gain/loss on extinguishment due to related party treatment. The conversion option was valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> model, with the following inputs: volatility of 92.22%, estimated fair value of Company&#x2019;s stock of $1.96, expected dividend yield of 0% and a risk<FONT CLASS="nobreak">-free</FONT> rate of return of 4.33%. The resulting value of the convertible option of $158,099 based on the allocation of fair value to cash proceeds, was applied towards additional paid<FONT CLASS="nobreak">-in</FONT> capital and added as a discount on the convertible note. The note will be accreted over the remaining period through maturity at the calculated effective interest rate of approximately 41.4%.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of September<FONT CLASS="nobreak"> </FONT>30, 2024 and December<FONT CLASS="nobreak"> </FONT>31, 2023, there was accrued interest in connection with the 2022 Convertible Notes of $31,575 and $22,137, respectively, and are included within accounts payable and accrued expenses on the accompanying unaudited condensed balance sheets. Interest expenses were $9,438 and $9,688 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024 and 2023, respectively. Accretion on the notes debt discount was $21,742 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, which is included within interest expense on the unaudited condensed statements of operations. There was no accretion on the note&#x2019;s debt discount for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2023.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">At September<FONT CLASS="nobreak"> </FONT>30, 2024 and December<FONT CLASS="nobreak"> </FONT>31, 2023, the outstanding balance on the 2022 Convertible notes agreement, net of the unamortized debt discounts of $134,361 and $156,102, was $125,639 and $103,898, respectively.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2021 </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Convertible note&#x00a0;&#x2014;&#x00a0;related party</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On August<FONT CLASS="nobreak"> </FONT>30, 2021, the Company received $400,000 in a convertible note agreement (&#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2021 Convertible Note</FONT>&#x201d;) with Apimeds Korea, one of its shareholders. The <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2021 Convertible Note</FONT> bears interest at 5% per annum and matures on the earlier of (a) the sale of the Company or (b) August<FONT CLASS="nobreak"> </FONT>30, 2026. The <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2021 Convertible Note </FONT>was convertible at any time up through the maturity date. The number of shares of common stock shall be determined by dividing (x) the outstanding principal balance hereof plus accrued but unpaid interest by the first closing price on the first day of trading following a Qualified Direct Listing.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December<FONT CLASS="nobreak"> </FONT>5, 2023, the Company amended their convertible note to be convertible at $2.60 per share (the &#x201c;Conversion Price&#x201d;) and extended the maturity date to be the earlier of (i) December<FONT CLASS="nobreak"> </FONT>31, 2026 or (ii) consummation of a Qualified Offering. As amended, the 2021 Convertible Note will automatically convert at the Conversion Price simultaneously with the consummation of a Qualified Offering.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The repurchase and cancellation of the old note was accounted for as a debt extinguishment that did not result in any gain/loss on extinguishment due to related party treatment. The conversion option was valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> model, with the following inputs: volatility of 92.22%, estimated fair value of Company&#x2019;s stock of $1.96, expected dividend yield of 0%, and a risk<FONT CLASS="nobreak">-free</FONT> rate of return of 4.33%. The resulting value of the convertible option of $240,079, based on the allocation of fair value to cash proceeds, was applied towards additional paid<FONT CLASS="nobreak">-in</FONT> capital and added as a discount on the convertible note. The note will be accreted over the remaining period through maturity at the calculated effective interest rate of approximately 40.6%.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of September<FONT CLASS="nobreak"> </FONT>30, 2024 and December<FONT CLASS="nobreak"> </FONT>31, 2023, there was accrued interest in connection with the 2021 Convertible Note of $61,261 and $46,740, respectively, and is included within accounts payable and accrued expenses on the accompanying unaudited condensed balance sheets. Interest expenses were $14,521 and $15,000 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024 and 2023. Accretion on the 2021 Convertible Note debt discount was $33,359 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, respectively, which is included within interest expense on the unaudited condensed statement of operations. There was no accretion on the 2021 Convertible Note debt discount for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2023.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">At September<FONT CLASS="nobreak"> </FONT>30, 2024, and December<FONT CLASS="nobreak"> </FONT>31, 2023, the outstanding balance on the 2021 Convertible Note, net of the unamortized debt discounts of $203,647 and $237,007, was $196,353 and $162,993, respectively. </P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">2024 Promissory Notes &#x2014; Related Parties</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On May<FONT CLASS="nobreak"> </FONT>20, 2024, the Company received $100,000 in a promissory note agreement with Inscobee Inc., one of its shareholders. On August<FONT CLASS="nobreak"> </FONT>19, 2024, the Company received an additional $150,000 from Inscobee, as part of another promissory note agreement (together as &#x201c;2024 Promissory Notes&#x201d;). The 2024 Promissory Notes bear interest at 5% per annum and mature on the earlier of (a) the closing of an equity financing by the Company with gross proceeds of at least $3,000,000; or (b) May<FONT CLASS="nobreak"> </FONT>19, 2025.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of September<FONT CLASS="nobreak"> </FONT>30, 2024, there was accrued interest in connection to the 2024 Promissory Notes of $2,610. Interest expense was $2,610 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024 and is included within accounts payable and accrued expenses on the accompanying unaudited condensed balance sheet. </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		 <P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Cash Flow for the Nine Months Ended September 30, 2024 as Compared to the Nine Months ended September 30, 2023 </P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes our sources and uses of cash for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, and 2023 as presented within the condensed interim financial statements:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-20" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Nine</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> months <BR>ended <BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">September</FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"> 30, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(633,910</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(287,217</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(346,693</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,032,100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(782,100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net (decrease) increase in cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(383,910</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">744,883</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1,128,793</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Operating Activities</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash used in operating activities was $633,910 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, which consisted of a net loss of $1,078,357 offset by non<FONT CLASS="nobreak">-cash</FONT> interest expense &#x2014; related parties of $26,568, accretion expense of $55,101, and a net change of $362,778 in our net operating assets and liabilities.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash used in operating activities was $287,217 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2023, which consisted of a net loss of $210,728 offset by stock<FONT CLASS="nobreak">-based</FONT> compensation expense of $69,994 non<FONT CLASS="nobreak">-cash</FONT> interest expense &#x2014; related parties of $16,500, and a net change of $162,983 in our net operating assets and liabilities.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Financing Activities</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash provided by financing activities was $250,000 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2024, which was attributable to proceeds received through notes payable &#x2014; related party of the entire $250,000 amount.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash provided by financing activities was $1,032,100 for the nine months ended September<FONT CLASS="nobreak"> </FONT>30, 2023, which consisted of $500,000 in cash advances for obligation to issue common shares, $500,000 in proceeds due to issuance of common stock, and $64,000 from cash advances from a related party, offset by $31,900 in cash advances paid to related parties.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Cash Flow for the Year Ended December 31, 2023 as Compared to the Year ended December 31, 2022 </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes our sources and uses of cash for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2023, and 2022 as presented within the condensed interim financial statements:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year&#x00a0;ended <BR>December&#x00a0;31, <BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Year&#x00a0;ended <BR>December&#x00a0;31, <BR> 2022</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Change</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(627,790</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(448,167</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(179,623</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_bracket" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,032,100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">282,900</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">749,200 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase (decrease) in cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">404,310</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(165,267</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">569,577 </P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Operating Activities</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash used in operating activities was $627,790 for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2023, which consisted of a net loss of $772,625 offset by stock<FONT CLASS="nobreak">-based</FONT> compensation expense of $69,993, non<FONT CLASS="nobreak">-cash</FONT> interest expense &#x2014; related parties of $33,000, accretion expense of $5,069, and a net change of $41,842 in our net operating assets and liabilities.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash used in operating activities was $448,167 for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2022, which consisted of a net loss of $668,666 offset by stock<FONT CLASS="nobreak">-based</FONT> compensation expense of $193,543, non<FONT CLASS="nobreak">-cash</FONT> interest expense&#x00a0;&#x2014; related parties of $29,137 and a net change of $(2,181) in our net operating assets and liabilities.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Financing Activities</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash provided by financing activities was $1,032,100 for the year ended December<FONT CLASS="nobreak"> </FONT>31, 2023, which consisted of $1,055,000 of cash proceeds from the issuance of common stock, $9,000 from cash advances from related parties offset by $31,900 from cash advances paid to related party.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Cash provided by financing activities was $282,900 for the year ended December&#x00a0;31, 2022, which consisted of $260,000 from the proceeds received through the notes payable&#x00a0;&#x2014;&#x00a0;related party and $22,900 from cash advances from a related party.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Contractual Obligations and Commitments</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We enter into contracts in the normal course of business with clinical research organizations, CMOs, and other third parties for clinical trials, preclinical research studies, and testing and manufacturing services. These contracts are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. The amount and timing of such payments are not known.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Critical Accounting Policies and Estimates</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Use of Estimates</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our material accounting policies, which we believe are the most critical to investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. As we begin to generate increased revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Revenue Recognition</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">ASC&#x00a0;606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, Revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC&#x00a0;606 is carried out in five steps: Step 1 &#x2014;&#x00a0;Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 &#x2014;&#x00a0;Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 &#x2014;&#x00a0;Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step&#x00a0;4&#x00a0;&#x2014;&#x00a0;Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 &#x2014;&#x00a0;Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity&#x2019;s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity&#x2019;s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Recent Authoritative Guidance</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In December&#x00a0;2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&#x00a0;2019<FONT CLASS="nobreak">-12</FONT> Income Taxes (Topic&#x00a0;740)&#x00a0;&#x2014;&#x00a0;Simplifying the Accounting for Income Taxes, to remove certain exceptions and improve consistency of application including, among other things, requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The amendments in this update are effective for fiscal&#x00a0;years beginning after December&#x00a0;15, 2020. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In October&#x00a0;2020, the FASB issued ASU No.&#x00a0;2020<FONT CLASS="nobreak">-10</FONT> Codification Improvements, to make incremental improvements to generally accepted accounting principles (GAAP) and address stakeholder suggestions, including, among other things, clarifying that the requirement to provide comparative information in the financial statements extends to the corresponding disclosures section. The amendments in this update are effective for fiscal&#x00a0;years beginning after December&#x00a0;15, 2020. The amendments in this update should be applied retrospectively and at the beginning of the period that includes the adoption date. The Company adopted the amendments in this update during 2021. The adoption of the amendments in this update did not have a material impact on its consolidated financial position and results of operations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Off-Balance</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Sheet Arrangements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have no off<FONT CLASS="nobreak">-balance</FONT> sheet arrangements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Emerging Growth Company and Smaller Reporting Company Status</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act. For as long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#x00a0;404 of the Sarbanes<FONT CLASS="nobreak">-Oxley</FONT> Act&#x00a0;of&#x00a0;2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. In particular, in this prospectus, we have provided only two&#x00a0;years of audited financial statements and have not included all of the executive compensation<FONT CLASS="nobreak">-related</FONT> information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to utilize this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&#x00a0;are no longer an emerging growth company or (ii)&#x00a0;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will remain an emerging growth company until the earliest of (i)&#x00a0;December&#x00a0;31, 2026, (ii)&#x00a0;the last&#x00a0;day of the fiscal year in which we have total annual gross revenue of at least $1.235&#x00a0;billion, (iii)&#x00a0;the last&#x00a0;day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule&#x00a0;12b<FONT CLASS="nobreak">-2</FONT> under the Exchange&#x00a0;Act, which would occur if the market value of our common stock held by non<FONT CLASS="nobreak">-affiliates</FONT> exceeded $700&#x00a0;million as of the last business&#x00a0;day of the second fiscal quarter of such year or (iv)&#x00a0;the date on which we have issued more than $1.0&#x00a0;billion in non<FONT CLASS="nobreak">-convertible</FONT> debt securities during the prior three<FONT CLASS="nobreak">-year</FONT> period.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are also a &#x201c;smaller reporting company&#x201d; meaning that the market value of our stock held by non<FONT CLASS="nobreak">-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&#x00a0;million and our annual revenue was less than $100&#x00a0;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&#x00a0;the market value of our stock held by non<FONT CLASS="nobreak">-affiliates</FONT> is less than $250&#x00a0;million or (ii)&#x00a0;our annual revenue was less than $100&#x00a0;million during the most recently completed fiscal year and the market value of our stock held by non<FONT CLASS="nobreak">-affiliates</FONT> is less than $700&#x00a0;million.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T13"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">BUSINESS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom<FONT CLASS="nobreak">-based</FONT> toxin. Our focus is primarily on developing innovative therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. (&#x201c;Apimeds Korea&#x201d;) in South Korea as &#x201c;Apitoxin&#x201d; for the treatment of OA. Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not yet been approved by the FDA for any indication.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apitox is a purified, pharmaceutical grade venom (bee venom), of the <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Apis mellifera, </FONT>or western honeybee, which is classified by the FDA as an active pharmaceutical ingredient (&#x201c;API&#x201d;). Bee venom has been used in Asia and Europe to treat pain for hundreds of&#x00a0;years. While not FDA approved in a controlled, prescription based biologic environment for defined indications, the use of bee venom has been FDA approved as a &#x201c;under the skin injection&#x201d; to reduce the allergic reactions to bee stings. Apimeds Korea has developed a proprietary method and process for turning extracted bee venom into a lyophilized powder for reconstitution prior to intradermal dose injections, which they sell in South Korea as Apitoxin. We intend to use a similar process with respect to Apitox, pursuant to the Business Agreement, which gives us a license to utilize all prior clinical development data associated with Apitoxin. The advancement of extracted bee venom for treatment of inflammatory conditions, including but not limited to knee OA and MS is speculative but based on direction provided by prior clinical data.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea successfully completed Phase I, Phase II, and Phase III trials in OA in 2003, at which point Apitoxin was approved by the Korean Ministry of Food and Drug Safety (&#x201c;MFDA&#x201d;) to treat pain and mobility in patients with OA. Since 2003, a post<FONT CLASS="nobreak">-marketing</FONT>/approval safety study in South Korea followed 3,194 patients from 2003 through 2009, with no serious adverse events.&#x00a0;The purpose of a Phase&#x00a0;I trial is to test to determine whether a new treatment is safe and look for the best way to give the treatment. Phase&#x00a0;II trials test to determine whether a condition or disease responds to the new treatment. Phase&#x00a0;III trials test to determine whether a new treatment is better than a standard treatment. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In 2013, the first of two required U.S. Phase III clinical trials was authorized to enroll patients to study the use of Apitoxin to study the same indication as approved in South Korea in 2023&#x00a0;&#x2014;&#x00a0;treatment of pain and lack of mobility in patients with OA (the &#x201c;Apimeds Korea Phase III OA Trial&#x201d;). The Apimeds Korea Phase III OA Trial (330 patients) was completed in 2018, and displayed no serious adverse events.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Based on the results from the Apimeds Korea Phase III OA Trial, which demonstrated therapeutic (statistical and clinically significant improvements in all outcome measures of pain, physical function, and disease assessment) effect compared to the placebo group, but in combination with prior development by Apimeds Korea, did not meet the FDA&#x2019;s standards for approval, as the study population was too small and the methods for handling missing data were inadequate, resulting in a study that did not demonstrate a significant treatment effect. We will be pursuing a second Phase III trial to meet agreed upon FDA standards. Based on results from the Apimeds Korea Phase III OA Trial, we have evaluated the most appropriate population, defined as advanced knee OA patients, which will range from defined grade<FONT CLASS="nobreak"> </FONT>2, 3 and 4 within this treatment group, to continue to progress our own Phase III trial. Pursuant to our previous correspondence with the FDA, we have designed and will implement our Phase III trial to best address our patient population, appropriate dosing, and the most effective way to evaluate Apitox in meeting the patient population&#x2019;s needs.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe the progress we are making in clinical trials provides us support in our belief in the potential of Apitox to be an innovative therapy. We aim to treat the inflammation and pain management symptoms associated with knee OA and to help manage the devastating symptoms of this disease. In the future, we also aim to leverage our research in knee OA to investigate how Apitox may be used to treat similar symptoms associated with MS.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Treatment of OA</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">OA is typically treated with painkillers known as&#x00a0;non<FONT CLASS="nobreak">-steroidal</FONT> anti<FONT CLASS="nobreak">-inflammatory</FONT> drugs (NSAIDs). These medications have an anti<FONT CLASS="nobreak">-inflammatory</FONT> and pain<FONT CLASS="nobreak">-relieving</FONT> effect. These medications include ibuprofen (Motrin, Advil) naproxen (Aleve) and diclofenac (Voltaren and others). All of these medications work by blocking enzymes </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">that cause pain and swelling. The problem is that some of those enzymes also help blood to clot and protect the lining of your stomach. Without them, you can bruise easily, develop ulcers and may even bleed in your intestines. NSAIDs also increase your chance of heart attack, stroke and heart failure. The risk increases the longer you use them and the more you take. We believe Apitox could be a successful alternative to NSAIDs in the treatment of the inflammation and pain management symptoms associated with OA without the harmful side effects.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">According to MedicalNewsToday, OA is the most common form of arthritis, affecting around 500&#x00a0;million people worldwide, or around 7% of the global population. Currently, in the United&#x00a0;States,&#x00a0;over 32&#x00a0;million&#x00a0;people suffer from OA.&#x00a0;As the 15<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">th</FONT> highest cause of&#x00a0;years lived with disability (YLDs) worldwide, the burden OA poses to individuals is substantial, characterized by pain, activity limitations, and reduced&#x00a0;quality of life. The economic impact of OA, which includes direct and indirect (time) costs, is also substantial, ranging from 1 to 2.5% of gross national product (GNP) in countries with established market economies, like the United&#x00a0;States. Though trends in OA prevalence vary by geography, the prevalence of OA is projected to rise in regions with established market economies such as North America and Europe, where populations are aging and the prevalence of obesity is rising.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">While OA can occur in any joint, it occurs most frequently in the knee, which, according to ScienceDirect, currently accounts for 365&#x00a0;million cases worldwide and 61% of YLDs lost due to OA, followed by the hand.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our current efforts are focused on the development of Apitox in the United&#x00a0;States for the treatment of inflammation and pain management relating to OA in the knee.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Treatment of MS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Additionally, we believe the previous clinical trial success of Apimeds Korea with respect to the use of Apitoxin to treat symptoms associated with knee OA, and pending the success of our anticipated Phase III trial in knee OA, we will be in a position to further explore the use of Apitox as a potential treatment for the symptoms of MS.&#x00a0;MS is a chronic disease of the central nervous system. It is an autoimmune condition that is characterized by the body&#x2019;s own immune cells (macrophages and lymphocytes) attacking the myelin that coats nerve cells, which&#x00a0;can lead to inflammation throughout the central nervous system. MS is an unpredictable disease that affects people differently. Some people with MS may have only mild symptoms. Others may lose their ability to see clearly, write, speak, or walk when communication between the brain and other parts of the body becomes disrupted.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">MS is the most common progressive neurologic disease of young adults worldwide. A study funded by the National MS Society estimates that nearly one million individuals&#x00a0;are currently affected by this disease in the United&#x00a0;States. The total economic burden of MS in the United&#x00a0;States is estimated to be&#x00a0;$85.4&#x00a0;billion, with $63.3&#x00a0;billion in direct medical costs and $22.1&#x00a0;billion in indirect and nonmedical costs. MS typically affects patients at a young age, resulting in a greater loss of productivity and quality of life.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Beta interferon drugs are among the most common medications used to treat MS.&#x00a0;Interferons are signaling molecules that regulate immune cells. Potential side effects of these drugs include flu<FONT CLASS="nobreak">-like</FONT> symptoms (which usually fade with continued therapy), depression, or elevation of liver enzymes.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pain from MS<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT>can be felt in different parts of the body. Trigeminal neuralgia (facial pain) is treated with anticonvulsant or antispasmodic drugs, or less commonly, painkillers. Central pain, a syndrome caused by damage to the brain and/or spinal cord, can be treated with gabapentin and nortriptyline. Treatments for chronic back or other musculoskeletal pain may include heat, massage, ultrasound, and physical therapy.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to use a portion of the proceeds of this offering to facilitate the early prosecution of appropriate MS patient populations through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">OA and the Current Standard of Care</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">OA is&#x00a0;a degenerative joint disease in which the tissues in the joint break down over time. It is the most common type of arthritis and is more common in older people. People with osteoarthritis usually have joint pain and, after rest or inactivity, stiffness for a short period of time.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">There are four stages of OA: (1)&#x00a0;Minor&#x00a0;&#x2014;&#x00a0;minor wear<FONT CLASS="nobreak">-and</FONT><FONT CLASS="nobreak">-tear</FONT> in the joints and little to no pain in the affected area, (2)&#x00a0;Mild&#x00a0;&#x2014;&#x00a0;more noticeable bone spurs, the affected area feels stiff after sedentary periods and patients may need a brace, (3)&#x00a0;Moderate&#x00a0;&#x2014;&#x00a0;cartilage in the affected area begins to erode, the joint becomes inflamed and causes discomfort during normal activities, and (4)&#x00a0;Severe&#x00a0;&#x2014;&#x00a0;the patient is in a lot of pain, the cartilage is almost completely gone leading to an inflammatory response from the joint, and overgrowth of bony spurs may cause severe pain. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">With the progression of OA of the knee, there is obvious joint inflammation which causes frequent pain when walking, running, squatting, extending or kneeling. Along with joint stiffness after sitting for long or when waking up in the morning, there may be popping or snapping sounds when walking.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The data from the Apimeds Korea Phase III OA Trial suggest that Apitox would have the most potential in treating OA in stages 3 and 4.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">MS and the Current Standard of Care</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">MS is increasingly recognized as a neurodegenerative disease&#x00a0;triggered by an inflammatory attack of the central nervous system. There is no cure for multiple sclerosis. Treatment typically focuses on&#x00a0;speeding recovery from attacks, reducing new radiographic and clinical relapses, slowing the progression of the disease, and managing MS symptoms.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">MS&#x00a0;is unpredictable and can vary substantially from person to person. MS is divided into four types: clinically isolated syndrome (CIS),&#x00a0;relapsing<FONT CLASS="nobreak">-remitting</FONT> MS&#x00a0;(RRMS),&#x00a0;secondary progressive MS&#x00a0;(SPMS) and&#x00a0;primary progressive MS&#x00a0;(PPMS).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">CIS refers to a first episode of neurologic symptoms caused by inflammation and demyelination&#x00a0;in the central nervous system.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">RRMS, the most common disease course, shows clearly defined attacks of new or increasing neurologic symptoms. These attacks are also called relapses&#x00a0;or exacerbations. They are followed by periods of partial or complete recovery, or remission. In remissions, all symptoms may disappear or some symptoms may continue and become permanent. However, during those periods, the disease does not seem to progress.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">SPMS follows the initial relapsing<FONT CLASS="nobreak">-remitting</FONT> course. Some people diagnosed with RRMS eventually go on to have a secondary progressive course, in which neurologic function worsens progressively or disability accumulates over time.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">With PPMS, neurologic function worsens or disability accumulates as soon as symptoms appear, without early relapses or remissions. PPMS can be further characterized as either&#x00a0;active&#x00a0;(with an occasional relapse and/or evidence of new MRI activity over a specified period of time) or&#x00a0;not active, as well as&#x00a0;with progression (evidence of disability accrual over time, with or without relapse or new MRI activity) or&#x00a0;without progression.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Patients with MS tend to be more educated about their disease and better organized than patients with other diseases, resulting in patients that are aggressive in their approach to treatment. This is due to MS impacting otherwise healthy people in the prime of their lives.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">MS treatment has undergone significant evolution in the last ten&#x00a0;years with the development and approval of certain new drugs, including several oral agents such as Ocrevus, in the United&#x00a0;States. These new agents not only give patients additional treatment options, but also have improved the efficacy and safety of treatment for MS overall. In general, these drugs are &#x201c;disease modifying agents,&#x201d; intended to slow down the immune mediated damage to the myelin sheaths that underlie symptoms in MS.&#x00a0;However, they often do not adequately address the symptoms that MS patients experience such as walking problems, bladder control, dizziness, and especially pain. A 2022 study estimated that the average cost of treatment for patients with MS is approximately $88,000 annually. The out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> expense for patients can be significantly reduced through certain insurance plans. However, we believe there is the ability for Apitox to be positioned as an important and cost<FONT CLASS="nobreak">-effective</FONT> therapy.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe the data from the Apimeds Korea Phase&#x00a0;III OA Trial suggest that Apitox may have the potential as an adjunctive therapy for all four types of MS. We intend to Apitox as a potential adjunctive therapy through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies to begin determining the appropriate MS patient populations.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Market Opportunity</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe there is a significant market opportunity in the United&#x00a0;States for Apitox in the treatment of certain symptoms of knee OA and eventually MS.&#x00a0;According to Precedence Research the osteoarthritis therapeutics market size accounted for $8.28&#x00a0;billion in 2022 and it is expected to hit around $20.24&#x00a0;billion by 2032, expanding at a CAGR of 9.4% from 2023 to 2032. Although OA can damage any joint, the disorder most commonly affects joints in your&#x00a0;hands, knees, hips and spine. OA symptoms can usually be managed, although the damage to joints can&#x2019;t be reversed. Apitox has certain anti<FONT CLASS="nobreak">-inflammatory</FONT> properties, which we believe give it significant potential to help treat the symptoms of certain chronic diseases that involve difficult to control pain and inflammation.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">According to Pharmaceutical Technology the MS market size in the United&#x00a0;States accounted for $ 10.73&#x00a0;billion in 2022 and is expected to hit $ 24.4&#x00a0;billion by 2030, expanding at a CAGR of 10.32%. Starting in the first quarter of 2025, we intend to begin the early prosecution of appropriate MS patient populations through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies. Subject to FDA approval, our development of Apitox in the United&#x00a0;States will in the near term, have two distinct focuses (i)&#x00a0;the treatment of the certain symptoms of knee OA and (ii)&#x00a0;the quality of life issues surrounding knee OA, such as pain and lack of mobility. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Living with a chronic disease is challenging, as it interferes with physical, mental, and social functions and thus greatly affects a person&#x2019;s quality of life. Indeed, chronically ill patients are facing major struggles such as higher expenditures, social isolation and loneliness, disabilities, fatigue, pain/discomfort, feelings of distress, anger, hopelessness, frustration, anxiety, and depression. There is the general assumption that symptom reduction increases a patient&#x2019;s quality of life. Our approach with Apitox centers around this concept&#x00a0;&#x2014;&#x00a0;effectively treating certain symptoms of the patient&#x2019;s disease, thus improving their overall quality of life. Bee venom has been shown to have anti<FONT CLASS="nobreak">-inflammatory</FONT> effects. At low doses, bee venom can suppress inflammatory cytokines such as interleukin<FONT CLASS="nobreak">-6</FONT> (IL<FONT CLASS="nobreak">-6</FONT>), IL<FONT CLASS="nobreak">-8</FONT>, interferon<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b3;</FONT> (IFN<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b3;</FONT>), and tumor necrosis factor<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT> (TNF<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03b1;</FONT>). A decrease in the signaling pathways responsible for the activation of inflammatory cytokines, such as nuclear factor<FONT CLASS="nobreak">-kappa</FONT> B (NF<FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak" STYLE="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#x03ba;</FONT><FONT CLASS="nobreak">B</FONT>), extracellular signal<FONT CLASS="nobreak">-regulated</FONT> kinases (ERK1/2) and protein kinase Akt, and porphyromonas gingivalis lipopolysaccharide (PgLPS)<FONT CLASS="nobreak">-treated</FONT> human keratinocytes has been associated with treatments involving bee venom. We believe the driver of pain in the highest category of OA is correlated to the key inflammatory elements treated by bee venom, meaning the evaluation of our Phase&#x00a0;III data may lead to a small indication for narcotic use reduction in the treatment of stage 4 OA.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Product Candidate</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apitox is purified honeybee (Apis mellifera) venom manufactured as a lyophilized powder for reconstitution in 0.5% preservative<FONT CLASS="nobreak">-free</FONT> lidocaine (lmg/mg) prior to intradermal dose injections that are administered up to 1,500 micrograms per weekly visit. The biologically active components include melittin (40<FONT CLASS="nobreak">-50</FONT>%), apamin (2<FONT CLASS="nobreak">-3</FONT>%), mast cell degranulating (&#x201c;MCD&#x201d;) peptide (Peptide 401,2<FONT CLASS="nobreak">-3</FONT>%), phospholipase A2 (10<FONT CLASS="nobreak">-15</FONT>%), hyaluronidase (1.5<FONT CLASS="nobreak">-2</FONT>%) and other components in small amounts, including dopamine and norepinephrine. According to a publication entitled &#x201c;<FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;">Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective</FONT>&#x201d; by Shi et al., certain components of honeybee venom have been found to have both anti<FONT CLASS="nobreak">-inflammatory</FONT> and analgesic effects. The anti<FONT CLASS="nobreak">-inflammatory</FONT> and analgesic effects are attributed to the presence of Peptide 401, adolapin and other components that inhibit prostaglandin synthesis. The hormone<FONT CLASS="nobreak">-stimulating</FONT> effects are attributed to the presence of melittin, cardiopep and other components that stimulate the pituitary<FONT CLASS="nobreak">-adrenal</FONT> axis to produce cortisol. Results from an animal study entitled &#x201c;<FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;">Effect of bee venom and melittin on plasma cortisol in the unanesthetized monkey</FONT>&#x201d; published by Vick et al., indicate that melittin appears to stimulate the production of cortisol from the adrenal gland. The immune<FONT CLASS="nobreak">-modulating</FONT> effects, especially as it pertains to MS, are suggested to be mediated by CD4+CD2S+Foxp3+ regulatory T cells (Tregs) that are influenced by phospholipase A2. While the exact mechanism of action of Apitox is not fully understood, research such as the publication entitled &#x201c;<FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;">Therapeutic Use of Bee Venom and Potential Applications in Veterinary Medicine</FONT>&#x201d; by Bava et al., suggests that certain components in Apitox may ameliorate immune<FONT CLASS="nobreak">-inflammatory</FONT> responses associated with MS.&#x00a0;Such studies suggested that treatments with melittin prevent inflammatory cytokine expression and produces anti<FONT CLASS="nobreak">-inflammatory</FONT> effects. The proposed indication for Apitox is to provide add<FONT CLASS="nobreak">-on</FONT> therapy for the signs and symptoms of MS in patients whose condition is relapsing<FONT CLASS="nobreak">-remitting</FONT> (RRMS), primary<FONT CLASS="nobreak">-progressive</FONT> (PPMS) or secondary progressive (SPMS).</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Clinical Development History</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Founded in 1989, Apimeds Korea pursued a traditional drug development process in South Korea for Apis mellifera, the bee venom API for Apitoxin. Apimeds Korea completed a formal preclinical study to validate dosing and safety for human administration with a focus on antigenicity and toxicology in 1993.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">A Phase I trial was completed in 1994, studying the toxicity and safety of Apitoxin in 20 healthy subjects. The purpose of the Phase I trial was to determine if therapeutic doses of Apitoxin was safe and to identify possible side<FONT CLASS="nobreak">-effects</FONT>, if any. Injections of Apitoxin were given two to three times a week, for a total of 12 sessions spanning over four to six weeks. Laboratory and physical examination of the subjects included (i) serum cortisol levels (to see if Apitoxin stimulated the release of cortisol), (ii) serum ionized calcium level (to determine if Apitoxin decreased the serum calcium level), (iii) urinalysis, (iv) hematology and blood chemistry, and (v) vital signs. The Phase I trial demonstrated that there were no significant changes pre- and post<FONT CLASS="nobreak">-testing</FONT> of the serum cortisol levels, serum ionized calcium levels, hematology, blood chemistry, urinalysis, and vital signs after the subjects were injected with Apitoxin according to the protocol. There were no significant physiological changes in the clinical evaluations of the subjects and localized itching was the most frequent side effect and was managed with ice packs or external anti<FONT CLASS="nobreak">-itching</FONT> gels. No severe side effects or aftereffects were observed. The Phase I trial indicated that Apitox is safe for humans when applied in therapeutic doses.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Phase I trial was followed by a Phase II trial in 101 subjects to determine the efficacy of Apitoxin at various dose levels. This was a randomized active<FONT CLASS="nobreak">-controlled</FONT> clinical trial with three groups receiving the study drug at various dose levels and one group receiving the control drug (nabumetone) for a six<FONT CLASS="nobreak">-week</FONT> period. Patients received twice weekly injections of Apitox intradermally at dosages titrated to a maximum of 0.7 mg (Group A), 1.5 mg (Group B), and 2.0 mg (Group C) for a period of six weeks. Control group patients (Group D) received 1,000 mg of nabumetone orally each day for the same six<FONT CLASS="nobreak">-week</FONT> period. There were<FONT CLASS="nobreak"> </FONT>25,<FONT CLASS="nobreak"> </FONT>26, 25 and 25 patients assigned to Groups A, B, C and D, respectively. Efficacy of treatment was evaluated by the physician investigators using a 4<FONT CLASS="nobreak">-point</FONT> Likert<FONT CLASS="nobreak">-like</FONT> symptom severity rating scale developed by the authors to assess Pain, Disability and Physical Signs. A similar 5<FONT CLASS="nobreak">-point</FONT> scale was used for patient self<FONT CLASS="nobreak">-evaluation</FONT>. Safety of the Apitoxin injection was evaluated by patient reaction, hematologic examination, and laboratory chemistry analysis of blood and urine. Efficacy data was reported for the 81 patients who completed the study. While there were no significant differences in symptom severity scores among the four groups at baseline, symptom scores were significantly better in the bee venom injection groups than in the control group at six weeks and 10 weeks after the start of treatment (p&lt;0.01). A treatment was considered effective if there was a 20% improvement from baseline in symptom scores after 6 weeks of treatment. Based on this definition, therapy demonstrated overall efficacy in 70.0% of patients in Group A, 85.7% in Group B, 90.0 % in Group C, and 61.9% in Group D (drug control). Overall efficacy was significantly greater in treatment Groups B and C combined than in the nabumetone<FONT CLASS="nobreak">-treated</FONT> control group D (p&lt;0.0177). Importantly, efficacy of treatment among all patients treated with Apitoxin injection was greater than among nabumetone<FONT CLASS="nobreak">-treated</FONT> patients for each category assessed: Pain: 85.2% versus 76.2%; Disability: 77.0% versus 71.4%; and Physical Signs: 62.3% vs. 23.8%. It is also noteworthy that, unlike the drug control group, the Apitoxin injection groups continued to demonstrate improved symptom scores at four weeks after the last treatment (10 weeks). There were no significant changes in vital signs or results of laboratory examinations of any patient in this clinical trial. Localized itching was experienced by all patients who received Apitox injections. Itching at the injection site generally lasted for two to three weeks; several patients had this reaction for a longer period. This Phase II study showed that Apitoxin was significantly more effective than the control drug, nabumetone, in the treatment of knee and spinal osteoarthritis patients. It clearly showed that improvement in pain, disability and physical signs was greater in the bee venom injection groups than in the nabumetone control group. No significant side effects developed at the therapeutic doses studied. However, research should be continued to minimize itching and pain at bee venom injection sites, and possible allergic reaction should always be considered with treatment at high doses.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In 2002, a formal Phase III double<FONT CLASS="nobreak">-blind</FONT>, placebo<FONT CLASS="nobreak">-controlled</FONT> trial was completed with 407 subjects (311 of which obeyed the trial protocol and completed the clinical study). The purpose of the Phase III trial was conducted to verify the efficacy and safety of the medicine resulting from the prior Phase I and Phase II trials. The therapeutic course treatment included a total of 12 injections over a period of 6 weeks. Final evaluations were completed in the 8<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> week, following two weeks of no injections. During the trial period, laboratory tests were carried out three times (before injection, in the second week, in the sixth week), and the efficacy evaluation was performed four times (before injection, in the second week, in the sixth week, and in the eighth week). Safety of the Apitoxin injection was evaluated by, hematologic examination, measurement of cortisol and calcium levels, and laboratory chemistry </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">analysis of blood and urine. The primary efficacy variable for the trial was the ratio of the subjects who showed more than 20% improvement in the total points of test items for efficacy evaluation <FONT CLASS="nobreak">6 weeks </FONT>after injection, compared with the total points before injection of the medicine (the &#x201c;improvement rate&#x201d;). Data obtained from subjects of the clinical test were analyzed by two methods, ITT (Intention to Treat) analysis and PP (Per Protocol) Among 310 subjects who participated in the efficacy evaluation, 153 and 157 patients belonged to the Apitoxin group and the nabumetone group, respectively. For the Apitoxin group, the ratio of the subjects who showed more than 20% improvement in the total points was 48.70% (75/154 subjects, 95% confidence interval (&#x201c;CI&#x201d;): 40.8~56.6%), while for the nabumetone group, it was 46.15% (72/156 subjects, 95% CI: 38.3~54.0%), indicating that the improvement rate in the Apitoxin group was greater than in the nabumetone group; however, there was no statistical significance.(p=0.6533). Among a total of 407 subjects (Apitoxin group: 204; Nabumetone group : 203), 38.24% (78/204) of the Apitoxin group showed more than 20% improvement during the 6<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> week of injection, while 38.42% of the Nabumetone group improved by more than 20%, indicating that the two groups showed similar improvement rate (p=0.9688). The second efficacy variable was the improvement rate during the 8<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> week (2 weeks after the completion of the final injection). According to results from comparing the total points of efficacy evaluation items during the second week after completion of injection (during the 8<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> week after injection) with the total points before injection, 58.44% (90/154) of the Apitoxin group showed a higher improvement rate than during the 6<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> week (48.70%), while 42.95% (67/156) of the Nabumetone group showed lower improvement rate than during the 6<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT> week (46.15%). There was statistical difference in total point of efficacy evaluation items between the two groups (p=0.0064). These results suggest that even after treatment stops, the efficacy of Apitoxin continues. With respect to safety, among a total of 407 subjects who participated in the safety evaluation, 69 (33.82%) of the Apitoxin group showed an adverse event, while 59 (29.06%) of the Nabumetone indicated adverse event. These results indicate that the Apitoxin group had an elevated adverse event rate than the Nabumetone group, but there was no statistically significant difference between the two groups (p=0.3526).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In May&#x00a0;2003, MFDA granted approval for the use of Apitoxin in the treatment of pain and mobility in patients with OA.&#x00a0;A post<FONT CLASS="nobreak">-marketing</FONT>/approval safety study in South Korea followed 3,194 patients from 2003 through 2009, with no serious adverse events or negative safety signals.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In 2013, preliminary Phase III clinical trials were authorized to enroll patients by the FDA to study the same indication approved in South Korea&#x00a0;&#x2014;&#x00a0;treatment of pain and lack of mobility in patients with OA. The results of the preliminary Phase III clinical trial indicated statistical and clinically significant improvements in all outcome measures of pain, physical function, and disease assessment in the study group. The study group included 330 patients with diagnosed osteoarthritis of the knee. The subjects were evaluated for relief of pain using Western Ontario and McMaster Osteoarthritis Index (WOMAC) and physician and patient global assessments. The primary efficacy measure was relief of pain and inflammation over a 12<FONT CLASS="nobreak">-week</FONT> treatment period after randomization into the trial. The secondary efficacy measure was improvement of mobility. Treatment effect will be compared in a 2<FONT CLASS="nobreak">-1</FONT> Apitox vs active control. Compared with the placebo group (histamine), subjects in the Apitox group who received a maximum dose (1500 micrograms) at each weekly visit over 12 weeks showed a significantly more improvement in all outcome measures (WOMAC pain, WOMAC physical function, visual analog scale (&#x201c;VAS&#x201d;) pain, patient and physician global assessments of OA). Further, post hoc analyses showed that a statistically significant greater percentage of Apitox<FONT CLASS="nobreak">-treated</FONT> subjects had at least a 40% and 60% reduction in WOMAC pain as compared to placebo<FONT CLASS="nobreak">-treated</FONT> subjects. Sensitivity analyses confirmed the validity of the statistical methods and population definitions. The improvements in pain endpoints were highly significant for both the modified intention to treat and per protocol populations and the improvement was sustained during the four weeks following Apitox treatment.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Except for an expected higher incidence of injection site reactions (&lt;5%) in the Apitox group, the overall safety profiles were comparable between the treatment groups. A serious adverse event of the anaphylactic reaction occurred in an Apitox<FONT CLASS="nobreak">-treated</FONT> subject because of a quick injection rate. However, the subject was treated, and the event was resolved within one day. The incidence of adverse events overall was similar between the Apitox and Placebo groups (49.0% and 46.3%, respectively), and there were no clinically meaningful changes, within and between groups, in laboratory parameters, vital signs, physical examination, or electrocardiogram results. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">During Apimeds Korea meetings with the FDA, the FDA highlighted concerns regarding the opioid crisis. As Apitoxin has been previously approved in South Korea, we believe Apitox could be a viable treatment option within the United&#x00a0;States after additional clinical investigation, including our anticipated Phase III trial. Initially, Apimeds </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Korea elected not to pursue the OA indication in the United&#x00a0;States based on its evaluation of potential market adoption and the existing competitive environment for OA.&#x00a0;Based on results from the Apimeds Korea Phase III OA Trial and correspondence with the FDA, we believe we are now in a position to continue to advance our Phase III trial for knee OA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to conduct an additional Phase&#x00a0;III trial in knee OA. Based on our previous correspondence with the FDA, we have started to design and will implement our Phase III trial to best address our patient population of patients with grade<FONT CLASS="nobreak"> </FONT>2, 3 and 4 knee OA, appropriate dosing, and the most effective way to evaluate Apitox in meeting a patient&#x2019;s needs. This trial will be an update to the plan of execution based on review of data, discussions with former principal investigators from Apimeds Korea. Upon successful completion and FDA clearance of our Phase III trial in knee OA, we will be positioned to submit a BLA. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend that the purpose of this trial will be to evaluate the effectiveness of Apitox in the treatment of grade<FONT CLASS="nobreak"> </FONT>2, 3 and 4 OA of the knee. The trial will be designed with a specific focus on the identified subgroup from which we see the highest degree of benefit.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table summarizes the preliminary clinical trial activity by Apimeds Korea with respect to Apitoxin:</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><IMG ALT="" SRC="ttable_01.jpg" STYLE="width:597.76px;max-width:100%;"></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Preliminary Clinical Data in MS Patients</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The United&#x00a0;States data from the literature on bee venom studies in MS patients, Table A (Hauser et al. 2001) below, showed clinically significant improvements in disability symptoms following treatment.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In Table A, results were categorized into the following groups: dramatic disability improvement (&gt;12 points on the Related Observable Symptom Scale (&#x201c;ROSS&#x201d;), good improvement (7<FONT CLASS="nobreak">-12</FONT> points on ROSS), minimal improvement (&lt;7 points on ROSS), no improvement (&lt;2 points on ROSS), and negative (any total negative response on ROSS). Descriptive analysis of the ROSS clinical outcomes showed that more than 68% of MS patients showed some kind of positive improvement in disability (dramatic, good or minimal) and 58% demonstrated a marked improvement (dramatic or good).</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Table A.&#x00a0;Summary of Patient Disability Improvement to Bee Venom Treatment Using ROSS</FONT></P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">N</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">% of <BR>Participants</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Follow-up Survey<BR>(% improvement)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.28%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related Observable<BR>Symptoms Scale<BR>(points improvement)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-top:2pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dramatic</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 29.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&gt;30%, or</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:4pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 26.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">&gt;12 points</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Good</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">10&#x00a0;&#x2013;&#x00a0;29%, or</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">7&#x00a0;&#x2013;&#x00a0;12 points</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Minimal</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.8</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&lt;10%, or</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;">&lt;</FONT>7 points</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">None</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">15</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.4</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">&lt;2%, or</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><FONT CLASS="CharOverride-3" STYLE="font-style:italic;font-weight:normal;">&lt;</FONT>2 points</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 15.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Negative</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.0</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_centeralign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">Any total negative response</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.28%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">Any total negative response</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After 1 year of bee<FONT CLASS="nobreak">-venom</FONT> injections, 68.6 percent of participants showed improvement. N = number of participants.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea used data from its first Phase&#x00a0;III clinical trial for OA and peer reviewed publications, including those referenced in Table&#x00a0;A above and formal Phase&#x00a0;I (the &#x201c;Castro Phase I Trial&#x201d;) and Phase&#x00a0;II (the &#x201c;Wesselius Phase II Trial&#x201d;) publications specific to MS, to support its submission in 2014 of its Investigational New Drug Application (&#x201c;IND&#x201d;) 122804 (A Phase&#x00a0;III, Multi<FONT CLASS="nobreak">-Center</FONT>, Randomized, Double<FONT CLASS="nobreak">-Blind</FONT>, Placebo<FONT CLASS="nobreak">-Controlled</FONT>, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add<FONT CLASS="nobreak">-on</FONT> Therapy for Improving Disability and Quality of Life in Patients with Multiple Sclerosis).</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Castro Phase I Trial</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Castro Phase I Trial involved a total of nine bee venom nonallergic patients with progressive forms of MS, who were 21&#x2013;55 years of age with no other illnesses. The subjects distributed across four groups (A, B, C, and D) and followed a structured 1<FONT CLASS="nobreak">-year</FONT> immunization schedule. Hyperreactivity to bee venom was evaluated by questionnaire, physical examination, and a battery of hematologic, metabolic, and immunologic tests. Responses to therapy were evaluated by questionnaire, functional neurological tests, and changes in measurement of somatosensory<FONT CLASS="nobreak">-evoked</FONT> potentials. While no serious adverse allergic reactions were observed in any of the subjects, four experienced worsening of neurological symptoms, requiring their discontinuation in the study. The observed negative effects could not be conclusively attributed to adverse reactions arising from the administered therapy. Of the remaining five subjects, three reported subjective amelioration of symptoms and two exhibited objective improvement. Despite suggesting safety in this preliminary study, the small sample size precluded definitive conclusions regarding the efficacy of the treatment for MS. Larger and more carefully conducted multicenter studies were required to establish efficacy.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Wesselius Phase II Trial</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Wesselius Phase II Trial involved a randomized crossover study of 26 patients diagnosed with relapsing<FONT CLASS="nobreak">-remitting</FONT> or relapsing secondary progressive MS. Participants were assigned to 24 weeks of medically supervised bee sting therapy, or a control period of 24 weeks of no treatment. Live bees (up to a maximum of 20) were used to administer bee venom three times per week. The primary outcome was the cumulative number of new gadolinium<FONT CLASS="nobreak">-enhancing</FONT> lesions on T1<FONT CLASS="nobreak">-weighted</FONT> MRI of the brain. Secondary outcomes were lesion load on T2*<FONT CLASS="nobreak">-weighted</FONT> MRI, relapse rate, disability (Expanded Disability Status Scale, Multiple Sclerosis Functional Composite, Guy&#x2019;s Neurologic Disability Scale), fatigue (Abbreviated Fatigue Questionnaire, Fatigue Impact Scale), and health<FONT CLASS="nobreak">-related</FONT> quality of life (Medical Outcomes Study 36<FONT CLASS="nobreak">-Item</FONT> Short Form General Health Survey). The results of the Wesselous Phase II Trial indicated that during bee sting therapy, there was no significant reduction in the cumulative number of new gadolinium<FONT CLASS="nobreak">-enhancing</FONT> lesions. The T2*<FONT CLASS="nobreak">-weighted</FONT> lesion load further progressed, and there was no significant reduction in relapse rate. There was no improvement of disability, fatigue, and quality of life. Bee sting therapy was well tolerated, and there were no serious adverse events. In this trial, treatment with bee venom in patients with relapsing multiple sclerosis did not reduce disease activity, disability, or fatigue and did not improve quality of life measured using gadolinium<FONT CLASS="nobreak">-enhancing</FONT> MRI.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">From June&#x00a0;2014 to June&#x00a0;2018, Apimeds Korea corresponded with the FDA and there were no clinical holds at that time. Sponsorship of IND&#x00a0;122804 was transferred from Apimeds Korea to us in October&#x00a0;2020. On September&#x00a0;21, 2021, we responded to customary non<FONT CLASS="nobreak">-clinical</FONT> hold comments from the FDA.&#x00a0;In November&#x00a0;2021, we received a customary clinical hold from the FDA due to the retirement of the former principal investigator. We have subsequently updated the FDA with a new principal investigator via our Chief Medical Officer, Dr.&#x00a0;Christopher Kim. In February 2023, the FDA removed the clinical hold and concluded it may be initiated. We have subsequently made </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">the strategic decision to focus our efforts and capital on our Phase III trial in knee OA, and instead focus our MS efforts on the early prosecution of appropriate MS patient populations through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Our Commercialization Strategy</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are dedicated to the effective implementation of regulatory, clinical and legal strategies to create value in Apitox. The effective execution of this strategy will provide us the opportunity to evaluate and potentially acquire other assets that fit within our space for development. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:11pt;text-align:center;margin-top:11pt;"><IMG ALT="" SRC="tflowchart_001.jpg" STYLE="width:364.8px;max-width:100%;"></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Manufacturing</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to continue to engage a third<FONT CLASS="nobreak">-party</FONT> manufacturer, Piramal Pharma Solutions, in Lexington, Kentucky to support our Phase&#x00a0;III trial and, if Apitox is approved by the FDA, commercial manufacturing. This manufacturer has dedicated experience in development and technology transfer of sterile dose formulations, including liquid and lyophilized formulations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and Development</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are currently engaged exclusively in the clinical development of Apitox for continued use in knee OA through a Phase III trial in knee OA and potential use for MS through the early prosecution of appropriate patient populations through non<FONT CLASS="nobreak">-registered</FONT> corporate sponsorship studies.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Sales and Marketing</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The healthcare providers associated with the treatment of inflammation and pain management symptoms associated with OA and MS are not limited to one specialist but involve a comprehensive team of providers focused on slowing the progression of the disease along with the physical, emotional and&#x00a0;day<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-day</FONT> management of the condition. Each of these providers represents a potential customer for Apitox.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apitoxin, which will be known as Apitox in the United&#x00a0;States, has established technological credibility through its preclinical testing, Phase&#x00a0;I, Phase&#x00a0;II and preliminary Phase&#x00a0;III clinical studies completed by Apimeds Korea. Apimeds Korea received regulatory approval for Apitoxin by the MFDA in South Korea, as well as long<FONT CLASS="nobreak">-term</FONT> safety data from treatment of patients in Korea from 2003 to 2009. There were no serious adverse events from over 3,000 patients monitored, and Apitoxin has been approved and marketed in South Korea for OA since 2003. We update the FDA annually on safety data generated by Apimeds Korea from South Korea.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We aim to obtain FDA approval for Apitox in the United&#x00a0;States market for treatment of inflammation and pain management symptoms associated with knee OA, and eventually MS, and expand the indication portfolio in the autoimmune market with a strategic marketing partner. The marketing partner strategy is common in the pharmaceutical marketplace, as the infrastructure, overhead, and barriers to entry dilute the focus and can rapidly erode the financial well<FONT CLASS="nobreak">-being</FONT> of small, product development<FONT CLASS="nobreak">-based</FONT> companies such as us. By identifying the strategic marketing partner at an early stage, the companies can deliver a final product, or family of products, in a form factor or variety of form factors over time, that specifically suit the target market. We believe that Apitox represents a significant opportunity as a platform technology, with numerous product<FONT CLASS="nobreak">-line</FONT> extensions, and the potential for new, ancillary products such as delivery devices.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Reimbursement Strategy</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds expects to apply to the Centers for Medicare and Medicaid Studies (&#x201c;CMS&#x201d;) for temporary generic reimbursement codes 12 to 18&#x00a0;months prior to a BLA approval. Temporary codes are used until manufacturers apply for, and receive, permanent codes, which identify the drug and its therapeutic class. Permanent codes are issued by CMS on a rolling quarterly basis.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will engage third party contractors to assist the us with reimbursement, coding and policy development prior to, during and at the time of approval of Apitox. We will look for a contractor to provide the following services to us:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Coding Assessment and Strategy</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">/</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Execution&#x00a0;&#x2014;&#x00a0;CPT Review of Apitox Administration by Multiple Intradermal Injections</FONT>. Assess the landscape to ensure a clear understanding of the key dynamics and analyze relevant proxies and precedent. Further assess relevant drug administration codes and whether appropriate codes exist.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Medical Coverage Policy Analysis</FONT>&#x00a0;&#x2014;&#x00a0;Provide a framework and set expectations for Medicare&#x2019;s anticipated coverage approach to Apitox, specifically in the context of intra articular hyaluronic acid use agent coverage policies and implications of their efficacy uncertainty.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Medicare Local Coverage Analysis and Implications</FONT>&#x00a0;&#x2014;&#x00a0;Given the significance of Medicare policy standards, local and national Medicare policies often shape payer and provider perceptions and decisions. As complex statutory and regulatory guidance shape Medicare decision<FONT CLASS="nobreak">-making</FONT>, ADVI analyzes, investigates, and synthesize Medicare policies that could affect access (coverage, coding and reimbursement) for Apitox.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Medicaid and Commercial Coverage Analysis and Implications</FONT>&#x00a0;&#x2014;&#x00a0;Analyze available medical policies for five large state Medicaid agencies (based on population and geographic variation) and major commercial payers (where publicly available).</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Payer Policy Internal Expert Interviews</FONT>&#x00a0;&#x2014;&#x00a0;Conduct payer interviews with relevant Medicare, Medicaid and commercial policy advisors.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">HCPCS Coding and Payment Assessment</FONT>&#x00a0;&#x2014;&#x00a0;Assess the coding and reimbursement landscape to ensure Apimeds has a clear understanding of the key dynamics with the HCPCS application process and the Medicare Hospital Outpatient Prospective Payment System (OPPS) pass<FONT CLASS="nobreak">-through</FONT> status application process. Through this assessment, identify the areas of concern, expectations, timing, timelines, and processes associated. This is especially relevant given the 2020 implementation of a new HCPCS review process.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Address key Part&#x00a0;B/medical benefit implications to Apitox in the following fields:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>HCPCS and OPPS application timelines (and potential evolution leading to launch).</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Coding/access implications prior to code assignment (e.g., NOC/miscellaneous codes), review the merits/risks of Q<FONT CLASS="nobreak">-code</FONT>.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>further review the application processes, expectations, case examples, timelines, and hurdles that APUS may face across settings of care, payers, and with CMS,</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Case examples, timelines, and hurdles across settings of care with payers and CMS,</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Review of reimbursement implications; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>Methodologies (ASP, WAC, AWP), role of sequestration, 340B, patient financial burden</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Develop Payer (with Emphasis on Medicare) Launch Recommendations&#x00a0;</FONT>&#x2014;&#x00a0;Based on the above primary and secondary research, synthesize the discussions and summarize the overall findings of the payer survey, highlighting themes, and provide recommendations and considerations for optimizing market access, given the current and evolving reimbursement landscape. This section will include payer (emphasis on Medicare) launch strategy recommendations (including timeline) and a local/national Medicare engagement strategy.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Competition</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We compete in an industry characterized by rapidly advancing technologies, intense competition, a changing regulatory and legislative landscape and a strong emphasis on the benefits of intellectual property protection and regulatory exclusivities.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Like any biopharmaceutical company, we face competition from multiple sources, including large or established pharmaceutical, biotechnology, and wellness companies, academic research institutions, government agencies, and private institutions. We believe our drug candidate will prevail amid the competitive landscape through its efficacy, safety, administration methods, cost, public and institutional demand, intellectual property portfolio, and treatment of the root cause of many&#x00a0;age<FONT CLASS="nobreak">-associated</FONT>&#x00a0;diseases.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical, and human resources than we do. Accordingly, our competitors may be more successful in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or&#x00a0;non<FONT CLASS="nobreak">-competitive</FONT>.&#x00a0;Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites, patient registration for clinical studies, and acquiring technologies complementary to, or necessary for, our programs. Smaller or early<FONT CLASS="nobreak">-stage</FONT> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, more tolerable, more convenient, or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our products&#x2019; entry. We believe the factors determining the success of our programs will be the efficacy, safety, and convenience of our drug candidates.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Additionally, consumer preference for branded, generic or private label products sold by competitors could adversely impact our financial performance. Our competitors, which differ within individual geographic markets, include large<FONT CLASS="nobreak">-scale</FONT> retailers, smaller high<FONT CLASS="nobreak">-growth</FONT> companies (which often operate on a regional basis and offer aggressive competition), multinational corporations moving into or expanding their presence in the consumer healthcare market, and &#x201c;private<FONT CLASS="nobreak">-label</FONT>&#x201d; products sold by retailers.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Our aim is to reduce the use of NSAIDS and opioid use as it relates to the pain management associated with OA.&#x00a0;We believe that if approved by the FDA, Apitox may be a non<FONT CLASS="nobreak">-addictive</FONT> option to patients experiencing debilitating pain.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">On August&#x00a0;2, 2021, we entered into an agreement with Apimeds Korea, a principal stockholder of the Company (the &#x201c;Business Agreement&#x201d;). Pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty<FONT CLASS="nobreak">-bearing</FONT> license to utilize all prior clinical development data associated with Apitoxin, Apitox, and all related names, advance clinical research, develop, manufacture and commercialize and sell Apitox in the United&#x00a0;States. In exchange for this license, the Company will pay Apimeds Korea a perpetual royalty of 5% of the Company&#x2019;s earnings before interest and taxes (as determined consistent with GAAP, derived from the sale or license of Apitox, less any shipping, handling, and insurance charges, credits (arising from returns or other adjustments), discounts, rebates, or allowances of any kind (if any). The Business Agreement can be terminated by mutual written agreement by the parties and will automatically terminate upon the bankruptcy or dissolution of the Company.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Assignment Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">On October&#x00a0;12, 2021, we entered into an intellectual property assignment agreement (the &#x201c;Assignment Agreement&#x201d;), which was effective as of May&#x00a0;12, 2020, with Apimeds Korea and Dr.&#x00a0;Christopher Kim, the Company&#x2019;s Chairman and Chief Medical Officer and the founder of Apimeds Korea. During Dr.&#x00a0;Kim&#x2019;s engagement with Apimeds Korea, he contributed to the development of the intellectual property as it relates to Apitoxin, which will be marketed in the United&#x00a0;States as Apitox (the &#x201c;Assigned IP&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Pursuant to the Assignment Agreement, Dr.&#x00a0;Kim sold, transferred, and conveyed all his rights, title and interest in the Assigned IP to Apimeds Korea. Dr.&#x00a0;Kim retained no right to use the Assigned IP.&#x00a0;Additionally, the Assignment Agreement acknowledged that the Assigned IP was licensed to us to use via the Business Agreement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Intellectual Property</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Apitox&#x2019;s API is bee venom, a natural, non<FONT CLASS="nobreak">-synthetic</FONT> compound that is not patentable, so we rely principally on trade secrets to protect our rights to Apitox, particularly the method and process of manufacturing Apitox.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Supplier</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">We purchase venom from our United&#x00a0;States supplier, Apico, Inc. (&#x201c;Apico&#x201d;), via a letter agreement. Pursuant to the letter agreement, Apico agreed that for a period of ten&#x00a0;years, or until November&#x00a0;3, 2031 it would not supply <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Apis Mellifea venom</FONT> for pharmaceutical use for any buyer other than us; <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">provided that</FONT> Apico may also supply Apimeds Korea for its use outside of the United&#x00a0;States. The letter agreement excludes customers using venom for immunology, cosmetic or any other &#x201c;non<FONT CLASS="nobreak">-pharmaceutical</FONT>&#x201d; use. The letter agreement may be terminated upon mutual written consent of both Apico and the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Apico has developed and practices a proprietary method of harvesting venom. It operates under and is certified in current good manufacturing practice regulations enforced by the FDA and has an active and current Drug Master File (&#x201c;DMF&#x201d;) with the FDA.&#x00a0;DMF&#x2019;s are submissions to the FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. We have an exclusive relationship with our supplier for pharmaceutical use in the United&#x00a0;States and they are not permitted to sell to any other party for pharmaceutical use.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Korea has a number of proprietary analytical methods for the classification and identification of specific pharmacologically active fractions of its venom, along with numerous manufacturing processes from filtration, vial filing and lyophilization required to produce Apitoxin. Apitoxin is the only approved and commercially available therapeutic product containing purified and sterile bee venom that is registered as an API in South Korea. The proprietary methods developed and practiced for the commercial manufacturing of Apitoxin include dilution, filtering, vial staging and lyophilization parameters and cycles.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We plan to file Apitox as a BLA with the Centers for Biologics and Research of the FDA following the successful completion of our Phase III trial for knee OA.&#x00a0;The FDA provides 12<FONT CLASS="nobreak">-year</FONT> market exclusivity at the time of approval of a BLA, with the potential for a six<FONT CLASS="nobreak">-month</FONT> extension upon approval for pediatric use. If the BLA is approved, the 12<FONT CLASS="nobreak">-year</FONT> period would be retroactive to the date of the application.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to file a U.S.&#x00a0;trademark application for &#x201c;Apitox&#x201d;.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Regulatory Environment</FONT></P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Government Regulation and Product Approval</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In the United&#x00a0;States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#x201c;FDCA&#x201d;), and the Public Health Service Act (the &#x201c;PHSA&#x201d;), and other federal, state, and local statutes and regulations. Both the FDCA and PHSA and their corresponding regulations govern, among other things, the research, development, clinical trials, testing, manufacturing, quality control, safety, purity and potency (efficacy), labeling, packaging, storage, record keeping, distribution, reporting, marketing, promotion, advertising, post<FONT CLASS="nobreak">-approval</FONT> monitoring, and post<FONT CLASS="nobreak">-approval</FONT> reporting involving biological products. Along with third<FONT CLASS="nobreak">-party</FONT> contractors, we will be required to navigate the various preclinical and clinical regulatory obligations and the commercial approval requirements of the governing regulatory agencies of the countries in which we wish to </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">conduct studies or seek approval or licensure of our product candidate. The processes for obtaining regulatory approvals in the United&#x00a0;States, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Government policies may change, and additional government regulations may be enacted that could prevent or delay further development or regulatory approval of any product candidates, product or manufacturing changes, additional disease indications or label changes. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or administrative action.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Review and Approval for Licensing Biologics in the United&#x00a0;States</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In the United&#x00a0;States, FDA regulates our current product candidate as a biological product, or biologics, under the FDCA, the PHSA, and associated implementing regulations. Biologics, like other drugs, are used for the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. In contrast to low molecular weight drugs, which have a well<FONT CLASS="nobreak">-defined</FONT> structure and can be thoroughly characterized, biologics are generally derived from living material (human, animal, or microorganism), are complex in structure, and thus are usually not fully characterized.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Biologics are also subject to other federal, state, and local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the product development process, approval process, or after approval may subject a sponsor or applicant to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by FDA, FDA&#x2019;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA, the Department of Justice (&#x201c;DOJ&#x201d;), and other governmental entities.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">An applicant seeking approval to market and distribute a biologic in the United&#x00a0;States must typically undertake the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>completion of non<FONT CLASS="nobreak">-clinical</FONT> laboratory tests and studies performed in accordance with FDA&#x2019;s good laboratory practice (&#x201c;GLP&#x201d;) regulations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>manufacture, labeling and distribution of investigational drugs in compliance with FDA&#x2019;s current good manufacturing practice (&#x201c;cGMP&#x201d;) requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>submission to FDA of an investigational new drug application (&#x201c;IND&#x201d;), which must become effective before clinical trials may begin and must be updated annually and when significant changes are made;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approval by an independent institutional review board (&#x201c;IRB&#x201d;) for each clinical site before each clinical trial may be initiated;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>performance of adequate and well<FONT CLASS="nobreak">-controlled</FONT> human clinical trials in accordance with FDA&#x2019;s Good Clinical Practices (&#x201c;GCP&#x201d;) to establish the safety, purity, and potency of the proposed biological product candidate for its intended purpose;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>after completion of all pivotal clinical trials, preparation of and submission to FDA of a BLA requesting marketing approval, which includes providing sufficient evidence to establish the efficacy, safety, purity, and potency of the proposed biological product for its intended use, including from results of nonclinical testing and clinical trials;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of an FDA advisory committee review, when appropriate, as may be requested by FDA to assist with its review;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or certain components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods, and controls are adequate to preserve the biological product&#x2019;s identity, strength, quality, and purity and, if applicable, FDA&#x2019;s good tissue practice (&#x201c;GTP&#x201d;) requirements for human cellular and tissue products;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of FDA inspections of selected clinical investigation sites to assure compliance with GCP requirements and the integrity of the clinical data;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>satisfactory completion of an FDA sponsor GCP inspection, often conducted at the applicant&#x2019;s headquarters facility;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>payment of user fees (unless there is a waiver, exemption, or reduction) under the Prescription Drug User Fee Act (&#x201c;PDUFA&#x201d;) for the relevant year;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>FDA&#x2019;s review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the United&#x00a0;States;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>compliance with post<FONT CLASS="nobreak">-approval</FONT> requirements, including the potential requirements to implement a risk evaluation and mitigation strategy (&#x201c;REMS&#x201d;), to report adverse events and biological product deviations, and to complete any post<FONT CLASS="nobreak">-approval</FONT> studies; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>completion of any post<FONT CLASS="nobreak">-approval</FONT> clinical studies required by FDA, such as confirmatory trials or pediatric studies.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, and marketing of biological products regulated by FDA.&#x00a0;In addition to new legislation, FDA regulations, guidance documents, and policies are often revised or interpreted by the agency in ways that may significantly affect the regulation of biological products in the United&#x00a0;States. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies, or interpretations will change, and the effects of any such changes.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Preclinical and Clinical Development</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Before an applicant can begin testing the potential product candidate in human subjects, the applicant must first conduct preclinical studies. Preclinical studies may include laboratory evaluations of product chemistry, toxicity, and formulation, as well as in vitro and animal studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical studies are subject to federal regulations and requirements, including GLP regulations, which govern the conduct of animal studies designed to test a product&#x2019;s safety. None of our preclinical studies to date have been animal studies. The results of an applicant&#x2019;s preclinical studies are submitted to FDA as part of an IND.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">An IND is a request for authorization from FDA to administer an investigational new drug product to humans. An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in a clinical trial. Such authorization must be secured prior to interstate shipment and administration of a biological drug that is not subject of an approved BLA.&#x00a0;In support of an IND, applicants must submit a protocol for each clinical trial, which details, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Human clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30&#x00a0;days after receipt by FDA, unless FDA raises safety concerns or questions about the proposed clinical trial within the 30<FONT CLASS="nobreak">-day</FONT> time period. In such a case, FDA may place the IND on clinical hold and the IND sponsor must resolve any of FDA&#x2019;s outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in regulatory authorization to begin a clinical trial.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">FDA may also place a clinical hold or partial clinical hold on a clinical trial following commencement of the trial under an IND.&#x00a0;A clinical hold is an order issued by FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.&#x00a0;For example, under a partial clinical hold, FDA may instruct a sponsor not to enroll any new patients into a study but permit the previously enrolled patients to continue in the study. No more than 30&#x00a0;days after imposition of a clinical hold or partial clinical hold, FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. FDA will base that determination on information provided by the sponsor addressing the deficiencies previously cited or otherwise satisfying FDA that the investigation can proceed.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. If a sponsor chooses to conduct a foreign clinical study under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with GCP regulations in order to use the study as support for an IND or application for marketing approval, including review and approval by an IRB and informed consent from subjects.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Furthermore, an independent IRB for all sites participating in a clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at each site and must monitor the trial until completed. Regulatory authorities, the IRB, or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (&#x201c;DSMB&#x201d;). DSMBs review unblinded study data at pre<FONT CLASS="nobreak">-specified</FONT> times during the course of the study. If the DSMB determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy, the DSMB can make a recommendation to the sponsor to modify or stop the trial.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Other grounds for a sponsor&#x2019;s decision to suspend or terminate a study may be made based on evolving business objectives or the competitive climate.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">For purposes of BLA approval, clinical trials are typically conducted in the following sequential phases:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;1:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The investigational product is initially introduced into a small group of healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These trials may also yield early evidence of effectiveness.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;2:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The investigational product is administered to a slightly larger patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#x00a0;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#x00a0;III clinical trials.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Phase&#x00a0;3:&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to generate sufficient data to statistically demonstrate the efficacy and safety of the product, to establish the overall risk/benefit ratio of the investigational product, and to provide an adequate basis for product approval by FDA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These phases may overlap or be combined. In some cases, FDA may require, or companies may voluntarily pursue, additional clinical trials after a product are approved to gain more information about the product, referred to as Phase&#x00a0;4 trials. Post<FONT CLASS="nobreak">-approval</FONT> trials are conducted following initial approval, often to develop additional data and information relating to the use of the product in new indications.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to FDA.&#x00a0;In addition, IND safety reports must be submitted to FDA for any of the following: serious and unexpected suspected adverse reactions in study subjects; findings from epidemiological studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">A sponsor&#x2019;s planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">During clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient<FONT CLASS="nobreak">-reported</FONT> outcomes (&#x201c;PROs&#x201d;), the process typically is an iterative one. FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on optimizing PRO instruments during the clinical development process, FDA usually reserves final judgment until it reviews the BLA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Concurrent with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP.&#x00a0;The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">BLA Submission and Review</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Assuming successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit a BLA requesting licensing to market the biologic for one or more indications in the United&#x00a0;States. The BLA must include the results of nonclinical studies and clinical trials; detailed information on the product&#x2019;s chemistry, manufacture, controls; and proposed labeling. Under the PDUFA, a BLA submission is subject to an application user fee, unless a waiver, reduction, or exemption applies.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">FDA will initially review the BLA for completeness before accepting it for filing. Under FDA&#x2019;s procedures, the agency has 60&#x00a0;days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After the BLA is accepted for filing, FDA reviews the BLA to determine, among other things, whether a product is safe, pure, and potent and if the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#x2019;s continued identity, strength, quality, safety, purity, and potency. To ensure cGMP, GLP, GCP, GTP, and other regulatory compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production and quality control. In addition, FDA expects that all data be reliable and accurate, and requires sponsors to implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#x2019;s responsibility to ensure the safety, efficacy and quality of its product or products.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">For cellular products, FDA will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. GTPs are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and cellular and tissue<FONT CLASS="nobreak">-based</FONT> products (&#x201c;HCT/Ps&#x201d;), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue<FONT CLASS="nobreak">-based</FONT> products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also specify how HCT/P establishments must register and list their HCT/Ps with FDA and how they must evaluate donors through screening and testing, where applicable.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The performance goals and policies implemented by FDA under the PDUFA generally provide for FDA action on an original BLA within 10&#x00a0;months of filing, which (as discussed above) typically occurs within 60&#x00a0;days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by FDA&#x2019;s requests for additional information or clarification.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate, and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will be produced, FDA may issue an approval letter or a Complete Response Letter (&#x201c;CRL&#x201d;). An approval letter authorizes commercial marketing of the biological with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that FDA has identified in the BLA, except that where FDA determines that the data supporting the application are inadequate to support approval, FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to FDA&#x2019;s satisfaction in a resubmission of the BLA, FDA will issue an approval letter. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional data, information, or clarification. FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied and may require additional testing or information and/or require new clinical trials. Even with submission of this additional information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">During the approval process, FDA will determine whether a REMS is necessary to help ensure the benefits outweigh the risks of the biologic. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If FDA concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and FDA will not approve the BLA without a REMS that the agency has determined is acceptable.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If the FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings, or precautions be included in the product labeling. FDA may also require that post<FONT CLASS="nobreak">-approval</FONT> studies, including Phase&#x00a0;4 clinical trials, be conducted to further assess the drug&#x2019;s safety after approval. FDA may prevent or limit further marketing of a product based on the results of post<FONT CLASS="nobreak">-market</FONT> studies or surveillance programs.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of products to the FDA, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In general, an approved BLA only allows the sponsor to market the biologic as approved, without modification. If, for example, a sponsor modifies an approved T cell product to target different peptides or in our case to target another HLA type, the sponsor would be required to either file a supplemental BLA with FDA or receive FDA approval for a comparability protocol in order to implement this change into the final product.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The FDA may withdraw the product approval if compliance with pre- and post<FONT CLASS="nobreak">-marketing</FONT> requirements is not maintained or if problems occur after the product reaches the marketplace.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Post-Approval</FONT><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"> Requirements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences, product sampling and distribution, and advertising and promotion of the product. After approval, many types of changes to the approved product, such as adding new </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post<FONT CLASS="nobreak">-approval</FONT> change. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA.&#x00a0;Biologic manufacturers and their third<FONT CLASS="nobreak">-party</FONT> contractors are required to register their facilities with the FDA and certain state agencies. These facilities are subject to routine and periodic unannounced inspections by FDA and certain state agencies for compliance with cGMP, post<FONT CLASS="nobreak">-marketing</FONT> safety reporting and data integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product. FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls ensuring complete and secure data; activities documented at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness, and compliance with established standards.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Post<FONT CLASS="nobreak">-approval</FONT> changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon the sponsor and any third<FONT CLASS="nobreak">-party</FONT> manufacturers that the sponsor may use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance, and other aspects of regulatory compliance.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post<FONT CLASS="nobreak">-approval</FONT> studies to assess new safety risks; or imposition of distribution or other restrictions under a REMS.&#x00a0;Other potential consequences include, for example:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market, or product recalls;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>fines, warning or untitled letters, or holds on post<FONT CLASS="nobreak">-approval</FONT> clinical studies;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>refusal of FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>product seizure or detention, or refusal of FDA to permit the import or export of products; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>permanent injunctions and consent decrees, including the imposition of civil or criminal penalties.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">FDA strictly regulates the marketing, labeling, advertising, and promotion of prescription drug products placed on the market. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved labeling. FDA&#x2019;s regulation includes, among other things, standards and regulations for direct<FONT CLASS="nobreak">-to</FONT><FONT CLASS="nobreak">-consumer</FONT> advertising, communications regarding unapproved uses, industry<FONT CLASS="nobreak">-sponsored</FONT> scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims relating to a product&#x2019;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not approved by FDA, as reflected in the product&#x2019;s prescribing information. In the United&#x00a0;States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#x2019;s labeling, known as off<FONT CLASS="nobreak">-label</FONT> uses, because FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#x2019; communications and prohibit the promotion of off<FONT CLASS="nobreak">-label</FONT> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non<FONT CLASS="nobreak">-promotional</FONT>, non<FONT CLASS="nobreak">-misleading</FONT> communication regarding off<FONT CLASS="nobreak">-label</FONT> information, such as distributing scientific or medical journal information.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If a company is found to have promoted off<FONT CLASS="nobreak">-label</FONT> uses, it may become subject to adverse public relations and administrative and judicial enforcement by FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services (&#x201c;HHS&#x201d;), as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil, administrative, and criminal fines, penalties, and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil, administrative, and criminal fines and penalties against </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">companies for alleged improper promotion and has also requested that companies enter into Corporate Integrity Agreements and Consent Decrees of Permanent Injunction under which specified promotional conduct is changed or curtailed.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The distribution of prescription drugs and biologics are subject to the Drug Supply Chain Security Act (&#x201c;DSCSA&#x201d;), which requires manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification, and licensing requirements. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Expedited Development and Review Programs</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">FDA offers a number of expedited development and review programs for qualifying product candidates. The fast<FONT CLASS="nobreak">-track</FONT> program is intended to expedite or facilitate the process of reviewing new products that meet certain criteria. Specifically, new products are eligible for fast<FONT CLASS="nobreak">-track</FONT> designation if they are intended to treat a serious or life<FONT CLASS="nobreak">-threatening</FONT> disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. A product intended to treat a serious or life<FONT CLASS="nobreak">-threatening</FONT> disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. Any marketing application for a biologic submitted to FDA for approval, including a product with a fast<FONT CLASS="nobreak">-track</FONT> designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite FDA review and approval process, such as priority review and accelerated approval. FDA also may grant accelerated approval to certain products studied for their safety and effectiveness in treating serious or life<FONT CLASS="nobreak">-threatening</FONT> diseases or conditions.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The RMAT designation, which we are currently planning to seek for some of our therapies, is intended to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1)&#x00a0;the drug is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#x00a0;the drug is intended to treat, modify, reverse, or cure a serious or life<FONT CLASS="nobreak">-threatening</FONT> disease or condition; and (3)&#x00a0;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long<FONT CLASS="nobreak">-term</FONT> clinical benefit, or reliance upon data obtained from a meaningful number of sites (including through expansion to additional sites) so as to remove any likelihood of site<FONT CLASS="nobreak">-specific</FONT> or investigator<FONT CLASS="nobreak">-specific</FONT> bias on the evidence of effectiveness. Once approved, when appropriate, FDA can permit fulfillment of post<FONT CLASS="nobreak">-approval</FONT> requirements for RMATs receiving accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real<FONT CLASS="nobreak">-world</FONT> evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post<FONT CLASS="nobreak">-approval</FONT> monitoring of all patients treated with the therapy prior to approval.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Patent Term Restoration and Marketing Exclusivity</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After approval, owners of relevant drug or biological product patents may apply for up to a five year term patent extension to restore a portion of patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a drug or biologic containing the active ingredient under the Drug Price Competition and Patent Term Restoration Act&#x00a0;of&#x00a0;1984, referred to as the Hatch<FONT CLASS="nobreak">-Waxman</FONT> Act. The allowable patent term extension is calculated as one<FONT CLASS="nobreak">-half</FONT> of the product&#x2019;s testing phase, which is the time between the effective date of an IND and initial BLA submission, and all of the approval phase, which is the time between BLA submission and approval, up to a maximum of five&#x00a0;years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">the extension may not exceed 14&#x00a0;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#x00a0;days of approval, even if the product cannot be commercially marketed at that time. The USPTO, in consultation with FDA, reviews and approves the application for patent term restoration.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">For patents that might expire during the BLA application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post<FONT CLASS="nobreak">-approval</FONT> patent extension is reduced by one year. The director of the USPTO must determine that approval of the product candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for which a BLA has not been submitted.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Biosimilars and Marketing Exclusivities</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Biologics Price Competition and Innovation Act (&#x201c;BPCIA&#x201d;) created an abbreviated approval pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. A biological product on which another biological product candidate&#x2019;s BLA relies to establish bio similarity is known as a reference product. Bio similarity sufficient to reference a prior FDA<FONT CLASS="nobreak">-approved</FONT> product requires that there be no differences in conditions of use, route of administration, dosage form and strength, and no clinically meaningful differences between the biological product candidate and the reference product in terms of safety, purity, and potency. Bio similarity must be shown through analytical trials, animal trials and at least one clinical trial, unless the Secretary of HHS waives a required element. A biosimilar product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biological product candidate and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics, as well as the process by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being resolved by FDA.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">A reference biologic is granted 12&#x00a0;years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four&#x00a0;years from the date of licensure of the reference product. The first biological product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&#x00a0;one year after first commercial marketing of the first interchangeable biosimilar, (ii)&#x00a0;18&#x00a0;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&#x00a0;18&#x00a0;months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&#x00a0;42&#x00a0;months after the first interchangeable biosimilar&#x2019;s application has been approved if a patent lawsuit is ongoing within the 42<FONT CLASS="nobreak"> </FONT>month period. At this time, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy laws and regulations.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Healthcare Regulation</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Coverage, Pricing, and Reimbursement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our ability to successfully commercialize any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third<FONT CLASS="nobreak">-party</FONT> payors provide coverage and establish adequate reimbursement levels for such products, and significant uncertainty exists as to the coverage and reimbursement status of any products for which may we obtain regulatory approval. In the United&#x00a0;States, third<FONT CLASS="nobreak">-party</FONT> payors include federal and state health care programs, private managed care providers, health insurers and other organizations. The process for determining whether a third<FONT CLASS="nobreak">-party</FONT> payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third<FONT CLASS="nobreak">-party</FONT> payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA<FONT CLASS="nobreak">-approved</FONT> products for a particular indication. Third<FONT CLASS="nobreak">-party</FONT> payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost<FONT CLASS="nobreak">-effectiveness</FONT> of medical products, therapies, and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco<FONT CLASS="nobreak">-economic</FONT> studies in order to demonstrate the medical necessity and cost<FONT CLASS="nobreak">-effectiveness</FONT> </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost<FONT CLASS="nobreak">-effective</FONT>. A payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third<FONT CLASS="nobreak">-party</FONT> reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third<FONT CLASS="nobreak">-party</FONT> payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United&#x00a0;States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third<FONT CLASS="nobreak">-party</FONT> reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Other Healthcare Laws and Compliance Requirements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Although we currently do not have any commercialized products, our current and future business operations may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti<FONT CLASS="nobreak">-kickback</FONT>, fraud and abuse, false claims, privacy and security, price reporting and physician sunshine laws. Some of our pre<FONT CLASS="nobreak">-commercial</FONT> activities are subject to some of these laws.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute makes it illegal for any person or entity, including a prescription drug manufacturer or a party acting on its behalf to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration in cash or in kind that is intended to induce or reward the referral of business, including the purchase, order, or lease of any item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value. The Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers and beneficiaries on the other.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute. Instead, the legality of the arrangement will be evaluated on a case<FONT CLASS="nobreak">-by</FONT><FONT CLASS="nobreak">-case</FONT> basis based on a cumulative review of all its facts and circumstances. Several courts have found that the Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute may be violated if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare program business. In addition, liability may be established without actual knowledge of the statute or specific intent to violate it. Violations of this law are punishable by up to ten&#x00a0;years in prison, and can also result in criminal fines, civil money penalties and exclusion from participation in federal healthcare programs.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Moreover, a claim including items or services resulting from a violation of the federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Persons and entities can be held liable under these laws if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off<FONT CLASS="nobreak">-label</FONT>. Many pharmaceutical and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe the company&#x2019;s products; and inflating prices reported to private price publication services, which are used to set drug payment </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">rates under government healthcare programs. Penalties for federal civil False Claims Act violations may include up to three times the actual damages sustained by the government, plus mandatory civil penalties of between $13,508 and $27,018 for each separate false claim, and the potential for exclusion from participation in federal healthcare programs. In addition, although the federal False Claims Act is a civil statute, False Claims Act violations may also implicate various federal criminal statutes.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The healthcare fraud provisions of the Health Insurance Portability and Accountability Act (&#x201c;HIPAA&#x201d;) prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third- party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti<FONT CLASS="nobreak">-Kickback</FONT> Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Many states have analogous laws and regulations, such as: state anti<FONT CLASS="nobreak">-kickback</FONT> and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non<FONT CLASS="nobreak">-governmental</FONT> third<FONT CLASS="nobreak">-party</FONT> payors, including private insurers; laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to certain healthcare providers; laws that require drug manufacturers to report information related to clinical trials or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; laws that restrict the ability of manufacturers to offer co<FONT CLASS="nobreak">-pay</FONT> support to patients for certain prescription drugs; and laws and local ordinances that require identification or licensing of sales representatives.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#x201c;HITECH&#x201d;), and their implementing regulations, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#x2019;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive, or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The U.S.&#x00a0;federal Physician Payment Sunshine Act, implemented as the Open Payments Program, requires manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals (and certain other practitioners as of 2022), as well as ownership and investment interests held in the company by physicians and their immediate family members.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Because we intend to commercialize products that could be reimbursed under a federal health care program and other governmental healthcare programs, we intend to develop a comprehensive compliance program that establishes internal control to facilitate adherence to the rules and program requirements to which we will or may become subject. Although the development and implementation of compliance programs designed to establish internal control and facilitate compliance can mitigate the risk of investigation, prosecution, and penalties assessed for violations of these laws, the risks cannot be entirely eliminated.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Health Care Reform</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In the United&#x00a0;States and some foreign jurisdictions, there have been, and continue to be, legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post<FONT CLASS="nobreak">-approval</FONT> activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United&#x00a0;States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United&#x00a0;States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">For example, the Affordable Care Act (&#x201c;ACA&#x201d;) substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.&#x00a0;pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#x00a0;D beneficiaries, and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#x2019; rebate liability by raising the minimum basic Medicaid rebate. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">There have been judicial challenges to certain aspects of the ACA, as well as efforts by Congress to modify, and by agencies to alter the implementation of, certain aspects of the ACA.&#x00a0;For example, Congress eliminated the tax penalty for failure to comply with the ACA&#x2019;s individual mandate to carry health insurance. Further, the Bipartisan Budget Act&#x00a0;of&#x00a0;2018, among other things, amended the ACA to increase from 50 percent to 70 percent the point<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-sale</FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part&#x00a0;D to close the coverage gap in most Medicare drug plans, commonly referred to as the donut hole.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">It is possible that the ACA, as currently enacted or as may be amended in the future, as well as other healthcare reform measures, including those that may be adopted in the future, may result in more rigorous coverage criteria, and less favorable payment methodologies, or other downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement or restriction on coverage under Medicare or other federal health care programs may result in a similar reduction or restriction by private payors.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Other legislative changes have been proposed and adopted in the U.S.&#x00a0;since the ACA was enacted. For example, the Inflation Reduction Act introduces several changes to the Medicare Part&#x00a0;D benefit, including a limit on annual out<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-pocket</FONT> costs and a change in manufacturer liability under the program which could negatively affect the profitability of our product candidates. The IRA sunsets the current Part&#x00a0;D coverage gap discount program starting in 2025 and replaces it with a new manufacturer discount program. Failure to pay a discount under this new program will be subject to a civil monetary penalty. In addition, the IRA establishes a Medicare Part&#x00a0;B inflation rebate scheme effective January&#x00a0;2023 and a Medicare Part&#x00a0;D inflation rebate scheme effective October&#x00a0;2022, under which, generally speaking, manufacturers will owe rebates if the price of a Part&#x00a0;B or Part&#x00a0;D drug increases faster than the pace of inflation. Failure to timely pay a Part&#x00a0;B or D inflation rebate is subject to a civil monetary penalty. The IRA also creates a drug price negotiation program under which the prices for Medicare units of certain high Medicare spend drugs and biologicals without generic or biosimilar competition will be capped by reference to, among other things, a specified non<FONT CLASS="nobreak">-federal</FONT> average manufacturer price starting in 2026. Failure to comply with requirements under the drug price negotiation program is subject to an excise tax and/or a civil monetary penalty. Congress continues to examine various policy proposals that may result in pressure on the prices of prescription drugs with respect to the government health benefit programs and otherwise. The IRA or other legislative changes could impact the market conditions for our product candidates.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In general, there has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug product pricing, </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Drug Pedigree Laws</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">State and federal governments have proposed or enacted various drug pedigree laws which can require the tracking of all transactions involving prescription drugs from the manufacturer to the pharmacy (or other dispensing) level. Companies are required to maintain records documenting the chain of custody of prescription drug products beginning with the purchase of such products from the manufacturer. Compliance with these pedigree laws requires implementation of extensive tracking systems as well as heightened documentation and coordination with customers and manufacturers. While we fully intend to comply with these laws, there is uncertainty about future changes in legislation and government enforcement of these laws. Failure to comply could result in fines or penalties, as well as loss of business that could have a material adverse effect on our financial results.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Federal Regulation of Patent Litigation Settlements and Authorized Generic Arrangements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As part of the Medicare Prescription Drug, Improvement, and Modernization Act&#x00a0;of&#x00a0;2003, companies are required to file with the U.S.&#x00a0;Federal Trade Commission (&#x201c;FTC&#x201d;) and the U.S.&#x00a0;Department of Justice certain types of agreements entered into between brand and generic pharmaceutical companies related to the settlement of patent litigation or manufacture, marketing and sale of generic versions of branded drugs. This requirement could affect the manner in which generic drug manufacturers resolve intellectual property litigation and other disputes with brand pharmaceutical companies and could result generally in an increase in private<FONT CLASS="nobreak">-party</FONT> litigation against pharmaceutical companies or additional investigations or proceedings by the FTC or other governmental authorities.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Other</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The U.S.&#x00a0;federal government, various states and localities have laws regulating the manufacture and distribution of pharmaceuticals, as well as regulations dealing with the substitution of generic drugs for branded drugs. Our operations are also subject to regulation, licensing requirements and inspection by the states and localities in which our operations are located or in which we conduct business.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Certain of our activities are also subject to FTC enforcement actions. The FTC enforces a variety of antitrust and consumer protection laws designed to ensure that the nation&#x2019;s markets function competitively, are vigorous, efficient and free of undue restrictions. Federal, state, local and foreign laws of general applicability, such as laws regulating working conditions, also govern us.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, we are subject to numerous and increasingly stringent federal, state and local environmental laws and regulations concerning, among other things, the generation, handling, storage, transportation, treatment and disposal of toxic and hazardous substances, the discharge of pollutants into the air and water and the cleanup of contamination. We are required to maintain and comply with environmental permits and controls for some of our operations, and these permits are subject to modification, renewal and revocation by the issuing authorities. Our environmental capital expenditures and costs for environmental compliance may increase in the future as a result of changes in environmental laws and regulations or increased manufacturing activities at any of our facilities. We could incur significant costs or liabilities as a result of any failure to comply with environmental laws, including fines, penalties, third<FONT CLASS="nobreak">-party</FONT> claims and the costs of undertaking a clean<FONT CLASS="nobreak">-up</FONT> at a current or former site or at a site to which our wastes were transported. In addition, we have grown in part by acquisition, and our diligence may not have identified environmental impacts from historical operations at sites we have acquired in the past or may acquire in the future.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Employees</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of the date of this prospectus, we have two full time employees. We have no part<FONT CLASS="nobreak">-time</FONT> employees and we engage one consultant. We believe that we maintain good relations with our employees.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Legal Proceedings</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Facilities</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We are located at 2 East Broad Street, 2<FONT CLASS="CharOverride-1" STYLE="font-size:58%;vertical-align:super;">nd</FONT> Floor, Hopewell, NJ&#x00a0;08525. This space is donated to us by one of our officers and we do not pay a monthly fee. We believe our current facilities are suitable for our current operations.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T12"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Executive Officers and Directors</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table sets forth information regarding our executive officers and non<FONT CLASS="nobreak">-employee</FONT> directors.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Age</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#x00a0;Christopher Kim, MD</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">74</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chairman and Chief Medical Officer</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Erik Emerson</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">54</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Executive Officer and Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mark Corrao</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">66</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jakap Koo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">64</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#x00a0;Bennett Weintraub, PhD.</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">56</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Hankil Yoon</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">62</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carol O&#x2019;Donnell</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">67</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Elona Kogan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">55</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 53.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Christopher Kim, MD. &#x2014;&#x00a0;Chairman and Chief Medical Officer</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Dr.&#x00a0;Christopher Kim has been our Chairman and Chief Medical Officer since our inception and served as our interim Chief Executive Officer from July 2022 to September 2023. Dr.&#x00a0;Kim is the inventor and developer of Apitox and the founder of Apimeds Korea, where he has served as a director since its inception. Mr.<FONT CLASS="nobreak"> </FONT>Kim served as the Chief Executive Officer of Apimeds Korea from May&#x00a0;2003 to August&#x00a0;2011. Prior to founding Apimeds Korea, Dr.&#x00a0;Kim lead with the support of Guju Pharmaceuticals, clinical trials for Apitoxin in Korea, which was approved by the Korea Food and Drug Administration in 2003 for relief of pain and inflammation for patients with Osteoarthritis. In 2005, he began focusing on the clinical development of Apitox in the United&#x00a0;States, including the first of two<FONT CLASS="nobreak">-Phase</FONT>&#x00a0;III clinical studies for Osteoarthritis. Prior to his time with Apimeds Korea, Dr.&#x00a0;Kim served as the President of the International Pain Institute of New Jersey from January 1983 to May 2003, a center for chronic pain and other disabling diseases that conducted clinical research and provided treatment. He served as a professor at Biomedical Center, CHA Graduate School of Medicine in Korea from March&#x00a0;2005 to February&#x00a0;2017. Dr.&#x00a0;Kim is a licensed physician in New Jersey, New&#x00a0;York and Korea and a Pain Medicine Specialist (American Board). Over the past twenty&#x00a0;years, Dr.&#x00a0;Kim has treated thousands of chronically disabled patients with autoimmune diseases, including MS.&#x00a0;Dr.&#x00a0;Kim received his medical degree from the School of Medicine, CN University in Korea.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe Dr.&#x00a0;Kim&#x2019;s extensive experience in pharmaceutical development and the biopharmaceutical industry, as well as his research and treatment of autoimmune diseases, and institutional knowledge of our product candidate, qualifies him to serve on our board of directors.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Erik Emerson&#x00a0;&#x2014;&#x00a0;Chief Executive Officer</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Erik Emerson has been our Chief Executive Officer since September&#x00a0;2023. Mr.&#x00a0;Emerson is a 25<FONT CLASS="nobreak">-year</FONT> veteran of the biopharmaceutical industry. He also serves as an advisor to Odyssey Neuropharma, Inc. where he has served since August 2022. In this role, Mr.&#x00a0;Emerson leads business development and positioning efforts for a Phase&#x00a0;II asset in evaluation for the treatment of mild traumatic brain injury (concussion). Mr.&#x00a0;Emerson was the Chief Commercial Officer for Mezzion Pharmaceuticals, a Korean company establishing operations in the United&#x00a0;States, for treatment of Single Ventricle Heart Disease post Fontan surgery, from February&#x00a0;2017 to January&#x00a0;2020. At Adhera Therapeutics, previously known as Marina Biotech, Mr.&#x00a0;Emerson served as the Chief Commercial Officer and board member from February&#x00a0;2018 to November&#x00a0;2019. Prior to that Mr.<FONT CLASS="nobreak"> </FONT>Emerson served as the Executive Chairman and Chief Executive Officer of BioMarisLLC from July 2017 to November 2019. He also served as the President and Chief Executive Officer of Symplmed Pharmaceuticals &amp; Technologies from July 2013 to May 2018. From May 2010 to July 2013, he served as the Senior Director of Commercial Development, Xoma Ltd. He was the director of marketing at Gilead Sciences from May&#x00a0;2007 to May&#x00a0;2010. Mr.<FONT CLASS="nobreak"> </FONT>Emerson has served as an advisory board member to NuGen Medical Devices since August 2022. Mr.&#x00a0;Emerson began his career in sales, sales training and marketing with King Pharmaceuticals from September&#x00a0;2001 to May&#x00a0;2007. Mr.&#x00a0;Emerson received a Bachelor&#x2019;s in Arts in Political Science from the University of Oregon.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Mark Corrao &#x2014; Chief Financial Officer</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Mark Corrao has served as our Chief Financial Officer since October 2024. Mr.<FONT CLASS="nobreak"> </FONT>Corrao is currently serving as the chief financial officer for Ealixir, Inc. (OTC:EAXR), a publicly traded software company specializing in the management and protection of digital identities. He began serving in this role in January 2024. Previously, Mr.<FONT CLASS="nobreak"> </FONT>Corrao was the chief financial officer for Amesite, Inc. (OTC:AMST), a publicly traded software company from December 2021 through December 2022. Since February 2012, Mr.<FONT CLASS="nobreak"> </FONT>Corrao has served as the chief financial officer of Neuropathix, Inc., a private biopharmaceutical company. From June 2012 to July 2020 Mr.<FONT CLASS="nobreak"> </FONT>Corrao was a Managing Director of The CFO Squad LLC, where he is currently an advisor. From January 2017 to June 2021 Mr.<FONT CLASS="nobreak"> </FONT>Corrao was the chief financial officer for Generex Biotechnology Corp (OTC:GNBT) and its subsidiaries. From December 2018 to October 2021, Mr.<FONT CLASS="nobreak"> </FONT>Corrao was the chief financial officer for Brain Scientific, Inc., a medical device company. Mr.<FONT CLASS="nobreak"> </FONT>Corrao served as the chairman of the audit committee for Success Holdings Group International from January 2015 through December 2017. In February 2003, Mr.<FONT CLASS="nobreak"> </FONT>Corrao founded Strikeforce Technology, Inc. (OTC:SFOR), a publicly traded software development and services company and served as the chief financial officer until June 2010, and he remained a board member until August 2013. Prior to starting Strikeforce, Mr.<FONT CLASS="nobreak"> </FONT>Corrao was a director at Applied Digital Solutions from December 2000 through December 2001. Mr.<FONT CLASS="nobreak"> </FONT>Corrao was one of the founders and a Vice President at Advanced Communication Sciences from June 1997 through December 2000, when the company was sold. Mr.<FONT CLASS="nobreak"> </FONT>Corrao has spent numerous years in the public accounting arena specializing in certified auditing, SEC accounting, corporate taxation and financial planning. Mr.<FONT CLASS="nobreak"> </FONT>Corrao&#x2019;s background also includes numerous years on Wall Street with Merrill Lynch, Spear Leeds &amp; Kellogg and Greenfield Arbitrage Partners. While on Wall Street, Mr.<FONT CLASS="nobreak"> </FONT>Corrao was involved in several initial public offerings and has been a guiding influence in several startup companies. Mr.<FONT CLASS="nobreak"> </FONT>Corrao has a B.S. in Accounting from The City University of New York. </P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Jakap Koo&#x00a0;&#x2014;&#x00a0;Director</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Mr.&#x00a0;Jakap Koo has served as a director since October&#x00a0;2023. Mr.&#x00a0;Koo is also the Chief Executive Officer and President of both Apimeds Korea and its parent company, Inscobee Inc. (KRX: 006490), where he has served since March&#x00a0;2020. Before joining Apimeds Korea and Inscobee, from March&#x00a0;2015 to December&#x00a0;2019 he served as the Chief Executive Officer at Lotte Auto Lease Co. Ltd., where he grew company revenue through various financial services of car rental, installment payment, automobile leasing and investment banking to both B2B and B2C clients. Mr.&#x00a0;Koo has spent more than 35&#x00a0;years mostly as C<FONT CLASS="nobreak">-level</FONT> executives in various financial institutions and IT companies. His management and operational experiences cover banking, asset management, venture capital, private equity, and biotechnology companies. Mr.&#x00a0;Koo has received his MBA from Stern School of New&#x00a0;York University. He graduated from Seoul National University majoring in Law.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe Mr.&#x00a0;Koo&#x2019;s extensive financial knowledge qualifies him to serve on our board of directors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Independent Directors:</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Dr.&#x00a0;Bennett Weintraub, PhD.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Dr.&#x00a0;Weintraub has served as a director since October&#x00a0;2023. Dr.&#x00a0;Weintraub currently serves as the President of inThought Research (&#x201c;inThought&#x201d;), a healthcare business intelligence consulting firm which he founded in 2009. inThought provides business development support, competitive intelligence monitoring, medical conference coverage, and other services both to professional investors and to pharma / biotech companies. Dr. Weintraub has also served as the Chief Scientific Officer of inPhronesis since 2018.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After completing his training in immunology and biochemistry, Dr.&#x00a0;Weintraub co<FONT CLASS="nobreak">-founded</FONT> Biotech Tracker, an online tool for investors, where he served as a financial analyst from 2000 to 2008. From 2006 to 2008, Dr.&#x00a0;Weintraub served as an analyst at Reuters Insight, providing analysis of drug development and trends in medicine to professional investors. Dr.&#x00a0;Weintraub served as a licensed security analyst with Variant Research from 2005 to 2006.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">From 1999 to 2000, Dr.&#x00a0;Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell. Dr.&#x00a0;Weintraub performed biochemistry and immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra, Australia. He earned his doctorate in Biology from the University of California, San Diego, and a Bachelor of Science in Life Science from the Massachusetts Institute of Technology.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe Mr.&#x00a0;Weintraub&#x2019;s extensive science background qualifies him to serve on our board of directors.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Carol O&#x2019;Donnell</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Carol O&#x2019;Donnell has served as a director since October&#x00a0;2023. Ms. O&#x2019;Donnell is currently a Director and Member of the Audit Committee of Sono<FONT CLASS="nobreak">-Tek</FONT> Corporation (NASDAQ: SOTK), where she has served since November&#x00a0;2018. Prior to that, she served as General Counsel to Boothbay Fund Management LLC, a registered investment adviser, from December&#x00a0;2019 through May&#x00a0;2021. Ms. O&#x2019;Donnell joined&#x00a0;Prot&#x00e9;g&#x00e9; Partners and MOV37, an industry leading firm investing in and seeding smaller and emerging hedge fund managers in April&#x00a0;2016 and has served as Chief Executive Officer since January&#x00a0;2018. Prior to joining Prot&#x00e9;g&#x00e9; Partners and MOV37, Ms. O&#x2019;Donnell was the Director of Legal and Compliance with DARA Capital US, Inc., a Swiss<FONT CLASS="nobreak">-owned</FONT> boutique registered investment advisory and wealth management firm from January&#x00a0;2013 to March&#x00a0;2016. She served as General Counsel and Chief Compliance Officer of each of the Permal Group and Framework Investment Group from June&#x00a0;2004 through February&#x00a0;2011 and from January&#x00a0;2002 to May&#x00a0;2004, respectively. She also served as a director of FSI Low Beta from 2012 to 2021. Ms. O&#x2019;Donnell was named one of the Top 50 Women in Hedge Funds in September&#x00a0;2018 and is currently admitted to practice law in the State of Connecticut.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe Ms. O&#x2019;Donnell&#x2019;s extensive experience in the financial industry qualifies her to serve on our board of directors.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Hankil Yoon, PhD.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Hankil Yoon has served as a director since October&#x00a0;2023. Dr.&#x00a0;Yoon has extensive experience in front<FONT CLASS="nobreak">-end</FONT> business areas such as product strategy and planning, software technology and product development, mobile services, global partnership, sales, investment, and mergers and acquisitions and extensive knowledge of the entire software stack, ranging from firmware and OS, middleware. He is the owner of multiple patents on data mining and mobile technology.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Dr.&#x00a0;Yoon was previously the Chief Executive Officer of Digital Domain Virtual Human, Inc. from January&#x00a0;2020 to November&#x00a0;2021 where he managed a global organization of developers throughout the United&#x00a0;States, Canada and Taiwan using AI technology to implement best quality digital human at optimal speed using minimal amount of facial data and created partnerships with Google, Amazon, and Microsoft to implement &#x201c;AI with a human&#x00a0;face&#x201d;. He served as the Executive Advisor to the Chief Executive Officer of Flipboard, Inc. from January&#x00a0;2019 to December&#x00a0;2020. Prior to that, Mr.&#x00a0;Yoon served as the Senior Vice President at Samsung Electronics, from May&#x00a0;2005 to December&#x00a0;2018. He served as the Chairperson at the Tizen Association from January&#x00a0;2015 to December&#x00a0;2018. Mr.&#x00a0;Yoon served as the Chief Technology Officer at Oracle Corporation, US, from August&#x00a0;2000 to May&#x00a0;2005. Dr.&#x00a0;Yoon has BS in Computer Engineering, Seoul National University (1985)&#x00a0;and an MBA (2017)&#x00a0;in Global Management, an MS in Electrical&#x00a0;&amp; Computer Engineering, University of California at Irvine (1995), PhD, in Computer&#x00a0;&amp; Information Science&#x00a0;&amp; Engineering, University of Florida (2000).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe Mr.&#x00a0;Yoon&#x2019;s extensive experience in product strategy and planning, software technology and product development qualifies him to serve on our board of directors.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Elona Kogan</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Elona Kogan has served as a director since October 2024. Beginning in August 2024, Ms. Kogan has served as the Chief Legal Officer of Terns Pharmaceutical, Inc. (Nasdaq: TERNS), a publicly traded biopharmaceutical company, Prior to joining us, from November 2020 through August 2024, Ms. Kogan served as the General Counsel and Chief Legal Officer of Seer Inc. (Nasdaq: SEER), a publicly traded life science company. From May 2018 through August 2021, Ms. Kogan served as a director of Cardax, Inc., a biotechnology company operating in the inflammatory health space. From March 2019 through August 2020, Ms. Kogan served as the General Counsel of Selecta Biosciences, Inc., a clinical<FONT CLASS="nobreak">-stage</FONT> biotechnology company. Ms. Kogan is a graduate of Southwestern University School of Law. Ms. Kogan graduated from Columbia University, Barnard College, with a B.A. in Economics.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe Ms. Kogan&#x2019;s extensive experience in biopharmaceutical and life science space, in addition to her experience serving as general counsel and chief legal officer of other publicly traded companies qualifies her to serve on our board of directors.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number and Terms of Office of Officers and Directors</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will consist of five members. The term of office of the directors will expire at our first annual meeting of stockholders.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In accordance with the NYSE American corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on the NYSE American. Subject to any other special rights applicable to the stockholders, any vacancies on our board of directors may be filled by the affirmative vote of a majority of the remaining members of the board of directors, although less than a quorum, or by a sole remaining director.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint people to the offices set forth in our Bylaws as it deems appropriate.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes. The division of our board of directors into multiple classes with staggered terms may delay or prevent a change of our management or a change in control.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Family Relationships</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">There are no family relationships among any of our executive officers, directors or director nominees.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Involvement in Certain Legal Proceedings</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the best of our knowledge, none of our executive officers, directors or director nominees were involved in any legal proceedings described in Item&#x00a0;401(f)&#x00a0;of Regulation&#x00a0;S<FONT CLASS="nobreak">-K</FONT> in the past ten&#x00a0;years.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Director Independence</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon completion of this offering, our independent directors will be the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Position</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#x00a0;Bennet Weintraub PhD</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#x00a0;Hankil Yoon PhD</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carol O&#x2019;Donnell</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Elona Kogan</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The NYSE American listing standards require that a majority of our board of directors be independent. An &#x201c;independent director&#x201d; is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the Company&#x2019;s board of directors, would interfere with the director&#x2019;s exercise of independent judgment in carrying out the responsibilities of a director. Our audit committee will be entirely composed of independent directors meeting the NYSE American&#x2019;s additional requirements applicable to members of the audit committee. Our independent directors will have quarterly scheduled meetings at which only independent directors are present.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Executive Officer and Director Compensation</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">After the completion of the offering decisions regarding the compensation to be paid to the members of our board of directors, if any, will determined and/or ratified by the board of directors with recommendations given by the compensation committee. It is anticipated that directors&#x2019; fees will consist of (i) an annual board cash retainer of $10,000 for all non<FONT CLASS="nobreak">-employee</FONT> directors, (ii) an annual cash retainer of $3,000 for service as a chairperson on a committee, and (iii) an annual equity award of $10,000 in stock options issued pursuant to the Equity Incentive Plan. The directors who also serve as an employee of the Company do not receive additional compensation for their service as a director. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Committees of the Board of Directors</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our board of directors will have three standing committees: an audit committee, a compensation committee and the nominating and corporate governance committee. Subject to phase<FONT CLASS="nobreak">-in</FONT> rules and a limited exception, the NYSE American rules and Rule&#x00a0;10A<FONT CLASS="nobreak">-3</FONT> of the Exchange&#x00a0;Act require that the audit committee of a listed company be comprised solely of independent directors, and the NYSE American rules require that the compensation committee of a listed company be comprised solely of independent directors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Audit Committee</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Under the NYSE American listing standards and applicable SEC rules, we are required to have at least three members of the audit committee, all of whom must be independent. Our audit committee will be chaired by Carol O&#x2019;Donnell and its other members will be Elona Kogan and Dr. Bennet Weintraub. Our board of directors will confirm that audit committee members are independent under the NYSE American listing standards and applicable SEC rules.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Each member of the audit committee will be financially literate. Carol O&#x2019;Donnell qualifies as an &#x201c;audit committee financial expert&#x201d; as defined in applicable SEC rules and meets the financial sophistication requirements of the NYSE rules. In making this determination, our board considered Ms. O&#x2019;Donnell&#x2019;s previous and current experience in actively supervising individuals in financial and accounting roles. We will adopt an audit committee charter, which will detail the purpose and principal functions of the audit committee, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>assisting board oversight of (1)&#x00a0;the integrity of our financial statements, (2)&#x00a0;our compliance with legal and regulatory requirements, (3)&#x00a0;our independent auditor&#x2019;s qualifications and independence, and (4)&#x00a0;the performance of our internal audit function and independent auditors.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>pre<FONT CLASS="nobreak">-approving</FONT> all audit and non<FONT CLASS="nobreak">-audit</FONT> services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre<FONT CLASS="nobreak">-approval</FONT> policies and procedures.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>setting clear hiring policies for employees or former employees of the independent auditors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>setting clear policies for audit partner rotation in compliance with applicable laws and regulations;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>obtaining and reviewing a report, at least annually, from the independent auditors describing (1)&#x00a0;the independent auditor&#x2019;s internal quality<FONT CLASS="nobreak">-control</FONT> procedures and (2)&#x00a0;any material issues raised by the most recent internal quality<FONT CLASS="nobreak">-control</FONT> review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five&#x00a0;years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d;;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing and approving any related party transaction required to be disclosed pursuant to Item&#x00a0;404 of Regulation&#x00a0;S<FONT CLASS="nobreak">-K</FONT> promulgated by the SEC prior to us entering into such transaction; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Compensation Committee</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of directors. Under the NYSE American listing standards and applicable SEC rules, we are required to have at least two members of the compensation committee, all of whom must be independent. The Chair of our compensation committee will initially be Carol O&#x2019;Donnell and, the other member will be Hankil Yoon. Our board of directors will confirm that all of our compensation committee members are independent under the NYSE American listing standards and applicable SEC rules.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will adopt a compensation committee charter, which will detail the purpose and responsibility of the compensation committee, including:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#x2019;s compensation, evaluating our Chief Executive Officer&#x2019;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing and making recommendations to our board of directors with respect to (or approving, if such authority is so delegated by our board of directors) the compensation, and any incentive<FONT CLASS="nobreak">-compensation</FONT> and equity<FONT CLASS="nobreak">-based</FONT> plans that are subject to board approval of all of our other officers;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing our executive compensation policies and plans;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>implementing and administering our incentive compensation equity<FONT CLASS="nobreak">-based</FONT> remuneration plans;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>assisting management in complying with our proxy statement and annual report disclosure requirements;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>producing a report on executive compensation to be included in our annual proxy statement; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The charter will also provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by the NYSE American and the SEC.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Nominating and Governance Committee</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our nominating and corporate governance committee will consist of two members. The chair of our nominating and corporate governance committee will be Elona Kogan, and the other member will be Carol O&#x2019;Donnell. Our board of directors will confirm that each member of the nominating and corporate governance committee is independent under the listing standards of the NYSE American.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Specific responsibilities of our nominating and corporate governance committee include:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our board of directors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>considering and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of directors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>overseeing periodic evaluations of the board of directors&#x2019; performance, including committees of the board of directors.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the committee considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our nominating and corporate governance committee will operate under a written charter, to be effective prior to the closing of this offering, which satisfies the applicable listing standards of the NYSE American.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Code of Business Conduct and Ethics</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon effectiveness of this offering, we will adopt a code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. Upon the closing of this offering, our code of business conduct and ethics will be available under the Corporate Governance section of our website at<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> </FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.ap</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">imedspharmaus.com</FONT>. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of the NYSE American concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T11"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">EXECUTIVE COMPENSATION</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Overview</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following discussion contains forward<FONT CLASS="nobreak">-looking</FONT> statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As an &#x201c;emerging growth company,&#x201d; we have opted to comply with the executive compensation disclosure rules applicable to &#x201c;smaller reporting companies,&#x201d; as such term is defined in the rules promulgated under the Securities Act. This section provides an overview of the compensation to be awarded to, earned by, or paid to our principal executive officer for the current fiscal year.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our executive compensation program is based on a pay for performance philosophy. Compensation for our principal executive officer is composed primarily of the following main components: base salary, bonus, and equity incentives in the form of stock options. Like all full<FONT CLASS="nobreak">-time</FONT> employees, our principal executive officer is eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we intend to evaluate our compensation philosophy and compensation plans and arrangements as circumstances require.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our named executive officers for the year ended December&#x00a0;31, 2023, consisting of our principal executive officer and the next two most highly compensated executive officers who were serving in such capacity as of December&#x00a0;31, 2023, were:</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Summary Compensation Table</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table sets forth information concerning the compensation of our named executive officers for the&#x00a0;years ended December&#x00a0;31, 2023, and 2022.</P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Name and Principal Position</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Year</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Salary</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Bonus</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Option</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Awards</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Nonequity</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Incentive</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Plan</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Compensation</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">All</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Other</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Compensation <BR>($)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">Total</FONT><FONT CLASS="CharOverride-3" STYLE="font-size:8pt;font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:8pt;font-style:normal;font-weight:bold;">($)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">Erik Emerson</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.57%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">90,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">90,000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">(Chief&#x00a0;Executive&#x00a0;Officer)</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">2022</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.57%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.59%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">Dr. Christopher Kim</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.57%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">24,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.59%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">24,000</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-16" STYLE="height:12pt;">
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 25.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">Interim </FONT><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">Chief Executive </FONT><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">Officer</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:6pt;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">2022</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.57%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.92%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.00%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.22%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.63%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB_Repeat" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.59%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-4" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Dr. Kim acted as Interim Chief Executive Officer until September 2023.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Employment Agreements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Erik Emerson</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company entered into an employment agreement with Erik Emerson on September<FONT CLASS="nobreak"> </FONT>21, 2023 (the &#x201c;Emerson Agreement&#x201d;). Pursuant to the Emerson Employment Agreement, he will serve as the Company&#x2019;s Chief Executive Officer and receive a yearly salary of $300,000. Mr.<FONT CLASS="nobreak"> </FONT>Emerson&#x2019;s employment shall continue for one year from the date of execution and shall automatically renew for successive one year periods in the event of a closing on a public offering of the company during the initial term unless either party gives 30 days&#x2019; written notice of its intent not to renew the Emerson Agreement prior to the end of the then<FONT CLASS="nobreak">-current</FONT> term.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If Mr.<FONT CLASS="nobreak"> </FONT>Emerson becomes disabled such that he is unable to perform his obligations hereunder, with or without reasonable accommodation, for a period of 180 days or more over a rolling consecutive twelve month period of time, or it is determined that Mr.<FONT CLASS="nobreak"> </FONT>Emerson is not able to perform the essential functions of his duties (incurs a &#x201c;Disability&#x201d;) the Company may terminate Mr.<FONT CLASS="nobreak"> </FONT>Emerson&#x2019;s employment, unless otherwise required by law. In the event employment is terminated as a result of Mr.<FONT CLASS="nobreak"> </FONT>Emerson Disability, the Company shall have no further obligation to pay any unaccrued compensation or unaccrued benefits to Mr.<FONT CLASS="nobreak"> </FONT>Emerson for periods after the date of such termination.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Emerson may be terminated with or without Cause (as defined in the Emerson Agreement) upon thirty (30)&#x00a0;days&#x2019; written notice to Mr.<FONT CLASS="nobreak"> </FONT>Emerson. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Emerson will not be eligible to receive an annual bonus at any time prior to the closing on a public offering (as&#x00a0;defined in the Emerson Agreement) of the Company For all fiscal years following the closing on a public offering of the Company, including any fiscal year during which the closing on a public offering occurs, Mr.<FONT CLASS="nobreak"> </FONT>Emerson will be eligible to receive an annual bonus based on the achievement of goals for the Company&#x2019;s and/or Mr.<FONT CLASS="nobreak"> </FONT>Emerson&#x2019;s performance, as determined by the board of directors in its sole discretion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Emerson is entitled to receive such other employee benefits and perquisites offered by the Company to any of the Company&#x2019;s similarly<FONT CLASS="nobreak">-situated</FONT> corporate employees, provided that the Company shall retain discretion to cancel, modify or amend such benefits provided to Mr.<FONT CLASS="nobreak"> </FONT>Emerson and similarly situated employees in its discretion. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the closing on a public offering, Mr.<FONT CLASS="nobreak"> </FONT>Emerson shall receive an incentive stock option to purchase a number of shares of the Company&#x2019;s common stock equal to 3% of the post<FONT CLASS="nobreak">-public</FONT> offering capitalization of the Company (the &#x201c;Equity Award&#x201d;), of which 40% of the options shall vest upon grant and the remainder will vest in three equal installments on the annual anniversary of the date of grant. Mr.<FONT CLASS="nobreak"> </FONT>Emerson will agree not to sell any shares underlying the Equity Award, even if exercised, for a period of three years from the date of grant. Mr.<FONT CLASS="nobreak"> </FONT>Emerson will be eligible for future equity incentive awards in the discretion of the board of directors.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Mr.<FONT CLASS="nobreak"> </FONT>Emerson irrevocably assigns to the Company (or its designees), and agrees to hold in trust for the sole right and benefit of the Company, without any additional consideration, and to promptly make full written disclosure to the Company of, all of his right, title, and interest in and to any and all Inventions (as defined in the Emerson Agreement) that Mr.<FONT CLASS="nobreak"> </FONT>Emerson invents during his employment and for a period of one year following the termination of his employment with the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">There is customary confidentiality and non<FONT CLASS="nobreak">-solicitation</FONT> clauses in Mr.<FONT CLASS="nobreak"> </FONT>Emerson&#x2019;s agreement whereby he has agreed to keep all confidential information confidential and will not directly or indirectly solicit any of the Company&#x2019;s employees or vendors after his employment with the Company ends.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">While the Company employs Mr.<FONT CLASS="nobreak"> </FONT>Emerson, he agrees that he will not, without the board of directors&#x2019; prior written consent, directly or indirectly, provide services to any other person for which Mr.<FONT CLASS="nobreak"> </FONT>Emerson receives compensation, nor will he otherwise engage in activities that would conflict or interfere with his full and faithful performance of his duties as an employee of the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On May&#x00a0;12, 2020 the Company granted Dr.&#x00a0;Christopher Kim, the Company&#x2019;s Chairman and Chief Medical Officer, a non<FONT CLASS="nobreak">-qualified</FONT> stock option award to purchase 138,900<FONT CLASS="nobreak"> </FONT>shares of the Company&#x2019;s common stock at an exercise price of $11.28 per share. The option vested in three equal installments and vested fully on May&#x00a0;12, 2023. The options have a term of ten&#x00a0;years from the date of grant and shall terminate at the expiration of that period, unless it is terminated at an earlier date pursuant to the provisions of the option grant agreement between the Company and Dr.&#x00a0;Kim.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Consulting Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Mark Corrao</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On October<FONT CLASS="nobreak"> </FONT>4, 2024, the Company entered into a consulting agreement with Mark Corrao (the &#x201c;CFO Consulting Agreement&#x201d;) to engage Mr.<FONT CLASS="nobreak"> </FONT>Corrao (the &#x201c;Consultant&#x201d;) to provide consulting services as the Company&#x2019;s non<FONT CLASS="nobreak">-employee</FONT> chief financial officer prior to the completion of the Company&#x2019;s initial public offering. It is anticipated that following the completion of the Company&#x2019;s initial public offering, the Consultant will become an employee of the Company on a full<FONT CLASS="nobreak">-time</FONT> basis. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Consultant has been duly appointed as the chief financial officer of the Company and will remain as an executive officer of the Company during the term of the CFO Consulting Agreement. The Consultant will report directly to <FONT CLASS="nobreak">Erik Emerson,</FONT> Chief Executive Officer and to any other party designated by Mr.<FONT CLASS="nobreak"> </FONT>Emerson in connection with the performance of the duties under the CFO Consulting Agreement and shall fulfill any other duties reasonably requested by the Company and agreed to by the Consultant.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The initial term of the CFO Consulting Agreement is one year. The CFO Consulting Agreement may only be extended thereafter by mutual agreement, unless earlier terminated. Either party may terminate the CFO Consulting Agreement at any time by providing thirty days&#x2019; written notice to the other party.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As compensation for the services rendered pursuant to the CFO Consulting Agreement, the Company shall pay Consultant a minimum $2,500 upon signing, and $2,500 per month for up to eight hours of services rendered per month, payable on the first business day of each month. Additional hours in excess of eight hours per month, if any, shall be billed at $250.00 per hour.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc. Equity Incentive Plan</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On September<FONT CLASS="nobreak"> </FONT>18, 2024, we adopted&#x00a0;an&#x00a0;equity&#x00a0;incentive&#x00a0;plan for our employees, the<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> </FONT>Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;). The purposes of the Equity Incentive Plan are to provide additional incentives to selected employees, directors and independent contractors of, and consultants to, the Company or its affiliates, to strengthen their commitment, motivate them to faithfully and diligently perform their responsibilities and to attract and retain competent and dedicated persons who are essential to the success of our business and whose efforts will impact our long<FONT CLASS="nobreak">-term</FONT> growth and profitability.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Awards</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan allows the Company to make equity and equity<FONT CLASS="nobreak">-based</FONT> incentive awards to officers, employees, directors, consultants, and advisors. The Board anticipates that providing such persons with a direct stake in the Company will assure a closer alignment of the interests of such individuals with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#x2019;s behalf and strengthening their desire to remain with the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan provides for the grant of non<FONT CLASS="nobreak">-qualified</FONT> stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, stock bonus awards, and performance compensation awards. All awards will be set forth in an award agreement which will detail all terms and conditions of the awards, including any applicable vesting and payment terms and post<FONT CLASS="nobreak">-termination</FONT> exercise limitations.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">A brief description of each award type follows.</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Non</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-Qualified</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Stock Options</FONT>&#x00a0;means the right to purchase shares pursuant to terms and conditions that are not intended to be, or do not qualify as, an Incentive Stock Options;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Incentive Stock Options</FONT>&#x00a0;means the right to purchase shares pursuant terms and conditions that are intended to qualify as, and that satisfy the requirements applicable to, an incentive equity option within the meaning of Code Section&#x00a0;422 of the United&#x00a0;States Internal Revenue Code of 1986, as amended;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Stock Appreciation Rights</FONT>&#x00a0;means a right, designated as an SAR, to receive the appreciation in the fair market value of shares;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Restricted Stock</FONT>&#x00a0;means an award of shares subject to vesting conditions;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Restricted Stock Units</FONT> shall mean a right to receive shares or cash upon vesting;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Stock Bonus Awards</FONT> means unrestricted common stock, or other awards denominated in common stock, either alone or in tandem with other awards; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Performance Compensation Awards</FONT>&#x00a0;means an award granted to a participant that entitles the participant to delivery of shares or cash upon achievement of performance goals.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">1,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock have initially been reserved for the issuance of awards under the Equity Incentive Plan (the &#x201c;Initial Limit&#x201d;). The Initial Limit is subject to adjustment in the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split or other similar change in the Company&#x2019;s capitalization. The maximum aggregate number of shares of common stock of the Company that may be issued upon exercise of incentive stock options under the Equity Incentive Plan shall not exceed the Initial Limit, as adjusted. Shares underlying any awards under the Equity Incentive Plan that are forfeited, cancelled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, satisfied without the issuance </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">of stock or otherwise terminated (other than by exercise) will be added back to the shares available for issuance under the Equity Incentive Plan and, to the extent permitted under Section&#x00a0;422 of the Code and the regulations promulgated thereunder, the shares that may be issued as incentive stock options.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan is currently administered by a committee of at least two&#x00a0;people as the Board may appoint to administer the Equity Incentive Plan or, if no such committee has been appointed by the Board, the Board, pursuant to the terms of the Equity Incentive Plan (the &#x201c;Committee&#x201d;). The plan administrator, which initially will be the Committee, has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the Equity Incentive Plan. The plan administrator may delegate to a committee consisting of one or more officers of the Company, the authority to awards to individuals who are not subject to the reporting and other provisions of Section&#x00a0;16 of the Exchange&#x00a0;Act and not members of the delegated committee, subject to certain limitations and guidelines.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Persons eligible to participate in the Equity Incentive Plan will be officers, employees,&#x00a0;non<FONT CLASS="nobreak">-employee</FONT>&#x00a0;directors, consultants, and advisors of the Company and its subsidiaries as selected from time to time by the plan administrator in its discretion. As of the date of this prospectus, approximately 12 individuals are eligible to participate in the Equity Incentive Plan, which includes approximately two officers, no employees who are not officers, five&#x00a0;non<FONT CLASS="nobreak">-employee</FONT>&#x00a0;directors, and five consultants/independent contractors.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Options</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan permits the granting of both options to purchase common stock of the Company intended to qualify as incentive stock options under Section&#x00a0;422 of the Code and options that do not so qualify. Options granted under the Equity Incentive Plan will be&#x00a0;non<FONT CLASS="nobreak">-qualified</FONT>&#x00a0;options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive stock options may only be granted to employees of the Company and its subsidiaries.&#x00a0;Non<FONT CLASS="nobreak">-qualified</FONT>&#x00a0;options may be granted to any persons eligible to receive awards under the Equity Incentive Plan. The option exercise price of each option will be determined by the plan administrator but generally may not be less than 100% of the fair market value of the common stock of the Company on the date of grant or, in the case of an incentive stock option granted to a ten percent stockholder, 110% of such share&#x2019;s fair market value. The term of each option will be fixed by the plan administrator and may not exceed ten&#x00a0;years from the date of grant. The plan administrator will determine at what time or times each option may be exercised, including the ability to accelerate the vesting of such options.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon exercise of options, the option exercise price must be paid in full either in cash, by certified or bank check or other instrument acceptable to the plan administrator or by delivery (or attestation to the ownership) of shares of common stock of the Company that are beneficially owned by the optionee free of restrictions or were purchased in the open market. Subject to applicable law, the exercise price may also be delivered by a broker pursuant to irrevocable instructions to the broker from the optionee. In addition, the plan administrator may permit&#x00a0;non<FONT CLASS="nobreak">-qualified</FONT>&#x00a0;options to be exercised using a &#x201c;net exercise&#x201d; arrangement that reduces the number of shares issued to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise price.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Stock Appreciation Rights</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The plan administrator may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock of the Company, or cash, equal to the value of the appreciation in the Company&#x2019;s stock price over the exercise price. The exercise price generally may not be less than 100% of the fair market value of common stock of the Company on the date of grant. The term of each stock appreciation right will be fixed by the plan administrator and may not exceed ten&#x00a0;years from the date of grant. The plan administrator will determine at what time or times each stock appreciation right may be exercised, including the ability to accelerate the vesting of such stock appreciation rights.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Restricted Stock and Restricted Stock Units</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The plan administrator may award restricted shares of common stock of the Company and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with the Company through a specified vesting period. The plan administrator may also grant shares of common stock of the Company that are </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">free from any restrictions under the Equity Incentive Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. The plan administrator may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock of the Company.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Stock Bonus Awards</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The plan administration may issue unrestricted common stock, or other awards denominated in common stock, under the Equity Incentive Plan to participants, either alone or in tandem with other awards, in such amounts as the plan administration shall from time to time in its sole discretion determine.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Performance Compensation Awards</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The plan administrator may grant awards under the Equity Incentive Plan to participants, which may be cash<FONT CLASS="nobreak">-based</FONT>, subject to the achievement of certain performance goals, including continued employment with the Company.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Other Material</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan requires the plan administrator to make appropriate adjustments to the number of shares of common stock that are subject to the Equity Incentive Plan, to certain limits in the Equity Incentive Plan, and to any outstanding awards to reflect stock dividends, stock splits, extraordinary cash dividends and similar events.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Except as set forth in a stock award agreement issued under the Equity Incentive Plan, in the event of (i)&#x00a0;a transfer of all or substantially all of the Company&#x2019;s assets, (ii)&#x00a0;a merger, consolidation or other capital reorganization or business combination transaction of the Company with or into another corporation, entity or person, or (iii)&#x00a0;the consummation of a transaction, or series of related transactions, in which any person becomes the beneficial owner directly or indirectly, of more than 50% of Company&#x2019;s then outstanding capital stock, each outstanding stock award (vested or unvested) will be treated as the plan administrator determines, which may include (a)&#x00a0;Company&#x2019;s continuation of such outstanding stock awards (if Company is the surviving corporation); (b)&#x00a0;the assumption of such outstanding stock awards by the surviving corporation or its parent; (c)&#x00a0;the substitution by the surviving corporation or its parent of new stock options or other equity awards for such stock awards; (d)&#x00a0;the cancellation of such stock awards in exchange for a payment to the participants equal to the excess of (1)&#x00a0;the fair market value of the shares subject to such stock awards as of the closing date of such corporate transaction over (2)&#x00a0;the exercise price or purchase price paid or to be paid (if any) for the shares subject to the stock awards (which payment may be subject to the same conditions that apply to the consideration that will be paid to holders of shares in connection with the transaction, subject to applicable law); or (e)&#x00a0;the opportunity for participants to exercise the stock options prior to the occurrence of the corporate transaction and the termination (for no consideration) upon the consummation of such corporate transaction of any stock options not exercised prior thereto.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan provides that a stock award may be subject to additional acceleration of vesting and exercisability upon or after a &#x201c;Change in Control&#x201d; (as defined in the Equity Incentive Plan) as may be provided in the award agreement for such stock award or as may be provided in any other written agreement between the Company or any affiliate and the participant, but in the absence of such provision, no such acceleration will occur.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Participants in the Equity Incentive Plan are responsible for the payment of any federal, state or local taxes that the Company or its subsidiaries are required by law to withhold upon the exercise of options or stock appreciation rights or vesting of other awards. The plan administrator may cause any tax withholding obligation of the Company or its subsidiaries to be satisfied, in whole or in part, by the applicable entity withholding from shares of common stock of the Company to be issued pursuant to an award shares with an aggregate fair market value that would satisfy the withholding amount due. The plan administrator may also require any tax withholding obligation of the Company or its subsidiaries to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares issued pursuant to any award are immediately sold and proceeds from such sale are remitted to the Company or its subsidiaries in an amount that would satisfy the withholding amount due.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Equity Incentive Plan generally does not allow for the transfer or assignment of awards, other than by will or by the laws of descent and distribution or pursuant to a domestic relations order; however, the plan administrator may permit the transfer of&#x00a0;non<FONT CLASS="nobreak">-qualified</FONT>&#x00a0;stock options by gift to an immediate family member, to trusts for the benefit of family members, or to partnerships in which such family members are the only partners.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The plan administrator may amend or discontinue the Equity Incentive Plan and the plan administrator may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may materially and adversely affect rights under an award without the holder&#x2019;s consent. Certain amendments to the Equity Incentive Plan will require the approval of the Company&#x2019;s stockholders. Generally, without shareholder approval, (i)&#x00a0;no amendment or modification of the Equity Incentive Plan may reduce the exercise price of any stock option or the strike price of any stock appreciation right, (ii)&#x00a0;the plan administrator may not cancel any outstanding stock option or stock appreciation right where the fair market value of the common stock underlying such stock option or stock appreciation right is less than its exercise price and replace it with a new option or stock appreciation right, another award or cash and (iii)&#x00a0;the plan administrator may not take any other action that is considered a &#x201c;repricing&#x201d; for purposes of the shareholder approval rules of the applicable securities exchange.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which Company securities are listed or as is otherwise required by the U.S.&#x00a0;Dodd<FONT CLASS="nobreak">-Frank</FONT> Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Company board may impose such other clawback, recovery or recoupment provisions in a stock award agreement as the Company board determines necessary or appropriate.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">No options or stock appreciation rights may be granted under the Equity Incentive Plan after the date that is ten&#x00a0;years from the Equity Incentive Plan Effective Date. No awards under the Equity Incentive Plan have been made prior to the date of this prospectus.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Director Compensation Table</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">None of our directors received any form of compensation for the&#x00a0;years ended December&#x00a0;31, 2023.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T10"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we describe transactions since January&#x00a0;1, 2022, and each currently proposed transaction in which:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>we have been or are to be a participant;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets as of December<FONT CLASS="nobreak">&#x00a0;</FONT>31, 2022 and 2023; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On August&#x00a0;2, 2021, we entered into an agreement with Apimeds Korea, a principal stockholder of the Company (the &#x201c;Business Agreement&#x201d;). Pursuant to the Business Agreement, Apimeds Korea granted to the Company a sublicensable, royalty<FONT CLASS="nobreak">-bearing</FONT> license to research, develop, manufacture and commercialize and sell Apitox in the United&#x00a0;States. In exchange for this license, the Company will pay Apimeds Korea a perpetual royalty of 5% of the Company&#x2019;s earnings before interest and taxes as determined consistent with GAAP, derived from the sale or license of Apitox, less any shipping, handling, and insurance charges, credits (arising from returns or other adjustments), discounts, rebates, or allowances of any kind (if any). The Business Agreement may be terminated by mutual written agreement by the parties and will automatically terminate upon the bankruptcy or dissolution of the Company.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Assignment Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On October&#x00a0;12, 2021 we entered into an intellectual property assignment agreement (the &#x201c;Assignment Agreement&#x201d;) with Apimeds Korea and Dr. Christopher Kim, the Company&#x2019;s Chairman and Chief Medical Officer and founder of Apimeds Korea, effective as of May&#x00a0;12, 2021. Pursuant to the Assignment Agreement Dr. Kim transferred to Apimeds Korea all right, title, interest and good will in all of the intellectual property as it relates to Apitoxin, which will be marketed in the United States as Apitox (the &#x201c;Assigned IP&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Dr.&#x00a0;Kim retained no right to use the Assigned IP.&#x00a0;Additionally, the Assignment Agreement acknowledged that the Assigned IP was licensed to us to use via the Business Agreement, as described above.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Patent License Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On October&#x00a0;12, 2021, we entered into a patent license agreement (the &#x201c;Patent License Agreement&#x201d;) Dr. Christopher Kim, the Company&#x2019;s Chairman and Chief Medical Officer and the founder of Apimeds Korea. During Dr.&#x00a0;Kim&#x2019;s engagement with Apimeds Korea, he contributed to the development of the intellectual property as it relates to Apitoxin. Pursuant to the Patent License Agreement, we were licensed certain patents. In consideration of its license under the Patent License Agreement, the Company paid Dr.&#x00a0;Kim $1.00.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The patents expired in 2023 and, presently, the Company does not intend renew the expired patents or apply for any additional patents.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business Establishment Agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On March&#x00a0;3, 2020, Apimeds Korea entered into a business establishment agreement with the Company pursuant to which Apimeds Korea agreed provide funding to us in the form of two tranches consisting of $500,000 each (for a total of $1,000,000). The first tranche was funded in March&#x00a0;2020 and the second tranche was funded in May&#x00a0;2020.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">August&#x00a0;2021 Promissory Note</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company issued to Apimeds Korea a convertible promissory note in the principal amount of $400,000, on August&#x00a0;30, 2021 (the &#x201c;August&#x00a0;2021 Note&#x201d;). The August&#x00a0;2021 Note is due and payable on the earlier of (i)&#x00a0;August&#x00a0;30, 2026 or (ii)&#x00a0;a sale of the Company (as defined in the August&#x00a0;2021 Note) (the &#x201c;Maturity Date&#x201d;). The August&#x00a0;2021 Note bears interest at an annual rate equal to the lesser of (i)&#x00a0;5% per annum, or (ii)&#x00a0;the maximum rate permissible by law.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company may prepay the August&#x00a0;2021 Note at any time without penalty. If not previously paid by the Company, principal and accrued interest on the August&#x00a0;2021 Note will automatically convert into common stock (i)&#x00a0;immediately prior to the closing of the Company&#x2019;s firm commitment underwritten initial public offering resulting in at least $40,000,000 gross proceeds to the Company (a &#x201c;Qualified IPO&#x201d;), (ii)&#x00a0;immediately prior to the closing of the Company&#x2019;s initial listing of its common stock on an international exchange by means of an effective registration statement on Form&#x00a0;S<FONT CLASS="nobreak">-1</FONT> that results in at least $40,000,000 of gross proceeds to the selling stockholders (a &#x201c;Qualified Direct Listing&#x201d;), or (iii)&#x00a0;upon the consummation of the Company&#x2019;s merger, consolidation, share exchange or other transaction with a publicly traded &#x201c;special purpose acquisition company&#x201d; resulting in a stock exchange listing (a &#x201c;SPAC Transaction&#x201d;). The number of shares of common stock shall be determined by dividing (x)&#x00a0;the outstanding principal balance of the Apimeds Korea Note plus accrued but unpaid interest by (y)&#x00a0;as applicable, (i)&#x00a0;in case of a Qualified IPO, the per share price for which shares of common stock are initially offered in the Qualified IPO as reflected in the final prospectus, (b)&#x00a0;in case of a Qualified Direct Listing, the fist closing price of the common stock on the first&#x00a0;trading day, following the Qualified Direct Listing, and (c)&#x00a0;in case of a SPAC Transaction, the price per share of the successor entity that is established in connection with such SPAC Transaction.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If there shall be any Event of Default (as defined below), the August&#x00a0;2021 Note shall accelerate and all principal and unpaid accrued interest shall become immediately due and payable, provided that the Company shall have 20&#x00a0;days from receipt of such notice to cure an Event of Default. The occurrence of any one or more of the following shall constitute an &#x201c;Event of Default&#x201d;: (a)&#x00a0;the Company fails to pay timely all or any part of the principal amount or accrued interest due under the August&#x00a0;2021 Note, (b)&#x00a0;the Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing, or (c)&#x00a0;an involuntary petition is filed against the Company, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any property of the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The terms of the August&#x00a0;2021 Note may only be amended with the written consent of both parties and my only be transferred upon its surrender to the Company for registration of transfer or accompanied by a duly executed written instrument of transfer in the form satisfactory to the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December<FONT CLASS="nobreak"> </FONT>5, 2023, the Company and Apimeds Korea amended the August 2021 Note (the &#x201c;August 2021 Note Amendment&#x201d;) as follows: the maturity date was extended to the earlier of (i) December<FONT CLASS="nobreak"> </FONT>31, 2026, or (ii) the consummation of an offering of our common stock (and other securities potentially) resulting in the listing for trading of our common stock on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing) (&#x201c;Qualified Offering&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Additionally, the August 2021 Note Amendment provided for conversion of the note, including accrued and unpaid interest, at a conversion price of $2.60 per share as follows: (i) at the option of the holder, in its sole discretion, in whole or in part, and (ii) mandatorily simultaneous with the consummation of a Qualified Offering, in each case, into fully paid and nonassessable shares of common stock at the conversion price. </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>12, 2024, Apimeds Korea assigned the August 2021 Note to Inscobee, Inc. a South Korean company, and the parent company of Apimeds Korea, (&#x201c;Inscobee&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If not converted earlier, upon the closing of this offering, the August 2021 Note will automatically convert into approximately 173,678<FONT CLASS="nobreak"> </FONT>shares of common stock.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">March&#x00a0;2022 Promissory Note</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company issued to Apimeds Korea, a promissory note in the principal amount of $160,000 on March&#x00a0;21, 2022 (the &#x201c;March&#x00a0;2022 Note&#x201d;). The March&#x00a0;2022 Note bears interest at a rate equal to 5% per annum (the &#x201c;Interest Rate&#x201d;). The March&#x00a0;2022 Note is due and payable on the earlier of (i)&#x00a0;the closing of an equity financing by the Company with gross proceeds to the Company of at least $3,000,000, or (ii)&#x00a0;July&#x00a0;15, 2022.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company may prepay the March&#x00a0;2022 Note at any time without penalty. If any payment due on the March&#x00a0;2022 Note is not paid within five days after the amount becomes due, the payment shall be considered in default and the interest rate will increase by an additional 5% on the defaulted payment amount and Inscobee may also, in its sole discretion, without notice or demand, declare the entire unpaid principal balance plus accrued interest due and payable immediately.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company and Apimeds Korea amended the March&#x00a0;2022 Note (the &#x201c;March&#x00a0;2022 Note&#x00a0;Amendment&#x201d;) as follows: the maturity date was extended to the earlier of (i)&#x00a0;December&#x00a0;31, 2026, or (ii)&#x00a0;the consummation of a Qualified Offering.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Additionally, the March&#x00a0;2022 Note&#x00a0;Amendment provided for conversion of the note, including accrued and unpaid interest, at a conversion price of $2.60 per share as follows: (i)&#x00a0;at the option of the holder, in its sole discretion, in whole or in part, and (ii)&#x00a0;mandatorily simultaneous with the consummation of a Qualified Offering, in each case, into fully paid and nonassessable shares of common stock at the conversion price.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>12, 2024, Apimeds Korea assigned the March 2022 Note to Inscobee.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If not converted earlier, upon the closing of this offering, the March&#x00a0;2022 Note will automatically convert into approximately 67,760<FONT CLASS="nobreak"> </FONT>shares of common stock.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">June&#x00a0;2022 Promissory Note</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On June&#x00a0;3, 2022, the Company issued to Inscobee, Inc. a South Korean company, and the parent company of Apimeds Korea, (&#x201c;Inscobee&#x201d;) a $100,000 promissory note (the &#x201c;June&#x00a0;2022 Note&#x201d;). Interest on the outstanding principal balance of the Second Loan accrues at a rate equal to 5% per annum, and interest on the outstanding principal balance of the First Loan shall accrue and be payable on the maturity date. The maturity date was the earlier of (i)&#x00a0;the closing of an equity financing by the Company with gross proceeds to the Company of at least $3,000,000), and (ii)&#x00a0;July&#x00a0;15, 2022.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company and Inscobee amended the June&#x00a0;2022 Note (the &#x201c;June&#x00a0;2022 Note&#x00a0;Amendment&#x201d;) as follows: the maturity date was extended to (i)&#x00a0;December&#x00a0;31, 2026, or (ii)&#x00a0;consummation of a Qualified Offering.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Additionally, the June&#x00a0;2022 Note&#x00a0;Amendment provided for conversion of the note, including accrued and unpaid interest, at a conversion price of $2.60 per share as follows: (i)&#x00a0;at the option of the holder, in its sole discretion, in whole or in part, and (ii)&#x00a0;mandatorily simultaneous with the consummation of a Qualified Offering, in each case, into fully paid and nonassessable shares of common stock at the conversion price.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the closing of this offering, the June 2022 Note will automatically convert into approximately 41,960<FONT CLASS="nobreak"> </FONT>shares of common stock.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>12, 2024, the Company and Inscobee amended the June 2022 Note to correct a scrivener&#x2019;s error.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">May 2024 Promissory Note</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On May<FONT CLASS="nobreak"> </FONT>20, 2024, the Company issued to Inscobee a $100,000 promissory note (the &#x201c;May 2024 Note&#x201d;). The May 2024 Note bears interest at a rate equal to 5% per annum (the &#x201c;Interest Rate&#x201d;). The May 2024 Note is due and payable on the earlier of (i) the closing of an equity financing by the Company with gross proceeds to the Company of at least $3,000,000, or (ii) May<FONT CLASS="nobreak"> </FONT>19, 2025.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company may prepay the May 2024 Note at any time without penalty. If any payment due on the May 2024 Note is not paid within five days after the amount becomes due, the payment shall be considered in default and the interest rate will increase by an additional 5% on the defaulted payment amount and Inscobee may also, in its sole discretion, without notice or demand, declare the entire unpaid principal balance plus accrued interest due and payable immediately.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">August 2024 Note</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On August<FONT CLASS="nobreak"> </FONT>19, 2024, the Company issued to Inscobee a $150,000 principal amount promissory note (the &#x201c;August 2024 Note&#x201d;). The August 2024 Note bears interest at a rate equal to 5% per annum (the &#x201c;Interest Rate&#x201d;). The August 2024 Note is due and payable on the earlier of (i) the closing of an equity financing by the Company with gross proceeds to the Company of at least $3,000,000, or (ii) May<FONT CLASS="nobreak"> </FONT>19, 2025. The outstanding principal and interest on the August 2024 Note will be repaid upon the closing of this offering.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company may prepay the August 2024 Note at any time without penalty. If any payment due on the August 2024 Note is not paid within five days after the amount becomes due, the payment shall be considered in default and the interest rate will increase by an additional 5% on the defaulted payment amount and Inscobee may also, in its sole discretion, without notice or demand, declare the entire unpaid principal balance plus accrued interest due and payable immediately.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Cash Advance Loans</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On October<FONT CLASS="nobreak"> </FONT>5, 2022, November<FONT CLASS="nobreak"> </FONT>10, 2022 and March<FONT CLASS="nobreak"> </FONT>16, 2023, Dr. Christopher Kim, the Company&#x2019;s Chairman and Chief Medical Officer and founder of Apimeds Korea, loaned the Company $9,900, $13,000 and $9,000 respectively. These loans carried no interest and did not have a maturity date. The loans were used for operating purposes. As of September 2023, all the loan amounts were repaid.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Policies and Procedures for Transaction with Related Persons</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Prior to the consummation of this offering, our board of directors will adopt a written related person transaction policy, to be effective upon the consummation of this offering, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item&#x00a0;404 of Regulation&#x00a0;S<FONT CLASS="nobreak">-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including without limitation purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including but not limited to whether the transaction is on terms comparable to those that could be obtained in an arm&#x2019;s length transaction with an unrelated third party and the extent of the related person&#x2019;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Indemnification Agreements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In connection with this offering, we intend to enter into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#x2019; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#x2019;s status as a member of our board of directors to the maximum extent allowed under Delaware law.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T9"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:5.5pt;">The following table sets forth information with respect to the beneficial ownership of our capital stock as of the date of this prospectus, by:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>each of our named executive officers;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>each of our directors;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>all of our executive officers and directors as a group; and</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:5.5pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:5.5pt;">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:5.5pt;">Certain of our existing stockholders have indicated an interest to purchase up to an aggregate of approximately $3.0<FONT CLASS="nobreak"> </FONT>million of shares of our common stock in this offering at the initial public offering price (which would represent approximately 30% of the shares sold in this offering, assuming an offering price of $3.00 per share, which is the low end of the estimated price range). However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of our common stock in this offering to these entities, or these entities may determine to purchase more, fewer or no shares of our common stock in this offering. The underwriters will receive the same underwriting discounts and commissions on any shares of our common stock purchased by these entities as they will on any other shares of our common stock sold to the public in this offering.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:5.5pt;">The beneficial ownership prior to the offering is based on the number of shares of our capital stock issued and outstanding as of the date of this prospectus. Applicable percentage ownership after the offering is based on 11,523,637<FONT CLASS="nobreak"> </FONT>shares of common stock outstanding immediately after the closing of this offering, assuming no exercise by the underwriters of their option to purchase additional shares and does not include any shares which may be purchase by any person or entity named in the table in this offering. In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to conversion from convertible preferred stock upon the completion of the offering and options held by the person that are currently exercisable, or exercisable within 60&#x00a0;days of the date of this prospectus. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:6pt;margin-top:5.5pt;">We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. Unless otherwise noted, the business address of each of the following entities or individuals is 65<FONT CLASS="nobreak">-1277</FONT> Ki Rd., Kamuela, Hawaii 96743.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Number of</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Shares</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Beneficially</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Owned</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Percentage of Common</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Shares Beneficially</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Owned</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:bold;text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Name of Beneficial Owner</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Prior to</FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Offering</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Before</FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Offering</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">After</FONT><FONT CLASS="CharOverride-3" STYLE="text-decoration:underline;"><BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Offering</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Directors and Named Executive Officers:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Christopher Kim, MD<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(1)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">213,692</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.54</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.82</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Erik Emerson</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mark Corrao</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Bennett Weintraub, PhD</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hankil Yoon</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carol O&#x2019;Donnell</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jakap Koo</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">615,385</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.32</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.24</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All directors and officers as a group (7 individuals)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">829,077</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.86</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.06</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5% or Greater Stockholders:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Inscobee Inc.<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">2</FONT><FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,908,783</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70.28</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50.33</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dominus IB, Inc.<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(3)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">800,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.52</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.81</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Busan Equity Partners Co., LTD<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">(4)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">520,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.19</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.43</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P> <P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 213,692<FONT CLASS="nobreak"> </FONT>shares issuable pursuant to outstanding options, which are exercisable within 60 days of the date hereof. </P>
		 <P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Represents 1,596,760<FONT CLASS="nobreak"> </FONT>shares or 18.99% held directly and 4,312,023<FONT CLASS="nobreak"> </FONT>shares or 51.29% held through its wholly owned subsidiary, Apimeds Inc. The business address for Inscobee Inc. is Room 613, Digital<FONT CLASS="nobreak">-ro</FONT> 130, 6F, Geumcheon<FONT CLASS="nobreak">-gu</FONT>, Seoul, 08580 Republic of Korea.</P>
		 <P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The business address for Dominus IB, Inc. is 1<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">st</FONT> floor, 16, Banpo<FONT CLASS="nobreak">-daero</FONT> 27<FONT CLASS="nobreak">-gil</FONT>, Seocho<FONT CLASS="nobreak">-gu</FONT>, Seoul, 06655 Republic of Korea.</P>
		 <P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>The business address for Busan Equity Partners Co., LTD is 137 Bangbae<FONT CLASS="nobreak">-ro</FONT>, Seocho<FONT CLASS="nobreak">-gu</FONT>, Seoul, 06672 Republic Of Korea.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T8"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF CAPITAL STOCK</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">General</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following descriptions of our capital stock and certain provisions of our Charter and Bylaws are summaries. The full text of our Charter and our Bylaws are filed as exhibits to the registration statement, of which this prospectus is a part. We urge you to read our Charter and our Bylaws in their entirety for a complete description of the rights and preferences of our capital stock.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Authorized Capitalization</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our Amended and Restated Certificate of Incorporation authorizes the issuance of 100,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock, par value $0.01 per share and 10,000,000<FONT CLASS="nobreak"> </FONT>shares of preferred stock, par value $0.01 per share.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December<FONT CLASS="nobreak"> </FONT>6, 2024, prior to the Reverse Stock Split, there were 20,555,600<FONT CLASS="nobreak"> </FONT>shares of common stock issued and outstanding held of record by seven stockholders. No shares of preferred stock are issued and outstanding.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Forward Stock Split</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On January&#x00a0;6, 2022, we amended our Certificate of Incorporation, to effect a forward stock split of our outstanding shares of common stock by a ratio of 1<FONT CLASS="nobreak">-for-10</FONT>,000.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Reverse Stock Split</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will effect a 1<FONT CLASS="nobreak">-for-2</FONT>.6 reverse stock split immediately prior to the completion of this offering, pursuant to which each 2.6<FONT CLASS="nobreak"> </FONT>shares of common stock held of record by the holder thereof will be reclassified into one share of common stock. No fractional shares will be issued.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December<FONT CLASS="nobreak"> </FONT>6, 2024, giving effect to the Reverse Stock Split, there were 7,903,846<FONT CLASS="nobreak"> </FONT>shares of common stock issued and outstanding held of record by seven stockholders. No shares of preferred stock are issued and outstanding.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Common Stock</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Voting Rights.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The holders of shares of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Dividends.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>The board of directors of our company may cause dividends to be paid to the holders of shares of common stock out of funds legally available for the payment of dividends by declaring an amount per share as a dividend. When and as dividends are declared on the common stock, whether payable in cash, in property or in shares of stock or other securities of our company, the holders of common stock shall be entitled to share ratably according to the number of shares of common stock held by them, in such dividends.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Liquidation Rights.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>In the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of our company, the holders of shares of common stock shall be entitled to share ratably, according to the number of shares of common stock held by them, in all remaining assets of our company available for distribution to its shareholders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Blank Check Preferred Stock</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our board of directors has the authority to issue undesignated shares of &#x201c;blank check&#x201d; preferred stock in one or more series and to fix the designation, relative powers, preferences and rights and qualifications, limitations or restrictions of all shares of each such series, including, without limitation, dividend rates, conversion rights, voting rights, redemption and sinking fund provisions, liquidation preferences and the number of shares constituting each such series, without any further vote or action by the shareholders. The issuance of additional preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock and could, among other things, have the effect of delaying, deferring or preventing a change in control of our company without further action by the stockholders. We have no present plans to issue any shares of preferred stock.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Authorized but Unissued Capital Stock</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Delaware law does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of the NYSE American, which would apply if and so long as the common stock remains listed on the NYSE American, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock. Additional shares that may be issued in the future may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">One of the effects of the existence of unissued and unreserved common stock may be to enable our company to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise and thereby protect the continuity of management and possibly deprive stockholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Charter and Bylaws</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The DGCL provides generally that the affirmative vote of a majority of the outstanding stock entitled to vote on amendments to a corporation&#x2019;s certificate of incorporation or bylaws is required to approve such amendment, unless a corporation&#x2019;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our Bylaws may be amended, altered or repealed by the affirmative vote of the holders of at least a majority of the voting power of the shares of our then outstanding voting stock entitled to vote generally in the election of directors, voting together as a single class.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Limitations on Liability and Indemnification of Officers and Directors</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors&#x2019; fiduciary duties, subject to certain exceptions. We have entered into, or expect to enter into, agreements to indemnify our directors, executive officers and other employees as determined by our board of directors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The transfer agent and registrar for our common stock upon the closing of this offering will be VStock Transfer, LLC. The transfer agent and registrar&#x2019;s address are 18 Lafayette Place, Woodmere, NY 11598.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">National Securities Exchange Listing</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our common stock is currently not listed on any securities exchange. We intend to apply to have our common stock listed on the NYSE American under the symbol &#x201c;APUS.&#x201d;</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T7"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">SHARES ELIGIBLE FOR FUTURE SALE</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we have applied to have our common stock listed on the NYSE American, we cannot assure you that there will be an active public market for our common stock.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Following the closing of this offering, based on the number of shares of our common stock outstanding as of the date of this prospectus and assuming (i)&#x00a0;the issuance of 3,333,334<FONT CLASS="nobreak"> </FONT>shares of common stock in this offering, and (ii)&#x00a0;no exercise of the underwriters&#x2019; option to purchase additional shares, we will have an aggregate of approximately 11,523,637<FONT CLASS="nobreak"> </FONT>shares of common stock outstanding.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Of these shares, all shares of common stock sold in this offering (except for any shares which may be purchased by our officers, directors, principal stockholders and their affiliates) will be freely tradable without restriction or further registration under the Securities Act, except for any shares of common stock purchased by our &#x201c;affiliates,&#x201d; as that term is defined in Rule&#x00a0;144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule&#x00a0;144 resale restrictions described below, other than the holding period requirement.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The remaining shares of common stock outstanding after this offering (including any shares which may be purchased by our officers, directors, principal stockholders and their affiliates) will be &#x201c;restricted securities,&#x201d; as that term is defined in Rule&#x00a0;144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule&#x00a0;144 or Rule&#x00a0;701 under the Securities Act, each of which is summarized below. We expect that all of these shares will be subject to either a six<FONT CLASS="nobreak">-month</FONT> or eight<FONT CLASS="nobreak">-month</FONT> lock<FONT CLASS="nobreak">-up</FONT> period under the lock<FONT CLASS="nobreak">-up</FONT> and market stand<FONT CLASS="nobreak">-off</FONT> agreements described below.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We may issue shares of common stock from time to time as consideration for future acquisitions, investments or other corporate purposes. In the event any such acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may also be significant. We may also grant registration rights covering those shares of common stock issued in connection with any such acquisition, investment or other transaction.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In addition, shares of common stock that are either subject to outstanding options or warrants or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock<FONT CLASS="nobreak">-up</FONT> agreements described below and Rules 144 and 701 under the Securities Act.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Lock-Up</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Agreements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We, along with our directors, executive officers and all of our other securityholders, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions as detailed further in the section entitled &#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Underwriting</FONT>,&#x201d; we or they will not, except with the prior written consent of the representative offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. All of our security holders are subject to a market stand<FONT CLASS="nobreak">-off</FONT> agreement with us which imposes similar restrictions.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon the expiration of the lock<FONT CLASS="nobreak">-up</FONT> period, substantially all of the shares subject to such lock<FONT CLASS="nobreak">-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Rule&#x00a0;144</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In general, under Rule&#x00a0;144 as currently in effect, once we have been subject to public company reporting requirements of Section&#x00a0;13 or Section&#x00a0;15(d)&#x00a0;of the Exchange&#x00a0;Act for at least 90&#x00a0;days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation or notice provisions of Rule&#x00a0;144, subject to compliance with the public information requirements of Rule&#x00a0;144. To be an eligible stockholder under Rule&#x00a0;144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90&#x00a0;days preceding a sale and must have beneficially owned the shares proposed </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">to be sold for at least six&#x00a0;months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule&#x00a0;144, subject to the expiration of the lock<FONT CLASS="nobreak">-up</FONT> agreements described above.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In general, under Rule&#x00a0;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock<FONT CLASS="nobreak">-up</FONT> agreements described above. Beginning 90&#x00a0;days after the date of this prospectus, within any three<FONT CLASS="nobreak">-month</FONT> period, such stockholders may sell a number of shares that does not exceed the greater of:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>1% of the number of shares of our common stock then outstanding, which will equal approximately 115,236<FONT CLASS="nobreak"> </FONT>shares immediately after this offering; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>the average weekly trading volume in our common stock on the NYSE American during the four calendar&#x00a0;weeks preceding the filing of a notice on Form&#x00a0;144 with respect to such sale.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Sales under Rule&#x00a0;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. Notwithstanding the availability of Rule&#x00a0;144, the holders of substantially all of our restricted securities have entered into lock<FONT CLASS="nobreak">-up</FONT> agreements as referenced above and their restricted securities will become eligible for sale (subject to the above limitations under Rule&#x00a0;144) upon the expiration of the restrictions set forth in those agreements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Rule&#x00a0;701</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Rule&#x00a0;701 generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90&#x00a0;days, to sell these shares in reliance on Rule&#x00a0;144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule&#x00a0;144. Rule&#x00a0;701 also permits affiliates of our company to sell their Rule&#x00a0;701<FONT CLASS="nobreak"> </FONT>shares under Rule&#x00a0;144 without complying with the holding period requirements of Rule&#x00a0;144. All holders of Rule&#x00a0;701<FONT CLASS="nobreak"> </FONT>shares, however, are required by that rule to wait until 90&#x00a0;days after the date of this prospectus before selling those shares under Rule&#x00a0;701, subject to the expiration of the lock<FONT CLASS="nobreak">-up</FONT> agreements described above.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Form&#x00a0;S-8 Registration Statement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to file one or more registration statements on Form&#x00a0;S<FONT CLASS="nobreak">-8</FONT> under the Securities Act to register all shares of common stock subject to issuance under the Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan. We expect to file the registration statement covering shares offered pursuant to the Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan shortly after the date of this prospectus, permitting the resale of such shares by non<FONT CLASS="nobreak">-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the public market subject to compliance with applicable lock<FONT CLASS="nobreak">-up</FONT> agreements described above, and the resale provisions of Rule&#x00a0;144.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T6"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR </FONT><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">NON-U</FONT><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">.S. HOLDERS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following summary describes the material U.S.&#x00a0;federal income tax consequences of the acquisition, ownership, and disposition of our common stock acquired in this offering by non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holders (as defined below). This discussion is not a complete analysis of all potential U.S.&#x00a0;federal income tax consequences relating thereto, and does not deal with foreign, state and local consequences that may be relevant to non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holders in light of their particular circumstances, nor does it address U.S.&#x00a0;federal tax consequences (such as gift and estate taxes) other than income taxes. Special rules different from those described below may apply to certain Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holders that are subject to special treatment under the Internal Revenue Code of 1986, as amended, or the Code, such as financial institutions, insurance companies, tax<FONT CLASS="nobreak">-exempt</FONT> organizations, broker<FONT CLASS="nobreak">-dealers</FONT> and traders in securities, U.S.&#x00a0;expatriates, &#x201c;controlled foreign corporations,&#x201d; &#x201c;passive foreign investment companies,&#x201d; corporations that accumulate earnings to avoid U.S.&#x00a0;federal income tax, corporations organized outside of the United&#x00a0;States, any state thereof or the District of Columbia that are nonetheless treated as U.S.&#x00a0;taxpayers for U.S.&#x00a0;federal income tax purposes, persons that hold our common stock as part of a &#x201c;straddle,&#x201d; &#x201c;hedge,&#x201d; &#x201c;conversion transaction,&#x201d; &#x201c;synthetic security&#x201d; or integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons subject to the alternative minimum tax or federal Medicare contribution tax on net investment income, persons subject to special tax accounting rules under Section&#x00a0;451(b)&#x00a0;of the Code, &#x201c;qualified foreign pension funds&#x201d; as defined in Section&#x00a0;897(l)(2)&#x00a0;of the Code and entities all of the interests of which are held by qualified foreign pension funds, partnerships and other pass<FONT CLASS="nobreak">-through</FONT> entities or arrangements, and investors in such passthrough entities or arrangements. Such non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holders are urged to consult their own tax advisors to determine the U.S.&#x00a0;federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and Treasury Regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked, or modified, perhaps retroactively, so as to result in U.S.&#x00a0;federal income tax consequences different from those discussed below. We have not requested a ruling from the U.S.&#x00a0;Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that the non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder holds our common stock as a &#x201c;capital asset&#x201d; within the meaning of Section&#x00a0;1221 of the Code (generally, property held for investment).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This discussion is for informational purposes only and is not tax advice. Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S.&#x00a0;federal income, estate, and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local or foreign tax consequences.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">For the purposes of this discussion, a &#x201c;non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder&#x201d; is, for U.S.&#x00a0;federal income tax purposes, a beneficial owner of common stock that is neither a U.S.&#x00a0;Holder, nor a partnership (or other entity treated as a partnership for U.S.&#x00a0;federal income tax purposes regardless of its place of organization or formation). A &#x201c;U.S.&#x00a0;Holder&#x201d; means a beneficial owner of our common stock that is for U.S.&#x00a0;federal income tax purposes any of the following:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an individual who is a citizen or resident of the United&#x00a0;States;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a corporation or other entity treated as a corporation for U.S.&#x00a0;federal income tax purposes created or organized in or under the laws of the U.S., any state thereof or the District of Columbia;</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>an estate the income of which is subject to U.S.&#x00a0;federal income taxation regardless of its source; or</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>a trust if it (i)&#x00a0;is subject to the primary supervision of a court within the U.S.&#x00a0;and one or more U.S.&#x00a0;persons have the authority to control all substantial decisions of the trust or (ii)&#x00a0;has a valid election in effect under applicable U.S.&#x00a0;Treasury regulations to be treated as a U.S.&#x00a0;person.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As described in the section entitled &#x201c;Dividend Policy,&#x201d; we have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Distributions, if any, made on our common stock to a Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder to the extent made out of our current or accumulated earnings and profits (as determined under U.S.&#x00a0;federal income tax principles) generally will constitute dividends for U.S.&#x00a0;tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding, and foreign accounts. To obtain a reduced rate of withholding under a treaty, a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder generally will be required to </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">provide us with a properly executed IRS Form&#x00a0;W<FONT CLASS="nobreak">-8BEN</FONT> (in the case of individuals) or IRS Form&#x00a0;W<FONT CLASS="nobreak">-8</FONT><FONT CLASS="nobreak">BEN-E</FONT> (in the case of entities), or other appropriate form, certifying the Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder&#x2019;s entitlement to benefits under that treaty. This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. In the case of a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder that is an entity, Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder holds stock through a financial institution or other agent acting on the holder&#x2019;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#x2019;s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S.&#x00a0;federal withholding tax under an income tax treaty and you do not timely file the required certification, you may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We generally are not required to withhold tax on dividends paid to a Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder that are effectively connected with the Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder&#x2019;s conduct of a trade or business within the United&#x00a0;States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains in the United&#x00a0;States) if a properly executed IRS Form&#x00a0;W<FONT CLASS="nobreak">-8ECI</FONT>, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S.&#x00a0;federal income tax, on a net income basis at the regular rates applicable to U.S.&#x00a0;residents. A corporate non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder receiving effectively connected dividends may also be subject to an additional &#x201c;branch profits tax,&#x201d; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder&#x2019;s effectively connected earnings and profits, subject to certain adjustments. Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder&#x2019;s adjusted basis in our common stock, but not below zero, and then will be treated as gain to the extent of any excess amount distributed, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Gain on Disposition of Our Common Stock</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Subject to the discussions below regarding backup withholding and foreign accounts, a Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder generally will not be subject to U.S.&#x00a0;federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (i)&#x00a0;the gain is effectively connected with a trade or business of such holder in the United&#x00a0;States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United&#x00a0;States), (ii)&#x00a0;the Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder is a nonresident alien individual and is present in the United&#x00a0;States for 183 or more&#x00a0;days in the taxable year of the disposition and certain other conditions are met, or (iii)&#x00a0;we are or have been a &#x201c;United&#x00a0;States real property holding corporation&#x201d; within the meaning of Code Section&#x00a0;897(c)(2)&#x00a0;at any time within the shorter of the five<FONT CLASS="nobreak">-year</FONT> period preceding such disposition or such holder&#x2019;s holding period. In general, we would be a United&#x00a0;States real property holding corporation if our interests in U.S.&#x00a0;real estate comprise (by fair market value) at least half of our business assets. We believe that we have not been, and we are not, and do not anticipate becoming, a United&#x00a0;States real property holding corporation. Even if we are treated as a United&#x00a0;States real property holding corporation, gain realized by a Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder on a disposition of our common stock will not be subject to U.S.&#x00a0;federal income tax so long as (1)&#x00a0;the Non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder owned, directly, or indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (A)&#x00a0;the five<FONT CLASS="nobreak">-year</FONT> period preceding the disposition or (B)&#x00a0;the holder&#x2019;s holding period and (2)&#x00a0;our common stock is regularly traded on an established securities market. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. If any gain on your disposition is taxable because we are a United&#x00a0;States real property holding corporation and your ownership of our common stock exceeds 5%, you will be taxed on such disposition generally in the manner as gain that is effectively connected with the conduct of a U.S.&#x00a0;trade or business (subject to the provisions under an applicable income tax treaty), except that the branch profits tax generally will not apply.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If you are a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder described in (i)&#x00a0;above, you will be required to pay tax on the net gain derived from the sale at regular U.S.&#x00a0;federal income tax rates, and corporate non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holders described in (a)&#x00a0;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">income tax treaty. Gain described in (ii)&#x00a0;above will be subject to U.S.&#x00a0;federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable income tax treaty, which gain may be offset by certain U.S.<FONT CLASS="nobreak">-source</FONT> capital losses (even though you are not considered a resident of the United&#x00a0;States), provided that the non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder has timely filed U.S.&#x00a0;federal income tax returns with respect to such losses.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Information Reporting Requirements and Backup Withholding</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Generally, we must report information to the IRS with respect to any dividends we pay on our common stock (even if the payments are exempt from withholding), including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#x2019;s country of residence.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Dividends paid by us (or our paying agents) to a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder may also be subject to U.S.&#x00a0;backup withholding. U.S.&#x00a0;backup withholding generally will not apply to a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder who provides a properly executed IRS Form&#x00a0;W<FONT CLASS="nobreak">-8BEN</FONT>, IRS Form&#x00a0;W<FONT CLASS="nobreak">-8</FONT><FONT CLASS="nobreak">BEN-E</FONT>, or IRS Form&#x00a0;W<FONT CLASS="nobreak">-ECI</FONT>, or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S.&#x00a0;person who is not an exempt recipient.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">U.S.&#x00a0;information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock effected by or through a U.S.&#x00a0;office of any broker, U.S.&#x00a0;or foreign, except that information reporting and such requirements may be avoided if the holder provides a properly executed IRS Form&#x00a0;W<FONT CLASS="nobreak">-8BEN</FONT> or IRS Form&#x00a0;W<FONT CLASS="nobreak">-8</FONT><FONT CLASS="nobreak">BEN-E</FONT> or otherwise meets documentary evidence requirements for establishing non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;person status or otherwise establishes an exemption. Generally, U.S.&#x00a0;information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;Holder where the transaction is effected outside the United&#x00a0;States through a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;office of a non<FONT CLASS="nobreak">-U</FONT>.S.&#x00a0;broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S.&#x00a0;person. For information reporting purposes, certain brokers with substantial U.S.&#x00a0;ownership or operations will generally be treated in a manner similar to U.S.&#x00a0;brokers.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against the tax liability of persons subject to backup withholding, provided that the required information is timely furnished to the IRS.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Foreign Accounts</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Sections 1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S.&#x00a0;federal withholding tax of 30% on certain payments, including dividends paid on, and the gross proceeds of a disposition of, our common stock paid to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with the U.S.&#x00a0;government to withhold on certain payments and to collect and provide to the U.S.&#x00a0;tax authorities identifying information regarding certain U.S.&#x00a0;account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S.&#x00a0;owners). FATCA also generally imposes a federal withholding tax of 30% on certain payments, including dividends paid on, and the gross proceeds of a disposition of, our common stock to a non<FONT CLASS="nobreak">-financial</FONT> foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S.&#x00a0;owners or provides information regarding substantial direct and indirect U.S.&#x00a0;owners of the entity. An intergovernmental agreement between the United&#x00a0;States and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign financial institution or non<FONT CLASS="nobreak">-financial</FONT> foreign entity otherwise qualifies for an exemption from the rules.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW.</FONT></P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T5"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNDERWRITING</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">D. Boral Capital Securities, LLC is acting as the representative of the underwriters of this offering. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						 <P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Underwriter</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Number of <BR>Shares</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">D. Boral Capital Securities, LLC</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,333,334</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The underwriting agreement provides that the obligations of the underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to various conditions and representations and warranties, including the approval of certain legal matters by their counsel and other conditions specified in the underwriting agreement. The shares of common stock are offered by the underwriters, subject to prior sale, when, as and if issued to and accepted by them. The underwriters reserve the right to withdraw, cancel or modify the offer to the public and to reject orders in whole or in part. The underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares of common stock are taken, other than those shares of common stock covered by the over<FONT CLASS="nobreak">-allotment</FONT> option described below.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Over-Allotment</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Option</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have granted a 45<FONT CLASS="nobreak">-day</FONT> option to the representative of the underwriters to purchase up to 500,000 additional shares of our common stock at a public offering price of $3.00 per share, solely to cover over<FONT CLASS="nobreak">-allotments</FONT>, if any. The underwriters may exercise this option for 45&#x00a0;days from the date of this prospectus solely to cover sales of shares of common stock by the underwriters in excess of the total number of shares of common stock set forth in the table above. If any of these additional shares are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Discounts and Commissions</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The underwriters propose initially to offer the shares of common stock to the public at the public offering price set forth on the cover page of this prospectus and to dealers at those prices less a concession not in excess of $<FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT> per share of common stock. If all of the shares of common stock offered by us are not sold at the public offering price, the underwriters may change the offering price and other selling terms by means of a supplement to this prospectus.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us. The information assumes either no exercise or full exercise of the over<FONT CLASS="nobreak">-allotment</FONT> option we granted to the representative of the underwriters.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Per Share</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.09%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total Without <BR>Over-Allotment <BR>Option</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Total With Full <BR>Over-Allotment <BR>Option</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Initial public offering price</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Underwriting discount (7.0%)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds, before expenses, to us</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have agreed to pay a non<FONT CLASS="nobreak">-accountable</FONT> expense allowance to the underwriters equal to 1.0% of the gross proceeds received in this offering.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We will be responsible for and will pay all expenses relating to the offering, including, without limitation, (a) all filing fees and expenses relating to the registration of the shares of common stock with the SEC; (b) all fees and expenses relating to the listing of the common stock on a national exchange; (c) all fees, expenses and disbursements relating to the registration or qualification of the shares under the &#x201c;blue sky&#x201d; securities laws of such states and </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">other jurisdictions as the representative may reasonably designate (including, without limitation, all filing and registration fees, and the reasonable fees and disbursements of our &#x201c;blue sky&#x201d; counsel), if applicable; (d) all fees, expenses and disbursements relating to the registration, qualification or exemption of the shares of common stock under the securities laws of such foreign jurisdictions as the representative may reasonably designate; (e) the costs of all mailing and printing of the offering documents; (f) transfer and/or stamp taxes, if any, payable upon the transfer of shares from the Company to the underwriters; (g) all filing fees and communication expenses associated with the review of the offering by FINRA; (h) up to $30,000 of the representative&#x2019;s actual accountable road show expenses and due diligence expenses for the offering; (i) the $29,500 cost associated with the Ipreo&#x2019;s book building, prospectus tracking and compliance software for the offering; (j) the costs associated with bound volumes of the offering materials as well as commemorative mementos and lucite tombstones in an aggregate amount not to exceed $5,000; (k) the fees and expenses of legal counsels to the underwriters in an amount not to exceed $175,000; and (l)&#x00a0;up to $10,000 for background checks of our directors and officers; provided, however, that the total costs and expenses relating to this offering for which we will reimburse the underwriter shall not exceed $222,500.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have also agreed to pay an aggregate of $26,493 to prior underwriters in this offering, consisting of $26,493 payable to ThinkEquity LLC pursuant to the provisions of the TE Termination Agreement (defined below), to reimburse each of them for expenses incurred for services provided in connection with this offering, including legal fees.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non<FONT CLASS="nobreak">-accountable</FONT> expense allowance, will be approximately $158,000.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Representative&#x2019;s Warrants</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Upon closing of this offering, we have agreed to issue to the representative or its designees warrants to purchase up to a total of 166,667 (or 191,667 if the over<FONT CLASS="nobreak">-allotment</FONT> option is exercised in full) shares of our common stock (5.0% of the aggregate number of shares of common stock sold in this offering), or the Representative&#x2019;s Warrants. The Representative&#x2019;s Warrants will be exercisable at a per share exercise price equal to 100% of the public offering price per share of the shares of common stock sold in this offering. The Representative&#x2019;s Warrants are exercisable at any time, from time to time, in whole or in part, during the four- and one<FONT CLASS="nobreak">-half</FONT> year period commencing 180&#x00a0;days from the commencement of sales of the securities in this offering.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Representative&#x2019;s Warrants have been deemed compensation by FINRA and are therefore subject to a 180<FONT CLASS="nobreak">-day</FONT> lock<FONT CLASS="nobreak">-up</FONT> pursuant to Rule&#x00a0;5110(e)(1)&#x00a0;of FINRA.&#x00a0;The representative (or permitted assignees under Rule&#x00a0;5110(e)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180&#x00a0;days from the effective date of the registration statement of which this prospectus is a part. In addition, the warrants provide for registration rights upon request, in certain cases. The Representative&#x2019;s Warrants will provide for adjustment in the number and price of the Representative&#x2019;s Warrants and the shares underlying the Representative&#x2019;s Warrants in the event of recapitalization, merger, stock split, or other structural transaction, or a future financing undertaken by us. Consistent with FINRA Rule 5110.05 the number of shares underlying the Representative&#x2019;s Warrants shall be reduced if necessary to comply with FINRA rules and regulations. The sole demand registration right provided will not be greater than five&#x00a0;years from the effective date of the registration statement in compliance with FINRA Rule&#x00a0;5110(g)(8)(A). The piggyback registration rights provided will not be greater than seven&#x00a0;years from the effective date of the registration statement in compliance with FINRA Rule&#x00a0;5110(g)(8)(A). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Right of First Refusal</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The underwriting agreement will provide that for a period of twelve months from the closing of the offering, we will grant the representative an irrevocable right of first refusal to act as sole investment banker, sole book<FONT CLASS="nobreak">-runner</FONT>, sole financial advisor, sole underwriter and/or sole placement agent, at the representative&#x2019;s sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings, during such </P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Twelve<FONT CLASS="nobreak">-month</FONT> period for us, or any successor to or any subsidiary of us, on terms customary to the representative. The representative has the sole right to determine whether or not any other broker dealer shall have the right to participate in any such offering and the economic terms of any such participation.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Tail Financing Payments</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have also agreed to pay the representative a tail fee equal to 8% of the total gross proceeds received by us from any investor who was contacted by the underwriter during the term of its engagement, if such investor provides us with capital in any public or private offering or other financing or capital raising transaction within twelve months after final closing of this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Advisory Services</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have also engaged the representative to provide advisory services from time to time.  As part of the advisory services, the representative may introduce us to third parties which may be interested in financing or entering into an M&amp;A transaction.  We have agreed that if during the twelve months following the final closing of this offering we or any party the representative to whom we were introduced, directly or indirectly, by the representative, or which was contacted by the representative on our behalf in connection with the advisory services proposes a financing or M&amp;A transaction, we shall pay the representative an agreed upon fee, payable upon closing of such transaction.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Lock-Up</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> Agreements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pursuant to &#x201c;lock<FONT CLASS="nobreak">-up</FONT>&#x201d; agreements, we, our executive officers and directors, and stockholders, have agreed, without the prior written consent of the representative not to directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of ours or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days after the date of this prospectus in the case of our officers and directors and six&#x00a0;months after the date of this prospectus in the case of, the Company and any successor of the Company and other securityholders.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Termination Agreement</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>19, 2024, we entered into a termination agreement (the &#x201c;TE Termination Agreement&#x201d;) with ThinkEquity LLC, acting as financial advisor and underwriter in connection with this offering. Pursuant to the TE Termination Agreement, ThinkEquity LLC retained $50,000 of the advance we paid to it, which it used as a reimbursement for actual out<FONT CLASS="nobreak">-of-pocket</FONT> expenses, including payment of its legal expenses. We agreed to pay ThinkEquity the amount of $26,493 for payment of additional legal expenses, upon the closing of this offering.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Discretionary Accounts</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">NYSE American Listing</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We intend to apply to list our shares of common stock for trading on the NYSE American under the symbol &#x201c;APUS.&#x201d; No assurance can be given that our listing application will be approved. The closing of this offering is contingent upon the successful listing of our common stock on the NYSE American.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Determination of Offering Price</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The public offering price of the securities we are offering was negotiated between us and the underwriters. Factors considered in determining the public offering price of the shares include the history and prospects of the Company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Other</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">From time to time, certain of the underwriters and/or their affiliates may in the future provide, various investment banking and other financial services for us for which they may receive customary fees. In the course of their businesses, the underwriters and their affiliates may actively trade our securities or loans for their own account or for the accounts of customers, and, accordingly, the underwriters and their affiliates may at any time hold long or short positions in such securities or loans. Except for services provided in connection with this offering, no underwriter has provided any investment banking or other financial services to us during the 180<FONT CLASS="nobreak">-day</FONT> period preceding the date of this prospectus.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Indemnification</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have agreed to indemnify the underwriters against liabilities relating to this offering arising under the Securities Act and the Exchange&#x00a0;Act, liabilities arising from breaches of some or all of the representations and warranties contained in the underwriting agreement, and to contribute to payments that the underwriters may be required to make for these liabilities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Price Stabilization, Short Positions, and Penalty Bids</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In connection with this offering, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock. Specifically, the underwriters may over<FONT CLASS="nobreak">-allot</FONT> in connection with this offering by selling more shares than are set forth on the cover page of this prospectus. This creates a short position in our common stock for its own account. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares of common stock over<FONT CLASS="nobreak">-allotted</FONT> by the underwriters is not greater than the number of shares of common stock that they may purchase in the over<FONT CLASS="nobreak">-allotment</FONT> option. In a naked short position, the number of shares of common stock involved is greater than the number of shares common stock in the over<FONT CLASS="nobreak">-allotment</FONT> option. To close out a short position, the underwriters may elect to exercise all or part of the over<FONT CLASS="nobreak">-allotment</FONT> option. The underwriters may also elect to stabilize the price of our common stock or reduce any short position by bidding for, and purchasing, common stock in the open market.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter or dealer repays selling concessions allowed to it for distributing shares of common stock in this offering because the underwriter repurchases the shares of common stock in stabilizing or short covering transactions.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Finally, the underwriters may bid for, and purchase, shares of our common stock in market making transactions, including &#x201c;passive&#x201d; market making transactions as described below.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These activities may stabilize or maintain the market price of our common stock at a price that is higher than the price that might otherwise exist in the absence of these activities. The underwriters are not required to engage in these activities and may discontinue any of these activities at any time without notice. These transactions may be effected on the national securities exchange on which our shares of common stock are traded, in the over<FONT CLASS="nobreak">-the</FONT><FONT CLASS="nobreak">-counter</FONT> market, or otherwise.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Electronic Distribution</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This prospectus in electronic format may be made available on websites or through other online services maintained by one or more of the underwriters, or by their affiliates. Other than this prospectus in electronic format, the information on any underwriter&#x2019;s website and any information contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Selling Restrictions</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">No action has been taken in any jurisdiction (except in the United&#x00a0;States) that would permit a public offering of our common stock, or the possession, circulation or distribution of this prospectus or any other material relating to us or our common stock in any jurisdiction where action for that purpose is required. Accordingly, our common stock may not be offered or sold, directly or indirectly, and this prospectus or any other offering material or advertisements in connection with our common stock may be distributed or published, in or from any country or jurisdiction, except in compliance with any applicable rules and regulations of any such country or jurisdiction.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Australia</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This prospectus is not a disclosure document under Chapter&#x00a0;6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter&#x00a0;6D of the Australian Corporations Act. Accordingly, (i)&#x00a0;the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter&#x00a0;6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii)&#x00a0;this prospectus is made available in Australia only to those persons as set forth in clause (i)&#x00a0;above, and (iii)&#x00a0;the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i)&#x00a0;above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12&#x00a0;months after its transfer to the offeree under this prospectus.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">China</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&#x2019;s Republic of China (excluding, for purposes of this paragraph, Hong&#x00a0;Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to &#x201c;qualified domestic institutional investors.&#x201d;</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">European Economic Area&#x00a0;&#x2014;&#x00a0;Belgium, Germany, Luxembourg and Netherlands</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&#x201c;Prospectus Directive&#x201d;), as implemented in Member States of the European Economic Area (each, a &#x201c;Relevant Member State&#x201d;), from the requirement to produce a prospectus for offers of securities.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, <FONT CLASS="CharOverride-2" STYLE="">whose corporate purpose is solely to invest in securities;</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to any legal entity that has two or more of (i)&#x00a0;an average of at least 250 employees during its last fiscal year; (ii)&#x00a0;a <FONT CLASS="CharOverride-2" STYLE="">total balance sheet of more than &#x20ac;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii)&#x00a0;an annual net turnover of more than &#x20ac;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article&#x00a0;2(1)(e)&#x00a0;of the <FONT CLASS="CharOverride-2" STYLE="">Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in any other circumstances falling within Article&#x00a0;3(2)&#x00a0;of the Prospectus Directive, provided that no such offer of <FONT CLASS="CharOverride-2" STYLE="">securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article&#x00a0;3 of the </FONT><FONT CLASS="CharOverride-2" STYLE="">Prospectus Directive.</FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">France</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article&#x00a0;L.411<FONT CLASS="nobreak">-1</FONT> of the French Monetary and Financial Code (Code Mon&#x00e9;taire et Financier) and Articles&#x00a0;211<FONT CLASS="nobreak">-1</FONT> et seq. of the General Regulation of the French Autorit&#x00e9; des march&#x00e9;s financiers (&#x201c;AMF&#x201d;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Such offers, sales and distributions have been and shall only be made in France to (i)&#x00a0;qualified investors (investisseurs qualifi&#x00e9;s) acting for their own account, as defined in and in accordance with Articles L.411<FONT CLASS="nobreak">-2-II-2</FONT>&#x00b0; and D.411<FONT CLASS="nobreak">-1</FONT> to D.411<FONT CLASS="nobreak">-3</FONT>, D.744<FONT CLASS="nobreak">-1</FONT>, D.754<FONT CLASS="nobreak">-1</FONT> ;and D.764<FONT CLASS="nobreak">-1</FONT> of the French Monetary and Financial Code and any implementing regulation and/or (ii)&#x00a0;a restricted number of non<FONT CLASS="nobreak">-qualified</FONT> investors (cercle restreint d&#x2019;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411<FONT CLASS="nobreak">-2-II-2</FONT>&#x00b0; and D.411<FONT CLASS="nobreak">-4</FONT>, D.744<FONT CLASS="nobreak">-1</FONT>, D.754<FONT CLASS="nobreak">-1</FONT>; and D.764<FONT CLASS="nobreak">-1</FONT> of the French Monetary and Financial Code and any implementing regulation.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pursuant to Article&#x00a0;211<FONT CLASS="nobreak">-3</FONT> of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411<FONT CLASS="nobreak">-1</FONT>, L.411<FONT CLASS="nobreak">-2</FONT>, L.412<FONT CLASS="nobreak">-1</FONT> and L.621<FONT CLASS="nobreak">-8</FONT> to L.621<FONT CLASS="nobreak">-8-3</FONT> of the French Monetary and Financial Code.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Ireland</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &#x201c;Prospectus Regulations&#x201d;). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i)&#x00a0;qualified investors as defined in Regulation&#x00a0;2(l)&#x00a0;of the Prospectus Regulations and (ii)&#x00a0;fewer than 100 natural or legal persons who are not qualified investors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Israel</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Italy</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&#x00a0;&#x2014;$$&#x2014;&#x00a0;Aga e la Borsa, &#x201c;CONSOB&#x201d; pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article&#x00a0;1.1(t)&#x00a0;of Legislative Decree No. 58 of 24 February&#x00a0;1998 (&#x201c;Decree No. 58&#x201d;), other than:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>to Italian qualified investors, as defined in Article&#x00a0;100 of Decree no.58 by reference to Article&#x00a0;34<FONT CLASS="nobreak">-ter</FONT> of CONSOB <FONT CLASS="CharOverride-2" STYLE="">Regulation no. 11971 of 14 May&#x00a0;1999 (&#x201c;Regulation no. 1197l&#x201d;) as amended (&#x201c;Qualified Investors&#x201d;); and</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in other circumstances that are exempt from the rules on public offer pursuant to Article&#x00a0;100 of Decree No. 58 and Article <FONT CLASS="CharOverride-2" STYLE="">34</FONT><FONT CLASS="nobreak" STYLE="">-ter</FONT><FONT CLASS="CharOverride-2" STYLE=""> of Regulation&#x00a0;No. 11971 as amended.</FONT></P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance <FONT CLASS="CharOverride-2" STYLE="">with Legislative Decree No. 385 of 1 September&#x00a0;1993 (as amended), Decree No.</FONT><FONT CLASS="nobreak" STYLE=""> </FONT><FONT CLASS="CharOverride-2" STYLE="">58, CONSOB Regulation&#x00a0;No. 16190 of 29 October&#x00a0;2007 and any other applicable laws; and</FONT></P>
		<P CLASS="BL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><FONT CLASS="bullet" STYLE="font-size:10pt;">&#x2022;<FONT STYLE="width: 27px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT>in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation&#x00a0;No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Japan</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The securities have not been and will not be registered under Article&#x00a0;4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &#x201c;FIEL&#x201d;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article&#x00a0;2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Portugal</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This document is not being distributed in the context of a public offer of financial securities (oferta p&#x00fa;blica de valores mobili&#x00e1;rios) in Portugal, within the meaning of Article&#x00a0;109 of the Portuguese Securities Code (C&#x00f3;digo dos Valores Mobili&#x00e1;rios). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comiss&amp;abreve;o do Mercado de Valores Mobili&#x00e1;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &#x201c;qualified investors&#x201d; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Sweden</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#x201c;qualified investors&#x201d; (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Switzerland</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#x201c;SIX&#x201d;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">This document is personal to the recipient only and not for general circulation in Switzerland.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">United Arab Emirates</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">United Kingdom</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act&#x00a0;2000, as amended (&#x201c;FSMA&#x201d;) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#x201c;qualified investors&#x201d; (within the meaning of section 86(7)&#x00a0;of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1)&#x00a0;FSMA.&#x00a0;This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section&#x00a0;21(1)&#x00a0;of FSMA does not apply to the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">In the United Kingdom, this document is being distributed only to, and is directed at, persons (i)&#x00a0;who have professional experience in matters relating to investments falling within Article&#x00a0;19(5)&#x00a0;(investment professionals) of the Financial Services and Markets Act&#x00a0;2000 (Financial Promotions) Order 2005 (&#x201c;FPO&#x201d;), (ii)&#x00a0;who fall within the categories of persons referred to in Article&#x00a0;49(2)(a)&#x00a0;to (d)&#x00a0;(high net worth companies, unincorporated associations, etc.) of the FPO or (iii)&#x00a0;to whom it may otherwise be lawfully communicated (together &#x201c;relevant persons&#x201d;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Canada</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument&#x00a0;45<FONT CLASS="nobreak">-106</FONT> Prospectus Exemptions or subsection&#x00a0;73.3(1)&#x00a0;of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&#x00a0;31<FONT CLASS="nobreak">-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#x2019;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#x2019;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument&#x00a0;33<FONT CLASS="nobreak">-105</FONT> Underwriting Conflicts (NI&#x00a0;33<FONT CLASS="nobreak">-105</FONT>), the underwriters are not required to comply with the disclosure requirements of NI33<FONT CLASS="nobreak">-105</FONT> regarding underwriter conflicts of interest in connection with this offering.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T4"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Nelson Mullins Riley&#x00a0;&amp; Scarborough LLP, Raleigh, North Carolina. Certain legal matters in connection with this offering will be passed upon for the underwriters by Blank Rome LLP, New&#x00a0;York, New&#x00a0;York.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T3"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">EXPERTS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The financial statements of Apimeds Pharmaceuticals US, Inc. as of and for the fiscal&#x00a0;years ended December&#x00a0;31, 2023, and 2022, included in this prospectus, have been audited by Kreit &amp; Chiu CPA LLP, an independent registered public accounting firm, as set forth in their report thereon, which includes an explanatory paragraph as to Apimeds Pharmaceuticals US, Inc.&#x2019;s ability to continue as a going concern, appearing elsewhere in this prospectus, and are included in reliance upon the report of such firm given their authority as experts in accounting and auditing.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2"></A><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have filed with the SEC a registration statement on Form&#x00a0;S<FONT CLASS="nobreak">-1</FONT> under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus is a part of the registration statement and does not contain all of the information set forth in the registration statement and its exhibits, portions of which have been omitted as permitted by the rules and regulations of the SEC.&#x00a0;For further information about us and our common stock, you should refer to the registration statement and its exhibits. Statements contained in this prospectus regarding the contents of any contract or other document referred to in those documents are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement or other document. Each of these statements is qualified in all respects by this reference.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Following the completion of this offering, we will become subject to the informational reporting requirements of the Exchange&#x00a0;Act and, in accordance with the Exchange&#x00a0;Act, we will file annual, quarterly and current reports, proxy statements and other information with the SEC.&#x00a0;Our filings with the SEC will be available to the public on the SEC&#x2019;s website at <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">http:</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">//</FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.sec.gov</FONT>. Those filings will also be available to the public on, or accessible through, our website <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">www.apimedspharmus.com</FONT> under the heading &#x201c;Investor Relations.&#x201d; The information we file with the SEC or contained on or accessible through our corporate website or any other website that we may maintain is not part of this prospectus or the registration statement of which this prospectus is a part.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T1"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;">UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS </P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2007">Unaudited Condensed Balance Sheets &#x2014; September 30, 2024 and December 31, 2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-2</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2008">Unaudited Condensed Statements of Operations &#x2014; Nine Months Ended September 30, 2024 and 2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-3</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2009">Unaudited Condensed Statements of Changes in Shareholders&#x2019; (Deficit) Equity &#x2014; Nine Months Ended September 30, 2024 and 2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-4</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2010">Unaudited Condensed Statements of Cash Flows &#x2014; Nine Months Ended September 30, 2024 and 2023</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-5</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2011">Notes to the Unaudited Condensed Interim Financial Statements</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-6</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED <BR>DECEMBER 31, 2023 AND DECEMBER 31, 2022</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-4" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2001">Report of Independent Registered Public Accounting Firm (PCAOB ID: 6651)</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-12</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2002">Balance Sheets </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-13</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2003">Statements of Operations </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-14</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2004">Statements of Changes in Shareholders&#x2019; Deficit</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-15</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2005">Statements of Cash Flows </A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-16</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 86.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><A HREF="#T2006">Notes to Financial Statements</A></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-17</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T2007"></A> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.</FONT> </P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited Condensed Balance Sheets</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September&#x00a0;30,<BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.53%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">December&#x00a0;31,<BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,571</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">410,481</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,336</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,595</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,907</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">422,076</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">36,907</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">422,076</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities and shareholders&#x2019; (deficit) equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable and accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">511,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">123,314</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes payable&#x00a0;&#x2013;&#x00a0;related party</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">761,401</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">123,314</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes, net of discount&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">321,992</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">266,891</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,083,393</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">390,205</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (note 5)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shareholders&#x2019; (deficit) equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preferred stock, par value $0.01, 10,000,000 shares authorized; none issued and outstanding as of September&#x00a0;30, 2024 and December&#x00a0;31, 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, par value $0.01, 100,000,000 shares authorized; 20,550,000 issued and outstanding as of September&#x00a0;30, 2024 and December&#x00a0;31, 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,828,305</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,828,305</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4,080,291</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(3,001,934</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total shareholders&#x2019; (deficit) equity</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,046,486</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,871</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 69.66%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total liabilities and shareholders&#x2019; (deficit) equity</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">36,907</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">422,076</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these unaudited condensed interim financial statements. </FONT></P>
		 <P CLASS="Text_ind_center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT></P>
	</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><A NAME="T2008"></A> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited Condensed Statements of Operations</FONT> </P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">For the Nine&#x00a0;Months Ended<BR>September&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">118,372</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(999,482</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(188,365</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other (expense) income:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,794</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,228</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(81,669</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,591</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(78,875</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(22,363</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-brack-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(1,078,357</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(210,728</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Weighted average shares outstanding</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">20,550,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">10,421,245</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basic and diluted loss per share</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.05</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.02</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT></P>
	</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><A NAME="T2009"></A> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited Condensed Statement of Changes in Shareholders&#x2019; (Deficit) Equity</FONT> </P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 15.99%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Preferred Stock</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 16.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Common Stock</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Additional<BR> Paid-in <BR>Capital</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accumulated <BR>Deficit</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Obligation <BR>to Issue <BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-24" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number&#x00a0;of <BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number&#x00a0;of <BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Balance at December&#x00a0;31, 2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">20,550,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">205,500</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">2,828,305</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(3,001,934</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">31,871</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(1,078,357</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(1,078,357</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Balance at September&#x00a0;30, 2024 (Unaudited)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">20,550,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">205,500</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">2,828,305</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">(4,080,291</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">(1,046,486</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Balance at December&#x00a0;31, 2022</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">10,000,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">100,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">1,410,634</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(2,224,240</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(713,606</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-23" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Stock-based compensation</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">69,994</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">69,994</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Private placement purchase of shares</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">5,000,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">50,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">450,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">500,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Cash advances for shares </FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">to be issue</FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">d</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">500,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">500,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">Net loss</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(210,728</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">(210,728</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;"></FONT><FONT CLASS="CharOverride-2" STYLE="font-size:9pt;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-25" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 23.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">Balance at September&#x00a0;30, 2023 (Unaudited)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 8.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">15,000,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">150,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">1,930,628</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.06%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">(2,434,968</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">500,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.12%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:9pt;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">145,660</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-3" STYLE="font-size:9pt;font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT></P>
	</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>






	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><A NAME="T2010"></A> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Unaudited Condensed Statement of Cash Flows</FONT> </P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-26" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">For the Nine&#x00a0;Months Ended <BR>September&#x00a0;30,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-15" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from operating activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,078,357</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(210,728</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,994</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash interest expense&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">26,568</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accretion expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,101</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Changes in operating assets and liabilities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,259</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(171,673</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable and accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">361,519</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,690</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(633,910</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(287,217</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from investing activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by investing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from financing activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from notes payable&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash advances from a related party</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">64,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash advances paid to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31,900</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash advances for obligation to issue common shares</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">500,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of common stock</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">500,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,032,100</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net (decrease) increase in cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(383,910</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">744,883</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash, beginning of period</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">410,481</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash, end of period</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">26,571</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">751,054</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these unaudited condensed interim financial statements.</FONT></P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT></P>
	</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><A NAME="T2011"></A> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to the Unaudited Condensed Interim Financial Statements</FONT> </P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1.&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;DESCRIPTION OF BUSINESS</FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business Description</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">Apimeds Pharmaceuticals US, Inc. (the &#x201c;Company&#x201d; or &#x201c;Apimeds&#x201d;) was formed as a service corporation in May&#x00a0;2020 and was incorporated in the State of Delaware. On August&#x00a0;21, 2021, Apimeds Inc., the shareholder of the Company (&#x201c;Apimeds Korea&#x201d;), and Apimeds Pharmaceuticals US Inc. entered into the business agreement, under which the Company was designated to operate a pharmaceutical business which provides the biological drug named Apitox&#x2122; to clients in the biological drug commercial transaction area.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">Apimeds is a clinical stage company that is in the process of developing Apitox&#x2122;, a proprietary intradermally administered bee venom<FONT CLASS="nobreak">-based</FONT> toxin which completed a positive Phase&#x00a0;3 trial for the treatment of pain associated with Osteoarthritis in 2018 and is now proceeding with FDA discussions on next steps in approval while initiating phase 3 trials for the treatment of quality<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-life</FONT> issues associated with multiple sclerosis (&#x201c;MS&#x201d;) and other future indicia. Apitox is currently marketed and sold by Apimeds Korea in South Korea (Republic of Korea) as &#x201c;Apitoxin&#x201d; for the treatment of osteoarthritis. Apimeds Inc. holds the majority of the Company&#x2019;s outstanding common stock and is a subsidiary of Inscobee Inc. (&#x201c;Inscobee&#x201d;).</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals of its product candidates, marketing its products and achieving profitable operations. The continuation of the research and development activities and the commercialization of its products, if approved, are dependent on the Company&#x2019;s ability to successfully complete these activities and to obtain additional financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development or commercialization programs, or the Company&#x2019;s ability to fund these programs.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Going Concern</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the issuance date of these financial statements. As of September&#x00a0;30, 2024, the Company had an accumulated deficit of $4,080,291. The Company incurred net losses of $1,078,357 for the nine&#x00a0;months ended September&#x00a0;30, 2024, and expects to continue to incur substantial losses in the future. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year of the date that the financial statements are issued.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals of its product candidates, marketing its products and achieving profitable operations. The continuation of the research and development activities and the commercialization of its products, if approved, are dependent on the Company&#x2019;s ability to successfully complete these activities and to obtain additional financing through a combination of financing activities and operations. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;"></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"></P>
	</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to the Unaudited Condensed Interim Financial Statements</FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT></P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis of Presentation</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The Company has prepared these condensed interim financial statements in accordance with accounting principles generally accepted in the United&#x00a0;States of America (&#x201c;US GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Except as disclosed herein, there have been no material changes in the information disclosed in the Notes to the Financial Statements included in the Annual Report for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022. Accordingly, the unaudited condensed interim financial statements and related disclosures herein should be read in conjunction with our 2023 Annual Report.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accrued Expenses</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">Accrued expenses consist of accrued interest for the convertible and promissory notes held with related parties, monies owed to vendors, as well as others, such as the taxing authority and employees.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">As of September&#x00a0;30, 2024 and December&#x00a0;31, 2023, the accounts payable and accrued expenses balance consists of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-26" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September&#x00a0;30,<BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">December&#x00a0;31,<BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">95,445</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68,877</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Credit card payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,565</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Professional fees payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">336,391</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,437</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">77,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">511,401</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">123,314</FONT></P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basic and Diluted Loss per Share</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">Basic loss per share data for each period presented is computed using the weighted average number of shares of common stock outstanding during each such period. Diluted net loss per share is computed by giving effect to all potential shares of common stock to the extent they are dilutive.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The following table sets forth the number of potential shares of common stock that have been excluded from basic net loss per share because their effect was anti<FONT CLASS="nobreak">-dilutive</FONT>:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-26" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September&#x00a0;30,<BR>2024</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">September&#x00a0;30,<BR></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee stock options</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">555,600</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">555,600</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes and interest&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">752,836</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">441,740</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1,308,436</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">997,340</FONT></P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The Company considers the applicability and impact of all accounting standard updates. ASUs not discussed in these financial statements were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">In December&#x00a0;2023, the FASB issued ASU No.&#x00a0;2023<FONT CLASS="nobreak">-09</FONT>, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Income Taxes&#x00a0;&#x2014;&#x00a0;Improvements to Income Tax Disclosures (Topic&#x00a0;740)</FONT>. The amendments require that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments also require that all entities disclose on an annual basis the income taxes paid disaggregated by jurisdiction. The amendments eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12&#x00a0;months or make a </P>
		 <P STYLE="margin:0;padding:0;border-width:0;"></P>
	</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to the Unaudited Condensed Interim Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">2.<FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT><FONT CLASS="CharOverride-4" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">statement that an estimate of the range cannot be made. The amendments are effective for fiscal&#x00a0;years beginning after December&#x00a0;15, 2024. The amendments should be applied on a prospective basis, although early adoption is permitted. The Company is currently evaluating the potential impact adopting ASU&#x00a0;2023<FONT CLASS="nobreak">-09</FONT> will have on the Company&#x2019;s financial statements and related disclosures.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">In November&#x00a0;2024, the FASB issued&#x00a0;Accounting Standards Update No.&#x00a0;2024<FONT CLASS="nobreak">-03</FONT>,&#x00a0;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Disaggregation of Income Statement Expenses</FONT>. This guidance will require additional disclosures and disaggregation of certain costs and expenses presented on the face of the income statement. The amendments are effective for annual reporting periods beginning after December&#x00a0;15, 2026 and interim reporting period beginning after December&#x00a0;15, 2027 with early adoption permitted. The Company is currently evaluating the impact of this new guidance to our condensed consolidated financial statements.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">In the period from January&#x00a0;2024 through September&#x00a0;2024, the FASB has not issued any additional standards updates that have a significant impact on the Company. Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our condensed interim financial statements and related disclosures.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;LICENSE AGREEMENT</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On August&#x00a0;2, 2021, the Company entered into a business agreement with Apimeds Korea. Under the agreement, the Company received the right to continue any clinical trial and acquire the permits and approval necessary from the U.S.&#x00a0;Food and Drug Administration. The Company will pay Apimeds Korea a royalty of 5% of the earnings before interest and taxes, delivered from the sale or license of Apitox less any credits and charges, however, the royalty terms shall not apply when shares of the Company are transferred or sold through merger, acquisition, or share transfer agreement to a third party.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On October&#x00a0;12, 2021, the Company entered into an exclusive patent license agreement with Apimeds Korea, a shareholder of the Company. Under the agreement, the Company was granted the exclusive right and license under the licensed patents to make and sell the licensed products in the United&#x00a0;States of America.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The agreement shall commence on the effective date and shall remain in force for each licensed product on a licensed<FONT CLASS="nobreak">-product</FONT><FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">by-licensed</FONT><FONT CLASS="nobreak">-product</FONT> basis for rights and obligations concerning the licensed patent, until the expiration of the last to expire valid claim of a licensed patent. The total consideration exchanged for the exclusive license agreement was $1.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;DEBT</FONT></P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2022 Convertible notes&#x00a0;&#x2014;&#x00a0;related parties</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On March&#x00a0;21, 2022, the Company entered into a promissory note agreement in the amount of $160,000 with Inscobee, one of its shareholders. On June&#x00a0;3, 2022, the Company received an additional $100,000 from Inscobee, as part of another promissory note agreement (together as &#x201c;2022 <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Convertible Notes </FONT>&#x201c;). The 2022 <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Convertible Notes </FONT>bear interest at 5% per annum and mature on the earlier of (a)&#x00a0;the closing of an equity financing with proceeds to the Company of at least $3&#x00a0;million, or (b)&#x00a0;July&#x00a0;15, 2022.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company amended their promissory notes to be convertible and extended the maturity date of the convertible notes with the related parties to be the earlier of (i)&#x00a0;December&#x00a0;31, 2026 or (ii)&#x00a0;consummation of a qualified offering. The notes are convertible at a price of $1 per share. The purchase of convertible notes and cancellation of the old promissory notes was accounted for as a debt extinguishment that did not result in a gain/loss on extinguishment due to related party treatment recognized on December&#x00a0;5, 2023. The conversion option was valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> model, with the following inputs: volatility of 92.22%, the fair value of the stock of $1.96, expected dividend yield of 0% and a risk<FONT CLASS="nobreak">-free</FONT> rate of return of 4.33%. The resulting value of the convertible option of $158,099 based on the allocation of relative fair value to cash proceeds, was applied towards additional paid<FONT CLASS="nobreak">-in</FONT> capital and added as a discount on the convertible note. The note will be accreted over the remaining period through maturity at the calculated effective interest rate of approximately 41.4%.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;"></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"></P>
	</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to the Unaudited Condensed Interim Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>DEBT</FONT><FONT CLASS="CharOverride-4" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">As of September&#x00a0;30, 2024 and December&#x00a0;31, 2023, there was accrued interest in connection with the 2022 Convertible Notes of $31,575 and $22,137, respectively, and are included within accounts payable and accrued expenses on the accompanying unaudited condensed balance sheets. Interest expenses were $9,438 and $9,688 for the nine&#x00a0;months ended September&#x00a0;30, 2024 and 2023, respectively. Accretion on the note&#x2019;s debt discount was $21,742 for the nine&#x00a0;months ended September&#x00a0;30, 2024, which is included within interest expense on the unaudited condensed statements of operations. There was no accretion on the note&#x2019;s debt discount for the nine&#x00a0;months ended September&#x00a0;30, 2023.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">At September&#x00a0;30, 2024 and December&#x00a0;31, 2023, the outstanding balance on the&#x00a0;2022 Convertible notes agreement, net of the unamortized debt discounts of $134,361 and $156,102, was $125,639 and $103,898, respectively.</P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2021 Convertible note&#x00a0;&#x2014;&#x00a0;related party</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On August&#x00a0;30, 2021, the Company received $400,000 in a convertible note agreement (&#x201c;2021 Convertible Note&#x201d;) with Apimeds Korea, one of its shareholders. The 2021 Convertible Note bears interest at 5% per annum and matures on the earlier of (a)&#x00a0;the sale of the Company or (b)&#x00a0;August&#x00a0;30, 2026. The 2021 Convertible Note is convertible at any time up through the maturity date. The number of shares of common stock shall be determined by dividing (x)&#x00a0;the outstanding principal balance hereof plus accrued but unpaid interest by the first closing price on the first&#x00a0;day of trading following a Qualified Direct Listing.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company amended their convertible note to be convertible at $1 per share and extended the maturity date to be the earlier of (i)&#x00a0;December&#x00a0;31, 2026 or (ii)&#x00a0;consummation of a qualified offering. The repurchase and cancellation of the old note was accounted for as a debt extinguishment that did not result in any gain/loss on extinguishment due to related party treatment. The conversion option was valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> model, with the following inputs: volatility of 92.22%, the fair value of the stock of $1.96, expected dividend yield of 0%, and a risk<FONT CLASS="nobreak">-free</FONT> rate of return of 4.33%. The resulting value of the convertible option of $240,079, based on the allocation of relative fair value to cash proceeds, was applied towards additional paid<FONT CLASS="nobreak">-in</FONT> capital and added as a discount on the convertible note. The note will be accreted over the remaining period through maturity at the calculated effective interest rate of approximately 40.6%.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">As of September&#x00a0;30, 2024 and December&#x00a0;31, 2023, there was accrued interest in connection with the 2021 Convertible Note of $61,261 and $46,740, respectively, and is included within accounts payable and accrued expenses on the accompanying unaudited condensed balance sheets. Interest expense was $14,521 and $14,903 for the nine&#x00a0;months ended September&#x00a0;30, 2024 and 2023. Accretion on the 2021 Convertible Note debt discount was $33,359 for the nine&#x00a0;months ended September&#x00a0;30, 2024, respectively, which is included within interest expense on the unaudited condensed statement of operations. There was no accretion on the 2021 Convertible Note debt discount for the nine&#x00a0;months ended September&#x00a0;30, 2023.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">At September&#x00a0;30, 2024, and December&#x00a0;31, 2023, the outstanding balance on the&#x00a0;2021 Convertible Note, net of the unamortized debt discounts of $203,647 and $237,007, was $196,353 and $162,993, respectively.</P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2024 Promissory Notes&#x00a0;&#x2014;&#x00a0;Related Parties</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On May&#x00a0;20, 2024, the Company received $100,000 in a promissory note agreement with Inscobee Inc., one of its shareholders. On August&#x00a0;19, 2024, the Company received an additional $150,000 from Inscobee, as part of another promissory note agreement (together as &#x201c;2024 <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Promissory Notes </FONT>&#x201c;). The 2024 Promissory Notes bear interest at 5% per annum and mature on the earlier of (a)&#x00a0;the closing of an equity financing by the Company with gross proceeds of at least $3,000,000; or (b)&#x00a0;May&#x00a0;19, 2025.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">As of September&#x00a0;30, 2024, there was accrued interest in connection with the 2024 Promissory Notes of $2,610. Interest expense was $2,610 for the nine&#x00a0;months ended September&#x00a0;30, 2024 respectively and is included within accounts payable and accrued expenses on the accompanying unaudited condensed balance sheet.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;"></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"></P>
	</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to the Unaudited Condensed Interim Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>DEBT</FONT><FONT CLASS="CharOverride-4" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2024 Short Term Borrowing</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On July&#x00a0;19, 2024, the Company entered into a non<FONT CLASS="nobreak">-interest</FONT><FONT CLASS="nobreak">-bearing</FONT> loan agreement with a private lender for $20,000. The note matures on August&#x00a0;31, 2024, or may be extended upon mutual agreement. This loan was paid off in full on August&#x00a0;27, 2024.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">5.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</FONT></P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Legal</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">Periodically, the Company reviews the status of any significant matters that exist and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. As of September&#x00a0;30, 2024 and December&#x00a0;31, 2023, there are no pending claims or litigation that are expected to materially affect the Company&#x2019;s results going forward.</P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Executive employee agreement</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On September&#x00a0;21, 2023, the Company signed an executive employee agreement with the CEO of the Company. Under the executive employee agreement terms, if the Company closes on a public offering, the CEO will be eligible to receive an incentive stock option to purchase a number of shares of the Company&#x2019;s common stock equal to 3% of the post<FONT CLASS="nobreak">-Public</FONT> Offering capitalization of the Company. 40% of the options shall vest immediately upon grant and the remainder will vest in three equal installments on the annual anniversary of the date of grant.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">6.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SHAREHOLDERS&#x2019; DEFICIT</FONT></P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Common Stock</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">As of September&#x00a0;30, 2024 and December&#x00a0;31, 2023, the Company had 100,000,000 authorized shares of common stock, respectively, at a par value of $0.01. The Company had 20,550,000 common shares issued and outstanding, as of September&#x00a0;30, 2024 and December&#x00a0;31, 2023, respectively. Each Common share is entitled to one vote.</P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Preferred Stock</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company authorized 10,000,000<FONT CLASS="nobreak"> </FONT>shares of preferred stock with a par value of $0.01. The rights and preferences of preferred shareholders have not been determined as of the date of filing. The Company had no preferred shares issued or outstanding as of September&#x00a0;30, 2024 and December&#x00a0;31, 2023.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">STOCK-BASED</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> COMPENSATION</FONT></P>
		 <P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Stock Options</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On September&#x00a0;18, 2024, the Company adopted&#x00a0;an&#x00a0;equity&#x00a0;incentive&#x00a0;plan for its employees, the Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan (the &#x201c;2024 Equity Incentive Plan&#x201d;). 4,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock have initially been reserved for the issuance of awards under the 2024 Equity Incentive Plan with no stock options granted or outstanding as of the issuance date of the financial statements.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">On May&#x00a0;12, 2020, the Company granted one of its executive officers a total of 555,600 nonqualified stock option awards issued outside of the 2024 Equity&#x00a0;Incentive&#x00a0;Plan. The stock options vested in three equal tranches of 185,200 on the grant anniversary date through May&#x00a0;12, 2023. The shares have an exercise price of $2.82 per share and expire in 10&#x00a0;years on May&#x00a0;12, 2030.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;"></P>
		 <P STYLE="margin:0;padding:0;border-width:0;"></P>
	</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to the Unaudited Condensed Interim Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">STOCK-BASED</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> COMPENSATION</FONT><FONT CLASS="CharOverride-4" STYLE="font-style:normal;font-weight:normal;"> (cont.)</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The following is a summary of stock options issued and outstanding as of September&#x00a0;30, 2024 and December&#x00a0;31, 2023:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-32" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"></P>



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Number of <BR>Options</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Weighted <BR>Average <BR>Exercise Price</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Weighted <BR>Average <BR>Remaining <BR>Life <BR>(in&#x00a0;years)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Aggregate <BR>Intrinsic <BR>Value</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#x00a0;31, 2023</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">555,600</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.82</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.37</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Outstanding as of September&#x00a0;30, 2024</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">555,600</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2.82</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">5.62</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Exercisable as of September&#x00a0;30, 2024</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">555,600</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2.82</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">5.62</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						 <P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>

		</TABLE>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">There was no stock<FONT CLASS="nobreak">-based</FONT> compensation recognized during the nine&#x00a0;months ended September&#x00a0;30, 2024. During the nine&#x00a0;months ended and September&#x00a0;30, 2023, there was $69,994 of stock<FONT CLASS="nobreak">-based</FONT> compensation recognized.</P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">As of September&#x00a0;30, 2024, there were no remaining unrecognized compensation costs related to unvested options.</P>
		 <P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">8.&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;SUBSEQUENT EVENTS</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:0;widows:3;margin-top:8pt;">The Company evaluated subsequent events through the issuance date of the financial statements and determined that there have been no subsequent events except those mentioned throughout the footnotes that would require recognition in the financial statements or disclosure in the notes to the financial statements.</P>
		 <P STYLE="margin:0;padding:0;border-width:0;"></P>
	</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>




	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2001"></A> <FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT> </P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Board of Directors<BR>Apimeds Pharmaceuticals US, Inc.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying balance sheets of Apimeds Pharmaceuticals US, Inc. as of December&#x00a0;31, 2023 and 2022, and the related statements of operations, shareholders&#x2019; deficit, and cash flows for each of the&#x00a0;years ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of Apimeds Pharmaceuticals US, Inc. as of December&#x00a0;31, 2023 and 2022, and the results of its operations and its cash flows for each of the&#x00a0;years ended, in conformity with accounting principles generally accepted in the United&#x00a0;States of America.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Going Concern</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note&#x00a0;1 to the financial statements, the entity has suffered recurring losses from operations and has accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note&#x00a0;1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>
		<P CLASS="H3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="BoldItalic" STYLE="font-style:italic;font-weight:bold;">Basis for Opinion</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These financial statements are the responsibility of the entity&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#x00a0;States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to Apimeds Pharmaceuticals US, Inc. in accordance with the U.S.&#x00a0;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB.&#x00a0;Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Apimeds Pharmaceuticals US, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">/s/ Kreit&#x00a0;&amp; Chiu CPA LLP</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as Apimeds Pharmaceuticals US, Inc.&#x2019;s auditor since 2023.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">New&#x00a0;York, New&#x00a0;York<BR>May&#x00a0;13, 2024</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2002"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Balance Sheets</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">December&#x00a0;31,<BR>2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">December&#x00a0;31,<BR>2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">410,481</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,595</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">422,076</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total assets</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">422,076</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Liabilities and shareholders&#x2019; deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable and accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">123,314</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,877</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Advance payable to related party</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,900</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notes payable&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">260,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">123,314</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">319,777</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes, net of discounts&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">266,891</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">390,205</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">719,777</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (note 6)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shareholders&#x2019; deficit:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preferred stock, par value $0.01; 10,000,000 shares authorized; no shares issued and outstanding as of December&#x00a0;31, 2023 and 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, par value $0.01; 100,000,000 shares authorized (15,000,000 as of December&#x00a0;31, 2022); 20,550,000 and 10,000,000 issued and outstanding as of December&#x00a0;31, 2023 and 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,828,305</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,410,634</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,001,934</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,224,240</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total shareholders&#x2019; deficit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,871</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(713,606</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_3" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total liabilities and shareholders&#x2019; deficit</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">422,076</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these financial statements.</FONT></P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2003"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Statements of Operations</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">For the&#x00a0;Years Ended<BR>December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">98,544</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">368,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">648,892</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">271,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(747,436</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(639,529</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other (expenses) income:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,811</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(38,069</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(29,137</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(30,258</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(29,137</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss </FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(777,694</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(668,666</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Weighted average shares outstanding: basic and diluted</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">11,955,479</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">10,000,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Net loss per share, basic and diluted</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.07</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(0.07</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these financial statements.</FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2004"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Statements of Changes in Shareholders&#x2019; Deficit</FONT></P>
		<TABLE CLASS="No-Table-Style _idGenTablePara-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Preferred Stock</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="4" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 20.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Common Stock</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Additional<BR>Paid-in<BR>capital</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.53%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accumulated<BR>Deficit</FONT></P>
					</TD>
					<TD CLASS="TCH" ROWSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" ROWSPAN="2" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number&#x00a0;of<BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number&#x00a0;of<BR>Shares</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Amount</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance at December&#x00a0;31, 2021</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,000,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,217,091</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,555,574</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(238,483</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Stock-based compensation expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">193,543</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">193,543</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(668,666</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(668,666</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance at December&#x00a0;31, 2022</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">10,000,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">100,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,410,634</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(2,224,240</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(713,606</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Stock-based compensation expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Issuance of common stock shares</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,550,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">105,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">949,500</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,055,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Embedded conversion feature of amended convertible notes</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">398,178</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">398,178</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(777,694</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(777,694</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 21.80%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Balance at December&#x00a0;31, 2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">20,550,000</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">205,500</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2,828,305</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(3,001,934</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.13%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">31,871</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these financial statements.</FONT></P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2005"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Statements of Cash Flows</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-6" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">For the&#x00a0;Years Ended<BR>December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from operating activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(777,694</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(668,666</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation expense</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69,993</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">193,542</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash interest expense&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29,137</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accretion of convertible notes&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,069</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Changes in operating assets and liabilities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11,595</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">731</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable and accrued expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,437</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,911</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(627,790</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">(448,167</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">)</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from investing activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by investing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash flows from financing activities:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash advances from a related party</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,900</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash advances paid to related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(31,900</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock shares</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,055,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from notes payable&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">260,000</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,032,100</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">282,900</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase (decrease) in cash</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">404,310</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(165,267</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash, beginning of period</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,171</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">171,438</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash, end of period</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">410,481</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6,171</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x00a0;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Supplemental cash flow and non-cash information:</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Embedded conversion feature of convertible debt&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">398,178</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">The accompanying notes are an integral part of these financial statements.</FONT></P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><A NAME="T2006"></A><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">1.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>DESCRIPTION OF BUSINESS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Business Description</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds Pharmaceuticals US, Inc. (the &#x201c;Company&#x201d; or &#x201c;Apimeds&#x201d;) was formed as a service corporation in May&#x00a0;2020 and was incorporated in the State of Delaware. On August&#x00a0;21, 2021, Apimeds Inc., the shareholder of the Company (&#x201c;Apimeds Korea&#x201d;), and Apimeds Pharmaceuticals US Inc. entered into the business agreement, under which the Company was designated to operate a pharmaceutical business which provides the biological drug named Apitox&#x2122; to clients in the biological drug commercial transaction area.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Apimeds is a clinical stage company that is in the process of developing Apitox&#x2122;, a proprietary intradermally administered bee venom<FONT CLASS="nobreak">-based</FONT> toxin which completed a positive Phase&#x00a0;3 trial for the treatment of pain associated with Osteoarthritis in 2018 and is now proceeding with FDA discussions on next steps in approval while initiating phase 3 trials for the treatment of quality<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-life</FONT> issues associated with multiple sclerosis (&#x201c;MS&#x201d;) and other future indicia. Apitox is currently marketed and sold by Apimeds Korea in South Korea (Republic of Korea) as &#x201c;Apitoxin&#x201d; for the treatment of osteoarthritis. Apimeds Inc. holds the majority of the Company&#x2019;s outstanding common stock and is a subsidiary of Inscobee Inc. (&#x201c;Inscobee&#x201d;).</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals of its product candidates, marketing its products and achieving profitable operations. The continuation of the research and development activities and the commercialization of its products, if approved, are dependent on the Company&#x2019;s ability to successfully complete these activities and to obtain additional financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development or commercialization programs, or the Company&#x2019;s ability to fund these programs.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Going Concern</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the issuance date of these financial statements. As of December&#x00a0;31, 2023, the Company had accumulated losses amount to $3,001,934. The Company incurred net losses of $777,694 for the year ended December&#x00a0;31, 2023, and expects to continue to incur substantial losses in the future. Based on such conditions and the Company&#x2019;s current plans, which are subject to change, management believes that the Company&#x2019;s existing cash as of December&#x00a0;31, 2023, is not sufficient to satisfy its operating cash needs for 12&#x00a0;months from the issuance date of the report</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals of its product candidates, marketing its products and achieving profitable operations. The continuation of the research and development activities and the commercialization of its products, if approved, are dependent on the Company&#x2019;s ability to successfully complete these activities and to obtain additional financing through a combination of financing activities and operations. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-bottom:10pt;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basis of Presentation</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company has prepared its financial statements in accordance with accounting principles generally accepted in the United&#x00a0;States of America (&#x201c;U.S.&#x00a0;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASUs&#x201d;) promulgated by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Use of Estimates</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with U.S.&#x00a0;GAAP requires management to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, stock<FONT CLASS="nobreak">-based</FONT> compensation and accruals for research and development expenses. Actual results could differ from those estimates, and such differences could be material to the financial statements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Fair Value Measurement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-10" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Level&#x00a0;1</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 0.85%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 85.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-21" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Level&#x00a0;2</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 0.85%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 85.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Observable inputs other than Level&#x00a0;1 inputs. Examples of Level&#x00a0;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-22" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Level&#x00a0;3</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 0.85%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 85.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Unobservable inputs based on the Company&#x2019;s assessment of the assumptions that market participants would use in pricing the asset or liability.</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Concentrations of Credit Risk</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in financial institutions which, at times, may exceed the federal depository insurance corporation limit of $250,000. As of December&#x00a0;31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Segment Information</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision<FONT CLASS="nobreak">-making</FONT> group, in making decisions on how to allocate resources and assess performance. The Company has one operating segment.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Cash</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company considers all highly liquid investments with an original maturity of three&#x00a0;months or less at the date of purchase to be cash equivalents. As of December&#x00a0;31, 2023 and 2022, the Company had no cash equivalents.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Accrued Expenses</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Accrued expenses consist of accrued interest for the convertible note&#x00a0;&#x2014;&#x00a0;related party and for the promissory notes&#x00a0;&#x2014;&#x00a0;related parties, monies owed to vendors, as well as others, such as the taxing authority and employees.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and 2022, the accounts payable and accrued expenses balance consists of the following:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="5" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest&#x00a0;&#x2013;&#x00a0;related parties</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68,877</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,877</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Taxes payable</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Professional fees accrued</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,437</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">123,314</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">36,877</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Convertible Instruments</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC&#x00a0;815 &#x201c;Derivatives and Hedging Activities&#x201d;.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Applicable U.S.&#x00a0;GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free<FONT CLASS="nobreak">-standing</FONT> derivative financial instruments according to certain criteria. The criteria include circumstances in which (a)&#x00a0;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#x00a0;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re<FONT CLASS="nobreak">-measured</FONT> at fair value under other U.S.&#x00a0;GAAP with changes in fair value reported in earnings as they occur and (c)&#x00a0;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">If a security or instrument becomes convertible only upon the occurrence of a future event outside the control of the Company, or, is convertible from inception, but contains conversion terms that change upon the occurrence of a future event, then any contingent beneficial conversion feature is measured and recognized when the triggering event occurs and contingency has been resolved.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Patent Costs</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">All patent<FONT CLASS="nobreak">-related</FONT> costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statements of operations.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Leases</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company accounts for a contract as a lease when it has the right to direct the use of the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines the initial classification and measurement of its right<FONT CLASS="nobreak">-of</FONT><FONT CLASS="nobreak">-use</FONT> assets (&#x201c;ROU&#x201d;) and lease liabilities at the lease commencement date and thereafter if modified. ROU assets and liabilities are to be represented on the balance sheet at the present value of future minimum lease payments to be made over the lease term. The Company has elected as an accounting policy not to apply the recognition requirements in ASC&#x00a0;2016<FONT CLASS="nobreak">-02</FONT>, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Leases</FONT> (&#x201c;ASC&#x00a0;842&#x201d;) to short<FONT CLASS="nobreak">-term</FONT> leases. Short<FONT CLASS="nobreak">-term</FONT> leases are leases that have a term of 12&#x00a0;months or less and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company recognizes the lease payments for short<FONT CLASS="nobreak">-term</FONT> leases on a straight<FONT CLASS="nobreak">-line</FONT> basis over the lease term. As of December&#x00a0;31, 2023 and 2022, the Company did not have leases that qualified as ROU assets.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Related&#x00a0;Parties</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company follows ASC&#x00a0;850,&#x00a0;&#x201c;<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Related&#x00a0;Party&#x00a0;Disclosures</FONT>&#x201d;&#x00a0;for the identification of&#x00a0;related&#x00a0;parties and disclosure of&#x00a0;related&#x00a0;party&#x00a0;transactions.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">General and Administrative</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of personnel costs including costs incurred in development and protection of intellectual property, professional service fees, and other general overhead and facility costs, including rent and insurance, which relate to the Company&#x2019;s general and administrative functions.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Research and Development</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Research and development expenses consist primarily of consulting, regulatory and manufacturing related costs, third<FONT CLASS="nobreak">-party</FONT> license fees and external costs of vendors engaged to conduct preclinical development activities. These expenses are expensed as incurred and non<FONT CLASS="nobreak">-refundable</FONT> prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized in prepaid expenses and other current assets.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company enters into arrangements with contract research organizations in connection with pre<FONT CLASS="nobreak">-clinical</FONT> and clinical trials. Such arrangements often provide for payment prior to commencing the project or based upon predetermined milestones throughout the period during which services are expected to be performed. As part of the process of preparing the Company&#x2019;s financial statements, management is required to estimate prepaid and accrued clinical trial expenses. The date on which services commence, the level of services performed on or before a given date, and the cost of such services are often determined based on subjective judgments informed by the facts and circumstances known to management from the terms of the contract and the Company&#x2019;s ongoing monitoring of service performance. The Company makes these judgments based upon the facts and circumstances known to management based on the terms of the contract and the Company&#x2019;s ongoing monitoring of service performance.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In line with the guidance suggested under ASC&#x00a0;450, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Contingencies</FONT> and ASC&#x00a0;730, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Research and Development, </FONT>all research and development expenses will be expensed as incurred. Development and regulatory milestone payments are accounted for by estimating the probability of milestone achievement. If and when products are commercialized and net sales are realized, royalties of net sales for each product will be a selling expense.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Stock Based Compensation</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company accounts for share<FONT CLASS="nobreak">-based</FONT> compensation in accordance with the fair value recognition provision of FASB ASC&#x00a0;718, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Compensation&#x00a0;&#x2014;&#x00a0;Stock Compensation</FONT> (&#x201c;ASC&#x00a0;718&#x201d;), which prescribes accounting and reporting standards for all share<FONT CLASS="nobreak">-based</FONT> payment transactions in which employee services are acquired. Transactions include </P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share<FONT CLASS="nobreak">-based</FONT> payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on the estimated grant date fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for forfeitures as they occur. The Company classifies share<FONT CLASS="nobreak">-based</FONT> compensation expense in its statements of operations in the same manner in which the award recipient&#x2019;s cash compensation costs are classified.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Given the absence of an active market for the Company&#x2019;s equity, the Company and the board of directors were required to estimate the fair value of the Company&#x2019;s common stock and equity awards at the time of each grant. The Company and the board of directors determined the estimated fair value of the Company&#x2019;s equity instruments based on a number of factors, including external market conditions affecting the pharmaceutical industry sector. The Company and the board of directors utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its equity instrument. Each valuation methodology includes estimates and assumptions that require the Company&#x2019;s judgment.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Income Taxes</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company&#x2019;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the&#x00a0;years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company assesses its income tax positions and records tax benefits for all&#x00a0;years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Basic and Diluted Loss per share</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Basic loss per share data for each period presented is computed using the weighted average number of shares of common stock outstanding during each such period. Diluted net loss per share is computed by giving effect to all potential shares of common stock to the extent they are dilutive.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table sets forth the number of potential shares of common stock that have been excluded from basic net loss per share because their effect was anti<FONT CLASS="nobreak">-dilutive</FONT>:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">As of December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee stock options</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">555,600</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">555,600</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible notes and interest</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">728,877</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">1,284,477</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">555,600</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Emerging Growth Company</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company intends to elect as an Emerging Growth Company, as defined in Section&#x00a0;2(a)&#x00a0;of the Securities Act&#x00a0;of&#x00a0;1933, as modified by the Jumpstart Our Business Startups Act&#x00a0;of&#x00a0;2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#x00a0;is no longer an emerging growth company or (ii)&#x00a0;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company considers the applicability and impact of all accounting standard updates. ASUs not discussed in these financial statements were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In August&#x00a0;2020, the FASB issued ASU No.&#x00a0;2020<FONT CLASS="nobreak">-06</FONT>, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Debt&#x00a0;&#x2014;&#x00a0;Debt with Conversion and Other Options (Subtopic&#x00a0;470</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-20</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic&#x00a0;815</FONT><FONT CLASS="nobreak"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">-40</FONT></FONT><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity</FONT>. ASU&#x00a0;2020<FONT CLASS="nobreak">-06</FONT> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred shares. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S.&#x00a0;GAAP.&#x00a0;Convertible instruments that continue to be subject to separation models are (i)&#x00a0;those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (ii)&#x00a0;convertible debt instruments issued with substantial premiums for which the premiums are recorded as additional paid<FONT CLASS="nobreak">-in</FONT> capital. ASU&#x00a0;2020<FONT CLASS="nobreak">-06</FONT> also amends the guidance for the derivatives scope exception for contracts in an entity&#x2019;s own equity to reduce form<FONT CLASS="nobreak">-over</FONT><FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">substance-based</FONT> accounting conclusions. ASU&#x00a0;2020<FONT CLASS="nobreak">-06</FONT> will be effective for the Company for fiscal&#x00a0;years beginning after December&#x00a0;15, 2023. Early adoption is permitted. The Company adopted this policy as of January&#x00a0;1, 2023 and applied it in the determination of the conversion feature on the amendments of convertible debt.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In December&#x00a0;2023, the FASB issued ASU No.&#x00a0;2023<FONT CLASS="nobreak">-09</FONT>, <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Income Taxes&#x00a0;&#x2014;&#x00a0;Improvements to Income Tax Disclosures (Topic&#x00a0;740)</FONT>. The amendments require that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The amendments also require that all entities disclose on an annual basis the income taxes paid disaggregated by jurisdiction. The amendments eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12&#x00a0;months or make a statement that an estimate of the range cannot be made. The amendments are effective for fiscal&#x00a0;years beginning after December&#x00a0;15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis, although early adoption is permitted. The Company is currently evaluating the potential impact adopting ASU&#x00a0;2023<FONT CLASS="nobreak">-09</FONT> will have on the Company&#x2019;s financial statements and related disclosures.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2.</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">BASIS&#x00a0;OF&#x00a0;PRESENTATION&#x00a0;AND&#x00a0;SUMMARY&#x00a0;OF&#x00a0;SIGNIFICANT&#x00a0;ACCOUNTING&#x00a0;POLICIES</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In November&#x00a0;2023, the FASB issued ASU No.&#x00a0;2023<FONT CLASS="nobreak">-07</FONT>,<FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;"> Segment Reporting&#x00a0;&#x2014;&#x00a0;Improvements to Reportable Segment Disclosures (Topic&#x00a0;280). </FONT>The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments require that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit and loss. The amendments are effective for fiscal&#x00a0;years beginning after December&#x00a0;15, 2023. Early adoption is permitted. The Company adopted this policy as of January&#x00a0;1, 2023 without material impact to the financial statements and related disclosures.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">3.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>LICENSE AGREEMENT</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On October&#x00a0;12, 2021, the Company entered into an exclusive patent license agreement with Apimeds Korea, a shareholder of the Company. Under the agreement, the Company was granted the exclusive right and license under the licensed patents to make and sell the licensed products in the United&#x00a0;States of America.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The agreement shall commence on the effective date and shall remain in force for each licensed product on a licensed<FONT CLASS="nobreak">-product</FONT><FONT CLASS="nobreak">-</FONT><FONT CLASS="nobreak">by-licensed</FONT><FONT CLASS="nobreak">-product</FONT> basis for rights and obligations concerning the licensed patent, until the expiration of the last to expire valid claim of a licensed patent. The total consideration exchanged for the exclusive license agreement was $1.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On August&#x00a0;2, 2021, the Company entered into a business agreement with Apimeds Korea. Under the agreement, the Company received the right to continue any clinical trial and acquire the permits and approval necessary from the U.S.&#x00a0;Food and Drug Administration. The Company will pay Apimeds Korea a royalty of 5% of the earnings before interest and taxes, delivered from the sale or license of Apitox less any credits and charges, however, the royalty terms shall not apply when shares of the Company are transferred or sold through merger, acquisition, or share transfer agreement to a third party.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>DEBT</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2022 Convertible notes (amended from notes payable) &#x2014; related parties</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On March&#x00a0;21, 2022, the Company entered into a promissory note agreement in the amount of $160,000 with Inscobee, one of its shareholders. On June&#x00a0;3, 2022, the Company received an additional $100,000 from Inscobee, as part of another promissory note agreement (together as &#x201c;2022 <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Convertible Notes</FONT>&#x201d;). The 2022 <FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Convertible Notes </FONT>bear interest at 5% per annum and mature on the earlier of (a)&#x00a0;the closing of an equity financing with proceeds to the Company of at least $3&#x00a0;million, or (b)&#x00a0;July&#x00a0;15, 2022.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company amended their promissory notes to be convertible and extended the maturity date of the convertible notes with the related parties to be the earlier of (i)&#x00a0;December&#x00a0;31, 2026 or (ii)&#x00a0;consummation of a qualified offering. The notes are convertible at a price of $1 per share. The purchase of convertible notes and cancellation of the old promissory notes was accounted for as a debt extinguishment that did not result in a gain/loss on extinguishment due to related party treatment. The conversion option was valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> model, with the following inputs: volatility of 92.22%, estimated fair value of Company&#x2019;s stock of $1.96, expected dividend yield of 0% and a risk<FONT CLASS="nobreak">-free</FONT> rate of return of 4.33%. The resulting value of the convertible option of $158,099 based on the allocation of relative fair value to cash proceeds, was applied towards additional paid<FONT CLASS="nobreak">-in</FONT> capital and added as a discount on the convertible note. The note will be accreted over the remaining period through maturity at the calculated effective interest rate of approximately 41.4%.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and 2022, there was accrued interest in connection to the 2022 Convertible Notes of $22,137 and $9,137, respectively. Interest expenses were $13,000 and $9,137 for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022, respectively, and are included within accounts payable and accrued expenses on the accompanying balance sheet. Accretion on the notes for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022 was $1,997 and $0, respectively, which is included within interest expense on the income statements.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="Note_H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:-24pt;widows:1;margin-bottom:10pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">4.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>DEBT</FONT><FONT CLASS="CharOverride-2" STYLE="font-style:normal;font-weight:normal;">&#x00a0;(cont.)</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">2021 Convertible note&#x00a0;&#x2014;&#x00a0;related party</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On August&#x00a0;30, 2021, the Company received $400,000 in a convertible note agreement (&#x201c;2021 Convertible Note&#x201d;) with Apimeds Korea, one of its shareholders. The 2021 Convertible Note bears interest at 5% per annum and matures on the earlier of (a)&#x00a0;the sale of the Company or (b)&#x00a0;August&#x00a0;30, 2026. The 2021 Convertible Note is convertible at any time up through the maturity date. The number of shares of common stock shall be determined by dividing (x)&#x00a0;the outstanding principal balance hereof plus accrued but unpaid interest by the first closing price on the first&#x00a0;day of trading following a Qualified Direct Listing.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company amended their convertible note to be convertible at $1 per share and extended the maturity date to be the earlier of (i)&#x00a0;December&#x00a0;31, 2026 or (ii)&#x00a0;consummation of a qualified offering. The repurchase and cancellation of the old note was accounted for as a debt extinguishment that did not result in any gain/loss on extinguishment due to related party treatment. The conversion option was valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> model, with the following inputs: volatility of 92.22%, estimated fair value of Company&#x2019;s stock of $1.96, expected dividend yield of 0%, and a risk<FONT CLASS="nobreak">-free</FONT> rate of return of 4.33%. The resulting value of the convertible option of $240,079, based on the allocation of relative fair value to cash proceeds, was applied towards additional paid<FONT CLASS="nobreak">-in</FONT> capital and added as a discount on the convertible note. The note will be accreted over the remaining period through maturity at the calculated effective interest rate of approximately 40.6%.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and 2022, there was accrued interest in connection to the 2021 Convertible Note of $46,740 and $26,740, respectively. Interest expense was $20,000 for both of the&#x00a0;years ended December&#x00a0;31, 2023 and 2022 and is included within accounts payable and accrued expenses on the accompanying balance sheet. Accretion on the note for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022 was $3,072 and $0, respectively, which is included within interest expense on the income statements.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">5.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>ADVANCE PAYABLE&#x00a0;&#x2014;&#x00a0;RELATED PARTY</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2022, the Company had received $22,900 from an officer of the Company.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In March&#x00a0;2023, the Company received an additional $9,000 from the officer. During September&#x00a0;2023, the Company then remitted $31,900 back to the officer, leaving a net balance of $0 as of the year ended December&#x00a0;31, 2023.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">6.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>COMMITMENTS AND CONTINGENCIES</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Legal</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Periodically, the Company reviews the status of any significant matters that exist and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. As of December&#x00a0;31, 2023 and 2022, there are no pending claims or litigation that are expected to materially affect the Company&#x2019;s results going forward.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Executive employee agreement</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On September&#x00a0;21, 2023, the Company signed an executive employee agreement with the CEO of the Company. Under the executive employee agreement terms, if the Company closes on a public offering, the CEO will be eligible to receive an incentive stock option to purchase a number of shares of the Company&#x2019;s common stock equal to 3% of the post<FONT CLASS="nobreak">-Public</FONT> Offering capitalization of the Company. 40% of the options shall vest immediately upon grant and the remainder will vest in three equal installments on the annual anniversary of the date of grant.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-bottom:10pt;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">7.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SHAREHOLDERS&#x2019; DEFICIT</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Common Stock</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023 and 2022, the Company had 100,000,000 and 15,000,000 authorized shares of common stock, respectively, at a par value of $0.01. The Company had 20,550,000 and 10,000,000 common shares issued and outstanding, respectively, as of December&#x00a0;31, 2023 and 2022. Each Common share is entitled to one vote.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Preferred Stock</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company authorized 10,000,000<FONT CLASS="nobreak"> </FONT>shares of preferred stock with a par value of $0.01. The rights and preferences of preferred shareholders have not been determined as of the date of filing. The Company had no preferred shares issued or outstanding as of the year ended December&#x00a0;31, 2023.</P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Activity during the period ended December&#x00a0;31, 2023</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On September&#x00a0;7, 2023, the Company issued 5,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock of the Company to related parties for cash consideration in aggregate of $500,000.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;5, 2023, the Company increased their authorized common shares from 15,000,000 to 100,000,000 and established a preferred stock class by authorizing 10,000,000<FONT CLASS="nobreak"> </FONT>shares; both share classes have a par value of $0.01.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On December&#x00a0;6, 2023, the Company issued 5,550,000<FONT CLASS="nobreak"> </FONT>shares of common stock of the Company to related parties for cash consideration in aggregate of $555,000.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">8.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT></FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">STOCK-BASED</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;"> COMPENSATION</FONT></P>
		<P CLASS="H4" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">Stock Options</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On May&#x00a0;12, 2020, the Company granted one of its executive officers a total of 555,600 nonqualified stock option awards. The stock options vest in three equal tranches of 185,200 on the grant anniversary date through May&#x00a0;12, 2023. The shares have an exercise price of $2.82 per share and expire in 10&#x00a0;years on May&#x00a0;12, 2030.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following is a summary of stock options issued and outstanding as of December&#x00a0;31, 2023 and 2022:</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-28" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Number of<BR>Options</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="2" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Weighted<BR>Average<BR>Exercise&#x00a0;Price</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Weighted<BR>Average<BR>Remaining&#x00a0;Life<BR>(in&#x00a0;years)</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Aggregate<BR>Intrinsic&#x00a0;Value</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding as of December&#x00a0;31, 2022</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">555,600</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.82</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.37</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Outstanding as of December&#x00a0;31, 2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">555,600</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2.82</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6.37</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Exercisable as of December&#x00a0;31, 2023</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">555,600</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">$</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">2.82</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">6.37</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">&#x2014;</FONT></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">During the&#x00a0;years ended December&#x00a0;31, 2023 and 2022, there was $69,993 and $193,542, respectively, of stock<FONT CLASS="nobreak">-based</FONT> compensation recognized.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The options were valued utilizing the Black<FONT CLASS="nobreak">-Scholes</FONT> options pricing model with the following inputs: 0.20% risk<FONT CLASS="nobreak">-free</FONT> rate, 66.8% volatility, 0% dividend rate, vesting term of 3&#x00a0;years, and the expected term of 6.5&#x00a0;years. The total fair value of shares vested during each of the&#x00a0;years ended December&#x00a0;31, 2023 and 2022 was $193,542.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">As of December&#x00a0;31, 2023, there were no remaining unrecognized compensation costs related to unvested options.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-bottom:10pt;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Apimeds Pharmaceuticals US, Inc.<BR>Notes to Financial Statements</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">9.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>INCOME TAXES</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">There were no income tax expenses reflected in the results of operations for the&#x00a0;years ended December&#x00a0;31, 2023 and 2022.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year Ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per book</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(777,694</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(668,666</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Federal statutory income tax rate (21%)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(163,315</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(140,420</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax, net of federal benefit</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(32,268</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(51,318</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State rate change</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">34,245</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,632</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">156,706</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">191,738</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The tax effects of temporary differences which give rise to deferred tax assets (liabilities) are summarized as follows:</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="7" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Year Ended December&#x00a0;31,</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-11" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2023</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" COLSPAN="3" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">2022</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carry forwards</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">537,878</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">437,457</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">172,436</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,981</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90,501</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">43,512</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intangible assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(638</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(479</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">800,177</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">643,471</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(800,177</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(643,471</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule1-bracket-" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-7" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax assets</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x2014;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" VALIGN="bottom">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company had cumulative federal net operating losses of approximately $2.1&#x00a0;million and state net operating losses of approximately $2.1&#x00a0;million, which do not expire but are subject to an 80% utilization against future taxable income.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that the same portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Deferred tax assets consist primarily of the tax effect of NOL carry<FONT CLASS="nobreak">-forwards</FONT>. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realizability.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company&#x2019;s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December&#x00a0;31, 2023, the Company had no unrecognized tax benefits. There were no changes in the Company&#x2019;s unrecognized tax benefits during the&#x00a0;years ended December&#x00a0;31, 2023 and 2022. The Company did not recognize any interest or penalties during the 2023 fiscal year related to unrecognized tax benefits.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">10.<FONT STYLE="width: 13px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>SUBSEQUENT EVENTS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The Company evaluated subsequent events through the issuance date of the financial statements and determined that there have been no additional subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></DIV>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:31pt;text-align:center;margin-top:31pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"> 3,333,334 Shares of Common Stock</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;text-align:center;margin-top:12pt;"><FONT CLASS="CharOverride-3" STYLE="font-size:14pt;"><IMG ALT="" SRC="tapimeds_logo.jpg" STYLE="width:175.36px;max-width:100%;"></FONT></P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:16pt;">Apimeds Pharmaceuticals US, Inc.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:40pt;text-align:center;margin-top:40pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">____________________________</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:8pt;text-align:center;margin-top:8pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">PRELIMINARY PROSPECTUS</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-bottom:8pt;margin-top:0pt;text-align:center;margin-top:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">____________________________</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:-24pt;widows:1;margin-top:40pt;text-align:center;margin-top:40pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:14pt;"></FONT></P>
		<P CLASS="Text_flush_Center" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:40pt;margin-top:40pt;">&#x00a0;<FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>, 2024</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:40pt;margin-top:40pt;">Through and including <FONT STYLE="width: 10px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;</FONT><FONT STYLE="width: 30px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>, 2024 (the 25<FONT CLASS="Superscript" STYLE="vertical-align:super;font-size:58%;">th</FONT>&#x00a0;day after the date of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#x2019;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</P>
		<DIV STYLE="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"><P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:32pt;margin-top:32pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;font-size:12pt;">&#x00a0;</FONT></P></DIV>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#x00a0;</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">PART&#x00a0;II&#x00a0;&#x2014;&#x00a0;INFORMATION NOT REQUIRED IN PROSPECTUS</FONT></P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item&#x00a0;13.<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Other Expenses of Issuance and Distribution.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of common stock being registered. All amounts are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority, or FINRA, filing fee and NYSE American listing fee.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">



						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC Registration Fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,698</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FINRA Filing Fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,600</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Initial NYSE American Listing Fee</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Printing and Engraving Expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Fees and Expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounting Fees and Expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Accountable Expenses to Underwriters</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">175,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transfer Agent&#x2019;s and Registrar&#x2019;s Fees and Expenses</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody_rightalign" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,500</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Miscellaneous Fees</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="top">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#x00a0;</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" VALIGN="top">
						<P CLASS="Tbody_rule1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15,000</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 83.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Tbody-ind_1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Total</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="top">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 13.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" VALIGN="top">
						<P CLASS="Tbody_rule2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">528,798</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item&#x00a0;14.<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Indemnification of Directors and Officers.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Section&#x00a0;102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides that no director of the registrant shall be personally liable to the fullest extent permitted by subsection 102(b)(7) of the DGCL.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Section&#x00a0;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#x2019; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our Bylaws and Amended and Restated Certificate of Incorporation authorize the indemnification of our officers and directors, consistent with Section&#x00a0;145 of the DGCL, as amended. Reference is made to Section&#x00a0;102(b)(7)&#x00a0;of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director&#x2019;s fiduciary duty, except (i)&#x00a0;for any breach of the director&#x2019;s duty of loyalty to the corporation or its stockholders, (ii)&#x00a0;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#x00a0;pursuant to Section&#x00a0;174 of the DGCL, which provides for liability of directors for unlawful payments of dividends of unlawful stock purchase or redemptions or (iv)&#x00a0;for any transaction from which a director derived an improper personal benefit.</P>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">In any underwriting agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item&#x00a0;15.<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Recent Sales of Unregistered Securities.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Set forth below is information regarding shares of capital stock issued by us within the past three&#x00a0;years. Also included is the consideration received by us for such shares and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. Unless otherwise specified all figures are presented on a pre<FONT CLASS="nobreak">-Reverse</FONT> Stock Split basis.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">On June<FONT CLASS="nobreak"> </FONT>15, 2020 we issued 10,000,000<FONT CLASS="nobreak"> </FONT>shares of our common stock for the aggregate subscription amount of $1,000,000. On September<FONT CLASS="nobreak"> </FONT>7, 2023 we issued 5,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock of the Company to the related parties for cash consideration in aggregate of $500,000. On September<FONT CLASS="nobreak"> </FONT>7, 2023, we received a total of $500,000 from related parties for the purchase of 5,000,000<FONT CLASS="nobreak"> </FONT>shares of common stock. These 5,000,000<FONT CLASS="nobreak"> </FONT>shares of Common stock were issued subsequent to December<FONT CLASS="nobreak"> </FONT>5, 2023 when the Company amended its Certificate of Incorporation increasing the number of common stock shares authorized to 100,000,000<FONT CLASS="nobreak"> </FONT>shares.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We believe the offers, sales and issuances of the above securities by us were exempt from registration under the Securities Act by virtue of Section&#x00a0;4(a)(2)&#x00a0;of the Securities Act and Rule&#x00a0;506 thereunder as transactions not involving a public offering. All of the investors were accredited investors as such term is defined in Rule&#x00a0;501 under the Securities Act. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates, notes and warrants issued in these transactions. All recipients had adequate access, through their relationships with us, to information about our Company. The sales of these securities were made without any general solicitation or advertising.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item&#x00a0;16.<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Exhibits and Financial Statement Schedules.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">(a)&#x00a0;Exhibits.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">See the Exhibit Index immediately preceding the signature pages hereto, which is incorporated by reference as if fully set forth herein.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">(b)&#x00a0;Financial Statement Schedules.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">None.</P>
		<P CLASS="H2" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">Item&#x00a0;17.<FONT STYLE="width: 17px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Undertakings.</FONT></P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The undersigned hereby undertakes that:</P>
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">1.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#x00a0;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&#x00a0;424(b)&#x00a0;(1)&#x00a0;or (4)&#x00a0;or 497(h)&#x00a0;under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="NL_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">2.<FONT STYLE="width: 20px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>For the purpose of determining any liability under the Securities Act, each post<FONT CLASS="nobreak">-effective</FONT> amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">EXHIBITS</FONT></P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">



						 <P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Exhibit&#x00a0;No.</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Description</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">1.1**</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020112409ex1-1_apimeds.htm">Form of Underwriting Agreement.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex3-1_apimeds.htm">Amended and Restated Certificate of Incorporation of Apimeds Pharmaceuticals US, Inc.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.2*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex3-2_apimeds.htm">Bylaws of Apimeds Pharmaceuticals US, Inc.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024095559/ea020112408ex5-1_apimeds.htm">Opinion of Nelson Mullins Riley&#x00a0;&amp; Scarborough LLP.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-1_apimeds.htm">Letter Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apico Inc., dated November 3, 2021</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.2*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-2_apimeds.htm">Business Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated August 2, 2021</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-3_apimeds.htm">Assignment Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated October 12, 2021</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.4*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-4_apimeds.htm">Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.5*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-5_apimeds.htm">Business Establishment Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated March&#x00a0;3, 2020</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.6*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-6_apimeds.htm">August&#x00a0;2021 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated August&#x00a0;30, 2021</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.7*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-7_apimeds.htm">Amendment to the August 2021 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated December<FONT CLASS="nobreak"> </FONT>5, 2023</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.8*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-8_apimeds.htm">March 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated March<FONT CLASS="nobreak"> </FONT>21, 2022</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.9*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-9_apimeds.htm">Amendment to the March&#x00a0;2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated December<FONT CLASS="nobreak"> </FONT>5, 2023</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.10*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-10_apimeds.htm">June&#x00a0;2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated June&#x00a0;3, 2022</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable_wrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.11*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-11_apimeds.htm">Amendment to the June&#x00a0;2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated December<FONT CLASS="nobreak"> </FONT>5, 2023</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.12*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-12_apimeds.htm">Intellectual Property Assignment Agreement by and between Apimeds Pharmaceuticals US, Inc. Apimeds Inc. and Christopher Kim, dated October&#x00a0;12, 2021</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.13*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-13_apimeds.htm">Patent License Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated October<FONT CLASS="nobreak"> </FONT>12, 2021</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.14*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-14_apimeds.htm">Employment Agreement dated September<FONT CLASS="nobreak"> </FONT>21, 2023 between Apimeds Pharmaceuticals US, Inc. and Erik Emerson</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.15*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-15_apimeds.htm">Form of Indemnification Agreement</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.16*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-16_apimeds.htm">Loan Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated October<FONT CLASS="nobreak"> </FONT>5, 2022</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.17*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-17_apimeds.htm">Loan Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated November<FONT CLASS="nobreak"> </FONT>10, 2022</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.18*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-18_apimeds.htm">Loan Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated March<FONT CLASS="nobreak"> </FONT>16, 2023</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.19*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-19_apimeds.htm">Advisory Agreement by and between Apimeds Pharmaceuticals US, Inc. and Murdock Capital Partners, dated September<FONT CLASS="nobreak"> </FONT>8, 2023</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.20*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-20_apimeds.htm">May 2024 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated May<FONT CLASS="nobreak"> </FONT>20, 2024</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.21*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-21_apimeds.htm">Convertible Note Assignment Agreement (August 2021 Promissory Note), by and between Apimeds Pharmaceuticals US, Inc., Apimeds, Inc., and Inscobee Inc., dated June<FONT CLASS="nobreak"> </FONT>12, 2024</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.22*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-22_apimeds.htm">Convertible Note Assignment Agreement (March 2022 Promissory Note), by and between Apimeds Pharmaceuticals US, Inc., Apimeds, Inc., and Inscobee Inc., dated June<FONT CLASS="nobreak"> </FONT>12, 2024</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.23*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex10-23_apimeds.htm">Amended Amendment to the June 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated June<FONT CLASS="nobreak"> </FONT>12, 2024</A></P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="Basic-Text-Frame" STYLE="margin:0;padding:0;border-width:0;">
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">



						 <P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Exhibit&#x00a0;No.</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="top">
						 <P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">Description</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.24*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024095559/ea020112408ex10-24_apimeds.htm">CFO Consulting Agreement, by and between Apimeds Pharmaceuticals US, Inc. and Mark Corrao, dated October<FONT CLASS="nobreak"> </FONT>4, 2024</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.25**</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020112409ex10-25_apimeds.htm">August 2024 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated August 19, 2024</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">21.1*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex21-1_apimeds.htm">Subsidiaries of the Registrant</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.1**</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="ea020112409ex23-1_apimeds.htm">Consent of Kreit &amp; Chiu CPA LLP, Independent Registered Certified Public Accounting Firm.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.2*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024095559/ea020112408ex5-1_apimeds.htm">Consent of Nelson Mullins Riley &amp; Scarborough LLP (included in Exhibit 5.1).</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">24.1*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea0201124-07.htm#T2023">Power of Attorney, dated September 25, 2024.</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="background: #CCEEFF;height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.1*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex99-1_apimeds.htm">Code of Business Conduct and Ethics</A></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">107*</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 88.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						 <P CLASS="Tbody_nowrap" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><A HREF="http://www.sec.gov/Archives/edgar/data/1894525/000121390024081766/ea020112407ex-fee_apimeds.htm">Filing Fee Table</A></P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Tablefootnotef" STYLE="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</P><P CLASS="Tablefootnote_f" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">#<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Certain confidential information contained in this agreement has been omitted because it is not material and would be competitively harmful if publicly disclosed.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">*<FONT STYLE="width: 24px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Previously filed.</P>
		<P CLASS="Tablefootnote_m" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">**<FONT STYLE="width: 18px;display: inline-block;">&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;</FONT>Filed herewith.</P>
		</DIV>

		<P CLASS="LRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</P>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><A HREF="#TOC001">Table of Contents</A></P>



	<DIV CLASS="_idGenObjectStyleOverride-1" STYLE="margin:0;padding:0;border-width:0;border-width:0pt;">
		<P CLASS="H1" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">SIGNATURES</FONT></P>
		 <P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act&#x00a0;of&#x00a0;1933, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Kamuela, State of Hawaii, on December<FONT CLASS="nobreak"> </FONT>6, 2024.</P>
		<TABLE CLASS="No-Table-Style" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style TB" STYLE="width: 51.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" COLSPAN="3" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Bold-AllCaps" STYLE="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">APIMEDS PharmaCEUTICALS US, Inc</FONT><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">.</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-top:10pt;width: 51.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 5.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">/s/ Erik Emerson</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style TB" STYLE="width: 51.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Erik C.&#x00a0;Emerson</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style TB" STYLE="width: 51.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Executive Officer</P>
					</TD>
				</TR>

		</TABLE>
		<P CLASS="Text_flush" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act&#x00a0;of&#x00a0;1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>
		<TABLE CLASS="No-Table-Style TableOverride-1" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="No-Table-Style _idGenTableRowColumn-8" STYLE="height:12pt;">
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-style:none;border-bottom-width:0pt;border-left-style:none;border-right-style:none;padding-left:0pt;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">



						<P CLASS="TCH_left" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">SIGNATURE</P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-style:none;border-bottom-width:0pt;border-left-style:none;border-right-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-style:none;border-bottom-width:0pt;border-left-style:none;border-right-style:none;padding-left:0pt;padding-right:0pt;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="CharOverride-1" STYLE="font-style:normal;font-weight:bold;">TITLE</FONT></P>
					</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-style:none;border-bottom-width:0pt;border-left-style:none;border-right-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TCH" STYLE="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-style:none;border-bottom-width:0pt;border-left-style:none;border-right-style:none;padding-left:0pt;padding-right:0pt;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="TCH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><FONT CLASS="Bold" STYLE="font-style:normal;font-weight:bold;">DATE</FONT></P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-17" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-8" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">/s/ Erik Emerson</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-8" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-8" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Chief Executive Officer and Director</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-8" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-8" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">December<FONT CLASS="nobreak"> </FONT>6, 2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-9" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:top;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Erik Emerson</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">(Principal Executive Officer)</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">/s/ Mark Corrao</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">December<FONT CLASS="nobreak"> </FONT>6, 2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-9" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mark Corrao</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">(Principal Financial Officer and Principal Accounting Officer)</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-10" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:top;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">*</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Chairman of the Board and Chief Medical Officer</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">December<FONT CLASS="nobreak"> </FONT>6, 2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#x00a0;Christopher Kim</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">*</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Director</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">December<FONT CLASS="nobreak"> </FONT>6, 2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jakap Koo</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-18" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">*</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Director</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						 <P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">December<FONT CLASS="nobreak"> </FONT>6, 2024</P>
					</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Bennett Weintraub, PhD</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Director</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Hankil Yoon</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Director</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carol O&#x2019;Donnell</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-13" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">&#x00a0;</FONT></P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Director</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-12" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="No-Table-Style _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 29.27%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Elona Kogan</P>
					</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 48.93%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="No-Table-Style CellOverride-11" STYLE="border-left-style:none;border-left-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;vertical-align:bottom;width: 19.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>

		</TABLE>
		<TABLE CLASS="Basic-Table" STYLE="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<TR CLASS="Basic-Table _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 5.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">



						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">*By:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 42.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" VALIGN="bottom">
						<P CLASS="Signature_rule" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><FONT CLASS="Italic" STYLE="font-style:italic;font-weight:normal;">/s/ Erik Emerson</FONT></P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="bottom">&#x00a0;</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="bottom">&#x00a0;</TD>
				</TR>
				<TR CLASS="Basic-Table _idGenTableRowColumn-5" STYLE="height:12pt;">
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 5.24%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</P>
					</TD>
					<TD CLASS="TB" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" VALIGN="top">&#x00a0;</TD>
					<TD CLASS="TB" COLSPAN="3" STYLE="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 93.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" VALIGN="top">
						<P CLASS="Texttable" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Erik Emerson, Attorney<FONT CLASS="nobreak">-in-fact</FONT>, pursuant to the Power of Attorney filed as Exhibit 24.1 hereto.</P>
					</TD>
				</TR>

		</TABLE>
		</DIV>

		<P CLASS="RRH" STYLE="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</P>



</DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea020112409ex1-1_apimeds.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APIMEDS PHARMACEUTICALS US, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>D. BORAL CAPITAL SECURITIES,
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>as Representative of the Several Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APIMEDS PHARMACEUTICALS US, INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, New York<BR>
[&#9679;], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Boral Capital Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of the several Underwriters named on Schedule 1 attached
hereto<BR>
590 Madison Avenue, 39<SUP>th</SUP> Fl</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10022</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned, Apimeds Pharmaceuticals
US, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including,
without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or
affiliates of Apimeds Pharmaceuticals US, Inc., the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;)
with D. Boral Capital Securities, LLC (hereinafter referred to as &ldquo;you&rdquo; (including its correlatives) or the &ldquo;<B>Representative</B>&rdquo;)
and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative is acting as representative (the Representative
and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">1.</FONT> <FONT STYLE="font-weight: normal"><U>Purchase and Sale of Shares</U>.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.1&nbsp;</FONT><FONT STYLE="font-weight: normal"><U>Firm
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.1.&nbsp;<U>Nature
and Purchase of Firm Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;On
the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate of [&#9679;] shares (&ldquo;</FONT>Firm Shares<FONT STYLE="font-weight: normal">&rdquo;)
of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;</FONT>Common Stock<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;The
Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares set forth opposite their respective
names on <U>Schedule 1</U> attached hereto and made a part hereof at a purchase price of $[&#9679;] per share (93.0% of the per Firm Share
offering price). The Firm Shares are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus
(as defined in Section 2.1.1 hereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.2.&nbsp;<U>Shares
Payment and Delivery</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;Delivery
and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on the first (1st) Business Day following the effective date
(the &ldquo;</FONT>Effective Date<FONT STYLE="font-weight: normal">&rdquo;) of the Registration Statement (as defined in Section 2.1.1
below) (or the second (2nd) Business Day following the Effective Date if the Registration Statement is declared effective after 4:01 p.m.,
Eastern time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices of Blank Rome LLP
(&ldquo;</FONT>Representative Counsel<FONT STYLE="font-weight: normal">&rdquo;), or at such other place (or remotely by facsimile or other
electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment for
the Firm Shares is called the &ldquo;</FONT>Closing Date<FONT STYLE="font-weight: normal">.&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;Payment
for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company
upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares (or through the
facilities of the Depository Trust Company (&ldquo;</FONT>DTC<FONT STYLE="font-weight: normal">&rdquo;)) for the account of the Underwriters.
The Firm Shares shall be registered in such name or names and in such authorized denominations as the Representative may request in writing
at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except
upon tender of payment by the Representative for all of the Firm Shares. The term &ldquo;</FONT>Business Day<FONT STYLE="font-weight: normal">&rdquo;
means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by
law to close in New York, New York.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.2&nbsp;</FONT><FONT STYLE="font-weight: normal"><U>Over-allotment
Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.1.&nbsp;<U>Option
Shares</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Company
hereby grants to the Representative an option to purchase up to [&#9679;] additional shares of Common Stock, representing fifteen percent
(15%) of the Firm Shares sold in the offering, from the Company (the &ldquo;</FONT>Over-allotment Option<FONT STYLE="font-weight: normal">&rdquo;).
Such [&#9679;] additional shares of Common Stock, the net proceeds of which will be deposited with the Company&rsquo;s account, are hereinafter
referred to as &ldquo;</FONT>Option Shares<FONT STYLE="font-weight: normal">.&rdquo; The purchase price to be paid per Option Share shall
be equal to the price per Firm Share set forth in Section 1.1.1 hereof. The Firm Shares and the Option Shares are hereinafter referred
to together as the &ldquo;</FONT>Public&nbsp;Securities<FONT STYLE="font-weight: normal">.&rdquo; The offering and sale of the Public
Securities is hereinafter referred to as the &ldquo;</FONT>Offering<FONT STYLE="font-weight: normal">.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.2.&nbsp;<U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to all (at
any time) or any part (from time to time) of the Option Shares within 45 days after the Effective Date. The Underwriters shall not be
under any obligation to purchase any Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted
hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in writing by overnight
mail or facsimile or other electronic transmission setting forth the number of Option Shares to be purchased and the date and time for
delivery of and payment for the Option Shares (the &ldquo;</FONT>Option Closing Date<FONT STYLE="font-weight: normal">&rdquo;), which
shall not be later than one (1) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company
and the Representative, at the offices of Representative Counsel or at such other place (including remotely by facsimile or other electronic
transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Shares does not
occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with
respect to all or any portion of the Option Shares, subject to the terms and conditions set forth herein, (i) the Company shall become
obligated to sell to the Underwriters the number of Option Shares specified in such notice and (ii) each of the Underwriters, acting severally
and not jointly, shall purchase that portion of the total number of Option Shares then being purchased as set forth in <U>Schedule 1</U>
opposite the name of such Underwriter.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.3.&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds,
payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing
the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option Shares shall be registered in such
name or names and in such authorized denominations as the Representative may request in writing at least one (1) full Business Day prior
to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment by the
Representative for applicable Option Shares. The Option Closing Date may be simultaneous with, but not earlier than, the Closing Date,
and in the event that such time and date are simultaneous with the Closing Date, the term &ldquo;</FONT>Closing Date&rdquo; <FONT STYLE="font-weight: normal">shall
refer to the time and date of delivery of the Firm Shares and Option Shares.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.3&nbsp;</FONT><FONT STYLE="font-weight: normal"><U>Representative&rsquo;s
Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.1.&nbsp;<U>Purchase
Warrants</U>. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date and Option
Closing Date, as applicable, an option (&ldquo;</FONT>Representative&rsquo;s Warrant<FONT STYLE="font-weight: normal">&rdquo;) for the
purchase of an aggregate number of shares of Common Stock representing 5% of the Public&nbsp;Securities purchased on such Closing Date
or Option Closing Date, for an aggregate purchase price of $100.00. The Representative&rsquo;s Warrant agreement, in the form attached
hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;</FONT>Representative&rsquo;s Warrant Agreement<FONT STYLE="font-weight: normal">&rdquo;),
shall be exercisable, in whole or in part, commencing on a date which is [one hundred eighty (180) days] after the Effective Date and
expiring on the five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[&#9679;], which
is equal to 100% of the initial public offering price of the Firm Shares. The Representative&rsquo;s Warrant Agreement and the shares
of Common Stock issuable upon exercise thereof (the &ldquo;</FONT>Underlying Shares<FONT STYLE="font-weight: normal">&rdquo;) are hereinafter
referred to together as the &ldquo;</FONT>Representative&rsquo;s Securities<FONT STYLE="font-weight: normal">.&rdquo; The Representative
understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative&rsquo;s
Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its
acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrant Agreement,
or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective
economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than
(i) an Underwriter or a selected dealer in connection with the Offering, or (ii) an officer or partner, registered person or affiliate
of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.2.&nbsp;<U>Delivery</U>.
Delivery of the Representative&rsquo;s Warrants shall be made on the Closing Date and any Option Closing Date and shall be issued in the
name or names and in such authorized denominations as the Representative may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">2.&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below),
as of the Closing Date and as of the Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.1&nbsp;</FONT><FONT STYLE="font-weight: normal"><U>Filing
of Registration Statement</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.1.&nbsp;<U>Pursuant
to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;</FONT>Commission<FONT STYLE="font-weight: normal">&rdquo;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]), including any related prospectus or
prospectuses, for the registration of the Public Securities and the Representative&rsquo;s Securities under the Securities Act of 1933,
as amended (the &ldquo;</FONT>Securities Act<FONT STYLE="font-weight: normal">&rdquo;), which registration statement and amendment or
amendments have been prepared by the Company in all material respects in conformity with the requirements of the Securities Act and the
rules and regulations of the Commission under the Securities Act (the &ldquo;</FONT>Securities Act Regulations<FONT STYLE="font-weight: normal">&rdquo;)
and will contain all material statements that are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations. Except as the context may otherwise require, such registration statement, as amended, on file with the Commission at
the time the registration statement became effective (including the Preliminary Prospectus included in the registration statement, financial
statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to
be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act Regulations (the &ldquo;</FONT>Rule
430A Information<FONT STYLE="font-weight: normal">&rdquo;)), is referred to herein as the &ldquo;</FONT>Registration Statement<FONT STYLE="font-weight: normal">.&rdquo;
If the Company files any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the
term &ldquo;Registration Statement&rdquo; shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement
has been declared effective by the Commission on the date hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Each
prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that
was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &ldquo;</FONT>Preliminary
Prospectus<FONT STYLE="font-weight: normal">.&rdquo; The Preliminary Prospectus, subject to completion, dated [&#9679;], 2024, that was
included in the Registration Statement immediately prior to the Applicable Time is hereinafter called the &ldquo;</FONT>Pricing Prospectus<FONT STYLE="font-weight: normal">.&rdquo;
The final prospectus in the form first furnished to the Underwriters for use in the Offering is hereinafter called the &ldquo;</FONT>Prospectus<FONT STYLE="font-weight: normal">.&rdquo;
Any reference to the &ldquo;most recent Preliminary Prospectus&rdquo; shall be deemed to refer to the latest Preliminary Prospectus included
in the Registration Statement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Applicable
Time<FONT STYLE="font-weight: normal">&rdquo; means [TIME] [a.m./p.m.], Eastern time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Issuer
Free Writing Prospectus<FONT STYLE="font-weight: normal">&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in
Rule 433 of the Securities Act Regulations (&ldquo;</FONT>Rule 433<FONT STYLE="font-weight: normal">&rdquo;), including without limitation
any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the Securities Act Regulations) relating to the Public Securities
that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &ldquo;road show that is a written communication&rdquo;
within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii)&nbsp;exempt from filing with
the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Public Securities or of the Offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in
the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Issuer
General Use Free Writing Prospectus<FONT STYLE="font-weight: normal">&rdquo; means any Issuer Free Writing Prospectus that is intended
for general distribution to prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule
433 (the &ldquo;</FONT>Bona Fide Electronic Road Show<FONT STYLE="font-weight: normal">&rdquo;)), as evidenced by its being specified
in <U>Schedule 2-B</U> hereto.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Issuer
Limited Use Free Writing Prospectus<FONT STYLE="font-weight: normal">&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer
General Use Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&#9;&ldquo;</FONT>Pricing
Disclosure Package<FONT STYLE="font-weight: normal">&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to
the Applicable Time, the Pricing Prospectus and the information included on <U>Schedule 2-A</U> hereto, all considered together.&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.2.&nbsp;<U>Pursuant
to the Exchange Act</U>. The Company has filed with the Commission a Form 8-A (File Number 000-[&#9679;]) providing for the registration
pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the &ldquo;</FONT>Exchange Act<FONT STYLE="font-weight: normal">&rdquo;),
of the shares of Common Stock. The registration of the shares of Common Stock under the Exchange Act has been declared effective by the
Commission on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the
registration of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is
contemplating terminating such registration.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.2&nbsp;<U>Stock
Exchange Listing</U>. The shares of Common Stock have been approved for listing on the NYSE American (the &ldquo;</FONT><FONT STYLE="font-style: normal">Exchange<FONT STYLE="font-weight: normal">&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange,
nor has the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.3&nbsp;<U>No
Stop Orders, etc</U>. Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued any order
preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to
the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied with each
request (if any) from the Commission for additional information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.4&nbsp;<U>Disclosures
in Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.1.&nbsp;<U>Compliance
with Securities Act and 10b-5 Representation</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects
with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus
filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus,
at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the
Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the
Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or at any
Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;The
Pricing Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does not and
will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto
does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus
as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information
furnished to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing
Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided
by or on behalf of any Underwriter consists solely of the following statements concerning the Underwriters contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: (i) the first sentence and last two sentences of the first paragraph of the subsection entitled &ldquo;Price
Stabilization; Short Position and Penalty Bids&rdquo; and (ii) the first sentence of the second paragraph of the subsection entitled &ldquo;Price
Stabilization; Short Position and Penalty Bids&rdquo; (the &ldquo;</FONT>Underwriters&rsquo; Information<FONT STYLE="font-weight: normal">&rdquo;);
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing
with the Commission pursuant to Rule 424(b) of the Securities Regulations, at the Closing Date or at any Option Closing Date, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that
this representation and warranty shall not apply to the&nbsp;Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.2.&nbsp;<U>Disclosure
of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
conform in all material respects to the descriptions thereof contained therein and there are no agreements or other documents required
by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed.
Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound
or affected and (i)&nbsp;that is referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or (ii)&nbsp;is
material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is in full force and effect in
all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance
with its terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors&rsquo; rights generally, (y)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the
federal and state securities laws, and (z)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. Except
as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, none of such agreements or instruments
has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in default thereunder
and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute
a default thereunder. To the best of the Company&rsquo;s knowledge, performance by the Company of the material provisions of such agreements
or instruments will not result in a violation of any existing applicable law, rule, regulation, ordinance, judgment, order or decree of
any governmental or regulatory agency, body, authority or court, domestic or foreign, having jurisdiction over the Company or any of its
assets or businesses (each, a &ldquo;</FONT>Governmental Entity<FONT STYLE="font-weight: normal">&rdquo;), including, without limitation,
those relating to environmental laws and regulations. Except as disclosed in the Registration Statement, the Disclosure Package and the
Prospectus, the Company has no subsidiaries and has no other interest, nominal or beneficial, direct or indirect, in any other corporation,
joint venture or other business entity.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.3.&nbsp;<U>Prior
Securities Transactions</U>. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of,
any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the Registration Statement,
the Pricing Disclosure Package and the Preliminary Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.4.&nbsp;<U>Regulations</U>.
The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects of federal, state,
local and all foreign regulation on the Offering and the Company&rsquo;s business as currently contemplated are correct in all material
respects and no other such regulations are required to be disclosed in the Registration Statement, the Pricing Disclosure Package and
the Prospectus which are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.5.&nbsp;<U>No
Other Distribution of Offering Materials</U>. The Company has not, directly or indirectly, <U>distributed</U> and will not distribute
any offering material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Pricing Package, the Prospectus
and other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.5&nbsp;<U>Changes
After Dates in Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.1.&nbsp;<U>No
Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no material adverse change in the
financial position or results of operations of the Company, nor any change or development that, singularly or in the aggregate, would
involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results
of operations, business, general affairs, management, assets, properties or prospects of the Company (a &ldquo;</FONT>Material Adverse
Change<FONT STYLE="font-weight: normal">&rdquo;); (ii)&nbsp;there have been no material transactions entered into by the Company, other
than as contemplated pursuant to this Agreement; (iii)&nbsp;no officer or director of the Company has resigned from any position with
the Company; and (iv) the Company has not sustained any material loss of interference with its business or properties from fire, explosion,
flood, earthquake, hurricane, accident or other calamity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.2.&nbsp;<U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued any securities or incurred any liability
or obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other distribution on
or in respect to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.6&nbsp;<U>Independent
Accountants</U>. To the knowledge of the Company, Kreit &amp; Chiu CPA, LLP (the &ldquo;</FONT><FONT STYLE="font-style: normal">Auditor<FONT STYLE="font-weight: normal">&rdquo;),
whose report is filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is
an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company
Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g)
of the Exchange Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.7&nbsp;<U>Financial
Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules included in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, fairly present the financial position and the results of operations of the Company
at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with U.S. generally
accepted accounting principles (&ldquo;</FONT><FONT STYLE="font-style: normal">GAAP<FONT STYLE="font-weight: normal">&rdquo;), consistently
applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments
that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules
included in the Registration Statement present fairly the information required to be stated therein. No historical or pro forma financial
statements are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the Securities
Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information and the related notes, if any, included
in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly compiled and prepared in accordance
with the applicable requirements of the Securities Act and the Securities Act Regulations and present fairly the information shown therein,
and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to
the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement, the Pricing Disclosure
Package or the Prospectus regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations of
the Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent
applicable. Each of the Registration Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet
transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated
entities or other persons that may have a material current or future effect on the Company&rsquo;s financial condition, changes in financial
condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses.
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) neither the Company nor any
of its direct and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus as being a subsidiary of the Company (each, a &ldquo;</FONT>Subsidiary<FONT STYLE="font-weight: normal">&rdquo;
and, collectively, the &ldquo;</FONT>Subsidiaries<FONT STYLE="font-weight: normal">&rdquo;), has incurred any material liabilities or
obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company
has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been
any change in the capital stock of the Company or any of its Subsidiaries, or, other than in the course of business, any grants under
any stock compensation plan, and (d) there has not been any material adverse change in the Company&rsquo;s long-term or short-term debt.</FONT></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.8&nbsp;<U>Authorized
Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date the adjusted
stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing Disclosure
Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option Closing Date, there
will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock
of the Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments
to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.9&nbsp;<U>Valid
Issuance of Securities, etc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.9.1.&nbsp;<U>Outstanding
Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have
been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission, rights
of first refusal or rights of participation or similar rights with respect thereto or put rights, and are not subject to personal liability
by reason of being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal
or rights of participation or similar rights of any holders of any security of the Company or similar contractual rights granted by the
Company. The authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock were at all
relevant times either registered under the Securities Act and the applicable state securities or &ldquo;blue sky&rdquo; laws or, based
in part on the representations and warranties of the purchasers of such Shares, exempt from such registration requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.9.2.&nbsp;<U>Securities
Sold Pursuant to this Agreement</U>. The Public Securities and Representative&rsquo;s Securities have been duly authorized for issuance
and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not
be subject to personal liability by reason of being such holders; the Public Securities and the Representative&rsquo;s Securities are
not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities and the
Representative&rsquo;s Securities has been duly and validly taken. The Public Securities and the Representative&rsquo;s Securities conform
in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing Disclosure Package
and the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Representative&rsquo;s Warrant
Agreement has been duly and validly taken; the Underlying Shares have been duly authorized and reserved for issuance by all necessary
corporate action on the part of the Company and when paid for and issued in accordance with the Representative&rsquo;s Warrant and the
Representative&rsquo;s Warrant Agreement, such Underlying Shares will be validly issued, fully paid and non-assessable; the holders thereof
are not and will not be subject to personal liability by reason of being such holders; and such shares of Common Stock are not and will
not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.10&nbsp;<U>Registration
Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no
holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have
the right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities
in a registration statement to be filed by the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.11&nbsp;<U>Validity
and Binding Effect of Agreements</U>. This Agreement, the Representative&rsquo;s Warrant and the Representative&rsquo;s Warrant Agreement
have been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements
of the Company, enforceable against the Company in accordance with their respective terms, except: (i)&nbsp;as such enforceability may
be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii)&nbsp;as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii)&nbsp;that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.12&nbsp;<U>No
Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Representative&rsquo;s Warrant Agreement
and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by
the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both:
(i)&nbsp;result in a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under,
or result in the creation, modification, termination or imposition of any lien, charge, mortgage, pledge, security, interest, claim, equity,
trust or other encumbrance, preferential arrangement or restriction of any kind whatsoever upon any portion of any property or assets
of the Company pursuant to the terms of any indenture, mortgage, deed of trust, note, lease, loan agreement or any other agreement or
instrument, license or permit, to which the Company is a party, or to which any of its properties or any of its assets are bound; (ii)&nbsp;result
in any violation of the provisions of the Company&rsquo;s Amended and Restated Certificate of Incorporation (as the same may be amended
or restated from time to time, the &ldquo;</FONT><FONT STYLE="font-style: normal">Charter<FONT STYLE="font-weight: normal">&rdquo;) or
the by-laws of the Company; or (iii)&nbsp;violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental
Entity as of the date hereof (including, without limitation, those promulgated by the Food and Drug Administration of the U.S. Department
of Health and Human Services (the &ldquo;</FONT>FDA<FONT STYLE="font-weight: normal">&rdquo;) or by any foreign, federal, state or local
regulatory authority performing functions similar to those performed by the FDA).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.13&nbsp;<U>No
Defaults; Violations</U>. No material default exists in the due performance and observance of any term, covenant or condition of any material
license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing
an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which the Company
may be bound or to which any of the properties or assets of the Company is subject. The Company is not in violation of any term or provision
of its Charter or by-laws, or in violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of
any Governmental Entity.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.14&nbsp;<U>Corporate
Power; Licenses; Consents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.14.1.&nbsp;<U>Conduct
of Business</U>. The Company has all requisite corporate power and authority, and has all necessary consents, authorizations, approvals,
orders, licenses, certificates, qualifications, registrations and permits of and from all governmental regulatory officials and bodies
that it needs as of the date hereof to conduct its business purpose as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.14.2.&nbsp;<U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions
and conditions hereof, and all consents, authorizations, approvals, registrations, orders, licenses, certificates, qualifications and
permits required in connection therewith have been obtained. No consent, authorization or order of, and no filing with, any court, government
agency or other body is required for the valid issuance, sale and delivery of the Public Securities and the consummation of the transactions
and agreements contemplated by this Agreement and the Representative&rsquo;s Warrant Agreement and as contemplated by the Registration
Statement, the Pricing Disclosure Package and the Prospectus, except with respect to applicable federal and state securities laws and
the rules and regulations of Exchange and the Financial Industry Regulatory Authority, Inc. (&ldquo;</FONT>FINRA<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.15&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;</FONT><FONT STYLE="font-style: normal">Questionnaires<FONT STYLE="font-weight: normal">&rdquo;)
completed by each of the Company&rsquo;s directors and officers immediately prior to the Offering (the &ldquo;</FONT>Insiders<FONT STYLE="font-weight: normal">&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal stockholders as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section 2.26 below),
provided to the Underwriters, is true and correct in all material respects and the Company has not become aware of any information which
would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.16&nbsp;<U>Litigation;
Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding
pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s knowledge, any executive
officer or director which has not been disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus or in
connection with the Company&rsquo;s listing application for the listing of the Public Securities on the Exchange. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.17&nbsp;<U>Good
Standing</U>. The Company has been duly incorporated and is validly existing as a corporation and is in good standing under the laws of
the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction in
which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to be so qualified
or in good standing, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.18&nbsp;<U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which
the Company believes are adequate, including, but not limited to, directors and officers insurance coverage at least equal to $5,000,000
and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing
insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary
or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.19&nbsp;<U>Transactions
Affecting Disclosure to FINRA</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.1.&nbsp;<U>Finder&rsquo;s
Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims, payments,
arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee by the Company or
any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings of the
Company or, to the Company&rsquo;s knowledge, any of its stockholders that may affect the Underwriters&rsquo; compensation, as determined
by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.2.&nbsp;<U>Payments
Within Twelve (12) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&rsquo;s fee,
consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who
raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp; any person or entity that has any direct or indirect
affiliation or association with any FINRA member, within the twelve (12) months prior to the Effective Date, other than the payment to
the Underwriters as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.3.&nbsp;<U>Use
of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates,
except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.4.&nbsp;<U>FINRA
Affiliation</U>. There is no (i) officer or director of the Company, (ii) beneficial owner of 10% or more of any class of the Company's
securities or (iii) beneficial owner of the Company's unregistered equity securities which were acquired during the 180-day period immediately
preceding the filing of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering
(as determined in accordance with the rules and regulations of FINRA). Except as disclosed in the Registration Statement, the Disclosure
Package and the Prospectus, the Company (i) does not have any material lending or other relationship with any bank or lending affiliate
of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Public Securities to repay any outstanding
debt owed to any affiliate of any Underwriter. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.5.&nbsp;<U>Information</U>.
All information provided by the Company in its, and, to the Company&rsquo;s knowledge, all information provided by the Company&rsquo;s
officers and directors in their, FINRA questionnaire to Representative Counsel specifically for use by Representative Counsel in connection
with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all material respects.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.20&nbsp;<U>Foreign
Corrupt Practices Act</U>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries, has,
directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in
the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any
governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic
or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection
with any actual or proposed transaction) that (i)&nbsp;might subject the Company to any damage or penalty in any civil, criminal or governmental
litigation or proceeding, (ii)&nbsp;if not given in the past, might have had a Material Adverse Change or (iii)&nbsp;if not continued
in the future, might adversely affect the assets, business, operations or prospects of the Company, or (iv) violated or is in violation
of any provision of the Foreign Corrupt Practices Act (the &ldquo;</FONT><FONT STYLE="font-style: normal">FCPA<FONT STYLE="font-weight: normal">&rdquo;)
or any applicable non-U.S. anti-bribery statute or regulation; (v) made any bribe, rebate, payoff, influence payment, kickback or other
unlawful payment; or (vi) received notice of any investigation, proceeding or inquiry by any Governmental Entity regarding any of the
matters in clauses (i) or (ii) above; and the Company has conducted its business in compliance with the FCPA in all material respects.
The Company has no operations outside of the United States. The Company has taken reasonable steps to ensure that its accounting controls
and procedures are sufficient to cause the Company to comply in all material respects with the FCPA.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.21&nbsp;<U>Compliance
with OFAC</U>. None of the Company or any of its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any of its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries, is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;</FONT><FONT STYLE="font-style: normal">OFAC<FONT STYLE="font-weight: normal">&rdquo;),
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any U.S. sanctions administered by OFAC.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.22&nbsp;<U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in either the Registration Statement, Disclosure Package or Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.23&nbsp;<U>Money
Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;</FONT><FONT STYLE="font-style: normal">Money Laundering
Laws<FONT STYLE="font-weight: normal">&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving the Company
with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</FONT></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.24&nbsp;
<U>Regulatory</U>. (a) All preclinical studies and clinical trials conducted by or on behalf of the Company that are material to the Company
and its Subsidiaries, taken as a whole, are or have been adequately described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus in all material respects. The preclinical studies and clinical trials conducted by or on behalf of the Company and
its Subsidiaries that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of
which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still ongoing, to
the best knowledge of the Company, are being conducted in material compliance with all laws and regulations applicable thereto in the
jurisdictions in which they are being conducted and with all laws and regulations applicable to preclinical studies and clinical trials
from which data will be submitted to support marketing approval. The descriptions in the Registration Statement, the Pricing Disclosure
Package and the Prospectus of the results of such studies are accurate and complete in all material respects and fairly present the data
derived from such studies, and the Company has no knowledge of, or reason to believe that, any large well-controlled clinical study the
aggregate results of which are inconsistent with or otherwise call into question the results of any clinical study conducted by or on
behalf of the Company that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results
of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received any written notices or statements
from the FDA, the European Medicines Agency (&ldquo;</FONT><FONT STYLE="font-style: normal">EMA<FONT STYLE="font-weight: normal">&rdquo;)
or any other governmental agency or authority imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or
material modification for or of any preclinical studies and clinical trials that are described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package
and the Prospectus. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
has not received any written notices or statements from the FDA, the EMA or any other governmental agency, and otherwise has no knowledge
of, or reason to believe that, (i) any investigational new drug application for any potential product of the Company is or has been rejected
or placed on clinical hold; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential product
of the Company has been, will be or may be suspended, revoked, modified or limited. Neither the Company nor any of its subsidiaries has
failed to file with the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions similar
to those performed by the FDA, any filing, declaration, listing, registration, report or submission that is required to be so filed. &nbsp;All
such filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory
authority (including, without limitation, the FDA or any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA) with respect to any such filings, declarations, listings, registrations, reports or submissions.
To the knowledge of the Company, there are no facts that would be reasonably likely to result in any warning, untitled or notice of violation
letter or Form FDA-483 from the FDA. The Company is not aware of any studies, tests or trials the results of which the Company believes
reasonably call into questions (i) the study, test or trial results of any of its products, (ii) the efficacy or safety of any of its
products or (iii) any of the Company&rsquo;s filings with any Governmental Entity. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) <U>Regulatory Filings and
Permits</U>. The Company and its Subsidiaries have such permits, licenses, clearances, registrations, exemptions, patents, franchises,
certificates of need and other approvals, consents and other authorizations (&ldquo;<B>Permits</B>&rdquo;) issued by the appropriate domestic
or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company, including,
without limitation, any Investigational New Drug Application (an &ldquo;<B>IND</B>&rdquo;), Biologics License Application (&ldquo;<B>BLA</B>&rdquo;)
and/or New Drug Application (an &ldquo;<B>NDA</B>&rdquo;), as required by FDA, the Drug Enforcement Administration (the &ldquo;<B>DEA</B>&rdquo;),
or any other Permits issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of
pharmaceuticals such as those being developed by the Company and its Subsidiaries (collectively, the &ldquo;<B>Regulatory Permits</B>&rdquo;),
except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect;
the Company is in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits
are valid and in full force and effect; the Company has not received any notice of proceedings relating to the revocation, termination,
modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect; the Company has not failed to submit
to the FDA any IND, BLA or NDA necessary to conduct the business of the Company, any such filings that were required to be made were in
material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such
filings or submissions that were made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) <U>Compliance with Health
Care Laws</U>. Each of the Company and its Subsidiaries is, and at all times has been, in compliance in all material respects with all
applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties,
or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of this
Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.),
the Public Health Service Act (42 U.S.C. &sect;&sect; 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal,
state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback
Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h), the U.S. Civil False Claims
Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health
care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under
the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;) (42 U.S.C. Section 1320d et seq.), the
exclusion laws (42 U.S.C. &sect; 1320a-7), the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a), HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant
to such statutes; (iii) Medicare (Title XVIII of the Social Security Act); (iv) Medicaid (Title XIX of the Social Security Act); (v) the
Controlled Substances Act (21 U.S.C. &sect;&sect; 801 et seq.) and the regulations promulgated thereunder; and (vi) any and all other
applicable health care laws and regulations. Neither the Company nor, to the knowledge of the Company, any subsidiary has received notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any
Health Care Laws, and, to the Company&rsquo;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action is threatened. Neither the Company nor, to the knowledge of the Company, any subsidiary is a party to or has
any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements,
consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company, its Subsidiaries nor any of its respective employees, officers or directors has been excluded, suspended
or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company,
is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in
debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.25&nbsp;<U>Officers&rsquo;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Representative Counsel
shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.26&nbsp;<U>Lock-Up
Agreements. Schedule 3</U> hereto contains a complete and accurate list of the Company&rsquo;s officers, directors and each owner of the
Company&rsquo;s outstanding shares of Common Stock (or securities convertible into or exercisable for shares of Common Stock) (collectively,
the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up Parties<FONT STYLE="font-weight: normal">&rdquo;). The Company has caused each
of the Lock-Up Parties to deliver to the Representative an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit B</U>
(the &ldquo;</FONT>Lock-Up Agreement<FONT STYLE="font-weight: normal">&rdquo;), prior to the execution of this Agreement. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.27&nbsp;<U>Subsidiaries</U>.
All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct
of business requires such qualification, except where the failure to qualify would not have a Material Adverse Change. The Company&rsquo;s
ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.28&nbsp;<U>Related
Party Transactions</U>. There are no business relationships or related party transactions involving the Company or any other person required
to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not been described as required.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.29&nbsp;<U>No
Relationships with Customers and Suppliers</U>. No relationship, direct or indirect, exists between or among the Company on the one hand,
and the directors, officers, 5% or greater stockholders, customers or suppliers of the Company or any of the Company&rsquo;s affiliates
on the other hand, which is required to be described in the Pricing Disclosure Package and the Prospectus or a document incorporated by
reference therein and which is not so described. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.30&nbsp;<U>No
Unconsolidated Entities</U>. There are no transactions, arrangements or other relationships between and/or among the Company, any of its
affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but not limited to, any
structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company&rsquo;s
liquidity or the availability of or requirements for its capital resources required to be described in the Pricing Disclosure Package
and the Prospectus or a document incorporated by reference therein which have not been described as required.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.31&nbsp;<U>Board
of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing Prospectus
and the Prospectus captioned &ldquo;Management.&rdquo; The qualifications of the persons serving as board members and the overall composition
of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
(the &ldquo;</FONT><FONT STYLE="font-style: normal">Sarbanes-Oxley Act<FONT STYLE="font-weight: normal">&rdquo;) applicable to the Company
and the listing rules of the Exchange. At least one member of the Audit Committee of the Board of Directors of the Company qualifies as
an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of the Exchange.
In addition, at least a majority of the persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo; as defined under
the listing rules of the Exchange.</FONT></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.32&nbsp;<U>Sarbanes-Oxley
Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.32.1.&nbsp;<U>Disclosure
Controls</U>. Except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange
Act Regulations, and such controls and procedures are effective to ensure that all material information concerning the Company will be
made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s Exchange Act filings and other
public disclosure documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">2.32.2.&nbsp;<U>Compliance</U>.
The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley
Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company&rsquo;s future
compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley
Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.33&nbsp;<U>Accounting
Controls</U>. The Company and its Subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo; (as defined
under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been
designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is
not aware of any material weaknesses in its internal controls. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors
of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls
over financial reporting which are known to the Company&rsquo;s management and that have adversely affected or are reasonably likely to
adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and (ii) any fraud known
to the Company&rsquo;s management, whether or not material, that involves management or other employees who have a significant role in
the Company&rsquo;s internal controls over financial reporting.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.34&nbsp;<U>No
Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof
as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to register as an
&ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.35&nbsp;<U>No
Labor Disputes</U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company,
is imminent. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.36&nbsp;<U>Intellectual
Property Rights</U>. The Company and each of its Subsidiaries owns or possesses or has valid rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets
and similar rights (&ldquo;</FONT><FONT STYLE="font-style: normal">Intellectual Property Rights<FONT STYLE="font-weight: normal">&rdquo;)
necessary for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, to the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary for
the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will involve or
give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. Neither the Company nor
any of its Subsidiaries has received any notice alleging any such infringement of, licensee or similar fees for, or conflict with, any
asserted Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate,
in a Material Adverse Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties
of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened
action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and
the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate,
together with any other claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual
Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have
not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the
Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual
Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually
or in the aggregate, together with any other claims in this Section 2.36, reasonably be expected to result in a Material Adverse Change;
(D) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the Company
infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has
not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any
such claim that would, individually or in the aggregate, together with any other claims in this Section 2.36, reasonably be expected to
result in a Material Adverse Change; and (E) to the Company&rsquo;s knowledge, no employee of the Company is in or has ever been in violation
in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee&rsquo;s employment with the Company, or actions undertaken by the employee while employed with
the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s
knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential.
The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any
other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus contain in all material respects
the same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained
or is being used by the Company in violation of any contractual obligation binding on the Company or any of its Subsidiaries or, to the
Company&rsquo;s knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons.</FONT></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">To
the Company&rsquo;s knowledge, all licenses for the use of the Intellectual Property described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus are in full force and effect in all material respects and are enforceable by the Company and, to
the Company&rsquo;s knowledge, the other parties thereto, in accordance with their terms, except (x) as such enforceability may be limited
by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification
or contribution provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company, and the Company,
has no knowledge, that any other party is in default thereunder and no event has occurred that, with the lapse of time or the giving of
notice, or both, would constitute a default thereunder. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.37&nbsp;<U>Taxes</U>.
Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior
to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries has paid all
taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the
Company or such respective Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part
of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including
the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no issues have been raised
(and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or
its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by
or requested from the Company or its Subsidiaries. The term &ldquo;taxes&rdquo; means all federal, state, local, foreign and other net
income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding,
payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees,
assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with
respect thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements and other documents required to be
filed in respect to taxes.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.38&nbsp;<U>ERISA
Compliance</U>. The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security Act
of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">ERISA<FONT STYLE="font-weight: normal">&rdquo;))
established or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects
with ERISA. &ldquo;ERISA Affiliate&rdquo; means, with respect to the Company, any member of any group of organizations described in Sections
414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
&ldquo;</FONT>Code<FONT STYLE="font-weight: normal">&rdquo;) of which the Company is a member. No &ldquo;reportable event&rdquo; (as defined
under ERISA) has occurred or is reasonably expected to occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained
by the Company or any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any
of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit
liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to
incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit
plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee benefit plan&rdquo; established or maintained
by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to
the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.39&nbsp;<U>Compliance
with Laws</U>. The Company: (A) is and at all times has been in compliance with all statutes, rules, regulations, ordinances, judgments,
orders and decrees of all Governmental Entities applicable to the Company&rsquo;s business (&ldquo;</FONT><FONT STYLE="font-style: normal">Applicable
Laws<FONT STYLE="font-weight: normal">&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to result
in or have a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from
any other Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances,
authorizations, consents, permits, orders, and supplements or amendments thereto required by any such Applicable Laws (&ldquo;</FONT>Authorizations<FONT STYLE="font-weight: normal">&rdquo;);
(C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation
of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, litigation, proceeding, hearing, enforcement,
investigation, inquiry, arbitration or other action from any Governmental Entity or third party alleging that any product operation or
activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Entity or third party
is considering any such claim, litigation, arbitration, action, suit, litigation, proceeding, hearing, enforcement, investigation, inquiry,
arbitration or other action; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to
limit, suspend, modify or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action;
(F) has filed, obtained, maintained or submitted all material reports, documents, forms, filings, notices, applications, records, claims,
submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were
corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or
issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning,
&ldquo;dear doctor&rdquo; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged
product defect or violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to initiate any
such notice or action.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.40&nbsp;<U>Ineligible
Issuer</U>.&nbsp; At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness
of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant
made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at the date
hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405, without taking account of any determination
by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.41&nbsp;<U>Environmental
Laws</U>. Each of the Company and each of its Subsidiaries is in material compliance with all federal, state, local and foreign rules,
laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of
health and safety or the environment which are applicable to their businesses (&ldquo;</FONT><FONT STYLE="font-style: normal">Environmental
Laws<FONT STYLE="font-weight: normal">&rdquo;), except where the failure to comply would not, singularly or in the aggregate, result in
a Material Adverse Change. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission,
or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company or any of its
Subsidiaries (or, to the Company&rsquo;s knowledge, any other entity for whose acts or omissions the Company or any of its Subsidiaries
is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company or any of its Subsidiaries, or
upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would,
under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any
liability; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment
surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.
</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.42&nbsp;<U>Real
Property</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and each
of its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real
or personal property which are material to the business of the Company and each of its Subsidiaries taken as a whole, in each case free
and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect
the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries;
and all of the leases and subleases material to the business of the Company and any of its Subsidiaries, considered as one enterprise,
and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received any notice of any material
claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases
mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or
subleased premises under any such lease or sublease.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.43&nbsp;<U>Contracts
Affecting Capital</U>. There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates
(as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to,
any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company&rsquo;s
or any of its Subsidiaries&rsquo; liquidity or the availability of or requirements for their capital resources required to be described
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have not been described
or incorporated by reference as required.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.44&nbsp;<U>Loans
to Directors or Officers</U>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course
of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers or directors
of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.45&nbsp;<U>Smaller
Reporting Company</U>.&nbsp; As of the time of filing of the Registration Statement, the Company was a &ldquo;smaller reporting company,&rdquo;
as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.46&nbsp;<U>Industry
Data</U>.&nbsp; The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.47&nbsp;<U>Margin
Securities</U>. The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the &ldquo;</FONT><FONT STYLE="font-style: normal">Federal Reserve Board<FONT STYLE="font-weight: normal">&rdquo;),
and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security,
for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for
any other purpose which might cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings
of Regulation T, U or X of the Federal Reserve Board.</FONT></FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.48&nbsp;<U>Minute
Books</U>. The minute books of the Company have been made available to the Underwriters and Representative Counsel, and such books (i)
contain a complete summary of all meetings and actions of the board of directors (including each board committee) and stockholders of
the Company (or analogous governing bodies and interest holders, as applicable), and each of its Subsidiaries since the date of its incorporation
through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all transactions referred to in
such minutes. There are no material transactions, agreements, dispositions or other actions of the Company and each Subsidiary that are
not properly approved and/or accurately and fairly recorded in the minute books of the Company or its Subsidiary, as applicable.</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.49&nbsp;<U>Integration</U>.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated
with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under
the Securities Act.</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.50&nbsp;<U>No
Stabilization</U>. Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of
the Representative) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Public Securities.</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.51&nbsp;<U>Confidentiality
and Non-Competition</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant of the Company is subject
to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer or prior employer that
could reasonably be expected to materially affect his ability to be and act in his respective capacity of the Company or be expected to
result in a Material Adverse Change.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.52&nbsp;<U>Emerging
Growth Company</U>. From the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier,
the first date on which the Company engaged directly in or through any Person authorized to act on its behalf in any Testing-the Waters
Communication) through the date hereof, the Company has been and is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a)
of the Securities Act (an &ldquo;</FONT><FONT STYLE="font-style: normal">Emerging Growth Company<FONT STYLE="font-weight: normal">&rdquo;).
&ldquo;Testing-the-Waters Communication&rdquo; means any oral or written communication with potential investors undertaken in reliance
on Section 5(d) of the Securities Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.53&nbsp;<U>Testing-the-Waters
Communications</U>. The Company has not (i) alone engaged in any Testing-the-Waters Communications, other than Testing-the-Waters Communications
with the written consent of the Representative and with entities that are qualified institutional buyers within the meaning of Rule 144A
under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii)
authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company confirms that the Representative
has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written
Testing-the-Waters Communications other than those listed on <U>Schedule 2-C</U> hereto. &ldquo;Written Testing-the-Waters Communication&rdquo;
means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.54&nbsp;<U>Electronic
Road Show</U>. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule&nbsp;433(d)(8)(ii) of the Securities
Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule&nbsp;433(h) of the Securities Act Regulations)
is required in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0"></TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal"><U>Covenants of the Company</U>. The Company covenants and agrees as
follows:</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.1&nbsp;<U>Amendments
to Registration Statement</U>. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration
Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Representative
shall reasonably object in writing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.2&nbsp;<U>Federal
Securities Laws</U>.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.1.&nbsp;<U>Compliance</U>.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will notify
the Representative promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration Statement
shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii)&nbsp;of the receipt of any comments
from the Commission; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement
to the Prospectus or for additional information; (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus
or the Prospectus, or of the suspension of the qualification of the Public Securities and Representative&rsquo;s Securities for offering
or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant
to Section&nbsp;8(d) or 8(e) of the Securities Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject
of a proceeding under Section&nbsp;8A of the Securities Act in connection with the Offering of the Public Securities and Representative&rsquo;s
Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within
the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain
promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the
event that it was not, it will promptly file such prospectus. The Company shall use its best efforts to prevent the issuance of any stop
order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.2.&nbsp;<U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act
Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or,
but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;</FONT>Rule 172<FONT STYLE="font-weight: normal">&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend
the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;amend or supplement
the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will
not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration
Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements
of the Securities Act or the Securities Act Regulations, the Company will promptly (A)&nbsp;give the Representative notice of such event;
(B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement,
the Pricing Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed
filing or use, furnish the Representative with copies of any such amendment or supplement and (C)&nbsp;file with the Commission any such
amendment or supplement; provided, however, that the Company shall not file or use any such amendment or supplement to which the Representative
or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment
or supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant
to the Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative
notice of its intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full
or expiration of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related
document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document
to which the Representative or counsel for the Underwriters shall reasonably object. </FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.&nbsp;<U>Exchange
Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts to maintain
the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister the shares of Common Stock under
the Exchange Act without the prior written consent of the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.4.&nbsp;<U>Free
Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make
any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule 433; provided, however, that the Representative shall be deemed to have consented to each Issuer General Use Free
Writing Prospectus hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i) that
has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free writing
prospectus consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo; as defined in
Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely
filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus
there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict
with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at
that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at its
own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.5.&nbsp;<U>Testing-the-Waters
Communications</U>. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs
an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement
of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative and shall promptly
amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or
omission.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.3&nbsp;<U>Delivery
to the Underwriters of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available to
the Representative and counsel for the Representative, without charge, signed copies of the Registration Statement as originally filed
and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will
also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and each amendment
thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished
to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.4&nbsp;<U>Delivery
to the Underwriters of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to each Underwriter,
without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents
to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge,
during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required
to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may
reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.5&nbsp;<U>Effectiveness
and Events Requiring Notice to the Representative</U>. The Company shall use best efforts to cause the Registration Statement to remain
effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative immediately
and confirm the notice in writing: (i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&nbsp;of
the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii)&nbsp;of
the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for
offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv)&nbsp;of the mailing
and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v)&nbsp;of the
receipt of any comments or request for any additional information from the Commission; and (vi)&nbsp;of the happening of any event during
the period described in this Section 3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration
Statement, the Pricing Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration
Statement in order to make the statements therein not misleading, or (b) in the Pricing Disclosure Package or the Prospectus in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state
securities commission shall enter a stop order or suspend such qualification at any time, the Company shall make every reasonable effort
to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.6&nbsp;<U>Review
of Financial Statements.</U> For a period of three (3) years after the date of this Agreement, the Company, at its expense, shall cause
its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.7&nbsp;<U>Listing</U>.
The Company shall use its best efforts to maintain the listing of the shares of Common Stock (including the Public Securities) on the
Exchange for at least three (3) years from the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.8&nbsp;<U>Financial
Public Relations Firm</U>. As of the Effective Date, the Company shall have retained a financial public relations firm reasonably acceptable
to the Representative and the Company, which firm shall be experienced in assisting issuers in initial public offerings of securities
and in their relations with their security holders, and shall retain such firm or another firm reasonably acceptable to the Representative
for a period of not less than two (2) years after the Effective Date.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.9&nbsp;<U>Reports
to the Representative</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.1.&nbsp;<U>Periodic
Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the
Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally
to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company
shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release
and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form
8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act;
(v) a copy of such report or other communication furnished to stockholders; and (vi) such additional documents and information with respect
to the Company and the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably request;
provided, however, the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which
is reasonably acceptable to the Representative and Representative Counsel in connection with the Representative&rsquo;s receipt of such
information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Representative
pursuant to this Section 3.9.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.2.&nbsp;<U>Transfer
Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer agent
and registrar acceptable to the Representative (the&nbsp;&ldquo;</FONT>Transfer Agent<FONT STYLE="font-weight: normal">&rdquo;) and shall
furnish to the Representative at the Company&rsquo;s sole cost and expense such transfer sheets of the Company&rsquo;s securities as the
Representative may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. V Stock
Transfer, LLC is acceptable to the Representative to act as Transfer Agent for the shares of Common Stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.3.&nbsp;<U>Trading
Reports</U>. During such time as the Public Securities are listed on the Exchange, the Company shall provide to the Representative, at
the Company&rsquo;s expense, such reports published by Exchange relating to price trading of the Public Securities, as the Representative
shall reasonably request.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.10&nbsp;<U>Payment
of Expenses</U></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.10.1.&nbsp;<U>General
Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any,
to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (a) all filing fees and expenses relating to the registration of the shares of Common Stock with the Commission,
(b) all fees and expenses relating to the listing of the Common Stock on a national exchange; (c) all fees, expenses and disbursements
relating to the registration or qualification of the shares under the &ldquo;blue sky&rdquo; securities laws of such states and other
jurisdictions as the Representative may reasonably designate (including, without limitation, all filing and registration fees, and the
reasonable fees and disbursements of our &quot;blue sky&quot; counsel), if applicable; (d) all fees, expenses and disbursements relating
to the registration, qualification or exemption of the shares of Common Stock under the securities laws of such foreign jurisdictions
as the Representative may reasonably designate; (e) the costs of all mailing and printing of the Offering documents; (f) transfer and/or
stamp taxes, if any, payable upon the transfer of shares from the Company to the Underwriters; (g) the fees and expenses of the Company&rsquo;s
Auditor; (h) all filing fees and communication expenses associated with the review of the offering by FINRA; (i) up to $30,000 of the
Representative&rsquo;s actual accountable road show expenses and due diligence expenses for the Offering; (j) the $29,500 cost associated
with the Representative&rsquo;s use of Ipreo&rsquo;s book building, prospectus tracking and compliance software for the Offering; (k)
the costs associated with bound volumes of the Offering materials as well as commemorative mementos and lucite tombstones in an aggregate
amount not to exceed $5,000; (l) the fees and expenses of legal counsels to the Representative in an amount not to exceed $175,000; and
(m) up to $10,000 for background checks of our directors and officers; provided that the total costs and expenses related to the Offering for which the Company shall reimburse to the Representative shall
not exceed $222,500. The Representative may deduct from the net proceeds of the Offering
payable to the Company on the Closing Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company
to the Representative, provided, however, that in the event that the Offering is terminated, the Company agrees to reimburse the Representative
pursuant to section 8.3 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.10.2.&nbsp;<U>Non-accountable
Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10.1, on the Closing Date it
shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense allowance
equal to one percent (1%) of the gross proceeds received by the Company from the sale of the Public Securities, less the Advance (as such
term is defined in Section 8.3 hereof), provided, however, that in the event that the Offering is terminated, the Company agrees to reimburse
the Representative pursuant to Section 8.3 hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.11&nbsp;<U>Application
of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure Package and the
Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.12&nbsp;<U>Delivery
of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement, an earnings
statement (which need not be certified by independent registered public accounting firm unless required by the Securities Act or the Securities
Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of
at least twelve (12) consecutive months beginning after the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.13&nbsp;<U>Stabilization</U>.
Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Representative)
has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Public Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.14&nbsp;<U>Internal
Controls</U>. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary
in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii)&nbsp;access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv)&nbsp;the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.15&nbsp;<U>Accountants</U>.
As of the date of this Agreement, the Company shall retain an independent registered public accounting firm reasonably acceptable to the
Representative, and the Company shall continue to retain a nationally recognized independent registered public accounting firm for a period
of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable to the Representative.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.16&nbsp;<U>FINRA</U>.
The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer
or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company's securities or (iii) any beneficial owner
of the Company's unregistered equity securities which were acquired during the 180 days immediately preceding the filing of the Registration
Statement is or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance
with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.17&nbsp;<U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely contractual
in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.18&nbsp;<U>Company
Lock-Up Agreements</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.18.1.&nbsp;<U>Restriction
on Sales of Capital Stock</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent
of the Representative, it will not, for a period of 180 days after the date of this Agreement (the &ldquo;</FONT>Lock-Up Period<FONT STYLE="font-weight: normal">&rdquo;),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of
the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or
cause to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company
or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering
of debt securities of the Company or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any
of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii),
(iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">The
restrictions contained in this Section 3.18.1 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance
by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on
the date hereof, which is disclosed in the Registration Statement, Pricing Disclosure Package and Prospectus, provided that such options,
warrants, and securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities or to extend the term of such securities or (iii) the issuance
by the Company of stock options or shares of capital stock of the Company under any equity compensation plan of the Company, provided
that in each of (ii) and (iii) above, the underlying shares shall be restricted from sale during the entire Lock-Up Period.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">Notwithstanding
the foregoing, if (i) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material
event relating to the Company occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release
earnings results or becomes aware that material news or a material event will occur during the 16-day period beginning on the last day
of the Lock-Up Period, the restrictions imposed by this Section 3.18.1 shall continue to apply until the expiration of the 18-day period
beginning on the issuance of the earnings release or the occurrence of such material news or material event, as applicable, unless the
Representative waives, in writing, such extension; provided, however, that this extension of the Lock-Up Period shall not apply to the
extent that FINRA has amended or repealed NASD Rule 2711(f)(4), or has otherwise provided written interpretive guidance regarding such
rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member of a national securities association from publishing
or distributing any research report, with respect to the securities of an Emerging Growth Company prior to or after the expiration of
any agreement between the broker, dealer, or member of a national securities association and the Emerging Growth Company or its shareholders
that restricts or prohibits the sale of securities held by the Emerging Growth Company or its shareholders after the initial public offering
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">3.18.2.&nbsp;<U>Restriction
on Continuous Offerings</U>. Notwithstanding the restrictions contained in Section 3.18.1, the Company, on behalf of itself and any successor
entity, agrees that, without the prior written consent of the Representative, it will not, for a period of twelve (12) months after the
date of this Agreement, directly or indirectly in any &ldquo;at-the-market&rdquo; or continuous equity transaction, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.19&nbsp;<U>Release
of D&amp;O Lock-up Period</U>. If the Representative, in its sole discretion, agrees to release or waive the restrictions set forth in
the Lock-Up Agreements described in Section 2.26 hereof for an officer or director of the Company and provide the Company with notice
of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees
to announce the impending release or waiver by a press release substantially in the form of <U>Exhibit C</U> hereto through a major news
service at least two (2) Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.20&nbsp;<U>Blue
Sky Qualifications</U>. The Company shall use its best efforts, in cooperation with the Underwriters, if necessary, to qualify the Public
Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as
the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution of the
Public Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to
qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself
to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.21&nbsp;<U>Reporting
Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded
by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission
pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company
shall report the use of proceeds from the issuance of the Public Securities as may be required under Rule 463 under the Securities Act
Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.22&nbsp;<U>Emerging
Growth Company Status</U>. The Company shall promptly notify the Representative if the Company ceases to be an Emerging Growth Company
at any time prior to the later of (i) completion of the distribution of the Public Securities within the meaning of the Securities Act
and (ii) fifteen (15) days following the completion of the Lock-Up Period.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.23&nbsp;<U>Press
Releases</U>. Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other communication
directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business
affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with
the past practices of the Company and of which the Representative is notified), without the prior written consent of the Representative,
which consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and after notification to the
Representative, such press release or communication is required by law.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.24&nbsp;<U>Sarbanes
Oxley</U>. The Disclosure Package and Prospectus, the Company shall at all times comply with all applicable provisions of the Sarbanes
Oxley Act in effect from time to time. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.25&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has irrevocably reserved, and the Company shall continue to reserve and keep available
at all times, free of pre-emptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Underlying Shares. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.26&nbsp;<U>Stipulation</U>.
Upon the Closing, the Company shall register with the Corporation Records Service (including annual report information published by Standard
&amp; Poor&rsquo;s Corporation and shall maintain such registration for a period of two (2) years after the Closing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.27&nbsp;<U>Keyman
Life Insurance</U>. The Company shall maintain the key man insurance plans in place on the lives of [&#9679;] and [&#9679;] with an insurance
rated at least AA or better in the most recent edition of &ldquo;Best&rsquo;s Life Reports&rdquo; in the amounts in place as of the date
of this Agreement with the Company as the sole beneficiary. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">4.&nbsp;<U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase and pay for the Public Securities, as provided
herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof and
as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made
pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.1&nbsp;<U>Regulatory
Matters</U>.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.1.&nbsp;<U>Effectiveness
of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not later than 5:00 p.m., Eastern
time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at each of the Closing
Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge,
contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. The
Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required
by Rule 424(b) of the Securities Regulations (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information
shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.2.&nbsp;<U>FINRA
Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount of
compensation allowable or payable to the Underwriters as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.3.&nbsp;<U>Exchange
Stock Market Clearance</U>. On the Closing Date, the Company&rsquo;s shares of Common Stock, including the Firm Shares, the Options Shares
and the Underlying Shares shall have been approved for listing on the Exchange, subject only to official notice of issuance. On the first
Option Closing Date (if any), the Company&rsquo;s shares of Common Stock (including the Option Shares and the Underlying Shares), shall
have been approved for listing on the Exchange, subject only to official notice of issuance.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.2&nbsp;<U>Company
Counsel Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.1.&nbsp;<U>Closing
Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion and negative assurance
letter of Nelson Mullins Riley &amp; Scarborough LLP (&ldquo;</FONT>Company Counsel<FONT STYLE="font-weight: normal">&rdquo;), counsel
to the Company, dated the Closing Date and addressed to the Representative, substantially in the form of <U>Exhibit D-I</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.2.&nbsp;<U>Closing
Date Opinion of Regulatory Expert.</U> On the Closing Date, the Representative shall have received the opinion of [ &#9679; ], as special
regulatory expert for the Company, and a written statement providing certain &ldquo;10d-5&rdquo; negative assurances, dated as of the
Closing Date and addressed to the Representative substantially in the form of Exhibit D-III attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.3.&nbsp;<U>Option
Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable opinions
of each counsel listed in Sections 4.2.1 and 4.2.2, dated the Option Closing Date, addressed to the Representative and in form and substance
reasonably satisfactory to the Representative, confirming of the Option Closing Date, the statements made by such counsels in their respective
opinions delivered on the Closing Date.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.4.&nbsp;<U>Reliance</U>.
In rendering the opinion set forth in Sections 4.2.1 and 4.2.2, such counsel may rely: (i)&nbsp;as to matters involving the application
of laws other than the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper
and to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to
the Representative) of other counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii)&nbsp;as
to matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company and officers
of departments of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company,
provided that copies of any such statements or certificates shall be delivered to Representative Counsel if requested. The opinion of
Company Counsel listed in Sections 4.2.1 and 4.2.2 shall include a statement to the effect that it may be relied upon by Representative
Counsel in its opinion delivered to the Underwriters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.3&nbsp;<U>Comfort
Letters</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.1.&nbsp;<U>Cold
Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter from the Auditor containing statements
and information of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements and certain
financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.2.&nbsp;<U>Bring-down
Comfort Letter</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from the Auditor
a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements
made in its letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date not more than three
(3) business days prior to the Closing Date or the Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.4&nbsp;<U>Officers&rsquo;
Certificates</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.1.&nbsp;<U>Officers&rsquo;
Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing Date
(if such date is other than the Closing Date), of its Chief Executive Officer and its Chief Financial Officer stating that (i) such officers
have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus
and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date (or
any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement of a material fact and did not
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the Pricing
Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing
Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date if such date is other
than the Closing Date) and the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing
Date, did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances in which they were made, not misleading, (ii) since the effective date of the Registration
Statement, no event has occurred which should have been set forth in a supplement or amendment to the Registration Statement, the Pricing
Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable investigation, as of the Closing Date (or
any Option Closing Date if such date is other than the Closing Date), the representations and warranties of the Company in this Agreement
are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied
hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and (iv) there has
not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference in the Pricing
Disclosure Package, any material adverse change in the financial position or results of operations of the Company, or any change or development
that, singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting
the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except as set forth in the
Prospectus.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.2.&nbsp;<U>Secretary&rsquo;s
Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate
of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively, certifying:
(i)&nbsp;that each of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect; (ii)&nbsp;that
the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full force and effect and have not been modified;
(iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv)&nbsp;as
to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.3.&nbsp;<U>[Chief
Financial Officer&rsquo;s Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have
received a certificate of the Chief Financial Officer of the Company, dated the Closing Date or the Option Date, as the case may be, respectively,
with respect to the accuracy of certain information contained in the Registration Statement, the Disclosure Package and the Prospectus,
in a form reasonably acceptable to the Representative.]</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.5&nbsp;<U>No
Material Changes</U>. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i)&nbsp;there shall have been no
material adverse change or development involving a prospective Material Adverse Change and no change in the capital stock or debt of the
Company, in each case, from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; (ii)&nbsp;no action, suit or proceeding, at law or in equity, shall have been pending or threatened against
the Company or any Insider before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable
decision, ruling or finding may materially adversely affect the business, operations, properties, assets, prospects or financial condition
or income of the Company, except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iii)&nbsp;no
stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the
Commission; (iv) no action shall have been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued
by any Governmental Entity which would prevent the issuance or sale of the Public Securities or materially and adversely affect or potentially
materially and adversely affect the business or operations of the Company, (v) no injunction, restraining order or order of any other
nature by any federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the
Public Securities or materially and adversely affect or potentially materially and adversely affect the business or operations of the
Company, and (vi)&nbsp;the Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendments or supplements
thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations,
and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.6&nbsp;<U>Corporate
Proceedings</U>. All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement,
the Public Securities, the Registration Statement, the Disclosure Package and the Prospectus and all other legal matters relating to this
Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all material respects to counsel for
the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably request
to enable them to pass upon such matters. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.7&nbsp;<U>Delivery
of Agreements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.1.&nbsp;<U>Lock-Up
Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the
Lock-Up Agreements from each of the persons listed in <U>Schedule 3</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.2.&nbsp;<U>Representative&rsquo;s
Warrant Agreement</U>. On the Closing Date, the Company shall have delivered to the Representative executed copies of the Representative&rsquo;s
Warrant Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.8&nbsp;<U>Additional
Documents</U>. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall have been furnished with such
documents and opinions as they may require for the purpose of enabling Representative Counsel to deliver an opinion to the Underwriters,
or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein
contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities and the Representative&rsquo;s
Securities as herein contemplated shall be satisfactory in form and substance to the Representative and Representative Counsel. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.1&nbsp;<U>Indemnification
of the Underwriters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">5.1.1.&nbsp;<U>General</U>.
Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each
of its and their respective directors, officers, members, employees, representatives, partners, stockholders, affiliates, counsel, and
agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act (collectively the &ldquo;</FONT>Underwriter Indemnified Parties<FONT STYLE="font-weight: normal">,&rdquo; and each
an &ldquo;</FONT>Underwriter Indemnified Party<FONT STYLE="font-weight: normal">&rdquo;), against any and all loss, liability, claim,
damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between
any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party,
or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common
law or otherwise or under the laws of foreign countries (a &ldquo;</FONT>Claim<FONT STYLE="font-weight: normal">&rdquo;), (i) arising
out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement,
the Pricing Disclosure Package, any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written
Testing-the-Waters Communication (as from time to time each may be amended and supplemented); (B) any materials or information provided
to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including any &ldquo;road show&rdquo;
or investor presentations made to investors by the Company (whether in person or electronically); or (C) any application or other document
or written communication (in this Section 5, collectively called &ldquo;application&rdquo;) executed by the Company or based upon written
information furnished by the Company in any jurisdiction in order to qualify the Public Securities and Representative&rsquo;s Securities
under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national
securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission
was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information or (ii) otherwise arising in connection with or
allegedly in connection with the Offering. The Company also agrees that it will reimburse each Underwriter Indemnified Party for all fees
and expenses (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending
against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter
Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) (collectively,
the &ldquo;</FONT>Expenses<FONT STYLE="font-weight: normal">&rdquo;), and further agrees wherever and whenever possible to advance payment
of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending any Claim. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">5.1.2.&nbsp;<U>Procedure</U>.
If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant
to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and
the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval
of such Underwriter Indemnified Party) and payment of actual expenses if an Underwriter Indemnified Party requests that the Company do
so. Such Underwriter Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses
of such counsel shall be at the expense of the Company, and shall be advanced by the Company. The Company shall not be liable for any
settlement of any action effected without its consent (which shall not be unreasonably withheld). In addition, the Company shall not,
without the prior written consent of the Underwriters, settle, compromise or consent to the entry of any judgment in or otherwise seek
to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought
hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement, compromise, consent or termination
(i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified Party, from all
liabilities, expenses and claims arising out of such action for which indemnification or contribution may be sought and (ii) does not
include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any Underwriter Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.2&nbsp;<U>Indemnification
of the Company</U>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, its
officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity
from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions made in the Registration
Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application,
in reliance upon, and in strict conformity with, the Underwriters&rsquo; Information. In case any action shall be brought against the
Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package
or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter,
such Underwriter shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have
the rights and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the
Representative of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection
with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package,
the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.3&nbsp;<U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">5.3.1.&nbsp;<U>Contribution
Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless
an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred
to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable
by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as
shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other, from
the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of
the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in such loss,
claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to be in the
same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement (before deducting
expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total underwriting
discounts and commissions received by the Underwriters with respect to the shares of the Common Stock purchased under this Agreement,
as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by reference
to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates
to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and
equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were
treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action
in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of
the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Offering of the
Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-weight: normal">5.3.2.&nbsp;<U>Contribution
Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party
(&ldquo;</FONT>Contributing Party<FONT STYLE="font-weight: normal">&rdquo;), notify the contributing party of the commencement thereof,
but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other
than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing
party or its representative of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate
therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable
to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution
on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent
of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted
by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available. Each Underwriter&rsquo;s obligations
to contribute pursuant to this Section 5.3 are several and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">6.
<U>Default by an Underwriter</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.1&nbsp;<U>Default
Not Exceeding 10% of Firm Shares or Option Shares</U>. If any Underwriter or Underwriters shall default in its or their obligations to
purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised hereunder, and if the number of the Firm Shares
or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm Shares or Option
Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which the default relates shall
be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.2&nbsp;<U>Default
Exceeding 10% of Firm Shares or Option Shares</U>. In the event that the default addressed in Section 6.1 relates to more than 10% of
the Firm Shares or Option Shares, the Underwriter may in its discretion arrange itself or for another party or parties to purchase such
Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one (1) Business Day after such default
relating to more than 10% of the Firm Shares or Option Shares, the Underwriter does not not arrange for the purchase of such Firm Shares
or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure another party
or parties satisfactory to the Underwriter to purchase said Firm Shares or Option Shares on such terms. In the event that neither the
Underwriter nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this
Section 6, this Agreement will automatically be terminated by the Underwriter or the Company without liability on the part of the Company
(except as provided in Sections 3.9 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however,
that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided,
further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company
for damages occasioned by its default hereunder.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.3&nbsp;<U>Postponement
of Closing Date</U>. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the non-defaulting
Underwriters, or are to be purchased by another party or parties as aforesaid, the Underwriter or the Company shall have the right to
postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order
to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus
or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing
Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary. The term &ldquo;Underwriter&rdquo;
as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been a party
to this Agreement with respect to such shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">7.
<U>Additional Covenants</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.1&nbsp;<U>Board
Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as members of
the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the
listing rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its
Public Securities listed on another exchange or quoted on an automated quotation system, and (ii)&nbsp;if applicable, at least one member
of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined
under Regulation S-K and the listing rules of the Exchange.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.2&nbsp;<U>Prohibition
on Press Releases and Public Announcements</U>. The Company shall not issue press releases or engage in any other publicity, without the
Representative&rsquo;s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1<SUP>st</SUP>) Business Day
following the forty-fifth (45<SUP>th</SUP>) day after the Closing Date, other than normal and customary releases issued in the ordinary
course of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.3&nbsp;<U>Right
of First Refusal</U>. Provided that the Firm Shares are sold in accordance with the terms of this Agreement, the Representative shall
have an irrevocable right of first refusal (the &ldquo;</FONT><FONT STYLE="font-style: normal">Right of First Refusal<FONT STYLE="font-weight: normal">&rdquo;),
for a period of twelve (12) months after the closing of the Offering, to act as sole investment banker, sole book-runner, sole placement
agent, at the Representative&rsquo;s sole discretion, for each and every future public and private equity and debt offering, including
all equity linked financings (each, a &ldquo;</FONT>Subject Transaction<FONT STYLE="font-weight: normal">&rdquo;), during such period,
of the Company, or any successor to or subsidiary of the Company, on terms and conditions customary to the Representative for such Subject
Transaction. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment banker, book-runner,
financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of the Representative.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal"><FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company shall notify the
Representative of its intention to pursue a Subject Transaction, including the material terms thereof, by providing written notice thereof
by registered mail or overnight courier service addressed to the Representative.&nbsp; If the Representative fails to exercise its Right
of First Refusal with respect to any Subject Transaction within ten (10) Business Days after the mailing of such written notice, then
the Representative shall have no further claim or right with respect to the Subject Transaction. The Representative may elect, in its
sole and absolute discretion, not to exercise its Right of First Refusal with respect to any Subject Transaction; provided that any such
election by the Representative shall not adversely affect the Representative&rsquo;s Right of First Refusal with respect to any other
Subject Transaction during the twelve (12) month period agreed to above.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">8.
<U>Effective Date of this Agreement and Termination Thereof</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.1&nbsp;<U>Effective
Date</U>. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered counterparts
of such signatures to the other party.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.2&nbsp;<U>Termination</U>.
The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i)&nbsp;if any domestic or
international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt,
general securities markets in the United States; or (ii)&nbsp;if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC
shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for
prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction;
or (iii)&nbsp;if the United States shall have become involved in a new war or an increase in major hostilities; or (iv)&nbsp;if a banking
moratorium has been declared by a New York State or federal authority; or (v)&nbsp;if a moratorium on foreign exchange trading has been
declared which materially adversely impacts the United States securities markets; or (vi)&nbsp;if the Company shall have sustained a material
loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss
shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Shares or Option Shares;
or (vii)&nbsp;if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii)&nbsp;if
the Representative shall have become aware after the date hereof of such a Material Adverse Change, or an adverse material change in general
market conditions as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery
of the Public Securities or to enforce contracts made by the Underwriters for the sale of the Public Securities; or (ix) the Common Stock
shall fail for any reason to open for trading on the Exchange by the end of regular trading hours on [trade date] ,2024].</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.3&nbsp;<U>Expenses</U>.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section 6.2
above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein or any extensions
thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative its actual and accountable out-of-pocket
expenses related to the transactions contemplated herein then due and payable (including the fees and disbursements of Representative
Counsel) up to $100,000, inclusive of the $50,000 advance for accountable expenses previously paid by the Company to the Representative
(the &ldquo;</FONT><FONT STYLE="font-style: normal">Advance<FONT STYLE="font-weight: normal">&rdquo;) and upon demand the Company shall
pay the full amount thereof to the Representative on behalf of the Underwriters; provided, however, that such expense cap in no way limits
or impairs the indemnification and contribution provisions of this Agreement. Notwithstanding the foregoing, any advance received by the
Representative will be reimbursed to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.4&nbsp;<U>Survival
of Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force
and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or
any part hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.5&nbsp;<U>Representations,
Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any investigation
made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors
or any person controlling the Company or (ii)&nbsp;delivery of and payment for the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">9.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.1&nbsp;<U>Notices</U>.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by electronic mail transmission and confirmed and shall be deemed
given when so delivered and confirmed or if mailed, two (2) days after such mailing</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to the Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">D. Boral Capital Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">590 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, New York 10022<BR>
Attention:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">e-mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt"><BR>
Blank Rome LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">1271 Avenue of the America</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">New York, New York 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">Attention: Brad L. Shiffman, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">e-mail: brad.shiffman@blankrome.com:&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Apimeds Pharmaceuticals US, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2 East Broad Street, 2nd Floor<BR>
Hopewell, NJ 08525</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Erik Emerson, Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">e-mail: erik.emerson@apimedspharmaus.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-style: normal; font-weight: normal">Nelson
Mullins Riley &amp; Scarborough LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">301 Hillsborough Street, Suite 1400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Raleigh, NC 27603</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: W. David Mannheim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">e-mail: david.mannheim@nelsonmullins.com</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.2&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.3&nbsp;<U>Amendment</U>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.4&nbsp;<U>Entire
Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this
Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything
to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that certain
engagement letter between the Company and D. Boral Capital Securities, LLC (f/k/a EF Hutton LLC) dated July 18, 2024 as amended, shall remain in full force and effect.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.5&nbsp;<U>Binding
Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company
and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo; shall not include
a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.6&nbsp;<U>Governing
Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance with the
laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action,
proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York
Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits
to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.7&nbsp;<U>Execution
in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall
become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties
hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient
delivery thereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.8&nbsp;<U>Waiver,
etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or
construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the
right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by
the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Signature Page Follows]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">APIMEDS PHARMACEUTICALS US, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Erik Emerson</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 222.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 276.9pt 0pt 0">Confirmed as of the date first written above mentioned,
on behalf of itself and as Representative of the several Underwriters named on <U>Schedule 1</U> hereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">D. Boral Capital Securities, LLC</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[ISSUER]
&ndash; Underwriting Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Underwriter</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Total<BR>
Number of<BR>
 Firm Shares<BR>
to be<BR>
 Purchased</B> &nbsp; <B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of<BR>
 Option<BR>
 Shares to be<BR>
 Purchased if the<BR>
 Over-Allotment<BR>
Option is Fully<BR>
Exercised<BR>
 by the<BR>
 Representative</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">D. Boral Capital Securities, LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">TOTAL</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sch.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Pricing Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Firm Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Option Shares: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Public Offering Price per Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriting Discount per Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriting Non-accountable expense allowance per Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds to Company per Share (before expenses): $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sch. 2-A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[None.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sch. 2-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2-C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Written Testing-the-Waters Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[None.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sch. 2-C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 50; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sch. 3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U STYLE="text-decoration: none">&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Representative&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.2pt">THE REGISTERED HOLDER OF THIS
PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED
AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE
WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) D. BORAL CAPITAL SECURITIES, LLC, OR
AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF D. BORAL CAPITAL SECURITIES, LLC OR OF ANY
SUCH UNDERWRITER OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.2pt">THIS PURCHASE WARRANT IS NOT
EXERCISABLE PRIOR TO [________________] [<B>DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE OF THE OFFERING</B>]. VOID AFTER 5:00 P.M.,
EASTERN TIME, [___________________] [<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APIMEDS PHARMACEUTICALS US, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Initial Exercise Date: ______, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">THIS WARRANT TO PURCHASE COMMON
STOCK (the &ldquo;<B><U>Warrant</U></B>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<B><U>Holder</U></B>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
____, 2025 (the &ldquo;<B><U>Initial Exercise Date</U></B>&rdquo;) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00
p.m. (New York time) on the date that is five (5) years following the Effective Date (the &ldquo;<B><U>Termination Date</U></B>&rdquo;)
but not thereafter, to subscribe for and purchase from Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;),
up to ______ shares (the &ldquo;<B><U>Warrant Shares</U></B>&rdquo;) of Common Stock, par value $0.01 per share, of the Company (the &ldquo;<B><U>Common
Stock</U></B>&rdquo;), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be
equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Effective
Date</U>&rdquo; means the effective date of the registration statement on Form S-1 (File No. 333-_______), including any related prospectus
or prospectuses, for the registration of the Company&rsquo;s Common Stock and the Warrant Shares under the Securities Act, that the Company
has filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the New York Stock Exchange is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c)&nbsp;if Common
Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock are then reported in the &ldquo;Pink
Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of Common Stock so reported or (d) in all other cases, the fair market value of the Common Stock as
determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">a)&nbsp;
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly
executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within two (2) Trading Days following the
date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice
of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in
Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt
of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">b)&nbsp;
<U>Exercise Price</U>. The exercise price per share of the Common Stock under this Warrant shall be <B>$_______</B><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>,
subject to adjustment hereunder (the &ldquo;<B><U>Exercise Price</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">c)&nbsp;
<U>Cashless Exercise</U>. In lieu of exercising this Warrant by delivering the aggregate Exercise Price by wire transfer or cashier&rsquo;s
check, at the election of the Holder this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: center; width: 0.15in">=</TD>
                                                                                   <TD STYLE="text-align: left">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the VWAP on the Trading Day
immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD><TD STYLE="text-align: left; width: 0.15in">=</TD>
                                                                                   <TD STYLE="text-align: left">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD><TD STYLE="text-align: left; width: 0.15in">=</TD>
                                                                                   <TD STYLE="text-align: left"> the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: left; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a &ldquo;cashless exercise,&rdquo; the parties acknowledge and agree that in accordance with Section
3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the
holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares.&nbsp;&nbsp;The Company agrees
not to take any position contrary to this Section 2(c).</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">100% of the public offering price per share of Common Stock
in the Company&rsquo;s initial public offering.</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: left; text-indent: -31.5pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">i.&nbsp;
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its
transfer agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<B><U>DWAC</U></B>&rdquo;) if the Company is then a participant
in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as
defined below), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the
Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is two (2)&nbsp;Trading Days after the delivery to the Company of the Notice
of Exercise (such date, the &ldquo;<B><U>Warrant Share Delivery Date</U></B>&rdquo;). If the Warrant Shares can be delivered via DWAC,
the transfer agent shall have received from the Company, at the expense of the Company, any legal opinions or other documentation required
by it to deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation from the Holder,
including with respect to affiliate status) and, if applicable and requested by the Company prior to the Warrant Share Delivery Date,
the transfer agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder
to provide a confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant Shares upon a
cashless exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall
be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder
of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise
Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section&nbsp;2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares
subject to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date, the Company shall pay to the Holder,
in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of
the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth
Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">ii.&nbsp; <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall
have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time
of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased
Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">&nbsp;
iii.&nbsp; <U>Rescission Rights</U>. If the Company fails to cause its transfer
agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will
have the right to rescind such exercise; <U>provided</U>, <U>however</U>, that the Holder shall be required to return any Warrant Shares
or Common Stock subject to any such rescinded exercise notice concurrently with the return to Holder of the aggregate Exercise Price paid
to the Company for such Warrant Shares and the restoration of Holder&rsquo;s right to acquire such Warrant Shares pursuant to this Warrant
(including, issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">&nbsp;
iv.&nbsp; <U>Compensation for Buy-In on Failure to Timely Deliver Warrant
Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to
transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date
the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<B><U>Buy-In</U></B>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock
so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to
timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">v.&nbsp; <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would
otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">vi.&nbsp; <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall
be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant
Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder
or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are
to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing
of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">vii.&nbsp; <U>Closing of Books</U>. The Company will not close its stockholder
books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">viii.&nbsp; <U>Signature</U>. This Section 2 and the exercise form attached
hereto set forth the totality of the procedures required of the Holder in order to exercise this Purchase Warrant.&nbsp; Without limiting
the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any exercise form be required in order to exercise this Purchase Warrant.&nbsp; No additional legal opinion, other
information or instructions shall be required of the Holder to exercise this Purchase Warrant.&nbsp; The Company shall honor exercises
of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance with the terms, conditions and time periods
set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">e)&nbsp;
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e),
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company&rsquo;s
transfer agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the
Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The &ldquo;<B><U>Beneficial Ownership Limitation</U></B>&rdquo; shall be 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this
Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section
2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP>
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">a)&nbsp;
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price of this Warrant
will not be adjusted in the event that the Company or any Subsidiary thereof, as applicable, sells or grants any option to purchase, or
sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or
other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then in
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">b)&nbsp;
[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">c)&nbsp;
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<B><U>Purchase Rights</U></B>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">d)&nbsp;
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other
than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way
of return of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B><U>Distribution</U></B>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be
held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such
Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">e)&nbsp;
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its
assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
&ldquo;<B><U>Fundamental Transaction</U></B>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number
of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the &ldquo;<B><U>Alternate Consideration</U></B>&rdquo;) receivable by holders of Common Stock as a result of such Fundamental
Transaction for each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<B><U>Successor Entity</U></B>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and
approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity
(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">f)&nbsp;&nbsp;
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">g)&nbsp;
<U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">&nbsp;
i.&nbsp; <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price
is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise
Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 1.25in">&nbsp;&nbsp;&nbsp;
ii.&nbsp; <U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring
cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock
rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders
of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the
Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed a notice
to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to provide such notice or any defect therein shall not affect the validity of the corporate action required
to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">a)&nbsp;
<U>Transferability</U>. Pursuant to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant
shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call
transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately
following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant is being issued, except the
transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.75in">i.&nbsp;
by operation of law or by reason of reorganization of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.75in">ii.&nbsp;
to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this Section 4(a) for the remainder of the time period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.75in">iii.&nbsp;
if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.75in">iv.&nbsp;
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages
or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the
fund; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.75in">&nbsp;&nbsp;&nbsp;v.&nbsp;
the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a)
for the remainder of the time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -1in"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">Subject to the foregoing
restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">b)&nbsp;
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder
or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">c)&nbsp;
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<B><U>Warrant Register</U></B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and,
upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 5. Registration
Rights.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>5.1. Demand Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.1.1&nbsp;Grant
of Right. The Company, upon written demand (a &ldquo;<B><U>Demand Notice</U></B>&rdquo;) of the Holder(s) of at least 51% of the Warrants
and/or the underlying Warrant Shares (&ldquo;<B><U>Majority Holders</U></B>&rdquo;), agrees to register, on one occasion, all or any portion
of the Warrant Shares underlying the Warrants (collectively, the &ldquo;<B><U>Registrable Securities</U></B>&rdquo;). On such occasion,
the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt
of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject
to compliance with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice
if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant
to Section 5.2 hereof and either: (i) the Holder has elected to participate in the offering covered by such registration statement or
(ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until the offering covered
by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. The demand for registration
may be made at any time beginning on the Initial Exercise Date and expiring on the fifth anniversary of the Effective Date. The Company
covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders of the
Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such Demand Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.1.2 Terms.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 5.1.1, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. The Company agrees to use its commercially reasonable efforts to cause
the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably
requested by the Holder(s); provided, however, that in no event shall the Company be required to register the Registrable Securities in
a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or
submit to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to escrow their
shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted
under Section 5.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the
Registrable Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holders
shall only use the prospectuses provided by the Company to sell the Warrant Shares covered by such registration statement, and will immediately
cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due
to a material misstatement or omission. Notwithstanding the provisions of this Section 5.1.2, the Holder shall be entitled to a demand
registration under this Section 5.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary
of the date of the Underwriting Agreement (as defined below) in accordance with FINRA Rules 5110(g)(8)(B) and 5110(g)(8)(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><U>5.2
&ldquo;Piggy-Back&rdquo; Registration.</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.2.1 Grant
of Right. In addition to the demand right of registration described in Section 5.1 hereof, the Holder shall have the right, for a period
of no more than seven (7) years from the date of the Underwriting Agreement in accordance with FINRA Rule 5110(g)(8)(D), to include the
Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction
contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that
if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof
shall, in its reasonable discretion, impose a limitation on the number of Shares which may be included in the Registration Statement because,
in such underwriter(s)&rsquo; judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution,
then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities
with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable
Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless
the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such
Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.2.2 Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5.2.1 hereof, but
the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of
filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by
the Company during the seven (7) year period following the date of the Underwriting Agreement until such time as all of the Registrable
Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the &ldquo;piggy-back&rdquo; rights
provided for herein by giving written notice within ten (10) days of the receipt of the Company&rsquo;s notice of its intention to file
a registration statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may
request registration under this Section 5.2.2; provided, however, that such registration rights shall terminate on the second anniversary
of the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><U>5.3</U>&nbsp;<U>General Terms</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.3.1&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and
each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange
Act against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities
Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement
between the Underwriters and the Company, dated as of [___], 2024. The Holder(s) of the Registrable Securities to be sold pursuant to
such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss,
claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise,
arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion
in such registration statement to the same extent and with the same effect as the provisions contained in Section 5.2 of the Underwriting
Agreement pursuant to which the Underwriters have agreed to indemnify the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.3.2 Exercise
of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or after
the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.3.3 Documents
Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company,
dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion
dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold comfort&rdquo; letter dated the
effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the
date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report
on the Company&rsquo;s financial statements included in such registration statement, in each case covering substantially the same matters
with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants&rsquo; letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer&rsquo;s counsel
and in accountants&rsquo; letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver
promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing
underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating
to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do
such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement
as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access
to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditors,
all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.3.4
Underwriting Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by
any Holders whose Registrable Securities are being registered pursuant to this Section 5, which managing underwriter shall be
reasonably satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each
Holder and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such
other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties
to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require
that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also
be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or
agreements with the Company or the underwriters except as they may relate to such Holders, their Warrant Shares and their intended
methods of distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.3.5 Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a completed
and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.3.6 Damages.
Should the registration or the effectiveness thereof required by Sections 5.1 and 5.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s),
be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions
or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other
security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 6</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">a)&nbsp;
<U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">b)&nbsp;
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and
in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall
not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company
will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">c)&nbsp;
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">d)&nbsp;<U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">e)&nbsp;
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the underwriting agreement, dated ___, 2024, by and between the Company and D. Boral Capital Securities, LLC as representatives
of the underwriters set forth therein (the &ldquo;<B><U>Underwriting Agreement</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">f)&nbsp;&nbsp;
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">g)&nbsp;
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">h)&nbsp;
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">i)&nbsp;&nbsp;&nbsp;
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to
purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">j)&nbsp;&nbsp;&nbsp;
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense
in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">k)&nbsp;
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">l)&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">n)&nbsp;
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>APIMEDS PHARMACEUTICALS US, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Erik Emerson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">TO:</FONT></TD><TD STYLE="text-align: left; width: 35%"><FONT STYLE="text-transform: uppercase">APIMEDS PHARMACEUTICALS
US, INC.</FONT></TD>
    <TD>&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(1)&nbsp;&nbsp; The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full),
and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(2)&nbsp;&nbsp; Payment shall
take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: left">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: left">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(3)&nbsp;&nbsp; Please register
and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Warrant Shares shall be delivered to the following
DWAC Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(4)&nbsp;&nbsp; <U>Accredited
Investor</U>. If the Warrant is being exercised via cash exercise, the undersigned is an &ldquo;accredited investor&rdquo; as defined
in Regulation D promulgated under the Securities Act of 1933, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Investing Entity: _______________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Investing Entity</I>: _________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory: ___________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory: ____________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: _______________________________________________________________________________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To assign the foregoing warrant, execute<BR>
this form and supply required information.<BR>
Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">FOR VALUE RECEIVED, [____] all
of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">_______________________________________________
whose address is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">_______________________________________________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">_______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0.5in">Dated: ______________,
_______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Holder&rsquo;s Signature: _____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Holder&rsquo;s Address: _____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0.5in">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">NOTE: The signature to this Assignment Form must
correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever. Officers
of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the
foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>[&#9679;], 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Boral Capital Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">590 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">As Representative of the several Underwriters
named on Schedule 1 to the Underwriting Agreement referenced below</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned understands
that D. Boral Capital Securities, LLC (the &ldquo;<B>Representative</B>&rdquo;), proposes to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;) with APIMEDS PHARMACEUTICALS US, INC., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), providing for
the initial public offering (the &ldquo;<B>Public Offering</B>&rdquo;) of shares of common stock, par value $0.01 per share, of the Company
(the &ldquo;<B>Common Shares</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">To induce the Representative
to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent
of the Representative, the undersigned will not, during the period commencing on the date hereof and ending 180 days after the date of
the Underwriting Agreement relating to the Public Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (1) offer, pledge, sell, contract
to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into
or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the undersigned or with respect to which
the undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;); (2) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the
Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities,
in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4)
publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other
arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may
transfer Lock-Up Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up
Securities acquired in open market transactions after the completion of the Public Offering; <U>provided</U> that no filing under Section
13 or Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), or other public announcement
shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in such open market
transactions; (b) transfers of Lock-Up Securities as a <I>bona fide</I> gift, by will or intestacy or to a family member or trust for
the benefit of the undersigned or a family member (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means any relationship
by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution;
(d) if the undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up
Securities to another corporation, partnership or other business entity that controls, is controlled by or is under common control with
the undersigned or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates (as defined
in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned; (e) if the undersigned is a trust, to a trustee
or beneficiary of the trust; <U>provided</U> that in the case of any transfer pursuant to the foregoing clauses&nbsp;(b), (c) (d) or (e),
(i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver to the Representative a lock-up
agreement substantially in the form of this lock-up agreement and (iii) no filing under Section 13 or Section&nbsp;16(a) of the Exchange
Act or other public announcement shall be required or shall be voluntarily made; (f) the vesting of restricted stock awards or stock units
or upon the exercise of options to purchase the Company&rsquo;s Common Shares issued under an equity incentive plan of the Company or
an employment arrangement described in the Pricing Prospectus (as defined in the Underwriting Agreement) (the &ldquo;<B>Plan Shares</B>&rdquo;)
or the transfer of Common Shares or any securities convertible into Common Shares to the Company upon a vesting event of the Company&rsquo;s
securities or upon the exercise of options to purchase the Company&rsquo;s securities, in each case on a &ldquo;cashless&rdquo; or &ldquo;net
exercise&rdquo; basis or to cover tax obligations of the undersigned in connection with such vesting or exercise, but only to the extent
such right expires during the Lock-up Period, <U>provided</U> that no filing under Section 13 or Section 16(a) of the Exchange Act or
other public announcement shall be required or shall be voluntarily made within 180 days after the date of the Underwriting Agreement,
and after such 180<SUP>th</SUP> day, if the undersigned is required to file a report under Section 13 or Section 16(a) of the Exchange
Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned shall include a statement
in such schedule or report to the effect that the purpose of such transfer was to cover tax withholding obligations of the undersigned
in connection with such vesting or exercise and, <U>provided further</U>, that the Plan Shares shall be subject to the terms of this lock-up
agreement; (g) the transfer of Lock-Up Securities pursuant to agreements described in the Pricing Prospectus under which the Company has
the option to repurchase such securities or a right of first refusal with respect to the transfer of such securities, <U>provided</U>
that if the undersigned is required to file a report under Section 13 or Section 16(a) of the Exchange Act reporting a reduction in beneficial
ownership of Common Shares during the Lock-Up Period, the undersigned shall include a statement in such schedule or report describing
the purpose of the transaction; (h) the transfer of Lock-Up Securities that occurs by operation of law, such as pursuant to a qualified
domestic order or in connection with a divorce settlement, <U>provided</U> that the transferee agrees to sign and deliver a lock-up agreement
substantially in the form of this lock-up agreement for the balance of the Lock-Up Period, and <U>provided further</U>, that any filing
under Section 13 or Section 16(a) of the Exchange Act that is required to be made during the Lock-Up Period as a result of such transfer
shall include a statement that such transfer has occurred by operation of law; and (i) the transfer of Lock-Up Securities pursuant to
a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Shares involving
a change of control (as defined below) of the Company after the closing of the Public Offering and approved by the Company&rsquo;s board
of directors; <U>provided</U> that in the event that the tender offer, merger, consolidation or other such transaction is not completed,
the Lock-Up Securities owned by the undersigned shall remain subject to the restrictions contained in this lock-up agreement. For purposes
of clause (i) above, &ldquo;change of control&rdquo; shall mean the consummation of any bona fide third party tender offer, merger, amalgamation,
consolidation or other similar transaction the result of which is that any &ldquo;person&rdquo; (as defined in Section 13(d)(3) of the
Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority
of total voting power of the voting stock of the Company. The undersigned also agrees and consents to the entry of stop transfer instructions
with the Company&rsquo;s transfer agent and registrar against the transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance
with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If (i) during the last 17
days of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company occurs,
or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results or becomes aware that
material news or a material event will occur during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions
imposed by this lock-up agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings
release or the occurrence of such material news or material event, as applicable, unless the Representative waives, in writing, such extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned agrees that,
prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement during the period
from the date hereof to and including the 34<SUP>th</SUP> day following the expiration of the initial Lock-Up Period, the undersigned
will give notice thereof to the Company and will not consummate any such transaction or take any such action unless it has received written
confirmation from the Company that the Lock-Up Period has expired, taking into account any extension of the Lock-Up Period as described
in the immediately preceding paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the undersigned is an officer
or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any issuer-directed
or &ldquo;friends and family&rdquo; Shares that the undersigned may purchase in the Public Offering; (ii) the Representative agrees that,
at least three (3) business days before the effective date of any release or waiver of the foregoing restrictions in connection with a
transfer of Lock-Up Securities, the Representative will notify the Company of the impending release or waiver; and (iii) the Company has
agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least
two (2) business days before the effective date of the release or waiver. Any release or waiver granted by the Representative hereunder
to any such officer or director shall only be effective two (2) business days after the publication date of such press release. The provisions
of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration
and (b) the transferee has agreed in writing to be bound by the same terms described in this lock-up agreement to the extent and for the
duration that such terms remain in effect at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned understands
that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering.
The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned&rsquo;s heirs,
legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned understands that, if the Underwriting Agreement is
not executed by [&#9679;], 2024 or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Common Shares to be sold thereunder, then this lock-up agreement shall be void
and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Whether or not the Public
Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to
an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Name - Please Print)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Signature)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Name of Signatory, in the case of entities - Please Print)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Title of Signatory, in the case of entities - Please Print)</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>APIMEDS PHARMACEUTICALS US, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>[Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Apimeds Pharmaceuticals US, Inc. (the &ldquo;Company&rdquo;)
announced today that D. Boral Capital Securities, LLC, acting as representative for the underwriters in the Company&rsquo;s recent public offering of&nbsp;
_______ shares of the Company&rsquo;s common stock, is [waiving] [releasing] a lock-up restriction with respect to _________&nbsp; shares
of the Company&rsquo;s common stock held by [certain officers or directors] [an officer or director] of the Company.&nbsp; The [waiver]
[release] will take effect on&nbsp; _________, 20___, and the shares may be sold on or after such date.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>This press release is not an offer or sale
of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not
be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT D-I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form of Opinion of Counsel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(i)&nbsp;The
Company has been duly organized and is validly existing as a corporation and is in good standing under the laws of the State of Delaware
with the requisite corporate power and authority to own or lease, as the case may be, and operate its respective properties, and to conduct
its business, as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and to enter into and perform
its obligations under the Underwriting Agreement. The Company is duly qualified as a foreign corporation to transact business and is in
good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property
or the conduct of business, except where the failure to so qualify or to be in good standing would not result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(ii)&nbsp;All
issued and outstanding securities of the Company have been duly authorized and validly issued and are fully paid and non-assessable and
none of such securities were issued in violation of the preemptive rights of any stockholder of the Company arising by operation of law
or under the Charter, the Bylaws or, to such counsel&rsquo;s knowledge, the Material Contracts (as defined below). The offers and sales
of the outstanding securities were at all relevant times either registered under the Securities Act or exempt from such registration requirements.
The authorized and outstanding shares of capital stock of the Company is as set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(iii)&nbsp;The
Public Securities have been duly authorized for issuance and sale to the Underwriters pursuant to the Underwriting Agreement and, when
issued and paid for pursuant to the terms of the Underwriting Agreement, will be validly issued and fully paid and non-assessable; the
holders thereof are not and will not be subject to personal liability solely by reason of being such holders. The issuance of the Public
Securities is not and will not be subject to the preemptive or similar rights of any holders of any security of the Company arising by
operation of law or under the Charter, the Bylaws or the Material Contracts. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(iv)&nbsp;The
Underwriting Agreement has been duly and validly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(v)&nbsp;The
Representative&rsquo;s Warrant Agreement has been duly and validly authorized, executed and delivered by the Company and constitutes the
valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except (a) as such
enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (b)
as enforceability of any indemnification or contribution provisions may be limited under the Federal and state securities laws, and (c)
that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and
to the discretion of the court before which any proceeding therefore may be brought. The shares of Common Stock issuable upon exercise
of the Representative&rsquo;s Warrant Agreement have been duly authorized and reserved for issuance by all necessary corporate action
on the part of the Company and, when issued in accordance with the terms of the Representative&rsquo;s Warrant Agreement, will be validly
issued, fully paid and non-assessable and will not be subject to the preemptive or similar rights of any holders of any security of the
Company arising by operation of law or under the Charter, the Bylaws or the Material Contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. D-I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(vi)&nbsp;The
execution, delivery and performance of the Underwriting Agreement and the Representative&rsquo;s Warrant Agreement, and compliance by
the Company with the terms and provisions thereof and the consummation of the transactions contemplated thereby, and the issuance and
sale of the Public Securities, do not and will not, whether with or without the giving of notice or the lapse of time or both, (a)&nbsp;violate,
conflict with, or result in a breach of, any of the terms or provisions of, or constitute a default under, or result in the creation or
modification of any lien, security interest, charge or encumbrance upon any of the properties or assets of the Company pursuant to the
terms of, any mortgage, deed of trust, note, indenture, loan, contract, commitment or other agreement or instrument filed or incorporated
by reference as an exhibit to the Registration Statement (collectively, the &ldquo;Material Contracts&rdquo;), (b)&nbsp;result in any
violation of the provisions of the Charter, the Bylaws or any other governing documents of the Company, or (c)&nbsp;violate any law, statute
or any judgment, order or decree, rule or regulation applicable to the Company of any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(vii)&nbsp;The
shares of Common Stock offered pursuant to the Prospectus conform in all material respects to the description thereof contained in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. No United States or state statute or regulation required to
be described in the Prospectus is not described as required (except as to the &ldquo;blue sky&rdquo; laws of the various states, as to
which such counsel expresses no opinions), nor are any contracts or documents of a character required to be described in the Registration
Statement, Pricing Disclosure Package or the Prospectus or to be filed or incorporated by reference as exhibits to the Registration Statement
not so described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(viii)&nbsp;The
form of certificate used to evidence the Common Stock complies in all material respects with all applicable Delaware law requirements,
with any applicable requirements of the Charter and Bylaws and with the requirements of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(ix)&nbsp;The
statements in the Registration Statement, Pricing Disclosure Package and the Prospectus under the heading &ldquo;Description of Capital
Stock,&rdquo; insofar as such statements purport to summarize legal matters, legal conclusions, the Charter, the Bylaws, or other agreements
or documents discussed therein, are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(x)&nbsp;The
statements in the Registration Statement, Pricing Disclosure Package and the Prospectus under the heading &ldquo;Material United States
Federal Tax Considerations for Non-U.S. Holders of Common Stock,&rdquo; insofar as such statements purport to summarize matters of U.S.
federal tax law and regulations or legal conclusions with respect thereto, are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(xi)&nbsp;The
Registration Statement has been declared effective by the Commission under the Securities Act and the Securities Act Regulations. No stop
order suspending the effectiveness of the Registration Statement has been issued under the Securities Act or any order preventing or suspending
the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus has been issued, and no proceedings for any
such purpose have been instituted or, to such counsel&rsquo;s knowledge, are pending by the Commission or any other Governmental Entity.
Any required filing of the Prospectus, and any required supplement thereto, pursuant to Rule 424(b) under the Securities Act Regulations,
has been made in the manner and within the time period required by Rule 424(b) (without reference to Rule 424(b)(8)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. D-I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(xii)&nbsp;The
Company is not required and, after giving effect to the Offering and sale of the Public Securities and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required, to register
as an &ldquo;investment company,&rdquo; under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(xiii)&nbsp;From
the time of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which
the Company engaged directly in or through any Person authorized to act on its behalf in any Testing-the Waters Communication) through
the date hereof, the Company has been and is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(xiv)&nbsp;No
filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity (other
than under the Securities Act and the Securities Act Regulations, which have been obtained, or as may be required under the securities
or blue sky laws of the various states, as to which we need express no opinion) is necessary or required for the performance by the Company
of its obligations under the Underwriting Agreement, in connection with the offering, issuance or sale of the Public Securities thereunder
or the consummation of the transactions contemplated thereby, except such as have been already made or obtained or as may be required
under the rules of the Exchange, state securities laws or the rules of FINRA. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.1pt"><FONT STYLE="font-weight: normal">(xv)&nbsp;The
Public Securities have been approved for listing on the Exchange upon official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">(xvi)&nbsp;To
such counsel&rsquo;s knowledge, there are no persons with registration rights or other similar rights to have any securities registered
pursuant to the Registrant Statement or otherwise registered for sale by the Company under the Securities Act, except as disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">(xvii)&nbsp;To
such counsel&rsquo;s knowledge, there are not (1) any pending legal proceedings to which the Company is a party or of which the Company&rsquo;s
property is the subject, or (2) any proceedings contemplated by any Governmental Authority, in each case, which are required to be disclosed
in the Registration Statement, Pricing Disclosure Package and the Prospectus and are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">(xviii)&nbsp;To
such counsel&rsquo;s knowledge, neither the Company, nor any of its affiliates, nor any person acting on its behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering
to be integrated with prior offerings by the Company for purposes of the Securities Act, which would require the registration of the sales
of any such securities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">(xix)&nbsp;Each
of (1) the Registration Statement, as of the time it became effective, (2) the Pricing Disclosure Package, as of the Applicable Time,
and (3) the Prospectus, as of its date (in each case other than the financial statements and supporting schedules included therein, as
to which no opinion need be rendered), complied as to form in all material respects with the requirements of the Securities Act and Securities
Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. D-I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 39pt"><FONT STYLE="font-weight: normal">(xx)&nbsp;Based
on our review of the statements in the Registration Statement, the Prospectus and the Pricing Disclosure Package and the document incorporated
by reference therein relating to the FDC Act, the FDA and all state laws comparable to the FDC Act, and the rules and regulations promulgated
thereunder and promulgated by the FDA, the Covered Disclosures are correct and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">The opinion shall
further include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Nothing
has come to such counsel&rsquo;s attention that caused such counsel to believe that (1) the Registration Statement, as of the time it
became effective, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary to make the statements therein not misleading; (2) the Pricing Disclosure Package, as of the Applicable Time, contained
an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; or (3) the Prospectus, as of its date and as of the Closing Date
or Option Closing Date, as applicable, contained or contains an untrue statement of a material fact or omitted or omits to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading
(except that, in each case, such counsel need express no view, and make no statement, with respect to the financial statements and schedules
and notes thereto and other financial data derived therefrom that are contained in or omitted from the Registration Statement, the Pricing
Disclosure Package or the Prospectus).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ex. D-I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT D-II </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Opinion of Regulatory Expert</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;Except as set forth in
the Prospectus Supplement, the Company (a) is in all material respects in compliance with the provisions of all laws relating to the regulation
of the Company&rsquo;s products, including the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDC Act&rdquo;) and all state laws comparable
to the FDC Act, the rules and regulations promulgated thereunder and all rules and regulations promulgated by the United States Food and
Drug Administration (&ldquo;FDA&rdquo;) and all comparable state regulatory authorities and (b) has all authorizations, approvals, consents,
orders, registrations, licenses or permits of any court or the FDA and all state regulatory authorities comparable to the FDA which are
necessary or required for it to conduct its current business in material compliance with the FDC Act or comparable state law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;Based on my review of the
statements in the Prospectus Supplement under the captions &ldquo;Summary &ndash; [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],&rdquo; &ldquo;Business &ndash; [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]&rdquo; and &ldquo;Risk
Factors &ndash; [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]&rdquo; (the &ldquo;Covered Disclosures&rdquo;), the Covered Disclosures are correct and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Negative Assurances</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We advise you that in and on the basis of our review of the Registration
Statement, the Prospectus and the Disclosure Package and our participation in their preparation, nothing has come to our attention that
causes us to believe that the Registration Statement, at the time the Registration Statement became effective, contained an untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading
with respect to the General Disclosures, or that the Prospectus or any amendment or supplement thereto, at the time the Prospectus was
issued, at the time any such amendment or supplement was issued or at the Applicable Time, included or includes an untrue statement of
a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading with respect to the General Disclosures. Also, nothing has come to our attention that causes
us to believe, based upon the procedures described in this opinion letter, that either the Registration Statement, the Prospectus and
the Disclosure Package, as of the Applicable Time and Closing Date, contains an untrue statement of a material fact or omits to state
a material fact necessary to make the statements therein, in light of the circumstances in which they were made, not misleading with respect
to the General Disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This letter is being furnished by me solely for the benefit of the
several Underwriters as underwriters in connection with the sale to you of the Company&rsquo;s Shares pursuant to the Underwriting Agreement,
and it may not be relied on for any other purpose by you or anyone else, other than Blank Rome LLP in connection with providing their
opinion to the Underwriters. It should not be quoted in whole or in part or otherwise be referred to, nor be filed with nor furnished
to any governmental agency or other person or entity, without my prior written consent.</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ex. D-II-1</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>3
<FILENAME>ea020112409ex10-25_apimeds.htm
<DESCRIPTION>AUGUST 2024 PROMISSORY NOTE BY AND BETWEEN APIMEDS PHARMACEUTICALS US, INC. AND INSCOBEE INC., DATED AUGUST 19, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.25</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APIMEDS PHARMACEUTICALS US, INC.<BR>
PROMISSORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left">$150,000.00</TD><TD STYLE="text-align: right; width: 50%">August 19, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">FOR VALUE RECEIVED, APIMEDS
PHARMACEUTICALS US, INC., a Delaware limited liability company <I>(&ldquo;Borrower&rdquo;), </I>promises to pay to the order of INCOBEE
INC., a South Korean company <I>(&ldquo;Payee&rdquo;), </I>at such place as Payee may from time to time designate, the principal sum of
ONE HUNDRED AND FIFTY THOUSAND 00/100 DOLLARS ($150,000.00) (the <I>&ldquo;Loan&rdquo;), </I>together with interest on the unpaid principal
balance outstanding from time to time, all as hereinafter set forth. Payments of both principal and interest shall be paid in lawful money
of the United States of America, which shall be legal tender in payment of all debts and dues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>1.</U>&nbsp;<U>Use of
Loan Proceeds.</U> The proceeds of the Loan shall be used by Borrower for repayment of outstanding fees and expenses and other general
working capital purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>2.</U>&nbsp;<U>Interest.
</U>Interest on the outstanding principal balance of the Loan shall accrue at a rate equal to five percent (5%) per annum (the <I>&ldquo;Interest
Rate&rdquo;) </I>and shall be computed on the actual number of days outstanding based on a three hundred sixty-five (365) day year. Interest
on the outstanding principal balance of the Loan shall accrue and be payable on the Maturity Date (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>3.</U>&nbsp;<U>Loan Term.
</U>The entire outstanding principal balance of and all accrued and unpaid interest thereon shall be due upon the earlier of (i) the
closing of an equity financing by Borrower with gross proceeds to the Company of at least $3,000,000 (the <I>&ldquo;Closing Date&rdquo;);
</I>and (ii) August 19, 2025 (the earlier of such dates, the <I>&ldquo;Maturity Date&rdquo;). </I>In the event the Maturity Date is the
Closing Date, within five (5) business days following the Closing Date, any outstanding principal balance of the Loan not previously
used by Borrower shall be paid to Payee, and the remaining outstanding principal balance of the Loan, together with all accrued and unpaid
interest on the principal balance of the Loan up to and including the Closing Date, shall be paid to Payee in four (4) equal monthly
installments commencing on the date which is thirty (30) days following the Closing. In the event August 19, 2025 is the Maturity Date,
a single payment for the entire outstanding principal balance of the Loan, together with all accrued and unpaid interest thereon, shall
be due and payable on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>4.</U>&nbsp;<U>Prepayment.
</U>This Promissory Note (this <I>&ldquo;Note&rdquo;) </I>may be prepaid, without penalty or premium, which consent shall not be unreasonably
withheld, delayed or conditioned. Any prepayment shall be accompanied by payment of all unpaid late payment penalties, if any, which
are due plus all accrued and unpaid interest due as of the date of such prepayment. All partial prepayments of principal shall be applied
to any principal installment payments in the inverse order of their maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>5.</U>&nbsp;<U>Events of
Default; Acceleration.</U> If any payment due hereunder is not paid within five (5) days after the date that the amount was due, a default
interest rate of the Interest Rate plus five percent (5%) shall be assessed against the defaulted payment (and any future defaults) until
such payment (and any future defaulted payments) is made in full to Payee. In addition, Payee, in Payee&rsquo;s sole discretion and without
notice or demand, may declare the entire unpaid principal balance plus accrued interest and all other sums due hereunder immediately
due and payable. Failure by Payee to exercise this option shall not constitute a waiver of the right to exercise the same in the event
of any subsequent default. Notwithstanding any other provision contained herein, if, at any time, any rate of interest charged under
this Note shall be deemed by any competent court of law, governmental agency or tribunal to exceed the maximum rate of interest permitted
by any applicable law, for such time as such rate of interest would be deemed excessive, its application shall be suspended and there
shall be charged instead the maximum rate of interest permitted under such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>6.</U>&nbsp;<U>Costs and
Expenses; Waiver by Borrower.</U> Borrower shall pay to Payee and reimburse Payee for any and all costs and expenses, including attorney&rsquo;s
fees and court costs, if any, incurred by Payee to enforce or collect this Note. Borrower waives presentment, protest and demand, notice
of protest, notice of dishonor and nonpayment of this Note and expressly agrees that this Note or any payment hereunder may be extended
from time to time without in any way affecting the liability of any Borrower hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>7.</U>&nbsp;<U>Cumulative
Remedies; No Waiver by Payee.</U> The rights and remedies of Payee hereunder shall be cumulative and concurrent and may be pursued singularly,
successively or together at the sole discretion of Payee, and may be exercised as often as occasion therefor shall occur, and the failure
to exercise any such right or remedy shall in no event be construed as a waiver or release of the same or any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>8.</U>&nbsp;<U>Evidence of
Indebtedness.</U> This Note is given and accepted as evidence of indebtedness only, and not in payment or satisfaction of any indebtedness
or obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>9.</U>&nbsp;<U>Headings.
</U>The headings used in this Note are for convenience only and are not to be interpreted as a part of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>10.</U>&nbsp;<U>Governing
Law.</U> This Note, its validity, enforcement and interpretation, shall be governed by the laws of the State of Delaware, without regard
to conflict of law principles. <B>EACH PARTY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY
RIGHTS UNDER, OR IN ANY PROCEEDING IN ANY WAY ARISING OUT OF OR IN CONNECTION WITH THIS NOTE OR ANY OTHER DOCUMENT OR AGREEMENT EXECUTED
AND DELIVERED IN CONNECTION HEREWITH, WHETHER IN CONTRACT OR TORT, AT LAW OR IN EQUITY, AND EACH PARTY AGREES THAT ANY SUCH ACTION OR
PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY, AND THAT THE OTHER PARTY MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF
THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES TO THE WAIVER OF THEIR RIGHTS TO TRIAL BY JURY. EACH PARTY
ACKNOWLEDGES THAT IT HAS HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL REGARDING THIS SECTION, THAT IT FULLY UNDERSTANDS ITS TERMS, CONTENT
AND EFFECT, AND THAT IT VOLUNTARILY AND KNOWINGLY AGREES TO THE TERMS OF THIS SECTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><U>11.</U>&nbsp;<U>CONFESSION
OF JUDGMENT.</U> UPON THE OCCURRENCE OF AN EVENT OF DEFAULT HEREUNDER, BORROWER HEREBY IRREVOCABLY AUTHORIZES AND EMPOWERS ANY ATTORNEY
OR THE PROTHONOTARY OR CLERK OF ANY COURT IN THE STATE OF DELAWARE, OR ELSEWHERE, TO APPEAR AT ANY TIME FOR BORROWER IN ANY ACTION BROUGHT
AGAINST BORROWER ON THIS NOTE, WITH OR WITHOUT DECLARATION FILED, AS TO ANY TERM, AND THEREIN TO CONFESS OR ENTER JUDGMENT AGAINST BORROWER
FOR THE ENTIRE UNPAID PRINCIPAL AND INTEREST OF THIS NOTE AND ALL OTHER SUMS PAID BY PAYEE ON BEHALF OF BORROWER TO OR ON BEHALF OF PAYEE
PURSUANT TO THE TERMS OF THIS NOTE AND ALL ARREARAGES OF INTEREST THEREON, INCLUDING BUT NOT LIMITED TO REASONABLE COUNSEL FEES TOGETHER
WITH COSTS OF SUIT; AN BORROWER HEREBY RELEASES ALL ERRORS IN SUCH PROCEEDINGS. IF A COPY OF THIS NOTE, VERIFIED BY AN AFFIDAVIT, SHALL
HAVE BEEN FILED IN SAID ACTION, IT SHALL NOT BE NECESSARY TO FILE THE ORIGINAL AS A WARRANT OF ATTORNEY. BORROWER WAIVES THE RIGHT TO
ANY STAY OF EXECUTION AND THE BENEFIT OF ALL EXEMPTION LAWS NOW OR HEREINAFTER IN EFFECT. NO SINGLE EXERCISE OF THE FOREGOING WARRANT
AND POWER TO BRING ANY ACTION OR TO CONFESS JUDGMENT THEREIN SHALL BE DEEMED TO EXHAUST THE POWER, BUT THE POWER SHALL CONTINUE UNDIMINISHED
AND MAY BE EXERCISED FROM TIME TO TIME AS OFTEN AS PAYEE SHALL ELECT UNTIL ALL AMOUNTS PAYABLE TO PAYEE UNDER THIS NOTE&bull; SHALL HAVE
BEEN PAID IN FULL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>BORROWER, IN GRANTING THE WARRANT OF ATTORNEY
TO CONFESS JUDGMENT, HEREBY ACKNOWLEDGES THAT, WITH RESPECT TO THE ENTRY OF JUDGMENT AUTHORIZED BY THE WARRANT OF ATTORNEY HEREIN, BORROWER
KNOWINGLY, INTENTIONALLY, VOLUNTARILY AND UNCONDITIONALLY, WAIVES ANY AND ALL RIGHTS WHICH BORROWER HAS OR MAY HAVE TO PRIOR NOTICE AND
AN OPPORTUNITY FOR HEARING PRIOR TO THE ENTRY OF SUCH JUDGMENT. IN ADDITION, BORROWER ACKNOWLEDGES THAT: (I) BORROWER HAS HAD THE OPPORTUNITY
TO BE REPRESENTED BY LEGAL COUNSEL IN CONNECTION WITH THIS NOTE; AND (II) IN THE EVENT PAYEE EXERCISES THE WARRANT OF ATTORNEY GRANTED
HEREIN, SUCH ACTION MAY BE ADVERSE TO BORROWER&rsquo;S INTERESTS. BORROWER HEREBY EXPRESSLY WAIVES THE DUTIES THAT MAY BE IMPOSED UPON PAYEE
PURSUANT TO STATE LAW IN EXERCISING ITS RIGHTS HEREUNDER.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in"><U>12.</U>&nbsp;<U>Successors
and Assigns.</U> This Note shall bind Borrower and the successors and assigns of Borrower and the benefits hereof shall inure to the
benefit of Payee and its successors and assigns. All references herein to &ldquo;Borrower&rdquo; shall be deemed to apply to Borrower
and to the successors and assigns of Borrower, and all references herein to &ldquo;Payee&rdquo; shall be deemed to apply to Payee and
its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">{Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, Borrower
and Payee have executed this Note as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 12pt">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>BORROWER:</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">APIMEDS PHARMACEUTICALS US, INC.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">/s/ Erik Emerson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Erik Emerson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>Accepted and agreed on the date hereof by:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><B>PAYEE:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">INSCOBEE, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Jakap Koo</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Jakap Koo</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President &amp; CEO</TD></TR>
  </TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea020112409ex23-1_apimeds.htm
<DESCRIPTION>CONSENT OF KREIT & CHIU CPA LLP, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We consent to the inclusion in this
Registration Statement on Amendment-2 to Form S-1 of Apimeds Pharmaceuticals US, Inc. to be filed on December 6, 2024, of our report dated
May 13, 2024, which includes an explanatory paragraph as to ability to continue as a going concern, with respect to our audits of the
financial statements of Apimeds Pharmaceuticals US, Inc as of December 31, 2023 and 2022 and for each of the years then ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We also consent to the reference to our firm under the heading
&ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%">/s/ Kreit &amp; Chiu CPA LLP</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Kreit &amp; Chiu CPA LLP</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>New York, NY</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>December 6, 2024</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tapimeds_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tapimeds_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M$DD<-1F,DH6EP6WZ.24K$E?N'.5--0P%B%$M0I8@7/LXY?V6ZYBWK;-DL_\
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M:)]TXV94"I$M6^2H846RTHO?W$W-/LUR?S&LDUK;?N_<3D36H 0G^G#A"/\
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M')Y&ME@HZ&AHZ>-GEEE=41%)8@#V[!!-<S16]M"TEP[!$1 69F)H H%223P
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M?GO?0$VJR)>VUX4O&"SS'^C"!C^GFO800+SAN\B+'LEEFZGH'IQ"M@*/F_\
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M *.>U_\ .2?_ +9NO?U\V?\ Y1KG_>4_ZV=>_P"@@?X:?\^T^3?_ *!O5?\
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M#_L'/5A?\K'^8KEOA]V+%U[V%D*O(?';L/+4\>XZ6222<]=;@JC'2P;_ ,+
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MFCKJ.=)8W4E61@1]?> <\$UK/-;7,3)<1N4D1A0JRFC*1Y$$4/4XHZ2(LD;
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M - 7=_\ ]L;W[_@?N1_^4O<?^<L7_6CKW]>]Y_WS;_[RW_0?7O\ A_'YM?\
M/-= ?^@+N_\ ^V-[]_P/W(__ "E[C_SEB_ZT=>_KWO/^^;?_ 'EO^@^O?\/X
M_-K_ )YKH#_T!=W_ /VQO?O^!^Y'_P"4O<?^<L7_ %HZ]_7O>?\ ?-O_ +RW
M_0?7O^'\?FU_SS70'_H"[O\ _MC>_?\  _<C_P#*7N/_ #EB_P"M'7OZ][S_
M +YM_P#>6_Z#ZIY[ WA-V%OG=V^ZK![=VU5[QW%EMRUN!VE15>-VSC*[-5LV
M0K:;!8VMK\G/C<6*JH<PT_G>.!"$CTQJJK,NVV*[9M]GMR7$DJ01K$LDQ!<A
M10:B%4$T&32IXFIJ>@C<SFYGFN#&JL[%BJ5"@G)H"305^?76P-];IZPWOM/L
M79&5GP>[]D[@Q6Y]N96GL7HLOAJR*NHY6B<&*H@,L(66&0-'-$61U9&(/MQV
M^TW:PO-LOX@]G/&T4B'S5A0_8?0\0<C/7K>XEM9X;F!J2HP93\Q_D]>OH6_%
MWOW;?R>Z%ZU[OVQX8:7>^WJ>KRN+BE\K;?W11.^-W5MR5FM(S83<%)44Z.P4
MS1(DH&EU)YU\T;!=<K[]N>QW=3);R%5;AK0Y1Q\G0@_*M/+J?=NO8MQLK>]B
M^&1:T]#P(_(XZUU?Y_7QD@V[O?KOY5;<H_%1[_2+K;L?Q*!'_>S 8Z6LV;FI
M-,19ZG,[6HZFBE9G"JF(@"KJ=B<CON^<T-/9[ERE<O5X*W5M7^!B!*O'@KD,
M*#\;5\NH_P">]M"2V^Z1C#_I2?:,J?S%0?L'1U?^$_V=J\A\/^Q,-4NTD6W_
M ) [FCQY/C"PT63V'US7-2H$C5B$R#5$I9V8DSVX"@>P3]X2WCBYSV^9!1I=
MNC+_ #*RS+7_ 'D ?ET<<B2,VT3HQPL[ ?850_X2>KTO<$=#7H!/E7F(MN_%
M[Y([@GADJ(,%T)W#F)J>(JLL\6,Z\W%6R0Q,_H625("JD\ GGV?<K6[7?,_+
MEJK -+?V\8)X M*@J?V](MRD$6WW\K"H6%V-/DI/6EM_*:Q#YO\ F&?&JC37
M>'<6[LN?&T:-HP'6N],])<RD*4"8TZ@/4RW"^HCWFS[O2B'VYYF<^<<2_P"]
M3Q+_ )>H>Y475S!MP^;G]D;'K?$]X$=3=U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5#O_"@
M?;D^0^*/5FY8*=YAMSOC$4E7(GD84E#GMB[Y0U$P4>)8&K\;3Q:FY$DJ*/U'
MW/?W>KE(N;]TMF8 R[>Q4'S*RQ&@^>DD_8#T">?(V;:;=P,+.*_(%6'^&G5=
MW_"?WL$8'Y1=G]>5#:*;L+I^IR-*=:@RYO9&Y<-4TE/XRMV#87.Y&34&NOBM
MI(:ZR-]X;;O'Y7VC<E^.WO-!']&5&J?]Z11^?0?Y"N-&X7=L1B2+57YHP_R,
M>MO/WA]U*W7O?NO=5K?S _Y;/5_S?VZF;CFI=A]Z;=QDE%M'LB"D,D&1I(V>
M>GVMOJCIPLV9VZ:AV,$RWK,:\C20:T::GGDOV]]R]VY%N3" ;C8I7U36I/ \
M"\1/PO3CY-0!N (#V^\O6N]1ACV7BBB2#_ WJM?S'EQ-=>#XQ=D?(?\ D_\
MRD;;??\ LG/X;JW?TD."W_14Z29/;>YL#1UDD>*[)Z^S-('Q^;R&UWJ6F$49
M^X>CJ)Z2HA@J'7PY%<T[;RY[R<K?5\NWL;[Q;#Q+<GMD1B*M!,IRH>E*_#J
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M[M^V3<J7;;YLT1/+D[]RC/T\C?@/F8V_ ?+X#^$M+_*W,8W2(6=VP&X(./\
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MD:EO**RDE:6604<Q<X)S?$EQOVW(.8$4*+^V 0RJ :+<1? QX .A0J!0JXH
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MR&8V5M++5\VGS5V3VYAZ^LETBR^2IJJ.6:32/I=C;W%4=[>PH(XKN54' *[
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M%%+%C=RP(N2VEFM$R2(),'N>AI*M#;4K0@@@V(/>6-[FY;Y@VG>X"==O,KL
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M!F<LL?SJU>W,8;3MS<P;]>;O. =O28E?Z9&$'V!0"W[//&V8 % 50     +
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M$N44J5:A(61"6TD@&E"0:<0<=#+8^9+3>]4:H8[M1J:-C6H]5.*@?8#U3O\
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MRDHG12B,"['E64^PW]WJT$7*.Z79!URW[+\M*114I_MF:O1ASY*6W2UB_"L
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M!.T&!=384#4031G\^EMY=<V7-M+?JGT]HHU:%H&TC-<]QH./#Y#IPPW?7?\
MLZE.S-L5D?8)W'44=%M*MW/19_>V_-LUR+)]]B\;C,7%2U6^\?7T,7F2MS>5
MIFP<J3U594UM&5IJ99O_ +><GB:/=KFY^@V^,'ZA(R%1SQ726KX;<0556U"@
M55:I*;;.9MYDC>SC@^HNS_9L?PCSU4I4<,DCYD])G.Y;O_;VY\70=D[I[PV7
MO/,[>GW'MK,UN_MI-C\E#B*JAH<Y&NSNN<OD>JSE=JUF;H/O*>KPLE%.M? 8
MVJU$HA6;#M?MSOUK=P[/MD$L,+A) ZRAZ-72P>2DFE])I1@10U"XJSN=YS1M
MDD,EY=E=8JNG25J.*D 4J*_8?4]6'=&]J5&^.H:;>F]:C&8S+[>EW1A][5J:
M<=BXJG9F3R%!5;B>":>9<109S#T4.76!I9!2P5BH9'"ZS!G->P#8^8[S9[34
M\6I3!7+%9%#*O :F4MI) R1PZ'VT;A^\-MM[V0!6*G7Z J2"?D#2OV=$FW3W
M/W1WGNS [9V#F,KLC%[WRM1CMF[;QLE=MG(1;>IJ2JRM;OCLO=%#3_WQP\M)
M@:!ZE,=C)L4L574P8V:2:IECJ4E>WY-Y:Y-V&7>>9;47=^BJ60FJ^(U (HU!
MTMDY9M6 6 H*$(MOFY[WN0L-JE\&VJ>^F=(XL:Y'R IY5/4==X=^?'/L#,;5
MR.^<IVA_ ,9A-R38#.5>3R&([!VIN!LA%!6X+(;TSNZ-V;!WA!E=N9/'P02;
M@K\6#"L]1"R5$/VMK/EWE/G[8'O]LVM=NW .T7Z9J$=0" X4*KQLK*20BM6H
M!P=6KG=-WY=W%(+RZ-S:,H:K  D$T-#FC CA4C]N#U;T[SVMMKI^@[=Q .XZ
M#=&+P-1L+%QO+15&ZLMNV"&3;.,9_M:RIQD,OW FR$YIY6QM##45$D96G<>X
M@VGEG<-SY@7EW3X=TLK).3D1B,GQ&.0#I -!7N- ,D=#*\W*WM-O;<2VJ'0&
M2GXM7P@?;7\N/1&, GR#^0N\<I@HNVLUMZKP^)HMPY_,82JW3M'9&TX<U4Y"
MBP>"V_MG8FZ-H[BW/496HP]:RC)YVJEI(:=I):B[TT$DP;[8\D<A6%D)=A6]
MO)2543,"[!:%G9F5E0"H TH*_D3T#-MNM^YAGN'2_P#I[9*? N 3P4<"<<:G
M_".@QRF#[%P_:6]8.U]U5VY-Y8? ;.V?&:U,?-%_=;$5V\MQ[=S&'S%)CL17
M9K#9EMYU**]? ]=35=+44TM34F'R ;<G2[#/L4=QR[:>!9RS/+)$224E*HCK
MDM2@0$4-""" *TZ#_,"[C'?^#N4HDF1 J2  :DJQ!Q3S)'^?CT?#JO?%/UM\
M.MB;XJ**3)G;W5.$JZ/$PS+3S9G+2TD%)A,)!4.DB4\^:S%3!2I(RE4:8,00
M#[Q]WO;9=WY_W3;(6"O/N,D>H\%!D-6/R45/Y=2597*6?+]I=."4CM5<@>=$
M&/SZ*[M'$_(/Y#;HW9X^^JG:>4V=0[9S%708^HWCB,1-)NN?< I\/A-L[!WM
ML-\3MFD;;4B4V3S,VY*RHD,L;J_V\AED7F"'D[D./;K.3E/ZTSJQ::5@#VT!
M.IDD!;NRJA !I/G@-;9+O7,'U5RF[^ J, L:*",BN<@T^9K7/4GI_LKN?&_(
M/8FR-_[^W;FLK6;UW/U?OG:6X:C;53B,'%A^J-^]EXR7!G;>U=J0Y-<H^(Q=
M?0YBL@;*U6(JHTG,1>2G2O,O+W)\_(EUS#R_MRQ ".>)P7+5:9(71M;O33J8
M%0=(85%>)WM>Y;U'S FV;E<:Q1E(HH&%+AA0"M:?L.>K2_<#=#[HIGS&_P"9
M<[4_\2?M?_W SWN1O:S_ )6V#_FA+_QWH-<V_P#)$G_TZ?\ 'ATC?AQ_Q=^X
MO^HG8?\ [K,Y[//>+_DI[-_SSM_Q\]%_)'^X-Y_S6_Y]'2 ^4>0HZKO:AQU(
MRFMPW5.%FS>E2=29W=FYSM^%Y+A!+2KA*]S&+L$J59M(9-8A]GX)DV?=KAP?
M >Y"I]J("_\ QY>BSGAT-U8Q@_J"-B1\B13_  'ILI*6HI_@OD)98I(*;(=T
MT62QD3J4!Q]9\LL3)'6PQ_YO[7+S^2MB=+K/'4K-<F0^RNYFBF]XX6B<-I*H
MQ'\2VE"/M4BA]"*>71A CQ\DN'!!,;,*^AD)'[0:] UAMS=K[8WY%'U#2MD=
MR[KV;F,$:+#[?7<F\8:>CRV&K6R6!AR]10;$P$$$LR1RY?<50,123RP1212M
M4IID+G#;.7+^ULKGF:^\';[>4M2ND.6%-/:#(W"NE!J(J013H+[!=[G;R7,.
MUVWB7,B@5/!0*YS0>?F:?;TZ5.?[SVMO#,8C<6].X]F=CXFCP>X8Y]R[SQVZ
MMOYG$9MJQ<=E8-IXC,YCK*7%U.0P=;05E)%04%3!+2S&(1))35<I=M6Q>W_,
MFU-)M>UP-::FB8JKI*C#U=N\FA# DL#4 U(*A7>[ES+M-VBW=V=9 8#M*,/L
M I\CP/IY'JQ[ =RXZJZ#3O/<-!)C:+%]=93?.Z\50.:UL;/MC$5M=NO&8Z:9
M:<UZ4-;BZF&GE81B=45[*&L,?;S89X.9)>7('#S_ %?TL3'&HLX5">--502/
M+J1X+Z.7;H]Q<:8S%XK#T&FI_9U7I6;T[X[@WWLK:F4[?J^O*CL+,Y7'T,.U
MZ?/TNT=GUF/VYF-T4>"ITV9N/KW>NX'KL?@9X'R.2SZ0RUJ+XJ2$54=)'.-]
MRMROR;L$VYG8!N,L 3QFG?2S!F"%@"LB* S"BA"0#ECI)Z 5IO.Z;YN0M%W#
MZ:-ZZ B@\,T)J#6@XUICAGITVMW+VOTCN[*X[>.],AN3;NPMV-MOM;;>YLM5
M;KAH,$\./R,F^]K[MSGDWICZREVKEJ'/"BKJROI7H)):,0K4R1UL*:_Y.Y<Y
MIY93>]AVWZ6^DA,T CP&920T3(.PU964,H4UHQQ5>GK?>]SVK>#MVXW/C0!P
MC,0*@-0A@<'@02#7SIZ]63]F;KS.Q]B;DW7M[:.3WWF<+0K4X_:F(%8U=EII
M*F"F(1<;C,WE7IZ..9JB=:.AKJUH(G%/35$WCA>"MILX-PW*SLKJ^2VMY'"O
M/)\*#U-2!^T@5XD"I ]NIGM[>::*!I)%4D1KQ8^@ZJOW-\F^_*^#"]EXK<5;
M6-C=Y;26#JG;NVVV1A*W%OOS$X+=&W-RQ[PQ.7WO'EOX--64E955ST\5%-']
MU'04LD6D9%6GMARL-KGMDK+<S0,8[UWU48H2CH(R$T:J$#)(QJ(/4:R\V[K]
M<C2*(X$>CP@9(!HP)(K7]F?+IHQW<F^NPHJW>Y[IWO!EJ6JJ6DK=NU^7V1M/
M 2I3PUM-+A]A9$-M[);4EQM1!78NIS5-F4R>+J(*LU-9!.D\AM:\A<I6UJ+,
M;3#,M-#2.=;L02&K(IJKA@0P73I8%: @CI%/S)O;3^*;EHZT94 H*'(P1D$9
M!-:\>AAS?RO[QRN,V%MM-MR=89'=/7&U-RU78E;L7<E9'NJNR^S\/F<_-UVF
M=QTVP]JS8?(YN,)39BJSM?&\,\4V.\2QU4T?\O>W?+%]?;F\N\BYB@NI8UM(
MW4.$CD*HTK*=;!P.*!5-00]:J!-NO,>Z6EO:Z+'0TD2,TS@Z=3+4JHX5'S)/
MJ/,I+:G87RNW<<_UULW<&Z=WT.,SL4TNZL%0[<3=F-Q^4Q&W:DX;=O8>\8\1
MLG"FFKI:RH_A^,IJO</\,K:6>%HD"(QOO?+?MOR_>KN&[40-&/#L5+D$C4"X
M1"9#JQ0LRIJ# U\D6W[IS-N=L(+-02&(>X8 <<@"HTX'&@)R.'3'M7MGMSK^
MHGW)29[>G\3VWE,AC=]=:]R[^RN9Q$YPE;+1;AQF1S^0FW\=KU%)#%)4T.4P
MCR4<MH966JHY"C'-YR3RCS)M,<FUVT4(E0/;W5NE"*\*I5-0\F5LC/ ]%\7,
M&];5?M%?R-($.F2-R/Y&F/4>73WN[>_R<W7M^I[-W93=LX+K6*IHY)'V7447
M4^#P6(JYQ3C<,.+7<6'[PRV%QK2Q_?5E<WAEB_RRFI%I3)H(MGVWVQL+^WV)
M)(KS=G.CQ90TBE_X 0/ !)^$"M.!:M.C.]NN;)[:7< GT]HHU:%H&T\:FO=@
M<>'V=&%^,':NZZO>V3ZJW;N+([KIZO:5?O;9N0S3?>9W$T6V,MMW;^Y\-DLV
MRBISE$\^[L9/12U9FKTD-4)9YD,*PASW-Y0V[9X++>=IMA# \O@31J>W4RLZ
M,H).FH1@0,8% ,U7\J;U<W[3V=Y)KE5=:,>)%:$&G&A(_;UQ^1G=.^Z3>\O6
M6P<XVSJ'"8?$97=FZJ"AQ]=N.MR.;DK)J+;.$?-4M?B\-24F*I$GKJHTE343
MBOB2FDI9()'??MSR1M>\V4N];S&98O%,44&HJIT@5=RM&.6HH!' UJ"!UKF?
M?[K;Y4LK(A92@=I"*D5)  KCRS4?9T5S'+WKM[8?5G;LW=F]9X>TYY\3-3XS
M=&\,A7=9;P7$9K+56"RN)[!W3V#U]O.#'UVV<CCIZQ</CHHJ^"%(J%X:AC *
MK&'DS=M_W?E2XY2AAFMM6B0'^U5&"U#(L<B$JP8#4U16IJ!4MNI-\LMMM-XB
MWAY(Y-)92H[=0KYE@:'!P.K#OCIVUE.U=H9;^\U-24V\=E9]]J;FEQT4M/BL
MS+_"L7F\7N3$TL\DLU'1YG$9>$RTY>44M='40+)*D2RO$?.W+*\K[R;.&1GL
MI8Q- 6IJ"DLI5J8)5E(KBHH:"M +MBW3][6"W#*%F5BD@'"HH:CY$$'Y<.DW
M\B.],IUY+BMC[%3&S;_W#CY<Q4Y'*1-78W9.UTJ'HH\[78N&HIILCE<Y7Q34
MV)II)(:>5Z6KJ)'D2C:FJ#'D3DO^M%Q-<WKNFTP$!RF&=SG0I((%!EC0T! I
MW A-S!O@VB%%B4-=R5T@\ !^(_Y!Y_ET1_*)WKD^OZ?O*N[FWQ2XBIWAB-M;
M9Q<VX]W4.;[!6IW53[>JL[2XK8^YM@=>[1P],ZUV0@<X3,)7XNC\_A\4D4/N
M2(HN2EYE3DZPY4@F<*WCW#MB,JA9@"RR2.0 !\24<T\J]!MI-]_=+[W<[NT8
M-#'$JCNJ:#T J?D<9Z-U\9NXMX[ESV=ZWW]E(]R5]!@HMT[3W5-3T&/SF6Q$
M%=!B=QXK<%!BJ''XB>JV]7Y"@>&NIHH/N:?(+%- LM,:FL!'N/R=M_+S66X[
M2K)9SLT;PDE@C@5!5B2U&%<&I!4FI!HIURQO=QNB3P7=#/& 0XQJ!QD#%0?3
MUX=!+WU\F=XY/,Y_;'5^1K,#MO;F?CV4V=P2X:7>'8_84N:I=L_W0VE59M*G
M$[=PZ[KJ1@C52QI7UN6,G@EH::GCJ:\^Y-]OML&U#F'F="\;1&X2 E@J0A2W
MB2::,Q*C6 #0+2NHMI5#O?,=U]:-KVD@2ZQ&TF"=1(&E:U H<$GS]*5Z0^Z,
M-\D_C_F]GU>0[ER60GWI25T]*\V8W=O?:F.W/A8J;(U.P-P8CLK<F?JMP8S(
MXZ:HJ(,KAO[LUE1!0U*LE$XIV=?L,?(O//[RL(N6A:2PC5&\9"NR$Z?$!10J
MLII56\0=PH6STQN4F_[ MK=/N?CQN=+JRX#4K3C4@YR*''1@=T?+3,4/0U-V
MMMWKRMR6=Q^X,CM;L?%TM)N7=>,ZKJ\#B:_,9W<6:IMH8*OW)F=M+CZ:FK*&
M3[;'I44&2I9JJ:AUL% T'(D4?-L_+F[;Q';P!!)#,^E3.&("*FM@H=JD$5-&
M5@-71^V^M)M$>YV5DTKDZ6C7\!%=18@$T'V<"#CI =*=G=M9SO/:M-O#L*NW
M!0[GQ6ZJ7)[<IL1AL+L^B?'XB/+4<NW\33TM1EZ%J2LHG\<E7DJ^J:*HDCEG
ME41>(6\]\G<O;#RJ)MMLB+I)T'CN[,[!M0(;@GIP51@4'&I)R]ONX[GNSQW,
MH\$Q,0B@  @CAQ/[2>E)\@_D3VAMCL2IZGVMA*SKRCJ<='+BNTLQM+,;@CW6
M\F)I<CD8^O\ )5&+?K/%Y3 FK,9CRU3D\A+)2U+'#K2)#63E'(/(VQ;_ &@W
M'<=T6696.JPB<*Z@&@:7/B:6_H #(_4U54+>8M^O]L?P+:S(0@4G<56I\E\J
MCYG\J9+'UQ%W[VIU3NVCVCW)F:#=VR.YYZ.ERF?DP\,NY-L5?6^S\U4;;RN>
MBV=N!L5#29[=TM=3SPXRH<+3I2:5A8/%;F6#E/ECFX0W?+XEVA[-3X*.X*/J
M8:U[P22$H06IDGCUO:I=VW79%EBW#1>B4]Y534#R(I3S].B>["H=RYG#=!XS
M86G [QR<FTX=J5=1NJ2FBVY7#8F4JI9:G<3;)W ^46'$05%/K;##[EI YCA)
M]$R\QW&U6_+VY7.YVC3;2L:EX5P64N@48=:48@_%Y>?0&VR*\DWF**VN EYK
M<"0BH! :II3S%?+JS[)[M[GZ@Z!ILYNO;0[C[6P]1]A7T.Q8,_DX*ZBKMTU%
M'BLO/#@-ES[ERTV&VK/329(XW :ZJMBE:.GIX',D.-$-EL&^\SFVL[O]V['*
M=2/=%3X=$J5J7"T+@A=3X!%6)XRF\U_8[9XDL7U-\@H1$*:LT!I0GADT'K0=
M%'ZU[V[3[#[4Z1W/4=FR5^T]^9ZG$.V=L8&@P&Q:[:^8V'NO,4+IC\I3Y7=D
M\]4T=)5&:LR4DJ30+XDIXVEA>5N9>0N7>7^4-YD@LV?<8E4BXE8EPWBQJ:!2
MJ 4)%-/ Y)(! 0VKF+<MRWNTAE<);,6!B4"F%8BI-6K@>?Y=&R^0W>==ULN(
MV=LR&@J^Q-T457DZ>IRE/-6X7:.W*&H@I*K<>8HZ:HI):VJK*RH%-C*(S0?=
MS)/+K,5'.ICGD;DUN:KN:6YD:/:8"/%9:!F8UHB5!%:"K&ATBGF1T)=_WM=G
M@30H:[DKX:G@*<6/R%>'G^WHB>37O7,]<U_>E9W9OB#"T&Z<5M+!T]9G=X8K
M*]AY5M[P;&JYJ7 ]>;AZXV-LO"T^?EE2.N;"Y855-32U34CTHA:HDX0\EV_,
MMOR;8\IPSS$$S3,PI%V&0]SB1W8(,C4E&[0:UH&/$WU]JEWNYW=HTI6.-5'=
MF@X4 !/R.,]&V^,W<&\L]N3*]9;\S#[JJX]O56[MI;HJ:2AH\U/B<7E,7B-P
M83<:8JCQ^+JIL34[@QS459'#'-503R)4*TM.:FI!?N3R=MVP"SW/:4,=K,YB
MDA)+!6IJ4H6):C &H)-",&AHIQROO=SN:SV]Y1IHP&#@4J#C(&*@^G'\LEU[
M_P#D7V)F:GL.JVQNZNV-U_U_G-T;8GI\$&HLQD1L+<==MS?VZ]P9NGIO[RK!
MAZO"UTN.QF$JL;+54]*/)5M)5H*,7\G^WNTQ[+:;IN5A]9N<\(N(HG:B .FN
M)  :$N"-3," 30+VDL3[SS)>'<7L;2X\"V23PWD JU0:,<^2FM .-..<<,]'
M\@N@=[4FW)>Y<UN')5&#3=>$RV5K-S;AV?NV""MJ,;EMNY[9_86[-_Y_"18:
MI>B:>;%YNEGJ(ZN-HIX6$T0WL6W\E\^;;>O%RXMG/$PC;PF[DU"JNK*J*U:,
M*,AI3[#U[<KS?.7KFWU[C]1"X)HZ@ TP0>)'$9!ZLBZOWY1]F[ VOOFCI7QP
MS^-$M=BI)EJ)L)FZ.>;&[AP%14(D:3U.!SM%4T<CJJJ\D!( !]P7O&V3;-NE
M_M<YK)!(4U# 8?A8?)EH1\CT/;.Y2\M;>ZC^"1 P!\J^7VCAU69WI_S-[Y#_
M /:^P7_OCNL?>27ME_RI^V?Z>7_JZ_47\W_\EJ7_ )II_@Z.YF^QY^JOC/M;
M>%!00Y3-1;(ZXPFW<?4^4451N/<\&W]NX5\F8'CJ!AJ&OR:5-<8F$PHH93'=
M](,#;7LC<P\V':1)H22XE+OYA$+.Y']+2II\Z=2+>7R[;M37C+71&M!ZDT '
MV5.>B@;*VK\C>]Y=\[KPW?.3Q&2V-N)=N1XNKRN\,'0[CS4FUMN[OCCI:'8F
MX\!M/9NW:2#<\%)!-68+<]5.T,C5"S%+S2;S#)R1R9=66RS<H"XCDA65YV8:
MPI9D)&I27;L)-&C )H*>06VS]^[W!-?IO/A$.56-5%*@ T.<#/F">E1\9.QN
MULCW3%MG?6_-\;BFR6W=]TV[-N;WBVG%/MO<>P\GMG%P8NCH]H[=V]@Z)L;-
MD:P&KI(B,Q#41U$DU5$*.2-+S[L'*UKRG8;QR_8QQH\\?AR1M(VI)$=CJULS
M5JHP?A((H#4=.\O[CN\N\7=CN<Q9DC-5(44*LH!&D 9!_/'5E?N$>AQU[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW56O;.\]JYSYB827>N>Q>#V%UO
MG]I82NK=PRQ085<CL/ 5O;45?BZ^61J=<M5]A[IV[2O&;2$X":RW@+>YPV+;
M-PM/;#<'VVREEW+<7(40@LWAEA$=0&=.A)/]['KT![^ZMIN:K5;FX1+>U342
MY &LBN"?/*_LZ3_<.Y^NMR]U9C*]>[IV_N[%[\VECLYG?[OS)E(J+=6UOM=I
M92?-U<&NGI3FMJRX*&BAEL\PQM4R:PCA!;[:0[Q9[%/MN[[?/ T$U83,K+5)
M*MI4,!72X8FG\8]<D7-K64U[!=V=S')K32^@@T*\":'S! _+HYWQ$W2V>Z5P
MNWJN=I\OU;7UW5F3\M2:RJ%+M6.E;9M3D*IOW9\EE^N,CA:^I9_69JMKEOU-
M"_N#M/[IYJW)$2EO.?JHL4%)*E@!PHLFI1_I?RZ'?+UY];M-I(QK(H\-_,U7
M&?F10_GT!ORY_P"9M]:?^(YWW_[TVQ_<B>S7^X?,/_-6#_CLO07YY^/;/LD_
MY\Z&7X7?]D^X7_Q(O?W_ ,$!VA[ GN?_ ,KOO'^DM_\ M%AZ$7*W_)!L?]O_
M -7'Z*GW;04D'>W;T2P1O'F:K9V6R*2HCK454_7FV<!(LBE=,D+8W 4ZZ6#'
MAN;$ 3#[7S22<H6:NU5CFE1/D->O_CS$] CG!%7>68#+1J3]N1_@ Z6N\:ZK
MR/PT^,M57SRU=:8>G(*JNF8O+DIJ39=;1R91V:Y)RC0?<?5K>2VIOU$"\K0Q
MVWNIO4$*@1+-=A5'D-34'Y<.A)O,C2\I6\CGO:.$D_/MZ7?PX_XN_<7_ %$[
M#_\ =9G/=/>+_DI[-_SSM_Q\]5Y(_P!P;S_FM_SZ.B7?*K_CZ/F]_P!/?_@6
M>I_<I>VG_*H<K?\ -W_M+GZ"G-/_ "7K[_:?]6TZM/\ D?%'/\>.^8)E#Q3=
M,=HQ2H;V>.38^<1U-B#9E)'O&3EQVCYAV&1#1UO8"#Z$2J1U*U\H:RO%854Q
M."/]J>B3?'G_ +*'VA_XC_LG_P!S=B>Y\]V/^533_GMB_P".2]1OR7_R5I?^
M:#?\>3H1_F'_ ,S Z9_\,[N3_P!W?2_L*^S?]OS!_I(?\,G1SSQ_N-8?\U&_
MP#H+Z?)S8SX;]NK$H>'.]T;>V7DH6-DJ<%O[L'JW9&X:23TL&BK,%N"HB=2+
M,KD?GVOW"U2\]X-JB<T"QK,/]-#!)*O_ !I!TQ:S&#DJX=1DZD_WN0*?Y'H/
M=I;FWCL_M3 Y_KS;3;QW>FPM]XR/;YV_G\W&F K\_P!<SY;.B;"U5-'13XZN
MQU#3*)-32)7OHL%>XRYZLMHW':+>UWK>/H[3ZE7#T!U.$D 6E*\&)],9\NB+
MEJ>]M[N>6QL/'E\/216E 2#7\R.E7O2H[R[)W92;MW7T_NO'U5!MT[<AI=M[
M(W&L573_ ,2?)Q5%;+E*ZJ824<DTJQK&J@B9RQ-E"A[E2]Y+Y4@O+>WYKCF2
M9U<ZP1I*@C%!FM?Y=&F]6V^[RUN[[.8S&",,#6M/F.%.FW=N+W9M+9/QTZYW
MM13T%6V1^1G:=!C*MHWKL:B;VQE-M2&OCAEF@HJS&;1[FJJ04ZLQ@B8(VAU=
M%4\I2[;NW.7.6^[4VJU\.W@#TH"77O(!S1G@K7SZ:WQ;FSV#9;"[Q/J9B.-
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M!].JNI1[MLVW;YN%MNT3E+V&,JT)XYJ*U\U 8\!YBM.'5@7N)^A9T4SYC?\
M,N=J?^)/VO\ ^X&>]R-[6?\ *VP?\T)?^.]!KFW_ )(D_P#IT_X\.BD=:[P[
MOVIE]^T_2>R:7><^6I]K29VJK,&F5AVW74T.8BQJ&&?L+8,>07)TC,?&LZ>
MIK9R&$?N3.>]LY3OMPVR7F3?'M2D9"QHI)==520PCDTD'Y'[.@MRW=;O!9W2
M;;MRS O4NS 4-!BA()Q\^E?LWXV=V]@YG(9;LTY#8D&Y:YLIOO<>;S>ULIVC
MGZQ:>CQD=%@,=L"IS&Q=LTBX2BBIJ:M6O=L?#3QK'02R,T\91?>XO+?+^UIM
M7*$!E9%TQ.RLL2UJ2[>)221M1K0J 3YT%"MAY9W+<KPWN]RA02"R*06-."X[
M5%/0G]N>C(?)S!8C:_QLGVUM_'TV)P.W\[T=A,+BZ-/'28W%8OMSKJAQ]#3)
M<E(*2D@2-!<D*H]Q[R+<377/&UW5S*7N))97=VR69HY"23ZDGH3;\B1[%?1Q
MJ BQ  #@ "*#H$_BK_S.?/\ _B,)O_>KQ7N1?>+_ ))NR_\ -=_^.#H*\C?V
M^X?Z1/\ "W7OE5_S.? ?^(PA_P#>KROOWL[_ ,DW>O\ FNG_ !P]>YY_M]O_
M -(_^%>AM^,N#Q.ZOC7#MG<5##EL#N',]X[?S6+J]34V1PN4[8[%QE?CJ@*R
ML::IH)FB8 CT&PM[CGGJ:6UYXW6YMW*3QRQ2(R\0RQQD$?,$5Z%6PHLFQV,;
MBJ-%0@^8)((Z(_6[AV!U'OJBW-UWF=Z=QOL>MJ,=@-P;YK,)0[!Q^XLY35VT
MH9=JT^R]E'?/<^](TRG\-HH*84N-KY,DRTU54UX58)92UYKYQV'PN8I;;;=J
MD422E%;Q9$2CU</)X<,>-1)R-()4+Q!YEV;8]Q)VR.6ZOP2BJ2-*DXH"%JS>
M6*_;7H+-^5VY-U4_R4K>QL5-B][9FHR$>]<.V$7;-#!(_2>Q:/"KB<7'N[>6
M0HJ*NV.F,G<560^\6JFF$D5.P$*#CE6#:[/9-E@V.[:?;$#>#*V2WZ\A>O8@
MQ)J HM* 9/$A[>9+N7<KF2_A$=T=.I%X#M73YG\-//\ 9PZO(P53-683#5E2
M_DJ*O%8^IJ)-*)Y)IZ2&65]$:JBZI&)LH 'X'O#J90DTJ*.T,0/R/4UJ:JI/
M&G5*.3IY\C1;@V_254U!6[R[<W)L"@R%.VB?'Y#L+NC(;(H,A ]B$FH:S<"2
MJ3Z0R FPN?>7UG=&QY4M+\+4V^UI/0^?AVP>GYZ>H7GA%SOTUNW"2\*'_;24
M_P O5MV7Z+Z8W!6X3)9[JGKW-9#;F-Q>&PE=EMHX/(U>.Q&#?R83%PSU=%-*
M<?AIOW*2%BT=-*2\85SJ]XIV^_;Y:17,%KN]S'#,S-*D<CJK%L,2 0"6&"?,
M8/4OR6-E*\<DMI&TB4"LR@D4X4)'ET6_YC_\7?IW_J)WY_[K,'[DSV=_Y*>\
M_P#/.O\ Q\=!3G?_ '!L_P#FM_SZ>G[X8_\ 'L=N?^)C?_WTG4GLL]VO^5G@
M_P">-/\ C\G2SD__ )(R_P#-5O\ )T0_Y/?\"OF!_K[S_P#?0[=]S1[<?\JK
MRS_I6_ZOR= ;F?\ Y+E_]J_\<7JT#Y2_]DR?(L_E>BNW&4_D,NP-P,K _AE8
M @_@^\:N4/\ E;.5_P#I8VW_ %>3J4MV_P"25N?_ #SR?\</1-_C7_V4W@?_
M !!'</\ [\#X_>YP]W/^53MO^EC%_P!6;GJ/^2?^2K<?\\[?\?CZ$WY8[3ZN
MH<[C=XY?>?86W=_[DPHP%%M/K:DVAF,QO.@V]-4U,>6;&;RP^0PV#.W#FVBE
MS%5445!:HIZ6I-1*:"$ ;VWW?FQ4N-HV.QMYK(/XKR70<)$6 &61E8Z]/P@,
M30E0.X]"+F:RV9O#O-RFD24+I41$:G S2A!&*\<#.3T5+/=G;JW%M/9&P<+L
M:CV_U!L7>N/P,U5A5S&]9Z/<]%09N;'1;A[4W'E=GT&4S&2EFEFRU'CL)EJ^
MFK9E-1-&C^5Y#V7ES;-IYG>^W'F W'-=PCRF(*J+1AW_ *:ARH ^ LR @84\
M.@WN&YW=[LYAM=M\+9XRJ!V-3@]M"2*FO&@;[>C=?#C_ (N_<7_43L/_ -UF
M<]@7WB_Y*>S?\\[?\?/1[R1_N#>?\UO^?1T7/N;+U57W5WUF)=$[87,X#;V%
MDE#:H\-@.LMHY48Z10RL*:'=N=R\R@$$_=,U_5Q(WMM:QV_)VT,@H\QEED^;
M&5T!_P!X11^708YLF:7>[E3P140?9I#?X6/1XL'U#MC??QJZRZTR51E\?BZ#
MKWK+^#9C$5-+39_"Y#;6#PD^&R]!45%#58YZV"6D7RQSTLU)51/)#/#)#+)&
MT +S!N&T\UWN^VS*;SZF9F#@E6ULP=6%:T()X$$<000#U)+[?;7FUQV$JGP#
M&JBF"-(%"/F*=1-D=,X+X_X7L'?D6X=R[VW'_=>NG?)[C_@\0H,-M^BJ\M%A
M</BL%CL)C*>*KKD::HFD5ZJIDT*\WBA@CB6;_P V[GSG<[9;7L4,5NCZ5CA#
M :G(!9BQ9B:4'&@ P*DDI]MV:TV2*Y>V+L["K,Y!-%!H!0 4ZK5VNV7V_C>I
MFQM.^Z-U8O+[-R&+Q51C,AGY=W;HP]+_ !L-5P8]J>NGJWKZ!\F]1=6$]/Y&
MY^N2',5M82;#N=I<W0M-M,7AM*HQ&A95  ]"*+3T/47[5-<_O6WGB@\:ZU%P
MA--1H237^?0[]E;D^0O;J;.HMV],YO&X_9V[7WC3-@-C;L:NJJ\[/W;L^.E:
M3(Y.2G@I_M=WS2LVAV)B"@#466,^5HN2.5=PFW"VYP65GA,!1EH*%D>N 3@H
M.A;N[;]N]H+5]CT .'#!P<@$?+UZ4VU=H;VVW\??E[E-Q;=R.UL'N;JW=-7B
M,;G(119RKSN-ZWW1BMQ9F?&K+*:7&5.+I\12T[3>.IEDHYB4\(IW<KYOWK9]
MZYPY2DVJZ$S1RQ)(Z@Z:&<,J@D DBK$^61FM:+-AL+VPV?<X[R+1JU,JD@GX
M*$X)'ETG>C/^9]]:_P#4-O?_ -Y:K]C7W3_Y5*7_ )Z(O^?N@YR;_P E@_\
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M'/M/9E/D<HKR*(Q)2(A8,Z7A#D;8AO\ S%96LT.NQCK-<<::%R U*$!VHO\
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MI.#0@$>F#Z="LW44G*3_ $\X,D=LJ/I.5-%!!IP/2CZ?ZNV+WKT9MC Y&>7
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M*HU32"IK:^5V\]=7)KD:>I3R1-[=2W^[\\7N[7"EI"DLD[' 4N:!?*F30 <
M,"@P,^9UM[3E];6,@+5$C'K3/^ 5Z";I?OO8O2N>WIC]TQ[AR>;WQE=K4^W<
M!M;#2YG*U%%@<+D:C<>=JE,M+0X_!;?AR%,*B>>>,M-504\*RU$\,3BKW!Y6
MWCF?=K%-JA4K!:%I'=@JC4Y"K4\6<@T ]"30 D$_+.ZV6U[=.]Y(5#ST4 $D
M]JU-!Y#SZ3W9\F(J^WMU[HQ5=_%MN=X[>V-W)L_(R4TE-2Y7;\^Q-J]?U=)2
M0U<4-3+/C!L^CJJV.1!)3+F:9954NH]G_MQ<2#EX[/<)HOMNN);6:/S4F1Y
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M5V-V=GD3!9&62JRU#44$#-CZ1I*>65W>* *6_).WW'-.U;)M^_17UI)5[F2
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M*_+RJ7_Y(?)S<]1_-([=WE-T[NKN#MKI^N_T2?$[J6HP-1EL)C-TX&4T6-[
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M=JX+#;8VWBZ'![>V[BL?@\%A<93QT>-Q&'Q-)%0XW&4%)"JQ4U%0T<"111J
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MAIYZR9B2\KJ78GD^U-U?7M^ZR7UY+-(!I#2NSD#T!8DTZ;BAA@4K#$J+6M%
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8KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tboral_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tboral_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M)2C(SE'VEVW:=-[S!IN[CB$H?!0UKP--9_TPT\1I.#T';S=I):I;]B^OF?\
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MMW.?LB<\?]*QK_2)H.CNTW@&D=U_O0_RC_-UM^; [#V'VML_!=@]9;QVSO\
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MOY>W_>=_PT_]*?Z1_P#LX]V_JGS5_P!&R[_[)YO^@.M?5VO^_4_WH?Y^O?\
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M8T'56G:W\]?^5EU'6/C,I\J-N;TRB>0BEZIVSO7LZCD$=KE-S;/V[D]GG46
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MC_\ 9Q[]_5/FK_HV7?\ V3S?] =>^KM?]^I_O0_S]>_X<:_E[?\ >=_PT_\
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MG0AZ][]U[KWOW7NO>_=>Z][]U[K7(_GQ?\SW_DZ?^+Z[-_\ >QZI]RE[<?\
M)/W_ /YX)?\ CK]%>Y?'!_S47K8W]Q;T:=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW6G/WS_ ,)4LQNK<.\][]3_ #(QIR^Y<OF]Q4^U.Q.GZJ@QRY7,9"LR<M/-
MO/;6^LM4TV/\]4$4K@YY(T74?(383QM/O5]+;16E[M^H1JJZDEH=*@"NADXX
M_B /RZ(9MEUN722E:FA'F?G7_)UJE?*OXK=S_#+NS=/07?&W8=O;\VO]I5:Z
M"L7)X#<."R<;3X;=&V,ND<*Y3 9B!2T,A2*:-U>&>*&HBEB2<-BWW;N8MN3=
M-L8M&]10BC*PXJPS0C\QP()!!Z([BWDMI#%+Q_D>BZ>SCIGHZ?P?^ 7R0_F#
M]E97K/X[[<Q-;4[:Q$.>WGN[=F6;;^Q]E8FKJOL<?4[AS,='DJO[G*5:NE+1
MT=+5UU2(II(X6B@G>,.<R\U;1RI:+=[JS?J$A$0!G<C)T@D"@KDD@"HS4CI3
M:VDUVY6+RXD\!U?OA/\ A)U\@*C&TTNY/EKT[BLP\:FLH,)L7>NX,;!*54NE
M-EJ^KVS55<:N2 ST4)( .D7L(MD]\; .1#M\C+Y$RJI_,!6I^T]&@V-_.0?L
M_P!GI%=@_P#"4[Y?8:D:IZU^0WQ\WW-&49Z#<T>_^OZJ:/QR&1:-Z7;6^*&2
MH68(%6::GC9"S%U*A64VGO=LLC4OK.:(>J%)/VU,?^7[.JOL<P'8ZG[:C_/U
M3W\G?Y8WS]^"\QW=V]T?O?;6V<+5K/2=O[ K(MX;%H)(Y(UI:^?>VR:O()M"
M6>:0"G7*_P -JI&!"QW!]CW9^=.5>9E^FM+A&=Q0PRC2Y^6E\-_M=72":RN[
M7O92 /,9_F.'3ET#_-W_ )C7QOR%)4["^5?:.<Q-//%)+M'M/-R]N;2J:>,*
MCT"8CL3^\)P])41KI8XV2BG7]22(]F]UW3D#E'=D(N+*.-J4#1#PF'S[* G_
M $P/7HMPNX3VN3\CG_#ULL?"#_A45U_O2NPVQ/G-UK3]69.J\-'_ *:>K(<O
MFM@/5-XXUJ-T["JY,INS;%(]B9*F@J\ROD87IX(@76(.8_9F]M5:YY<E^H49
M\*2BR4_HL**WYA?E4]'%MO,;T6Y&D^HX?L\NMK39.]]F]E;2V_OWKW=.W][[
M)W7C*?,[9W9M7+4.=V]GL55KJI\AB<OC9ZBAKJ64 @/&["X(/((]PK/;SVLS
M6URC1R(2&5@592.((.0>CM65U#*:@\".E3[9ZWU[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=53?S4_Y7&"_F?[%ZOV?F.X\MTW5=5YK=>?PV
M6QNRZ/>\&0R&YL5C<8BY/&56X]L2-14'\-#E(JJ-YM977':_L9\E\XS<G7DM
MU% LXF558%BN U<$!L_:#]G2.]LUO$"%M-#7UZT__P"87_PGO^2?P>ZMSW>V
MTNQ=J_(GJ'9L,57OK(8+;N3V/OS:&*DG$$FY,CLFLRFYZ"MVO1/)&*JHH\O4
MU%*)#+)3K31RSI//*WNMM/,5\FV7,+6D\AHE6#HQ\EUT0ACY K0\*UH"076T
MS6\9E5@ZCCY']F>J /<J=%73I@\)EMRYK#[<P-!4Y7.Y_*8_"87%T<9EK,EE
MLK5PT..H*6(6,E365DZ1HOY9@/;<TT5O"T\S:40%F)X!0*DG[ .MJ"Q"KDGK
M9QZE_P"$KGS$W9M^@S/:_>'1_4F1R%)'5G:N/3=78N>P[RQ0.N/SU1C\?M_;
M<61AD:19109#(TZZ%*32:B$AJ_\ >S9(92EA:2SJ/Q,5C!XY4=YI]H!^0Z.H
M]DF(K(X4^@J?\W03]^?\)D_Y@G5.&R6X^LLKU#\B*#'Q+,NW]C;ER.UNP*J(
M2Z:F2GV_O[$X#;M2::G/E\4&;FJI@K)%$\FA'7;7[R<L7KK%?I+:$_B8!XQC
M%60EL\/@IZFG!N79KI!6,A_Y'^>/Y]:_><P.]>L]WUV W+AMT]?[^V9F?M\E
MA<YCLMM3=^U-PXJH63P5V.KX:#-8+,XVJC5M,B13PR*#8$>Y3CEM;ZV$D+)-
M#(,$$.CJ<'(J"#^SHJ(>-J&JD?D1U;/\-/YZ7S\^(>6QE'5=HY;Y!=703PKD
MNLN\LOE=X*<>KJ)8-K[ZKYZG>NT*F*GU+3+%53XV%R&DH9@NCV!.8/;+E??$
M+10BSF\GA 45_I1BBGYX#'^+I?;[I=0&C'6OHW^0];]7P(^??1?\PSI2D[?Z
M9R4M)7X^6FQ78O7&9GICO'K3<\T4DHP^?IZ=BE109!())<;D8A]KD*=&*:98
MYX8<8^9>6MRY6W$[?N*\<HXKHD7^)3_A'$'CT)[:YBNH_$C/VCS!^?1WO8>Z
M4=>]^Z]U[W[KW6.::&GAEJ*B6."""-YIYYG6*&&&)2\DLLCE4CCC1268D  7
M/OP%<#KW6J3_ #,O^%)FS.G\EN#I?X'T&W.U]^T(J<9G>^\\&RG5FUL@L@@G
M@V#AZ6:$]D9:D3R%<A+-#A()UC9$R<1DC6:N3O:2ZW)$W'F0M;PG*PC$KBF"
MQ([!\J%B*_#@]$MYNRQ$Q6_<P\_(?Y^M0_L7NSYB?/[MW 8_L#?7;?R1[7WC
MF:?%;.VDT^1S\CY6JB$$6-V1L3#10[?V[ \4;/)#C*&DIU'DE<"\C^YWM-MY
M=Y4L'EM8HK."-:N^ :5KWR-5FR<5)/ #R'1"TEQ=R ,2['@/\PZV+_B%_P )
M8NR-XX7$;O\ F;W2G4AR%+!5S=1]34>)W;O;'+4PQ2?9[A[!R,U5LK#9BA<L
MDL..HL_2L;%*O@@Q1OWO5;P2M!R];>-I-!+*2J&E<K&*,0?(EE/JO1M!LK,
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M?_,FOAS_ .)-[2_]Y7:_N;_9#_DK7W_-%?\ C_1)OG]@G^F_R= ?_P )*?\
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MCBA3-Q97$YJ1VD>2>ORE6UE55OE-[0;^VZ<OMM<[5EL6"BOG$]3'FN:$,OR
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M>Z#/NG_F3G;/_B,]^?\ O+97VHM/]RHO].O^$=5?X#]AZII_X3=_]NL>LO\
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MZ1W#5?Z1]QU%-)$VB3<$%/C7((;'>2,.L \]\]<[!&LC92;7 ]5+$%G?U F
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M7NO>_=>Z][]U[KWOW7NB:?S&O^W>WSO_ /%-/D__ .^1WQ[$'*?_ "M6V?\
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M*[_[<G=&?^*S=E_^YW8'LTYS_P"5\O/^>@?X5Z;L_P#<!/\ 2]!E_P )N_\
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MTSU]=KXH?]DM?&O_ ,0#TY_[[O;GO [=?^2I<_\ -63_ (^>A['_ &:_8/\
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MTD-!C,7CJ.!4@I*''T5.D4,2*$CC0*  />*#N\KF20EF8DDG)).22?4]"L
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MW3_S)SMG_P 1GOS_ -Y;*^U%I_N5%_IU_P (ZJ_P'[#U\?/WGQT >A_^)_\
MV5-\:O\ Q/\ TW_[\7;GLGYA_P"2!??\\\W_ %;;IZW_ -R(_P#3+_A'7UV?
M>"_0ZZ][]U[K5U_X4G_RY7[QZ8HOFUU9@_N.T/C]@9Z+MJBQ\,*U&Z^C:>2I
MR51N&<+'Y:K(]55TTM83=?\ <+55KNS"E@03'[1\V?NO<CR]>-^A=L/#K7MF
MX #Y/@?Z8+PST3;O:>+%]0GQ)Q^8_P!CK0Q]Y.]!CHU_PF^8'9_P6^1VP?D7
MU5-Y\KM2K>BW+M:HK)J/#]@;%RCPQ[IV+GI(HJ@+C\Y1Q Q3&&9J&NAIZR-#
M-3QV(N9.7[/F;:)-IO<!\JP%3&X^%Q]E<BHJ"145Z46UP]K,)4\N(]1Z=?4R
M^-'R.ZL^6?2.P>_NF\]#G]B=@8:+)43ZXOXCALC&33YG;&?I8I)?X=N+;F3B
MEI*VG8DQS1&Q9"K-A;NVU7NR[A+MFX)HEB-"/(^C ^8(R#YCH:12I/&)8S4'
MH=_9=TYU[W[KW5-?\]OYA1_$?^7QV@,)F&QG9_?<4G1/6XI:BHI\G3R;SH*M
M-\[BHIZ)XZW'R;;Z_@R,E/6HR"FR<U&-0>1 P]]M]A._<TP)(NJ&V_6DJ 11
M"-*D'!U-I!'I7TZ0;E<>!:M3XF[1^?'^76H;_P )X/C*GR$_F/;"W3F,>*W9
MWQPV]FN\,WYZ:.:BEW#B6IMN]=TC2S QPU]/O7<%+E8 %:1EQ,A6VDNL[>[.
M\?NSE-[:,TDO&$0S0Z?BD/V472?]-T1;1#XMV'/!!7\^ Z^D-[Q,Z%G7O?NO
M=>]^Z]UTRA@58!E8%65@"&!%B"#P01[]U[KY5?\ -,^+J?#WYY_(KI/&8QL7
MLVAWM/O#K6!*6.EHDZX[!@AWEM*AQH@5:::DV[09C^$L\85!48^1=*,I1<U.
M1]Z._P#*]I?R-JETZ),U/B1]K$_-J!O]MT"KZ#Z>Z>,"@K4?8<]5^>Q9TDZ^
ME/\ R"?F!%\K/Y?/7N$S>5:N[,^.+Q=%;XCJ9A)7U.*VU04TG6VX)!)--53T
MV5V'+24KU,MFJ,CCJSZZ"3B![F;"=CYJF,:TANOUDIP&LG6OH*-6@\E(Z&&V
M7'CVJUXKVG\N'\NKL?<?=&'7O?NO=>]^Z]U\B;Y8?]E3?)7_ ,3_ -R?^_%W
M'[SHY>_Y(%C_ ,\\/_5M>@+<?[D2?Z9O\)Z #V<=,]?7:^*'_9+7QK_\0#TY
M_P"^[VY[P.W7_DJ7/_-63_CYZ'L?]FOV#_!T/WM!U?KWOW7N@M[M[FZ[^/'4
MW8'=O;&?AVSUYUIMG)[KW1EY5,TL=!C8&D%)CJ-#Y\GF<I4:*:AI(@TU75S1
MPQAG=05FWV%UN=[%M]DNN69@JCU)-,GR'J3@#)QU21UB0R.:!14]?+A^3'>O
M:'\S'YTYGL&O22'=?R#[6VOL'K;;-3435%'M#;V7S.-V1UGLZG"/+&D>)QTU
M*M6\"HM77O456@23O?,S9]ML^3.5Q;C*VL3R2,* NP4O(W <2#2O!0!Y= R:
M1[VZU?QD ?(<!U]++_9)>C_^>=H?^R0/]DE_XMU+_P R/_YYWZ?\ ?\ IG_S
M7O#_ /?FX_[\/^Y'U/$_VW\7V_/CT,?!C]/PZ?RZ^3+[SHZ G7V6/?/_ *D#
MKWOW7NB-_P Q#YR;/_EY_&?</R+WALS<'8*46=PFT-N[1V]64&+ES.ZMR"M.
M(@RF:R'FCP>#44$K5-7'3ULT2*/'3RL0OL0\K\NW'-&\1[1;R+$6!8LU2 JB
MIH!Q/H,?:.D]U<+:PF9@33R'SZUG_E7\4/YE7S^^+OR ^:W\PGL:L^//4'4_
M3/8W<G0OPQV-"M,3D-O[-KL[M;(]@XZ:IJ4QKG[:-IY<TV1W(PEJ8(XL-&ZH
M);V/?.4N6-ZM-@Y5A%W//-%%->2>C.%<1</4TTT7 J9./11<07=U \]T="J"
M0@^617_5^SJYG^5/@<'@_P"2AT^^%PV)P[YKX\]J9O,/B\=1X]LMF:VMWX*S
M+Y-J2&$U^3JQ$HEJ)=<L@4:F-A[CWG:627GV[,C%M,X J2: :0 *^0\AT8V0
M L$H*=O2(_X3=_\ ;K'K+_Q)G<O_ +W%=[7>['_*[W/^DA_ZM+TWM/\ N"OV
MG_">@JZX_P"XFKO[_P 4*PW_ +D]*>U5S_TZ*W_Y[S_U;EZJO_)7/_-/_*.O
M?RG?^WL/\\#_ ,2WUA_[O.W??N<_^5(Y;_YIS_X8NO6?^YUS]J_X#U[^;%_V
M]A_D?_\ B6^S_P#W>=1>_<F?\J1S)_S3@_PR]>O/]SK;[6_P#H&?^%(?1VR^
MX=^_RS]I9&AH<%F^W_DFW2F;W_B\1C'W?2;1WCEM@8AZ:/)30>>MI<//F9:N
MFI9W:G2H+,%&MR3'VGW.YVZ'>+B,EE@M6F"$G07C#$$@'SI0GC3IO=HED\%3
M^)P*^=#TP8'Y9?S!OY'VXMO=4?.['YWYB_!3(9BDV]UY\K-JI-4=@;!IJB*8
MT6 SD.6KJFMJZBE2 LN$SU89O$7&+S-7!2BC5V39.5_<2)KSE@KM^Y %GM6_
MLY*<60@ #[5%,=R+74=">ZVXA+K]2+R<<1]O^K\SPZVLJ&L@R-%1Y"E8O2UU
M+3UE,[*R%X*J))X6*. R%HW!L0"/<,$$$@^71SUIH_S^_P"2_#0#>/ST^)^U
M8X*,FLW+\D^J-OT=/3TM'I1JG+=S;0QM,(E6.9U:;<E%"C$R,^24>JL(GWVO
M]PBICY9WQZC"V\K'(\A"Q]/)">'P\--"#=-NK6Y@&>+#_*/\O[>J0/Y37\TC
ML3^6QW8,C)_$]V_'7L2NQ])W9UA3-#+45--3)+34&^]E?=S04^.WWMA*@LJF
M2.GRU&&HZDJ?MJJDDCGKDJUYNV[LHEY"#X,G >IC?U4_M4Y&-08ML+UK27.4
M;B/\H^?7TM>J.UNO>\>N=G]L]4[JQ.]>OM]X6DS^U]RX2JCJJ'(X^K4\$H2]
M-6T<ZO!54\H2>EJ8WAE5)$91B%>6=SM]T]E>(8Y8R596%""/]7Y]"]'610Z&
MH/ ]"%[3=6Z][]U[KWOW7NO>_=>Z][]U[K7(_GQ?\SW_ ).G_B^NS?\ WL>J
M?<I>W'_)/W__ )X)?^.OT5[E\<'_ #47K8W]Q;T:=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW10>T/Y@7P<Z72N'9WRW^/.TZ['"J-5@:OMC9E;NL&BEJ(*N.#:&
M*RU?NBLFIZFEDB=(:.1Q,OCMKLOL[LN6^8-Q -C93R@T[EB<KGA5J4'YGIE[
MFWB_M'4?:1U\_K^>#_,)V-_,)^6^-W;T]-EJCI/J?8-#UQL#)9C%SX6IW75M
MF<ON'=.^%Q&1IX,SBJ;-UN4@HZ>GJQ'-]GC897A@EEEC&47MMRI=<K;(\6X@
M"YN'UN =6D !40D$@D9-1_%2IH.@MN5VEU.#'\*B@^?J>J:O<A]%W5E?\K/^
M8UO'^6O\CH^UL;@6WMUOO+#ILKN'84=2E'79W:+Y"GR-/EMMUDUZ2CWAM>O@
M%30M./!41M/22-$E29X@;SMRC!S?M/TA;PYXB7B?B U*%6''2W TR#0YI0K+
M&\:SEUTJIP1_F^?6\1U;_P *"?Y5W9F,HJFM^0E;UAFJFA^^JMK=G];]AX3(
M8O3X1+2U>=P^W-P[%J*R.28*(Z7+U#/I9DU*I(QPO?;#G6R8_P")^*H- T;H
MU?F%U!J?:H^?0E3<[)_QT^T$?['3_O7^??\ RHMD17G^5./W+6/2O54^.V5U
MMV[NB6H53(HA_B&.V&^"HZIWCL(ZFK@:Q#$!3J]M6WMISM=92Q90#3O>-/Y,
MX)_('K;[E9)QD!^P$_X!U4#\LO\ A5/M"CQN8VW\+NBLWFLY*E31T/:'>K4N
M&P6.ELB)E,7UQM?*Y'*9Z-@SM!]]E<6494:6G<%HO8\V/V4NY'6;F&Y6-,$Q
MP]SGY%V 5?R#=()]Z0 K;K4^IP/V?\5UJW9W)_-+^9?\@,GN6KH.UOE!WINE
M:=*E<#@:W/3XC"Q5$BT5%28S!T4.W]B;)Q4U4_CCCCH<72&1W.@N[&:(UY;Y
M+VI80T=G;)4]S4+-YFIJSL?S/ < .B4FYO9BU"['^7^8=;,O\N;_ (3)U<5;
MM_M?^8;E:800"')4?QIV1G$J6FG*(\5+VEV#@ZIJ8PT[LWEQNWZB1975"<F8
M_) \/<V^\)=7L>55(!P;AQFGK$AX5_B85H?A!H>CBTV>E)+K_>1_E/\ FZW#
M=G[.VGU]M;;^Q]B;:P6S=F[4Q-%@ML;5VQBJ+![>V_A<= M-08K#XC&PT]#C
MJ"C@0)'%$BHH' ]P///-<S-<7#F21R69F)+,QR22<DGS)Z/E4* JB@'D.E'[
M:ZWU[W[KW7R,/E]2YZA^6?RAH=TECN>C^1/==+N,NDT;G/4_96YH<N6CJ:FL
MJ$8Y!)+B2:5P>&=C=CG/RX8VY>L#%\)MX*?9X2T].@+<U^HDK_$W^$]%V]G/
M3/6YW_PDKQN[H\9\XLO*E8FPZNOZ#QM#),TAQ\^[L=3]M5663'JUXEK*3#92
MB-85TLR34NK4 FG'KWR>W,VVQK3Q0LQ/KH)C"U^50U/SZ$.QAM,A\NW]N:_Y
M.MQWW G1_P!>]^Z]U[W[KW7O?NO=(+L#M3K#J?%Q9SM/L?876F%J&J$@S'8&
M\-O;-Q<STE.]95I%D-Q9'&TDC4U)&TL@#DI&I8V47]J+>UNKM_"M(WE;T12Q
MSC@ >JLRJ*L:?;U15_-"_G>_"WJKXT]Q]==%]Y[/[P[X[(Z]W9L/8]#U#DXM
M[[<VS6[LQ-=MN3>>>WY@VJMETM-MF.N>KAI8ZZ>MJYXXE2$PL\J2/R?[<\P[
MAN\$^XVKVUK$ZM(908RP4AM*HU&):E*TH/,]%UWN5O'$PC8,Q! IG\R1CKYW
M/O+'H)=>]^Z]UO\ '\NO_A15\3NR^G]A;&^8N^Y^D._=MX*@VWN3<^X,!G<C
MUUV16X:A6F7>-!N;;F,RM+M?(9ZEI?N:^ERL>/IH:YWCIIIE:)?>+?-?M3OM
MA?2W&Q1?56C$LH4CQ$!/P%"06I6@*UJ,FF:"FTW:"1 LYTOYUX'YUZL<WM_.
MF_E=;#V_5[BROS'ZMS%-2!0,=LD[AW]N"JFD8)##28#9N#S>6D,DC &0Q+!$
M#JE=$#, G;<@\Y74PACV^92?-P(U_-G*C^>?+I6U_9H-1D'Y9_D.M7O^;'_P
MH;RGRAV3N?XW?#K";GZZZ=W51U6#[%[5W/X<5V#V-@*M)J3);2V_@J&>L39N
MR\Q3,5K)IJF3)Y.FE-.\5%%YXZF9>1_:D;3<)N_,++).A#1Q+E$84(9V_$P/
M  :016K>1-?;MXJF&VJ >+>9^0ZUINNNM.Q.WMWX?K_JO8V[.QM\9^?[?"[2
MV3@,GN7<.2E%B_VN*Q%-5UDD<*G5(^C1$@+.54$^YAO;ZSVZW:[OY5AB7BSL
M%4?F?/T'$^71.D;R-HC!8GR'6[)_)R_X3]S] [HVI\J?F[18;+=M;?FHL_U9
MT3!-19W!]8;AI9DJ\=O7?>8H:JLPVYM]8B9$DQM#2--CL14(*HSU-6(/L<=.
M?O='][POLG+I*6[562;*M*O H@(!5#^(GN88HHJ&$6W[7X)$]QEAP'D/F?G_
M (/\&U[[A3H[Z][]U[KWOW7NB2?/#X"]"?S">F:OJ3NS#RPUM U5DNO>Q<)'
M31[TZUW--3^%<SM^MGC=)Z&JT(F0QTUZ3(0HJR!9$AFB$'+?,NY\K[@+_;6^
M3H?@D7^%A_@/$>72>YMHKJ/PY!]A\P?4=?.>_F _RNOE'_+NWI4XSMC:T^Y.
MKLADYJ78_>FT:"OJ^N]U4SRS''4N0K#%(=G;OGI(M4V&R#K.KI(::2KIT%2^
M6/*O.VR\UP V;^'.!WPN1K7U*_Q+_2'RJ%)IT$[JQGM&[Q5?)AP_V.BK?&_Y
M(=P_$WN':/>G1>[JS9O8.S:SST=9!>;'9?'3%%RFVMRXMG6FSFV<Y3+X:RCF
MNDB$,I614=3O>=FV_?MODVS<X_$BD_:I\F4^3#R/Y&H)'3$,TD$@EB-"/]5#
MUON? #_A0Q\0?E'@,)M7Y![BP/Q:[T6"&ERM!OG*#']2;GK8T@CFRFTNQ\EX
M</@Z>NGD++CLY-1U,!/BBFK AF;&'FCVMW_8Y6FVY&O;;R:,5D49P\8J<4XJ
M"/6G#H46NZ6\X"R'0WH>'Y'J_7#9S"[CQM+F=O9C%Y[#UT23465PV0I,IC:R
M%U#I+2UU#-/2U$3HP(9&((-_<9NCQL4D!4CR(H?V=&0(.1TANT^Z>H>CMMU>
M\.Y.S]A=6[7HH6FJ,[O[=>$VKC@BLJ:8JC,UM(M3,\C!$CCUR.[!54L0/:BT
ML;W<)A;V,3S2-P5%+$_D >M.Z1C4Y 'S-.M-?^<!_P *$\9V_M'=/QA^".2S
ME#LG<<%;@.S?D)/35NW\GNO 5*34>3VGUABJZ"FS>&P.9IW\=9F*M*6MJ(&>
M"G@BC8U$L^\A^U<EI.F\\SJ-24:.## -Q#2D5!IY**BOQ'\/0?O]U#J8;4\>
M+?Y!_GZUC/CU\;>\OE9V5B>H_C]UON/LW?F7'E3$X&F3[7%X])8H:C-[DS59
M)383:^WJ.29%FK\A44U)&SJIDU.JF9MWWG;-BLS?;K,L,8\SQ8_PJHRQ^0!/
MGPZ)H8);A_#B%3_@^WKZ#W\HC^2]UQ_+LP,':/8E7B.S/EGN/"RT&>WG1I--
MM/K;&9*-?XAM#K&.OI:6L85"?M5^:J(H:S((#''%34[20R8K\]>X%YS;-]+;
M@PV*&JH?B<C@\E"17T45"^I.>A58;>EHNILN>)]/D.KRO<==&/7O?NO=!_V)
MVQU9U#AUW%VSV7U_U?M]A5E<YV)O+;FRL.PH*62NKBN3W+DL91$4=%$TTOK_
M &XE+M903[46UG=WL@ALXGF<T[45F.3084$Y..JLZH-3D ?/'5#7\U+^=Y\,
M^M?B_P!R]8=!=W;0[S[W[2Z_W1UWL^DZGR-+O/;&TVWEBJG;F0WMN#?&/@R>
MR$BVSC\C+54U%'45=375D<41A6!Y:B&2N3/;KF"_WF"YW.U>VM875W,H*%@I
MU:%0Z6[J4K2@&:UH"6WFXV\<++$P9B"!3-/F3PZ^>9[RNZ"?3GA,SD]N9G$[
MAPM7)C\S@LG09G$U\2QO+19/%U45;05<:S))$TE-50(X#*RDKR"./;<T4<\3
M03#4C@JP]010C]G6U)4AEXCKZ5OPZ_GG_ 3Y,=9;6S6^.^>N_C[VH<1CX]_=
M=]R[BH>NZ;"[E6FC3*?W?W;NJ;'[3W'MVHK5DDHIX*YJ@4[)]S#!-JC&(&^^
MW/-.SWCPPVLEU%4Z)(5,FI?*JJ"5/J"./"HST,(-QM)D#%PI\P<?X>K<-H;W
MV7V#ADW%L+=^U][[?DJ)Z2/.[0S^*W+AGJZ4JM32ID\-5UM$U13LP$B!]2$B
MX'L#RPS6[^'.C(WHP(/[#3I<"&%5->E!5TE)D*2JH*^EIZVAK:>:DK*.KACJ
M:2KI*F-H:BEJJ>97AJ*>HA<HZ."KJ2""#[;!*D,IH1UOKYSG\[+^4/N_X*=J
MY[NKJ';==E_B!V-GWKL!7XRGFJTZ5W!F:@/)UQNQHT8T&!;(3,FWJ^6T4],T
M='([5<1:?*[VYY\@YCLDVO<7TW\2T-3_ &RC\:^K ?&./XA@G2$]RL&MG,L8
M_3/_ !D^G^;]G5"7N4>BOJXW^3__ #7=Y_RW.W:C&[E7,;N^,79F1I1VML"A
MDCEK,'E---0TW:&RZ>HTQKNK#4$"PU5*)(8LQ0(()6$L-)-3Q[S]R/!S;8B:
MWHE["/TW/!ER?#;Y$FH/X3\B>C';[XVCZ6RC<1Z?,=?1AZ#^1727RAZZP_:W
M0G9&V.R]CYJ".6'*[=KXYY\?.X;R8O/XJ3Q97;F<I71DGHJZ&GJH74AD'O%#
M<MLW#:+MK'<HFAE3BK"GY@\"#Y$5!\NA9')'*NN,A@?3HM'>_P#-/_E\?'+&
M9:M[)^5_3KY/$4[33;-V1N[%]C[\FE('@HXMF[%GS^=AJ*IF 0U$,,(!UNZ1
MAG!MMG)_,^[LHL;*5E8T#LA2/_>WHO\ /IF6\MH?[1P/E6I_8.OGY?S9?YEF
MZ/YEGR&IM^QXC*;-Z9ZYQU?M;I3K_+5%-/D\3A<A5PU6<W5N44,U3CH]Y[VJ
M**FDKXZ:6:GI:>CI:1):@4WW,V4O(O)\7)^UFW=A)<S$-*XK0D"BHM:'2M30
MD DDF@K0!:_O#>2A@**N #_,GHUG\@3^8ST-\ ^].W*/Y%/D-N]?]Y;4VIA%
M[+QV$K]Q#8V;V;E,S7T*YK%82DK]PR;;ST&?F2HEH8*J6&IIZ8O"T1>6$B]T
MN4]TYGV^WDVD!Y+5G)C)"EU<+4J20*C3P)%030UP7]JNXK:1A-@-3/I2O^?K
M>DZT_F!?!KN&:CH^M/EW\<]V9:O$9I-O4/;^QH-U2B6HI*.(_P!TZ_-4FY8Q
M+65\,*ZZ5=4TJH/60/>-MYRUS#MZF2]L9XE'XFB<+P)^+33@">/ET)$N;>0T
MC=2?D17]G1OO9)T_U[W[KW03=L=]='=#8F'.]W]Q=7]08>I2=Z/)=F;\VOL>
MDKOMGIXYTQ\NY<IC1D)DEJXD\</D<R2HH!9U!6V6W;AN4G@[?!)._I&C.?V*
M#Z=4>2.,5D8*/F:=?/I_X4*_+/XP_+OYB;(W=\:=S4V_Z38G3F-ZYWQV)B:+
M(4FVMQYK';OW9GJ"BP,]>M*,[3X&CW"\;Y**G$-095CCFGBAC*91>U&Q[UL>
MQ2Q;NAA$LOB)&U-2@JJL6 R*Z1@FHI6@KD+;M/!/.#":T%"?+CU0M[E'HKZM
M4_E&?S)LQ_+8^24F_,KC<MNGI/LC%4VT.Z]FX44SYFKPU)4RUN W;MJ&MJZ"
MAFW9LS(5$KTT=1-'#4T=75TQ>)IUGB _/O*"<W[2((B$N8"6A8UI4X9&H#A@
M!FF" >%05VWWGTDU6RK8/^?KZ"O1G\SOX _(S&XFMZN^6'2U9D<S%!)2[/W1
MO7$;![ 26;0K4LVP]\5&W]UF>">01.8Z22(N1I=@REL6=RY2YEVAF%_93(JF
MA<(6C_*1:K_/H517=M-_9N#7RK0_L.>C7=@]M=5]2T%-E>U>S.ONL\96+6M2
M9'L'>>W-F4%4N-A2IR+4U9N/)8VGG6@IY%DF*L?$C!FL"#[);>TNKQ_#M(GE
M;&$4L<X&%!Z>9E7+$#[>JJ/F#_/0^ /QHZSW1F]D][]??(/M)<5D(MA]==,[
MBHNP(,WN3P21XT9[=VV),EM/;6WH*TH]745%:)S3!C30U$NF-AKL7MSS3O%X
MD,UK):Q5&N293&%7SHK4+'T ''C09Z13[C:0H2'#'R -?\'7S4LWF<GN/,Y;
M<.:JY,AF<[DZ_,Y:OE6-):W)Y2JEK:^KD6%(XEDJ:J=W(554%N !Q[R_ABC@
MB6"$:40!5'H * ?LZ![$L2S<3TV>W.M=;UW\L;_A0=\+]M_$WIWI[Y;[YW-U
M!VETQL7;W6%3G:S8F_NP-N;ZP6R<738#:^XZ')]>[>W?FH<O6;?H:=<C'D*6
M%C7)+(LDJ.&]XS\W^UG,4F^W%[L<2SP7#M( 'CC*%R69"KL@H"32E12G XZ$
MUGNML(%2<E644X$UIYX!ZM=A_G9?RKYXHID^9?6RI-&DJ";%;\IY0LBAU$L$
M^T8YX) #ZD=5=3P0"+>P.>0.<@:';I<?(?Y^E_U]G_OQ?V](7?O\^[^5/L''
MBLD^4=!N^KEBGEI,-L+K[M#=&0JC3F,/$:FEV;%@\;*YE&@5M92B3DJ2%:RJ
MU]M>=KMB$L60"E2[1H,_Z9@3^0/5'W*R3BX/V5/^#K3T_F[?SHNP/YC^3Q_6
MFP,)F^IOBUM7)IF,9LC*5M+)N_L7<5,94H-V=ER8FHJ<7 N*@D(Q^%I9ZJDH
MIGDGDJ*N;P/33YR'[>6W*:F]O&6>]<4U@'1&OFL=0#4^;$ D8  KJ#]_N+7?
M8@TH/+S)^?3%_P )^NA$[V_F>=*U-=2T]9@.C\9NKOO.P5$32V?9%'!B=G54
M%@4CJ,?V7NC!U"LW $1MZM/MSW5W,[;R;.BU#7+)""/Z1+-7Y%$8?GU[:HO$
MO%/\(+?Y/\)Z^E?[Q%Z%W7QI_?0#J/\ K[+'OG_U('7O?NO=:]?_  IK_P"W
M9E1_XG[JC_W&W9[D_P!H?^5SC_YI2_\ '>BS=_\ <)OM'^'JP/\ F)?]NM?E
MY_XIIVG_ .^LR?L+<I_\K?MW_/7#_P!75Z4W?^X<G^D/^#HO?\KO_MR=T9_X
MK-V7_P"YW8'LQYS_ .5\O/\ GH'^%>J6?^X"?Z7H,O\ A-W_ -NL>LO_ !)G
M<O\ [W%=[,?=C_E=[G_20_\ 5I>FMI_W!7[3_A/05=<?]Q-7?W_BA6&_]R>E
M/:JY_P"G16__ #WG_JW+U5?^2N?^:?\ E'7OY3O_ &]A_G@?^);ZP_\ =YV[
M[]SG_P J1RW_ ,TY_P##%UZS_P!SKG[5_P !Z]_-B_[>P_R/_P#Q+?9__N\Z
MB]^Y,_Y4CF3_ )IP?X9>O7G^YUM]K?X!U[^?%_S/?^3I_P"+Z[-_]['JGW[V
MX_Y)^_\ _/!+_P =?KVY?'!_S47I1_\ "FO_ +=F5'_B?NJ/_<;=GNGM#_RN
M<?\ S2E_X[UO=_\ <)OM'^'J_'9W_'H[6_\ #<PG_NLI?<9R?VC?:?\ #T9#
M@.E!+%'-')#-&DL,J/%+%*BR1R1R*5>.1&!5T=200000?=.M]?/7_P"%!W\L
M;KSX3=N[1[VZ0EH<#U)\C\YNMI.K8TDC3KOL#$+1Y?<$.U$2$4L&P<Y#EUJ*
M.BUWQ<XEIX5%)]M%#E)[5\Y7?,%D^T;E5Y[15I)_''\(U_TAPK^(9/=4D+;K
M9+;N)H\*YX>A^7RZL7_X2==F[_R^)^8'4V5W9F,CUQLH]0[NVCM"LJ/N,3MO
M<.\ZCL:BW5D<-'*K2X\YZ#;=":F*-UADDIQ(4\A9F"GOA96L4]A?1QA9I1*K
ML.+!/"T ^M-1H>-,< .E6QNY$D9.!0@>E:UZW%/<#='_ %[W[KW7O?NO=>]^
MZ]U[W[KW6N1_/B_YGO\ R=/_ !?79O\ [V/5/N4O;C_DG[__ ,\$O_'7Z*]R
M^.#_ )J+UL;^XMZ-.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K3ZWK_PE"_OAO+=
MN[O]GV_AW]Z=SY[<?\/_ -E;^[^Q_C>5J\G]G]W_ +,92_=?:_=:/)XH]>F^
ME;V$\6?O9]):16O[LU>$BI7ZBE=*@5IX!I6GKT0OLFMR_BTJ2?A]?]MTF/\
MH$?_ /!@7_LJ7_ZR?M1_KZ?](O\ [.?^W?JO[B_X;_QG_H;KW_0(_P#^# O_
M &5+_P#63]^_U]/^D7_V<_\ ;OU[]Q?\-_XS_P!#=>_Z!'__  8%_P"RI?\
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MG8LQ^TL2>EZHJ+I0 #T&!TOO:?JW7O?NO=>]^Z]U[W[KW6K_ /S?/^$_]?\
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MO]?3_I%_]G/_ &[]>_<7_#?^,_\ 0W7O^@1__P &!?\ LJ7_ .LG[]_KZ?\
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M4,4"Z(5"C_5QZ,![+.G>O>_=>Z][]U[JI#^;+_*R_P"'1-F].;1_TZ_Z#?\
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M_P"LG['W^OI_TB_^SG_MWZ0?N+_AO_&?^ANO?] C_P#X,"_]E2__ %D_?O\
M7T_Z1?\ V<_]N_7OW%_PW_C/_0W7O^@1_P#\&!?^RI?_ *R?OW^OI_TB_P#L
MY_[=^O?N+_AO_&?^ANE/LK_A*%_<_>6TMW?[/M_$?[K;GP.X_P"'_P"RM_:?
M??P3*TF3^S^[_P!F,JOM?NOM='D\4FC5?2UK%/>>]GU=I+:_NS3XJ,E?J*TU
M*16G@"M*^O5DV30X?Q:T(/P^G^VZMO\ YN'\H_\ X=-_V7[_ )R!_P!!7^@K
M_2M_S2G_ $G?WI_TG?Z-O^_D]>_P3^"?Z/?^FS[G[S_=7B_< _(O/7]2OJO\
M5^I^I\+_ $7P]/A^)_PMZUU_*E/.N%U]8_6Z._3IKY5K6GS'IU33_P! C_\
MX,"_]E2__63]R!_KZ?\ 2+_[.?\ MWZ+_P!Q?\-_XS_T-U[_ *!'_P#P8%_[
M*E_^LG[]_KZ?](O_ +.?^W?KW[B_X;_QG_H;KW_0(_\ ^# O_94O_P!9/W[_
M %]/^D7_ -G/_;OU[]Q?\-_XS_T-U[_H$?\ _!@7_LJ7_P"LG[]_KZ?](O\
M[.?^W?KW[B_X;_QG_H;KW_0(_P#^# O_ &5+_P#63]^_U]/^D7_V<_\ ;OU[
M]Q?\-_XS_P!#=>_Z!'__  8%_P"RI?\ ZR?OW^OI_P!(O_LY_P"W?KW[B_X;
M_P 9_P"ANO?] C__ (,"_P#94O\ ]9/W[_7T_P"D7_V<_P#;OU[]Q?\ #?\
MC/\ T-U<%_*8_DX8#^5WF^Z-TR]W_P"G?=/;6+V=M^BR[]71]9_W/P&V:O.Y
M')XVFA'8/8$N5_O-D<E22SL9:98_X;$ C$D@ \\\^R\YK;Q?3?3);ES3Q/$U
M,VD5)T)2@7&#Q.>C"QL!9:CJU%J>5*4_,]75>X]Z,.OC3^^@'4?]?98]\_\
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MW[KW7O?NO=>]^Z]UKD?SXO\ F>_\G3_Q?79O_O8]4^Y2]N/^2?O_ /SP2_\
M'7Z*]R^.#_FHO6QO[BWHTZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KXT_OH!U'_7
MV6/?/_J0.O>_=>ZUZ_\ A37_ -NS*C_Q/W5'_N-NSW)_M#_RN<?_ #2E_P".
M]%F[_P"X3?:/\/5@?\Q+_MUK\O/_ !33M/\ ]]9D_86Y3_Y6_;O^>N'_ *NK
MTIN_]PY/](?\'1>_Y7?_ &Y.Z,_\5F[+_P#<[L#V8\Y_\KY>?\] _P *]4L_
M]P$_TO09?\)N_P#MUCUE_P"),[E_][BN]F/NQ_RN]S_I(?\ JTO36T_[@K]I
M_P )Z"KKC_N)J[^_\4*PW_N3TI[57/\ TZ*W_P">\_\ 5N7JJ_\ )7/_ #3_
M ,HZ]_*=_P"WL/\ / _\2WUA_P"[SMWW[G/_ )4CEO\ YIS_ .&+KUG_ +G7
M/VK_ (#U[^;%_P!O8?Y'_P#XEOL__P!WG47OW)G_ "I',G_-.#_#+UZ\_P!S
MK;[6_P  Z]_/B_YGO_)T_P#%]=F_^]CU3[][<?\ )/W_ /YX)?\ CK]>W+XX
M/^:B]*/_ (4U_P#;LRH_\3]U1_[C;L]T]H?^5SC_ .:4O_'>M[O_ +A-]H_P
M]7X[._X]':W_ (;F$_\ =92^XSD_M&^T_P"'HR' =*/W3K?6I!_PK+_YDU\.
M?_$F]I?^\KM?W-_LA_R5K[_FBO\ Q_HDWS^P3_3?Y.@/_P"$E/\ Q]WSG_\
M#<^/G_NS[B]FGOG_ &>V?;<?X(>F=BXR_P"U_P O6Z?[Q\Z$/7O?NO=>]^Z]
MU[W[KW7O?NO=:Y'\^+_F>_\ )T_\7UV;_P"]CU3[E+VX_P"2?O\ _P \$O\
MQU^BO<OC@_YJ+UL;^XMZ-.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^-/[Z =1_U
M]ECWS_ZD#KWOW7NM>O\ X4U_]NS*C_Q/W5'_ +C;L]R?[0_\KG'_ ,TI?^.]
M%F[_ .X3?:/\/5@?\Q+_ +=:_+S_ ,4T[3_]]9D_86Y3_P"5OV[_ )ZX?^KJ
M]*;O_<.3_2'_  =%[_E=_P#;D[HS_P 5F[+_ /<[L#V8\Y_\KY>?\] _PKU2
MS_W 3_2]!E_PF[_[=8]9?^),[E_][BN]F/NQ_P KO<_Z2'_JTO36T_[@K]I_
MPGH*NN/^XFKO[_Q0K#?^Y/2GM5<_].BM_P#GO/\ U;EZJO\ R5S_ ,T_\HZ]
M_*=_[>P_SP/_ !+?6'_N\[=]^YS_ .5(Y;_YIS_X8NO6?^YUS]J_X#U[^;%_
MV]A_D?\ _B6^S_\ W>=1>_<F?\J1S)_S3@_PR]>O/]SK;[6_P#KW\^+_ )GO
M_)T_\7UV;_[V/5/OWMQ_R3]__P">"7_CK]>W+XX/^:B]*/\ X4U_]NS*C_Q/
MW5'_ +C;L]T]H?\ E<X_^:4O_'>M[O\ [A-]H_P]7X[._P"/1VM_X;F$_P#=
M92^XSD_M&^T_X>C(<!TH_=.M]:D'_"LO_F37PY_\2;VE_P"\KM?W-_LA_P E
M:^_YHK_Q_HDWS^P3_3?Y.@/_ .$E/_'W?.?_ ,-SX^?^[/N+V:>^?]GMGVW'
M^"'IG8N,O^U_R];I_O'SH0]>]^Z]U[W[KW7O?NO=>]^Z]UKD?SXO^9[_ ,G3
M_P 7UV;_ .]CU3[E+VX_Y)^__P#/!+_QU^BO<OC@_P":B];&_N+>C3KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IESNY=N
M;7HSD-S9_";=H ')KL[E:'$48$8#2$U.0GIX0$4@GU<#VBOMQV_;(3<[E/';
MQCB\KK&HIQ[G('2[;]KW/=IOIMKMY;F0_@BC>1L\.U 3T%2?)CXZ257V:=\=
M/-/H#BW9&T/"P9E14CJOXO\ :R3%F'[:N7_PX/L%K[M>UCRB%.9-K+'A2_M<
MUP #XM"?EQZ&#>U7N<L7CMR[N07_ )XKFOVE?#J!\Z4^?0KX;<6W]Q4YJ]OY
MW#YVE%KU.&R=%DZ<:A=;S44\\8U#Z<\^QM:7]CN$?C6$T<Z?Q1NKC]JDCH'7
MNV[CMLG@[C;R6[_PR(R']C 'IX]J^D77O?NO=>]^Z]U[W[KW46NKJ+&4=5D<
ME64N/Q]#!+55M=75$5)1TE- ADFJ:JIG>."G@AC4LSNP50+DV]M330VT+7%P
MZQQH"S,Q"JJ@5)8F@  XD\.G8()[J9+:U1I))"%5%!9F8F@55%22?(#)ZB8/
M/83<^)HL]MO,8O<&#R41GQV9PM?2Y3%9" 2/$9Z'(4,L])5P^2-EUQNRW!Y]
ML;?N%ANUE'N.USQW-O,-4<L3K)&Z_P 2.A*L/F"1T_N&WW^U7DFW;I!);7$1
MH\4J-'(AH#1T<!E-#P(!Z=?:SI'U[W[KW7O?NO=>]^Z]TE?[];(_Y[':O_H0
MXC_ZL]EO[YV?_E+A_P"<J?\ 071M^X-]_P"4*?\ YPR?] ]>_OULC_GL=J_^
MA#B/_JSW[]\[/_REP_\ .5/^@NO?N#??^4*?_G#)_P! ]/\ 15]#DH!58ZMI
M*^F8@+4453#50,2B2 "6!Y(R3'(K?7Z,#]#[6Q30SIXD#JZGS4@CUXCHOGM[
MBVD\*Y1HV'DRE3Z<"!Z=2_;O3/7O?NO=>]^Z]UBGG@I8)JJJFBIJ:FBDGJ*B
M>1(8(((4,DLTTLA6.***-2S,Q 4"YX]U=TC0R2$*J@DDF@ &223P ZO'')+(
ML42EF8@  5))P  .)/D.DU_?K9'_ #V.U?\ T(<1_P#5GLO_ 'SL_P#REP_\
MY4_Z"Z,_W!OO_*%/_P X9/\ H'K+!O/9]5/#2TNZ]M5-34RQP4]/!G<7-///
M,XCBAABCJFDEEED8*JJ"6)L.?=DW;:I'$<=S$S,0 !(A))P  #DGJDFR;S%&
MTLMI,JJ"23$X  R225P!YGI2^S#HLZ][]U[KWOW7N@WQ'</5F=R&Y,5B^P-I
MU&3V?G:S;6YL?)FJ*DK,/FZ"1X:N@JZ:LEIY0\,\;QZU#1F2-U#%D< -6'.7
M*FZ7%U:6&XV\DMC,T%P@E35%,AHT;@D$$$$>E01Q!H)[WDKF[;K:UO+S;;A(
MKV)9X'\)F66)P"KJR@C((-.-"#2A%7[^_6R/^>QVK_Z$.(_^K/9G^^=G_P"4
MN'_G*G_071=^X-]_Y0I_^<,G_0/7O[];(_Y[':O_ *$.(_\ JSW[]\[/_P I
M</\ SE3_ *"Z]^X-]_Y0I_\ G#)_T#TP9/N+JW$9C;6WJW?NV!G-X96/"[:Q
M-+E:?(Y#*Y*4$I#!2XYJJ6..XL99 D*L0"X+ $MN^<.5K&^M-MNMP@6XOI/"
M@C$BL\KTK154D\!D\!YG(Z,;3DKFV]LKK<K?;IS;V49EGD:-D2-!YEGTBOR%
M6.:#!Z$GV).@QU[W[KW7O?NO=>]^Z]U%KJZBQE'59')5E+C\?0P2U5;75U1%
M24=)30(9)JFJJ9WC@IX(8U+,[L%4"Y-O;4TT-M"UQ<.L<: LS,0JJH%26)H
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MVZ]F;9WB]7#!28W-Y/S;<SN!^RJ#C'R<M9)5YC#9:GJ?+'!6FHYBG21GC*J
MW[]^W5W[!<P6/-OM=>7.W65^Q4I'-)2&>'2RH79RTL<@)8)+K%5D#$JP4"#V
M-]P;?WRY>O>6?<>TM[^[L0I+/%'2:&;4NL(%"HZ%=):/3Q0J P)-H'P<^2&3
M^1G4T^1W4L WWLS*#;VZ:BE@BI:;,"6G6LQ&?AI(?VJ1\A2EHYHU"I]S3RLB
MI&R(N8'W>?=:[]UN1SN&[J%W&QE-O<E0%60Z0\<RJ"::E:C# UJU %H.L3/?
M_P!KK3VPYR6UV@D[??1^-;AB6:.C%9(2QR=+94FIT,H)+ DG0]SSU!?7O?NO
M=-N9P^+W%A\MM_.4-/D\+G<;78?,8VK3R4N0Q>3I9:+(4-3'<>2GJZ2=XW7\
MJQ'M+?6-GN=E-MNX1K-;W"/%+&XJCQR*5=&!XAE)!'F#TJL;V[VR]AW*PD:*
M>W=)(W4T9)(V#(ZGR*L 1\QUKM_S&NA^O.D^R=ER];82/;6%WEMBLK:W!4U3
M5U%#39;$Y(TL]51)62U$E)#64M5"#$K^,/&Q55U&_+C[V/MMRMR!S1MMSRG;
M+9P[C!(7A0GPQ)"Z@NBFNG4K@%0=-5J "37IE]V#W#YEY\Y7OX^:;@W<]C.B
MI*RJ':.1-05RH&HJ5;)%:$ DTZ-[_+;^-O5>:ZMQG=&Z=KT6X=]#?5?5;:RM
M?45LJ;;BVM58\8N2@QXFBQ\>1AS-))4BH:.2470!@ 5]SI]T_P!I^2[ODBWY
M_P!VLH[O<GNI'AEDJW@"VD"Q^&A.E6#QE]="U2.Z@ $*_>D]TN;['F^;D3:+
MM[;;_I$6>- H\<W"N9 [T+%2C!--0..#6O5O/O-WK"WKWOW7NO>_=>ZI5^.7
MQ"V9\ANU/D+W#VYCZ_*[1D[F[!QFV=OT]?D<%!FLE)N?)9/-92MJ\54T63%%
M0"LA@A2"=%>9I@Y_: . WM?[#\N^Y7.?-7///4+SV3[M?Q6T >2%9&%S(\LS
M-$R.0I8(H5@-6NM:"F=ON=[U[[[:\H<L\D\ERI#>C;+*2>8HDIB3Z=$BC59%
M=-3:2S%E)"Z*?$>@W_F+?&WI;HC;G6%?U3LS^ZM7N+-[CH\Q+_>+=F<^\IZ"
M@QDU)'X]QYW,1T_BEJ'-XE1FOR2 + _[U'M'[>^V^P[5>\E[?]%+<W$B2-X]
MS-J58PP%)YI0*'S !Z%7W8_=/GSW#W;=K;G"_P#K$MH86C'@V\6EG=PQK!%&
M34 <:CTZ=/Y=_P 9.C^]-@[_ ,UVILG^].3PF[Z3%XRI_O)N["?;4$N%IJN2
M#P[<S^(IYM51(6U2([B]KVX]J_NM^SWMS[C<I;CN?.>W?63P7GA(WU%U%IC\
M&-].F":('+$U()^=.D?WF?=?G_V^YDVZPY0O_I(9[9I)%\"VEU.)64&LT,A&
M !0$#Y=+7N?XK;4^-?R3^+W9'5M++B=A;G[EV1M3,8?)9"NRE-MW-56>H=#T
MN2RM549!Z/+8-JMU6>:5H)J-F+LCA$$G/GLULGM'[K\F\W\D1^!M]WNEK:30
MR222K%++( &1Y&9Z/$9#W,=+(#D&@(N1O=_>/=/VMYMY6YO<3;C:;9=7,4J(
MD;31+$V&2-574DF@'2HU*X% 14W4^\^NL$>O>_=>Z][]U[KWOW7NJU?YG7<0
MV+TG2=<XRL6+/]K9,4%5'%,$J8-H81X*_.3Z55W$=?6FDHR#H$L,TP!.EE]X
MH?>[Y\_JQ[<CEJSDTW6]R>$0&HPMHZ/.U*'#'1$>%0[9Q3K*;[I_)']8>?GY
MFNTU6VSIK4D54W,M4B'EE5UR>=&5?4'I&_RJ.V/X_P!:;NZCR%06K^O\Q_'<
M#$Y/JVSNJ6>>K@IQJ:ZX_<<-1+*;* :]/J2;$'W,.=1NO)=YR3<M^KM4OB1#
M_EWN2SD#.2LHD)P*!UZ/?O@<G?NWFNRYTME_3W*+PI3_ ,/MP I/^FB*@<?[
M,]6N>\SNL/.O>_=>Z][]U[KWOW7NJ(/YE'QOZHZDPW7>]NM-K4>SY<YFLMM[
M.XW%S58QE=HH(\CCJR*@J)9X**>F\$R.8?&LBR+J4E01SD^]O[4<E<F[3M?,
MO*=DE@\T[V\T<55C<&,R(WAY5670PJM*AL@T%.AGW6/='G'G*_W/8.:KQ[Y8
M(HYHGD"^(G?H=2X + ZE(U5H0:$5ZQ_RV/C;U5V[B>Q-[=F[7H]X-@<UAL#M
M_&Y*IKEQ]%(U#49'*5E304L]/35[U*U%.D8G\J((WLH+7]T^Z3[3\E\Z;7N?
M,W-MDE^T$Z00QRZC&E(Q)(QC!"L6UJ!JU4"F@%36WWIO=+G#DR^VS8.5+M[$
M7$4DTSQA-;C6$C578$K32Q.FA-1DTZOC]]'NN>/7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=:$'\P#_A-/\@>C6SO8WPVS%;\CNK:;[C(2==9&.CQ_>FUJ%/6:
M>DI:=:7 =H04T:EC+CEQ^3D++''C)=+2MDSRO[P;9?A;3F)?I9CCQ%J86/SX
MLGEQU+Q)8#'09NMGE2KVQU#T\Q_GZHG^/WR>^4OP6[4KMT])=@;[Z4[ Q->F
M,W=MYXIZ2BRLN&GJHVV[V)L'<%++AL_#CYJB=?M,I12M2RNS1B.7U"2]UV78
M^:+%8MPC2YB851P:D5IW1R*:BM!P-#3-1T6133VLE8R5/F/\X/6X]_+^_P"%
M,G27;YPO7'S<P-%T!V'4""AI^V=O1U^1Z3W%5G[*FCDSE/++D-R]:5E;4SNQ
M:?\ B.'ABB>6>OI5*Q^X!YH]G]SV[5=\O,;N$9\,T$RC/"E ]*#A1B3A#QZ$
M%KO$4E$N!H/K^'_8_P!6>AL_X4D[CV]N_P#E7T.Z-IY[#;HVSGN\.H,I@]Q;
M=RE#F\%F<;5T6ZY:7(XG+XV>IQ^1H:F,AHYH9'C=3<$CV5^TL<D/.Z13*598
MY000000,@@Y!Z=W8@V)(R*C_  ]6.?S$O^W6OR\_\4T[3_\ ?69/V$^4_P#E
M;]N_YZX?^KJ]*KO_ '#D_P!(?\'1>_Y7?_;D[HS_ ,5F[+_]SNP/9CSG_P K
MY>?\] _PKU2S_P!P$_TO09?\)N_^W6/67_B3.Y?_ 'N*[V8^['_*[W/^DA_Z
MM+TUM/\ N"OVG_">@JZX_P"XFKO[_P 4*PW_ +D]*>U5S_TZ*W_Y[S_U;EZJ
MO_)7/_-/_*.O?RG?^WL/\\#_ ,2WUA_[O.W??N<_^5(Y;_YIS_X8NO6?^YUS
M]J_X#U[^;%_V]A_D?_\ B6^S_P#W>=1>_<F?\J1S)_S3@_PR]>O/]SK;[6_P
M#KW\^+_F>_\ )T_\7UV;_P"]CU3[][<?\D_?_P#G@E_XZ_7MR^.#_FHO2C_X
M4U_]NS*C_P 3]U1_[C;L]T]H?^5SC_YI2_\ '>M[O_N$WVC_  ]6T]S?+#X\
M_#_H[ =H?(SM+;/66U(MO8B#'G,5339W<V2CPL-2,)L_;% E5N'=F<D@B9Q2
MX^FJ)5B5I'"Q([J!]MV7=-]OC9;3 TTA)J%&%%::F8T"C/$D#I;)-%!'KE8*
M/]7#K3._F*_\*3.\>^!F^L/A?19KX\]45)J:"M[+KFI?].6\*%M46K'5=#45
MN,ZNQ]2A)MCY:K+W"LM? #) <@>4_:';]OTWO,9%S,*$1"O@J?Z7 N?MHO'#
M<>@_=[Q))V6W:/7S/^;JCCXN_#GY3?/+L^JV?T+U[N;LW<M5D(\CO7>-?.\&
MV-KC,UKO4[D[!WUF)!CL;]Q*TU0?--)D*\QR"FAJ)O09)WKF'8^5K(2[E*L*
M@42-1W-I&%C0?L\E&*D#HM@MI[IZ1 GU/E^9_P!1Z^@'_)X_E)TW\L796_\
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M *-^Z_\ ."S_ .V[KW_ <^YO_*=M?_.:[_[8NO?\.P?';_GC.Z?_ $'=C?\
MVQO?O^#6]J_^C?NO_."S_P"V[KW_  '/N;_RG;7_ ,YKO_MBZ]_P[!\=O^>,
M[I_]!W8W_P!L;W[_ (-;VK_Z-^Z_\X+/_MNZ]_P'/N;_ ,IVU_\ .:[_ .V+
MKW_#L'QV_P">,[I_]!W8W_VQO?O^#6]J_P#HW[K_ ,X+/_MNZ]_P'/N;_P I
MVU_\YKO_ +8NO?\ #L'QV_YXSNG_ -!W8W_VQO?O^#6]J_\ HW[K_P X+/\
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MH:2)8::DI*:%4B@IX(D"JJ@  >\KK2TM;"UCL;&-88855$1%"HB***JJ*
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M;_TT>Z?]E]W_ -;>O?[+;\=O^?"=+?\ HK=C?_6+W[_6F]J_^F9VK_N76?\
MUIZ]_KI>YO\ TT>Z?]E]W_UMZ]_LMOQV_P"?"=+?^BMV-_\ 6+W[_6F]J_\
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M;_TT>Z?]E]W_ -;>O?[+;\=O^?"=+?\ HK=C?_6+W[_6F]J_^F9VK_N76?\
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MQ_W$U=_?^*%8;_W)Z4]I;G_IT5O_ ,]Y_P"K<O5U_P"2N?\ FG_E'7OY3O\
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MJ:VOK)8:6E@0'EW95']?:2^O[';+.7<=RF2WMX5+R2R.J1HBBI9W8@*!YDD
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M<)7GGF8O))(S.[NQJS.[$EB3DDDDGCTX>U/2;KWOW7N@6_V6WX[?\^$Z6_\
M16[&_P#K%[C_ /UIO:O_ *9G:O\ N76?_6GH=_ZZ7N;_ --'NG_9?=_];>O?
M[+;\=O\ GPG2W_HK=C?_ %B]^_UIO:O_ *9G:O\ N76?_6GKW^NE[F_]-'NG
M_9?=_P#6WH9(((*6"&EI88J:FIHHX*>G@C2&"""%!'%##%&%CBBBC4*JJ %
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M@1/(RE]"*+V 'L3[)RYR]RS;-9\N6%OM\+MK:.V@B@1G("EV6)5!:B@5(K0
M< .@YO/,._\ ,=PMWS#?7%_*BZ%>XFDG=4J3I5I68@5)- :5)/GTG]R],=/;
MTRTV>WCU1UKNS.U$4$,^:W+L7:^=RT\--&(::*;(Y3%U59)%3Q*%16<A%%A8
M>RS>.0N1>8;T[EO^RV%]<$!3+<6=O-(57X5+R1LU!Y"M!Y=&6U<]<[;%9C;M
MCWB^L[=22(H+N>&,%C5B$CD502<DTR>F#_9;?CM_SX3I;_T5NQO_ *Q>RO\
MUIO:O_IF=J_[EUG_ -:>C'_72]S?^FCW3_LON_\ K;T+.)Q.*P.,H,+@\9C\
M-A\72PT.,Q.)HJ;'8S'45,@BIZ.@H*..&EHZ6"-0J1QHJ*HL ![&]G96>W6D
M5AM\2000JJ1QQJJ1QHHHJ(B@!5 %    ,#H&WEY>;C=27VX2O//,Q>221F=W
M=C5F=V)+$G))))/'IP]J>DW6*>""J@FI:J&*IIJF*2"HIYXTF@G@F0QRPS12
M!HY8I8V*LK A@;'CW5T21#'( RL"""*@@X((/$'J\<DD4BRQ,592""#0@C((
M(X$>1Z!O_9;?CM_SX3I;_P!%;L;_ .L7L _ZTWM7_P!,SM7_ '+K/_K3T./]
M=+W-_P"FCW3_ ++[O_K;U[_9;?CM_P ^$Z6_]%;L;_ZQ>_?ZTWM7_P!,SM7_
M '+K/_K3U[_72]S?^FCW3_LON_\ K;U[_9;?CM_SX3I;_P!%;L;_ .L7OW^M
M-[5_],SM7_<NL_\ K3U[_72]S?\ IH]T_P"R^[_ZV]"UBL5B\%C:##83&T&'
MP^*I(*#&8G%4=/C\;CJ&EC6&EHJ"AI(X:6CI*:% D<<:*B*   ![&]G9V>W6
MD5AM\2000JJ1QQJJ1QHH 5$10 J@"@   &!T#;R\N]PNI+Z_E>>>9B\DDC,[
MN[&K,[L268DU))))X]3_ &IZ3=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW0;=L].]5][['S'6O<O7^T^S-AYZ+Q93:V\<+19O%3
ME;^*ICAK(I&H\A2L=<%3 8ZB"0!XW5@"%5G>WFW7"W=C*T,J<&0E2/S'571)
M%*.*@^1ZU%OG_P#\)@'B_C'8_P#+XW:7B FK:CX[=H9MVE14CGE-+UOV=D'=
MYR[+'%!C]QG5<O))ESZ8A.?*_O*XTVG-,>KR\>, '_FY&*#\TI_I#QZ(KK9@
M:O:FG]$_Y#_G_;TG/Y=__"8W.YPX3M#^83G9-NX=UI\A1?'/8&;#;CKHI(HY
M4INS.P<7(U-M]0Q9)L=@9:BJ9"#_ !*ED5HO;W-?O&JZK/E1:G@;B1<<>,<9
MX_:X_P!IY]:M-F_'=G_:C_*?\W[>MQ#JGJ+J_HO8N$ZSZ<V#M7K38.W83#A]
MJ;.PU%@\/2:@OGJ6IJ**/[K(5CKKJ*J8R5-3*3)*[N2Q@:\O;O<+AKN^D::5
M^+.2S'\S_J'1\B)&H1!0#R'0B^TO5NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
COW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ttable_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ttable_01.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M +'7OXN?Z_[P??O"^SKU?G_/_8Z]_%S_ %_W@^_>%]G7J_/^?^QU[^+G^O\
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MOLZ]7Y_S_P!CKW\7/]?]X/OWA?9UZOS_ )_['7OXN?Z_[P??O"^SKU?G_/\
MV.O?Q<_U_P!X/OWA?9UZOS_G_L=>_BY_K_O!]^\+[.O5^?\ /_8Z]_%S_7_>
M#[]X7V=>K\_Y_P"QTL<96^3:V6J+_P";J)5^G]$A/_$^RV9/\80?+_H+I9%_
M9-]O^;I'?Q<_U_W@^S+POLZ1U^?\_P#8Z]_%S_7_ '@^_>%]G7J_/^?^QU[^
M+G^O^\'W[POLZ]7Y_P _]CKW\7/]?]X/OWA?9UZOS_G_ +'7OXN?Z_[P??O"
M^SKU?G_/_8Z]_%S_ %_W@^_>%]G7J_/^?^QU[^+G^O\ O!]^\+[.O5^?\_\
M8Z]_%S_7_>#[]X7V=>K\_P"?^QU[^+G^O^\'W[POLZ]7Y_S_ -CKW\7/]?\
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M #_V.O?Q<_U_W@^_>%]G7J_/^?\ L=>_BY_K_O!]^\+[.O5^?\_]CKW\7/\
M7_>#[]X7V=>K\_Y_['7OXN?Z_P"\'W[POLZ]7Y_S_P!CKW\7/]?]X/OWA?9U
MZOS_ )_['7OXN?Z_[P??O"^SKU?G_/\ V.O?Q<_U_P!X/OWA?9UZOS_G_L=>
M_BY_K_O!]^\+[.O5^?\ /_8Z]_%S_7_>#[]X7V=>K\_Y_P"QU[^+G^O^\'W[
MPOLZ]7Y_S_V.O?Q<_P!?]X/OWA?9UZOS_G_L=>_BY_K_ +P??O"^SKU?G_/_
M &.O?Q<_U_W@^_>%]G7J_/\ G_L=+'=-;]O2X1@;>6GF;Z?T6'_BOLML$JTG
MVC_"W2RZX+]A_P G2._BY_K_ +P?9EX7V=(Z_/\ G_L=>_BY_K_O!]^\+[.O
M5^?\_P#8Z]_%S_7_ '@^_>%]G7J_/^?^QU[^+G^O^\'W[POLZ]7Y_P _]CKW
M\7/]?]X/OWA?9UZOS_G_ +'7OXN?Z_[P??O"^SKU?G_/_8Z]_%S_ %_W@^_>
M%]G7J_/^?^QU[^+G^O\ O!]^\+[.O5^?\_\ 8Z]_%S_7_>#[]X7V=>K\_P"?
M^QU[^+G^O^\'W[POLZ]7Y_S_ -CKW\7/]?\ >#[]X7V=>K\_Y_['7OXN?Z_[
MP??O"^SKU?G_ #_V.O?Q<_U_W@^_>%]G7J_/^?\ L=>_BY_K_O!]^\+[.O5^
M?\_]CKW\7/\ 7_>#[]X7V=>K\_Y_['7OXN?Z_P"\'W[POLZ]7Y_S_P!CKW\7
M/]?]X/OWA?9UZOS_ )_['7OXN?Z_[P??O"^SKU?G_/\ V.O?Q<_U_P!X/OWA
M?9UZOS_G_L=>_BY_K_O!]^\+[.O5^?\ /_8Z]_%S_7_>#[]X7V=>K\_Y_P"Q
MU[^+G^O^\'W[POLZ]7Y_S_V.LU-E2U1 M_U31#Z'\L/=7BP>' ]64Y&?/_5Y
M=*7>%=]KDX([_6AB?Z'\R2C_ (CVAVU-2'_3'_ .E-X>X?9_E/24_BY_K_O!
M]F'A?9TDK\_Y_P"QU[^+G^O^\'W[POLZ]7Y_S_V.O?Q<_P!?]X/OWA?9UZOS
M_G_L=>_BY_K_ +P??O"^SKU?G_/_ &.O?Q<_U_W@^_>%]G7J_/\ G_L=>_BY
M_K_O!]^\+[.O5^?\_P#8Z]_%S_7_ '@^_>%]G7J_/^?^QU[^+G^O^\'W[POL
MZ]7Y_P _]CKW\7/]?]X/OWA?9UZOS_G_ +'7OXN?Z_[P??O"^SKU?G_/_8Z]
M_%S_ %_W@^_>%]G7J_/^?^QU[^+G^O\ O!]^\+[.O5^?\_\ 8Z]_%S_7_>#[
M]X7V=>K\_P"?^QU[^+G^O^\'W[POLZ]7Y_S_ -CKW\7/]?\ >#[]X7V=>K\_
MY_['7OXN?Z_[P??O"^SKU?G_ #_V.O?Q<_U_W@^_>%]G7J_/^?\ L=>_BY_K
M_O!]^\+[.O5^?\_]CKW\7/\ 7_>#[]X7V=>K\_Y_['7OXN?Z_P"\'W[POLZ]
M7Y_S_P!CKW\7/]?]X/OWA?9UZOS_ )_['7OXN?Z_[P??O"^SKU?G_/\ V.O?
MQ<_U_P!X/OWA?9UZOS_G_L=>_BY_K_O!]^\+[.O5^?\ /_8Z]_%S_7_>#[]X
M7V=>K\_Y_P"QU[^+G^O^\'W[POLZ]7Y_S_V.O?Q<_P!?]X/OWA?9UZOS_G_L
M=>_BY_K_ +P??O"^SKU?G_/_ &.@^_B)_J?9GX1_U#I/XH_U'KW\1/\ 4^_>
M$?\ 4.O>*/\ 4>O?Q$_U/OWA'_4.O>*/]1Z]_$3_ %/OWA'_ %#KWBC_ %'K
MW\1/]3[]X1_U#KWBC_4>O?Q$_P!3[]X1_P!0Z]XH_P!1Z]_$3_4^_>$?]0Z]
MXH_U'KW\1/\ 4^_>$?\ 4.O>*/\ 4>O?Q$_U/OWA'_4.O>*/]1Z]_$3_ %/O
MWA'_ %#KWBC_ %'KW\1/]3[]X1_U#KWBC_4>O?Q$_P!3[]X1_P!0Z]XH_P!1
MZ]_$3_4^_>$?]0Z]XH_U'KW\1/\ 4^_>$?\ 4.O>*/\ 4>O?Q$_U/OWA'_4.
MO>*/]1Z]_$3_ %/OWA'_ %#KWBC_ %'KW\1/]3[]X1_U#KWBC_4>O?Q$_P!3
M[]X1_P!0Z]XH_P!1Z]_$3_4^_>$?]0Z]XH_U'KW\1/\ 4^_>$?\ 4.O>*/\
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MU"''1M TU.;R15$,KI+&Z%[44H1Y<<>OET_<Q&WIY@^?#IZZZ_G%X??77?\
M-D['J^B,KA<9_*U[,[PZ\R-!3]AQ9:?>R])P9B2>M@U8:DCV^:^7#RI'"[Y#
MQK(CM,Q#1C:W.H2&G]F2/MI7]G#K1CH4%?C /V5ZKXZI_P"%&WR?WOT=BOEC
MN3^31\AU^)67Q&X\O3=V=+=VT/=^B+:.8GPN3GGQ']T]O34E%0U=!DUGJ*BJ
MB6-J<,R_;N:B-,E\[+K,3:?4&O T]!T\UNH.G6-7H<=7Z?#;YN]!?//HG;GR
M(^-^[IMU=?[@J\CB*F')8]\+D\5D\,P2MQ.8Q\I,E%D*4M&Q74\4T,D-532S
MTL\$\AC ZW*ZD-1]G#I)+6$T8?SZIW^47_"BSK?XR?S(<;\$Z_X]9S=W7F)[
M%Z5ZG[=^4%+V2,)C]J9WNF 5=-3SX:7;LU+608ZDD2:=VW-2RO'3Y+PP.^/=
M)4,U^(I?#IBH!:O G\O\O2E+<NFNOD2!ZTZV+_XB?ZGV:>$?]0Z1>*/]1ZIH
M_F&_S".Z^FOFA_+E^"_QC@V')VE\LNTLCN#M/,[^Q%1G8,3UUL&-I\V]'3TM
M3!*F6KZ6'+2T4SJT*OC7CETI*9(T-S(T<B1KQ8YJ/(=*8@'5G/ >GKTM>QOY
MK%'UY_-PZ$_E75'2E7DYN]^D\SVW0]YP=A)3)CI\/C=Z94XN;;385FJ(GIMF
MS**M<\C"6J1?M"D;.VVGTSB&G$5K^T\/RZT$K&9*\#2G[/\ /TV=&_S::+Y/
M?S'NXO@]\>ND9>R>I/CAMMY>_?EQ2]F14>*PFXV-9!#MNAP282I7,2RY&F:C
M$XW!3GR4^3=:=XL?KJ?1S^-*8T%0O%J\#Z4_V>O.GAH'8T)X#JO&+_A0Q\J>
MSOD/\J>BOB1_*)['^4=)\4.VL[U3OG=^U_DM3[=D$F-RN9Q-'6U.-.PLBM#'
ME9\!E7IXQD:@^.$EW#74)1?.[,J1EM)H2#]H]/ET\8%0 LP%148_V?GT;KYZ
M_P Y_=_\O[X#_'OY@]M?#3=5-V?W=O';NP<]\:,]VQ#M6JVME,IB\QE*N&NW
M"NW<B*N.ECPTRQ,F"C:H\L3,E."P5^YN3:QJ[*:DTTUI3CYT^73<,8F<J#@>
M?KT!.2_X4%]@_'++[93^97_+$^3_ ,'-B;IW--MRE[AQ^?I_D+M6D/AC>*2O
MR.+P^%D$SR&:]-24U94F*/S4\=2?)'"V;TP_VJ,@/GQ'^3JX@$G]FP;Y<#U>
M!W!\I.L>H/C)V#\L<AGJ'<74FP^G<[W9'G=O5J9"#*XC%8I\M3/C9XO+'4?Q
M.$1+2L@82M+'IU:A=>Y"(7K@"OY=)5.IM/G6G567\GS^=_A?YJN;[JV-G/CO
ME_C%V7U%@>O=\46SLSV0.Q?XYMSL2&26FS%'-)M[;-3%'#>A=@<?)#)3Y"@J
M(:F1:@JB2QN_K*BFDBAIQJ#^0Z?N8OIZ&M0:_+(Z7'=/\P#O#X\_SA?B_P#$
M/L&GV=5_%#YE=*[T3JC-T."DBSN,["V$9*FKILA7&L$<N)J*.GI8842A>0U6
M5@U.L4#L+22-%.L9^%@:8S4?ZOY]54!XRPX@Y^SJY3^(G^I]KO"/^H=)_%'^
MH]>_B)_J??O"/^H=>\4?ZCU[^(G^I]^\(_ZAU[Q1_J/7OXB?ZGW[PC_J'7O%
M'^H]";55)'6>-GYN:UQ_ZLSC_B/9*B?XZP^7_/J]&#/_ (N#\_\ *>@R_B)_
MJ?9UX1_U#HO\4?ZCU[^(G^I]^\(_ZAU[Q1_J/7OXB?ZGW[PC_J'7O%'^H]>_
MB)_J??O"/^H=>\4?ZCU[^(G^I]^\(_ZAU[Q1_J/0#?*3Y#4'Q@^-O?'R-RVW
MZ[=F-Z,ZDW_VM6[7QU:F,GR,>Q<94Y%J**IE26.G>J^W\8E:)Q'JU:'MI+<P
M\%"Y\@3^SJ\;>(P4>9IUKG[!_P"%,7:3=!;1^8?>O\J;OCKCX9[VS;8/$?(O
MJ_N;%]X4$,E)F:S;]7)DJ&3;VUY\7!%FJ*2CBDJIHDJ:FT$+-*\"SE:[@V@2
M-&0I_$#4<:>@Z6&V&K0&&H>7#HYG\S/^;IO/XV="_ #Y!?$BFZM[(V+\ROD#
MU1LE\OV)@LKDXWVKV)CY<B*G')CLQAY*/*:%1;U'W"1-K1Z<N.%%U<&%49*$
M,0,^A_/IJ% Y96P5!/YCJ]W^(G^I]F'A'_4.DOBC_4>O?Q$_U/OWA'_4.O>*
M/]1Z]_$3_4^_>$?]0Z]XH_U'KW\1/]3[]X1_U#KWBC_4>O?Q$_U/OWA'_4.O
M>*/]1Z]_$3_4^_>$?]0Z]XH_U'JIWL;^:Q1]>?S<.A/Y5U1TI5Y.;O?I/,]M
MT/><'824R8Z?#XW>F5.+FVTV%9JB)Z;9LRBK7/(PEJD7[0I&SLB:?3.(:<16
MO[3P_+I0$K&9*\#2G[/\_4?^7G_-;_V>#Y!_-_XR;OZ#RWQ][6^%79@V3E<;
M7[]_OY#N''2Y+,XN/,TKM@\%-1 S8A9# T$\34];1S05DZR/X_6T_P!0[H10
MH:>M>/R'IUZ9/"56K4,*^G2E[B_F>T_7?\S;XS?RTME],9+M#=W=O7&Z.V.S
M.QJ'>,F$I]AX/#T^7EH:NLQXP=?#DOXA+A:F(A\OC_ \U$H\TE9!&VY)M,RQ
M 5)%2?09^7RZTJZHS(32AH/GT1#Y>?SS,]\</E_T7T)NKI7M_J6&?N?N#:F^
M=A[EZHE[!RW8^TL=@<BVR=Q]:Y7 U57BT?-;KHJ"@FHZV>.JI(\G3S5L5-3K
M/54R>>[,+A2",FHI4D4P13Y_X>G8X?$4D$' S7AZUZOFZ6[+W3V;U1L#L#>O
M6>Y.F=V[NVQC<WN'JO=V0H\MDL#55B:I<=5U./EFHYY8&XUQO9E()5&U(IC&
MA< D$5\O3I*T@4T%#\^A._B)_J?=_"/^H=5\4?ZCU[^(G^I]^\(_ZAU[Q1_J
M/7OXB?ZGW[PC_J'7O%'^H]>_B)_J??O"/^H=>\4?ZCU[^(G^I]^\(_ZAU[Q1
M_J/0AY*K*]<8"?F[Y:9?]L];_P 4]E$*?XY(/Z _P)TND?\ 04_TO^@N@\_B
M)_J?9OX1_P!0Z0^*/]1Z]_$3_4^_>$?]0Z]XH_U'KW\1/]3[]X1_U#KWBC_4
M>O?Q$_U/OWA'_4.O>*/]1ZJV_FP_S.Y/Y8O2'6G:>-Z)R_R)W7VUW;MCH_9O
M76+WU'UT)<AN:AR5?'++DWQ.<9?1C7BCC3&R&6:6-6:)-3A'>S?2*#2I)H!P
M_P _2BW7QR16E!6O'H2_Y:_\Q38/\R;XT47R#V3M+.];93';SW1UMV1U=N?(
MP93([<W#M%H6JL=530I#Y-=)5453$TE+3RF&H3R01."HO:R"[34*C-"/0CJL
MX\!J'[0?4=5E]X?\*)]F]4_S$</\&]K_ !:WEV1LJ'Y']7_%;??R2I>R:; 8
M[&[O[+:EB-!C\,<+6C+-AZBHFBK4DS=!,CTM1IB91"9DDE\$E\/22-04M\ST
M^EOJ357R) ^71C_G#_-\W7T'\H-N?!?XC?$G>GS;^7^9V"O:.>Z_P>_<?U7A
M\!@Y' CJ<KG,C35D2U$L5I!$8HHT26FUU"O411L]<7!C?PT4NU*TX4'3<2!U
MUL0HK2O'HYGP9^6O;/RFZUW7G>\?B;VM\..U.OM\R[ W=U=V;60Y^&HGBQF-
MR:Y3;N<IH*6GSV#F3)"%*N.EC4U$$\5B8B?;]N6F!U*5(-"#GR!Z;E(C.""#
MYCH//YE'\S'KO^6_U5L?>.Y=B;O[A[*[A[!QG5/2'2VQ)8Z3);DSV5L4IQ53
M)+'1TL6J)9)OMYW\DT$4<$LDJK[I=2BU4$U))H /,];@7QS08 R3Z=!S\(_G
M_P#,?O/MVMZ6^7W\M+MOX8YFJV'G.Q-G]A?Z1<;W1M#(4V"JL52R8JKS6,HJ
M*+%9]_XJLD-%()))H8*B2T7B916!Y)&TNA7%0>(\O3SSU:0(HJK!OY'JV#^(
MG^I]K/"/^H=)_%'^H]>_B)_J??O"/^H=>\4?ZCTR;FSN;QVV]P9#;F)7/[AH
M,'EJS X%ZM,>M;6TL$CTM(:B0B. 5,ZI&9&(5-6H\ ^]&(@8Z\)1T4OX&]W_
M "Q[OZ$I]\_,SXX8_P"+/<TF\-S8I^KL9NN+>$?\*Q[0_P /R+5,,U0L;U>N
M93$9F/[0D](D"*S;J\BU==)]./3DKJIHIJ/7AT<_^(G^I]O^$?\ 4.F_%'^H
M]$>['_F.?'#JOYM=*_R_-UY;=L?R,[\V+4=B[ Q-!M2:LQ38NG7<C>2LRH98
M*:5_[J9D+'I9KQQZ@HE0E.\JI((B3J85&/M_S=.J"REQP''/V?Y^CP_Q$_U/
MM1X1_P!0Z:\4?ZCU[^(G^I]^\(_ZAU[Q1_J/7OXB?ZGW[PC_ *AU[Q1_J/7O
MXB?ZGW[PC_J'7O%'^H]>_B)_J??O"/\ J'7O%'^H]>_B)_J??O"/^H=>\4?Z
MCT)O8%28<?M0B_[E%4G_ &R4O_%?9+M*:GE^T?X6Z,+U]*I]A_R=!E_$3_4^
MSKPC_J'1?XH_U'KW\1/]3[]X1_U#KWBC_4>O?Q$_U/OWA'_4.O>*/]1Z]_$3
M_4^_>$?]0Z]XH_U'KW\1/]3[]X1_U#KWBC_4>O?Q$_U/OWA'_4.O>*/]1ZI=
M_FL?S@-Q?RXNQ_B-TWUY\5,M\JNUOF#NS/[,V!M2B[=INH43(8ZOV_BJ"C2K
MJ,!GTJ*O*Y+<5'#$KQTT,8#/)4 6'M!>7!M2JA=18T K3T'S]>E-O&)@230#
MCY])SXI_SO\ "]M_++"?!#Y5_$SNOX+_ "QW1MW^\&T-C]FY.AWCA,VL=+4U
M;IAMPTD- ,A')'0Y 4]2F.%+4/2SP+,M5$].NH;K6_ANI1O('SZW)%I76I##
MU'2M_E(_S'N[?GANCY]X/N+;?6> IOBW\L=U=(=>R]<X7*8=ZK#8:HR$$$N7
M_B68RPJ,C:B1GE@%-$Q=K0*-(%K*5KDN#3M:@H#_ )^JW $.FGF*YZN8_B)_
MJ?:[PC_J'2?Q1_J/7OXB?ZGW[PC_ *AU[Q1_J/7OXB?ZGW[PC_J'7O%'^H]>
M_B)_J??O"/\ J'7O%'^H]>_B)_J??O"/^H=>\4?ZCTW9C</\)Q.4RK1M.N,Q
MU;D&A#>,N**)I"H:QTEM-KV-OZ>]&,CK8D!ZUR.N?^%%%)V'_*7[[_FA4_Q*
MJ\94]$=]X;HFNZ)G[S2I3(SYBHV6@R,.Z5V@K4\24V\H9#$VVW8RTKPZPDBS
MJ5K?ZH3-IX&E*_9YT^?ITL-O201UXBM?V^7Y=7O?&SO>D^1OQUZ#^0N.P55M
M;']\=*]6=S4.V*VM7)S8Z'M#!4&<BH)JF..)*B6C2N6)I5B19&0L$4&P,8AX
MJAO4 _M%>DCOH8KZ$C]G0U?Q$_U/MSPC_J'5?%'^H]>_B)_J??O"/^H=>\4?
MZCU[^(G^I]^\(_ZAU[Q1_J/7OXB?ZGW[PC_J'7O%'^H]>_B)_J??O"/^H=>\
M4?ZCU*H<@6K:1;GFJIQ_MW'NDL9"G[#_ (.K)+D?:.ESV75F#.TB"_.)@;_;
MS3C_ (CV5[*FJ(_Z<_X%Z67[Z7'^E'^$]!Y_$3_4^S?PC_J'2'Q1_J/7OXB?
MZGW[PC_J'7O%'^H]>_B)_J??O"/^H=>\4?ZCU[^(G^I]^\(_ZAU[Q1_J/1$O
MYE/SOHOY=7PX[4^6^0ZYK.V8^MIMET5/L&BW.FS&KZC>^<Q^#IU?*24.3%'#
M%-D$ED<8^=M",%C9B/:>[?Z6,N16E,<.)IT]!^NP7JNWX7_S@OGI\K=^]!IN
M7^3=VUU!\>.]*3;NX*?Y)_[,-3[YQF.P.\<;_$L5GOX<=CX9ZR@JXY:,_P#
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MVG_5CKW7ONC_ %'_ "5[]I_U8Z]U[[H_U'_)7OVG_5CKW7ONC_4?\E>_:?\
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M^U/V#_!UL$_='^H_Y*]FVG_5CI#U[[H_U'_)7OVG_5CKW7ONC_4?\E>_:?\
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MKW7ONC_4?\E>_:?]6.O=>^Z/]1_R5[]I_P!6.O=##N6;3U;M606]60I1]?\
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M%F4Q K<YFUDQM+CJFLD?(TJU65,&NH\M7#2RKDE26UC,[-DD46M7H2M,9/\
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MWO\  ;M3 [GZ'[/Z,Z_^#_?6#Q'4NY>LOX9'CTI]J[8K)_X[@\ *FFAIJ39
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MO"=A2ON3JOY'=*=2TO:5!B3&5RN.VW74;YREH&J R1QY!GJ8*=JO4J!(GG+
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MT$$63QF+V=6IXO*Z25]<@?3))-67VY?J9I9_*NA?L'\O3K5V?"C2/Y:C^?\
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M^K\^A!_F^_RP/^'+NK>JGV/V>>DOD?\ '#?,W8_0/:;T)KZ>CK:YJ)ZVAK3
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M]W#TX=-12E8&(IVF@QY8_P _5B7\P+!Y;^5]_,A_E-?++9.\]_#XSYO ;/\
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M<<?!SXFC]7]-A8#V*;%?T8_](GI_".B:X_M&_P!,W^$]'C^Z/]1_R5[5:?\
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MWZ./U^D3>0R_L7]^OU_QN'335Y_Z6O\ FKUZV_L)*\/+[?\ 53HG?9/\P?\
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MI8W-O0I.0B2+&5X."*-\JUZK=$/'5F0N#Q4CAU>[_-EJ2W\L/^8"MQS\0/D
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MO5I7F'^J/^W_ .-^U]#\NDU1U[S#_5'_ &__ !OWZA^77JCKWF'^J/\ M_\
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M7JCKWF'^J/\ M_\ C?OU#\NO5'7O,/\ 5'_;_P#&_?J'Y=>J.O>8?ZH_[?\
MXW[]0_+KU1U[S#_5'_;_ /&_?J'Y=>J.A>[ID";IH 21_N I3];?\I%5[#_+
M8K W#^T/_'5Z,MU-)!_I1_A/00^8?ZH_[?\ XW[$%#\NBVHZ]YA_JC_M_P#C
M?OU#\NO5'7O,/]4?]O\ \;]^H?EUZHZ+]\K^CT^4'QC[_P#CDVZFV0.\^H.P
M>J?[XC##<G\+.^L94XX5_P##_NZ#[X4AJ!(8/OJ?RA='FBU:PS<0&>-DP-2D
M5IPJ*=7BE$;!O0@_LZ+?U;_+PZXVQ_+:V]_+:[3W)+VSU]1=*9#IK<>\HL N
MSJBM2N-1(F6HZ UN57&UM%4S1U%+_EM1X9X8I-;VM[8CL0L'@-0C3I)I3_/T
MXUS63Q!@UKQZ(U\*_P"1AM_X>_"OYQ_#:/Y+9?L+%_,[$[JV_P#W\;JN#:E1
MMNCS^WZG P#[ ;@R4>8J:9:IYI)/NJ%)R!&L,'+^TMKM'TT4D6JNNHK2E*BG
MKGIZ:^\5U>@&GRKQS7HNG5G_  GZ^4.QNBL3\2,W_./[X7XCXO'[DQC=+].]
M$8SIB:2GW=E*G,9*E?/?WKSU7+15]=75[U%//!/%*)VC8>"\+,1[+(B>&9CH
M_A"Z>)KQJ?7IQK]&;5H&KU)K_D'1]NT_Y/?5;?RRMT?RR_BCV-D_B]L7>57A
M*G=79LNW).T<SES#EJ+*YF;,!<SMV2NJMP&@AI:EA714\=#_ )!#2K0)'2HK
MDVL> 8(SI!XFE2<U-<CC_L<.F%O/U/$:AIY5I_GZL,Z7^-_4G2/1W6'0>W-J
MX*NV=U=UGM/J[&-DL1!4RU5%M7&P8U9:IY?+))-51PEYF>5V9W8L[$DE=%;B
M) @ H !^P4Z8>4N2U>)KQZ);_*M_EJ-_*_V)WCU/@.]\AVUU9V3W'D>U.N-I
MY#9$NTWVC#DX$HY<7]W+N'-_Q@O24F,5ZH04)DDIWF:$M.1&DV_;S8!E#:@6
MJ 1P_F>GKFZ%R0:4(%#GC_@ZKI_F,8BJ^)W\\'^6%\^:NKK,=U)W=C\U\(>V
M<I]M%54=+E-S0YN+;*U+:34P'(U.X(I_*EDCCPDC2.L7E25%>J;:ZBF\F_3/
MI4UI_A_ET_;L)873S'</\O\ @_GU89V-_+&H^POYL_0?\TB7NRHQ<W1?3.9Z
MHINCX^OEJUR4N7QF],4<D^Y#FXS2QQP[QD?[48&4EZ5?\I"S%8UK[?KN%N*C
MM6FFG'##C7^EZ=,+=:8C'3B:UK]G^;I.]=?RJ:;HO^9SOK^8-\?.]3U1L/N_
M;59COD5\5:+K,Y#$;JR^0CJ))L_#EX=QT,&)KWROV62+';M9+]V<H1.$R\ZQ
MU3;?"G,R, &'<E,$^O''KP]?7K;78>,1L*TX&O#^72B_EW_RQJ/X#=Z?/KNZ
M+NRH[5J?G+W-1=KR[=?KY=D)MB+'9C>.7BQJU(S>6;,R:MWS1/5&"A#"F1UI
MD,C*EK+;_HWD>H/B-6E*4RQ]37CUJ>Z\=5%*:13CQX?YNN_YN_\ +&HOYJ_Q
M^V+T=4=UU/1=1L3MK%]J4.[(NOT[+2=Z#$Y?$O12XYLW@6"R199Y%E7( HT8
M!C<,;>W+;_W@@2H6AK6E?(CU'KUZUNOIF+4K44XT_P _1+,[_(@[)^2F4VO'
M_,D_F=?)'YJ]>;0W%!N'']/8;:-#\=MMUC0(BA,I18K+9AZB5K2+]U3RTE9'
M%(Z4]1 SO(Z4[,T]/'E9P#PII'YTK_GZ>%\L?]FJJ3YUJ>CF;C_E9[/W7_,8
MZ!^<69[(I3UK\7.@'Z1Z)^*-!UZ*#!X&9Z;)4/\ &(<@N<-&RK096>%:0;;2
MP@H2:D_8P*%1V[5.LM11%TJE,#B*\?GZ>G3(NJ1E/-C4M7)_U?;T\?S2?Y86
MP/YE?QSQ/2:;TI.A]W;3[+VOVAL7M?!;%3=,^-K<#%5TD\;8^GRVWWJHJN@K
MZJ, Y.,13>&I"N\"*=[AM_UZ:*A2"""!6G\QZ]>MKKZ=M7'%*5_XOJKSYR;,
MS/RR_G&?RD?A;6[IKNP7^$_7N0^8/R0W'!%4;?I:RHP]3@5Q>0JZ+[FL5)Z[
M-;:QX$)J9VIX<V8ON6$TC,7W:&XNH8N.@:V/[./YC^?2F%A%"[\-1TC^?^?^
M76T9YA_JC_M_^-^S^A^71;4=>\P_U1_V_P#QOWZA^77JCKWF'^J/^W_XW[]0
M_+KU1U[S#_5'_;_\;]^H?EUZHZ&RN<?Z%,.]S8Y&7F__ $VU7L-Q#_=D_P#I
M1_QQ>C5S_BJ_;_S\>@3\P_U1_P!O_P ;]B2A^7154=>\P_U1_P!O_P ;]^H?
MEUZHZ]YA_JC_ +?_ (W[]0_+KU1U[S#_ %1_V_\ QOWZA^77JCKWF'^J/^W_
M .-^_4/RZ]4=%^^5_1Z?*#XQ]_\ QR;=3;('>?4'8/5/]\1AAN3^%G?6,J<<
M*_\ A_W=!]\*0U D,'WU/Y0NCS1:M89N(#/&R8&I2*TX5%.KQ2B-@WH0?V=!
M-_+G^'E+_+\^&?3'Q$I>Q)^U8NHX=]JV_P"?;"[*;(R;[W/FMS3,,6N0RHHT
M@ES+P(O\0G)2)79[L0&[*T^CB6.H-*YI2M23\_7J]Q.)W+\*TQ7T%.@?_F9_
MRYX_YC&!^-N"D[D;I]/CY\A]K=\M4KU^-_G,#;4,\)Q(4YS"C'&<37^ZO5:+
M6^V>_#5_8&]"BH72P;A6O\QU:WN1!7%:BG&G47YY?RV,;\X?D=_+S^0=9W%6
M];S? CO"I[FIMJ4VQX]UKNGSYG9V:&->M?+8\X;34;.ID^X%+6WCJ)/V R*W
MOUWM_P!6\;U \-M5*5KE3Z_T>MP7/@JR\=0IQX<?\_10<E_)?[GV!\L_E#WO
M\/OYA>_/BGU;\W=T_P!]?E!U?A.E-N]DYC(9&KJ<W75TFW]T[@FJGP/W-;N'
M+S4\D.,\U ]7*(Y)H4IH($QVITD=XY- <U8!03Y\">'$_9TZ+U64*ZABO UI
M_(?9T*WPS_E#YSX-_!3O/X;=(?,GLC:FZ.TN^<AWGLGY$[;V#CL-F]L2_P"_
M1CH\:V+J*_(X[-0-1[1AI<D9&IHLC3UM9$*>D1U"N6NV&TA:)7H2VH-3(X?;
M7AGUZI->"9PY P*$5X\?\_33\;_Y4/>.+^977OSH^>OSHS'S3[GZ.V=G-E="
MT6*Z.P7Q_P 3@8=STV1I,A5UE+@:F2'+U$E/E*Q(5:F@\3L9II*IQ3BEU!MK
MB42ROK911>T*!6OIQX];DNUT%$4*#QS6O[>@UF_DV_)?H'M;NC>/\MC^91NW
MX9=:_(/?67[([%Z7SWQ\VYW[BZ7,YZWW57@I<U5P?PY6!945*=9XXUAA^[:.
M&)8V_P!U20LQ@ET!C4KI#"ORKU;ZQ' $BAB!0&M/\'5R_P :^L=_=*],[1ZY
M[2[VWI\D]_84YNIW+W)OW%4& R&7J,YD*JN_X 8U$I**DHTJ5IJ6!6D,5-#%
M&97*W]F<$+1*%9M1\V/$_LZ222!S4  >@Z(SV-_+&H^POYL_0?\ -(E[LJ,7
M-T7TSF>J*;H^/KY:M<E+E\9O3%')/N0YN,TL<<.\9'^U&!E)>E7_ "D+,5C2
MOM^NX6XJ.U:::<<,.-?Z7IT\MUIB,=.)K6OV?YNIG\U_^67A_P"9]TYUIL&'
MN7+_ !\[$Z?[7Q?:O7G;V!VE_?2JH)J6EJ:6II%I$R^"J$6I,M+4)-!E8)8:
MJCI907"-&WMPV_Z]0*Z2IJ& K_E'7K:Z^G)- 010BO\ Q?0Z_P NWX6[2_EZ
M?$7JOXJ;3W/-OB/8$.?K<_ORHPO]VI,WEMU9&JR5?D6Q_P!]D11*\M3XHH!7
M3^*"**,RN5+%ZRL_HHQ&*&E<TXDFO5)Y_'<L<5\NCM>8?ZH_[?\ XW[54/RZ
M9J.O>8?ZH_[?_C?OU#\NO5'7O,/]4?\ ;_\ &_?J'Y=>J.O>8?ZH_P"W_P"-
M^_4/RZ]4=>\P_P!4?]O_ ,;]^H?EUZHZ]YA_JC_M_P#C?OU#\NO5'7O,/]4?
M]O\ \;]^H?EUZHZ%[,R =.;3:YL<_4B]_P#FYDO8?MQ_NQEX?V8_P1]&4I_Q
M5/\ 3'_G[H(?,/\ 5'_;_P#&_8@H?ET6U'7O,/\ 5'_;_P#&_?J'Y=>J.O>8
M?ZH_[?\ XW[]0_+KU1U[S#_5'_;_ /&_?J'Y=>J.JU/YF/\ +U3^8KLGX^;/
M/<#=/MT/\E=B?(=<E_<$=@C*C95)DJ4X<P?QO"?9&J_B ;[OS3^+QE?MI->I
M$-]8F]"BH72P;A6M*XXCUZ46]R("3QJ".-.BZ?S:?Y+76_\ -8WE\<]Z[D[@
MRG3N4Z0J\[BMS-B=BQ;R?<VW-Q56/JYL.9FRV)DQ-53R4=3]I6 U:0FLJ&>C
MF.C2QN.TC<"I)TZ>-!6H]/+IRUO?I@1@U^? ]#U\Z?Y;N%^96<^"U?A^T8^F
M\-\(_D+L/N_#[=H]@C>469H]BS8UX<!'(<UBOX.KQ8V.)*OQUOB#7-+)IL7K
MNP^I,="%T,&X5K2F.(].FX;GP=7GJ!''AT#/RB_ES?-[?G?787=?Q#_FM]T?
M%K#]M5.&KMZ]/;BZVQW=VW:*JPV'H<,M1M>'(9&A&!6>"@6:HB2"1I:J1YQ4
M1Z40-7%A,[EXY2E>*TU# IBO#J\=S&J@,@:G UH>-<]&$_EO_P MOJC^7)L+
ML/%[6W=NCMKM[O#>)[![\[XWU##3YG=.75ZN6)Y8H6D6EH:2;(9&6GIS43ND
MM95S23RRSR.7[&P%D" =18U9CQ)Z;N+GQR*T & !P'7/YZ_#'O7Y0UO6&^?C
M9\X^X/A9VSU11[RQF-RVR\33[XVYFZ/>[XN2I@W'MJJJZ&#)2TQQ4?V4[51%
M*9IG\$Q*A?7EF]Q0HY0BO#(-:<1^6.O03K'4,H8&G'CCT/17/BC_ ";X-@]_
M[G^7WSD^2NY_GQ\H=P=<9WJ+$;PWEL6@ZZPN!V[N:CK<9D*/$X2AJJQ8IZS%
M9'(T<DR5,2"GK:Q(Z=&J9I'3V^U:',DK>(Q&FI%  <8 Z=EO RZ$ 45K2M:G
MHI>(_D'_ ":ZMVCV#\9?CE_-@[=ZB^!?9>>S]7F?CU5=.8W>.8H<1O0*F<P>
M-W;49J&II8<A$)E,M-1TD1,\DM515<SU,M8F&RR1@HDI$9_#IJ:'B*UZ=^O1
MB&9 6'G6G#Y=62]B_P HKXE[\_ESXS^6C2X[/[8Z8VQBZ*79FYZ"JAJ\[C]P
M4%9/DQN=IY(E@J<I59.KK)JM3"D,\=344RI%"ZJBZ3;$>#P."C@?.O&O^?I.
MMVRR>)45\_2GIT#?Q$_EH_,?IO,T#?)K^:)VI\JMC;$ZKW5U9U-UO5=7TFP,
M;2+N?%2X;^,;BE7-93(;HR-#1.HI7K*UIXF,Q-9)YF]MV^W2Q'OE+@ @"E!D
M4J<FIZM+=(_PH!FI-:_L].EK\./Y1_7'QO\ Y<&^?Y;W:W9%5W[UYV14]E'=
MN[J/9_\ HMG>#L-XI%%)1#+Y\TM7C)(898*C[Z3]]$D\:A='NUMM@@@,#'4#
M6II0Y_,]:FN_$D\08(IYUX?LZ+'U5_*3_F+])[7VST+U?_.G[2VC\4ME0PX;
M:&Q:3XN;.K]V8["TJE(<32;RJZN>MIQ3HQCAE6+PPHJ"*B141%8CVN>(!%G(
M4<!H%:>E>G&NXW.HH-1\]1I^SH=OYC?\J#=7S%[Y^-ORU^/_ ,I\M\3/E-\;
ML)E=H83MFEZRH>RI,AA\G]VR4]1!)7XD++229++F,.TU*\>0K(FI5\OD5V]V
MQKEUD1]#J*5I6H_EZG]O5(+L1*58!@?*M.@D_GR['V#A/Y)?:&T?D?V1G-^;
MOZ]V=TK1;8[4GP=)19;</86V:O&4-%E9*" -1T<FXZG[XY%( $I:*KK3 1XT
M]M[O&%M2'-2 M#3)84_P^?5[)JS KYUQZ#H</Y"_Q0C^(/\ +'^/>V,GC)<7
MO[MS#O\ (3LQ*O#G!5?\3[8C@K**EK:>1C.E7B=O)A,=*)2)-=(Q:.&_AC=V
MBU-M HH*MW&HS4_[%!U2]F$LA^6!^75QOF'^J/\ M_\ C?LSH?ETDJ.O>8?Z
MH_[?_C?OU#\NO5'7O,/]4?\ ;_\ &_?J'Y=>J.O>8?ZH_P"W_P"-^_4/RZ]4
M=#9VTX7$;#-R+XZM_-O]U4/L-["*R3_Z8?X7Z-=R-%C^P_X%Z!/S#_5'_;_\
M;]B2A^7154=>\P_U1_V__&_?J'Y=>J.O>8?ZH_[?_C?OU#\NO5'7O,/]4?\
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MST=7E]PS0^"CH:978Y27SU!GJF"R3N/;EA8?0H5J&))8L1Q)_,]4N+GQVKP
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MU?ZL]>_B;_ZH_P"V]^\$?ZJ=>U?ZL]>_B;_ZH_[;W[P1_JIU[5_JSU[^)O\
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M_5GKW\3?_5'_ &WOW@C_ %4Z]J_U9Z]_$W_U1_VWOW@C_53KVK_5GKW\3?\
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M]M[]X(_U4Z]J_P!6>O?Q-_\ 5'_;>_>"/]5.O:O]6>O?Q-_]4?\ ;>_>"/\
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MU?ZL]>_B;_ZH_P"V]^\$?ZJ=>U?ZL]>_B;_ZH_[;W[P1_JIU[5_JSU[^)O\
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MOP_RE[/H-B=A==5%375U?C&PO\7H]R4.WYE7'&OR-)F<)7TM#+/3+!5 1R:
MDJL#VZWWP;:&Y1*B1M)7-12H('"IJ"!Z]%T.WZY9(F:A45!Q\J5X^1Z0WS(^
M7'S&VW_*X^0/>7\Q#X/_ !9J\C#VWU9+U1\>MTBIW[ACMW=M?C!1-NGQYZKF
MEW-A*JHE262$8V-Y(@5I(E9T%+^>>*S>6ZAC^)=*&I&DD<>XY'Y?9U:WBC>=
M4AD;@:L* U'IC@?SZ(S_ #B^_OEUCOD-_)M7JG:6V.ONNLYE.OL_T+M/9_9&
M0VIC]RYS)2]92U>VMRT%+)'#0X##54^+H:*5XW)I*VM]("'67;[).DMKH 56
MTE &(#$^'@_(5 'R)Z5;<L;)-J))%=1(&!W9'S/5BW\ROY0]C]7?''X";G^8
M?P[^+/8?=/8?RYP>R]S=?;EDJNS<%M26KK,H*#+[;R.NFF;*OA8*%V>0/%'4
M32(T<JQ*":[M,]O%"9XHR[2A2#5@N30@^M*=(K*-97D$;L%"5!% 3PX_GTOO
MDY_,R^8.5_F&[A_ES?!G8OQ7Q?8_7_56([1W5V#\R,[N7$XG,MF(,;4KA-L4
M>WGHJJLKT@S6-=9%J*E9&CR,;10"ADE]N7>X3M=FTMUCU*H8F4L :T-!IIG(
M_GZ=5@MHQ#XTI:A- $ICCDU^S_!U<MTQN;M?-]7;+R?>FU=K;([=J<0!O[;&
MR<Z^Y<135\$LD;G&UTJ)-/13HB31>5%E1) DH$BM[/H(9&0&10&ID DBORZ+
M9'4,=!J/(F@/0G_Q$?U'M[P/E_AZIXGSZ]_$1_4>_>!\O\/7O$^?7OXB/ZCW
M[P/E_AZ]XGSZ]_$1_4>_>!\O\/7O$^?7OXB/ZCW[P/E_AZ]XGSZ0OWX_U1_V
M_LP\+[.DOB?/KWWX_P!4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5
M'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q/GU[[\?Z
MH_[?W[POLZ]XGSZ]]^/]4?\ ;^_>%]G7O$^?7OOQ_JC_ +?W[POLZ]XGSZ]]
M^/\ 5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q/GU
M[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^
MO??C_5'_ &_OWA?9U[Q/GU[[\?ZH_P"W]^\+[.O>)\^O??C_ %1_V_OWA?9U
M[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.
MO>)\^EEUU6A^P=B+J/JWEMA?K_6M@'LOW>.EI-P_LI/^.'I39/6://XU_P"/
M#H4/DU5"+M6N0L1_N'PQ^O\ 6(^R7DU-5B/]._\ AZ,-^>EP?]*O^#HOOWX_
MU1_V_L5>%]G1-XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??
MC_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_P!O[]X7V=>\3Y]>
M^_'^J/\ M_?O"^SKWB?/KWWX_P!4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)
M\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q
M/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?\ ;^_>%]G7O$^?7OOQ_JC_ +?W[POL
MZ]XGSZ]]^/\ 5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA
M?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\
M+[.O>)\^O??C_5'_ &_OWA?9U[Q/GT;?KFHU?&7M"4$G1G<F+_ZU+B?^*^P'
MNZ4WFV']!?\ CTO0CLFK82G^D?\  G12/OQ_JC_M_8\\+[.@YXGSZ]]^/]4?
M]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC
M_M_?O"^SKWB?/KWWX_U1_P!O[]X7V=>\3Y]>^_'^J/\ M_?O"^SKWB?/KWWX
M_P!4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_;^_>%]G7O$^?7O
MOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]
M]^/]4?\ ;^_>%]G7O$^?7OOQ_JC_ +?W[POLZ]XGSZ]]^/\ 5'_;^_>%]G7O
M$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]
MXGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_ &_OWA?9
MU[Q/GU[[\?ZH_P"W]^\+[.O>)\^C;]C5&GXR]7RDD:\[C!?_ %Z7+?\ %/8#
MVA*[S<C^@W_'HNA'>M2PB/\ 2'^!^BD??C_5'_;^QYX7V=!SQ/GU[[\?ZH_[
M?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_
M &_OWA?9U[Q/GU[[\?ZH_P"W]^\+[.O>)\^O??C_ %1_V_OWA?9U[Q/GU[[\
M?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??
MC_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_P!O[]X7V=>\3Y]>
M^_'^J/\ M_?O"^SKWB?/KWWX_P!4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)
M\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q
M/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?\ ;^_>%]G7O$^?7OOQ_JC_ +?W[POL
MZ]XGSZ]]^/\ 5'_;^_>%]G7O$^?1@OC+5"7M6A0,3_N'S)^O](A["O.2:;$_
MZ=/\/1SL+UN!_I6_P=!EV36A.Q=_+J/IWKNI?K_2NG'LYV>.MI!P_L8O^.+T
M@OGI/)G\;_\ 'CTBOOQ_JC_M_9CX7V=)?$^?7OOQ_JC_ +?W[POLZ]XGSZ]]
M^/\ 5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?9U[Q/GU
M[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^
MO??C_5'_ &_OWA?9U[Q/GU[[\?ZH_P"W]^\+[.O>)\^O??C_ %1_V_OWA?9U
M[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.
MO>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_P!O[]X7
MV=>\3Y]>^_'^J/\ M_?O"^SKWB?/KWWX_P!4?]O[]X7V=>\3Y]>^_'^J/^W]
M^\+[.O>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_
MOWA?9U[Q/GT9_P"6-2(>Q<*I)%]E8YOK_6NR0_XCV"^14U6C_P#-9O\ CD?1
M]S$VF=?](/\ CS=%@^_'^J/^W]C3POLZ(?$^?7OOQ_JC_M_?O"^SKWB?/KWW
MX_U1_P!O[]X7V=>\3Y]>^_'^J/\ M_?O"^SKWB?/KWWX_P!4?]O[]X7V=>\3
MY]>^_'^J/^W]^\+[.O>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB
M?/KWWX_U1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?\ ;^_>%]G7
MO$^?7OOQ_JC_ +?W[POLZ]XGSZ]]^/\ 5'_;^_>%]G7O$^?7OOQ_JC_M_?O"
M^SKWB?/KWWX_U1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X
M7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_ &_OWA?9U[Q/GU[[\?ZH_P"W
M]^\+[.O>)\^O??C_ %1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?
M]O[]X7V=>\3Y]&WR]1;XE[7FN;'.U O_ .1;(C_B/8#@3_=[(/Z _P"K4?0C
MD;_=<A_I'_C[=%(^_'^J/^W]CSPOLZ#GB?/KWWX_U1_V_OWA?9U[Q/GU[[\?
MZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C
M_5'_ &_OWA?9U[Q/GU[[\?ZH_P"W]^\+[.O>)\^O??C_ %1_V_OWA?9U[Q/G
MU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\
M^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_P!O[]X7V=>\
M3Y]>^_'^J/\ M_?O"^SKWB?/KWWX_P!4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[
M.O>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_V_OWA?
M9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?\ ;^_>%]G7O$^?7OOQ_JC_ +?W
M[POLZ]XGSZ]]^/\ 5'_;^_>%]G7O$^?1G]U5('Q8ZVFN;/O6O6]_Z39__BGL
M%V*?[N[@?\)7_!!T?7#?[KXC_3/^&3HL'WX_U1_V_L:>%]G1#XGSZ]]^/]4?
M]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_;^_>%]G7O$^?1?/E)VW
MV[T]TENOL;HSI/(?(KL/;57MFHH^H<3N*';%9E*"HRE'!EVHJJ>.6,UE%BI*
MRIAA\3M/)"L*([NJE)?-);Q%XD\1A3L! )%16E?,"IZ?M],KA7?2#7N-33&/
MY]:M_P \*;N3^=1NSX_==]-_RZOD=\5>R=D]ET.:[)^5?R(ZN7K1L%@HZ>>G
MEH8<BWVU;EUIYS#61TJU*5 J*2-((4\DDR ?<XY>9&C2*WDB96JTLBZ=*^E<
M$^M...A!:.FU!F>57!&$4UJ?\GIT)/S![?[3Z)_X4'[ [(ZGZ/W7\D<MMOX5
M8Z+<W76S\I24>?J,&[9Y,E7XI*J2&/(9*C7QRI2(#)4^J.-0QUH]N,DEKNRM
M&AD(ARJTU:>ZI%>)^7GTW:JLUD0S::R8)K2N.G_X^_'[Y%_S)?FG\\OF!VOT
MAV1\2^E>YOA?V!\-NJ,+VWMZ7:VY:H]B8:GP<N1FH:I&E*8\09"HFG%(*?74
M4E-3FJ,-5(+V=A-O-S/<.C1(\+0H'%&.H 5I\LFM*< *YZK/<QV$4<2L'97#
MMI-1@UZ0'Q(^5'S2^!_PFS?\MS<?\MSY:[Y^06QI.W=A=2;^V#L&3=&P<DO;
M&3R>5HLM5[BCA2FCH*/(9RL,CQ&J@\$ -154C^>*D9L+NYVNW-FUM*TBZU1E
M6J'420=7H"?GPR1Y.W,,5Y+XXE0*:%@31A0 4I^72H[[^ ?R$Z+_ .$\%#\2
MZ386Z^T^_P!][[/WUN7K[J;;=;V)74]1N;>T>9J**FIL1#63UG\(H)(DJIH4
M>'R132(QATN7;O9IK3:/ TEI*ABJ L<O6F*UH./3<%_'->^)J 6A +&@PM//
MUZ%_^>/\?^^>[/Y4OP_ZOZDZ=[+[+[$VIVO\>,AN78VR-F5^Y<KCX,5UYNK$
MU<]904D$M3304>0KJ2"HDDC5('D7RL@N0_S-837%A$D:,S!HZJJDL/TV!J /
M(G/3>T74<5P[,P *M0DT'Q ]&2_F]5/QQWGD]I]<_*?^6S\J_EOLD;+7,=>]
MZ?%G9*;SRN!S67K:Z/(8%YZ+*8C*X=5I\;BZQVDEJ*&M$Z(U+(](UUG,"0L0
MD]M+*M*J\2U*L2:C!!' 'S!],=,;8SBK1RHAKE7- 1C.00>/VCJJ>H_ES?/G
MY%?R.J[IOL3&]C5':?77R>C^07QCZ9[8S48W9#L?%86;#4VV<LU9%"U%DA%F
M\_6TV/G:"2&18:4BF5DHH2/]QW=YMFAPVM9/$C1SWZ *:37@<D@'Y#'#HQ_>
M,$%WJ4C24TLP^'56M1^P9Z&+Y@_(WYA?S=_CWL3X-=??R_?E'T%O??&ZNN<S
M\@^T_D)L"HV+M#;U/LV:*IR#4&2K(*.7($918Y(XVI*2LF@AD2&B>1V$+]_<
M7',$2VJ6\L;,5,CR+I10,FA(%<_8<<.F[:.+;',S2HP .D*:L:_+[/\ B^C<
M4O1':FWOY^_5'9./ZS[(K.D=G? ZCZX?N$[)R/\ =P5^*BR=-'02YT4YQ29%
MU:$FF^[\WK!T6-_9B+&1-U1@K:!!IUZ3IJ*XK2E?ETD^I0V9&H:C)6E<^7EQ
MZ!#^=I\&LOV;\P_BY\U,W\9>P?F;\?-C==5G3_R*Z$ZKRF0H]PMC,55;AR6*
MRF+APE7C<W4/#6;CJ)W%-7!3)04T$X2GJ)F*;F7:&EN(KDQ--&JZ)$0G50%B
M"*$'\7D?(>O3VU7P2)X@X1B=2LW"N 1FH\OY]</AQ\4/@_W,_P CMD?&?^5K
M\OOA3)V7\6N[.H)_D;\FAN';X@?M'%# 2XO$8O<F[MSB>>>#)U,S5%/ RHE(
M4FMY HUMVVVUUXBPVLL.J)U\274/B&F@#.WKQ'IUZZNY8=)DF1Z.ITI0\#7-
M%'IT6+XR;_\ GGU3_+E[E_E&'^73WY7=SP['^1G6=)VWD:)L;L%-N]Q-E:K(
MY<9[[<Q9'(TJ[@KTQ]%CWK/OY$IM$@9IH(D-DUW!:/M_T[Z],BZR/T]+U)-?
M,]QH!6N/LZ43^#).MSXJZ:J=/XJBF*?EFO#J\'^1_P!?]A]-?RN_B]UQVOLC
M=O6N_L!#W'/G=D[YP%5M;*T*Y_L#=>2HQ68^MBAJZ5ZBAK*6=4EB5O'*C$"_
ML3\LVKP6,2R*58:ZJP((K(Q%01Z'HIW:=9+ARK CMH0:CX0/+JUW[\?ZH_[?
MV>^%]G1=XGSZ]]^/]4?]O[]X7V=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_
M &_OWA?9U[Q/GT;?Y,5'BVSTT22/)@LL?]M3XC_BOL!\FIJFN_\ 3K_QZ7H1
M[ZU(X?\ 2G_ G12/OQ_JC_M_8\\+[.@YXGSZ]]^/]4?]O[]X7V=>\3Y]>^_'
M^J/^W]^\+[.O>)\^O??C_5'_ &_OWA?9U[Q/GU[[\?ZH_P"W]^\+[.O>)\^O
M??C_ %1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?]O[]X7V=>\3Y
M]>^_'^J/^W]^\+[.O>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^SKWB?
M/KWWX_U1_P!O[]X7V=>\3Y]>^_'^J/\ M_?O"^SKWB?/KWWX_P!4?]O[]X7V
M=>\3Y]>^_'^J/^W]^\+[.O>)\^O??C_5'_;^_>%]G7O$^?7OOQ_JC_M_?O"^
MSKWB?/KWWX_U1_V_OWA?9U[Q/GU[[\?ZH_[?W[POLZ]XGSZ]]^/]4?\ ;^_>
M%]G7O$^?7OOQ_JC_ +?W[POLZ]XGSZ]]^/\ 5'_;^_>%]G7O$^?3QMZN!S^#
M&H\YC&#Z_P!9D]I[N/\ 2?A\#?X#T[#)WKG\0_P]&'^6-2(>Q<*I)%]E8YOK
M_6NR0_XCV$^14U6C_P#-9O\ CD?1SS$VF=?](/\ CS=%@^_'^J/^W]C3POLZ
M(?$^?7OOQ_JC_M_?O"^SKWB?/KWWX_U1_P!O[]X7V=>\3Y]>^_'^J/\ M_?O
M"^SKWB?/K7^_F^?%#Y)Y#Y"_$/\ F/\ PXV'0]K]R_%&OEPV]>JX1%393<.V
MGJY:N*"BF;U3K E?GZ>2!%DJ%7(F>CC>6-XY IS!MD_BQ7ELH=XL,GFR_+]I
M%..:CHYVR\CT/!*U%?@WH?\ 53]G1=?E?\\?F[_,<Z)W9\-OC-_+7^4_3^[.
M[,52;1[.[,^1^UWZYV]M_"5]13)EA#D*^FIZ>IDFC,L)U&.J^V\\U-13SH(T
M17NXW.\1&W@MI4+BC-(NE54\<D?[-. Z46]M%8N)9)D8+D!34D^7#HRGR*Z'
MZ"^)7P)^*?PT[N^"?<OSSZ.V;L_*XC>6Y/C7U_%GLQM[=E&M)++N&CQ,.4QF
M8QS[JR><W%.*VDRRO3E)(:MYON[LNO;&+;[6*WE@>= ""8EJRMC-*@C42<@X
M\^/2:"Y>ZF>5)%C8G <T!&<5H1B@\NBW?RQ/BO\ );,_$;^9[TY/MKO7I+XK
M?(O9?9'7GP>ZB^3VO^]6W:;>^"W3B*VJJL54-%/CJ";[_"!(FJ5CJC3O41,P
M=JZL1[)ML\EO<QT=(I RPI+\:U5A6GD,C[>/S*C<+R-98FJK.I!D*?":$'C^
M1_U8Z+U\/NI_D5\@_P"4CWS_ "A]W_$_Y%=(]J[#V5OG>6([8[0VBVS-GYK.
MX+LF@WAA-NT.4KHU\U7DZ@-$TD44M-]I3S525062(^T>W6DUY82;>T4B.JL0
M[C2A82!PH)]?V4S7I^ZGC@N5N1(K*2!I!J0"I!-!T7[H?XU?"G;&P.N>K.\?
MY"G\P3?OR[VQA\%MS?F9V_-O>EV;G<SAX$CGS9SK;\H\)1T>4FC%1,J8K^&P
MF5XXF:!44I+6PMT58Y;&X:4 !B->AB/.NL"A^RG3TUS*Q+)<1!"<5TZ@/2FF
MN/MKU:9_,CZ+[K^/7SS^!O\ ,U^/W0&_>]M@_&_J^3H/LWI/JBF_CV?Q6WY8
M-R8^FJ\7C8*>LJ:\0X_>>55S&TD<;T5/YI:2"22MC/-ZL9;.Z@O8HVD6-=#(
MF6"]PJ!0UPY_8.''HNL+E)X9+=W"ECJ#-@$X\_\ :_SZ@[!D^1/\S3^9U\5_
MEQ6?&#NKXK_&+X6[9WT*6K^1VUO[B;CW)N#>='40O3X_$N[2-2)++CB9T>:F
M1*:I5IA42+3KJ&.;>[V*X\)XHH0W]H-+,Q'D/3AGA@^>.MR/'M]N\>M7=R/A
M-0 #Z_MZJ(R?QH[G[:VO\Q.L?G%\!OG5\L/YD&7WCVUD>@^^,9G=R#J[;N.R
M^,H3CZK$Y6JW5B<"V/H\HM754E$N(K8JBG%!BUBADC:FC#[;?+.)H[F">6XJ
M_AN"WA*"!2AU 4KD"AK@?+HR^J2,HT4L:1474N-9-<U%">'G7Y]'3WA\:_D<
M?^$Q_6OQ[CZ$[FJ>]:+=\^1K>F*/K/,UVZH(:SN+.YE))MO0T3Y:(?PJI@JF
M#T@*0.)'"KS[,I-OG_<JQ>&^NOP:6U_VS'A2O#/V=)5NH_KR^M=-/BJ-/P <
M>''K8>W;U/N7M7^7/N?X\HM1MO>79'PIS73*19:B:.2@R>\-BRX,+4TTCP,K
MTM546DB>2,@J59D-R!<]DT]F8N#-"4SY$I3_  ]$BW CG#UJ ]?M :O50_\
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M[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/\
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MV=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/\ >/\
MBOOWA?9U[6>O?=G^H_WC_BOOWA?9U[6>O?=G^H_WC_BOOWA?9U[6>O?=G^H_
MWC_BOOWA?9U[6>O?=G^H_P!X_P"*^_>%]G7M9Z]]V?ZC_>/^*^_>%]G7M9Z]
M]V?ZC_>/^*^_>%]G7M9Z]]V?ZC_>/^*^_>%]G7M9Z]]V?ZC_ 'C_ (K[]X7V
M=>UGKWW9_J/]X_XK[]X7V=>UGHR/Q3G\G;V/6X-\)G/]XB'L(<\)IL&_TZ?X
M>CWEQB;D?Z5N@I[2J=/9O8JW'IWWNX?C\9"H]GFR1ULK?A_8Q?\ '%Z+MP8_
M42_\U'_X\>D)]V?ZC_>/^*^S/POLZ1ZSU[[L_P!1_O'_ !7W[POLZ]K/7ONS
M_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7
MONS_ %'^\?\ %??O"^SKVL]>^[/]1_O'_%??O"^SKVL]>^[/]1_O'_%??O"^
MSKVL]>^[/]1_O'_%??O"^SKVL]>^[/\ 4?[Q_P 5]^\+[.O:SU[[L_U'^\?\
M5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU[[L_P!1
M_O'_ !7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7O
MNS_4?[Q_Q7W[POLZ]K/7ONS_ %'^\?\ %??O"^SKVL]>^[/]1_O'_%??O"^S
MKVL]>^[/]1_O'_%??O"^SKVL]>^[/]1_O'_%??O"^SKVL]>^[/\ 4?[Q_P 5
M]^\+[.O:SU[[L_U'^\?\5]^\+[.O:ST;'YBS^/LW!+<<[$QA_P#6AE/8%]OT
MU63_ /-9O^.1]"/F=B+A?^:8_P"//T4[[L_U'^\?\5]CKPOLZ#FL]>^[/]1_
MO'_%??O"^SKVL]>^[/\ 4?[Q_P 5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU[
M[L_U'^\?\5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU[[L_P!1_O'_ !7W[POL
MZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[
MPOLZ]K/7ONS_ %'^\?\ %??O"^SKVL]>^[/]1_O'_%??O"^SKVL]>^[/]1_O
M'_%??O"^SKVL]>^[/]1_O'_%??O"^SKVL]>^[/\ 4?[Q_P 5]^\+[.O:SU[[
ML_U'^\?\5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:S
MU[[L_P!1_O'_ !7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[P
MOLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_ %'^\?\ %??O"^SKVL]',S,UOAOM
M.3^NX*D7_P#(QD_<>6Z?\B&4?T!_U:CZ%,I_W5H?Z1_X^W1,_NS_ %'^\?\
M%?<A^%]G06UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J
M/]X_XK[]X7V=>UGKWW9_J/\ >/\ BOOWA?9U[6>O?=G^H_WC_BOOWA?9U[6>
MO?=G^H_WC_BOOWA?9U[6>O?=G^H_WC_BOOWA?9U[6>O?=G^H_P!X_P"*^_>%
M]G7M9Z]]V?ZC_>/^*^_>%]G7M9Z]]V?ZC_>/^*^_>%]G7M9Z]]V?ZC_>/^*^
M_>%]G7M9Z]]V?ZC_ 'C_ (K[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/
M]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/\ >/\ BOOWA?9U[6>O
M?=G^H_WC_BOOWA?9U[6>O?=G^H_WC_BOOWA?9U[6>O?=G^H_WC_BOOWA?9U[
M6>O?=G^H_P!X_P"*^_>%]G7M9Z]]V?ZC_>/^*^_>%]G7M9Z]]V?ZC_>/^*^_
M>%]G7M9Z]]V?ZC_>/^*^_>%]G7M9Z-CNZ>WQ%ZMDN/5OO(#_ *S[C_XI[ M@
MG^[ZY'_"5_P6_0CN6/[LB/\ PP_X9>BG?=G^H_WC_BOL=>%]G0<UGKWW9_J/
M]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/\ >/\ BOOWA?9U[6>O
M?=G^H_WC_BOOWA?9U[6>O?=G^H_WC_BOOWA?9U[6>B.UWP<Z[K_GOAOY@4N\
M-Z)V3A.G)>FJ?9<;T P;4<KU9-6X-(:_[G35R"PJPEPK6M=25'9$:\%Y4Z@F
MC3C33.>%?/I:-P<0&"@H6U5\_P#-T>+[L_U'^\?\5]FOA?9TBUGKWW9_J/\
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M[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/\
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M#^@_WGWZ@Z]U[[H?T'^\^_4'7NEYU94W[.ZY%ASOS: _/YR%/[*]\ ^BN/\
MFA+_ -6VZ5[?_;Q_\U$_X\.A@^7,WC[FR*V'_%BP)_V\1]A_D(5VY?\ 3O\
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M]Y]^H.O=>^Z']!_O/OU!U[KWW0_H/]Y]^H.O=>^Z']!_O/OU!U[KWW0_H/\
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M[,-_KV#O,_3^N2J?9]L3#Z&W_P":$7_5M>BW<?\ <B7_ )J/_P >/0??;O\
MU_W@^S76.D?7OMW_ *_[P??M8Z]U[[=_Z_[P??M8Z]U[[=_Z_P"\'W[6.O=>
M^W?^O^\'W[6.O=>^W?\ K_O!]^UCKW7OMW_K_O!]^UCKW7OMW_K_ +P??M8Z
M]U[[=_Z_[P??M8Z]U[[=_P"O^\'W[6.O=>^W?^O^\'W[6.O=>^W?^O\ O!]^
MUCKW7OMW_K_O!]^UCKW7OMW_ *_[P??M8Z]U[[=_Z_[P??M8Z]U[[=_Z_P"\
M'W[6.O=>^W?^O^\'W[6.O=>^W?\ K_O!]^UCKW7OMW_K_O!]^UCKW7OMW_K_
M +P??M8Z]U[[=_Z_[P??M8Z]U[[=_P"O^\'W[6.O=>^W?^O^\'W[6.O='#^;
M43/VKM\C\=?8H?2__+RRWL ^W3 6+_\ -=O^K<70DYH_W(7_ )IC_CS]$\^W
M?^O^\'V/M8Z#?7OMW_K_ +P??M8Z]U[[=_Z_[P??M8Z]U[[=_P"O^\'W[6.O
M=>^W?^O^\'W[6.O=>^W?^O\ O!]^UCKW7OMW_K_O!]^UCKW7OMW_ *_[P??M
M8Z]U[[=_Z_[P??M8Z]U[[=_Z_P"\'W[6.O=>^W?^O^\'W[6.O=>^W?\ K_O!
M]^UCKW7OMW_K_O!]^UCKW7OMW_K_ +P??M8Z]U[[=_Z_[P??M8Z]U[[=_P"O
M^\'W[6.O=>^W?^O^\'W[6.O=>^W?^O\ O!]^UCKW7OMW_K_O!]^UCKW7OMW_
M *_[P??M8Z]U[[=_Z_[P??M8Z]U[[=_Z_P"\'W[6.O=>^W?^O^\'W[6.O='A
MSD1_V2+9T?Y&XZH_3_J]Y7W&]L1_6.4_\+'_ %9CZ%4O_)*3_3'_ *N-T1[[
M=_Z_[P?<D:QT%>O?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/OVL=
M>Z]]N_\ 7_>#[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/
MOVL=>Z]]N_\ 7_>#[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]
M?]X/OVL=>Z]]N_\ 7_>#[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]
M]N_]?]X/OVL=>Z]]N_\ 7_>#[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL
M=>Z]]N_]?]X/OVL=>Z]]N_\ 7_>#[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X
M/OVL=>Z]]N_]?]X/OVL=>Z.'O.)C\,NI4_([!R1^G_-_<W_%?8!V]A_6&Z/_
M  A?^.V_0DN?^29#_P U#_AEZ)Y]N_\ 7_>#['VL=!OKWV[_ -?]X/OVL=>Z
M]]N_]?\ >#[]K'7NO?;O_7_>#[]K'7NO?;O_ %_W@^_:QU[KWV[_ -?]X/OV
ML=>Z]]N_]?\ >#[]K'7NL4RI30RU$\J0P012332R>E52(%F9B> % ))_I[\7
M Z]UJV?S!_A%\01USVI_,\^"ORLH.A.V]O[?S?:YR_3/9E(^!W56@I5RTE-#
M15D-1C<KFJF!D,5/,:>HK'(J<>\CRN(VWW:;30^XV4_A2 %ZQN-+GC3!P2?3
M!/$="K;KV;4MK/'K4D+W*:K^T9 _P>?16_YF/9/9_P I/Y%'PE^3'<NSED[C
MRO>^W*#>&]/[J18ZKJ<5B:#L;#TN8F:&D@%#C]Q/2XFM*1I#12U%5 ],GCEI
MKEW,-U)N>RV]Q*OZAD 9M-"5 E6N *!J ^E2*>72K;(DM+^6)#VZ#05\ZH:?
MED>O1X_YQM9U#U_TK_+>WGL_^X>WNL]O?.?I?=FZ<QL>EH:7%P"DQ+5M565#
M8U13F8T$ E9C>1XD5N5"^SGFMX88;1TTA!<QLQ6FD=M2<?(=(-G5Y'F!J6,3
M 5K7C3SZ3W\W_M+K3?'\QG^2=M/96_MI;NW#M;Y2X+<&Y,7MK.T^;DH:+?&]
MNL4Q%14FFDD2),@<3D3#=KNL#L!I*EF^:KN*>_V]496*S D UH&DAIP]=)_9
MU?9X6CMKDL" 4(%12I"O7_".I\D.S<G_ ,*1.S:3Y)TNS?X!C?BQM_\ V6<=
MA)CS33U*8G;D\DF/6N9DDK(ZB;?NBRB91%4,@T)K.ZHW,#_4::"$>#JI2NE#
MBOG\?\^M=PVU?"K7Q#KI7U/I_M>@>^%77'QMW[_/2_F5=6=28W8F6^/6]OB'
MO?9U?AMDK!6X*9]TS]6TN\*6F2/72>(Y^HSD<B1@P)+Y$B41JH"7:(;>;>;N
M.(*8F@9:+\/=X(<?[T6^73U[)+'80L]=8D!J>.->G^5.B!UO9'9FU/C3O/\
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M^_>-U[POEU[[+_!??O&Z]X7RZ6O\.'^I/_))]D_U _U?\7TMT#KW\.'^I/\
MR2??OJ!_J_XOKV@=>_AP_P!2?^23[]]0/]7_ !?7M Z]_#A_J3_R2??OJ!_J
M_P"+Z]H'7OX</]2?^23[]]0/]7_%]>T#KW\.'^I/_))]^^H'^K_B^O:!U[^'
M#_4G_DD^_?4#_5_Q?7M Z]_#A_J3_P DGW[Z@?ZO^+Z]H'7OX</]2?\ DD^_
M?4#_ %?\7U[0.O?PX?ZD_P#))]^^H'^K_B^O:!U[^'#_ %)_Y)/OWU _U?\
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M]]0/]7_%]>T#KW\.'^I/_))]^^H'^K_B^O:!U[^'#_4G_DD^_?4#_5_Q?7M
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M Z]_#A_J3_R2??OJ!_J_XOKV@=>_AP_U)_Y)/OWU _U?\7U[0.O?PX?ZD_\
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M23[]]0/]7_%]>T#KW\.'^I/_ "2??OJ!_J_XOKV@=>_AP_U)_P"23[]]0/\
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M]]0/]7_%]>T#KW\.'^I/_))]^^H'^K_B^O:!U[^'#_4G_DD^_?4#_5_Q?7M
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M=>_AP_U)_P"23[]]0/\ 5_Q?7M Z]_#A_J3_ ,DGW[Z@?ZO^+Z]H'7OX</\
M4G_DD^_?4#_5_P 7U[0.O?PX?ZD_\DGW[Z@?ZO\ B^O:!U[^'#_4G_DD^_?4
M#_5_Q?7M Z]_#A_J3_R2??OJ!_J_XOKV@=>_AP_U)_Y)/OWU _U?\7U[0.O?
MPX?ZD_\ ))]^^H'^K_B^O:!U[^'#_4G_ ))/OWU _P!7_%]>T#KW\.'^I/\
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M0.K@?[PXO_CC-_U*3_H_W"GT3^H_G_FZD+ZI?G_+_/U[^\.+_P".,W_4I/\
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M7OJE^?\ +_/U[^\.+_XXS?\ 4I/^C_?OHG]1_/\ S=>^J7Y_R_S]>_O#B_\
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M\_7O[PXO_CC-_P!2D_Z/]^^B?U'\_P#-U[ZI?G_+_/U[^\.+_P".,W_4I/\
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M\_7O[PXO_CC-_P!2D_Z/]^^B?U'\_P#-U[ZI?G_+_/U[^\.+_P".,W_4I/\
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M^\.+_P".,W_4I/\ H_W[Z)_4?S_S=>^J7Y_R_P _7O[PXO\ XXS?]2D_Z/\
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M?_'&;_J4G_1_OWT3^H_G_FZ]]4OS_E_GZ]_>'%_\<9O^I2?]'^_?1/ZC^?\
MFZ]]4OS_ )?Y^O?WAQ?_ !QF_P"I2?\ 1_OWT3^H_G_FZ]]4OS_E_GZ]_>'%
M_P#'&;_J4G_1_OWT3^H_G_FZ]]4OS_E_GZ]_>'%_\<9O^I2?]'^_?1/ZC^?^
M;KWU2_/^7^?KW]X<7_QQF_ZE)_T?[]]$_J/Y_P";KWU2_/\ E_GZ]_>'%_\
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M?5+\_P"7^?KW]X<7_P <9O\ J4G_ $?[]]$_J/Y_YNO?5+\_Y?Y^O?WAQ?\
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M>'UZO^J@Z]_$#_5O]N??O#Z]7_50=3\77%\GCDNWJKZ1?J?[4BCVU<)2-O\
M2G_ >G(CW#[1Y#UZ=]VU?AS,B7/$$!X)'U'M/MZ5B'VG_#T[=GO_ "'ETF?X
M@?ZM_MS[6^'TFK_JH.O?Q _U;_;GW[P^O5_U4'7OX@?ZM_MS[]X?7J_ZJ#KW
M\0/]6_VY]^\/KU?]5!U[^('^K?[<^_>'UZO^J@Z]_$#_ %;_ &Y]^\/KU?\
M50=>_B!_JW^W/OWA]>K_ *J#KW\0/]6_VY]^\/KU?]5!U[^('^K?[<^_>'UZ
MO^J@Z]_$#_5O]N??O#Z]7_50=>_B!_JW^W/OWA]>K_JH.O?Q _U;_;GW[P^O
M5_U4'7OX@?ZM_MS[]X?7J_ZJ#I%8[MCKW,;ZW-U?B=^;1RG96R\+M[<>\.O\
M?N:DK,UBL?NUJE<76Y'%QS-6T5)D6HZL4TLT*)/X9/&S:#;6D$TKGTZW\_\
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M_;W56TL'189:-H7SNX\Y4-+'4945G^04]#AZ^680SO*((T#LND9EII4M7Y@
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M.70NF?4$0G22#F@Q]OG\NO&(+34P%0"//CTC\9_/9K.V?CY+\M/BE\ _DO\
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M@''V?Y3T'_WO^*^S;0>D6L=>^]_Q7W[0>O:QU[[W_%??M!Z]K'6N[0;:A_G
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M79S*20XS;V/GFL62.OSE=CJ<Z 9&\NF,&0J"S</X"%SY#IR(>*P7UZJGZO\
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M]5=-=JUV]Y<K%44F2I^XI,M%!20T@B2:GFH7Q,NMFE=9!(I7201[VKZG*4X
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MNRO<57EI<AF<]DV@P>V=N8V@PM6]9D:ZJ4"62EI:6"KJZJ&!KRL8[G ))CH
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M7J_ZL?YNO?<_X_[S_P ;]^\+_54]>K_JQ_FZ]]S_ (_[S_QOW[PO]53UZO\
MJQ_FZ]]S_C_O/_&_?O"_U5/7J_ZL?YNA:V[+JZSW.][Z:^I_/](J3V'[U*7L
M0_HC_"W1I;G_ !=_M/\ @7H)?N?\?]Y_XW[$'A?ZJGHKK_JQ_FZ]]S_C_O/_
M !OW[PO]53UZO^K'^;KWW/\ C_O/_&_?O"_U5/7J_P"K'^;KWW/^/^\_\;]^
M\+_54]>K_JQ_FZ]]S_C_ +S_ ,;]^\+_ %5/7J_ZL?YNO?<_X_[S_P ;]^\+
M_54]>K_JQ_FZ]]S_ (_[S_QOW[PO]53UZO\ JQ_FZTZ?@Y\L?Y9?QJ[M_G$[
M$_F [CZ-VKO?=/\ -4^7>[L'MKNGJ]MY5U;M?-U\;4L\$,F%R3S8ZM85#PQB
MZSA_)&CK*K.'K:6&%I5E*@^*V""<?L/1K*DD@0H#30O @9Z%3H?9N9VE_*"_
MGC[@VIUOV%TK\0^SJ#YN[Y^%/5/9>(K=I56/V;E]AU4=378O Y*0UNWMNYO.
M)6U6.Q\D%-I5I*A*<)4K)*Y%$1;S$ JAUE :C&GT\A7JCL#+&*@L-.HBG&O5
MB^'[9^1?2'\@3IKM7XZ;7KMW_([8?\MCXW9_9^#K,/)N&L_B4&R-N#(UK8V1
M)9<C78RE>NKA2O"[54].(71S(5*L:X[4,F6$:D#/H.F"%><AN&H^GJ>J2_DE
MVW\;N[=B_P NW</3WSR^87SQ[3D^;GPCWCV77Y?>V1K=E;>AW+O##--+N_;.
M'Q.W]G;8RPR%;14&'QM30',PEI0D3B/(58+IF201E79SK0G)H*D<0  /EY]*
MXPR%JJJC2U/4X\O,]7$8[SR?\*6,_71Q2O2TW\DZBHJFJ1"T<<M7W=!)%$[C
MTI)*D4K(I(+*CD A38P$?^.4_P"$_P#/_24G_%_^;G_/O3=3[-S'8_\ -)_F
M];!VW,E#GNP?Y=?QGV5AZ]F$*QUVZJ+?]!22NY!4:)94-VO95^EA[T(B\\JC
MCX:C]NKKVH+&A_I'_)T4SXH_S,>@NJ/Y4&V_ASN3#]A?[/+TS\>=U?&7=?PK
MP>Q<ADM^+N+:>/K<(U9+00T[4U)@*B 0Y6?,3U*4%+03&:HG60>(IX+I$@\,
MUUA2I2AU5&.'IYU].GI("TFK&DFNK%.F;>O6_9^\_P#A/Q_*^[ ZQVEO;L6M
M^+.3^"_ROWEU7L"CBR>5W-MKIR5:G,XVFHI;&N>"DJOXBD$;K)(]$FDL 8W\
MT+-:1LH)TZ&('$@<>O!PL[@XKJ%3Y$]+_P#F@_-#XU_S7/AA4? _X+]A?Z?N
M^/E7OKHW$T^W]H[5RDDVQ\3MG=V%W'F]Q[ZBK:6C.UJ+#T.&J8IXJYZ>J,\@
M@2)F+Z;7DJ7T?A1'4S%<"O:*@DFO"G5;>-K9M;B@%?3.*8]>MFRC/VE'2TGD
M\GVM-!3^2VG5X5"WMJ-KV^ES[.A%_JST7ZO]6/\ -U)^Y_Q_WG_C?OWA?ZJG
MKU?]6/\ -U[[G_'_ 'G_ (W[]X7^JIZ]7_5C_-U[[G_'_>?^-^_>%_JJ>O5_
MU8_S=>^Y_P ?]Y_XW[]X7^JIZ]7_ %8_S=>^Y_Q_WG_C?OWA?ZJGKU?]6/\
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MV 2?3Y]%X^'FW/AW\3-A=@_&?^85\YOF;\0_D'T]W1W@L^'F^:/8WQNV_N_
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M_P (Z0W!_4;_ $Q]/4_+H[_W/^/^\_\ &_:GPO\ 54],U_U8_P W7ON?\?\
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MVQ]J?8Y+][<DDZU<T<$E/-5U$M! "N:59K<DN[/3*BHTGSJ !0#Y]+8T,<H
M50M<-Z_8?4_+J\7Y3RUY_F_?\)^4I?O/##UG_,..:C@UZ5I_]%6&\?W2KP(1
M6K3:?)Z?.(K?N!/9E.A^H@'RD_XZ.D<9_2D/S7_#TI_YW_GK,Y_)U@IHI:F=
M/YV/P@K3# AF814!W%+/+I6Y\<,2L[M:R("S$ $^[;E'0Q?\UD_R]:M#A_\
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M/H/S/'[2WW]A)_I'_P".GIZW_M%_TR_X1TK.U9-.[Z@<\45#^/\ :/:'8O\
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M\9#*>?RK $'\$ CGW[KW4:MI:')0BFR-%2U].)8IA!6TL=4FN AD?1(&74C
M%3:X/(Y]^(KU[J2'4.T@4"1E5&<(+D(25!/U(!9K#\7/]3[]U[J&U%CGKHLH
M^/HGR<$3PP9%J.-IT27AD68KY%5A]0&L?S[U3KU>IWF/^/\ MA[WU[KWF/\
MC_MA[]U[KWF/^/\ MA[]U[KWF/\ C_MA[]U[KWF/^/\ MA[]U[KWF/\ C_MA
M[]U[KWF/^/\ MA[]U[H9=LR7ZJW8W/&0JA]/^;5'[#M[_N?%_I1_A?HUM_\
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M]U[KWF/^/^V'OW7NO>8_X_[8>_=>Z$?JJ35N^G'/-%7?C_:/9/OO^XY^U?\
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M!'$BQ("Q"1HJ"[DL386%R22?ZDW]^Z]UYS'(4,B+(8G$L9=%;2P! 9;_ $8
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M]U[KWF/^/^V'OW7NAEK9+=.8EN><A(/I_P!-E3[#L?\ R47_ -*/^.+T:O\
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MH12@IQZ,?Y!_JC_O/M[\NJ=>\@_U1_WGW[\NO=>\@_U1_P!Y]^_+KW7O(/\
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M[\NO=>\@_P!4?]Y]^_+KW7O(/]4?]Y]^_+KW7O(/]4?]Y]^_+KW7O(/]4?\
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M3K-D-E/OG#YRBSD>&_W\6YY8-O9RIQ$%;14S9.-::#Q0I0TCK,9DFUJ5EEC
M95&@JK<5J#6F3@TK_DZ?NVJB.2"3J!(X&E/D,]!I_(I^(W7_ '%\*?BA\].[
MM^]R]Q]_[>QO:]!U)E]U=DYK$XS:&(VCF]S[3DPE!@,;DX<+E(:QZ;(U=36Y
M2CK*ZJFJ@[RQ"**..FRV(FA2=RS-G34FB@$K2@-/S->K7]P8Y&C4 #%?4X!]
M.B<?$OXF[/[W_D#YWYM=V]K_ "!WE\AM@?'/Y1=B]([^3M[/X9NNS\:LIO!<
M-!M7&XC*XC'O+5U6W/O*^KKEJ*^NFJI$FK1#%3+"DM;,36)F<L6".5-3VZ"U
M*4(],^9Z>FG,=QX:A0"R@C&=5../GT+7?'QVG7^3IMK^:KF.^?D1N'^8A0]
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MO[2AR&.W@:JL[>KIXMN;:S&+HYI\RM#AAYJF2H>&AG73%$[)(%Y+ZW-Q)XS
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MJK:T\FE:FH@GIFJX:HHIE2$Q20I(M9$!8@@,I-*'4U37R-.E$;,X=9&0T5B
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MI/#4D<>X9(^?&GSZ:BC!G<8HNHT)QCA7Y?Y.@HAZHWGUAW%\3-]_R_/Y>?\
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M.2QM/HRQJ:6EI:,4E-2)$TC2L[?8B[:1W+'1.X45( (-:X(KQ\^G+JX, 0*
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MCG[1K=F4*[5I=O1U])M*#:%#09_[):$81DFBA\]:E=/-4_<,7%KX-FMSJ;Q
ML;!JG\17%*TIGA3IR*;7<&*BZ:L*?97/K7'KT<;YB?$O;OP?E^#?RYZA[<[^
MR/RBS'SE^+_6W>G<6^.W\]NR7L3!]X9-,3NC%;@P=97S;<H\95HX:DH\9B:.
MFQ@&FABA8)(BN[LA9>'*I;69$5F)/<&-#4</V#'ETS!<&?6A TZ&( IVD#'E
M7K!\KNTJ;Y(_S1N[.A>WOCG\OOE9T'\/.F.F'P7QY^.V1QVW\'D-T=Z03YVJ
MWANZGRV]MC0[A@QN/I:#'8I/O:RGI:D5[?;+/Y)/=;G]>X:-DD=8U7M6E"6S
M4U9:TX#\^O15BB#!E4L3W-Z#%!@_GT'6/[6^6GP?^)7\W3=VQNI?DK\=?C5L
MKJK8F\?@?MWY*9/%[JW%LK-[SH9\!N>@Q=13;NWZDV#Q&8?'Y7&05-<8J59#
M"83'Y2:5ELXIV"NB!08P]*J2*'\38!R.KC1.\8)4L2=>FM"!D>0STW?/3^5_
MTMT=_*/[E[BZ]['[UQWR"QGQLH=P=Q]O5_<FX]XOV6V:AHIL]2;QQ.:R=?AZ
M^CR4\\TM,\5%#4XZ58)*2=0DB3>O=K6"U9U+:M%6:I.KUK4D?YO+KUO>-),%
M(6FK QV_90=6!_S$NM>YNROCM\*,OLOKCL_OSHKK3=^S-Y_*OXT]-;YEV+N/
M>^UAM.IHJ2DI##DL.<]28S+55-65.#?)1Q9-8T5DD,2%%M];.\:%0S*""Z*:
M%AI^T5SY>?2>VE"LP) )J%)R :_R^WHRO\M3>/POSW5&_(_A:F_=I[5Q_9%;
M'V-TGV56;JQ^8V1N-Z.D2JP\^VMVU=37;62:&&*H%)2A,?+(\M13!FDE;V_M
MZQ.I\&H .5.JJGTHQQ_@Z:N3(I&NG#!!&1]H&>JQ?YVU+WCG?G[_ ">,9\9L
M_MO:_?\ 68?^953=0Y_>-&U;C:;/3=?;:% ]2H:T8::RI,R2QT\C)/+3U,<;
M4\I?N\3^/ (Z!CXNFHQ72.E5BX\.0OD=E:'RJ>CP?R3\_P!'1?"; ;(ZSV]N
M+9G;77>[=R[;^8>T>Q,XVYMYP=M>;R;QK]V9*;34Y2NS&1+U5+6LBQ34+T\=
M.L44 @A5[0BF*BU# D2 Y8/YU]:^OITQ?,PDJ2*'X2,#3Y4Z)U\#_C1TK_-@
MZ4[%^:7S2H^Q>W=V]S]W]SXOK+:V=["W-L>CZVVSUGN6NPVW<1MG#XG)XV+"
MY>B_AD=;/7M"<BU:5D>8/&;IK*S7<T,TM6+,U!4C2%)   (H<<>/3UQ.UHP1
M*"@%>!U$BIK4'HAG;/R5[NH?Y&7\R/8VX>W^P=T;O^ _\PT_%'KKO//YA=Q[
MIR6WNH>U-A28BNRU2RTD>2R,5%DI*63RD1U<$:1SV1W7VBED<6<P+$F*70&.
M20KK3_#TI1 ;A,"CIJ(\JE3_ )NK4ODGU/LS^41\"?FO\NND<SVKOCY2Y[J#
M TO8'=78F]\YV77[@W5E\E'B*'=-5A:VMJ<%BS093<,U:\..Q='0P4T?C>'[
M:"P,;BV&U022I4OI%6-34UI6E:<3Y"G2.*4WDBH:!:X H*#C3^75;^^>C-\;
M1^/VU=U_"OX*?S1<'_,&V0NPMW[6^9'9V_-N;D3>F5HJW&U.?.]WD[KJILSM
MW==!!61FDEP#)3"6G,-'"(FB*%[5D0&**;Q10AS0ZCBM?U,@_9TH6<%J.\>C
M/:*X^SLXC[>K0/FE%\"^W?D/A^N_D9U;\F_EKWS6=*8&7)?%7J"3>N^]N;5P
M]<]=/_&<QA\1D\/L["9#+S25-,N0R]>M95QP04].0GB60PNXX9)-+AW;3\"Z
MB%&<D @"OJ>/2:%Y$6JE5%?B) )^603^SIJ_D3=@[WR'5OS,ZHW,_<U!LWH/
MYR]K]?=*[%^0-6F3W?M#:&2QF#S>+VAF*M,SN%JJ7!/DJB-97SE:S:SIF6+Q
M00ZV8,RR*=5%D8*&^)5H" <GA7U/6[\T*D4R@)(P":D5&!U>C]\O]6_VW_&_
M9QX1_P!0Z0:SZ_SZ]]\O]6_VW_&_?O"/^H=>UGU_GT-&;J0.DMGS<V;<=4O_
M %DRG^/^'L.6R?[LI1_PL?X(NC69O\40_P!(^?S?H%_OE_JW^V_XW[$?A'_4
M.BK6?7^?7OOE_JW^V_XW[]X1_P!0Z]K/K_/KWWR_U;_;?\;]^\(_ZAU[6?7^
M?7OOE_JW^V_XW[]X1_U#KVL^O\^O??+_ %;_ &W_ !OW[PC_ *AU[6?7^?7O
MOE_JW^V_XW[]X1_U#KVL^O\ /KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V
M_P"-^_>$?]0Z]K/K_/IHS^[<#M7!YC<VYLQC]O[=V_C:W,YW.YFLCQM)1TF-
MC::HJ:FHF=(H(((D9W=V"JH)) 'O3)I%2: <2> ZV&+&@_P]4U?$J7='SH^=
MNX?YDM5A<EMCXO=3]29_XW_"!LFLM!6;WI]UY*&MWAV1+0S1QS4>$KYZ&GH,
M%J:]=1(]>\<:F N56L9O9C<4[ "D?]*IRWV8H/7CTMF?P(_"KW$U;/#T'^?I
M-_R3<C5S;F_F[U.X9J^?=LG\W_Y819"3*>1ZD8ZEAP4>'CU2'4*2*G$B4J "
M-( JQ?MZ0*[3&29_7QW_ &8IUN^:@CI_OM?/[>J8?Y@4^_J/IS_A4!5;7J\C
M3]>U_>O\O:CQD&%7PE<F]1MH;Y+O BRF*JHY\0E6K3,C0B02(J/,9"F]1@EW
M3@&B_;45_P G2VV8%H*\:/\ Y:=;&7\U*?;3_P I/YFP1K3';X^(F^QA5$:K
M$/'A2<9XU8D+IG%,8_R"%T\@>S[<XZ6TGIH/^#HMM&)F7_3#S^?1+.M_Y??R
M\WMGOA=\Z.JOF)M7H'O[$_RK_CE\3.R\-O7XUP]W0UU10M3[JS=>)&W3MN"D
MDK,K-!"47',85@E9&_?"0I(]ME?PYE<*W@JAJFJOXCYCSZ?:[1=496HUEA1J
M?+T/1K/Y>'S1^0/:/>/S,^%?RVH>N,A\@_A;N3K,9'L[I[&UN#V]NO;O<^+F
MS6W\@,97U-548K+PT"P_?TXG>!))E2!Y!'(Y46,TDKR0R4UQD94&A#"HQY'U
MZ:N4"*LB$Z6K@G((-#U;']\O]6_VW_&_9GX1_P!0Z1ZSZ_SZ]]\O]6_VW_&_
M?O"/^H=>UGU_GU[[Y?ZM_MO^-^_>$?\ 4.O:SZ_SZ]]\O]6_VW_&_?O"/^H=
M>UGU_GU[[Y?ZM_MO^-^_>$?]0Z]K/K_/KWWR_P!6_P!M_P ;]^\(_P"H=>UG
MU_GU[[Y?ZM_MO^-^_>$?]0Z]K/K_ #Z]]\O]6_VW_&_?O"/^H=>UGU_GT._<
M=0(L-UZ3?UXRN/ _I%0?\5]A?EY-4D_^F7_"_1SNC42+[#_@7H"/OE_JW^V_
MXW[%'A'_ %#HFUGU_GU[[Y?ZM_MO^-^_>$?]0Z]K/K_/KWWR_P!6_P!M_P ;
M]^\(_P"H=>UGU_GU[[Y?ZM_MO^-^_>$?]0Z]K/K_ #Z]]\O]6_VW_&_?O"/^
MH=>UGU_GU[[Y?ZM_MO\ C?OWA'_4.O:SZ_SZ]]\O]6_VW_&_?O"/^H=>UGU_
MGU[[Y?ZM_MO^-^_>$?\ 4.O:SZ_SZ]]\O]6_VW_&_?O"/^H=>UGU_GU[[Y?Z
MM_MO^-^_>$?]0Z]K/K_/KWWR_P!6_P!M_P ;]^\(_P"H=>UGU_GU[[Y?ZM_M
MO^-^_>$?]0Z]K/K_ #Z]]\O]6_VW_&_?O"/^H=>UGU_GU[[Y?ZM_MO\ C?OW
MA'_4.O:SZ_SZ]]\O]6_VW_&_?O"/^H=>UGU_GU[[Y?ZM_MO^-^_>$?\ 4.O:
MSZ_SZ]]\O]6_VW_&_?O"/^H=>UGU_GU[[Y?ZM_MO^-^_>$?]0Z]K/K_/KWWR
M_P!6_P!M_P ;]^\(_P"H=>UGU_GU[[Y?ZM_MO^-^_>$?]0Z]K/K_ #Z]]\O]
M6_VW_&_?O"/^H=>UGU_GU[[Y?ZM_MO\ C?OWA'_4.O:SZ_SZGXJM4Y3&B[<U
M]&/I_61?\?;4\1T-_I3_ (.KQ.=0^T>?SZ%GO2I$.[<<IOSMRD;C_&IJ_P#'
M_#V0\L)JMV_YJ'_CJ=&6\-24?Z4>?S;H%_OE_JW^V_XW[$?A'_4.BK6?7^?7
MOOE_JW^V_P"-^_>$?]0Z]K/K_/KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^
MV_XW[]X1_P!0Z]K/K_/KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V_XW[]X
M1_U#KVL^O\^O??+_ %;_ &W_ !OW[PC_ *AU[6?7^?7OOE_JW^V_XW[]X1_U
M#KVL^O\ /KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V_P"-^_>$?]0Z]K/K
M_/KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V_XW[]X1_P!0Z]K/K_/KWWR_
MU;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V_XW[]X1_U#KVL^O\^O??+_ %;_ &W_
M !OW[PC_ *AU[6?7^?7OOE_JW^V_XW[]X1_U#KVL^O\ /KWWR_U;_;?\;]^\
M(_ZAU[6?7^?7OOE_JW^V_P"-^_>$?]0Z]K/K_/KWWR_U;_;?\;]^\(_ZAU[6
M?7^?7OOE_JW^V_XW[]X1_P!0Z]K/K_/KWWR_U;_;?\;]^\(_ZAU[6?7^?7OO
ME_JW^V_XW[]X1_U#KVL^O\^O??+_ %;_ &W_ !OW[PC_ *AU[6?7^?7OOE_J
MW^V_XW[]X1_U#KVL^O\ /KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V_P"-
M^_>$?]0Z]K/K_/KWWR_U;_;?\;]^\(_ZAU[6?7^?7OOE_JW^V_XW[]X1_P!0
MZ]K/K_/I'_?+_5O]M_QOVOT?ZJ_['3'7OOE_JW^V_P"-^_:/]5?]CKW7OOE_
MJW^V_P"-^_:/]5?]CKW56/\ -F_ELT?\TKH_K?I6L[GJ>DJ;8/<6*[4J-PTW
M7R]B/6Q4&(S&)DQR4SYK"+222KEO*M29IPABTFFDUZD*]VVG]Z($U::-JK35
M7!%.(]>EEE>?1L6I6HIQIY@^AZ4'RJ_E\Q?)SYJ?![Y?OV_)LH?#/+[LRPZ\
M78']XO[QG<STCJG\7.;H?X.(&I1<_P ,K?(&^D=KFUUM?U,\4VJGAUQ2M:_.
MHI^P]:ANO!C>.E=7G7A_+J+VE_+JQG9G\TKXV_S,I.WJ[#Y#X\=)[CZ=BZ<3
M9"5T.6_CM+OBE3(MGCE8GH? F]ZHM3C$3^1J:*TT8=Q[U+M7BW27.JFA2NFG
M&NK-?]MZ=>2[T0M#3XC6M>'#R_+HF7S=_D,]:_,[YP8SY=UG>V4Z[VKN%^JC
MWYT50]:KGZ+?:]6U-,8TKLF-P8^.F6NQ]#04D@FPU>$%.DR#R<!%?<O+>3^-
MJH#IUK2NK3\ZCRQP/2BWW,V\>BE>-#7A7\NC^?S$?Y?O77\PCJ_8VT,]O;=G
M4'8?3V_,5V?TCW#L.&.;([;SF("B*>.FD>*.JI7T1,\(G@?R0P2Q3121*WLP
MW':UW!0"2I4ZE8<0>DUK=&U8D $$4(/F.@F^,/P__F&]>=N[/W_\HOYJ>\_D
M?L/8\.2CHNGMN?&[:?2]!EWK<?64,3[@R.-DJJ[(1TSU2U*1D"0U$,,C5)TZ
M?;-K87,;AI9RX'X0BJ#BF2*]7FN(F4A(PI/GJ)I]G12>UOY-WRI^30VMTY\N
M/YIG9O?_ ,,=I[VPF\1TQE>@=L;7W5EEVU'(M%29;?V-GAR=3*IGE$]9)33/
M,FIDA@J'CJ*=)+L<US1)IR\8(.G2 QIZL,_GT^FX)#5DC"L12NHD#\NC"?S#
MOY6&>^7/>?QQ^5/QX^2N0^(GR5^-^$R>S=M]CXKK.D[&%3A*_P"[\-$]//D<
M:RM0'(Y41"26HIVBKJN)Z>\OD"G<=G-VZ2QOX;I@&FK'\O4_M/35K>^ K(RZ
ME;-*TS_/I8]P_P M;.]U?([^7!\D=Y?)7*Y;=GP)P+4.YGRO5U/55G8>2JJ3
M&PUF8JJNES=#2[=J*ZKH)*F6*'%UL0:=HXQ&J*3:7:3-)#(SU,0SCXS09XBG
M"O ]52\$:2(%^/Y_#_+/6M?T=VOU#LSY9?S2,QVM_,;[V_E,;FS/RNWCNC%?
M'#;&/KLM%7RR&MJI=WUPS^-R\65J,_4SFH^PH4I6\+1I')+CYL6M.&H)$2:<
MO,T!\0G1Z\>[(-:^@I^RG1O(C,D8$8E[0-7^3%.'^KSZL0^-/QY^0O\ ._\
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M:MKXLI48O(X"GK!,\-/'/<0O3*H9G8.T!TF1C42L6Q@K4#[:T(KY=.B\*LC
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M7Q+.VF5R@+6N-J\>U^FU4[4752OP:<TQQT^O58KOPYO&I7+&E?XJ^?Y]#?\
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M3IC8859*&*FIP&ED6265V':DCB:)B6UZB['!8MQ.!CY>G5'NV9PXH-- H'
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M^8E20+[1H&^G]:RO_P"*>PCR8M;5O^:K?\<3H[W[^V'^D'_'FZ+K]Z/]4/\
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M2H ^,6W)K\',SB]O^KG7C_B/8*A7_=U(/Z _ZMIT?R?[@+_IO^?FZ+!]Z/\
M5#_;>QKH/1!U[[T?ZH?[;W[0>O=>^]'^J'^V]^T'KW7OO1_JA_MO?M!Z]TVU
M%'AJS(X[,5>,QE5E\.M8F)RE1013U-*N04)4"FG93+ )T 60(RZU #7 ]Z,5
M37%1P/6ZD8Z<OO1_JA_MO>]!ZUU[[T?ZH?[;W[0>O=>^]'^J'^V]^T'KW7OO
M1_JA_MO?M!Z]U[[T?ZH?[;W[0>O=>^]'^J'^V]^T'KW7OO1_JA_MO?M!Z]U[
M[T?ZH?[;W[0>O=>^]'^J'^V]^T'KW7OO1_JA_MO?M!Z]U[[T?ZH?[;W[0>O=
M>^]'^J'^V]^T'KW7OO1_JA_MO?M!Z]U[[T?ZH?[;W[0>O=>^]'^J'^V]^T'K
MW7OO1_JA_MO?M!Z]U[[T?ZH?[;W[0>O=>^]'^J'^V]^T'KW7OO1_JA_MO?M!
MZ]T8K<E0!\;NOY;BS;NK5O;_ )NYO_BGL(V:_P"[B<?\*'^"'H[G_P!P8_\
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M"KW,#JIFF,4%23UZ"UC:'QI&( 8J0 *G .*^>?/RZ[ZB[QW+5?S.=N="]R]
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M</W5XUB>%7G51'?W$,\<5PB 2ZM!C9CI91JHU0*X\P./3;6\4D;/$S$I34&
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MY6'1/;_<O2W0N#Q>9[/WWM*CP72_6 CV52[MW]O:2#!X&AI:>.-\9AI,C,T
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M>7W/+)3Q[8RHAK*BFBR=+BV?[6:58J>IK%O.-3;C=6>F6:-!$S*I 9C)'J-
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MUZO7ONC_ %'_ "5[]3KU>O?='^H_Y*]^IUZO7ONC_4?\E>_4Z]7KWW1_J/\
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MUZO7ONC_ %'_ "5[]3KU>O?='^H_Y*]^IUZO7ONC_4?\E>_4Z]7KWW1_J/\
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M_='^H_Y*]J]!Z3:_G_/KWW1_J/\ DKW[0>O:_G_/KWW1_J/^2O?M!Z]K^?\
M/KWW1_J/^2O?M!Z]K^?\^O?='^H_Y*]^T'KVOY_SZ]]T?ZC_ )*]^T'KVOY_
MSZ]]T?ZC_DKW[0>O:_G_ #Z]]T?ZC_DKW[0>O:_G_/KWW1_J/^2O?M!Z]K^?
M\^O?='^H_P"2O?M!Z]K^?\^O?='^H_Y*]^T'KVOY_P ^O?='^H_Y*]^T'KVO
MY_SZ]]T?ZC_DKW[0>O:_G_/KWW1_J/\ DKW[0>O:_G_/KWW1_J/^2O?M!Z]K
M^?\ /KWW1_J/^2O?M!Z]K^?\^O?='^H_Y*]^T'KVOY_SZ]]T?ZC_ )*]^T'K
MVOY_SZ]]T?ZC_DKW[0>O:_G_ #Z]]T?ZC_DKW[0>O:_G_/KWW1_J/^2O?M!Z
M]K^?\^EKUK4ENQ=@K<<[UVJ/U?UKH/9=O"GZ2?\ YHR_\<;I58M^O'G\:?\
M'AT*ORDG,?;5>HM_Q9<(?K;ZQ'V1\E+6P7_3O_AZ,>8&I<G/X5_P=%U^Z/\
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M1_R5[]H/7M?S_GU[[H_U'_)7OV@]>U_/^?7ONC_4?\E>_:#U[7\_Y]>^Z/\
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M[]H/7M?S_GU[[H_U'_)7OV@]>U_/^?7ONC_4?\E>_:#U[7\_Y]>^Z/\ 4?\
M)7OV@]>U_/\ GU[[H_U'_)7OV@]>U_/^?7ONC_4?\E>_:#U[7\_Y]>^Z/]1_
MR5[]H/7M?S_GU[[H_P!1_P E>_:#U[7\_P"?7ONC_4?\E>_:#U[7\_Y]>^Z/
M]1_R5[]H/7M?S_GU[[H_U'_)7OV@]>U_/^?7ONC_ %'_ "5[]H/7M?S_ )]>
M^Z/]1_R5[]H/7M?S_GU[[H_U'_)7OV@]>U_/^?7ONC_4?\E>_:#U[7\_Y]>^
MZ/\ 4?\ )7OV@]>U_/\ GU[[H_U'_)7OV@]>U_/^?7ONC_4?\E>_:#U[7\_Y
M]>^Z/]1_R5[]H/7M?S_GU[[H_P!1_P E>_:#U[7\_P"?7ONC_4?\E>_:#U[7
M\_Y]>^Z/]1_R5[]H/7M?S_GT<+,2G_90-JR?DY^H_/\ U=\D/8 MQ_N_E']
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M[H_U'_)7OV@]>U_/^?7ONC_4?\E>_:#U[7\_Y]>^Z/\ 4?\ )7OV@]>U_/\
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MOWA]>U?;^WKWW _J?]N??O#Z]J^W]O7ON!_4_P"W/OWA]>U?;^WKWW _J?\
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M_P"W/OWA]>U?;^WKWW _J?\ ;GW[P^O:OM_;U[[@?U/^W/OWA]>U?;^WKWW
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MY]^\/KVK[?V]>^X']3_MS[]X?7M7V_MZ]]P/ZG_;GW[P^O:OM_;U[[@?U/\
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M[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[H[/5D@/Q([?;\#<>6_\
M<3"^XWWP4WZU_P"::?\ 'YNA5M__ "3IO],W_'4Z)-YE_P!]_P B]R1H'05Z
M]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO
M>9?]]_R+W[0.O=>\R_[[_D7OV@=>Z]YE_P!]_P B]^T#KW7O,O\ OO\ D7OV
M@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H
M'7NO>9?]]_R+W[0.O=>\R_[[_D7OV@=>Z]YE_P!]_P B]^T#KW7O,O\ OO\
MD7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y
M%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D7OV@=>Z.SVG(!\2.H&_!W'B?\ W$S7
MN-]C%=^NO^:;_P#'X>A5N'_).A_TR_\ '7Z)-YE_WW_(O<D:!T%>O>9?]]_R
M+W[0.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_ 'W_
M "+W[0.O=>\R_P"^_P"1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?
M]]_R+W[0.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_
M 'W_ "+W[0.O=>\R_P"^_P"1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7N
MO>9?]]_R+W[0.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[K
MWF7_ 'W_ "+W[0.O=>\R_P"^_P"1>_:!U[HS7Q(D#=RXX#_G1Y[_ *TCV#.?
M5 VYO].G^'H^Y<_W)'^E;H).UY5':790_IO_ 'B/]MD:G_#V?;$H^AM_^:$7
M_5M>BW<?]R)?^:C_ /'CT@/,O^^_Y%[-= Z1]>\R_P"^_P"1>_:!U[KWF7_?
M?\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D7OV@=>Z]YE_WW
M_(O?M Z]U[S+_OO^1>_:!U[KWF7_ 'W_ "+W[0.O=>\R_P"^_P"1>_:!U[KW
MF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D7OV@=>Z]Y
ME_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_ 'W_ "+W[0.O=>\R_P"^_P"1>_:!
MU[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D7OV@=
M>Z]YE_WW_(O?M Z]T;SYI2!.TL #_P \!BS_ .M'*^P#[=*#8O\ \UV_ZMQ=
M"3FC_<A?^:8_X\_10_,O^^_Y%['V@=!OKWF7_??\B]^T#KW7O,O^^_Y%[]H'
M7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D
M7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%
M[]H'7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9?]]_R+W[0.O=>\R_
M[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^
M^_Y%[]H'7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9?]]_R+W[0.O=
M>\R_[[_D7OV@=>Z.SFY!_LE6SW_!W'5?^[G*>XWMA_R(Y1_PL?\ 5F/H52_\
MDI/],?\ JXW1)O,O^^_Y%[DC0.@KU[S+_OO^1>_:!U[KWF7_ 'W_ "+W[0.O
M=>\R_P"^_P"1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R+W[0
M.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_ 'W_ "+W
M[0.O=>\R_P"^_P"1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R
M+W[0.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_ 'W_
M "+W[0.O=>\R_P"^_P"1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?
M]]_R+W[0.O=>\R_[[_D7OV@=>Z-YO&0#X<]4-^#O_(C_ *S[E]@';U']8;H?
M\(7_ ([;]"2Y_P"29#_S4/\ AEZ*'YE_WW_(O8^T#H-]>\R_[[_D7OV@=>Z]
MYE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>
M9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D7OV@
M=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'
M7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9?]]_R+W[0.O=>\R_[[_D
M7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%
M[]H'7NO>9?\ ??\ (O?M Z]T=GY:2!=I=#D_VMN9K_W&PGN-^0Q6>]_YJ)_Q
MZ;H5<Q_V<'^E;_ G1)O,O^^_Y%[DC0.@KU[S+_OO^1>_:!U[KWF7_??\B]^T
M#KW7O,O^^_Y%[]H'7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9?]]_
MR+W[0.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7_??\
MB]^T#KW7O,O^^_Y%[]H'7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7NO>9
M?]]_R+W[0.O=>\R_[[_D7OV@=>Z]YE_WW_(O?M Z]U[S+_OO^1>_:!U[KWF7
M_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?\ ??\ (O?M Z]U[S+_ +[_ )%[]H'7
MNGS;$R_WEV]_VO,3_P"Y$?\ A[2WRCP9/](__'3T];_VB_Z9?\(Z-!\TI G:
M6 !_YX#%G_UHY7V"_;I0;%_^:[?]6XNC[FC_ '(7_FF/^//T4/S+_OO^1>Q]
MH'0;Z]YE_P!]_P B]^T#KW7O,O\ OO\ D7OV@=>Z]YE_WW_(O?M Z]U[S+_O
MO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R+W[0.O=>\R_[[
M_D7OV@=>Z]YE_P!]_P B]^T#KW7O,O\ OO\ D7OV@=>Z]YE_WW_(O?M Z]U[
MS+_OO^1>_:!U[KWF7_??\B]^T#KW7O,O^^_Y%[]H'7NO>9?]]_R+W[0.O=>\
MR_[[_D7OV@=>Z]YE_P!]_P B]^T#KW7O,O\ OO\ D7OV@=>Z]YE_WW_(O?M
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MKW7M9_P]^Z]T>/M=C_LH'3AXN=R8?_W#S?N-MC_Y+UW_ ,TW_P"/P]"K</\
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MW7M9_P /?NO=>UG_  ]^Z]U[6?\ #W[KW7M9_P /?NO=>UG_  ]^Z]U[6?\
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M?O%^SKW7O ?]3_O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_ %/^]^_>+]G7NO>
M_P"I_P![]^\7[.O=>\!_U/\ O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_4_[W[]
MXOV=>Z]X#_J?][]^\7[.O=>\!_U/^]^_>+]G7NO> _ZG_>_?O%^SKW7O ?\
M4_[W[]XOV=>Z]X#_ *G_ 'OW[Q?LZ]U[P'_4_P"]^_>+]G7NO> _ZG_>_?O%
M^SKW2\ZL@([/ZX-OIOS:']?^=A3^RS>Y*V5QP_L9?^.-TKV_^WC_ .:B?\>'
M0P_+J(OW-D3:_P#N"P/]?^.1]D'(CZ=O7_3O_AZ,^8_]R3_I5Z+%X#_J?][]
MC+Q?LZ(>O> _ZG_>_?O%^SKW7O ?]3_O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'
M_4_[W[]XOV=>Z]X#_J?][]^\7[.O=>\!_P!3_O?OWB_9U[KW@/\ J?\ >_?O
M%^SKW7O ?]3_ +W[]XOV=>Z]X#_J?][]^\7[.O=>\!_U/^]^_>+]G7NO> _Z
MG_>_?O%^SKW7O ?]3_O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_ %/^]^_>+]G7
MNO> _P"I_P![]^\7[.O=>\!_U/\ O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_4_
M[W[]XOV=>Z]X#_J?][]^\7[.O=>\!_U/^]^_>+]G7NO> _ZG_>_?O%^SKW1W
M.JXR/B-W EOKN/+_ /N'A?<<[V]=]M3_ ,+3_C\O0JV__DG3?Z9O^.IT2/P'
M_4_[W[D;Q?LZ"O7O ?\ 4_[W[]XOV=>Z]X#_ *G_ 'OW[Q?LZ]U[P'_4_P"]
M^_>+]G7NO> _ZG_>_?O%^SKW7O ?]3_O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'
M_4_[W[]XOV=>Z]X#_J?][]^\7[.O=>\!_P!3_O?OWB_9U[KW@/\ J?\ >_?O
M%^SKW7O ?]3_ +W[]XOV=>Z]X#_J?][]^\7[.O=>\!_U/^]^_>+]G7NO> _Z
MG_>_?O%^SKW7O ?]3_O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_ %/^]^_>+]G7
MNO> _P"I_P![]^\7[.O=>\!_U/\ O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_4_
M[W[]XOV=>Z]X#_J?][]^\7[.O='<[4C)^(W3Z6^FX\1_[AYKW'.R/3?;H_\
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MG\Y&I]GVQR4LK?A_81?]6UZ+=Q_W(E_YJ/\ \>/0?^ _ZG_>_9IXOV=(^O>
M_P"I_P![]^\7[.O=>\!_U/\ O?OWB_9U[KW@/^I_WOW[Q?LZ]U[P'_4_[W[]
MXOV=>Z]X#_J?][]^\7[.O=>\!_U/^]^_>+]G7NO> _ZG_>_?O%^SKW7O ?\
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M^\7[.O=>\!_U/^]^_>+]G7NO> _ZG_>_?O%^SKW1W,W&?]DFV>EOIN.JX_\
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M?LZ]U[P'_4_[W[]XOV=>Z]X#_J?][]^\7[.O=>\!_P!3_O?OWB_9U[KW@/\
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M_P"2??O%^WKU!U[[4_T'_)/OWB_;UZ@Z]]J?Z#_DGW[Q?MZ]0=>^U/\ 0?\
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M_P"2??O%^WKU!U[[4_T'_)/OWB_;UZ@Z]]J?Z#_DGW[Q?MZ]0=>^U/\ 0?\
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M;]E_B_;TKT'KWV?^T?[Q_P ;]^\7[>O:#U[[/_:/]X_XW[]XOV]>T'KWV?\
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MXW[]XOV]>T'KWV?^T?[Q_P ;]^\7[>O:#U[[/_:/]X_XW[]XOV]>T'KWV?\
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M?\;]^\7[>O:#U[[/_:/]X_XW[]XOV]>T'KWV?^T?[Q_QOW[Q?MZ]H/7OL_\
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M=>_V5OL/_E9VS_Y\IO\ ZE]^_K=;_P!/_>1_T%U[]Q3>J_M/^;KW^RM]A_\
M*SMG_P ^4W_U+[]_6ZW_ *?^\C_H+KW[BF]5_:?\W7O]E;[#_P"5G;/_ )\I
MO_J7W[^MUO\ T_\ >1_T%U[]Q3>J_M/^;KW^RM]A_P#*SMG_ ,^4W_U+[]_6
MZW_I_P"\C_H+KW[BF]5_:?\ -U[_ &5OL/\ Y6=L_P#GRF_^I??OZW6_]/\
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M;/\ Y\IO_J7W[^MUO_3_ -Y'_077OW%-ZK^T_P";KW^RM]A_\K.V?_/E-_\
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M\K.V?_/E-_\ 4OOW];K?^G_O(_Z"Z]^XIO5?VG_-U[_96^P_^5G;/_GRF_\
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M_96^P_\ E9VS_P"?*;_ZE]^_K=;_ -/_ 'D?]!=>_<4WJO[3_FZ]_LK?8?\
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MQ3>J_M/^;KW^RM]A_P#*SMG_ ,^4W_U+[]_6ZW_I_P"\C_H+KW[BF]5_:?\
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M+[]_6ZW_ *?^\C_H+KW[BF]5_:?\W7O]E;[#_P"5G;/_ )\IO_J7W[^MUO\
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M\K.V?_/E-_\ 4OOW];K?^G_O(_Z"Z]^XIO5?VG_-U[_96^P_^5G;/_GRF_\
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M=>_V5OL/_E9VS_Y\IO\ ZE]^_K=;_P!/_>1_T%U[]Q3>J_M/^;KW^RM]A_\
M*SMG_P ^4W_U+[]_6ZW_ *?^\C_H+KW[BF]5_:?\W7O]E;[#_P"5G;/_ )\I
MO_J7W[^MUO\ T_\ >1_T%U[]Q3>J_M/^;KW^RM]A_P#*SMG_ ,^4W_U+[]_6
MZW_I_P"\C_H+KW[BF]5_:?\ -U[_ &5OL/\ Y6=L_P#GRF_^I??OZW6_]/\
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M_P K.V?_ #Y3?_4OOW];K?\ I_[R/^@NO?N*;U7]I_S=>_V5OL/_ )6=L_\
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M+[]_6ZW_ *?^\C_H+KW[BF]5_:?\W7O]E;[#_P"5G;/_ )\IO_J7W[^MUO\
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M\K.V?_/E-_\ 4OOW];K?^G_O(_Z"Z]^XIO5?VG_-U[_96^P_^5G;/_GRF_\
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M>,W\1_U?GU[^\%9_RNS_ /G4W_%??OID_A'[.O>,W\1_U?GU[^\%9_RNS_\
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M]G7O&;^(_P"K\^O?W@K/^5V?_P ZF_XK[]],G\(_9U[QF_B/^K\^O?W@K/\
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M^(_ZOSZ]_>"L_P"5V?\ \ZF_XK[]],G\(_9U[QF_B/\ J_/KW]X*S_E=G_\
M.IO^*^_?3)_"/V=>\9OXC_J_/KW]X*S_ )79_P#SJ;_BOOWTR?PC]G7O&;^(
M_P"K\^O?W@K/^5V?_P ZF_XK[]],G\(_9U[QF_B/^K\^E109*>;;N2K&GD:2
M&:15E,I8C2L1X:]Q^H^T$L*B95H*$<*?;TKCD)B8U-:\?V=)?^\%9_RNS_\
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M>,W\1_U?GU[^\%9_RNS_ /G4W_%??OID_A'[.O>,W\1_U?GU[^\%9_RNS_\
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M.NUZ:N$\@E>9E,OE-S:61?U7O]![0+"IG*T%*<*?(=*S(?!!J:UX^?$])?\
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MU[QF_B/^K\^O?W@K/^5V?_SJ;_BOOWTR?PC]G7O&;^(_ZOSZ]_>"L_Y79_\
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M1^SKWC-_$?\ 5^?7O[P5G_*[/_YU-_Q7W[Z9/X1^SKWC-_$?]7Y]>_O!6?\
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MOXC_ *OSZ]_>"L_Y79__ #J;_BOOWTR?PC]G7O&;^(_ZOSZ]_>"L_P"5V?\
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M"NW=L;\[+PNT,C7FHD6&,45%D*VGJ:HO,Z(OBB;4[*HNQ ]J&"H:$@?:0/\
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MZJ.[@"?R/0GU^Y\3BL959O*93'8W#4-')D*W+U]9%1TL-/"NMYY:B1EBCA5
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M7K0:O0.;Y^7G06S-M]Q9>/MWJG/9SH_"9'([]V;C^S,+_$<?5P4M744F,R4
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M*T(5@:FN#P7IN656CTU+$&H)%*"G#B>@I_D^="=#_,7XS=T?*KY5=&=?=O\
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MRQ;OWG+GJZ5?.R%*6D*I&P?568>/%-/Y'M7_ $JFE?S->K1GPWCC],G[2/\
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M."ZOV90;+IJVKHNP]E4:5M;'000"LKC300QO4S:YY B^21R+^U&Z6ZP6SA
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M5BJ/J#:[Y7$9O#54Q,$F82U3#%(#J>4MMK.1BA6-$TL#4,"=/F/A%?V]:$R
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MQ..FVXW\C&/;SX*>CCJ*1Z$]U4M.:-Z=U:)Z9H/VS&R%"GI((-O;@3_'*?\
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M9/L"UA;_ $Y_XZO2_=/[0?Z4?X3T&'W1_P!4?]]_L/9YH_U?ZCT6UZ]]T?\
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MZOV90;+IJVKH8\W1I6UL=!! *RN--!%&]3-KGD"+Y)'(O[U?6ZP>$$ %9DX
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M6_\ :+_IE_PCI7=L2%=X5 Y_X T/T'^T>T&PBMN/M;_#TIW+^U/V#H-?,?\
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M]$*&BQZP8:.FHH(:>%EDG5-1EJ)78M[U!9K & -=3,QJ?-N/EPZW),9*$_A
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M-U_'7<V&HZ#>=-M&-H,5-N7;VY,%N'!U^4Q=,Q@H\@M%%5P0EXA*R2.K5DL
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M:Q& JY-L[H115[8RV-S6&SF#RF#$J1U-/!+C=5+5(D\$B%;%^>R$S!@Q5E!
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M/M'N[K#?75&Z,KM>:FI<E38_L#&5.*K)J"2KIJRECJXZ>JD:)I:2:-7"EHW
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MV8'T'XJ)/:^Q7]"/A\"?\='2:X_M&_TS?X3TP^8_X_[8>U6GYCIGKWF/^/\
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MNZML;EI\'G\D$0UE9COMS5%(VEC9HHRK9VX!BR.R:C4A2*$^M"#0_9U87)(
M8*U, D&M/R(Z&'N+^7KT3WW\:]D_&KMC.]Q;RI.L]QXG?O77=V8[0KZGLC";
MJP5745U'NW';Q)^_I\_35%5/HF">%8V\"P"!(XT=DL4F0(Q)ID-J[@?6OKU1
M)V1M0IG!%,4]*=(OIC^6ULC8/<.R>_\ NCY ?)/YC=M=4T6=Q_3.X/DMN_$9
MJCV@NY($I*ZKP>&P&#P&*3,UE(@AGR532U-8R$B.2*_ND=@$8.S%R/A+$8^P
M #/SZLUP6&D *#QH./[2>D[NW^5IUYE.[.Z.W.NODC\L^@L!\ELM0;B^1G2W
M2?9M#M+;.ZLI2TC4-1EEDDPU5N';>5RU(4CR-7@\[CIZH11-KCE02>]-MREF
M8.RZLL%:@)_94?.A'6Q<F@!"FG D9'^KY]1,I_**^+V0_E\;B_EI4F;[5P?Q
MTW%OFMWL\F(S^,CSE*M7OQ=_IBJ2MEP\U+'C:?(1QT4>J@>I% H5JAJF]2='
M;(S#X%3IK7CGXM7I^7V=>^J;Q/$Q7^7"GKU9YG,7B]R87+[=SM%%DL)G\7D,
M+F,=4"\=12Y2)X*B!])!T2PR.K6(-B;$>UQ2N#3I,#3HB/PL_E_[:^#V!S>P
M]@_(CY-]B]2##UFVNL^HNW]\XS=>$V5C*VNJ*]J/;XI\)0Y"01/4>&&3(UU<
M\%+''!$44RF5+;60M1I#L1P )!"CY8_P]/S3F;) !\R!Q_GTM?B_\(>I?B;\
M,-N?!KKG-[]R?4^V]H]D;/I<_NO*4-?GY8>U,EF<KE*B6JIL=24'W/WF<K3#
MIQJQ1J(U,3A3JM!9K;Q")3@ BI.<DGT^?59)C*^LTKC[,?\ %=!A7_RRNALG
MT?\  OH*LW5VI)LS^7IW!T=W;T]6C-8N.ORN8Z I*RFPB;DF7#B&JHY6K'EJ
MHZ*GH&D=45)(X]2,V=O0K&E32,JPR,E>%<=6^H;4S8JP(/V'TST-WS:^(G6G
MSS^-F^_BUW!F-YX/KOL2OV/6[AKM@Y"CQ.4(V)GL9N&GAAJ*ZAR,$4=158N"
M.8_:ES"T@B>.0K(KMU:+=H8V.#3@<X(/H?3JD,IA8,.(]?F*=!I\M_@%LGY5
M]E=-]WT/<_?OQP[TZ.H-X[=V?VY\>=UXW;F4FPF_XXX\M@\E!F<1G<77X^=H
M8IHQ)0>2"H198W^JFEQ9"=E;459:@%2.!\L@]7BG,0(H"#Y'Y?LZ6V]_A?UG
MV#\BOAU\G-S;I[(K^P_A+MON+;O5\4^=I*FDR9[OV_2;;S%=N0S4$E=D:]<?
M2EHGBK:9/N)9)9HY3H"W>T5W20G*5IGCJ%#7'55F*JRBE&I7\C7HN_;W\KO
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MD]TY><)+D*JOI3X6"I#!%"!'!#$G'MV&S2!2HS6NHDU+$\:GJDDS2$$^7"G
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MP]^T_,=>ZG8R8_Q+'_7_ ('4GX'_ !T7VW,O8V1P/^#J\?Q#[1T)G<LFG<]
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MZL?]3!_Q7W[P_EU[Q?E_J_9U[[V/_5C_ *F#_BOOWA_+KWB_+_5^SKWWL?\
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M0LS=>=;;H[#Q& S^>%.S+(<+AZNLBR.4",CAOMJ:6Q4@V(/MMF1&"DJ"> )
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M E+8_P"F7_#T8;8^J4?8>D?NZK1=U[G4N 5W#FE/K ^E3+[,+!*P1X_T-/\
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M/NC)4",]?C^INY-N]C3P*@#$S18?(UDD8"D$EE%@0?H?=XI8Y_@9&_TK*?\
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M_P!^<JD%8TL3=J?*6GJJ#%P5,2:8C-@]C4E94QK))(4DR:2>*)EBD=,4^KO
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M0-+4XT\_LKU=5_$A_JS_ +;_ (W[._#/^K_BNB^HZ]_$A_JS_MO^-^_>&?\
M5_Q77JCKW\2'^K/^V_XW[]X9_P!7_%=>J.ACZ)K1-V#21ZB;XW)FW^M'_K^P
M]S0FFT/^F7_#]G1ILY_6'V'I";XR 3>N[TU'T;HW OT_U-7,/Z^S/;(R;:+_
M )I1_P#'1\ND=V1XK_Z=O\)Z2_\ $A_JS_MO^-^UWAG_ %?\5TGJ.O?Q(?ZL
M_P"V_P"-^_>&?]7_ !77JCKW\2'^K/\ MO\ C?OWAG_5_P 5UZHZ]_$A_JS_
M +;_ (W[]X9_U?\ %=>J.O?Q(?ZL_P"V_P"-^_>&?]7_ !77JCHGO\P/KSM?
MO'X3?)_J+HS,-A^V>P^G-X[7V15#)_P4R5>2IBIHQ6 C[5LC!Y:43%E$9FUL
MR@%@CW"U>>!T3XBI SY_LZ?MI5CD5FX @GJKK^7_ -X?RRNTF^/WQPWG\8NO
M_B9\X_CY1;4J,)T)V[U-2]<;MQVX=DT\T-1D=H;@DH:)]SP53XZNJ?-25KU-
M;2ZIZ^D56<>RK;Y+:8I$R".5*=C+I8$?PFF>'D<CCTMN8Y4U.&+(U>X&HH?7
MTZ,ANSYI_-GO?Y%?(+I#X"]6?'"3:?Q0SVV-E=K=R?*;=NX*7'YW=67HZ;*U
MVU=LXS:<,]=2MB\?411564KG>.*KD*I03QPJ:A2US/<2O';JE(R S.30M2M
M%%<#S/GY=,B&*)%:4GNR M,#A4U_P=%L_FC[L[-W9LG^3!G.Y=A8KK#M&?\
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M<QNG,UG9J3TE'25BYK)8R.*?;N/VWDZ=<C4TM.,C/D8J4TCU!$CR1JY93SW
M$KJJ1E:Y)U_:<4 .?GU6XBCB.A6+.#3RT_9ZU_ET#6UOFO\ S.?D'TA+\P?C
M)\=/C#%T+D:7-;TZKZ8[AWMN*C['WQM;#K4_;UM/D<<J;7VKDL\D23XZGK(Z
M^/QE(ZJ:$3">-E+FZN8_'B1-&2JL3K91\Q@$^5:_/J[0PQ-X;LVK@2*:0?\
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M_,JR ?\ ES_/Q-1]?PH^5*_3_5;%SP_K[0[G&1;2_P#-*3_CI^72BT(\5/\
M3K_A'5%'\C^OIOAKV1T)T5/D#C.IOYD/P;Z4^4_4>,GEIZ>FA[,ZIVWC\;V+
MCJ(%4J)ZS.X48[-SCRRA132%5C6]R+8U^C9(_P ,T2R+_IU ##AYBAZ,MQ/U
M 9O.-RI_TI./\W27_GDU$?S!JOFA0SHV2Z<_EC_%^@RZG7*]'6]P_(^MQ\=/
MJTZ:6HGVCLB"9_&SRR4M5F(I6CA?PNU-]3ZOQ?X8$K_S<<C_  +_ (>M[<?
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MS%-[=\?'G8$?;GPMB^4_3W>O1VX&EWIL?<V3Z7V_)E;TIR%-!5U^TMR44],
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M9IKD%655A0$&M$^)O]L?.GEYCKVY31H!'$0027:A'$\!^0Z+5L[X??)+=O\
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MNO/]"^S\%UYU/7;SV3NY]F4\E!@<YC]_TZC;U#@\A31T4E;+7STLU"S3*8)
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MX_Q$_P!3[&'@_P"K_4.B/5_JQU[^(G^I]^\'_5_J'7M7^K'7OXB?ZGW[P?\
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M9F$IL\<9/%AI9J''T]+2+3Q5HI=8\8'B73]![.#9B&-EA"J=)T@"@U4QP'2
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M?:N$QV?IXLAF\CDZ_)LE7)3TIIJ.*,N9V+#2S<*V\20JB2*D<@D=W4I\(-%
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MNF<UD<#BQN*HZVZJPG7U543R4T J/O),704DLTC/&H?R,Q)4 _I%C&VVZ*V
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M>\3KW\0'^'_)1]^\/KWB=>_B _P_Y*/OWA]>\3KW\0'^'_)1]^\/KWB=>_B
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M^'_)1]^\/KWB=>_B _P_Y*/OWA]>\3HW78]3H^,75TW^KSV,'U_K2Y8_\1[
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ME\3KW\0'^'_)1]^\/KWB=>_B _P_Y*/OWA]>\3KW\0'^'_)1]^\/KWB=>_B
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M>\3KW\0'^'_)1]^\/KWB=>_B _P_Y*/OWA]>\3KW\0'^'_)1]^\/KWB=>_B
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M*^_:#U[5_J_U'KWW8_J?]Y_XK[]H/7M7^K_4>O?=C^I_WG_BOOV@]>U?ZO\
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M/ZG_ 'G_ (K[,]!Z1ZO]7^H]>^[']3_O/_%??M!Z]J_U?ZCU[[L?U/\ O/\
MQ7W[0>O:O]7^H]>^[']3_O/_ !7W[0>O:O\ 5_J/7ONQ_4_[S_Q7W[0>O:O]
M7^H]>^[']3_O/_%??M!Z]J_U?ZCU[[L?U/\ O/\ Q7W[0>O:O]7^H]>^[']3
M_O/_ !7W[0>O:O\ 5_J/7ONQ_4_[S_Q7W[0>O:O]7^H]>^[']3_O/_%??M!Z
M]J_U?ZCU[[L?U/\ O/\ Q7W[0>O:O]7^H]>^[']3_O/_ !7W[0>O:O\ 5_J/
M7ONQ_4_[S_Q7W[0>O:O]7^H]>^[']3_O/_%??M!Z]J_U?ZCU[[L?U/\ O/\
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M]C[]H'7NCM=IR6^(_4#FWJW'B?\ >:/->XWV,5WZZ_YIO_Q^'H5;A_R3H?\
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M#KW7ON!_A_OO]C[]H'7NO?<#_#_??['W[0.O=>^X'^'^^_V/OV@=>Z]]P/\
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M _P_WW^Q]^T#KW7ON!_A_OO]C[]H'7NO?<#_  _WW^Q]^T#KW7ON!_A_OO\
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MW[0.O=>^X'^'^^_V/OV@=>Z]]P/\/]]_L??M Z]U[[@?X?[[_8^_:!U[KWW
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M ).]^J.O=>\4G]?^3O?JCKW7O%)_7_D[WZHZ]U[Q2?U_Y.]^J.O=>\4G]?\
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MI/\ MO?OJ.O>'U[[ ?ZD_P"V]^^HZ]X?7OL!_J3_ +;W[ZCKWA]>^P'^I/\
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M@/\ 4G_;>_?4=>\/KWV _P!2?]M[]]1U[P^O?8#_ %)_VWOWU'7O#Z]]@/\
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M.O>'U[[ ?ZD_[;W[ZCKWA]>^P'^I/^V]^^HZ]X?7OL!_J3_MO?OJ.O>'U[[
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M[]_6FX_WT/VG_-U[]RQ?[\/\NO?[*_M#_GN:[_SFI_\ H_W[^M-Q_OH?M/\
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M  %SFA8_Y>E\-@D<+1!B0Q))QC _S=!9_LK^T/\ GN:[_P YJ?\ Z/\ 9O\
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M^;KW[EB_WX?Y=>_V5_:'_/<UW_G-3_\ 1_OW]:;C_?0_:?\ -U[]RQ?[\/\
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M?[\/\NO?[*_M#_GN:[_SFI_^C_?OZTW'^^A^T_YNO?N6+_?A_EU[_97]H?\
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M?[\/\NO?[*_M#_GN:[_SFI_^C_?OZTW'^^A^T_YNO?N6+_?A_EU[_97]H?\
M/<UW_G-3_P#1_OW]:;C_ 'T/VG_-U[]RQ?[\/\NO?[*_M#_GN:[_ ,YJ?_H_
MW[^M-Q_OH?M/^;KW[EB_WX?Y=>_V5_:'_/<UW_G-3_\ 1_OW]:;C_?0_:?\
M-U[]RQ?[\/\ +KW^RO[0_P">YKO_ #FI_P#H_P!^_K3<?[Z'[3_FZ]^Y8O\
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M_P NEQ_%W_U?^\G_ (K[:\#IRO7OXN_^K_WD_P#%??O Z]7KW\7?_5_[R?\
MBOOW@=>KU[^+O_J_]Y/_ !7W[P.O5Z]_%W_U?^\G_BOOW@=>KU[^+O\ ZO\
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M?XN_^K_WD_\ %?:[P.DM>O?Q=_\ 5_[R?^*^_>!UZO7OXN_^K_WD_P#%??O
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M\#KU>O?Q=_\ 5_[R?^*^_>!UZO7OXN_^K_WD_P#%??O Z]7KW\7?_5_[R?\
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M^+O_ *O_ 'D_\5]^\#KU>O?Q=_\ 5_[R?^*^_>!UZO7OXN_^K_WD_P#%??O
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M?7_4RL/:BWAK&I_HK_@'3,I[V^T_X>F[^+O_ *O_ 'D_\5]O>!TW7KW\7?\
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M@=(J]>_B[_ZO_>3_ ,5]^\#KU>O?Q=_]7_O)_P"*^_>!UZO7OXN_^K_WD_\
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M\#KU>O?Q=_\ 5_[R?^*^_>!UZO7OXN_^K_WD_P#%??O Z]7KW\7?_5_[R?\
MBOOW@=>KU[^+O_J_]Y/_ !7W[P.O5Z]_%W_U?^\G_BOOW@=>KU[^+O\ ZO\
MWD_\5]^\#KU>O?Q=_P#5_P"\G_BOOW@=>KU[^+O_ *O_ 'D_\5]^\#KU>O?Q
M=_\ 5_[R?^*^_>!UZO7OXN_^K_WD_P#%??O Z]7KW\7?_5_[R?\ BOOW@=>K
MU[^+O_J_]Y/_ !7W[P.O5Z]_%W_U?^\G_BOOW@=>KU[^+O\ ZO\ WD_\5]^\
M#KU>O?Q=_P#5_P"\G_BOOW@=>KU[^+O_ *O_ 'D_\5]^\#KU>O?Q=_\ 5_[R
M?^*^_>!UZO7OXN_^K_WD_P#%??O Z]7KW\7?_5_[R?\ BOOW@=>KU[^+O_J_
M]Y/_ !7W[P.O5Z]_%W_U?^\G_BOOW@=>KT&_W_\ M?LW\'I%XG7OO_\ :_?O
M!Z]XG7OO_P#:_?O!Z]XG7OO_ /:_?O!Z]XG7OO\ _:_?O!Z]XG7OO_\ :_?O
M!Z]XG7OO_P#:_?O!Z]XG7OO_ /:_?O!Z]XG6LS_-Z[S^2O\ +L^>WPC_ )@>
M$[D[AR7P@WEN3%_'7Y7=%2;^R<^SL6<T:E:?<R8!Q4XFFK'QM14U:U"4\4[U
MF%BIC4QKD)+D^X:[.1):G03I85P/G_J].E]KIG1DH-7$'SZ;L%\NNQOF#_.5
M[F[ P'R1WIU#_+3_ )476>4C[HRFVNT*[:&SMX[PJ*2LDKQN5:.ICQ66H,-,
MF0,B5?F6GCP5U"?Q%@=*YGN&(8B.(=QK0$_/RQ_DZV5$40%*LYQZ@?ZO\/1F
M=O\ _"BWX,9?<6V:C-[!^7_770&^-RT^T]C?-#LOXZ5NS^I,O65DJ01"FW)/
M7'(00F<S+)-5X.FBIQ!/)5-!#'Y"X-RB-*API- Y6B'\^J&T?^B2.*AN[_!T
M=WYH_P R_H[X19/8.T]Z;-[][D[.[2P>Y=R]?=1?&KI^O[?W#DZ#:,V/IZ^K
MCA@DI<?3PPS9.B354Y&$,9!IO[57,ZVU 0Q)J0%%20/^+Z9AC,U2* #S)H.F
M3X'_ ,U/XX?S!,GV=L[J_#=R]6]O=,-C3VIT9\A.N).M-UX2+-3U4%'-54B5
M61Q\B3FE9BL&2FEIUD@%5'3O-&C:M;A+LD+J!7BK"A'7IHF@H30@\"#4=%1K
M/^%#WP(_TH8_I3;E'WWOKMBH^2&;^->8V)L_K6DK:S#U>W<E18BLW3F&J<U2
M4M'LV+(U]/ M=]P]3,PF\%#(*:I,3'[QBU:1J)U:: <,TJ?ET[](]*XI2M:_
MRX<>KROO_P#:_9GX/2/Q.O??_P"U^_>#U[Q.O??_ .U^_>#U[Q.O??\ ^U^_
M>#U[Q.O??_[7[]X/7O$Z]]__ +7[]X/7O$Z]]_\ [7[]X/7O$Z>-NUNK<&"7
M7?5F,8+?Z\Z>TUY%2%_](W_'3T[ ]74?TA_AZ5'9E5XMU3IJM_D=&;?ZZ^T6
MRQZH ?F?\/2C<&TR?D.@_P#O_P#:_9MX/2+Q.O??_P"U^_>#U[Q.O??_ .U^
M_>#U[Q.O??\ ^U^_>#U[Q.O??_[7[]X/7O$Z]]__ +7[]X/7O$Z]]_\ [7[]
MX/7O$Z3N\,INN#:6Z)]ATN!R6^(=NYN79F.W37SXK%U&6CII3CH<E54L%54T
MU!+6"%:B6&FFECB+O'%(X"'30FAIQ\JGSZV'%<]:]?QGS_S3V#_/:J>FOD_\
MM<_WC!NW^5CDN],QUYLO'UG6O6V"S=;VE2X2G@VUL\Y&NC8XW'431+E\C/59
MBK-14M+414\D5%3E422+<Z':M8]5!A0=5,"I_;QZ6R,AAU**=]/4\/7H>_F-
MV5VS\A_YFG0O\MC!]O\ ;GQXZ0K?BIOOY9]P[VZ7SK]>[CW@U!N ;8Q>T,3N
MNG_W)82GH)5DK\BV/>*JFAEBB,J*5=79U:298:E1I+$C!.:4K_AZI&0D9DH"
M:T%<T\Z] @G?'<G\L#Y9_(_XZ3=B=V_*GX]U?\N[N#YW="8WO#L"N[>WEA]S
M]"U%1%G=E4V>KPV8RN%S-,U-4TPJZZ>:DDTT\!T,[>VSJLY&3N8>&76IJ05X
MCJXI<*&H =04TP,^?09[&Z'^3W<O\M'$?S):3Y^_+D_-_<WQWK/EOM6GP'<5
M5M_K&"M3%5&Y*+8S]9P(^TIMO"ETXNH\]!+5--JJVGUJ(Q5+9Y(?&UMK*ZAG
MMX5I3A3RZV9E23P](TUT\,^E:]6W==?S"-DS?RU>N?YA?;D46U<#F_C5LSNK
M=VW<0SUK?Q;.XJFEEP&(5AY:RJK,W+_#\>FCR3RR0*5#.0%BRCP1,V!I#?RX
M?MX=)V0^(8QG-.JM/Y7&[_FK2_S.OD3M_P"7W<_:&X-Q]M_"OJ_Y4YCX^Y[>
ME7E-J]:Y3M;>&12DV?MS#^=L91':^ @Q^+J:J& 2UM7%5U,LLIFU>TEFDGC,
M')J4#::X6I.!]@QTHN"@C!4##%:^9H./6RG]_P#[7[-O!Z0>)U[[_P#VOW[P
M>O>)U[[_ /VOW[P>O>)U[[__ &OW[P>O>)U[[_\ VOW[P>O>)U[[_P#VOW[P
M>O>)U[[_ /VOW[P>O>)U[[__ &OW[P>O>)T+6W:C5UGN>75?175(O_K14G_%
M?9!>)2]C']$?X6Z,X&K;N?F?\"]!+]__ +7[/_!Z+/$Z]]__ +7[]X/7O$Z]
M]_\ [7[]X/7O$Z]]_P#[7[]X/7O$Z]]__M?OW@]>\3KWW_\ M?OW@]>\3KWW
M_P#M?OW@]>\3KWW_ /M?OW@]>\3HOOR6I_DQN'KF+;OQ3WIU9UQV3G=QXS&Y
M+LKMG;-;OJCV]A98ZA\AE,;M^CJ*%,[G(W2FBHZ2JR='17E>HJ)G6 4U0U-
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M>O>)U[[_ /VOW[P>O>)U[[__ &OW[P>O>)T+6XJC3UGMB75;774PO_KQ5?\
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M-Q0=L]J]:T-/F<IM[;WQRP]15=I#:L]1'+0XC.3Y:F6BI*B>&:2A5JD1PO/
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M=3XN;5]:Z07_ .JNH'_$>R"-/\?8?T?^?5Z,V;_%@?G_ )3T$OW_ /M?L_\
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M6:6.98IJF.0BKD+(]J.J\D[]?9\0  -"@X#&.'3]X (%[=/=P.2/B]>CG?\
M"<G;FW(^Z/YQ&]%PF*&[JCYV[TVS)N4T,9K3CJ;+;AJTH14Z?*M**F:24Q!@
MC2$,P)52%6R("TQIGQ"/YGIF_-0G^E_S=;2GG/\ JO\ >_9_H^W^71=U[SG_
M %7^]^_:/M_EU[KWG/\ JO\ >_?M'V_RZ]U[SG_5?[W[]H^W^77NO><_ZK_>
M_?M'V_RZ]U[SG_5?[W[]H^W^77NO><_ZK_>_?M'V_P NO=/NUYB=S;=%_KG<
M0/S^:B/VEOU_0DX_V;^G\)Z>M_[1?],O^$=*[MJ71O&I6_\ R@T']?\ 4>R_
M8%K;C_3-_AZ4[C_:G[!T&GG/^J_WOV=:/M_ET@Z]YS_JO][]^T?;_+KW7O.?
M]5_O?OVC[?Y=>Z]YS_JO][]^T?;_ "Z]U[SG_5?[W[]H^W^77NO><_ZK_>_?
MM'V_RZ]U[SG_ %7^]^_:/M_EU[J+6Y6CQE%5Y'(UM+C\?CZ6HK:^OK9UI88(
M:5#)+--+(RI'%&BLSNS!54$D@#WXJ!Z_RZ]UKG5'R-Z '_"BRAW\>].G1L=_
MY/#[17>9[,PHQ)RH[AFK/X8,C]]]H<A]H#/]OYO-X1Y-&CU>R3Q8_K:ZA3P:
M5J*5U^M:=+M#>!2A_M/3^CU8E\XOC)\-/D_N3K"K[A[OS?Q_[^V3MW=67Z2[
MGZ7^0B]!]@XO$YY$ILK/A,C'4AJS%L[TYF$M%5TB2%-2CRLLBVZMHIR-3%6
M)4A@K >=,],0R/&#05!X@BHZJ^^&?1_1>\_YJO=/<_3W:O9GR+^/_P 8/B=N
MGH+NWY'=Z][9KOZGW!OWM3+09;*[<H\QF*V?"KB]J;4I8OOHL5#%10SUQ@GC
M26.Y06L*/<,R%F5$*LS-JJQ-:5.,#TZ4RN1$ 0 6:H %, <<>IZ0'R_^,/\
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M)?4LNO>-,M_^4&O_ *_ZCV2[^M+<_P"F7_#TOV[^U'V'I)[KF(W1N07^F?S
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MQ_6UU"G@TK44KK]:TZMH;P*4/]IZ?T>MC>&MBJ(8JBGGCG@GC2:">%_*CI*
MRNC*2K*RD$$&Q'(]G>D?/^72'K)YS_JO][]^T?;_ "Z]U[SG_5?[W[]H^W^7
M7NO><_ZK_>_?M'V_RZ]U[SG_ %7^]^_:/M_EU[KWG/\ JO\ >_?M'V_RZ]U[
MSG_5?[W[]H^W^77NO><_ZK_>_?M'V_RZ]U[SG_5?[W[]H^W^77NA<[GET;HH
M!>W^X"E/Y_Y6*KV0<N+6!O\ FH?^.KT9;I_:#_2C_">@C\Y_U7^]^S_1]O\
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MU[SG_5?[W[]H^W^77NO><_ZK_>_?M'V_RZ]U[SG_ %7^]^_:/M_EU[KWG/\
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M.::U1EK05TBAR>MN#)"A&=)8'Y5->@%W3UYC?YB?S7_G#=H_'_+T>]-IX?\
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M#JT;^85_,"^-/=W\H7L#(]1=L['['WG\Q^E<9TAT;UGL[<-'DMPYO=?>,<&
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ME@R:9NNR%' M+3O3*U2M3!.EX)5D]LVUY$EJ&)H532145U**4IQKU>6!FF(
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M7OXP/^.J_P#)0]^\ >AZ]K/7OXP/^.J_\E#W[P!Z'KVL]>_C _XZK_R4/?O
M'H>O:SU[^,#_ (ZK_P E#W[P!Z'KVL]-6>AP6Z<'F=L;GQ>'W'MK<>)R.!W#
MM[/4$&7H:^AR\+T]715M)4))3U5)54\DD4T,L;1R1LR.K*Q!T;96%"*@\1UL
M2$9'28ZWV)UATWLS&=<]0]?;!ZJZ]PC9%\-L/K?:6.V-AJ0Y>HEJZLTN+Q=/
M2T-.:JKGGFF*0+Y)9))'U.[,:QVB1#2JT'H!0?RZVTS.:DU/J:D]%]'P1^"
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M/7M9Z]_&!_QU7_DH>_> /0]>UGKW\8'_ !U7_DH>_> /0]>UGKW\8'_'5?\
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M9G#C#[>Q6/P> Q^+P>$Q-)!08K#X>CAQE+304RA8X*>GA5(888U "HB!5 L
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M#U[6>BS=L_$/X==];K&^^\?BO\;NX][C&4>%_OAVETGMG?V4^SQQD:GI/O\
M*XVJJOMH&EE,<?ET(7;2!J/MB3;89C5T5CZE03_,=.I=21BBL0/0$C_+T_\
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M>3];0X__ (K["G+<>N2X^3+_ (9.CO=FHD7V'_ O1??XP/\ CJO_ "4/8K\
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MO:SU[^,#_CJO_)0]^\ >AZ]K/7OXP/\ CJO_ "4/?O 'H>O:SU[^,#_CJO\
MR4/?O 'H>O:STXX?+!LMBU\J^K(T2_4?F5?;-Q !&V#\)_P'IR)SJ'VC_#T,
M'?U?]KO'&QZPM]LT;V) ^M56#_B/9!RK$'MV/_##_P =3HSWIJ2C_2#_  MT
M!W\8'_'5?^2A[$O@#T/11K/7OXP/^.J_\E#W[P!Z'KVL]>_C _XZK_R4/?O
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M/]7_ !77O%^WKW\6/_'0?[<>_?3C_5_Q77O%^WKW\6/_ !T'^W'OWTX_U?\
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M\6/_ !T'^W'OWTX_U?\ %=>\7[>O?Q8_\=!_MQ[]]./]7_%=>\7[>O?Q8_\
M'0?[<>_?3C_5_P 5U[Q?MZ]_%C_QT'^W'OWTX_U?\5U[Q?MZ]_%C_P =!_MQ
M[]]./]7_ !77O%^WKW\6/_'0?[<>_?3C_5_Q77O%^WKW\6/_ !T'^W'OWTX_
MU?\ %=>\7[>O?Q8_\=!_MQ[]]./]7_%=>\7[>O?Q8_\ '0?[<>_?3C_5_P 5
MU[Q?MZ]_%C_QT'^W'OWTX_U?\5U[Q?MZ]_%C_P =!_MQ[]]./]7_ !77O%^W
MKW\6/_'0?[<>_?3C_5_Q77O%^WKW\6/_ !T'^W'OWTX_U?\ %=>\7[>O?Q8_
M\=!_MQ[]]./]7_%=>\7[>O?Q8_\ '0?[<>_?3C_5_P 5U[Q?MZ]_%C_QT'^W
M'OWTX_U?\5U[Q?MZ]_%C_P =!_MQ[]]./]7_ !77O%^WKW\6/_'0?[<>_?3C
M_5_Q77O%^WKW\6/_ !T'^W'OWTX_U?\ %=>\7[>O?Q8_\=!_MQ[]]./]7_%=
M>\7[>O?Q8_\ '0?[<>_?3C_5_P 5U[Q?MZ]_%C_QT'^W'OWTX_U?\5U[Q?MZ
M-)OZM\?QUZWJ-5O)FL<+_P"O39,_\1[!&U1UW>X'HC?\>CZ$%X]+*(_TA_@?
MHK?\6/\ QT'^W'L;_3C_ %?\5T'_ !?MZ]_%C_QT'^W'OWTX_P!7_%=>\7[>
MO?Q8_P#'0?[<>_?3C_5_Q77O%^WKW\6/_'0?[<>_?3C_ %?\5U[Q?MZ]_%C_
M ,=!_MQ[]]./]7_%=>\7[>O?Q8_\=!_MQ[]]./\ 5_Q77O%^WKW\6/\ QT'^
MW'OWTX_U?\5U[Q?MZ]_%C_QT'^W'OWTX_P!7_%=>\7[>O?Q8_P#'0?[<>_?3
MC_5_Q77O%^WKW\6/_'0?[<>_?3C_ %?\5U[Q?MZ]_%C_ ,=!_MQ[]]./]7_%
M=>\7[>O?Q8_\=!_MQ[]]./\ 5_Q77O%^WKW\6/\ QT'^W'OWTX_U?\5U[Q?M
MZ]_%C_QT'^W'OWTX_P!7_%=>\7[>O?Q8_P#'0?[<>_?3C_5_Q77O%^WKW\6/
M_'0?[<>_?3C_ %?\5U[Q?MZ]_%C_ ,=!_MQ[]]./]7_%=>\7[>O?Q8_\=!_M
MQ[]]./\ 5_Q77O%^WKW\6/\ QT'^W'OWTX_U?\5U[Q?MZ]_%C_QT'^W'OWTX
M_P!7_%=>\7[>O?Q8_P#'0?[<>_?3C_5_Q77O%^WKW\6/_'0?[<>_?3C_ %?\
M5U[Q?MZ]_%C_ ,=!_MQ[]]./]7_%=>\7[>AT^.M?]QV911ZPU\5ES;_6C]AC
MFZ'19$_TD_P]&^R/JG'V'_!T'7863\>_M\1ZP-&[]RI:X_LULX]F^TP VL)_
MX5'_ ,<'2&]DI-)Q^-O^/'I(?Q8_\=!_MQ[,/IQ_J_XKI-XOV]>_BQ_XZ#_;
MCW[Z<?ZO^*Z]XOV]>_BQ_P".@_VX]^^G'^K_ (KKWB_;U[^+'_CH/]N/?OIQ
M_J_XKKWB_;U[^+'_ (Z#_;CW[Z<?ZO\ BNO>+]O7OXL?^.@_VX]^^G'^K_BN
MO>+]O7OXL?\ CH/]N/?OIQ_J_P"*Z]XOV]>_BQ_XZ#_;CW[Z<?ZO^*Z]XOV]
M>_BQ_P".@_VX]^^G'^K_ (KKWB_;U[^+'_CH/]N/?OIQ_J_XKKWB_;U[^+'_
M (Z#_;CW[Z<?ZO\ BNO>+]O7OXL?^.@_VX]^^G'^K_BNO>+]O7OXL?\ CH/]
MN/?OIQ_J_P"*Z]XOV]>_BQ_XZ#_;CW[Z<?ZO^*Z]XOV]>_BQ_P".@_VX]^^G
M'^K_ (KKWB_;U[^+'_CH/]N/?OIQ_J_XKKWB_;U[^+'_ (Z#_;CW[Z<?ZO\
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M^+'_ (Z#_;CW[Z<?ZO\ BNO>+]O7OXL?^.@_VX]^^G'^K_BNO>+]O7OXL?\
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M?3C_ %?\5U[Q?MZ]_%C_ ,=!_MQ[]]./]7_%=>\7[>O?Q8_\=!_MQ[]]./\
M5_Q77O%^WKW\6/\ QT'^W'OWTX_U?\5U[Q?MZ]_%C_QT'^W'OWTX_P!7_%=>
M\7[>O?Q8_P#'0?[<>_?3C_5_Q77O%^WKW\6/_'0?[<>_?3C_ %?\5U[Q?MZ]
M_%C_ ,=!_MQ[]]./]7_%=>\7[>O?Q8_\=!_MQ[]]./\ 5_Q77O%^WKW\6/\
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M^\'KWB?/KW\1?_5C_??[#W[P>O>)\^O?Q%_]6/\ ??[#W[P>O>)\^O?Q%_\
M5C_??[#W[P>O>)\^O?Q%_P#5C_??[#W[P>O>)\^O?Q%_]6/]]_L/?O!Z]XGS
MZ]_$7_U8_P!]_L/?O!Z]XGSZ]_$7_P!6/]]_L/?O!Z]XGSZ]_$7_ -6/]]_L
M/?O!Z]XGSZ]_$7_U8_WW^P]^\'KWB?/I:];5[OV+L%"X(?>NU5M_P:N@'LNW
MB*EI/_S1D_XXW2JQ>LT>?QI_QX="I\HZQH>VJ] P _@V$-O]>(^R/DJ/58J?
MZ;_X>C'F!]-R?]*O^#HNW\1?_5C_ 'W^P]BWP>B3Q/GU[^(O_JQ_OO\ 8>_>
M#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GU[^(O_JQ
M_OO]A[]X/7O$^?7OXB_^K'^^_P!A[]X/7O$^?7OXB_\ JQ_OO]A[]X/7O$^?
M7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_ &'O
MW@]>\3Y]>_B+_P"K'^^_V'OW@]>\3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_B+_Z
ML?[[_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/
MGU[^(O\ ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO]A[]X/7O$^?7OXB_^K'^^_P!A
M[]X/7O$^?7OXB_\ JQ_OO]A[]X/7O$^?7OXB_P#JQ_OO]A[]X/7O$^?7OXB_
M^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_ &'OW@]>\3Y]'!ZUJF?XN=J3%KE,_E #
M_K4N(_XK[ &\)3>K8?T%_P"/2]":Q:NWRG^D?\"=$^_B+_ZL?[[_ &'L?^#T
M&?$^?7OXB_\ JQ_OO]A[]X/7O$^?7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^
M^_V'OW@]>\3Y]>_B+_ZL?[[_ &'OW@]>\3Y]>_B+_P"K'^^_V'OW@]>\3Y]>
M_B+_ .K'^^_V'OW@]>\3Y]>_B+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>
M#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GU[^(O_JQ
M_OO]A[]X/7O$^?7OXB_^K'^^_P!A[]X/7O$^?7OXB_\ JQ_OO]A[]X/7O$^?
M7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_ &'O
MW@]>\3Y]>_B+_P"K'^^_V'OW@]>\3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_B+_Z
ML?[[_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/
MGU[^(O\ ZL?[[_8>_>#U[Q/GT<'LJJ9/BYU7,&L7S^+!/^O2Y?\ XI[ &SI7
M>KD?T&_X]%T)KYJ;?$?Z0_P/T3[^(O\ ZL?[[_8>Q_X/09\3Y]>_B+_ZL?[[
M_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/GU[^
M(O\ ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO]A[]X/7O$^?7OXB_^K'^^_P!A[]X/
M7O$^?7OXB_\ JQ_OO]A[]X/7O$^?7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^
M^_V'OW@]>\3Y]>_B+_ZL?[[_ &'OW@]>\3Y]>_B+_P"K'^^_V'OW@]>\3Y]>
M_B+_ .K'^^_V'OW@]>\3Y]>_B+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>
M#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GU[^(O_JQ
M_OO]A[]X/7O$^?7OXB_^K'^^_P!A[]X/7O$^?7OXB_\ JQ_OO]A[]X/7O$^?
M7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_ &'O
MW@]>\3Y]&)^+E8TW;5 A8$?P;-FW^M$/82YUCTV+'^FG^'H[Y??5<C_2M_@Z
M"[LZO=.R>PD#@!-\;L6W_!:^H'L[V:*MG!_S1B_XXO1??O2>3/\ HC_\>/2'
M_B+_ .K'^^_V'LR\'I)XGSZ]_$7_ -6/]]_L/?O!Z]XGSZ]_$7_U8_WW^P]^
M\'KWB?/KW\1?_5C_ 'W^P]^\'KWB?/KW\1?_ %8_WW^P]^\'KWB?/KW\1?\
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M3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_B+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\
M8>_>#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GU[^(
MO_JQ_OO]A[]X/7O$^?7OXB_^K'^^_P!A[]X/7O$^?7OXB_\ JQ_OO]A[]X/7
MO$^?7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_
M &'OW@]>\3Y]>_B+_P"K'^^_V'OW@]>\3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_
MB+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>#U[Q/GU[^(O_ *L?[[_8>_>#
MU[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GT<',53#X@[5GU<MGZ@7_ /(ODA_Q'L 6
MZ?[OY1_0'_5J/H32M_NL0_TC_P ?;HGW\1?_ %8_WW^P]C_P>@SXGSZ]_$7_
M -6/]]_L/?O!Z]XGSZ]_$7_U8_WW^P]^\'KWB?/KW\1?_5C_ 'W^P]^\'KWB
M?/KW\1?_ %8_WW^P]^\'KWB?/KW\1?\ U8_WW^P]^\'KWB?/KW\1?_5C_??[
M#W[P>O>)\^O?Q%_]6/\ ??[#W[P>O>)\^O?Q%_\ 5C_??[#W[P>O>)\^O?Q%
M_P#5C_??[#W[P>O>)\^O?Q%_]6/]]_L/?O!Z]XGSZ]_$7_U8_P!]_L/?O!Z]
MXGSZ]_$7_P!6/]]_L/?O!Z]XGSZ]_$7_ -6/]]_L/?O!Z]XGSZ]_$7_U8_WW
M^P]^\'KWB?/KW\1?_5C_ 'W^P]^\'KWB?/KW\1?_ %8_WW^P]^\'KWB?/KW\
M1?\ U8_WW^P]^\'KWB?/KW\1?_5C_??[#W[P>O>)\^O?Q%_]6/\ ??[#W[P>
MO>)\^O?Q%_\ 5C_??[#W[P>O>)\^O?Q%_P#5C_??[#W[P>O>)\^O?Q%_]6/]
M]_L/?O!Z]XGSZ]_$7_U8_P!]_L/?O!Z]XGSZ-1NRK9?B?UE/J%WWQ7J3_K3;
MA_XI[!-C'7?;@?\ "5_P0="&Y;_==$?^&'_#)T5?^(O_ *L?[[_8>QMX/0>\
M3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_B+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\
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M3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_B+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\
M8>_>#U[Q/GU[^(O_ *L?[[_8>_>#U[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GU[^(
MO_JQ_OO]A[]X/7O$^?7OXB_^K'^^_P!A[]X/7O$^?7OXB_\ JQ_OO]A[]X/7
MO$^?7OXB_P#JQ_OO]A[]X/7O$^?7OXB_^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_
M &'OW@]>\3Y]>_B+_P"K'^^_V'OW@]>\3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_
MB+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO\ 8>_>#U[Q/GU[^(O_ *L?[[_8>_>#
MU[Q/GU[^(O\ ZL?[[_8>_>#U[Q/GU[^(O_JQ_OO]A[]X/7O$^?7OXB_^K'^^
M_P!A[]X/7O$^?7OXB_\ JQ_OO]A[]X/7O$^?7OXB_P#JQ_OO]A[]X/7O$^?7
MOXB_^K'^^_V'OW@]>\3Y]>_B+_ZL?[[_ &'OW@]>\3Y]>_B+_P"K'^^_V'OW
M@]>\3Y]>_B+_ .K'^^_V'OW@]>\3Y]>_B+_ZL?[[_8>_>#U[Q/GU[^(O_JQ_
MOO\ 8>_>#U[Q/GTCOO/\?^3?9GX?2;KWWG^/_)OOWA]>Z]]Y_C_R;[]X?7NO
M?>?X_P#)OOWA]>Z]]Y_C_P F^_>'U[KWWG^/_)OOWA]>Z]]Y_C_R;[]X?7NO
M?>?X_P#)OOWA]>Z]]Y_C_P F^_>'U[KWWG^/_)OOWA]>Z]]Y_C_R;[]X?7NO
M?>?X_P#)OOWA]>Z]]Y_C_P F^_>'U[KWWG^/_)OOWA]>Z]]Y_C_R;[]X?7NO
M?>?X_P#)OOWA]>Z]]Y_C_P F^_>'U[KWWG^/_)OOWA]>Z]]Y_C_R;[]X?7NO
M?>?X_P#)OOWA]>Z]]Y_C_P F^_>'U[I=]75=^S>NA?Z[[VB/T_UR%/[+-[2E
ME<?\T)?^K;=*]OS/'_S43_CPZ%WY:U'C[CR*_P#5CP)^E_K$?8?Y#6NWK_IW
M_P /1GS'_N2?]*O19_O/\?\ DWV,_#Z(>O?>?X_\F^_>'U[KWWG^/_)OOWA]
M>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)OOWA]
M>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)OOWA]
M>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)OOWA]
M>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)OOWA]
M>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[HZW5L^KXE]O2?
MZG<66'T_Z9,-_P 5]QQO:TWZU'_"T_X_-T*MO_Y)TW^F;_CJ=$I^\_Q_Y-]R
M/X?05Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)O
MOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)O
MOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)O
MOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)O
MOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[KWWG^/_)O
MOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NCK=I3Z?B7U#)_JMQ8D?3_ID
MS/\ Q3W'&R+7?KH?\+?_ (_#T*MP_P"2=#_IE_XZ_1*?O/\ '_DWW(_A]!7K
MWWG^/_)OOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[K
MWWG^/_)OOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[K
MWWG^/_)OOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[K
MWWG^/_)OOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[K
MWWG^/_)OOWA]>Z]]Y_C_ ,F^_>'U[KWWG^/_ ";[]X?7NO?>?X_\F^_>'U[K
MWWG^/_)OOWA]>Z]]Y_C_ ,F^_>'U[HS'Q*J/)W'CE_ZL>>/TM](A[!G/BTV]
MO].G^'H^Y<_W)'^E;H)>UJK3VCV2M_T[^WB/T_TR-3[/]C2ME;_\T(O^K:]%
MNX_[D2_\U'_X\>D#]Y_C_P F^S3P^D?7OO/\?^3??O#Z]U[[S_'_ )-]^\/K
MW7OO/\?^3??O#Z]U[[S_ !_Y-]^\/KW7OO/\?^3??O#Z]U[[S_'_ )-]^\/K
MW7OO/\?^3??O#Z]U[[S_ !_Y-]^\/KW7OO/\?^3??O#Z]U[[S_'_ )-]^\/K
MW7OO/\?^3??O#Z]U[[S_ !_Y-]^\/KW7OO/\?^3??O#Z]U[[S_'_ )-]^\/K
MW7OO/\?^3??O#Z]U[[S_ !_Y-]^\/KW7OO/\?^3??O#Z]U[[S_'_ )-]^\/K
MW7OO/\?^3??O#Z]U[[S_ !_Y-]^\/KW7OO/\?^3??O#Z]U[[S_'_ )-]^\/K
MW1NOFA/XNT<"M_KL'%GZ7_Y>.5]@+VZ759/_ ,UV_P"K<70DYH_W(7_FF/\
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M6.O=>\,G]?\ DWW[6.O=>\,G]?\ DWW[6.O=>\,G]?\ DWW[6.O=>\,G]?\
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ML=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\
M)OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/
MZ_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z
M]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOV
ML=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\ )OOVL=>Z]X9/Z_\
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MO7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\
M\]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:
MO7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\
M\]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:
MO7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\
M\]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:
MO7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\
M\]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:
MO7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\
M\]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:
MO7OZO-_$O[#U[_92,_\ \]1@O_.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,_\
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M2P/56[.O9<OCIZO<>0JJR&OB@D6*,5$5'& ZGUD@TS'C^H]D=WOJW-Y'<A2
M@ I45-"Q_P"?NC*#;## \-1W$FM,9 '^3H&?]E(S_P#SU&"_\XI_9Y_7./\
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M[^KS?Q+^P]>_V4C/_P#/48+_ ,XI_?OZYQ_[[;]J]>_J\W\2_L/7O]E(S_\
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M_L/7O]E(S_\ SU&"_P#.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,__ ,]1@O\
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M[^KS?Q+^P]>_V4C/_P#/48+_ ,XI_?OZYQ_[[;]J]>_J\W\2_L/7O]E(S_\
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M_L/7O]E(S_\ SU&"_P#.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,__ ,]1@O\
MSBG]^_KG'_OMOVKU[^KS?Q+^P]>_V4C/_P#/48+_ ,XI_?OZYQ_[[;]J]>_J
M\W\2_L/7O]E(S_\ SU&"_P#.*?W[^N<?^^V_:O7OZO-_$O[#U[_92,__ ,]1
M@O\ SBG]^_KG'_OMOVKU[^KS?Q+^P]>_V4C/_P#/48+_ ,XI_?OZYQ_[[;]J
M]>_J\W\2_L/0L=Q=&Y/LS<U#GJ+,XW'14F"I<0T%93R2L6@J*J8N"G&DBH M
M];@^R?9.8%VF(QLI:KEJ@CS"CS^SI?N.U&^<."!10,BOF3_EZ"?_ &4C/_\
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M /GJ,%_YQ3^_?USC_P!]M^U>O?U>;^)?V'KW^RD9_P#YZC!?^<4_OW]<X_\
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M*$8H6/G_ *;HRO\ ;#>*@! T C(K6M/\W0,_[*1G_P#GJ,%_YQ3^SS^N<?\
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MW]7F_B7]AZ]_LI&?_P">HP7_ )Q3^_?USC_WVW[5Z]_5YOXE_8>O?[*1G_\
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MF_U9_P"2E]^\'_53KVK_ %?ZCU[^--_JS_R4OOW@_P"JG7M7^K_4>O?QIO\
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MO:O]7^H]>_C3?ZL_\E+[]X/^JG7M7^K_ %'KW\:;_5G_ )*7W[P?]5.O:O\
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M'UDE'Y_UO9?ML>N,G^D?+Y#I7>&C#[/\I^?22_C3?ZL_\E+[,/!_U4Z2:O\
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MF_U9_P"2E]^\'_53KVK_ %?ZCU[^--_JS_R4OOW@_P"JG7M7^K_4>O?QIO\
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MO:O]7^H]>_C3?ZL_\E+[]X/^JG7M7^K_ %'KW\:;_5G_ )*7W[P?]5.O:O\
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M-G2[BEPM+618^;)5M;408_$8J">;]J*?+9>LH:.)F! DG4Z6/I+%R%MHS(W
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ME=\;.J-Y[>ZY[2^0W1W6W86[M/\ =/8>_NV<#L[,Y3454?P[%Y'(4U=6W9U
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M'LACB_Q]E_H_\^KT9LY^F!^?^4]!7_$O]J_WGV??3C_4>BSQFZ]_$O\ :O\
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M^LBUK6:_4Q*Y&2*XX=:N&,3E1P'1X_XE_M7^\^U/TX_U'IGQFZ]_$O\ :O\
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MV/*P?PBIW=L:L8T55"B4\E-6S2_?D0JL1FK)9T1?N#=(G^X4HK4+( /LJO\
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ML[MJ8I&KNK,\JVRZF/\ AJ3Z#U/5XXS*:#_BNJ6*[XK_ "$ROP?_ )N7R_\
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M!Z(C_P )L9]'\FCXF+?Z9'Y!_G^O9>[_ /'VDV1:VR?[;_CQZ>O_ .V;\O\
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MVG_5GKW0SULUNF<1)?ZY&47O_P!-E5_C[#D0_P!V+_Z4?\<7HU?_ '%7[?\
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M^K/7NO?<_P"/^\_\;]^T_P"K/7NA:S$UNH-JR7_5GJ@7O_M>2_Q_P]D%N/\
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M5F)1@*ZABI'EP'1M&A,F"ND*0H# FE#\_P SU;3U5V_M[N;^?QU%WWA,'O[
M[![C_D_;WVEUL>S]A9;J_*R9+KWN6K;+TDN$S]+0Y6CF@IXI*A5>E3RTM1#5
M1%X)U=C"-O%NP]" T)I4$&H?."*])673 5Q42>1KQ7Y=#/\ *6DK-U?SW?Y5
MU/MO,_;UG5GQQ^;G8O8^*I*UEDFP&[,32;;Q:U<*2+>DDS]1%)%Y%:-IZ4E1
MY(@R.W"EKN(#R5R?L(I_AZK'B%Z^94#[>/\ @ZO*^Y_Q_P!Y_P"-^S73_JST
MCZ]]S_C_ +S_ ,;]^T_ZL]>Z]]S_ (_[S_QOW[3_ *L]>Z]]S_C_ +S_ ,;]
M^T_ZL]>Z]]S_ (_[S_QOW[3_ *L]>Z]]S_C_ +S_ ,;]^T_ZL]>Z]]S_ (_[
MS_QOW[3_ *L]>Z]]S_C_ +S_ ,;]^T_ZL]>Z]]S_ (_[S_QOW[3_ *L]>ZFX
MRIOD<>+_ /*;2?G_ )N+_C[;F7L;[#Z^G5X_B'VCH3>Y)O'N>@6]KX&E/U_Z
M:*K_ !]DG+HK W^G/_'5Z7[I_:#_ $H_PGH)?N?\?]Y_XW[/]/\ JST6]>^Y
M_P ?]Y_XW[]I_P!6>O=>^Y_Q_P!Y_P"-^_:?]6>O=>^Y_P ?]Y_XW[]I_P!6
M>O=>^Y_Q_P!Y_P"-^_:?]6>O=>^Y_P ?]Y_XW[]I_P!6>O=>^Y_Q_P!Y_P"-
M^_:?]6>O=>^Y_P ?]Y_XW[]I_P!6>O=>^Y_Q_P!Y_P"-^_:?]6>O=>^Y_P ?
M]Y_XW[]I_P!6>O=>^Y_Q_P!Y_P"-^_:?]6>O=4\?S#O@;\O/E?MSN3$]?_/[
M<NS^J=^8&.D?XI;IZDP0V=D:*DQ]+3U^WLINK;C[<[&CQ.X9(*QZUX]SLZ"L
M>)4:DC%,Q=>64EP"!(0#^ K@_*HHU#]O2J"=8J56I'G7/\ZC'V="%_+6^06+
M^;G\KWIKL'H[;_\ LHO]Z>IMT]5[+Q.RL30;CI]C9#KJ?(;2@JL!296FJ,;D
M*'&U6,6JH(JVDFB>,1PUL<C"93:QD^J@5D&BH(%!732HQBGEU6X3P9"#W9J?
MG7/5:??77_<GP ^<_P $OEK\K^\F_F'X'M3O+"_";K/+]C]>4/66Z>K,U\B(
MZM4W#M7';4J*+9==!64V,>FRLDFUHLJT%DIZ[2RT_M%-$UG+')(WB5;0*BA0
MMYBE ?GBO2A&$Z,JC30:C3(8#[<_9FG1E_A!%4[>_G??SL:7/TTM)D=];/\
MY>V\]G2U++>MPV#V/7XFKJ:<DZW@AR"I3,1Z5DB*'Z+[>M5(NIZ^8C(^S33I
MN;,,?RU_X>G#K*DK-P?\*'?D[N[ YGR;<ZY_EE]-];]@8>DK6DC&?WUO=L[A
MFJXDD\:5<&%H*MHA)&9!#5ED*I*VO<:EKQB/*( _:6J/Y=>;$ 'JY(^P"G5Y
M7W/^/^\_\;]FNG_5GI'U[[G_ !_WG_C?OVG_ %9Z]U[[G_'_ 'G_ (W[]I_U
M9Z]U[[G_ !_WG_C?OVG_ %9Z]U[[G_'_ 'G_ (W[]I_U9Z]U[[G_ !_WG_C?
MOVG_ %9Z]U[[G_'_ 'G_ (W[]I_U9Z]U[[G_ !_WG_C?OVG_ %9Z]U[[G_'_
M 'G_ (W[]I_U9Z]U[[G_ !_WG_C?OVG_ %9Z]U[[G_'_ 'G_ (W[]I_U9Z]U
M[[G_ !_WG_C?OVG_ %9Z]TD?XNO^I_Y/]K_IS_J_XKI)XA_U?\7U[^+K_J?^
M3_?OIS_J_P"*Z]XA_P!7_%]>_BZ_ZG_D_P!^^G/^K_BNO>(?]7_%]>_BZ_ZG
M_D_W[Z<_ZO\ BNO>(?\ 5_Q?7OXNO^I_Y/\ ?OIS_J_XKKWB'_5_Q?1>/E3\
M=>H_F5T9O+X\]WXW-Y'KS>SX"JR(VUN2JVKD*>KVID:3+XRMHJ^D9)8*FBR-
M#2SI</&Q31+')$SHS%QMZW2%'K0TX5!P:].17+0L&4Y'RK_EZJWZ7_D/_%?K
MKM?87;/;?>/R_P#F#7=29FFW#U-M#Y4]U)V)@<#7T4HF@K8,;3XO')/412)$
MZK*YIBZ*[4S,%TE\/+R1L&9G>G .:@?RZ52;FS A0JUXZ1D_SZ'#Y\?RD_C;
M\_>T^M>^-V;X[RZ+[VZNP_\ =?!=P?'??--L7.2XC76R+CYZBJQN24+#)D:X
MQ3PI%.BSRQ-(\+F/V]>;(EXP<EE88U*:&G[#Z]4M]P:W!6@(/D17/[>G?XB?
MRF/B!\(/D9N/Y.="P=F8S?N[>E7Z2W%CMS;UCW3CZVGK\OC<YD\_625-!_&:
MW<^8R6*I):RLJ,Q+$UF6&FA4@#=MLD=HYD354KI-34<0:\*U-,YZU-N#SKI:
ME*UP/RIQX=%*W=_PGF^&F;/:F;VAW-\O>J>R.X^W>Q^T]\]I]<=OX_;&6K*3
MM)HY<GLRHCI-OP8VMV?'5(U32TU50SUT,\DM\A)#-+"Z9^6XS4AG!9B20:'/
M$?#P_P!5>G5W5Q2H4@   CT\^/'HF'\VSX][%^)/\LG;?\IGX._$[Y(]E9/Y
M [EVWN/;F[=A[-E['HQE=I;NV[E,K7;VSL+12PYC+1PP1TQ% *6.")8P:*CI
M(HU0[K9"TMQ;0QNQ<@@@5%0P)J?4]*;*<SR^-(R@+Y''$'@.KD=V?RV?C_\
M(;X!?&GX5_)+;^;S&.Z&ZDZ1VOMG=6WMQ#";AP6;ZJVW18-,KBLM3P>**M"0
M3(Y^U>FF5V#TY72%.&V=9X5BD![545\P0*5!IT@%\T<C.IXD^6*$U]>D;\7/
MY4VTOC=W!L[NC<'S6_F$?)C.]<PY*'8&U/D;\FZS>VW,9_%<?68N208>FHJ"
M*I=*.NJ%C6:1Z>-B'6 .JL*6^R^ P8O*]. 9B0,4X4^?5IK\RB@55KQHN?\
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MZK?5/99RY#KM0?Z3?X>E>[/IF/V#H)_XNO\ J?\ D_V??3G_ %?\5T6^(?\
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M5U[Q#_J_XOKW\77_ %/_ "?[]].?]7_%=>\0_P"K_B^O?Q=?]3_R?[]].?\
M5_Q77O$/^K_B^B%?-7X247S:Q<^V-Q?*;Y9]([#S6P=T=;;YZZZ"WYM_;.$W
M)C-X)+!7)FZ7,[6S\E3)+23S4Q,<\*F!RI0D!O:.[VLW8H7=10@A2*$'UJIZ
M407G@>2DUJ"0:C^?4CX2?"O&_!_:\NQ-N?)CY3=Y;"H=H;.V+L?9'R#WS@MU
MXS:^,V1%+3TE-M^##[9P#4J-2O#!()9)U\5/ D:II.KUIM?T@TAG84  8@@
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M_)_OWTY_U?\ %=>\0_ZO^+Z]_%U_U/\ R?[]].?]7_%=>\0_ZO\ B^A8Z7R
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M^G/^K_BNO>(?]7_%]>_BZ_ZG_D_W[Z<_ZO\ BNO>(?\ 5_Q?7OXNO^I_Y/\
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M^^G/^K_BNO>(?]7_ !?7OXNO^I_Y/]^^G/\ J_XKKWB'_5_Q?7OXNO\ J?\
MD_W[Z<_ZO^*Z]XA_U?\ %]>_BZ_ZG_D_W[Z<_P"K_BNO>(?]7_%]>_BZ_P"I
M_P"3_?OIS_J_XKKWB'_5_P 7U[^+K_J?^3_?OIS_ *O^*Z]XA_U?\7U[^+K_
M *G_ )/]^^G/^K_BNO>(?]7_ !?15/E/\:<3\H</LV)>Z?D'\?MY=>YJMSFS
M>S/CCV5_H_S%.^3B2&KI*R.IHLGB<OC*R*.-9J6NQE1&0 T7BE"R*FN-N^H
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M^?\ D'V&[6*NYS+_ ,+'^"+HVF?_ !-#_2/^%^@4_BZ_ZG_D_P!B3Z<_ZO\
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MU20R4>*K]PSTD1BA#I,L401(-A6@4LY0$$(3VX\N%2/D3T^=R;B H;S8#/\
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MUJJP?\1[(.5HM=NQ_P"&'_CJ=&>\OIE'^E'^%N@4_BZ_ZG_D_P!B3Z<_ZO\
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M=[=)9)LWTACOD5V#BZK ;6R9@J*7^-T6W]M8/;N-KL_]O4,HK\C#62QLD4L
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MU[Q#_J_XOKW\77_4_P#)_OWTY_U?\5U[Q#_J_P"+Z]_%U_U/_)_OWTY_U?\
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M'KWBC_4>O?Q3_#_>?^-^_>#U[Q1_J/7OXI_A_O/_ !OW[P>O>*/]1Z]_%/\
M#_>?^-^_>#U[Q1_J/2TZXR.OL/826_7O3:Z_7_55T _K[+MWBI:3_P#-&3_C
MC=*K*0&:/_3I_P >'0I?)^M\':]?';_ES84_7^L1_P ?9)R7'JL0?Z;_ .'H
MPW^33<$?T5Z+S_%/\/\ >?\ C?L6>#T2^*/]1Z]_%/\ #_>?^-^_>#U[Q1_J
M/7OXI_A_O/\ QOW[P>O>*/\ 4>O?Q3_#_>?^-^_>#U[Q1_J/7OXI_A_O/_&_
M?O!Z]XH_U'KW\4_P_P!Y_P"-^_>#U[Q1_J/7OXI_A_O/_&_?O!Z]XH_U'KW\
M4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_  _WG_C?OW@]
M>\4?ZCU[^*?X?[S_ ,;]^\'KWBC_ %'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?
M[S_QOW[P>O>*/]1Z]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*/
M]1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'KW\4_P /]Y_X
MW[]X/7O%'^H]>_BG^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW[]X/7O%'^H]>
M_BG^'^\_\;]^\'KWBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]&\ZWJ_)\8.TI_^
M.>>R8^O]*7$G^O\ C[ .\)3>K8?T%_X]+T);%ZV$I_I'_ G10_XI_A_O/_&_
M8^\'H->*/]1Z]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z]
M_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'KW\4_P /]Y_XW[]X
M/7O%'^H]>_BG^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^
M'^\_\;]^\'KWBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]>_BG^'^\_\;]^\'KWB
MC_4>O?Q3_#_>?^-^_>#U[Q1_J/7OXI_A_O/_ !OW[P>O>*/]1Z]_%/\ #_>?
M^-^_>#U[Q1_J/7OXI_A_O/\ QOW[P>O>*/\ 4>O?Q3_#_>?^-^_>#U[Q1_J/
M7OXI_A_O/_&_?O!Z]XH_U'KW\4_P_P!Y_P"-^_>#U[Q1_J/7OXI_A_O/_&_?
MO!Z]XH_U'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_
M  _WG_C?OW@]>\4?ZCU[^*?X?[S_ ,;]^\'KWBC_ %'HWG9%7X_C!U;/_P =
M,]C!]?ZTN6/]?\/8!V=*[U<C^@W_ !Z+H2WSTL(C_2'^!^BA_P 4_P /]Y_X
MW['W@]!KQ1_J/7OXI_A_O/\ QOW[P>O>*/\ 4>O?Q3_#_>?^-^_>#U[Q1_J/
M7OXI_A_O/_&_?O!Z]XH_U'KW\4_P_P!Y_P"-^_>#U[Q1_J/7OXI_A_O/_&_?
MO!Z]XH_U'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_
M  _WG_C?OW@]>\4?ZCU[^*?X?[S_ ,;]^\'KWBC_ %'KW\4_P_WG_C?OW@]>
M\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[
MS_QOW[P>O>*/]1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'
MKW\4_P /]Y_XW[]X/7O%'^H]>_BG^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW
M[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]>_
MBG^'^\_\;]^\'KWBC_4>O?Q3_#_>?^-^_>#U[Q1_J/1AOC!6^?M>@CM_RYLT
M?K_2(?X^PGSI'IL2?Z:?X>CK8)-5P!_1;H,.S,CH['[ 2WZ-[[K7Z_ZFOJ!_
M7V=;-%6S@_YHQ?\ '%Z07\@$\G_-1_\ CQZ1'\4_P_WG_C?LR\'I)XH_U'KW
M\4_P_P!Y_P"-^_>#U[Q1_J/7OXI_A_O/_&_?O!Z]XH_U'KW\4_P_WG_C?OW@
M]>\4?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_  _WG_C?OW@]>\4?ZCU[^*?X
M?[S_ ,;]^\'KWBC_ %'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*
M/]1Z]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z]_%/\/]Y_
MXW[]X/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'KW\4_P /]Y_XW[]X/7O%'^H]
M>_BG^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\;]^
M\'KWBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>O?Q3
M_#_>?^-^_>#U[Q1_J/7OXI_A_O/_ !OW[P>O>*/]1Z]_%/\ #_>?^-^_>#U[
MQ1_J/7OXI_A_O/\ QOW[P>O>*/\ 4>C2?+:L^W['PB6^NR,:WU_K7Y(?U']/
M8)Y#CU6;_P#-9O\ CD?0@YD?3.O_ #3'_'FZ*W_%/\/]Y_XW[&W@]!_Q1_J/
M7OXI_A_O/_&_?O!Z]XH_U'KW\4_P_P!Y_P"-^_>#U[Q1_J/7OXI_A_O/_&_?
MO!Z]XH_U'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_
M  _WG_C?OW@]>\4?ZCU[^*?X?[S_ ,;]^\'KWBC_ %'KW\4_P_WG_C?OW@]>
M\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[
MS_QOW[P>O>*/]1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'
MKW\4_P /]Y_XW[]X/7O%'^H]>_BG^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW
M[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]>_
MBG^'^\_\;]^\'KWBC_4>O?Q3_#_>?^-^_>#U[Q1_J/7OXI_A_O/_ !OW[P>O
M>*/]1Z]_%/\ #_>?^-^_>#U[Q1_J/1O,O5V^(VUJG^N>J!]?^KMDA_7_  _K
M[ ,"?[OI!_0'_5J/H2R/_NM0_P!(_P#'VZ*'_%/\/]Y_XW['W@]!KQ1_J/7O
MXI_A_O/_ !OW[P>O>*/]1Z]_%/\ #_>?^-^_>#U[Q1_J/7OXI_A_O/\ QOW[
MP>O>*/\ 4>O?Q3_#_>?^-^_>#U[Q1_J/7OXI_A_O/_&_?O!Z]XH_U'KW\4_P
M_P!Y_P"-^_>#U[Q1_J/7OXI_A_O/_&_?O!Z]XH_U'KW\4_P_WG_C?OW@]>\4
M?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_  _WG_C?OW@]>\4?ZCU[^*?X?[S_
M ,;]^\'KWBC_ %'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z
M]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z]_%/\/]Y_XW[]
MX/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'KW\4_P /]Y_XW[]X/7O%'^H]>_BG
M^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\;]^\'KW
MBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>C2;KK-/Q
M3ZSJ+?KWO7K]?Z3;@_Q_P]@FQCKOEP/^$K_@@Z$%P_\ NNB/_##_ (9.BM_Q
M3_#_ 'G_ (W[&W@]!_Q1_J/7OXI_A_O/_&_?O!Z]XH_U'KW\4_P_WG_C?OW@
M]>\4?ZCU[^*?X?[S_P ;]^\'KWBC_4>O?Q3_  _WG_C?OW@]>\4?ZCU[^*?X
M?[S_ ,;]^\'KWBC_ %'KW\4_P_WG_C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*
M/]1Z]_%/\/\ >?\ C?OW@]>\4?ZCU[^*?X?[S_QOW[P>O>*/]1Z]_%/\/]Y_
MXW[]X/7O%'^H]>_BG^'^\_\ &_?O!Z]XH_U'KW\4_P /]Y_XW[]X/7O%'^H]
M>_BG^'^\_P#&_?O!Z]XH_P!1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\;]^
M\'KWBC_4>O?Q3_#_ 'G_ (W[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>O?Q3
M_#_>?^-^_>#U[Q1_J/7OXI_A_O/_ !OW[P>O>*/]1Z]_%/\ #_>?^-^_>#U[
MQ1_J/7OXI_A_O/\ QOW[P>O>*/\ 4>O?Q3_#_>?^-^_>#U[Q1_J/1O/DY5_;
M[8Z7/_'3 Y<_7^E/A_\ '_'V >2TU37?^G3_ (]+T)=_?3'!_I6_P)T4/^*?
MX?[S_P ;]C[P>@UXH_U'KW\4_P /]Y_XW[]X/7O%'^H]>_BG^'^\_P#&_?O!
MZ]XH_P!1Z]_%/\/]Y_XW[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>O?Q3_#_
M 'G_ (W[]X/7O%'^H]>_BG^'^\_\;]^\'KWBC_4>O?Q3_#_>?^-^_>#U[Q1_
MJ/7OXI_A_O/_ !OW[P>O>*/]1Z]_%/\ #_>?^-^_>#U[Q1_J/7OXI_A_O/\
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M^'^V_P"->_>#UZO7OO#_ (?[;_C7OW@]>KU[[P_X?[;_ (U[]X/7J]>^\/\
MA_MO^->_>#UZO7OO#_A_MO\ C7OW@]>KU[[P_P"'^V_XU[]X/7J]>^\/^'^V
M_P"->_>#UZO7OO#_ (?[;_C7OW@]>KU[[P_X?[;_ (U[]X/7J]>^\/\ A_MO
M^->_>#UZO7OO#_A_MO\ C7OW@]>KU[[P_P"'^V_XU[]X/7J]>^\/^'^V_P"-
M>_>#UZO7OO#_ (?[;_C7OW@]>KU[[P_X?[;_ (U[]X/7J]>^\/\ A_MO^->_
M>#UZO2ZZOJRW9G7:FUCOK:0^G]<A3_X>RS>XJ6<__-&7_CC=*[ UGC_YJ)_Q
MX="Y\LJDQ]Q9%!;C!X+_ 'F(^R#D2/5MZG^F_P#AZ,^8S_C)_P!*O1:?O#_A
M_MO^->QEX/1#7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&
MO?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]
M7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_
MP_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&
MO?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]
M7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7KWWA_
MP_VW_&O?O!Z]7KWWA_P_VW_&O?O!Z]7HZ?5TY;XF]N2_ZG<65'_JIAO^*^XY
MWM*;[:C_ (6G_'Y>A5MY_P!UTW^F;_CJ=$L^\/\ A_MO^->Y&\'H*UZ]]X?\
M/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QK
MW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5
MZ]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\
M/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QK
MW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5
MZ]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z]]X?\
M/]M_QKW[P>O5Z]]X?\/]M_QKW[P>O5Z.GVC.5^)O4<O^JW%BA_ZJ9G_BGN.=
MD2N^W0_X6_\ Q^+H5;@?]UT/^F7_ (Z_1+/O#_A_MO\ C7N1O!Z"M>O?>'_#
M_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]
M^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>
MO?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#
M_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]
M^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>
MO?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>O?>'_#
M_;?\:]^\'KU>O?>'_#_;?\:]^\'KU>C+?$VI,G<6.0VYP>=_WB(>P;SW'IV]
MC_33_#T?<N'_ !D?Z5N@F[5JRO:'9"\>G?N\%^G],C4>S[8XJV5O_P T(O\
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M;_C7OW@]>KU[[P_X?[;_ (U[]X/7J]>^\/\ A_MO^->_>#UZO7OO#_A_MO\
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M_P#C[*]\(^BN/^:$O_5MNE>W_P!O'_S43_CPZ&/Y?&3_ $T9'2#;^ X#Z?\
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MHZ]UZ\W]#_OO]C[]4=>Z]>;^A_WW^Q]^J.O=>O-_0_[[_8^_5'7NO7F_H?\
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MO>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\
MM/\ O'OWU/\ J_U'KWA?;U[^&_[3_O'OWU/^K_4>O>%]O7OX;_M/^\>_?4_Z
MO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\ J_U'KWA?
M;U[^&_[3_O'OWU/^K_4>O>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]
M]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\ J_U'KWA?;U[^&_[3_O'OWU/^K_4>
MO>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\
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MG_>/?OJ?]7^H]>\+[>O?PW_:?]X]^^I_U?ZCU[POMZ]_#?\ :?\ >/?OJ?\
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M^WKW\-_VG_>/?OJ?]7^H]>\+[>O?PW_:?]X]^^I_U?ZCU[POMZ]_#?\ :?\
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M^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\
MJ_U'KWA?;U[^&_[3_O'OWU/^K_4>O>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_A
MO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\ J_U'KWA?;U[^&_[3_O'O
MWU/^K_4>O>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7
MV]>_AO\ M/\ O'OWU/\ J_U'KWA?;U[^&_[3_O'OWU/^K_4>O>%]O7OX;_M/
M^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\
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M^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\
MJ_U'KWA?;U[^&_[3_O'OWU/^K_4>O>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_A
MO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\ J_U'KWA?;U[^&_[3_O'O
MWU/^K_4>O>%]O7OX;_M/^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7
MV]>_AO\ M/\ O'OWU/\ J_U'KWA?;U[^&_[3_O'OWU/^K_4>O>%]O7OX;_M/
M^\>_?4_ZO]1Z]X7V]>_AO^T_[Q[]]3_J_P!1Z]X7V]>_AO\ M/\ O'OWU/\
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MZQW_ -5^_?UKL_\ ?G_&'_Z!Z]^Y9_X/^-+_ -!=>_V73MC_ )Y%O_/UCO\
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MQA_^@>O?N6?^#_C2_P#077O]ET[8_P">1;_S]8[_ .J_?OZUV?\ OS_C#_\
M0/7OW+/_  ?\:7_H+KW^RZ=L?\\BW_GZQW_U7[]_6NS_ -^?\8?_ *!Z]^Y9
M_P"#_C2_]!=>_P!ET[8_YY%O_/UCO_JOW[^M=G_OS_C#_P#0/7OW+/\ P?\
M&E_Z"Z]_LNG;'_/(M_Y^L=_]5^_?UKL_]^?\8?\ Z!Z]^Y9_X/\ C2_]!=>_
MV73MC_GD6_\ /UCO_JOW[^M=G_OS_C#_ /0/7OW+/_!_QI?^@NO?[+IVQ_SR
M+?\ GZQW_P!5^_?UKL_]^?\ &'_Z!Z]^Y9_X/^-+_P!!=>_V73MC_GD6_P#/
MUCO_ *K]^_K79_[\_P",/_T#U[]RS_P?\:7_ *"Z]_LNG;'_ #R+?^?K'?\
MU7[]_6NS_P!^?\8?_H'KW[EG_@_XTO\ T%U[_9=.V/\ GD6_\_6._P#JOW[^
MM=G_ +\_XP__ $#U[]RS_P '_&E_Z"Z]_LNG;'_/(M_Y^L=_]5^_?UKL_P#?
MG_&'_P"@>O?N6?\ @_XTO_077O\ 9=.V/^>1;_S]8[_ZK]^_K79_[\_XP_\
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M+/\ P?\ &E_Z"Z]_LNG;'_/(M_Y^L=_]5^_?UKL_]^?\8?\ Z!Z]^Y9_X/\
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M'_/(M_Y^L=_]5^_?UKL_]^?\8?\ Z!Z]^Y9_X/\ C2_]!=>_V73MC_GD6_\
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MZQW_ -5^_?UKL_\ ?G_&'_Z!Z]^Y9_X/^-+_ -!=>_V73MC_ )Y%O_/UCO\
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MZQW_ -5^_?UKL_\ ?G_&'_Z!Z]^Y9_X/^-+_ -!=>_V73MC_ )Y%O_/UCO\
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M_P">1;_S]8[_ .J_?OZUV?\ OS_C#_\ 0/7OW+/_  ?\:7_H+HQ.1ZPWE/\
M'C [$BPI;<M%EIJJHQGW]*-*/D*V<-Y3,(#^U,C6$I/-OJ" &(]X@7<WN2W8
M5 #:6_@5>%*\1Z='#V,ALUBT]P-:5'\1/&M//UZ+M_LNG;'_ #R+?^?K'?\
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M #]8[_ZK]^_K79_[\_XP_P#T#U[]RS_P?\:7_H+KW^RZ=L?\\BW_ )^L=_\
M5?OW]:[/_?G_ !A_^@>O?N6?^#_C2_\ 077O]ET[8_YY%O\ S]8[_P"J_?OZ
MUV?^_/\ C#_] ]>_<L_\'_&E_P"@NO?[+IVQ_P \BW_GZQW_ -5^_?UKL_\
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M'_/(M_Y^L=_]5^_?UKL_]^?\8?\ Z!Z]^Y9_X/\ C2_]!=>_V73MC_GD6_\
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M]^Y9_P"#_C2_]!=>_P!ET[8_YY%O_/UCO_JOW[^M=G_OS_C#_P#0/7OW+/\
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M?\:7_H+KW^RZ=L?\\BW_ )^L=_\ 5?OW]:[/_?G_ !A_^@>O?N6?^#_C2_\
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MG\/7O'?U_P!7[>O?WGKO^5J7_DO_ (U[]]"G\/7O'?U_U?MZ]_>>N_Y6I?\
MDO\ XU[]]"G\/7O'?U_U?MZ]_>>N_P"5J7_DO_C7OWT*?P]>\=_7_5^WKW]Y
MZ[_E:E_Y+_XU[]]"G\/7O'?U_P!7[>O?WGKO^5J7_DO_ (U[]]"G\/7O'?U_
MU?MZ]_>>N_Y6I?\ DO\ XU[]]"G\/7O'?U_U?MZ]_>>N_P"5J7_DO_C7OWT*
M?P]>\=_7_5^WKW]YZ[_E:E_Y+_XU[]]"G\/7O'?U_P!7[>O?WGKO^5J7_DO_
M (U[]]"G\/7O'?U_U?MZ]_>>N_Y6I?\ DO\ XU[]]"G\/7O'?U_U?MZ]_>>N
M_P"5J7_DO_C7OWT*?P]>\=_7_5^WKW]YZ[_E:E_Y+_XU[]]"G\/7O'?U_P!7
M[>O?WGKO^5J7_DO_ (U[]]"G\/7O'?U_U?MZ]_>>N_Y6I?\ DO\ XU[]]"G\
M/7O'?U_U?MZ]_>>N_P"5J7_DO_C7OWT*?P]>\=_7_5^WKW]YZ[_E:E_Y+_XU
M[]]"G\/7O'?U_P!7[>I=!N*LFKJ.%JF1EEJZ>)E+7N)' (^G^/MN:S148TX
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M>._K_J_;U[^\]=_RM2_\E_\ &O?OH4_AZ]X[^O\ J_;U[^\]=_RM2_\ )?\
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MUW_*U+_R7_QKW[Z%/X>O>._K_J_;U[^\]=_RM2_\E_\ &O?OH4_AZ]X[^O\
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M8_RGY])W^\]=_P K4O\ R7_QKVL^A3^'I-X[^O\ J_;U[^\]=_RM2_\ )?\
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M\/7O'?U_U?MZ4^X<M44-/B7BF>,U,,KN5-KZ5B//_)1]H;2W65G!%:$?Y?\
M-TJN)"H6AI7_ &/GTF/[SUW_ "M2_P#)?_&O:[Z%/X>DOCOZ_P"K]O7O[SUW
M_*U+_P E_P#&O?OH4_AZ]X[^O^K]O7O[SUW_ "M2_P#)?_&O?OH4_AZ]X[^O
M^K]O7O[SUW_*U+_R7_QKW[Z%/X>O>._K_J_;U[^\]=_RM2_\E_\ &O?OH4_A
MZ]X[^O\ J_;U[^\]=_RM2_\ )?\ QKW[Z%/X>O>._K_J_;U[^\]=_P K4O\
MR7_QKW[Z%/X>O>._K_J_;U[^\]=_RM2_\E_\:]^^A3^'KWCOZ_ZOV]>_O/7?
M\K4O_)?_ !KW[Z%/X>O>._K_ *OV]>_O/7?\K4O_ "7_ ,:]^^A3^'KWCOZ_
MZOV]>_O/7?\ *U+_ ,E_\:]^^A3^'KWCOZ_ZOV]>_O/7?\K4O_)?_&O?OH4_
MAZ]X[^O^K]O7O[SUW_*U+_R7_P :]^^A3^'KWCOZ_P"K]O7O[SUW_*U+_P E
M_P#&O?OH4_AZ]X[^O^K]O7O[SUW_ "M2_P#)?_&O?OH4_AZ]X[^O^K]O7O[S
MUW_*U+_R7_QKW[Z%/X>O>._K_J_;U[^\]=_RM2_\E_\ &O?OH4_AZ]X[^O\
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M]+&N+I/MEAQ].\?[GDDFUC0G0EI62@H I_;7_-TZ:! V<DC]E.C_ /\ $O\
M:O\ >?:CPOLZ:UCKW\2_VK_>??O"^SKVL=>_B7^U?[S[]X7V=>UCKW\2_P!J
M_P!Y]^\+[.O:QU[^)?[5_O/OWA?9U[6.A![(J_M\Y2I>U\3 W^WFG'_$>RG9
MTU1'_3'_  +TMOVHX^S_ "GH/OXE_M7^\^S;POLZ1:QU[^)?[5_O/OWA?9U[
M6.O?Q+_:O]Y]^\+[.O:QU[^)?[5_O/OWA?9U[6.B3?S&/G!COY>_PQ[L^7^4
MV#7=ITW4%#LV2'8&/W%'M.3)5.^MQX?;-%$V2DI,@M%!'69F"6:44-0Z0I(4
MAE?2C,7+?3(7(K2F/M('^7IR$>,P7A7_ (OHA^(_F[_)CJ7,=8Y+^8%_+3WM
M\0^E.XNSMH=1[+[YV/\ )C:GRGP])E=^$IAZG<]%@J#$93;N%R<SP105DE-,
MPE9HZF"F<1"=/X[)3Q(]() J"&&?6G#IWPU:NEJD"M*$<.KR?XE_M7^\^U_A
M?9TFUCKW\2_VK_>??O"^SKVL=>_B7^U?[S[]X7V=>UCKW\2_VK_>??O"^SKV
ML=>_B7^U?[S[]X7V=>UCJLS^6;\U^U/F)C_G-4]JXK8V)F^-7\QKY-?$G87]
MQ<378A:G;/3:8%L75Y05V2R9GS,QR=1]S-"U/3N!'XZ6+2Q9+:L9]=0.UV7\
MA3[>GI@(]-*Y4']O5F?\2_VK_>?:KPOLZ9UCHOFU?E7UEO'Y(]M?%;#RY[_2
MKTML'K?LC><=5B?!COX9VH^0CQ34E8)6\\Y?&50FC,2>/T&[!N&Q1F*>8 )_
M/_BNKG"AO(U_ET8/^)?[5_O/MSPOLZIK'7OXE_M7^\^_>%]G7M8Z]_$O]J_W
MGW[POLZ]K'7OXE_M7^\^_>%]G7M8Z]_$O]J_WGW[POLZ]K'7OXE_M7^\^_>%
M]G7M8Z]_$O\ :O\ >??O"^SKVL=>_B7^U?[S[]X7V=>UCKW\2_VK_>??O"^S
MKVL="54U5NML=47_ %5CB_\ U4SC_B/9,B?XXP^7_/J]+V;] 'Y_Y3T&O\2_
MVK_>?9SX7V=(-8Z]_$O]J_WGW[POLZ]K'5<W\S#^81EOY?G4O3F]]J](5'R$
MW]WS\FNK/BUUQURO8]/U13RYSM6GR]113UV=J<7F8Z.E08>6._\ #Y 998@[
M11>25$UT_P!, :5)8*!6F3^7RZ>A43$BM* D_ET!_3?\U3N:C[TZ8^._S[^
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MOR'1_?BGVKWWVIT1LG?7R<Z%A^,?=F9?<J;QZ4I^QL=VNF(&,RU=28]USN)
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M-U?J_P"/;SGY_P"F67W5TP?L/^KCUM>/6KS_ ,)!9S%_+6[O47Y^<G91X_\
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MF":0*E14_+TZM9_X2Q_(3M;O+^63E:3M7=F7WG4]+_)+L7IW9>:S^3J\U7C
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ME_1C_P!(G_'1\^DUQ_:-_IF_PGIC^[;_ &K_ &_M5H_U?ZCTSU[[MO\ :O\
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M,N#IH:ZC7!KP^>.G-;QAB] *=N%XUQ3Y=7&XS=6XJ?\ X4:9?9D6X,\NS?\
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MFS.WIVPV?W9ELS0[IVY4XF*:>6IV[05;PRTM/+56IYZ1M*HBGC\-60-J#5!
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M13>@O3VWB-"9 0S&C9(SH/H?\'3<4N@2!*4&5P/7YCHWW;>V<?\ RY_YC?\
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M"JQ$F^,G6PO4?8?;R3P4]9"DD=.TL4EG=IT@0D_J98C%0%K2OS^75501M(P
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M8^AJH<13004RYN0TZWEEFJYFD>1.=F'@&$-DMJ+$5J<>51Z>O3HO3X@DIP%
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MB8Z'$;+ZOV1M;8&U<;30) D./VC10T%(@1;*"(8$O_4W))))]FT<(B4*!@
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M^*I8J:.CDM -6Y=O:14HYUH:AR*UKQJ,8/RI3KR7 4M5>UL$ TX<,YZE]*?
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MDTM5.),E4U%94D3S3!_>[>R,19W.IV%">  'D!Y#K4LVL!5%%'EQSZD]*O\
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MC!EI0M6))?MW1&-/,I*>TEY9?5!16FEU?UK2N/+UZ>AF\&N*U4K^WH^?F/\
MC_MA[5Z?E_/IGJIWL'^7[WOLSY)=P?)GX*_+:F^-N:^2(V]6_(+JOLOIN'OO
M9^8S>V*48^DW5BJ%LYM^NP&>^Q"QU)@KWI:XJK5,#,L;1ETEBZN7B?3JIJ!&
MH$C%1D4/^'I2LZE0KK6G @T/V<#TN.H_@!N;H_IKOK%]>_*3L*A^6WR4[!Q7
M;?;'S*RNQL#N'*5N?PE11&D@BVK713X*GVM2XNB.*@PZM^QCZBH6"LCJ'2HC
MO'8&)& 8ZV-2^":_92E/*GIUIIPY%5&D8"U/#[?7Y]-G3GP?[RG^4'7ORZ^8
MWR9VUWWV;TEL#L+KCI+;W5O1T?1>!Q%-VE]BF=RF1BFS^YLCE\M6T^/@AC'W
MU/24J-)H@D=ED345D_B"25@Q4$* -(%>)XFO7FF&DJ@H"034U./R'77PQ^#'
M=_PT[*['Q&VOE92[P^'^Z^S>VNW=I?'_ #?2E%3[@P^4[>K3DJJA;?"9AGK,
M-0Y*>NJ88_X%%4R/,J2U/CC99O6UD]LQHU4))"TR"<\:\/RZ]+,LH';W4 K7
M&/ET=/Y*=0P?(KXY]_?'VJSTVUJ;O7I3M3INHW/!CURKXV/L[!5^$>O2E:6!
M:EZ-:XRB(SQB0IH+I?4%4\'C(R<-2E:^E13IJ-_#8-Z$']AZ(GV5_+$PO9O\
MK78?\N#+=LY#&9GK/JCI[:&Q^_\ "[8?'5F-W)TH<=/B=STF*BRR30-]YCP6
MIDS0D$$LD258<B4)'VX/;B"N0  WS6F:?EZ]/+<:9/$IQ)Q\CY=..Z/Y8VQ9
M?Y5=9_*[ZXWP=A;7DZ7Q_5U-V:^S8<M(V0%;#ELGN&JPT%=CXYJK-9D5E94Q
M+D(_W:J0^5B+MMMN!M_ 4T[:5^?$FF.)ZT+@^)XASFM.L?R#^ /9VZ>[OCO\
MIOB_\C,5T3\B.B.E\O\ '7+97?73\7<6V]U[-S)AJ3CLEAQF\%6X^JH\O!'7
MTU529=6U@T\R2PL;:FL&9EDC;2RKIR-0(^RH\\\>MI. "K"H)K@T(/\ /I\^
M*'P&WE\>OD-\GODMV'\FMT_('L7Y3]?]1[9WE6;GV/1;5BQ]?UB^X5UXBFQ]
M8:.BP/V>7H::BQB4PDIDHWFJJ_(5=7-4>[6]B879V;47 !J*4I7A3RSP_F>M
M2S"10H% *^?K3H4?Y<?P\C_E^_##I;XBQ=@2=I#J2#?8EWX^VAM#^(2[[W/F
MMS3,N-%=DOM8X)<R\"*:Z8E(E=FNQ <LK/Z.)8ZZJ5SPK4D\,^O5;B7QW+TI
M6F/L%.BK;;_E"=9O\</F_P#'?LWL3);SIOF#\S.\?FC@M]X#;";-RVP=Q=H2
MXN?!S[?F-?D)#D]JU&(II8JX30&J9I8W@BAD:,IUVM=#HQKK=G!&"I-*4X\*
M<>G#='4K ?"H7UJ!_GZ4?9'\O#NGL/;GQ([0_P!G&RNU_GY\2=K9O9^,^66!
MZCI3B=Y8O=$4=/E\5O3855FJBDR>.S$-+12U CS4,D&06;(XYJ*22**#<E@[
MA&UTD3&NF&!XU6OG]O'(ZTLX74-/:WX:\/L-.C0?'#J_YB;0W+G]U?*3Y7[/
M[M@KL&N&VYUWU=\?:3I3 XV4S02R9.6>ISFYL]DLBZPM$H?*PTD<4CZ:0RD2
MA1!!(AK(P;Y!=('\R>FY&0_"M/F34_Y.B]?#[X(=X_#_ ']VGM[;'RPI-U_$
M'>G8?<7:NT.A,[TC1IG\+E>Y*ILA54;[VCS.NNPV/R516U4,7\$AJ97F5)*H
M1QLLS-M8O;L0&JA+$+3(+9XUX?EU>6990.WNH!6N,?+H YOY-<$W\FO#_P I
M _(.9::BJJ*HR'>@ZR4O*!V<W9%4L.WOX[I@,CR24$1;,R^,::AQ*082S^ZO
M\6^GU?[:G]+5PK^7'ISZO]7Q:?E7Y4XTZ/\ _-OXIGYB]9]?==?W\_T?#8WR
M&Z([V?+';/\ >G[I>E]PTN<?%B'[_'>!LDM.814^600%A(8)@-!675K]2H6M
M*,K>OPFM/+IB&7PB32N"/VBG5&/:F].MJ7^:W\]*_M+^8)O7^57,NU/B[MC;
M](NZ-L;-HNV(MM[?JZIM[BN[(PF6VW4C%"OBP<=/AP)8!0M)6N)JEH_91*5%
MQ)JD,.$'$ /CCW CY8].EB@^$M%UY;R)TYX8S\\]6#?RF?DCWAWME?E]@]S]
MQ5?RL^,_4?:VTMH?%KYCY7:.,V?6;[AJL2T^[J0K@\;BL%EZ+:F<"4$&6H:1
M8ZPF4$N8=7M9MLK3:P3K4$!'X:L9X  T.*],7,833C22,KZ>G'U].KC?,?\
M'_;#V::?E_/I+U[S'_'_ &P]^T_+^?7NA=S$ENG=J-SSGZD?3_:\E[#]N/\
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M]F8T]62W1N,OE=T9.5S),\LN0S];D)R[S2.VL:G;Z^UMG;?31*GF!GYDY/\
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M %#KW\4/^'^^_P"0O?O!'7M?^K_4.O?Q0_X?[[_D+W[P1U[7_J_U#KW\4/\
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MEU-BKTACCAACCBAB1(HHHD$:JL8LJJH("JH   %@/>_!'6M?^K_4.N?\4/\
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MQ5X(Z)-?^K_4.O?Q0_X?[[_D+W[P1U[7_J_U#KW\4/\ A_OO^0O?O!'7M?\
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M 'A5E.E-D3_\=,I1#_;P5Y_K_A_7V%=OC!W*8?T3_P >3H[NF_Q2,_,?X&Z
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M?\/]]_R%[]X(Z]K_ -7^H="UTI6F??=+&;?\6[(G_;)_KGV0\R1A;4G^DO\
MAZ,]I:LP^P](K>>1*;PW6G'HW+G5_P"2:J4?ZKV9;=$#;Q'_ (6G_'1TDNV_
M5?\ T[?X3\NDU_%#_A_OO^0O:SP1TGU_ZO\ 4.O?Q0_X?[[_ )"]^\$=>U_Z
MO]0Z]_%#_A_OO^0O?O!'7M?^K_4.O?Q0_P"'^^_Y"]^\$=>U_P"K_4.O?Q0_
MX?[[_D+W[P1U[7_J_P!0Z]_%#_A_OO\ D+W[P1U[7_J_U#H(.WODOT+\?<=A
M\OWWW?T_TCB=PUM1C<!E.WNRL-UK3UU12()9:>CGS-?115,T41#ND;,RJ0Q
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M_P"'^^_Y"]^\$=>U_P"K_4.O?Q0_X?[[_D+W[P1U[7_J_P!0Z]_%#_A_OO\
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M+P.4EFIJG:6<HER^T-ULE2\D]+%G,2*EV1G*I)33!3I'!I8W)N6E1P T3Z2
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MLK$SC[#T'N_Z]4WWO5-7Z-V[D7Z_ZFLF']/9MM4=;6''^A1_\<'2.\8^,_\
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MFWHX:EJ2ACQRO7962LF6"69:?^'L0LDC\UQ*]PT$(0%45B7)SJ)P OD*9/\
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M[S_QKW[POEU[6>C.9.J ^,NW:C5PV9G%[_\ 5RKQ_3_#^GL%PI_NYD'] ?\
M5M.CZ1C] I_I?\_-T6/^)+_J_P#>?^->QIX7RZ(=9Z]_$E_U?^\_\:]^\+Y=
M>UGKW\27_5_[S_QKW[POEU[6>O?Q)?\ 5_[S_P :]^\+Y=>UGKW\27_5_P"\
M_P#&O?O"^77M9Z]_$E_U?^\_\:]^\+Y=>UGKW\27_5_[S_QKW[POEU[6>O?Q
M)?\ 5_[S_P :]^\+Y=>UGK7A^9.X]K_%7^9AD?E]\R>@,SW9\.-]?&[:W56R
MNYZ+K]NYJ#J7+[6KJZOS(S&WTHJV?'8_<,<HDDRE/3O+=8Z94E1IQ"&;]18W
M7CSH6B*!0P&H1D$DU&: ^OY=&UN3<0^'&U'#$D5IK!X4/R].K*>NMS]9X/XL
M9+?7\J_KWX\]D8CL'=DNZ-F[?VKO6'K/8\^3W'7TM%G\G65.*QN2_AK8V*&>
M:KH:7$BIDJ:=J8PPU$LDBFD2((=5FJ,&-0 VE*D@$XK2GF *](V+%Z3EA09J
M*M2F.-.@*P'S)^9/2?S#^/'QG^9.P_CYG-H_+FG[2HNGNUOC3+N>BCP>;ZHP
M\.:JL+NJCW,U0)ER-']P:*KI*F)Y9/VS0B.GJ*@)UN)[>=(9U0B75I9-6"HK
M1M7KY$?LZ=,22QL\9:J4J&ID$TJ*=$SZAW-\\9OYTGRPGI=B?$VHJZ;I/XUX
M+>]3D>S=VQK1[ DW!GIL?5X%DVI)+/N:II&JY:S'U/V] E6D2QU\L9,BH8$N
M3?R=L?P1U[FPE32G;Q]0<5\^E$AC%LN7^)J8'Q4''/#Y\?ET;W;/S'^=WRAJ
M^Y-__##JSXQQ=!=5=D;SZNV-F._MW;D3.=CY#K&I%#GZK#K@*<4.UL3_ !2#
M(4%!4UPR$E3)"M5+3T\#%?:U+FXO-;6Z1Z%8J"Y:KE<&E. K4"M:\>F#%'!0
M2EM1 )T@46O"M>)ID]%A^='S3[4^5_\ )3WW\G/CIM?;VRL3O+K/>])W?@>P
M]UYG:>YMI/M#(2X?,4VWVQ^*D6MS.,SU!/$JU;8^.:FM.LD;D1%'N%T]YMYF
MB  *G6&)#+0T-*#)!'G3IZVA$%R(W)-"-- "#7(K\J?;T.&]/FW\R/A]\<.C
MN[?D_P!=?&=.L*KN+HGKCLW/=7=D;GW/)@]C=DP0XW^]U=59W"X!(J_'Y>>@
M6HIQ!4PO#,SB966Q42W4]A$DDRQZ=2*Q5F-$;&HU"Y!ITTL*7#LL9:NEB*@"
MK#-,$^71P/DC\O\ <W5WR6^%7QDZTVUA=V[R^3N^-\U^\:C+I72PX'8G4^(;
M);@S8DH],<-9+//CJ.@-2X@EJ)BFF1@%]KKNX,,T4*@$R%JUKA%%2<?D!7IB
M&+Q$=V- H%.&6)H!T>?^)+_J_P#>?^->S'POETEUGKW\27_5_P"\_P#&O?O"
M^77M9Z]_$E_U?^\_\:]^\+Y=>UGKW\27_5_[S_QKW[POEU[6>O?Q)?\ 5_[S
M_P :]^\+Y=>UGKW\27_5_P"\_P#&O?O"^77M9Z]_$E_U?^\_\:]^\+Y=>UGK
MW\27_5_[S_QKW[POEU[6>C$;DJPOQPV!/JX?=M8M[_TES?\ A_A["5FE=XG'
M_"A_@AZ.IV/T,9_IG_"_1=_XDO\ J_\ >?\ C7L6^%\NB76>O?Q)?]7_ +S_
M ,:]^\+Y=>UGKW\27_5_[S_QKW[POEU[6>O?Q)?]7_O/_&O?O"^77M9Z]_$E
M_P!7_O/_ !KW[POEU[6>O?Q)?]7_ +S_ ,:]^\+Y=>UGKW\27_5_[S_QKW[P
MOEU[6>M,?^3KV!_*OQ?\O[IW%?*GXJ;:[7[CQV8[1AS&\LW_ "Y]R?(F6:DG
MW1EZB@A3=-!U[N&DK(J>FF1!%'DY/MF#0LL;HR ";&UG],OC1ZFJU3X#/^(T
MR$(_GT(MP6?Q3X;4&,>(%\AY%AU9#_-(K/D_@OE[_*UVKT=L#XV2=>X#OJLD
MZ,P^\-V9W:2#<. V7FX)*#.8_%[<K:7$X#'8HZL=/CS4U"S*(6HX8U63V:[O
M',D]NL:QZ=?8"2.X(<$ &@ X4_9TCL61HY2Y:NG- #BHX5/'UKT'?<FZOYD$
MW\VOXI2#KGX55?:^*^'7==7LW%U/;N]EVV*3+5>VDW/-55W]RWRE+D:?)J*>
M@\..ECJZ&TM0]+*S0!J=;KZV,:8M7A.0-;Z:56N=-:UX8R/3J\9B^G;+TUK7
M"U\Z>=.K J_Y*[(VG_-<W1U3N[ICIS#Y[:W\L:H^16Z_D]2X-#NV+&X7?D>+
MK]JG*-3K52;6AT'(K"T@_P HC#E+VTF1F5+TQLB@BW\0R?BH'H17T\^D@C9H
M P8YDTZ?*NFM?MZ#GHSYE_S-_DOLS9?RHZF^,OQCH?BYO^LJ,MLSI[?_ &QG
M,+VKE=K25:Q4.X5RM-0U6R<=6U]$DM3%B9U=0LD2MDUT7F:MKB[NU$R1Q^&V
M0K,1(5K@U%5!(S3^?3DL4,),;.VH<2 -(/IZ_G_+HZ/?NZ_GW5[WDVS\5]F_
M%S"[*I-G4N3E[7^1.Z-R9QJK-UD]5&V)I-J[8IZ.H2DHX(Z6:6NGS\7E:8PP
MTW[;2DPN4N2U(5C I\3ECG.-*T_;7I-$T=*R%JUX*!P^T_YNBT=)?S1VKOB3
M\O\ OGY,=9?Z-.P_@=V/W!U+WSLC9.5?.4&4R_5<%-4TU1M*JR<=!//C]R)7
MT,>/:M2 F62[,:=HZB1';[E6"669=)A9U< U!*T/;6F#44KT]+:$2(B&H< J
M3Y ^M/3SZF=*=Y_S8=[/UQV5V#\=_B'@NH.V,=AJ]^NMN=K;DFWYL:GW1&\E
M)79RLK<?%MK="T4<U')7T>/_ (=.BI.E-)42,JQ[MVO9-+M'$%:G:&;6E?,X
MH:>8%.O2B!:A6<D>=!I;[/,?G7I^^-7\R?%]E_!+MOY8=R8'"]>[V^-$_?&U
MOD?UW@,E+EXL)N3H.2L_B&+@9A)4N];21T$]/&P,K+60J Q87M:;@)K9IY %
M,>L2*#\+)6H_93]O59K8I*(U-0VG2?4-Y]&K^'_</9O=GQ?Z+[B[DVGAM@]C
M]I]<[>["W!LK K614^+7>$7W]#1%,@6K(ZF#'3TBU*2D,E2)5TJ %"VQ+W$*
M2.H#,H8@5Q7-,YX=,7 $3LJFH!(KC-.C(?Q)?]7_ +S_ ,:]JO"^73.L]>_B
M2_ZO_>?^->_>%\NO:SU[^)+_ *O_ 'G_ (U[]X7RZ]K/7OXDO^K_ -Y_XU[]
MX7RZ]K/7OXDO^K_WG_C7OWA?+KVL]>_B2_ZO_>?^->_>%\NO:ST9SY!50AV_
MU02UO)ALF1S_ $@Q?^'^/L%\J)JENO\ 3K_ADZ/MY8A(?]*?\"=%C_B2_P"K
M_P!Y_P"->QIX7RZ(=9Z]_$E_U?\ O/\ QKW[POEU[6>O?Q)?]7_O/_&O?O"^
M77M9Z]_$E_U?^\_\:]^\+Y=>UGKW\27_ %?^\_\ &O?O"^77M9Z]_$E_U?\
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MH'CD:B/2G3#UMT/W1MC_ (3Y?(;H2LZ.WWM?MF>B^4V.Q'26,VQD,SE5^_[
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MKSL6#WA@*K;58U%G]_9VJH:L4M;##/\ ;5E-)'-!)X]$T3))&61E8N[#;/%
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MXL];37_7O6O6_'XFS_\ Q3V"[%/]W=P/^$K_ ((.CZX;_=?$?Z9_PR=%A_B
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M/5FOQN_F(;[[&HNF>HZ_X-_,/9?<YEVQL_N:BWWU34;)VCM)<*(J3.YH[UR
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M=>\3Y]&V^2]3X=L]-$FWDP66/^VI\1_Q7V ^34U37?\ IU_X]+T(]]:D</\
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M_%??O"^SKVL]>^[/]1_O'_%??O"^SKVL]>^[/]1_O'_%??O"^SKVL]>^[/\
M4?[Q_P 5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU[[L_U'^\?\5]^\+[.O:SU
M[[L_U'^\?\5]^\+[.O:SU[[L_P!1_O'_ !7W[POLZ]K/7ONS_4?[Q_Q7W[PO
MLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_4?[Q_Q7W[POLZ]K/7ONS_ %'^\?\
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MV=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/]X_XK[]X7V=>UGKWW9_J/\ >/\
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M]Y]^H.O=>^Z']!_O/OU!U[KWW0_H/]Y]^H.O=>^Z']!_O/OU!U[KWW0_H/\
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MH8_E]"S]T9%A]/X#@/Q_2$^R#D)@-O7_ $[_ .'HSYC_ -R3_I5Z*_\ ;O\
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M[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/OVL=>Z]]N_\
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MK'7NO?;O_7_>#[]K'7NO?;O_ %_W@^_:QU[KWV[_ -?]X/OVL=>Z]]N_]?\
M>#[]K'7NO?;O_7_>#[]K'7NO?;O_ %_W@^_:QU[KWV[_ -?]X/OVL=>Z]]N_
M]?\ >#[]K'7NO?;O_7_>#[]K'7NO?;O_ %_W@^_:QU[KWV[_ -?]X/OVL=>Z
M]]N_]?\ >#[]K'7NO?;O_7_>#[]K'7NO?;O_ %_W@^_:QU[KWV[_ -?]X/OV
ML=>Z]]N_]?\ >#[]K'7NO?;O_7_>#[]K'7NO?;O_ %_W@^_:QU[KWV[_ -?]
MX/OVL=>Z]]N_]?\ >#[]K'7NCP_+N(OM'H,#^SMS-@\?],N#]QOR&0)[W_FH
MG_'INA5S'_9P?Z5O\"=$>^W?^O\ O!]R1K'05Z]]N_\ 7_>#[]K'7NO?;O\
MU_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/OVL=>Z]]N_\ 7_>#[]K'7NO?
M;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/OVL=>Z]]N_\ 7_>#[]K'
M7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/OVL=>Z]]N_\ 7_>#
M[]K'7NO?;O\ U_W@^_:QU[KWV[_U_P!X/OVL=>Z]]N_]?]X/OVL=>Z]]N_\
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M?+KWV!_U(_VWOWC_ #_P=>\+Y=>^P/\ J1_MO?O'^?\ @Z]X7RZ]]@?]2/\
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M (.O>%\NO?8'_4C_ &WOWC_/_!U[POEU[[ _ZD?[;W[Q_G_@Z]X7RZ]]@?\
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M_4C_ &WOWC_/_!U[POEU[[ _ZD?[;W[Q_G_@Z]X7RZ]]@?\ 4C_;>_>/\_\
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M_P!2/]M[]X_S_P '7O"^77OL#_J1_MO?O'^?^#KWA?+KWV!_U(_VWOWC_/\
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M?+KWV!_U(_VWOWC_ #_P=>\+Y=>^P/\ J1_MO?O'^?\ @Z]X7RZ]]@?]2/\
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M ,'7O"^77OL#_J1_MO?O'^?^#KWA?+KWV!_U(_VWOWC_ #_P=>\+Y=>^P/\
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M_>UZ]]%)_ _^\G_-U[_1WO'_ )Y'='_G@J?^O/OW[W@_WXG^]KU[Z*3^!_\
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M7O\ 1WO'_GD=T?\ G@J?^O/OW[W@_P!^)_O:]>^BD_@?_>3_ )NO?Z.]X_\
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MQ_YY'='_ )X*G_KS[]^]X/\ ?B?[VO7OHI/X'_WD_P";KW^CO>/_ #R.Z/\
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MA';;V./<YY"RA2K4)(H>Y//\NCZ\@9K.-0#4$8 ->#?+HKG^CO>/_/([H_\
M/!4_]>?8N_>\'^_$_P![7HA^BD_@?_>3_FZ]_H[WC_SR.Z/_ #P5/_7GW[][
MP?[\3_>UZ]]%)_ _^\G_ #=>_P!'>\?^>1W1_P">"I_Z\^_?O>#_ 'XG^]KU
M[Z*3^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%3_UY]^_>\'^_$_WM>O?12?P/_O)_
MS=>_T=[Q_P">1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_ 'D_YNO?Z.]X_P#/
M([H_\\%3_P!>??OWO!_OQ/\ >UZ]]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\
MKS[]^]X/]^)_O:]>^BD_@?\ WD_YNO?Z.]X_\\CNC_SP5/\ UY]^_>\'^_$_
MWM>O?12?P/\ [R?\W7O]'>\?^>1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_>3
M_FZ]_H[WC_SR.Z/_ #P5/_7GW[][P?[\3_>UZ]]%)_ _^\G_ #=>_P!'>\?^
M>1W1_P">"I_Z\^_?O>#_ 'XG^]KU[Z*3^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%
M3_UY]^_>\'^_$_WM>O?12?P/_O)_S=>_T=[Q_P">1W1_YX*G_KS[]^]X/]^)
M_O:]>^BD_@?_ 'D_YNO?Z.]X_P#/([H_\\%3_P!>??OWO!_OQ/\ >UZ]]%)_
M _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]^]X/]^)_O:]>^BD_@?\ WD_YNO?Z
M.]X_\\CNC_SP5/\ UY]^_>\'^_$_WM>O?12?P/\ [R?\W7O]'>\?^>1W1_YX
M*G_KS[]^]X/]^)_O:]>^BD_@?_>3_FZ]_H[WC_SR.Z/_ #P5/_7GW[][P?[\
M3_>UZ]]%)_ _^\G_ #=>_P!'>\?^>1W1_P">"I_Z\^_?O>#_ 'XG^]KU[Z*3
M^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%3_UY]^_>\'^_$_WM>O?12?P/_O)_S=>_
MT=[Q_P">1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_ 'D_YNO?Z.]X_P#/([H_
M\\%3_P!>??OWO!_OQ/\ >UZ]]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]
M^]X/]^)_O:]>^BD_@?\ WD_YNAT^.NT-Q8;LRBKLEM_.8ZE7$Y:-JFOQ4]'&
M#)&  7>-5N?P+\^P]S/?QW%J55U8ZE- P)X_+HUV:V>*<$JP%#Q! _P=!UV%
ML/==9O[?%73[7W'44]5N_<M3!/!A*B5'2>MG971UB*LC*0002"#<>S3;=TAC
MMHE,B B- 066H(4#I%>6CM,Y"MEV/PG^(_+I(?Z.]X_\\CNC_P \%3_UY]K?
MWO!_OQ/][7I/]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]^]X/]^)_O:]>
M^BD_@?\ WD_YNO?Z.]X_\\CNC_SP5/\ UY]^_>\'^_$_WM>O?12?P/\ [R?\
MW7O]'>\?^>1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_>3_FZ]_H[WC_SR.Z/_
M #P5/_7GW[][P?[\3_>UZ]]%)_ _^\G_ #=>_P!'>\?^>1W1_P">"I_Z\^_?
MO>#_ 'XG^]KU[Z*3^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%3_UY]^_>\'^_$_WM
M>O?12?P/_O)_S=>_T=[Q_P">1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_ 'D_
MYNO?Z.]X_P#/([H_\\%3_P!>??OWO!_OQ/\ >UZ]]%)_ _\ O)_S=>_T=[Q_
MYY'='_G@J?\ KS[]^]X/]^)_O:]>^BD_@?\ WD_YNO?Z.]X_\\CNC_SP5/\
MUY]^_>\'^_$_WM>O?12?P/\ [R?\W7O]'>\?^>1W1_YX*G_KS[]^]X/]^)_O
M:]>^BD_@?_>3_FZ]_H[WC_SR.Z/_ #P5/_7GW[][P?[\3_>UZ]]%)_ _^\G_
M #=>_P!'>\?^>1W1_P">"I_Z\^_?O>#_ 'XG^]KU[Z*3^!_]Y/\ FZ]_H[WC
M_P \CNC_ ,\%3_UY]^_>\'^_$_WM>O?12?P/_O)_S=>_T=[Q_P">1W1_YX*G
M_KS[]^]X/]^)_O:]>^BD_@?_ 'D_YNO?Z.]X_P#/([H_\\%3_P!>??OWO!_O
MQ/\ >UZ]]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]^]X/]^)_O:]>^BD_
M@?\ WD_YNO?Z.]X_\\CNC_SP5/\ UY]^_>\'^_$_WM>O?12?P/\ [R?\W7O]
M'>\?^>1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_>3_FZ]_H[WC_SR.Z/_ #P5
M/_7GW[][P?[\3_>UZ]]%)_ _^\G_ #=>_P!'>\?^>1W1_P">"I_Z\^_?O>#_
M 'XG^]KU[Z*3^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%3_UY]^_>\'^_$_WM>O?1
M2?P/_O)_S=&.^3VU,_G=_8BKQ>"S.3IX]H4%,\^.QDU:@=*W(,4+QHRAPKJ2
M+WL0?R/87Y3OH[:V97=5/B$T+ &FE!Y_9T<[Y;M+,"JL>P# )_$WRZ+C_H[W
MC_SR.Z/_ #P5/_7GV*/WO!_OQ/\ >UZ)OHI/X'_WD_YNO?Z.]X_\\CNC_P \
M%3_UY]^_>\'^_$_WM>O?12?P/_O)_P W7O\ 1WO'_GD=T?\ G@J?^O/OW[W@
M_P!^)_O:]>^BD_@?_>3_ )NO?Z.]X_\ /([H_P#/!4_]>??OWO!_OQ/][7KW
MT4G\#_[R?\W7O]'>\?\ GD=T?^>"I_Z\^_?O>#_?B?[VO7OHI/X'_P!Y/^;K
MW^CO>/\ SR.Z/_/!4_\ 7GW[][P?[\3_ 'M>O?12?P/_ +R?\W7O]'>\?^>1
MW1_YX*G_ *\^_?O>#_?B?[VO7OHI/X'_ -Y/^;KW^CO>/_/([H_\\%3_ ->?
M?OWO!_OQ/][7KWT4G\#_ .\G_-U[_1WO'_GD=T?^>"I_Z\^_?O>#_?B?[VO7
MOHI/X'_WD_YNO?Z.]X_\\CNC_P \%3_UY]^_>\'^_$_WM>O?12?P/_O)_P W
M7O\ 1WO'_GD=T?\ G@J?^O/OW[W@_P!^)_O:]>^BD_@?_>3_ )NO?Z.]X_\
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M([H_\\%3_P!>??OWO!_OQ/\ >UZ]]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\
MKS[]^]X/]^)_O:]>^BD_@?\ WD_YNO?Z.]X_\\CNC_SP5/\ UY]^_>\'^_$_
MWM>O?12?P/\ [R?\W7O]'>\?^>1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_>3
M_FZ]_H[WC_SR.Z/_ #P5/_7GW[][P?[\3_>UZ]]%)_ _^\G_ #=>_P!'>\?^
M>1W1_P">"I_Z\^_?O>#_ 'XG^]KU[Z*3^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%
M3_UY]^_>\'^_$_WM>O?12?P/_O)_S=>_T=[Q_P">1W1_YX*G_KS[]^]X/]^)
M_O:]>^BD_@?_ 'D_YNO?Z.]X_P#/([H_\\%3_P!>??OWO!_OQ/\ >UZ]]%)_
M _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]^]X/]^)_O:]>^BD_@?\ WD_YNO?Z
M.]X_\\CNC_SP5/\ UY]^_>\'^_$_WM>O?12?P/\ [R?\W7O]'>\?^>1W1_YX
M*G_KS[]^]X/]^)_O:]>^BD_@?_>3_FZ]_H[WC_SR.Z/_ #P5/_7GW[][P?[\
M3_>UZ]]%)_ _^\G_ #=>_P!'>\?^>1W1_P">"I_Z\^_?O>#_ 'XG^]KU[Z*3
M^!_]Y/\ FZ]_H[WC_P \CNC_ ,\%3_UY]^_>\'^_$_WM>O?12?P/_O)_S=>_
MT=[Q_P">1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_ 'D_YNO?Z.]X_P#/([H_
M\\%3_P!>??OWO!_OQ/\ >UZ]]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]
M^]X/]^)_O:]>^BD_@?\ WD_YNO?Z.]X_\\CNC_SP5/\ UY]^_>\'^_$_WM>O
M?12?P/\ [R?\W7O]'>\?^>1W1_YX*G_KS[]^]X/]^)_O:]>^BD_@?_>3_FZ]
M_H[WC_SR.Z/_ #P5/_7GW[][P?[\3_>UZ]]%)_ _^\G_ #=>_P!'>\?^>1W1
M_P">"I_Z\^_?O>#_ 'XG^]KU[Z*3^!_]Y/\ FZ,=N7:F?G^-77N$BP69DR='
MN^MJ:C&QXR9ZB-&ESA#O"$,B(1+'R5 ]2_ZH7"]K?1KNLTA==)C #:A0FD7G
MP\NCF>W8V4::6J')I0UXOY4^?1<?]'>\?^>1W1_YX*G_ *\^Q1^]X/\ ?B?[
MVO1-]%)_ _\ O)_S=>_T=[Q_YY'='_G@J?\ KS[]^]X/]^)_O:]>^BD_@?\
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M_>UZ]]%)_ _^\G_-U[_1WO'_ )Y'='_G@J?^O/OW[W@_WXG^]KU[Z*3^!_\
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M>_T=[Q_YY'='_G@J?^O/OW[W@_WXG^]KU[Z*3^!_]Y/^;KW^CO>/_/([H_\
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M7O\ 1WO'_GD=T?\ G@J?^O/OW[W@_P!^)_O:]>^BD_@?_>3_ )NO?Z.]X_\
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M['7OJV]/Y=>_O+6_ZFF_Y)/_ $=[]] GK_/_ &.O?5MZ?RZ]_>6M_P!33?\
M))_Z.]^^@3U_G_L=>^K;T_EU[^\M;_J:;_DD_P#1WOWT">O\_P#8Z]]6WI_+
MKW]Y:W_4TW_))_Z.]^^@3U_G_L=>^K;T_EU[^\M;_J:;_DD_]'>_?0)Z_P _
M]CKWU;>G\NO?WEK?]33?\DG_ *.]^^@3U_G_ +'7OJV]/Y=>_O+6_P"IIO\
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M^^\?C?X9EZ'#4%1)EEPN&D<Y*NR=#!'$,8&$\BHI?4/;$5P)$UG Z=DCT-I
MKU:GUOV7LGM[8&R^T^M-S4.\>O>Q-L87>>R=UXB1WI<EB]Q4\=50UM.75',-
M33RQNFI%.EA< \>WU(85'31.DT(Z6OF/^J?_ &__ !OWOK6H>G7O,?\ 5/\
M[?\ XW[]U[4/3KWF/^J?_;_\;]^Z]J'IU[S'_5/_ +?_ (W[]U[4/3KWF/\
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MJFH>G7O,?]4_^W_XW[]U[4/3KWF/^J?_ &__ !OW[KVH>G7O,?\ 5/\ [?\
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MO:AZ=>\Q_P!4_P#M_P#C?OW7M0].O>8_ZI_]O_QOW[KVH>G7O,?]4_\ M_\
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MG^\K<%M.JI:+(Y&%A&:?PTE564L;@S![R*0A%R*ZA6GGU;RK3'0J>8_ZI_\
M;_\ &_=NJZAZ=%F^,WR6JODA1=QU=5T5W]T0W4/>N_.D8J3OK8IV+-N6/9"T
MC)NS;*_<3C)[4RPJ[4-<K*LS0S +9+FB/KK@BAIGS^?5WHOH<5QT9GS'_5/_
M +?_ (W[OU34/3KWF/\ JG_V_P#QOW[KVH>G5=7R]_F>=$?$;L;9W0[[.[U^
M2/R<W_@UW9M;XQ_%7K63MO>38,UL>/?<&3IS5X[%8'!154A#5F3RU(CK'.\
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MSDH%_P#@/3_FW]GVGV[^R'VG_#T]=FC_ )#I*>4_X_\ )7M=TEJ>O>4_X_\
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M7Q6Y9,-#08L5F:GKX6R"8=JJ"@HDAIRC*S/LA@PB#'@6)/Q4K]G6@V"Y X@
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M*S)C(9:F A8Y(IX_N6\FIU=&)[217S(I7/6V(5E('$#'E6O1B?Y"_0V?ZZ^
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MQU%+!1"FJ)Q5)20L\N@$@:*FG'C3'5T(6/414ZJ?RZ&+^7?NKY =/_.SYZ_
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M8\_A\#D*[/U]% PWAO2/#TD4,2232I25)0P^,RHBNG!94) !-37&!]OJ>E$
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M<5D6T*C&Y7&S3LRGRA594NL:7BD*%U8_#D'^B17^76G74%*^>/SZK7S'SO\
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M_)7OW7JGKWE/^/\ R5[]UZIZ]Y3_ (_\E>_=>J>O>4_X_P#)7OW7JGKWE/\
MC_R5[]UZIZ7F\G*T>WB+\TL_YM_8I_97M_QR?:/\+=+;LT"_8?\ )T@_*?\
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M@T_VAW)MO!YXTHE\@B_C%+%4>,-8:M'DM>W-K^S$&HKTC)(ZI"_E;45!N_\
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M0$'2<4S@Y'7K@'#9%1G[1UL(>4_X_P#)7M;TFJ>O>4_X_P#)7OW7JGIJ\_\
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M'E@6JD+^O+8SZ62@934$UX?EUJ"41U#<".@Z^6O\M7YJX/Y[T7\T?^7#V/\
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MX?YG.Y.QL1-\FNO_ (5]4=1XG'9(9^AZ;['WEW#N/-5TE/+'2&BGRVW]J8S
MXZ&I,4TGEBR51,@\*^ DRFT9E)[@H'R))_P#K3:0,5K\Z#_*>BBUOQ(^?_Q<
M^7?RB[F^"69^,.^NF_FUN7;'9/9'7?R9SNX]IS;'WOAL:F)K]Q8)]MXC(MN#
M&YNGB@J*RAJ*JBE\\$4,$\,;/.&O"DB=FCTD-DAJBAX5P,]7UJZ@-6H]/,=#
M)_+(^%OR!^'F1^9F:^1?<6T^]-Y?)?Y*)WC!V#MG#R[8>K6OVO@L=6_>88P+
M3841Y2BKHJ.BIZ[()#CXZ425DLQDM:VA:'5J-=1K7\AUJ60/2@I04ZM1\_\
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MT-O/=':N8DR3S0.^0RN?S>(VS00T:4ZSQQT5-A)9"[B62MLHB*B/Q">_2!Z
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MV)@Z*@P.RMMTE9NS"O51U5+A\:DM:8((86FE6+]W[<3/Z.T%6:0*Q+$\*T'
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M+U=UYF]TT.+S>XUV/2"OS38/%S3I6Y1<30D5%8::&04\)\LNA.?=3I! )R>
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MXE1TE 971E)5E92""#8CD>[:!UK6>LGG_P /]X_XW[]H'7M9Z]Y_\/\ >/\
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M7=?07QM^4G57?_0?:4-,,SMG-)L?+U-,PJJ&:>@RV&RM(WGQN2II3!6P RQ
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MWE%2;CSE0D&2DIZFGF:D4HLAC,T,Q==@RR)""0#5F(.:#R_,]*X*(C2$ D4
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M.I:J:EI3 U=54\E531R%PO3)J"(S:20<@#'S/$GT'Y]*S;!*:F4:@",$G/\
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M.3^&9FBEC29/\HA"J$9E/U"SQ.6![00Z$YP*\?GY'IKPC$ZZ2,T*M3Y]$?\
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MJ#UYX=(#*05)I6A&>BX_!S^;?OO^8#-TWN[H;X*]Q3_'?>4N1PO;WR(W+O\
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MDE\,<D+2J9K@H_AHI9J:B*@ #ADGIF.$,NMB%%:<"23]G57'Q]^9N?E^??\
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M(R]F =@C@MU9X*$@9"M4TX^I].J2-+*563 )Q5:?Y!T>3L;^9%TOUY_+@?\
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MKQ#'J*MYJ:+38U6[!5R00T8JRU%>%>/S\NMFWRH!!#<#0^M.BZ9[^=SF]O\
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M'%B3+-6G+KTQ\^%RPR!<U J3NKL,S"H\O[HG\A)?7Z]1.KGVSMP_Q/\ )_\
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M[]3Y#_5^77NA2[;?3N2B'/\ Q9*8\?\ +>I]D7+P_1;_ $Y_XZO1ENG]H/\
M2C_">@M\O^+>SVGR'^K\NBWKWE_Q;WZGR'^K\NO=>\O^+>_4^0_U?EU[KWE_
MQ;WZGR'^K\NO=>\O^+>_4^0_U?EU[KWE_P 6]^I\A_J_+KW7O+_BWOU/D/\
M5^77NO>7_%O?J?(?ZORZ]U[R_P"+>_4^0_U?EU[KWE_Q;WZGR'^K\NO=>\O^
M+>_4^0_U?EU[KWE_Q;WZGR'^K\NO=>\O^+>_4^0_U?EU[KWE_P 6]^I\A_J_
M+KW7O+_BWOU/D/\ 5^77NO>7_%O?J?(?ZORZ]U[R_P"+>_4^0_U?EU[KWE_Q
M;WZGR'^K\NO=>\O^+>_4^0_U?EU[KWE_Q;WZGR'^K\NO=>\O^+>_4^0_U?EU
M[KWE_P 6]^I\A_J_+KW7O+_BWOU/D/\ 5^77NA>K&_XQ%BFY_P"!\G_N74^P
M[&/]V+?Z7_GQ>C5O]Q1]O_/QZ"'R_P"+>Q%3Y#_5^715U[R_XM[]3Y#_ %?E
MU[JA#^=UC-X_*VM^'_\ *SZOW73[-W5\QNU\GV'V1O'(==CM*AP.QOC'2C<U
M5D,EAYZBDQM73U&Y4V[%%3UM2E/62H:-KF8 E.YJ9]$"T!<U)I6BKG_#3I;9
MTCU2'\(H,TJ3CHCW\QOX5?S3.DNF=L_.7L?^9U2_,NN_E[]@[7^4^U.FY/A3
MLKXXR5,&SZF*GW&%W/MG)5=;!3?W9J,H:FFEHJBGJ($93&)EA=$UY:SQ+XK2
M!_#(:FA5X<<CY=/6\T;MH":=0I743_(]&&Q/S#Z/^+?\TGL?Y:=][NAV#\4_
MYBOPD^,&[/CI\C\]&7VHU=UQ#62U.UJC*TZRI292OQN7CR<*2:8Y(5)\FHQH
M71<+!.9'H$D12K>6/+A\Z]4,1DC"KDJQJ//[>A!_E_\ >NV_E#_-K_F*]I;7
MV9OO"]:;A^+OQ'PFRLAV5LVJV=)N;#XS(;TI$W!1XO)PPUR8+,31U?V#U5-$
M]72QK5+%X)XR;VD@GN)& P52E12HSG/EUJ=/"B4&E:M6GD<=5S=*[*W57_*7
MKS^0UD\/N%>J?BK\[>POFKEZNHH98,;7=%;32CWSUYA'EJEG-;!+O[=5!CYD
M@D,*_P .:.22/B!DD2'Q!:^2N7_V@[@/VG^73[L-)F\RH7_;<#_(='9_FJ[%
MVWUS_,A^*?RV^0V_?DMUA\/=P?&WL+XN[Z[F^//8.Y>LQL#<T^X8-RX;)[BS
MFSIZ7<&)P&Z$OCZFI\CT(DHZ4UOV]/'),5-_&$F61RP325)4D:36N2,@'ATS
M;,6C95 +5!H0#44IY^G1@OA+M?\ EH;S^1>[NW_BQ\H>\/EOWAL'HC=6R<IV
M'V#\C]__ ":Q&$VWNJOQU748F+/[EJ\G@Z2LJJZGI:A:&#(_=!$FG:!8R[EV
MU2%G+1L78*14LS  T\SCJDID50&  KP  S^74K_A..]?%_)@^&)R8KA4_9=\
M.OWBR&0TX[.WK]F5#^MHOLQ (;#3X?&(_1I][V<?XLF/XO\ CS=:O_[9OR_P
M#JN;LCY _&+JWL[;O;G\G_Y0=D0?)?N7Y'[$_P!*/\M*#'YK)8'<TV_,_24^
M]:_.=;[BQ29KK?)T%#4Y'(U^5I?X7 C1&252A1PBDE1&#6['46%8\D&IS52*
MC[<=*%C9A24"@&'QCTR./0A?*[9O5'0O\W+OWM3YJ=Y?*GXY?'3Y=]']#/TO
M\A.G^\-W]![5Q^XND*2LPV6V/N7<>S*W'R44E5#/_%Z"/+2"BDEJ*D15 J)(
M(#>X18KAFE+*KJNE@Q4 C%"1^W/58B7B 0*2I-00":'SSU97_+7V=\!:G>_R
M$[J^&7=?;_R0W-NZFZVV1V]W9V=V]O7O:'(#9JY9L-C\;NK=LM5!E!C(ZFL6
M5<?D*B.F$D44QC8HGM;9)$2S1DMP!)9FX5IDC_!TGN"X #@#C0  ?R'14_\
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M[JK\=5U&)BS^Y:O)X.DK*JNIZ6H6A@R/W01)IV@6,NY>M4A9RT;%V"D5+,P
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MS2_W&VQ@L[78U\6(YZA5FDI@::!Y +"ZM;<-(C-+J*U*CL%:BA^$ ],&4A&
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MO6ER-37087'+)3TD,:5BTD1H87+:HT\6AF?)J225KI/R K]G2NC"-]2A<"@
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M@[#W]B-LT6.S.=@V7#+3X>'+Y.&%*S(QXNGGFCI%J)I!3QNR1!%8CWX(JDL
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MM/-;7!5T=5'+3U$+6%TDC920#;CWME#BA%1Z'AUX$KD= _T?\4?C#\9AFO\
M9=_CUTMT>^XV#;@GZKZTP^Q9:T*P94JYL=24\M1%&R@I&[LB6&A5]M16Z0?
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MX=W4&%DQ^'EG:F7*UR5-1$U)C6J5:(5,H6 R H'U CVZ9%7B0*"ISP'5 I/
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MM59[#ME_N?+_ *4_X4Z-)_\ <9/M_P C= L\@C1I)) D:*SN[MI "BY))X
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M]U[H6NY"1N>@L3_Q8:7_ -R*KV0\O?V#?Z<_\=7HRW3^T'^E'^$]!+<_U/\
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M22AW9LJJQ5)U%MA\KB,WAZJ8F"3+I:IBCD4W>4MM[>1V0I&D91@:JU3IX$?
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MLGLSO/?*[@E:M26*>FI\A#218R5H7#Z*\J;1&0@OBD(L8U%0&?2QX=ID:O\
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M2/KWOVL=>Z&O=/\ S*7:'_:QI/\ K36^PW8M3<)3_1/^%.C6X_W&3[1_@;H
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MA/NUE:PS6XUJ"76K,:5).:UXX_EU6>=TE-"1I- /*@^751=?N7?WR>_D[_\
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MX'Y"G3[,*.HX*H4?MS_/JTWY8_'+YN=$_,K._P Q3X&8+K[ONK[ Z=V[U/\
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MKLG4R5E4/XS/(5:)Y5]I]PA2VA"QK34R*QX%E)S4\<\"?GT[;2&5ZL> )'F
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MO7/]3_M_?J#KW7KG^I_V_OU!U[KUS_4_[?WZ@Z]UZY_J?]O[]0=>Z]<_U/\
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M]<_U/^W]^H.O=>N?ZG_;^_4'7NO7/]3_ +?WZ@Z]UZY_J?\ ;^_4'7NO7/\
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M3KWE_P!J_P!X_P"->_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$Z]Y?\ :O\ >/\
MC7OWA]>\3KWE_P!J_P!X_P"->_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$Z]Y?\
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M]>\3H;^_'T[PQHO;_?M49^E_^4JL]AKE5=5NW_-0_P#'4Z-MY;3*/](/\+=
MAY?]J_WC_C7L2^'T4^)U[R_[5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O
M^U?[Q_QKW[P^O>)U[R_[5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O^U?[
MQ_QKW[P^O>)U[R_[5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O^U?[Q_QK
MW[P^O>)U[R_[5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O^U?[Q_QKW[P^
MO>)U[R_[5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O^U?[Q_QKW[P^O>)U
M[R_[5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O^U?[Q_QKW[P^O>)U[R_[
M5_O'_&O?O#Z]XG7O+_M7^\?\:]^\/KWB=>\O^U?[Q_QKW[P^O>)U[R_[5_O'
M_&O?O#Z]XG1@,@__ !@'!M?_ )>DW-O^F^L]A2)?]VKC^B/^.)T=.W^)*?G_
M ,_-T7_R_P"U?[Q_QKV*_#Z)?$Z]Y?\ :O\ >/\ C7OWA]>\3KWE_P!J_P!X
M_P"->_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$ZII_G;_*#Y2_&?X_?&]OA_O;!]
M?]P]]_-SH_XWTNYL_M3&;OABI.QL=N6H,?VV7IJNB05%?BZ".65H#(E.TPA>
M*5DFC*-YFEMHT\(@,\BI4@'B#Z_9TNL$29FUBH"%N/I3_/U.V9_,/W;W+_*2
M^1WRNVP^,V+\H/CY\>_D=B^U]H/14^3.T.U^A-MY*7)4%5CZC[B QPY2FIJZ
M"GG$J24513B3R*[7\EX9K1Y1AT5]0_A= :_SS]G7FA\.94.59EH?56(Z,[\:
MOE;AD_EW_&KY:?*;L[:.STW9\9.E.T>U^QMT346SL8,EO;;^-K:V?1&L%)3F
MJKJIQ#3P1"[.L4,9)5?:JWG'TZ2RL!5%9B<"I /3,J'Q6C0$T8@ ?(].W07\
MQKX6_)[?M?U9TIWWMS='9-#BSG4V)E\'F=@Y:MQZQI,V1Q-#N+&8FHS6.2-P
M7JJ".IIT(=6D#1R!?6][#=-I1P3QI0@T^5:5_+KTL$D(JRT'K4'_  5IT=&:
MKCIX99Y9-$4,;RRMI+66,$L; $FP!^@O[6Z.D^OJNK<7\W;^6YM2BV-DL_\
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MYO;M)@<UO*;#8_(HTE/D=PG!8S)Q;;QTZ(3'5Y22CIW!73(=::O3WL-JVEW
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M)\HU'%,J-)&[1C7[NVYVRTK(N<CCP.,^GYTZH+65JT0XX_ZO/\NEONK^9?\
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M_)T\[/\ YDWP6[ [X;XS;+^3_5VY>[OXMF=OT^R\5E9*A:G);=0R9#%T.4\
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MA]>\3KWE_P!J_P!X_P"->_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$Z]Y?\ :O\
M>/\ C7OWA]>\3KWE_P!J_P!X_P"->_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$Z]
MY?\ :O\ >/\ C7OWA]>\3KWE_P!J_P!X_P"->_>'U[Q.O>7_ &K_ 'C_ (U[
M]X?7O$Z]Y?\ :O\ >/\ C7OWA]>\3KWE_P!J_P!X_P"->_>'U[Q.O>7_ &K_
M 'C_ (U[]X?7O$Z]Y?\ :O\ >/\ C7OWA]>\3KWE_P!J_P!X_P"->_>'U[Q.
MO>7_ &K_ 'C_ (U[]X?7O$Z]Y?\ :O\ >/\ C7OWA]>\3KWE_P!J_P!X_P"-
M>_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$Z]Y?\ :O\ >/\ C7OWA]>\3KWE_P!J
M_P!X_P"->_>'U[Q.O>7_ &K_ 'C_ (U[]X?7O$Z:/,/]4G^W_P"-^U&D?/IO
MKWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_ /&_?M(^?7NO>8?ZI/\ ;_\ &_?M
M(^?7NO>8?ZI/]O\ \;]^TCY]>Z]YA_JD_P!O_P ;]^TCY]>Z]YA_JD_V_P#Q
MOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_ /&_?M(^?7NO>8?ZI/\
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M_M_^-^_:1\^O=>\P_P!4G^W_ .-^_:1\^O=>\P_U2?[?_C?OVD?/KW7O,/\
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M7$'AE@I=JJ22*Z#D5K0^OKU2.Y:>*370D*.Z@!XC&.@BK=[;9^97S%^>&?\
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MOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_ /&_?M(^?7NO>8?ZI/\
M;_\ &_?M(^?7NO>8?ZI/]O\ \;]^TCY]>Z]YA_JD_P!O_P ;]^TCY]>Z]YA_
MJD_V_P#QOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_ /&_?M(^?7NO
M>8?ZI/\ ;_\ &_?M(^?7NO>8?ZI/]O\ \;]^TCY]>Z]YA_JD_P!O_P ;]^TC
MY]>Z]YA_JD_V_P#QOW[2/GU[HQ61D'^R[X%[K8Y:87OQ_P 7"M]A&$#][O\
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M"(TTZU9NS-:49:=W'\NFQH%NNK41J:ND@=WE6H/EPZ/E\)_B%WOT3\D_E_\
M(KN_M/I7<^?^5L'3.3SVQ.A]B9_KO T65ZQH<CB7SG\.S^Y]SS)79FADI4J9
M(JJ-9Y:4RR*TA)"^QL7@DDDD927TU"*P *@BN2W'I-<3K(BHH/;7+$$T.:8
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M@/22'XU^T?X>AF^0T@3>F,!*C_?KT1Y-O^4NM]AWE( VS?\ -4_\=3HTWO\
MM1_I!_A;H!_,/]4G^W_XW[%&D?/HGZ]YA_JD_P!O_P ;]^TCY]>Z]YA_JD_V
M_P#QOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_ /&_?M(^?7NO>8?Z
MI/\ ;_\ &_?M(^?7NO>8?ZI/]O\ \;]^TCY]>Z]YA_JD_P!O_P ;]^TCY]>Z
M]YA_JD_V_P#QOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_ /&_?M(^
M?7NO>8?ZI/\ ;_\ &_?M(^?7NO>8?ZI/]O\ \;]^TCY]>Z]YA_JD_P!O_P ;
M]^TCY]>Z]YA_JD_V_P#QOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KWF'^J3_;_
M /&_?M(^?7NO>8?ZI/\ ;_\ &_?M(^?7NO>8?ZI/]O\ \;]^TCY]>Z]YA_JD
M_P!O_P ;]^TCY]>Z]YA_JD_V_P#QOW[2/GU[KWF'^J3_ &__ !OW[2/GU[KW
MF'^J3_;_ /&_?M(^?7NO>8?ZI/\ ;_\ &_?M(^?7NO>8?ZI/]O\ \;]^TCY]
M>Z]YA_JD_P!O_P ;]^TCY]>Z]YA_JD_V_P#QOW[2/GU[KWF'^J3_ &__ !OW
M[2/GU[ID\O\ BWM_0>J:QU[R_P"+>_:#U[6.O>7_ !;W[0>O:QU[R_XM[]H/
M7M8Z]Y?\6]^T'KVL=>\O^+>_:#U[6.O>7_%O?M!Z]K'7O+_BWOV@]>UCKWE_
MQ;W[0>O:QU[R_P"+>_:#U[6.O>7_ !;W[0>O:QU[R_XM[]H/7M8Z]Y?\6]^T
M'KVL=>\O^+>_:#U[6.O>7_%O?M!Z]K'7O+_BWOV@]>UCKWE_Q;W[0>O:QU[R
M_P"+>_:#U[6.O>7_ !;W[0>O:QU[R_XM[]H/7M8Z]Y?\6]^T'KVL=*G8TO\
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M'.:EI9G_ $R_X>C79FK./L/2 WY);?.\Q=N-U[B'_JY-[-=K0FVA_P":4?\
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MH . &!TT9=637IX\O^+>]Z#UK6.O>7_%O?M!Z]K'7O+_ (M[]H/7M8Z]Y?\
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M)Z_[<VA1?QW(X?[7/]75:UV$KFEH:NFFJ11U**Y@GDDIY_TSQ2J;>[S6:W
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MK'7O+_BWOV@]>UCKWE_Q;W[0>O:QU[R_XM[]H/7M8Z]Y?\6]^T'KVL=>\O\
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MO,?]4/\ ;_\ &_?J'KW7O,?]4/\ ;_\ &_?J'KW1GM^.1\>NNFO]<SC^;_\
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M,A3?F) ('^_1H#];?\IE?[#/)@K:M_S5;_CB=&^_?VP_T@_X\W1=O,?]4/\
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M#Q^,P--3U,J46.Q<5?5Y!@TABC2G6MS=CZCZ=I952)%U%%9G=VR-11"0 !7
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MX-JKC\7BX]NDU='.E11P(:7P:84CNP>-YXY=NN80)7D64LKAR#D*6!% *<.
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M?OU.O5Z]YS_JO][]^IUZO1DMS2V^,O7;W^N\:T7Y_P".N=_XI[!]E_R69_\
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M0=,U/7O,W^^_Y%[]0=>J>O>9O]]_R+WZ@Z]4]>\S?[[_ )%[]0=>J>O>9O\
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MYF_WW_(O?J#KU3U[S-_OO^1>_4'7JGKWF;_??\B]^H.O5/0_?&F0MVE0@_\
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M'AII<&@(910@@YJ3^VO3=[;RO<F@)U-52.!!X4/"E/V=5=;:ZZ['ZH_EH?\
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M,VENS)5JJ^&Z9K=P4E2NW_!1UCU+9T_:U>-6KD@7[.I1YJC6MG-M$F_06TP
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M_A[3W8'A/_I&_P !Z=A)UK_IA_AZ,'\K)"G8>& _YXS''_U>R/L*<C"MH_\
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M2TF6R5#MEJAL=25^1CA6KJZ:@:KJ33QRS,D/E?QA=1]^%LJL7 &H@ M05('
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M\?\ ??[;W[P^O:QU[[G_ !_WW^V]^\/KVL=>^Y_Q_P!]_MO?O#Z]K'7ON?\
M'_??[;W[P^O:QU[[G_'_ 'W^V]^\/KVL=>^Y_P ?]]_MO?O#Z]K'7ON?\?\
M??[;W[P^O:QU[[G_ !_WW^V]^\/KVL=>^Y_Q_P!]_MO?O#Z]K'7ON?\ '_??
M[;W[P^O:QU[[G_'_ 'W^V]^\/KVL=&YR\O\ SB3M:3^N>J/_ ';9$>P% O\
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M\S?[[_D7OW7NO>9O]]_R+W[KW7O,W^^_Y%[]U[KWF;_??\B]^Z]U[S-_OO\
MD7OW7NEKUK*Q[&V /Z[UVJ/]O70?X>R[>/\ <2?_ )HR?\<;I58_V\?^G3_C
MPZ%7Y22%>VJ\#_G2X3_K4?9)R7_N"O\ IW_P]&/,'^Y)_P!*O^#HNOF;_??\
MB]BSHDZ]YF_WW_(O?NO=>\S?[[_D7OW7NO>9O]]_R+W[KW7O,W^^_P"1>_=>
MZ]YF_P!]_P B]^Z]U[S-_OO^1>_=>Z]YF_WW_(O?NO=>\S?[[_D7OW7NO>9O
M]]_R+W[KW7O,W^^_Y%[]U[KWF;_??\B]^Z]U[S-_OO\ D7OW7NO>9O\ ??\
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M\S?[[_D7OW7NO>9O]]_R+W[KW7O,W^^_Y%[]U[KWF;_??\B]^Z]U[S-_OO\
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MO>9O]]_R+W[KW7O,W^^_Y%[]U[KWF;_??\B]^Z]U[S-_OO\ D7OW7NO>9O\
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M^Z]J^?\ +I;]9R7[(Z^&KZ[WVH/I_6OI_9;O/^X<_P#S1E_XXW2JP/Z\>?\
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MO^U?[Q_QKW[KVKY_RZ]Y?]J_WC_C7OW7M7S_ )=>\O\ M7^\?\:]^Z]J^?\
M+KWE_P!J_P!X_P"->_=>U?/^77O+_M7^\?\ &O?NO:OG_+KWE_VK_>/^->_=
M>U?/^77O+_M7^\?\:]^Z]J^?\NO>7_:O]X_XU[]U[5\_Y=>\O^U?[Q_QKW[K
MVKY_RZ]Y?]J_WC_C7OW7M7S_ )=>\O\ M7^\?\:]^Z]J^?\ +KWE_P!J_P!X
M_P"->_=>U?/^77O+_M7^\?\ &O?NO:OG_+KWE_VK_>/^->_=>U?/^71C_BM)
MJ[=H!>_^X3.?BW^ZA["'/'^X#?Z=/\/1YRZ:W(S^%O\ !T%7:$ENS.Q!J^F^
MMW#Z?TR%1[/-E_W#@_YHQ?\ '%Z+MP/^,2Y_T1_+^D>D+Y?]J_WC_C7LSZ2:
MOG_+KWE_VK_>/^->_=>U?/\ EU[R_P"U?[Q_QKW[KVKY_P NJ1NCNU_G[_,!
MQ._?DG\?/D]U!\<^B<7VWO\ V3\>^O9NBJ7NJ+>&&ZWKJK#R9O=^;J\CCZZB
MCS5=3S2T\.%: TL2QAI:O2YJ I:7%YO(:>&5(XP[+&OAA]:J2*L2014\-/#Y
M^9W.D&WD1R*SMI!<ZM.DG-  #P^?0^?(;Y$_)2I[N^-?PEZ5SG66P._NU^J\
M_P!S=Y=MU^WY]]XO:.W]DFBQ]=-MW!54](^5J\OGJF2EQYKYTBAAB:2H21KA
M%E[>SF6*TB*K(Z%Y'(U!%6@.D&E22:"OY])K>&/0\[ZBBL%5>!8FIR:>0XTZ
M0^Q^]_E/\8OG'TO\1/D]V_M?Y(]>?+39W:V>Z)[:INLJ3JS<N*W!U!3QY?,X
M#-X_"*<%5XDXBHC:BK(XH:G6!%4AV!FG:BN[BPNTMKAQ*LRN8WTA&#)D@A<$
M4.#@^O3CQ17,#31 H8RH85U*0V 17-:\>DYU'V7\W_Y@.([0[MZ'^3&ROBKT
M?A^T-^=<]!8?'](XGNC(;F@ZMRDV,JMP;GKLU4K'2X_+Y&CJ8HJ+&Q0SQTFI
MQ6B?QR>V[:>[WD/+#*L48=EC&@.6T&A+%O(D<!Y>?5I4AL"J2*78J"W<5 U"
MM!0>7J?/RZR]9?/[N/L/^6_\U^Y-PX_9^TOE;\+:/Y5=4=C?W6H9\GMP[X^.
M^)J:N/(XR#)1B6;%UFJ@G,,VHAFEB8@  >@WF6:QGE8*)H/%1J977&*U%?(X
MZ]+9)'<QH"2DFAA7CI<\#3SZ1.R/DW\XNOOB)N#^99\B^SNK<AU6WQ4;M#:/
MQ$V7L.F?57YK'8^HVME*WL.&4U4U1G))8Y*RFI\,M%2)7Z*?R_:J[MPW]W#;
M&_G9"GA:UA51Q(!4E_GY@"@KCAU=X())1;1AM6O27)]":C3\O+-<=%M^=N _
MF9P?RR.Z^U^YN]^E^T<-V1T2N4[AZ!H>GHNN$VC2;K6EJ"^T]STN0K*S+56"
M:6)*B#*4\BUL23&"HAE$?E0;NE^+!Y)9$<-'5XPFG0#0]K DFGF#Q\CTHL7M
MC<JB*P(;M;5753U%!2ORX=6!;_\ DIV=UM\POY2WQXVQ5X2+K;Y(]<_)"3L^
MEKL'#75DK=1=?8[,X4T-:X\U#XZUG\WC-IHSH<$ $',U])#=6<*TTRK+JQ4]
MD884/EGI#' LD,\AK5"E/EJ<@_;T%F.[U^=GR*^=OSM^)O3W;?6W2/5WQJR?
M0>2C[:RW6E-V3N"BA[8V;!E*7"8K"5#T.-J_O<I!EZBKR.0K)S300P4E-1EI
MC41)UN[N^N[BVB=8TB,?>5#,-:5  - :FI))-!0 >?3AB@MX(I7!8OJ[:T!T
MM2I.3PI@?;T,_P +/D)\K>Z.J?EOU3V#D>K)OE7\6^Y^PN@<-V>^VZN@VON&
M>BQE%D=M[GR6"HJE:FCCJ(LC"];04M:MUCM%-"TI$2K:KVXNHYHWT>+$[1AJ
M'0QH"K$ XXY /[.F;R&*%HW75H=0VG\0S0@&GRP>BE=N?+;Y%?$/N/XO/N3Y
M[_'_ .7%#W/\A>L^A.V_CEC-C[.ZTR^%I.Q)Y:&?=>UAB<S6;DD@PF0GHHZB
MEKAD=224JO+3:JBH)=<[C/MLL6JXCFUR+&\85%*AC34NEBV#2H-?+AD]*XK:
M.[1Z1O&50LKU8@TS0U &?E3J+\B.N_EQF?YPW4,'7OR@Z\V/D,W\4^\LSUGD
M\U\;UWJ,!@:;.[;CR&"KJ<;MQJYRIJJQHYXLCY*1H(U,!I92WF&KV"Y;<T"2
MJI,,A4F+5I74M0>\5SYX^SK=O+$+1BR$T=0W?2IH<_":?9G[>CJ=\?(SN#JS
MY[_RQOC?0YW;^3V;\B,%\L(^Y*R;:D$%37U?3FR:3+XRJQSM)-+B%?)&622*
M*9PT3^%V<*&]FEW>RV]Y:P @K()M>,DH@(IZ9Z100I+!-)FJ%-/RU-3/KCH%
M^H^R_F__ # <1VAW;T/\F-E?%7H_#]H;\ZYZ"P^/Z1Q/=&0W-!U;E)L95;@W
M/79JI6.EQ^7R-'4Q146-BAGCI-3BM$_CD]I;:>[WD/+#*L48=EC&@.6T&A+%
MO(D<!Y>?3TJ0V!5)%+L5!;N*@:A6@H/+U/GY=9>LOG]W'V'_ "W_ )K]R;AQ
M^S]I?*WX6T?RJZH[&_NM0SY/;AWQ\=\34U<>1QD&2C$LV+K-5!.89M1#-+$Q
M   ]!O,LUC/*P430>*C4RNN,5J*^1QUZ6R2.YC0$E)-#"O'2YX&GGT7O>OR5
M_F<[4^"FS_YF,W:_2/\ =VAZUZL[IR_Q!HNK(Z^DRVSMTPXN6:>LWU)/3Y2E
MW-58ZN.1D6DQ,-!2.31105'A\LZ.6^OX[1;_ %QTTHYAT5!0TXO4'50UP !P
MH?-0D%L\YMJ-6K+KKD,*_AI2E13C7SZV <!G8-PX+"Y^E62*ESF)QV8IHIE
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MZ]J^?\NO>7_:O]X_XU[]U[5\_P"77O+_ +5_O'_&O?NO:OG_ "Z]Y?\ :O\
M>/\ C7OW7M7S_EU[R_[5_O'_ !KW[KVKY_RZ]Y?]J_WC_C7OW7M7S_EU[R_[
M5_O'_&O?NO:OG_+HUV[GM\2.KVO]=]9 7M_S>W%[ UA_R7KG_FBO^"#H17)_
MW6Q9_P!$/^&7HJ/E_P!J_P!X_P"->QST'=7S_EU[R_[5_O'_ !KW[KVKY_RZ
M]Y?]J_WC_C7OW7M7S_EU[R_[5_O'_&O?NO:OG_+KWE_VK_>/^->_=>U?/^77
MO+_M7^\?\:]^Z]J^?\NO>7_:O]X_XU[]U[5\_P"77O+_ +5_O'_&O?NO:OG_
M "Z]Y?\ :O\ >/\ C7OW7M7S_EU[R_[5_O'_ !KW[KVKY_RZ]Y?]J_WC_C7O
MW7M7S_EU[R_[5_O'_&O?NO:OG_+KWE_VK_>/^->_=>U?/^77O+_M7^\?\:]^
MZ]J^?\NO>7_:O]X_XU[]U[5\_P"77O+_ +5_O'_&O?NO:OG_ "Z]Y?\ :O\
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M?\NO>7_:O]X_XU[]U[5\_P"77O+_ +5_O'_&O?NO:OG_ "Z]Y?\ :O\ >/\
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M!B]O]^+C#]+_ /+PR?L'^W_^X;_\UF_XY'T>\SFEPN?]#'_'GZ*CY?\ :O\
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M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\
M%??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]
MY?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J
M^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M
M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\ %??M Z]J^0Z]Y?\
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MMBND^L=Q[ZQ>]MU9G</=5+!BLQF<PVW:RMPV-Q5)AZ5(J:E-=/423OYI B@
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MFRPV[N_&[DKJ.HH&PU955 %?0+613P$*E,CQJ)45E!=;&&MT@\6/6S1,CHM
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M/_SAIM)N.=PU/_NXR?N.[=?^1#*/^%C_ *M1]"F4_P"ZM/\ 3'_C[=$Q\O\
MBON1- Z"VKY#KWE_Q7W[0.O:OD.O>7_%??M Z]J^0Z]Y?\5]^T#KVKY#KWE_
MQ7W[0.O:OD.O>7_%??M Z]J^0Z]Y?\5]^T#KVKY#KWE_Q7W[0.O:OD.O>7_%
M??M Z]J^0Z]Y?\5]^T#KVKY#KWE_Q7W[0.O:OD.O>7_%??M Z]J^0Z]Y?\5]
M^T#KVKY#KWE_Q7W[0.O:OD.O>7_%??M Z]J^0Z]Y?\5]^T#KVKY#KWE_Q7W[
M0.O:OD.O>7_%??M Z]J^0Z]Y?\5]^T#KVKY#KWE_Q7W[0.O:OD.O>7_%??M
MZ]J^0Z]Y?\5]^T#KVKY#KWE_Q7W[0.O:OD.O>7_%??M Z]J^0Z-GN]_^<0^K
M&XYWYD!_UGW'[ E@O^[^Y'_"%_P6_0CN3_NLB_YJ'_#+T4SR_P"*^QWH'0<U
M?(=>\O\ BOOV@=>U?(=>\O\ BOOV@=>U?(=>\O\ BOOV@=>U?(=>\O\ BOOV
M@=>U?(=>\O\ BOOV@=>U?(=>\O\ BOOV@=>U?(=>\O\ BOOV@=>U?(=>\O\
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MZAZ]T=7-,?\ 9+=H'BYW%4_^[G*>XYMQ_P B*7_FF/\ JS'T*I?^24G^F/\
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M[]U[KWE_Q7W[KW7O+_BOOW7NO>7_ !7W[KW7O+_BOOW7NO>7_%??NO=>\O\
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M[]U[KWE_Q7W[KW7O+_BOOW7NO>7_ !7W[KW7O+_BOOW7NO>7_%??NO=>\O\
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M>7_%??NO=>\O^*^_=>Z]Y?\ %??NO=>\O^*^_=>Z.QFW_P"<*MGMQSN.J_\
M=SE/<;6W_*R2_P#-,?\ 5F/H52_\DI/],?\ JXW1)_+_ (K[DGH*]>\O^*^_
M=>Z]Y?\ %??NO=>\O^*^_=>Z]Y?\5]^Z]U[R_P"*^_=>Z]Y?\5]^Z]U[R_XK
M[]U[KWE_Q7W[KW7O+_BOOW7NO>7_ !7W[KW7O+_BOOW7NO>7_%??NO=>\O\
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MK5"T4,;O[]?[O<QWGT=O&KL8A(&8D*M68$L1FF, "I)Z];V430>/*Q #E2
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MA;S;_G#3J8V^O8.2XO\ \W]S>P!M_P#RL-U_S07_ ([;]"2Y_P"29#_S4/\
MAEZ)[Y/\/]Y]C_H-]>\G^'^\^_=>Z]Y/\/\ >??NO=>\G^'^\^_=>Z*[\X=N
M;AWK\*_E_LW:6$R6X]U[M^+OR VSMG;V'I7KZROR&>VGEJ6BHJ6",&2:IJJF
M6***-06=V50"2/9;O,;36<Z*"6:&4 #))*, !\STJL7"3QL30!T))\@&'1#,
M'\.-Q=__ ,HCXR]+93%9/K?Y!]8=$=*;\Z?RNY,4^!RVT>Q.M,335.&J)8JR
M):G&U,58KTE6KQK(D$\\;I>Z^R1-I:^VJ&$@I*D4;1DBC)*B@CCD9P?D3TO:
M]%O>.XRC,P8#(9&.>''UZ"#^55TAWMV!\/OYANT_DYUAO/HG?WRS^3_RFSN6
MP>Y<+7;3EBB[JVYB:"LKL8TB0SRX^+(2Y".FJZ=BD@@\D$C#2Y2\LV<T]I=)
M<HT;333$@@K_ &B*"1\JUH1^73VZSQQS0F)@XC1!4$'X23GYTZ?OC'\L>XOB
M[\5=C_$GL'X5_*7,_*'HW87^A_:F%V#U=6[OV;NM]HP/0X/-4&^X%& HL+74
M\=')62UT]-+1,9E,,@6-I+[=NDNVVRVLEO,9HU\-0J%HWTB@(<=H!Q6M*9ZK
M=6B74IF61 C'4:L RUR05XU^SCT>[^6K\9-Q?#CX1]#?'K>-;35^\MF8#-9+
M>#454M93P93?.7R&?KZ*GF1$6:"@J<G)3)(!:18O("0P/L[Y>VYMILXX'^)0
M2U.&IF+$?D33I!N=T+V=Y!P)%/L  '^#IE[F^=<O1W9F\>N.SOB'\L<]L^.'
M'ML3M/I_J*?O?;^YJ;(4%+)54\J8)JBMPE?!73U-']ID*2,3K":B.4PR !N[
MWKZ*1HY()ROX7C3Q%<$"OPY!K44(\J]6AL?'4,LD8/FK-H*Y^?$>=1U3E4?R
M_>\^S?B%\E=_8'XV'KBIW?\ /G9_SBZ)^%&XL[%M:IJ<)L&.&@K<-FH*=Y,;
MALKNO%29"3^&D214LZTT)TE(?$%#L<UQ:RR+#HU7*W$=N3I)5: AJ8!85[?(
MT^71R-QCBF12^JD1B:4"N3FHKD@'S\^C8=';+_EO;G['ZOI>N_Y4_<>Q>TH=
MU;;R<U=NSX=9'KBGV578JI@J/XCEMQY04N"7^$U"+(K8[)5\DSHII$F4AO9G
M91;?)(@CLI%?4#W0%!&0:U+-1<?(FOETCGDN55M4ZE:$8D#:AZ "IS\P/GT8
M>CZ\W^?YW&8[;_N3NM>KH_Y85)UW_I$? U4>$;/5':,>27#QY-HA1RY(4$,E
M0U.DS2I"!(ZJK*2O$#_O@RZ6T?1Z==#IU>-6E>%:9IZ=,&5?H0E1J\>M*YIH
MI6GIUZCZ\W^?YW&8[;_N3NM>KH_Y85)UW_I$? U4>$;/5':,>27#QY-HA1RY
M(4$,E0U.DS2I"!(ZJK*3X0/^^#+I;1]'IUT.G5XU:5X5IFGIUXRK]"$J-7CU
MI7--%*T].BY?#OM'>?\ +6V#O7X<]O\ QB^46\X-C=L=GYSH+L;I#JK+=YXC
M>FW>P\S59K&))D\>LIQ.?II*V:"M@RC0(NE9ONI+RZ"_:KE^7D:TEAF;2[F)
MHT:19$=BPR.#9H0U/6O2B]C7<F$R.@JJAU9@I4@4.#Q&,4_9TN>@/AAW<O\
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MW_).;_3I_AZ/N7/]R1_I6Z!_MMF_TK=F\_\ -0MZ?C_JY5/L_P!B_P!P;?\
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M..M<3^7A\2ME]_=K?S1]T;D[+^2&R*W#_P SWY28"&@Z7^1N[^FJ":*+)1U
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M+UM7O*MS]9EX5IJNKW!E,U49#)9RIJ:=$A>2MJYV,*K"+1*J"UI9P62&.-0
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MUG SQR:1JB#"/+44, IQ6G 4STE$\@5DKAR"W#)!J,\>/2DR71O6>7[EVO\
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M]^_:QUZG7O$_]/\ >_?M8Z]3HX?6B$?%OM5?R<_E/_<3$>P+NS5WBW/]!?\
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MZ0?\>;HJOB?^G^]^QEK'1#3KWB?^G^]^_:QUZG7O$_\ 3_>_?M8Z]3KWB?\
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M_?M8Z]3KWB?^G^]^_:QUZG7O$_\ 3_>_?M8Z]3KWB?\ I_O?OVL=>IU[Q/\
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M^UCKU.CA_*)"VU^DP/Q@,Q?_ ,Y\-[ O)[4FN_\ 3K_QZ7H1[Z/TX?\ 2G_
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MUCKU.O>)_P"G^]^_:QUZG7O$_P#3_>_?M8Z]3KWB?^G^]^_:QUZG7O$_]/\
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MWGW[Q.O=>\8_U)_WGW[Q.O=>\8_U)_WGW[Q.O=>\8_U)_P!Y]^\3KW7O&/\
M4G_>??O$Z]U[QC_4G_>??O$Z]U[QC_4G_>??O$Z]U[QC_4G_ 'GW[Q.O=>\8
M_P!2?]Y]^\3KW7O&/]2?]Y]^\3KW7O&/]2?]Y]^\3KW7O&/]2?\ >??O$Z]U
M[QC_ %)_WGW[Q.O=+/KA+=A[#.D\;SVO_7_E>@]H=T>MM-_S2D_XX>E-G_;1
M_P"G7_CPZ%+Y/)?M>O-B?]PV%_ZU'V3\HMILQ_IV_P /1AOW^Y!_TJ]%Z\8_
MU)_WGV)O$Z)NO>,?ZD_[S[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_P"\^_>)U[KW
MC'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/\ O/OWB=>Z
M]XQ_J3_O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_ +S[]XG7
MNO>,?ZD_[S[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_P"\^_>)
MU[KWC'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/\ O/OW
MB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_O/OWB=>Z-WUPO_ #C%VDMB+Y[)\?\ 5+B?
M8)W5J[M;G^@O_'I.A'8_[@R_Z8_X$Z*)XQ_J3_O/L;>)T'.O>,?ZD_[S[]XG
M7NO>,?ZD_P"\^_>)U[KWC'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/^\^_>
M)U[KWC'^I/\ O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_O/O
MWB=>Z]XQ_J3_ +S[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_[S
M[]XG7NO>,?ZD_P"\^_>)U[KWC'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/^
M\^_>)U[KWC'^I/\ O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3
M_O/OWB=>Z]XQ_J3_ +S[]XG7NC=]CK_SC%U:MB;9[&<?]4N6]@G:FINUP?Z#
M?\>CZ$=]_N#%_IA_@?HHGC'^I/\ O/L;>)T'.O>,?ZD_[S[]XG7NO>,?ZD_[
MS[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_P"\^_>)U[KWC'^I/^\^_>)U[KWC'^I/
M^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/\ O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J
M3_O/OWB=>Z]XQ_J3_O/OWB=>Z]XQ_J3_ +S[]XG7NO>,?ZD_[S[]XG7NO>,?
MZD_[S[]XG7NO>,?ZD_[S[]XG7NO>,?ZD_P"\^_>)U[KWC'^I/^\^_>)U[KWC
M'^I/^\^_>)U[KWC'^I/^\^_>)U[KWC'^I/\ O/OWB=>Z]XQ_J3_O/OWB=>Z]
MXQ_J3_O/OWB=>Z,+\84MVO0&Q'^X;-?]:A[#/-S:K,_Z=?\ #T<[#_N0/]*W
M08=EI?L?L Z3SO;=?]?^5^?V;[4]+6'_ )I1_P#'!T@OO[>3_3O_ ,>/2)\8
M_P!2?]Y]K_$Z2]4E_P X7#[K^2];\5?Y;?6^Y*?:6YOEAV;DM];_ -V5VP_]
M)%'A=F?'6F&XJFNR&*FGI:"J@GW F!BC@K*A8*N1#2M<R@$.[^6O/#M$-#(U
M6--0"1]V1@<:<>/#HVVLB#7.PJ$% *TJS8X_97HG'SZ^'G\R7I[J3;_S*W__
M #$Z;Y95GP6WQMSY)[:ZG?X@[0Z">H@VK410Y_3N+;U?4U<--_=Z?(FHIY*.
M>">%&!C$JQ.B#<K.\@07#S^+X+"0+X2)PXY4GRKTJLKJ"5C$L6CQ 5)ULW'A
M@_/HS'R0[XV#U-\ZO@7_ ##=XUE3#\.^V_BCO[J.7NF"D;)X7;%?V7-BMU;<
MK\U44ZRO1T>?IU2B@G"LGFX8H@=O:R[O%AN8;IO[)HF75Y*6HP)^WATQ! 9(
M9(!\:N&T^9 J#3[./6#8OR7Z_P#E%_.0Z)W5T_0[JS?5>VOA;\@L#M[MRNVY
M5X/ [IJ6W#M2>OEVO45D4$N7QF,,U+!)D(HC22U+O%32R^%V]^COEO-P1D!*
MB)P&I0-W+737B!Z\.O/;M;VK!J5+J2M<C!X^AZ)I\FMN[RZR^4?R4_E5;,Q^
M>Q>S_P":5WUTWWEUYF<+124M+B]M;R>IJ>]XA42)+3QL*7:=0XAIU\@3)AO'
M$I\OLOO-44TEDH(%RZ.*< I_M?\ CO\ /I7;D21I<'C$K*?F1\'^'^71GOYB
M?5NS.G?G+\4?D!VYN?OWJ?X=?[+7NOXL9WLKX_[TW!UQ#U_F*',4V:P-5FLM
MM*6FS>)P.?@1<?-.':B5J.F^[\$"22^UFZQK!<Q2N76+PS&61F70:U%2M" >
M'IC/2:QD,L+HH4OJ#T8 ZA2AH#@D<>C+?"?:O\O3>'R0RW:/QJ^1?<7RE[DV
M3U/E]GY'?.]^_-\?(G%XC ;FR6.J9L7%F\_4Y##4U74UL%-,M'#7_<A5EF,(
M34Y6;?\ 2O-KA=Y'"D5,CR *2#2K5''RK7IB[:=(],BJBEJT"JI) /D.FC^3
M0M6<)_,NEJEJVIS_ #=?FK_"WF$CJ:97VZ3]O>X:'[DU/Z/3Y3+_ &RWNFP.
M0+BO_*3+3_C/6]UXQ#_A*?Y>B+=@]V_'/KCL7 ]H?RK/D9OZ+Y#]L]_;+7L?
M^7K#09C(87<4V],Y2T^[JW,[ SV,3+]?Y"AHZBOKZW)4_P##H4:(O*"A1P72
MW44+A[)VULXU09*M4C42A%5.:DBG2Q(9)%TW*C2JFDF*B@Q1@:-]F>EU\FMF
M]8])?S1N[NROEYW'\E.@>@_E+TYTJ_4?>G5?<.ZNDMLT.?Z?I:O$Y39NX<_M
M*KH7HY*F*;^*T4>4D%)))/4".<3R0PER["6]Z[SM(B2(FEU=D4%:@J2M/M%<
M9ZI;LTUNJQ*C,C-J5E#&C9! /[,=6$?R^=G?"*JWAWKV[\2NW>TOD!N'=%/U
M_L[M+M_L3M+=_=$-<-IC)MB:''[EW1)4PY(8Y*BK644%=41TX>**4HQ1/9KM
M8M]3R0,SDZ0S,[/6E: %JUIG@>D5\TP"K*JJ!4A0 O&E<#HM'\_#(8/;?27P
M<WGN_P =-L+8O\SGXM[N[#S%;0R5]'C\)BJ#=GWU9D%2.4+1HLBHY9"&9TB
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MY"K+,80FIRLV_P"E>;7"[R.%(J9'D 4D&E6J./E6O3%VTZ1Z9%5%+5H%522
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M)>PCR6VFU?\ YJM_QQ.C[F'^W7_2#_CS=%=\8_U)_P!Y]B[Q.B'KWC'^I/\
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MWGW[Q.O=>\8_U)_WGW[Q.O=>\8_U)_WGW[Q.O=>\8_U)_P!Y]^\3KW7O&/\
M4G_>??O$Z]T\[=C_ -_!@O21_N9QG//_ !W3VQ=/6)_](W^ ].P?&O\ IA_A
MZ,3\M5U=CX4V)_WY.-_]S\E[#');:;5_^:K?\<3HYYA_MU_T@_X\W17?&/\
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M6.*.,01>"$)&J!$]/H6P]*^E>!QP/Z#WO7U[KD:>)G21D5I(PXCD*@LHDMJ
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M]^UGKW1I/]E8W]_SM]G?^?&N_P#K?[!O];+?^&3]B_\ 0?1W^X9O5/VM_P!
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M_?OZV6_\,G[%_P"@^O?N&;U3]K?] ]>_V5C?W_.WV=_Y\:[_ .M_OW];+?\
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MUO\ H'KW^RL;^_YV^SO_ #XUW_UO]^_K9;_PR?L7_H/KW[AF]4_:W_0/7O\
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M_P#/C7?_ %O]^_K9;_PR?L7_ *#Z]^X9O5/VM_T#U[_96-_?\[?9W_GQKO\
MZW^_?ULM_P"&3]B_]!]>_<,WJG[6_P"@>O?[*QO[_G;[._\ /C7?_6_W[^ME
MO_#)^Q?^@^O?N&;U3]K?] ]>_P!E8W]_SM]G?^?&N_\ K?[]_6RW_AD_8O\
MT'U[]PS>J?M;_H'KW^RL;^_YV^SO_/C7?_6_W[^MEO\ PR?L7_H/KW[AF]4_
M:W_0/7O]E8W]_P [?9W_ )\:[_ZW^_?ULM_X9/V+_P!!]>_<,WJG[6_Z!Z]_
MLK&_O^=OL[_SXUW_ -;_ '[^MEO_  R?L7_H/KW[AF]4_:W_ $#U[_96-_?\
M[?9W_GQKO_K?[]_6RW_AD_8O_0?7OW#-ZI^UO^@>O?[*QO[_ )V^SO\ SXUW
M_P!;_?OZV6_\,G[%_P"@^O?N&;U3]K?] ]>_V5C?W_.WV=_Y\:[_ .M_OW];
M+?\ AD_8O_0?7OW#-ZI^UO\ H'KW^RL;^_YV^SO_ #XUW_UO]^_K9;_PR?L7
M_H/KW[AF]4_:W_0/7O\ 96-_?\[?9W_GQKO_ *W^_?ULM_X9/V+_ -!]>_<,
MWJG[6_Z!Z]_LK&_O^=OL[_SXUW_UO]^_K9;_ ,,G[%_Z#Z]^X9O5/VM_T#T)
MG4O1FZ]A;QI]PY?(;=J**&AKZ5HL;5U,TNJJ32I"RTD*6!^OKO\ T!]E>\;]
M#N$)C0.#4'N"@8^QCTNV[:I+236Q4BA&":Y^T#I);K^-N]L[NC<F;I,IM2.E
MS&?S&5IHZBNK$D6/(5$DR"0+0NH<*X# .P!O8D<^UEIS-!;Q)&5DJJ*IH%I4
M #^/I/<;+++(S I0L2*D^9)_AZ8/]E8W]_SM]G?^?&N_^M_M1_6RW_AD_8O_
M $'TS^X9O5/VM_T#U[_96-_?\[?9W_GQKO\ ZW^_?ULM_P"&3]B_]!]>_<,W
MJG[6_P"@>O?[*QO[_G;[._\ /C7?_6_W[^MEO_#)^Q?^@^O?N&;U3]K?] ]>
M_P!E8W]_SM]G?^?&N_\ K?[]_6RW_AD_8O\ T'U[]PS>J?M;_H'KW^RL;^_Y
MV^SO_/C7?_6_W[^MEO\ PR?L7_H/KW[AF]4_:W_0/7O]E8W]_P [?9W_ )\:
M[_ZW^_?ULM_X9/V+_P!!]>_<,WJG[6_Z!Z]_LK&_O^=OL[_SXUW_ -;_ '[^
MMEO_  R?L7_H/KW[AF]4_:W_ $#U[_96-_?\[?9W_GQKO_K?[]_6RW_AD_8O
M_0?7OW#-ZI^UO^@>O?[*QO[_ )V^SO\ SXUW_P!;_?OZV6_\,G[%_P"@^O?N
M&;U3]K?] ]>_V5C?W_.WV=_Y\:[_ .M_OW];+?\ AD_8O_0?7OW#-ZI^UO\
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M ,,G[%_Z#Z]^X9O5/VM_T#U[_96-_?\ .WV=_P"?&N_^M_OW];+?^&3]B_\
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M>J?M;_H'KW^RL;^_YV^SO_/C7?\ UO\ ?OZV6_\ #)^Q?^@^O?N&;U3]K?\
M0/7O]E8W]_SM]G?^?&N_^M_OW];+?^&3]B_]!]>_<,WJG[6_Z!Z&NMZ@W'4]
M+8CKA*W!C-8_(RU<U4]34"E*O6U52 L@IC,6T3H.8 -0(O:Q)&F\Q+?-<T;2
M10"@U?"H_BIY>O1HVW.UJ(:KJ!K6II\1/I7S].@4_P!E8W]_SM]G?^?&N_\
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MG?\ GQKO_K?[]_6RW_AD_8O_ $'U[]PS>J?M;_H'KW^RL;^_YV^SO_/C7?\
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M&;U3]K?] ]>_V5C?W_.WV=_Y\:[_ .M_OW];+?\ AD_8O_0?7OW#-ZI^UO\
MH'H:^V.H-Q[\Q.Q*#$UN#IYMKXZMI*]LE4U$*NU3%1(IA,5-,64&F>^H(;%>
M#<V(]HWF+;WE9PQUD$:0#2A8YJP_B^?1IN.W/=J@4J-((-2?/3PH#Z= I_LK
M&_O^=OL[_P ^-=_];_9Y_6RW_AD_8O\ T'T5_N&;U3]K?] ]>_V5C?W_ #M]
MG?\ GQKO_K?[]_6RW_AD_8O_ $'U[]PS>J?M;_H'KW^RL;^_YV^SO_/C7?\
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M&;U3]K?] ]>_V5C?W_.WV=_Y\:[_ .M_OW];+?\ AD_8O_0?7OW#-ZI^UO\
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MJ[_CK#_U+7_BOOWT"?/_ %?GU[ZI_P#4/]CKW]YJ[_CK#_U+7_BOOWT"?/\
MU?GU[ZI_]0_V.O?WFKO^.L/_ %+7_BOOWT"?/_5^?7OJG_U#_8Z]_>:N_P".
ML/\ U+7_ (K[]] GS_U?GU[ZI_\ 4/\ 8Z]_>:N_XZP_]2U_XK[]] GS_P!7
MY]>^J?\ U#_8Z]_>:N_XZP_]2U_XK[]] GS_ -7Y]>^J?_4/]CKW]YJ[_CK#
M_P!2U_XK[]] GS_U?GU[ZI_]0_V.O?WFKO\ CK#_ -2U_P"*^_?0)\_]7Y]>
M^J?_ %#_ &.I%)N*LFJJ:%I(BLM1#&P$:CAV /Y_Q]TDLD12<X!/\NK)<NS
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M[ZI_]0_V.O?WFKO^.L/_ %+7_BOOWT"?/_5^?7OJG_U#_8Z]_>:N_P".L/\
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M_BOOWT"?/_5^?7OJG_U#_8Z]_>:N_P".L/\ U+7_ (K[]] GS_U?GU[ZI_\
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M -7Y]>^J?_4/]CKW]YJ[_CK#_P!2U_XK[]] GS_U?GU[ZI_]0_V.O?WFKO\
MCK#_ -2U_P"*^_?0)\_]7Y]>^J?_ %#_ &.O?WFKO^.L/_4M?^*^_?0)\_\
M5^?7OJG_ -0_V.O?WFKO^.L/_4M?^*^_?0)\_P#5^?7OJG_U#_8Z]_>:N_XZ
MP_\ 4M?^*^_?0)\_]7Y]>^J?_4/]CITP^:JJZM6GE>-D,<C65 #Z1_A[8N;5
M8DU"OET]!.TC4/\ J_EU#J]PUD%750K)$%AJ)HE!13Q&Q _/^'MR.R1U!SD
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MOJG_ -0_V.O?WFKO^.L/_4M?^*^_?0)\_P#5^?7OJG_U#_8Z]_>:N_XZP_\
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MZ]_>:N_XZP_]2U_XK[]] GS_ -7Y]>^J?_4/]CKW]YJ[_CK#_P!2U_XK[]]
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MA_L=>_O-7?\ '6'_ *EK_P 5]^^@3Y_ZOSZ]]4_^H?['7O[S5W_'6'_J6O\
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M2U_XK[4_0)\_]7Y],?5/_J'^QU[^\U=_QUA_ZEK_ ,5]^^@3Y_ZOSZ]]4_\
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MA_L=>_O-7?\ '6'_ *EK_P 5]^^@3Y_ZOSZ]]4_^H?['7O[S5W_'6'_J6O\
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M[ZI_]0_V.O?WFKO^.L/_ %+7_BOOWT"?/_5^?7OJG_U#_8Z]_>:N_P".L/\
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MWT"?/_5^?7OJG_U#_8Z]_>:N_P".L/\ U+7_ (K[]] GS_U?GU[ZI_\ 4/\
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MOJG_ -0_V.O?WFKO^.L/_4M?^*^_?0)\_P#5^?7OJG_U#_8Z]_>:N_XZP_\
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M<M$L)AKFH:L1Z)7(,;:PO%Z@*3IKD?Y>MZ:"M,="G]V?]\3[MH'6L=>^[/\
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MU*8SCSQ_FZO-*"JX&1^S/EGIJZN_F9]V]$?R\_YY'RM[%WSD.R]V_%7^9?\
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M 'Q'OU#UZHZ]]V/]\1[]0]>J.O?=C_?$>_4/7JCKWW8_WQ'OU#UZHZ]]V/\
M?$>_4/7JCKWW8_WQ'OU#UZHZ]]V/]\1[]0]>J.M''JSI+LBHQO\ -A^=GQHQ
M4U;\L?Y>W\]'YJ][[%Q6,0I4;MV<*B@3L/K^H:&AKZNHI-R[<CJ#'!# TK5=
M/ ("DL@<$B1G]1U^))6/VCS'YCI>SCM4\&0#_,>K/.@^_.O/DY_PH#Z>^0W5
M.6&:Z\[>_D'X3?&U:YE\4@I\YW-)*:>IC-F@K*.4R4]3"P#PU$4D3@,A 51N
M);@,.!BJ/]ZZ:8:(R#Y/_DZ-3VM7I\M/YRW1'3D,LV0ZO_EK],9?Y1=FTR-#
M)2/V7\@DEV[U]0U*C5.*W$;8AW)EH;Z(P*J)[2/H,3C#Q9@OD@U'[3@?RKU0
M'0A/\1H/L''H!OG!\H/C5NW^;_\ $[X_?)#O#ICIWI3X6=/[W^7>\YN[>U-L
M=;XC.[_[/@FV=LG!*,_DJ22NK,+@Z[/9HI!!:)9:5I)=,GBDI/(IF56( 4%C
M4@5)P./YGJ\:G02 34TQZ#/3U_(*[OZTHMC_ "T^!O7?;NR>Y-H?"'Y';KQG
M1>]-B=@4W95!D.K.Y)9MR;/-/F*:MR$-><343YC&S-'62K3M31TQ*/&4'K!A
M1HP:Z3BAKVG(ZU<C(8XJ,UQD<>M@C[L?[XCV84/2:HZ]]V/]\1[]0]>J.O?=
MC_?$>_4/7JCKWW8_WQ'OU#UZHZ]]V/\ ?$>_4/7JCKWW8_WQ'OU#UZHZ]]V/
M]\1[]0]>J.O?=C_?$>_4/7JCKWW8_P!\1[]0]>J.A'J9O^,<X^7^M8X_]6)Q
M[)T'^.-]G_/J]+F/Z ^W_*>@X^['^^(]G%#TAJ.O?=C_ 'Q'OU#UZHZ]]V/]
M\1[]0]>J.O?=C_?$>_4/7JCKWW8_WQ'OU#UZHZU6?GM\7MA_-;^?!G?C9V%J
MIL/V9_(PRV,Q6X::.-JO"9G']Q9FLP>>H'=)/%7X7+04E7"X6^J+3^EB"5SP
M^-/I/G%_S]TKCD\..H_C_P G1:N^_EAV#\B/C#_*9ZS^0Y>C^8?P\_GV_"CX
MQ_*O&50E26KW!UXFZ8*'=47FHZ!JC'[SQ"TF5@J8Z2.FFDFJ5IM4<0/MMY#(
ML8;XEE56^T5S^?'JZJ%+$<"A(^S'^#JWKLG?_;GSC_F7]V_"39WR0[0^.?Q]
M^%_2_4&]>Z3\?,U3;,WENK>/?<=7D<-C)=S2TE9587 8G 04]3)%01Q5-5/4
MJ'J%CTA%;%IY2@) 4 FG$D],"D:!B 22:5X4'3=\-^S>\?C#_,\[>_E@=D]^
M=H_*'J3*?$7;'S-^.W8/>%93;FWGMK'Q;G;9N9VKG=SH(*O=,4E>JU='6UE,
M:N.)3#/+*^J>74):*4Q$EAIU GB!6E/GUMZ.FL #-#3APKT=C^97\/,S\ZOB
MUFNFMF=CGJ3M' ;WZ^[AZ;[%FQD6<I,7NSJ?)19;"S9"AEBF2JQ[U$1CG0Q2
M:5?R"*4Q^)W[F SII&#@@T\QTW%*(S7CY'[#T4SXU?S-/D/M'Y"]6?!W^9K\
M9XOC[\ANVZ+.472?>G4^X!OWJOLFNV7CH*[)P8JK8+D]LY:2)IY(\;D$EX18
MVJ8YJBC@J&8[AU8)*M">!&5-.KM&I!9#4#B/,=$+W]\Y]C_)KYC_ #1VWW;\
MSOG%\>NB_C%VO7?%WIWJWX*=3]AY2:OW!L"AB.\MW;LW;L'86[:F6M7,Y!J#
M'XBIK::DABQ_W#T=4\CREAIA([!F8!3I 4'B.)) /[.G FA10*2<Y(_RD=!O
MVC_,,^9.V_Y*?SE[6G[+[+H^S_BK\O=A=7=$?)[?W6VX.E<SOGKZKW_L1\-N
M#.X2NP&V,M#55^!S=;B\PM/AH#-XI_"6G8R>ZM.X@8U-58 ,0145&> \CGK:
MQJ9 /(C(K6AH>K+>V.E_DM\-/@;_ #$OD5O'YT_(ON[Y#9WX;=P;\FDS^:Q^
M+V?LO=NS-L9[)QUW6& I,?#-M?'P5DL:0PS9"NE:.EI7FF>969E+QO#&[%F)
MTD_($ \/3II761E   J/M.?/H#]Z?,GY&;G^(/\ ) ^.O7W=E;L#Y*_S->J^
ME9.POD-58RCW)G\=@]G=88?=W8>?Q%/61/CVW+D9JRDA@J*BGDAIYJUI?"SB
M,HV96*1J#1G SYTTU)^WJVE0SD\%)Q^=!UG^0T7=_P#*G^17P/[&V;\P/E)\
MB>@OEI\N.NOACWITC\H]^4_=3IDNZ**LCV_N[:V8J:>@K-M38JIQ,CUM!37H
M*M7U)3P2&3S[D5K5E.IB&8*0V<G@1^SKRD3 B@! J",<.C,?"'O[M_?W\U;^
M=)TOO3L'<.Y.JNALI\ FZ:V1E*I9Z+;O^D_K_,9'<"XU= >),I7TL$\REV7R
M+J4+J:[D+LTLBFM!HH/2HSU60 (I]=7^'H!=O]__ #:W3UK_ #YZ'H/=&Y>P
M.]^D?D'O?9GQ*V_D$I]R280ML+;=?!0X*BKDDI9IZ>KK:VJH:2>.6GDK3'%)
M#+$YB:@:1A+IJ2"0ORP.K44:*\",_MZ$S^5AV-T/VGGY]R]5?S"_EUWCV;@.
MNDPWR&^+/RRWC$^;P^=K)J1I<U6[.S> QF?VG54E9%5TZ#%218*6&I$:12A:
M:06M2'-59B:95N(/V4Q^6.M357B ,X(ZN[^['^^(]K:'I/4=>^['^^(]^H>O
M5'7ONQ_OB/?J'KU1U[[L?[XCWZAZ]4=>^['^^(]^H>O5'2^R$]NOL%)_JLK,
M/Q_JJS_BGLJA'^-O_I1_@3I8Y_07[?\ H+I _=C_ 'Q'LUH>D=1U[[L?[XCW
MZAZ]4=:_/_"A&2.HZ^_E:12HDL3_ ,Z/X1"6.10ZLK4.] RL#P002"#P?9?N
M PG_ #47_+TIMC\7^D/^3J/_ "Z.UMG_ ,N[/_S+_@EVC(FR>H/@_N/=?S(Z
M+R51'3T5&.F>^$R6ZY:6@"RWE7:>X8<Y1S%HHAY*B"%/(RMI];M].70X"]P_
MTIS_ "SUZ0>*%8<3@_:,=5X=3=?[S@[T_DN?*SN#'3T/>OS^^?'RM^7_ &%2
MUVK[C'8GL#KFJI]A;?(>*!H8L#L2CV_!X#$/!4-4KJE):61.J$-&YXN[,?S&
M!^SIPL"& X* /YY_GU:Y\N/CI\Y>@_FKN#^9#\ <%UWW_6=B=,;;ZC^2_P 0
M.S-Q)U_5;CH^LWK*O 9;9>Z6IYH,9G*?SO3M3UG^22I)(S)/+)']LKFADC?Q
M(Q6HH5.*T]#TRDB,NEC3-0>CN? KY^==?/7K/>.[MK[+[ ZD["ZD[%SW3O>O
M1_:V)3#[AVCNG;0C>JQM:L324]53RQ2QRTU5#(4EC8I(D%5%44T+T$PN 2 0
M0:$'B#U21/".2,Y!]1U49_.>WWV'U_\ S1?Y$>].I^GLOW]V#@-R_P P6?;?
M4."WEA>OZO-25.T-F030PYC<%328>B:FI9)ZDFIJ$$BPF*.\KHI27A998B!4
M]^.%<#UZ>@H4>II\.?S/5P_QJ^0GR<[DQ_9I^0GPEWO\./[L8S#R[.J=V=W[
M'[>.??*)D?O13?W-RF0;'-B?MJ,N:KQ^;[M/ 6,,NE9$SO74I7[2#7]G3#A1
MP8']O^7JOG^4G\D>[^\?Y$_7?R#[;[-W3OKN[*]0_+7(Y'LW-5RME9:G8^[]
M^8W$5#U$2QGST%%C*"*.0 /:%&)+W8I[1VD@#$DFC9^PGIV<!9"!PQC\AT2K
MN3Y??,R'^6!_(AWYU7W]E-K_ "&^6'RD^&G3._.T]VT4F[*?)MWAMK<E'/5;
MCQL530'-T<.4-!D):5JF):F6DC21O&SJS+ROX41!RS**^M0>G%1=;@C !/[*
M=&FW%@/DK\ /G_\ R]<+C_FI\C?DWT]\T=V]M]*]^["^3.X<5O".#-[;VI5[
MDPVY=GKC<1B(MKWK*&I2IH:=#1_;E88XKL)(G2KV\B=S$,2"&]:5J,8ZH&65
M6P 1D4_9GIHZY7NO^:U\I_GU/)\V?D[\9_CE\,_D34?$KISKWXE;GH^G,C5;
MKZJI:*HW=N;=6:J\9DZS<"-G)FI:3'20IB6HX0)*>I$LTE1I0UVS]S *=("X
MR.)/^JG7B1"!@$D5SZ'H.OYSOQJ[5I_B+\-X-\_,[Y#;JW3LGY>?%'J[/Y_
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M]0L>D)9BT\I0$@* 33B2>JBD:!B 22:5X4'2>^)O:'>GQ=_F3]X_RP^Q>_\
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MJ45?1S&"2&9J/)8^IJJ2I1)D=X)I%5T8AU>OG:&(L,$4_P"/#INW D< _/\
MP'HCO\P/"_+K^6/T!A?YD]7\_/DIWMV!U'V-U+/\G.E=S5&&INK=U;?[+W-B
ML)G,9M;8T./@&U&HFR4*XB=<W+5PQ(?NZRIGDDF=BX5[5?%U,2"-0_"033 \
MOETY$RS'109K0^8QU9%_,2W)U%AY.G*_O+^8GV9\*>MLG5[@P5)U[TYN_$]?
M;B[!S.:-"N-BI,G_  K*[PE&)"R!:+!10O/+6)]W(X$,147-!34Q4>@P2?\
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M_G,=4RTQ*9#L7:E%7T<Q@DAF:CR6/J:JDJ429'>":15=&(=7KYVAB+#!%/\
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M.?[1JF):C^'PQRN4+ATZS2&&,@]S/IJ?.I8=.E%$CBF M:?D#U99N+ ?)7X
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M]#)64C?:_<I+3VNK"294(8%T-<_"QJ#_ ).JP7*QE@116Q@BHZ2O5/\ *_\
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M.J9@90S;;88X&B<CN)-1P&!3B!YCIV:\U2!U' #C3Y_,^O13<U_)Y_G0]Q_
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M]:Z0?7_IJJ/9#&O^/L/Z/_/J]&;'_%@?G_E/05?<#^I_VY]GV@=%FH_+KWW
M_J?]N??M Z]J/RZ]]P/ZG_;GW[0.O:C\NO?<#^I_VY]^T#KVH_+KWW _J?\
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MCKW7O,?]4/\ ;_\ &_?M/^K'7NO>8_ZH?[?_ (W[]I_U8Z]U[S'_ %0_V_\
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M *L=:Z]YC_JA_M_^-^_:?]6.O=>\Q_U0_P!O_P ;]^T_ZL=>Z]YC_JA_M_\
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M:PU(P/Y]N+1P".!R.'#JI&DT/2A\Q_U0_P!O_P ;][T_ZL=:Z]YC_JA_M_\
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M(D20 E7( H,Y!/#UQ2GKU5+9F9DP"H)->&*?Y^L/6_\ ,NWZ?E!TU\8_E/\
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M[J+K+O#K3)2Y;K[MS8NU^Q=F9&JI'Q\TN-W?1PUU(9Z>2TE-4"&95EB<:XI
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MFWJFDQ=562T6 3;^-CK8*G[>G@6I9Q/(7(]*BW*>-*%4AAHUFN#521]E.FI
MWAH2:@ZM(IPSG]O0<#^:_P!V[\ZVW!\E?C;_ "Y^Y^^_B!MNLW'51]PTG:.W
MMC;CW)@]GFICR6X=C]?5T<V8W%0+-3/]I'/68ZHR$2N])%+($AEI]>[KXB1L
MR"O=4 D#S XG^75OI@ITLP#>E"0#\ST*/>_\W7X]]-_&?XB?+?!X#>_;'3/S
M [3V-UELJ;8V%J,CG::;?>'SF2IU7 4U-5UV1RR5>#EQ9QL $K9"58O*J*[B
M\NX)$B2 $JY %!G()X>N*4]>JI;,S,F 5!)KPQ3_ #]8>M_YEV_3\H.FOC'\
MI_AAVA\2LM\G<+O3*_&O=^Y>Q=M=HT.>J=@4(RN3P>;7;E14+M;/P8MA,*6:
MHJ8G?]A*EI"@?R7C>(L<B%-5=))!K3-#3@>O-;C265@U*5P12OV\>K1\Y'0U
MN%S%'DZ=:S&U>+R%-D*36T?E@GB=98]2LK+KC++<,"+W!!]KRN.DW5"'Q7^>
M7Q*^(O\ (\ZP^:G1'QXW;U9\6=MYS*4>'Z0R'85;O3*8A-Y=OUVS\M629O(-
MEJVNC7-5M=E-'[DGV[?;0HK*B H@NH[>U$J*0GI6M*O3CGSSTMEA>28HQJWK
MP_#7H=JG^;)NS9F_>@:KO+X.=Y]%?&+Y2=I;:Z<Z6^16]=SX&HK/XWO\R+MA
M=V[$I)I-P[.I=P&(F%JYS/3*R_?TU(ZRQQO&_*%=<;*KD*K&G$\*CB*]5^F!
M!TL"0*D"O <:'SZN-\O^*^S*AZ2=4L;;_FV]G=V9WY [)^(OP%[<^1N^OC)W
M9W'TUVU&W9>!ZAV[25'5>8J<52I1[GW'%!29?.9U*9ZV+%4%-4M14CP/D*JG
M>H@CD+%OVE+".-F*L5;( %#3B?,^G[>E?TP6A=@*@$8).?D.C.=5_P PO!]]
M?#K_ &:SHGH;N?M;<D6YJSKK)_&W TF(Q6\,=NO!YI,%E\'DY,KE*#"4*X6J
M9JBLK)<F($H%-2GD9DA9^.Z\:/Q$5CFFG%0:T(R:8_P=-M!H?22!YU\J<>@W
MZ^_F.]E8OY8]0_$7Y??$3.?%G>GR4PW8N7^-F[,=W-@^]<'N67J?'TV3S^)K
MJC$4E!/@,O144[2B.:GGI)D\*Q5K3U"0+1+MA((Y$*%JZ34,#05(QP/5F@!4
MLC5I2N*$5ZB?$S=WQGF_F*?S9=O]4](YO8O??7]3\0:OY)=J5^^J_.4.]Y-X
M;-RV3VR^/Q-153TF".$H4JZ:<4U+"*IY%FDUL/3JW*&:4*I##1J-3FJDC'E3
MK4H;PT)-1W4'IG/18]A_SPM\]S_&%OF'T/\ RZN_NT.@-E;7RVZ.[]ZG?VWM
MD'#IM=ZF3.4VU:',BEK]_2[?HJ9I:^:@IJ>A6<24=/5U-13U B83<VEC\5(V
M*@58U I3C2O&GGTZ;,*VAF /D*$_M].KKNE^XMC]_=1=9=X=:9*7+=?=N;%V
MOV+LS(U5(^/FEQN[Z.&NI#/3R6DIJ@0S*LL3C7%(&C;U*?9G$XF4.O @$?8>
MDCJ4)!X@TZ,KU0^K>%../^ 5=]/^">RO?12W/VK_ (>ENW?VH^P])3=,EMS[
MC%UXSV7'_JQ)[76(/@1_Z1/^.CI-<?VC?Z9O\)Z8?+_BOM50],]>\O\ BOOU
M#U[KWE_Q7WZAZ]U[R_XK[]0]>ZI&_P"%&V0K*'^3)\S9J&KJ**>2FZ$HGFHZ
MAZ=VAR/:&R:>HB+(P)BJ*>66*1;Z7C=D8%6()7O-1;/_ +7_ (\O2RP_M5_/
M_ >C-?+OY_[%_E_],?%O?/8VR=Z[[PO=/:76G0D%+L"@GW#EZ>NW;MW*Y2EF
MI,32TU56YJJJ9<-]G3T4"++/4U,(UHFM@_<W0LU0L"0Q"XXY!/Y\.FHH3.2!
MY G/V_[/18]Q_P X_=O37;FS.EOE'\ ?D5TSOOOC:.9W%\3=K;4W+MSO3*[]
MR.%GHX9=KS4NWJLTFU=P1)D*6:I_B&1.,HH/)+6Y*"-$:1AMP:)@LD;*6'8!
M1BU/+' Y\\?/IP6H855@0/BXBGSSQZ,7\7OYANZ>W?DKNWX>_(KXL;^^(?R*
MQ'4=#W]L_:6Y]]8/M?%[BV?49&+$5-?0;AVY))C$R.,R=1!3UE"79D=F:":H
MCBD=7H+LR.8G0HU-0!(-5K3B.J20!5UJ0PK3@10_GT!&V_YMO9W=F=^0.R?B
M+\!>W/D;OKXR=V=Q]-=M1MV7@>H=NTE1U7F*G%4J4>Y]QQ04F7SF=2F>MBQ5
M!35+45(\#Y"JIWJ((Y&EOVE+".-F*L5;( %#3B?,^G[>K_3!:%V J 1@DY^0
MZ7FY?YO_ $EA?Y=&?_F+TFQMZ/LS8V]=O]<]G=6Y\I@=P;:SE1O+&[+S6-R:
MPQY",U&!K<B*F00+-]S3(K0>N55%FW!1"9J&@-"#@@U"FO'A7JHM6,GAXJ<@
M^1%*]9L7_-(RNV^GNY_DU\C/B+W'\<?C1M#";,SO0^^=U9_#;EW+V6N_ZYL?
MB*#'[$Q\QSVW,WDZB7&?:X_*>.=EK4,XIQ#-HW]:55I'1E44TDTJU?EQ!^1Z
M]]/4A58$YKQH*?/I+Y[^:3W1TCF>J]Q?,KX =F_&7X[]P[NVAL##=Z1]P;;[
M=.V<OOR9H,3%V'M_"QQU&TZ&JE>EA-8E?D88*J4TU3X91$)JF]>(@RQE5) #
M5!H3PJ!P_GUL6P>NA@2,TH16GI7CT<'I7YEX3MOY5_+/XCY'8>?V%V#\6O\
M17FEK\U5K54>Z]O=N8V6NQ^?PC"&&]+33P34=6NJ3PU:F$R%U=54Q7'B2/'0
M@I3\PPXCIIXM*JU<-7\B.D-UO_,7ZEWRGSUW?EZ%MG='? ;L;/\ 6&_>Z*W-
MPY:ARN3Z]P4&9W?%1T=-$:B!]MO54]&\9DEEJ:A]$2*P"&B7BOXA.%C-"WS
MJ?V=6: C2/-A4#[3CHK]?_-L[)Z_ZXV+\G?D)\">V>@OA7OW*;+IAWINSM;:
MV4S^V\?V96T&/V]G-Z;#I)37X'%5]5D:99C#EJZJHA)%]S3([Z%8-^R*)'C9
M4-.XD5%:4)'EQ]3TY],&)56!85Q0T-/0]#S\E/YAFX>L_D;MKX?_ !I^,V\_
MEW\D<IU8_>&[-KX#?>'ZFV_MG:DE:^-HLAF]U9P24,=7E:Z*6*CHH8)II GD
ME\,<D+2.S791_#C0NU-1%0 !PR3U2. ,NMCI%:<*DG[!T2?^7KWG6=]_S;_Y
MA6\,WU7V)TAO#$_&#X?[.WYU5VECX*3*8;,;?K=W?<TXJ:*>JQN6H)8YH9Z/
M(T-7-25E-+'-%)ZF1$UG(9KB0D%2%0$'B#4_M^WIZ=-$2BH.6H1Y\.K:?BI\
MG\?\JMB[NWSCNJ>X.GXMH]J[[ZKEV]W7M$;-R5:^QYHHSF*"!:BI6HPV0696
MI:@26<K(A ,9]F%O-]0"0K"A([A0X\_LZ2R1^&:5!P#C/1F_+_BOM^AZ;Z]Y
M?\5]^H>O=>\O^*^_4/7NO>7_ !7WZAZ]U[R_XK[]0]>Z%GN1].YZ$<?\6&E/
M/_415>R'ET5@;_3G_CJ]&6Z?V@_TH_PGH)O+_BOL^H>BWKWE_P 5]^H>O=>\
MO^*^_4/7NO>7_%??J'KW7O+_ (K[]0]>Z]Y?\5]^H>O=>\O^*^_4/7NO>7_%
M??J'KW7O+_BOOU#U[KWE_P 5]^H>O=>\O^*^_4/7NO>7_%??J'KW7O+_ (K[
M]0]>Z]Y?\5]^H>O=>\O^*^_4/7NO>7_%??J'KW7O+_BOOU#U[KWE_P 5]^H>
MO=>\O^*^_4/7NO>7_%??J'KW7O+_ (K[]0]>Z]Y?\5]^H>O=>\O^*^_4/7NA
MGK7_ .,-8AN.<C+_ .YE5[#D0_W8O_I1_P <7HU?_<5?M_Y^/0,>7_%?8CH>
MBKKWE_Q7WZAZ]T!/R?[]VO\ %[X[=U?(?>3Q_P!W.G.MMV;^KJ<D@U+8"DDF
MIJ*/3=C-750AIXP.3)*H'U]M3R> C.>"@G]G5XT,C!1YFG6N9_*RV9V]\ ?F
M=TYL[Y ;AW%F,A_-W^*[_(C?.0W5G):PT7>VPJW*;IW+@HZ<(V/I0-G;DAA!
MBJC)-)C%B_>6**0DUBC6DJAZ_K)J-?\ ?@J2/V'^72^Y83H2OX#0?Z4X'\QU
M;_\ )?\ F$[DZO\ DAMSX=_&WXQ[U^7'R4R'5TO=N\-J8/?.(ZDP.U]JM7/C
M*.OSFZ<Z'HHJW*5\4T5'0PP33N$\DOACDA:0PGNRC^$B%VIJ(J  .&2>DL<
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MFHIY9I)&,4;M&\:-:O&RDL%5:@EJ_9@?.O#J_P!.&-%8$ 5)H0!_GZ6?5/\
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M!PJ/3B#4 T_;U81+K U @^=#^PCHF/QK^5G9O>7\FS?V\/G;\4.T]V=.X/\
ME\YWL#??9VY^Z]LSS=NT-%MJLK,O%CQMK-R[FV]596CIY'%17TU%-"TBFPF!
M4)8)FEMBTJ,5\,DFH[\9X&H_/IV2,)* A%=5 *'MS\QT<["?-CX__%7^7C\'
M>P>O.I>P)]O=V]2_&S87Q%^+6S*P[UW5D:CL':M#6[;VG!79&LTS/B\2H%=D
MZVN$,45/)43S,S*)%(N4MX4(4]P4(HR348'[//IHPM([ D8)+$\./'KK:7\R
M+M#:/R&ZA^/?S2^&>\?B;4?(_*U^VOC]V?0=M8/OG:N7SN.HUK#MC-Y/"T]$
M=M;DJE6H%%320U-/7".]-6.1*D/EO&5PDJ%-6%-0P)]#3@>O&W!4LC:J<12A
M^W[.F7=O\TW<]5\JODG\+/CY\.^TOD1W_P#'3)=>MEJ+#;RQ6P-M-A]^;8Q^
MXTS&8W7FXX<5@1Y,C'04=#JK<AD*F*HEAIDI*>:=--?$R-$B%F6GF *$5J2>
M'^$];6W&D.S  U^9P:<.C-?!7YO;9^;O7&^]RTO7N\.FNR^F>V=W]$=[=,;_
M 'IZK)[8W9L?P-74!K:-WHLI1O#54\M/6T[>*96(LLD<B*_:7/U2DT(*DJRG
MB".FYH?!-*U!%01Y@]$__G@[]*_&?H[XRQUE?1#Y[_-7XO\ PRSE1BJL44RX
M#M+/+5;C5YM:RPTU=A\74X^5XOW *Y0-(9G5/NC414S^HZI^1.?Y"G3MF.XM
M_"K-^8'1GOG'\ZNLOY<^P^@<_O/8.[-S;.[3[NVE\<\)B.M<3/GLC05&;P>;
MR&,7'X6BIJJLR\T[8),?2T5.BR2U%3 -:1AV5^ZN19!20:%@N!\B>'GPITU#
M"9R0#P%<_E_GZ!K97\R[LK$_(7ICHWY9_"7LWXD8KY-UM=@?CMV5N/M+:W:5
M%E<Y0T<V1_NYN&EVY4SR;5SL]%$###)-5PRSEH%J+H7+2WC!U62,IJPI)!J>
M-#3@>KM;C22K!J<10C_#QZM$W1N:@VAMG<6[,K'D)\7MC!9?<62APV+J,Y6/
M3X6GDJ9EI:*DCFJJRI:.)A%!#$\LKZ8XT9V *]NT$FN,\.DX%<=5;?\ #SOQ
M3_Y]E\X/_2#NU?\ [%_9?^\H_1_^<;_YNE/TC>J_[T/\_5EW6?8N#[7Z^V=V
M5MFEW%0;?WQM[&;FQ%%O#;%?LK*0P96)98X\AB<I!2Y#'U:!K205%.DB,"&7
MVNC;Q%#"M"*Y!!_GTF9=)IZ=+CR_XK[O0]:Z]Y?\5]^H>O=>\O\ BOOU#U[K
MWE_Q7WZAZ]U[R_XK[]0]>ZAZU_K_ +Q[<JW7NO:U_K_O'OU6Z]U[6O\ 7_>/
M?JMU[KVM?Z_[Q[]5NO=>UK_7_>/?JMU[KVM?Z_[Q[]5NO=4L_P _;X1[Y^=_
M\NK?'7G4V#DW5V[U=O7:G>W6FU8*F6GER=;LR'(8_(4%,L8(J*ZJV]F<TE'
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M4M+'-EQ]N]1(6P2!XD25W\,!21X1 Q0T+9&FO\O/I3("KL45=6<ZQ]F!C/\
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MOJ_O"+_2C_"_1K;_ .XS_:?\"]50_P TR1!_+1_F!78"_P ,?DNH)XY;9V8
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M_P#LSXH;:;-93Y3]J=+9'NCLG^'2PC)[A[ WKFJ;?VZ,2TDL,,4L^7K%JL*
M8XP862)6B 5U\UDXLS$/B*ZCZEB=1_;PZ\)QXX8_"#0?(4H/\_14ML[E_DY_
M(OI';6R.Z/FY\Z9MS]CX7 [2[$^%W8WS"[GRFY*?.N(16[4K^L5R-9-)]ADH
MFC2*'%2XX)$E132M1B.;VF5K>= &=\X*%WK7TTU_R4Z<(EC-0JXR&"K2GK7H
MV&Y^ZNK_ .75_-[[U[%^4F:?J?X^?+'XG] [<Z7[UW53R?W:I\W\?9,A09+9
M]9DXXY/L\M4TE:,C$DP5)8D)\FMHT*EIA8W+-)VJZ*%8\*KBGV^?380SQ +D
MJQJ/.A\^GK^7YWS@ODG_ #;/YA/;6SMI[_VYU_E_C+\1L;L+,=@[2K-D3[AQ
M>&R.\J:+<=!CLA%!D(<+E:B*J./DJ::&2JIHEJTC$,T9-K.;Q[F1P#30E*BE
M14YSY>G6IT\.)0:5JU:9IPZM9^*'R^Z@^9NR-[=@=,_WR&W^O^W-]=*;@.]=
MGU>SI_XWUV].F2%+%5#_ "NB5JF-5J(V9/()8'T5$$T49A;70N@63@"5-13(
MZ321&(@'S /[>C0ZU_K_ +Q[45;IOKVM?Z_[Q[]5NO=>UK_7_>/?JMU[KVM?
MZ_[Q[]5NO=>UK_7_ 'CWZK=>Z%[NE@-TT%S_ ,N"E_\ <BJ]A_ENO@-3_?A_
MXZO1ENG]H/\ 2C_">@AUK_7_ 'CV(*MT6]>UK_7_ 'CWZK=>Z]K7^O\ O'OU
M6Z]U[6O]?]X]^JW7NO:U_K_O'OU6Z]U[6O\ 7_>/?JMU[KVM?Z_[Q[]5NO=>
MUK_7_>/?JMU[KVM?Z_[Q[]5NO=>UK_7_ 'CWZK=>Z]K7^O\ O'OU6Z]U[6O]
M?]X]^JW7NO:U_K_O'OU6Z]U[6O\ 7_>/?JMU[KVM?Z_[Q[]5NO=>UK_7_>/?
MJMU[KVM?Z_[Q[]5NO=>UK_7_ 'CWZK=>Z]K7^O\ O'OU6Z]U[6O]?]X]^JW7
MNO:U_K_O'OU6Z]U[6O\ 7_>/?JMU[KVM?Z_[Q[]5NO=#97,/]"N'-^/XC+_[
MFU7L-Q5_>3_Z4?\ '%Z-7_W%7[?^?CT">M?Z_P"\>Q)5NBKKVM?Z_P"\>_5;
MKW5#/\[+%[O^5-;\0OY7/5^ZJ79VZ?F'VMD^P>Q]XY#KP=H4."V/\9J4;FJJ
M_)8>>HI,=5T]1N1-O114];4I3UDJ&D:YF )1NH:YT6XP7-2:5HJY_P -./2R
MT(BU2'\(H,TJ3C_!7HD7\Q;X6_S1ND^F]M?.'L7^9K2?,>N_E^=@;8^4FU>G
M7^%FR_CI)50;0J(J?<07<VVLC55D--_=JHR9J::6BJ*>H@1E,8E6%T27MK<Q
M*)6EU^&0X&A5X<<@^G3\$T;G0$TZAIKJ)X\,'Y]&#Q7R^Z0^+O\ -$[%^6'?
M.[H-A?%7^8A\*/C)NOX[?(W.Q&3:K5W7,59+4[7J,K3I*E)DZ['9>/)PI):.
M2%2?)J,:%X72V]P9'PLB*58\,>7VYKTWX1DC"KEE8U'GGS_ET(/P$[QVW\GO
MYLO\Q#M#;&S=\X;K7<'Q@^)6%V5D.R=FU>SI-RX?&5^\Z1=P4>+R<,-<F"R\
MT=7]B]52Q/5TL:U2Q"&:,F]G+]1<R, :%$ J*5%6S0^1ZU.OAQ*#2M6X9IPZ
MKKZ7V5NFO^477O\ (CR>(SZ]5_%?YT]@_-'+UE10RP8VNZ,VHE'OCKW"/+5)
M,:R"7?NZ:"@F2"0PK_#VCDDCL(611H3(+.F$D,G^T'<H_::?ET^[#29O-E"_
M[;@?Y#HZG\T_8NV^NOYCGQ5^67R$WY\DNLOA_N#XW]@_&'?7<GQ[W]N7K0;!
MW+/N"#<F'R6XLWLZ:EW!B<#NA?\ (*FI\CT(DHZ8UOV]/')-[5;@FB=)7+!-
M)0LI(TFM14KD \/3IFV;5&54 M4&A -12F*^G1@?A1M?^6IO+Y$[M[=^+?R>
M[L^6G=VPNB]T[*RG8.__ )%[_P#DQB,+MS=-?CJNHQ46>W)59+!TE955U/2S
MK109#[H(DLY@6/6Y>M%A>0M&S.P4BI9G !^9)'Y=-S&0+1@%!/"@7/4G_A.B
MU;'_ ":/AJV4%:*G[+O9U^]20R&G'9N]/M-(<%S%]F(!#;T^'QB/T:?>]D)%
MJG^V_P"/-UN__M6_+_ .JZ^R._OC'U?V;M[MO^4-\G>Q8?DKW)\C-BCM#^6O
M#C<UDL#N:;?6?I:?>E?F^N-PXJ/,]<9*@H:G(Y"NRE+_  R!&B,DJE"CA"TZ
M1L&MF.IF%8LT-3FJG*^M<=/*C,*2C &'\QC&?/H0/E7LWJCH?^;9WWVE\T>\
M/E)\=/CK\N.D.B'Z8^0/4/=N[^AMJX_<72=)68?+;'W)N/9M90244E5#/_%Z
M"/+2"BDEJ*D15 J)(8"Y<J(;EFE9E5U72P8J*K@@E2/MSUJ-B\0" $J34$ F
MA\Q7JR?^6YLWX$5.]?D%W1\-NZ>V_D=N7=M-UQLCMSNGLWMS>O>D.079HRK8
M;'XW=.[9*J#*#&)4UBRC'U]1'3"2**8QL43VML5BJSQ$L30%BS-6E:9/'\ND
M]P7H X XD  #C\AT5;_A1/EMO[:Z&^ 6^-YF*FZ[Z^_FN_$C>O9>:KL?)D*'
M&X'#8_>(R%=DE2*4+0QK(B.60J[2)$ SR(K,;V:)&6X"5"3Z"C=.V&68#B4:
MGVXZ.U\9_P"8A_*X[P[:P_5?Q:[KZ.W1V_NS&YM<3MWK[:,^%R%7282F?)UR
M^88BD3P0T]$TSJ\X4F); N$'M3;WT$S:8RI8^0%#Z],R02(*L#3Y]46?*S;V
M]^JOEI\IOY0>Q\?N'$[)_FX?(GH_O_K3.X.AEHZ/$[7WR]55?(6$5,B34T;B
MDV=4N(*9?($RH;QQ*WF]E5PK1R/; 4$S*PIY _'_ ,=_GTLC(95E/X 0?M'P
M_P"'HV'\S+JK8O2G\P#X>_([N;=WR*Z>^$?^RM;Q^(NX>T?CAOK<G5\/7&:H
M,U2YW;U7G<QLV:ESV'V[N*GC3&SSB1Z%7HJ7[S[>GCDF]J+^/PIDD?4J:"E5
M)&DUJ*E<@'AZ=-V[EXV44+5U4(!J*4\_/HRWPHVO_+4WE\B=V]N_%OY/=V?+
M3N[871>Z=E93L'?_ ,B]_P#R8Q&%VYNFOQU748J+/;DJLE@Z2LJJZGI9UHH,
MA]T$26<P+'K<OVBPO(6C9G8*14LS@ _,DC\NFIC(%HP"@GA0+GH'/Y+--)3_
M /"=WJZGK::6%I>D?F?,8*J!HRT5=O7L66)]+@:HYH9$=3:SHP874@^V]KK]
M$/\ 2O\ \>;IR[_MS]J_X!T6[LVHFV]_PGE_EO=CU6*SE=M3IC+_ ,O7N7LF
MKP>%J<[-C=L[ W%B*[+Y:2EI8Y:EZ:AI1Y92D3:4]9L@+!/)5;*,TPOAL:9H
M 0:].+F=QZZ@/MZM?^3GR=_EE?)CX9ONSO'L;$=A_#KL[L.BZW;MC;6*W)48
MG%[@P0J,E194[@PM%]SMM<37XT+'G&FIZ.DR BII:M)9#$3&XN89XJN04)IJ
M%: \:U'"GKZ])8XY(WHHHP%:?+\^/V=%U_E8]U;MW!\D_D1T=U%\F^P?G!\"
M^N>K^NMP=6?(_LQDW=7XC=N9KZZFR&P:??$-#0IO2"@Q%-2U<D\QJ:ND9XHI
MZ@M+>1G;YF9V1&,D8 HQS0UX5Q7'V]7N4 4,1I8DU ]/6GEU>[K7^O\ O'LW
MJW2/KVM?Z_[Q[]5NO="]F6'^AS:AOQ_'ZG_H?)>P_;U_>,O_ #3'^"/HRE_W
M&3_3'_G[H(=:_P!?]X]B"K=%O7M:_P!?]X]^JW7NO:U_K_O'OU6Z]U[6O]?]
MX]^JW7ND-VALC']H=:=A]:92<T^,[$V-NW8N1G6+S%(-VX^HQ\SA+KJ*QU#&
MVH7M:X^ONDBF12I\P1^W'6U.D@^AZUX/Y=_\R?IK^7U\=-E_ 7^9CN.7XJ?(
MWXK8S</7M%7;RVEG3M?>NU]J5Q&"W'L[<$%!5T.7I9<564$#1>:*KDFAFD2C
MC0-% 36=^+)!#/V,E1D&C <"#Y]+Y[<SL7C[@<_,'T/3[\VOD30]IY_^6S_,
M^V1UQ\BJWXI_$KY2]MT';=-E.GLK@LC)M;M+;2;=A[/BVK5TJ;FJ-NX"N,NB
M88]*HP35,JT3@Q,-W<YE,5P VA'-<$8(IJIQH.M0IIUQDC4P%,^8-:5X==_,
M#OWI;^:CWE_+@Z2^$.^*3OA.C?G-U!\S.\.T]BX>JRVVMH;7Z,H\G.U'F<Q)
M'34D&8W#4Y*GIJ*A69JDR(S2PHJ#5ZYG7<7B2(ZM,@=B. "UXGU-<=>BC-LK
MEQ2JE0#Q)/0W_P OZ*4?SB_Y\U:8I11SYC^6W2P5?C;QO+1=:9HS1J]M+21"
M6(NH-U#H6 U"[MG7ZFX_YM?\=/5)O[*/_;_\>ZS?R4GK?X]_-_7)M5_=C^=#
M\TFC6NU^3[9DVW]F0)/5X#2B+P_V?$$T>C3[WM=:S?\ -=_\G7KO\'_--?\
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M[KVM?Z_[Q[]5NO=#9VRP&(V'<_7'5MO^I5#[#>PU\2>G\0_POT:[C\,?V'_
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M0W_R_HI1_.+_ )\U:8I11SYC^6W2P5?C;QO+1=:9HS1J]M+21"6(NH-U#H6
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MZ@VWGLSNC#95/X7MG+UD-/#GZC'210QUTE(KTU/-4P0^=YO-'"8+="[1_#R
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MS:40*JZF8DV'))/U/OP0CKWB'_4.I/W*_P"K'^W'OV@]>\0_ZAU[[E?]6/\
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M"JS:FN0 3<W^I]Z$=/+KWB'_ %#J2LD*-(Z"-7E*M*ZJJEBH"@L1R2  !?\
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ML"&4V((/U!'M;H/3'B'_ %#J)2T^-H88J:BI**CIZ=WD@IZ6FCIT1I-09D1
M%5FU-<@ FYO]3[T(Z>77O$/^H=25DA1I'01J\I5I7554L5 4%B.20  +_CCW
MO0>O>(?]0Z]')#"BQ1".*-!I2.-510/Z "P ]^T'KWB'_4.NTFBC18X]"1HJ
MHB(%4 *+  #@ #Z#W[0>O>(?]0Z%/IZ8/O:E4,#_ )!D/Z?A/\/9)S"M+8_Z
M9?\ #T8[6U9A]AZ1^[JA5W9N<:AQN'-#ZC\5,OLPV]3X$?\ S33_ (Z.DMTY
M$C_Z9O+YGI/?<K_JQ_MQ[5Z#TQXA_P!0Z]]RO^K'^W'OV@]>\0_ZAU[[E?\
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M[Q#_ *AT.=?*/]!V%DN+')RB_'_*[5_[#V&(A_NS<?T1_P <7HX=O\34_/\
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M6AHZ==$%)1PQTT2+<FR1H%51<G@ >_!".O>(?]0ZD_<K_JQ_MQ[]H/7O$/\
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MD0R3&[N5C"@NYY)M<_D^]!"/+KWB'_4.I*R0HTCH(U>4JTKJJJ6*@*"Q')(
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M_P!0ZGXNH4Y/'#6.:^D_(_XZ+[:G4Z&_TI_P=7C<EA]H\OGT*O>$HCW9CP6
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M+XX<)_$_XG))XHY'TK3$Z49K64D4^IAU:-::OX=0K^RM>K>%)35I:GKI-/\
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MI@%=T3I/-;RI'.$(DJ%9-0HP%:$$GCY'IYHTE1GB+ K2H:AJ#YBE.K@?N/\
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M)8T'GU1'@/G%_-4[@^-F:_F ],]'_%'$_&]=M[C[3ZY^,W8E9N>N[-W/LK;
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MI0R5]=5/_$)()8-L9:GK*2NFR,T4KTU53Y#[<2K.1V$]Q878LIF$@925;S%
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MAZ6[RU)S]@Z!7[IO^.C?[?V(_"^SHJUCKWW3?\=&_P!O[]X7V=>UCKWW3?\
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MS*Q)!1R:YI@\/3H=?F[.3_.=_D?OK-TQ_P#,AYO_ *KK*D]J+]*7UJ/^:_\
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M7+_CU$$DZN/'Y]&D]VZ7!4$T#!0OX:>E.@#^7DQ/_"4GK^/4;?[+U\-!IO\
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MQ'U$3>;"-F^TGJ7UM,?]F(_X2C'4?V_@WWT!S]+_ !YVN/>XD_4V_P"<3_\
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MV5NC;>Z=F[2W/LNNAKMG;CVS@<]M.MI$:&*;&9>EBJ*"6)'"NL<E+)$RAE!
M(! /'L11J'4,M*$ C[#T5LVDD'C7/V]*;[IO^.C?[?W?POLZKK'7ONF_XZ-_
MM_?O"^SKVL=>^Z;_ (Z-_M_?O"^SKVL=>^Z;_CHW^W]^\+[.O:QT8'Y(3&/?
M&*4,5OM2A-@;?\IE=["G)Z:K9O\ FJW_ !Q.CG?&I*/](/\ CS=%^^Z;_CHW
M^W]BOPOLZ)M8Z]]TW_'1O]O[]X7V=>UCKWW3?\=&_P!O[]X7V=>UCKWW3?\
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MNF_XZ-_M_?O"^SKVL=>^Z;_CHW^W]^\+[.O:QT8'<4Q'QWV')J-VW76#5?\
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M&*=(YZ5YJJ&)6*]SV4VEK.+=6=I&U,K4:F:G2 !D>7$^F>EEK?B::,R$*$%
M1CR\ZD\?/JIK+]1Y*MV)\7M@?RHNN?YN/47S%PFZNL,9N;=7=R[QV)LC$4&W
M,>PR4F\#E9)MITU'3UM/$124E$N.EC6>C6EGCD@HI21K4LL:V2W*R@K4N'"
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MUM-Q=)3*" 3Q'D?Y_P"7KA\6/Y6G2/QKQ_;U/N7M'Y"_*?)=W=<5736^<O\
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M!<& DK3((SZ$4Z#CY;_"CK;Y;5W5>\LIN_LGIWNKHK-9G.=-=]=+YRFV[N?
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MV&&X3C)Y99TJ*>6FFEIV8_J_&-2AY1&Q),88!*GC^&M/.E:?+J_[R8T-$U
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M6O\ MT-14)C7K)-<R&I$4TL;5MMG6"3Q7:21Z4#.0=(/$   "OV5ZW+>F1=
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M(5ZM5^[/^^)]G7A?;T@J.O?=G_?$^_>%]O7JCKWW9_WQ/OWA?;UZHZ]]V?\
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M1K_NS_OB?:SPOMZ8J.O?=G_?$^_>%]O7JCI@\Y_U(_V_M30=,U/7O.?]2/\
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MUY(3\:NS7M:V<R0L/^H;%>P+NX_W<6W^D7_CTO0BLC_B,O\ IC_@3HI_G/\
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MM;B)YT>J)\1TL*?D5!/Y#IN2QFB<1L*,W 5&?SK3HL/_ $$'_P HG_O+4?\
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M]0=>J>C89:0_[*CMA[<G.5 M_P"17(^P+ /]WLG^D'_5J/H12'_=<O\ IO\
MG]NBG^<_ZD?[?V.J#H.U/7O.?]2/]O[]0=>J>O><_P"I'^W]^H.O5/7O.?\
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ML:SHR+554$,+N"J.Q!L77>Z6]BP21NXBNE59VIZD*"0/F>E4%I+<#4HQPJ2
M*^E21GH>NF>\^J/D/UU@.VNDM^;;[+ZYW.E0V%W7M>N^]II6HI&AGA<$++3U
M-/,CQS031QS0R*4DC5@1[56]Q'=H)(B&4\".'3,L;PMI<$$>1ZX=T=[]3_'?
MK_*]I=U[YP77>P\--14E7G\[-)9ZC)R"*EHZ6G@2:KKJZJE(2"EIH):B9O3'
M&Q]^N;B.T0O(0JCS/S_PGY#KT4;SMI0$GTZ CH/^81\4/DKOO(=6=6]DUW^E
M#'8%-UMUOV%UYN;IW/5&*D(7^)T&*W=A\)6Y*@5N'GI89HT(];*+72VNZ6]X
M_AHW<!72RLC4]0'"DC[.GIK26!=3#%:5!#"OV@GH*OD/_-[_ )>?Q3[0W)TQ
MWS\A8-E=D[/CV\^Z=NTG5^]=ZB@;=="F2QT556X#;F4Q\5354#I4) :OS>)@
M[( ?;%WOUG8.8Y7TL*5&AS2HJ,JI'#/3D&W3W*AT6H-:'4HX8\R.C:?'?Y)]
M-_*_J;;G>?0.\!OWJS=E1G*7;^Z/[OY7:WW$FVZZHQM:OV6:H<=D8O#6TE1'
M>2D0/IUQEHV5BOM+J*_C$L1U*:T-".!H<$ \1TFGB>W8H^".(K7B*^1/0V^<
M_P"I'^W]J:#IJIZ]YS_J1_M_?J#KU3UCFK8Z>*6>=XH(((WFFFFD$:(D8+,S
M,Q 55 )))L!R??B .O5/1:.COFC\9_DKO_N7K+HCMC;_ &?NWH"NVUC>U8]K
M4U;68_'S[M%<:*.#,FE3#Y4LV-KHY?X?7U0IY87AJ#%*-'M%;7\%X[I$P8QT
M#4!H*UIFE#P/ FGGTHFMI(%5G! :M*^=/EQ''SZ,WYS_ *D?[?VMH.D]3T7/
MY0?+OX]_#+K1>W?DKV/C>LM@S;@QFU*++5>+R.X)ZK)9A99(**BQV)I*_)5L
MYAIZF9U@I)/'!#-/)HBB=U27M]#MR>),P5:@5H34GR  )/[.G[>"2Z;3&"3Q
MXTQ^=.ALV[O' ;KVK@M[X'(P5NU=R;?QFZL-F'22ACEQ^8IDJZ>I*U"12PI)
M32(Y$B(R V=5(("A&610PX$ @_(YZ98%30\0:= )T=\T?C/\E=_]R]9=$=L;
M?[/W;T!7;:QO:L>UJ:MK,?CY]VBN-%'!F32IA\J6;&UT<O\ #Z^J%/+"\-08
MI1H]I;:_@O'=(F#&.@:@-!6M,TH>!X$T\^GYK:2!59P0&K2OG3Y<1Q\^C-^<
M_P"I'^W]K:#I/4]>\Y_U(_V_OU!UZIZ]YS_J1_M_?J#KU3U[SG_4C_;^_4'7
MJGHV'R2D*[:Z=(%]6#RIY_ZA\3[ O)PK-=_Z=?\ CTO0BWTT2'_2G_ G13_.
M?]2/]O['5!T':GHM.R_F3\;>P_D3V3\3MF=J8/._(/J' 4FY^PNN*:AKX9Z"
MBJFI%,JUDM)'C:QJ=LA0K4QTM9-+2M41+4)$S@>T<=_!-,T"L#(@JRT.!CSI
M3S%:''GT^]O(B"0@Z6P#7_5Z=&6\Y_U(_P!O[64'3%3U[SG_ %(_V_OU!UZI
MZ+UT9\KND/D=B^VLUU/NYLUBNCNV-[]*=FUV5PE?M6/&[AZ[2GERU,S92FI!
M-3TT55"_W,>NG92=,A*L DMKR*\#F,U".R-4$49:5X@>O'AT]- \% WX@&&:
MU!X<.ARPNX</N/$X[/;>RN+SV#R])#7XG-86OBRE)505(U1S4]3 \D,T,BD%
M71V5AR"1[4J5<5%"#P(R#TT:J:&O3GYS_J1_M_=J#K53U[SG_4C_ &_OU!UZ
MIZ]YS_J1_M_?J#KU3U[SG_4C_;^_4'7JGKWG/^I'^W]^H.O5/7O.?]2/]O[]
M0=>J>O><_P"I'^W]^H.O5/5:?9W\XG^7+U#V!G^M-Y_); -N;:&1HL1O>IVC
ML[<O8F(P-57UKXY*;.;@V_ALG@<34I7QR0315.1CDII%*U"Q<7)I]_L[=RC2
M"HPU%9@IK3)52!GU.//I?'MUQ*H8*:'A4@$^> 2">K!-D[^VAV3M';F_NO\
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M[@?23_\ -&3_ (XW2JQ8^-'_ *=/^/#H5/E#/X^V*]=1'^X;"FP_QB/LDY+
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M.GJ>/+YK;^;QV#4X&LQ!Q%3&U%61Q0U.L"*I#L#-.Q%<SV-TEM.RR+*KF-]
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M-R5;P0KB0*%U(P)R. (IY<>F+F!76.2($>(2NDFM&! P?G7JONF_F4=V;O\
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M6>O?=?[4W^V]^H.O:ST6FF^;/P_K>PQU%1_*OXZU?:QW9-L,=9TW=6VY\_\
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M*JT:5&144!\J?GZ\#T4RS-#,S*:$,U.&,GJO#^7MM3:/7?\ -8_G%[*V%MG
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MMT-G\H<R];53T=$)OX326:0S"(FT0:VN>3;=O%Q*ZNBPJ50)I(-, MJ-:X'
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MQ34A<5-: 5(&237AUJ%T6RK)4@3&@&*G1YGR'$\.C%]#?+SO3I#Y/?)KX?\
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MN"2DJ]-/,M-E8P0QGA>55*$1S7<\<:NL+,Q^- Z!DQZDZ6IPP>BJ.%'<J9*
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M!XW;,6X:Q\-!6MMG:4=142SM4Q)4UBR14[S71ZARVM[NP@FG"*]Q*^LQZAI
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M]:2W\2P1BJO(@E-::8@=3>=36E*#HHVV=;9S(_%58H*5JYP/+RK7/14^U?\
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MEPW6?R+R?P^'4&>.:H*Y\LG4NS,AC,Y+]I35,U511TM?610J*J&!Y2':-&C
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M> _[7>*_ZWQ^Q/>?V,G^D;_CIZ*+<GQ%X_$/\(^71E/F'(4[,P8'_/"XP_\
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M)):R6BQU3-34X$:B3661$>PV,EGXK,GA*[ADB!!\,4 /# ).:# Z?W*Y6;0
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M;W'6]_\ )=M?^::_\?EZ%6W_ /).F_TS?\=3HEGG_P /]X_XW[D7H*]>\_\
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M[KW7O/\ X?[Q_P ;]^Z]U[S_ .'^\?\ &_?NO=>\_P#A_O'_ !OW[KW7O/\
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MZ]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>Z]Y_\/\
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M_P"-^_=>Z-O\S)-':&!%O^8"Q9_]:.4]@/V\_P!PG_YKM_U;CZ$G-'^Y"_\
M-,?\>?HI'G_P_P!X_P"-^QYT&^O>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>
MZ]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>Z]Y_\/\
M>/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW
M7NO>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_
M 'C_ (W[]U[KWG_P_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[
M]U[KWG_P_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P
M_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[HZ>:D_P"<,-HO
M;Z[AJ?\ W<Y3W'5O_P K%+_S3'_5F/H52_\ )*3_ $Q_ZN-T2SS_ .'^\?\
M&_<B]!7KWG_P_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[K
MWG_P_P!X_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P_P!X
M_P"-^_=>Z]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>
MZ]Y_\/\ >/\ C?OW7NO>?_#_ 'C_ (W[]U[KWG_P_P!X_P"-^_=>Z]Y_\/\
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M9M_^Y$7_ #43_CPZ&#Y<2%>Y<B.?^+'@?Q_S9/L/\@_\DY?]._\ AZ,N8_\
M<D_Z5>BR>8_X_P"V'L:=$/7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#
MW[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW
M7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?
M\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\
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M &P]^Z]U[S'_ !_VP]^Z]U[S'_'_ &P]^Z]U[S'_ !_VP]^Z]T;WYIR:>TL
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M20]H-1444:L$<<]:-ND=J)&'>[T3CA5XGCFI-.'0A[._F3_!WL#?.$Z[V?\
M(_8F;W%NC-5&V]IU,*5U/A\QD*9D1J'#;CFHXMO9>L+NJI#1Y2>21KJBLRL
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MF/\ C_MA[]U[KWF/^/\ MA[]U[KWF/\ C_MA[]U[KWF/^/\ MA[]U[KWF/\
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M\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\
M;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[
MKW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O
M,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\ '_;#W[KW7O,?\?\ ;#W[KW7O,?\
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MN>OI5$+UU-MG=F GH8ZDJ!YOMY*F0J6N0 @O9% -)D"[O&P&6MI 3Z@.M/\
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MZ]Y/\/\ >??NO=>\G^'^\^_=>Z/'G&_YP@V<;?7<E5Q?_J]Y7W&UM_RLDO\
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M(_TK=!#VU%?M7LP\<]@[S/U/YR53[/MB8?0V_P#S0B_ZMKT6[C_N1+_S4?\
MX\>@^\(_P_VY]FNL=(^O>$?X?[<^_:QU[KWA'^'^W/OVL=>Z]X1_A_MS[]K'
M7NB+_(K^6K\._E=NS);T[YZVW)O7-9C&X?$Y2&#NC?.T\=/!@"II!)A\+N/'
M8DO"R(WD^R\C,JNS,R@@EO\ 8;/<V+SJS$@ _J2*#3AA6 _ETNMMRFM!IC8
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MO:#U[[;_  _WW^W]^\4?ZO\ BNO:#T]_;C_#_??[#VAUGI1H/7OMQ_A_OO\
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M[[_8>QYK/0:T'KWVX_P_WW^P]^UGKV@]>^W'^'^^_P!A[]K/7M!Z]]N/\/\
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M]]_L/?M9Z]H/7OMQ_A_OO]A[]K/7M!Z]]N/\/]]_L/?M9Z]H/7OMQ_A_OO\
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M9Z]H/7OMQ_A_OO\ 8>_:SU[0>C7;NB!^)'5R<6&^L@?^L^XO\/\ 'V"[%O\
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M?],/\/1D_F'$'[,P9-O^/%Q@_P#6AD_\/83Y%:EH_P#S6;_CD?1WS(I,Z_\
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MMC_J#_MA[]K'7M!Z]]L?]0?]L/?M8Z]H/7OMC_J#_MA[]K'7M!Z]]L?]0?\
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M0]S9G-[6VU,@CTY26.?!8[)Y*.4R>JF0TA0K=9&7@^UMQ)*$_2"%\?&2%^?
M$_9TGB1"W?J"Y^&A/RXGJL7^7K\5?YD?Q7[,[H7M#'_"K*=1_)3Y5=O?*+M&
MNV+V'O?*[BQ-9VI3Q-)C<!35^U,;C:JFIZNBHU4U=5&_B>9B[N$7V2[5;7=D
M[ZQ%IDE>1J,Y8%O(54 \!QZ,+V6"X5=.O4J*@J%H:>N>L'<OQ5_F6;C^=&9^
M3NWZ#X0]O]>]?8^+!?%#9/=N_=[[:&RX\C @S&<;%X;:>1HI]UY*35#_ !!J
M^9J>D7Q4OA65E3UQ;7;W)F B=5Q$'9QHKQ- I[CZUX<.O12P+#X9\12?C*A3
MJ]!4GA\NK-OCFWRLK-KYR3Y:;?Z V_O-<^4VW2_'G<^X=U8Q\7]O"1)73;CQ
M.(JHZ[[LU T10/%XA&VO6S*#FTDF*GQP@-<:"2*?/4!GI!.D8(\+41YZJ U_
M(GH.?D;\K/AKL.'?'1?>'RGZ.Z<WAN/962Q&2V_OCLW"[8RM+2;RH9H(:P4-
M?5P2E'BE+Q$J$>W!M?VS=[C;Q5CDD5212A8 T(^9ZM#:RM1U1F /D"1CH(?B
MO\K_ .7OUMUC\>?BMUK\WOCOV1E]D[,ZMZ'V#34O<.W*S+YVIP=)18'%Q145
M)7,9LCDYHX%6&%"7FD"1J;@>V++<;2%(X$E1B J+W+4T 4>?$].7%K/(S2-&
MPJ2QP:"N3T>KM*/M*'K[=4O2E!L/(]J1XQFV30]H9'(8C 2U@=+)E*G%4M;D
M8*8Q^3U04LKAM/I(O[,II&"'PP"U,:JA:_.E3TEC0:AKK3SI2O\ /JF'X\_%
MG^:QU+\SODA\H]PX7X!5>.^7>:^/$/;& Q'9_855+A<9TCBS@6EV\LVS:9*F
MNJL=-43".LJ%B-2(T\D<>H^P]:6U[!<23D0TE,>H!GP$&G';QIZ]&L\MO)$L
M8\3LU4-%R6-<]W5HE;M_Y7/\M\/G*#='5D/PPBZ2J,?FMFS452V\I=^ME9W2
MMBF^P-(N#7$-2I;^)A_.LH-*05E]G1:;QZU7PM&1^/77C]E/G^71>%C\*E#X
MFKC^'33[>/15NS=N_P VOL&/>_56V*OX6=1;4W--N'!XGY(X/-[PW;N/%8;*
MF6.FK:'9-7BZ7'/N:FI'0?O;H^P6I!J%UHJTY13-?2ZD7PD!J!("Q8 ^BD4K
M_MJ=*(UMTHQ\1B*54Z0"?MKP_+H:*#XY]F?&+XF]9]#_  2DZMQF=Z=H,!BL
M!0]\TF3K,1FZ*B\\F6BR57A&2OQ^2S%5/)4_?0T]0D%0Q9J.>(F$J! UG L5
MMI!2@&NM"/.M,@GC7U\NFC(+B4O-6C<=-*CTX^GIT5C._$?YF?,?MGH3<_SB
M?XY];=)_&OMK;7?6SNG.@,WN'L#*;@WCLB*JCQ%=G-Q9F@P5/28:B:LDD2AI
ML5))-ZXZB=DD C1/:S[@Z&YT*D;APB%F+.M:$DA<"O #[>E(FCM580ZBS*5+
M-0 *>- "<]7 _;'_ %!_VP]GVL=%>@]>^V/^H/\ MA[]K'7M!Z]]L?\ 4'_;
M#W[6.O:#U[[8_P"H/^V'OVL=>T'HW?R;B+[8Z7%B=.!RX_\ 5?#^P3RBU);K
M_3K_ (9.A%O@JD-/X3_@3HHGVQ_U!_VP]C;6.@[H/7OMC_J#_MA[]K'7M!Z]
M]L?]0?\ ;#W[6.O:#U[[8_Z@_P"V'OVL=>T'KWVQ_P!0?]L/?M8Z]H/7OMC_
M *@_[8>_:QU[0>O?;'_4'_;#W[6.O:#U[[8_Z@_[8>_:QU[0>O?;'_4'_;#W
M[6.O:#U[[8_Z@_[8>_:QU[0>O?;'_4'_ &P]^UCKV@]>^V/^H/\ MA[]K'7M
M!Z]]L?\ 4'_;#W[6.O:#U[[8_P"H/^V'OVL=>T'KWVQ_U!_VP]^UCKV@]>^V
M/^H/^V'OVL=>T'KWVQ_U!_VP]^UCKV@]>^V/^H/^V'OVL=>T'KWVQ_U!_P!L
M/?M8Z]H/7OMC_J#_ +8>_:QU[0>O?;'_ %!_VP]^UCKV@]>^V/\ J#_MA[]K
M'7M!Z>=NTY&X,$=!XS.,_ _X[I[3W;CPG_TC?X#T["IUK_IA_AZ,3\M8O)V/
MA3I)MLG&C_U?R7L,<EM2U?\ YJM_QQ.CCF%29E_T@_X\W17?MC_J#_MA[%^L
M=$6@]>^V/^H/^V'OVL=>T'KWVQ_U!_VP]^UCKV@]>^V/^H/^V'OVL=>T'KWV
MQ_U!_P!L/?M8Z]H/7OMC_J#_ +8>_:QU[0>O?;'_ %!_VP]^UCKV@]>^V/\
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M:F]#_/KW7O''_P =(O\ ;CW[4WH?Y]>Z]XX_^.D7^W'OVIO0_P ^O=>\<?\
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M#_/KW7O''_QTB_VX]^U-Z'^?7NO>./\ XZ1?[<>_:F]#_/KW7O''_P =(O\
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M'OVIO0_SZ]U[QQ_\=(O]N/?M3>A_GU[KWCC_ ..D7^W'OVIO0_SZ]U[QQ_\
M'2+_ &X]^U-Z'^?7NO>./_CI%_MQ[]J;T/\ /KW7O''_ ,=(O]N/?M3>A_GU
M[KWCC_XZ1?[<>_:F]#_/KW7O''_QTB_VX]^U-Z'^?7NO>./_ (Z1?[<>_:F]
M#_/KW7O''_QTB_VX]^U-Z'^?7NO>./\ XZ1?[<>_:F]#_/KW7O''_P =(O\
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MZK>ZJT=<!:^5*5KULZ_/5_/H<O''_P =(O\ ;CVIU-Z'^?377O''_P =(O\
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MX]^U-Z'^?7NO>./_ (Z1?[<>_:F]#_/KW7O''_QTB_VX]^U-Z'^?7NO>./\
MXZ1?[<>_:F]#_/KW7O''_P =(O\ ;CW[4WH?Y]>Z]XX_^.D7^W'OVIO0_P ^
MO=>\<?\ QTB_VX]^U-Z'^?7NO>./_CI%_MQ[]J;T/\^O=>\<?_'2+_;CW[4W
'H?Y]>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tflowchart_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tflowchart_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMKO\
MD),Q^,G;:%F*+WOD&5+G2K/U_L,.P7Z D(H)_-A_3WAI]XX#^MUD?^7-?^KT
MW4]>U?\ R0I_^:[?]6X^KS?>/74G=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=:=W\[;_LMZM_\15U_P#_ ":]YP_=^_Y4#_J)
MF_P)UCU[F_\ *RC_ )HI_A;JHCW-_4>=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]UM<_R$O^R9NW?_ !.M=_[P&Q?>&GWC_P#E;K+_ )XU
M_P"KTW4]>U7_ "0I_P#FNW_5N/J\_P!X]=2=U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIW?SMO\ LMZM_P#$5=?_ /R:]YP_
M=^_Y4#_J)F_P)UCU[F_\K*/^:*?X6ZJ(]S?U'G7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=;7/\A+_ +)F[=_\3K7?^\!L7WAI]X__ )6Z
MR_YXU_ZO3=3U[5?\D*?_ )KM_P!6X^KS_>/74G=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:=W\[;_LMZM_\ $5=?_P#R:]YP
M_=^_Y4#_ *B9O\"=8]>YO_*RC_FBG^%NJB/<W]1YU[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6US_(2_[)F[=_\3K7?^\!L7WAI]X__E;K
M+_GC7_J]-U/7M5_R0I_^:[?]6X^KS_>/74G=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:=W\[;_LMZM_\15U__P#)KWG#]W[_
M )4#_J)F_P "=8]>YO\ RLH_YHI_A;JHCW-_4>=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UM<_P A+_LF;MW_ ,3K7?\ O ;%]X:?>/\
M^5NLO^>-?^KTW4]>U7_)"G_YKM_U;CZO/]X]=2=U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIW?SMO^RWJW_Q%77_ /\ )KWG
M#]W[_E0/^HF;_ G6/7N;_P K*/\ FBG^%NJB/<W]1YU[W[KW5]_\MCX _&SM
MWHS&]I?*&BKI\AW+VAE.NNCZ./=6>VS'7';6W\YD,A)CSAJJB6>JJ9]MYE52
MI\J 8>R#7(R-C;[K>Y7->R<QOL_*+!4L+=9KH^&DE/$= *ZPU% DCX4-7SP'
M4L<E\I;+N&U+?[VM6N9"D(ULM=*L33214DJW&N%ZIE[SZIS/1O<79746?\C9
M+K[>.;VT:F6-8CDJ&AK)!B<S'&K.!'74C05D0O\ HG6_/'N>.7-Z@YBV*TWR
MV^&YB1Z#\+$=Z?[5JJ?F.HWW;;Y-JW*?;I>,+E:^HKVM^8H?SZ"KV==%_7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T=OI#X:U'<WQ@^1'R47L.';L'0:Q$[/;:[Y
M:7=;OCZ?(,HSHW!C10@+4!0?M*RY'T'N/>8>?5V#F_;.4S:F4[E3]7Q-/AU8
MK\&AM7#^)>A1M?+1W+8KS>O&T?2U[-%=5%#?%J%./H>BE;+VV^\=X[3VC'5K
M02;JW-@=MQUSPFH2B?.92EQBU;P+)$7$9JM90.M[6N+W]C;<;P;?M\]^5U""
M-Y--:5T*6I7-*TZ#]I!]5=1VP.GQ'5:\::B!6GY]&/\ FK\6)?AWW=4]-3;X
MC[">FVOM[<AW%%MQMK*_\>BJ7-%_"FSFX2/$:8CR?<G7>^E?I["O('.0YZV
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M:FGS?YZM+2.+;N9+.!86N &DC(H"U%<!EH >+!N!..CV?[/EV!_PV%_LS_\
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M82.X@<&*BM<ADK7SKU'VV7_-'*\:7EHKI!. XU+JB>N ?0'["&X?+H_/\R+
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M:5<HU8YEPW U>X(%.(4D8%>A/=6IY?\ ;AK&_!CGO90P0_$*,AR/+MB!/H2
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M/)MB]AL,1C21M;EG9V9J4J2Q/    4'RJ23O>=]W+?[A;G<G#%!I4!0H XX
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MU\E%J91(Z44M.CO=G5BS7(>9O;7DWFVX^LWBT!GH!XJ,T;D#^(H0&]*L"0,
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6G=_.V_[+>K?_ !%77_\
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M16U,KK -Q01+) ^MWIX!4R-ZZ5U%>9O=BQM.0[?F39*/=[B/#MXCW%9L"0,
M,^$3G U'3Y-U[:.2;B;F27:MQJL%KW2O\(9,E*'RUT_(5\QT1/Y!3=.R=Q[\
MCZ!QF7Q?4-%F9,9LE<[DZC+Y3)8W&114,F>GJJI5D"Y":GDK(87&J*.9(V]2
MGW(W*Z[\NPVQYF=7OF75+H4*JEC4)08JH(4D<2">@KO)VT[E*-H4K;@T2I+$
M@8+5/J<CY'JV?^9/"O:7P9_EY_(BJ<S[A_N5!UON7(!J4G*5\VT\9-++4"*1
MVU)6['R4B*E@IJI X5M*B%?:=OW/[A\S<KQBD7BF9!GM"RL !]JS+]M!3J0.
M=1]?ROM&\.:OH",<9+("3^U#^T]49^\B>HLZ][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZVN?Y"7_9,W;O_B=:
M[_W@-B^\-/O'_P#*W67_ #QK_P!7INIZ]JO^2%/_ ,UV_P"K<?5Y_O'KJ3NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM.[^=M
M_P!EO5O_ (BKK_\ ^37O.'[OW_*@?]1,W^!.L>O<W_E91_S13_"W51'N;^H\
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZO@^9,T>3_D\_!')T+">AI-ZX/$5%0I73'D:7:?:E#-3$7O<2XBH
M4V%@8C>W%\<>0E,/OAS'%)AFCD8#^B9;=@?V,/V]2MS*0_MYM3KD!T'YB.4?
MY#T#_P#)GZCQ>Y?D3N?OC>!@I=A?&K8N7WKDLG6";[2CW%F,?DL=B)YPL3(5
MIJ"GRU?<M='I(F56^JGGOQO<MIRQ#RY95-QNLRQA12IC0JS >=2Y1?F"<^I=
M[;;<D^[R;K<8BLT+5/DS @?L4,?V="%VW1?RF.YNU=\]P;K^7WR-CW5OO=>2
MW77_ ,/Z]R,-+C:BNJVGI,?BO+U/-+'3T4:QTU(&D=UCA0%V8:B6[(_O3L.S
M6^Q66QV)AMXUC&J926 &6;_&0"6-2V *DXZ6;@.0-RW"7<KC<;@22L6-$( ]
M /T:T H!YT''H9_YMF V%\C/C#\??FCT_N"??.!V[65G6.X=V5&/?%Y7+X"M
MKJVAHLKG<?6TV.FIWH\[@:N P>",^3-:PGCLP(/92YW+E;F[<N0]\C^GDE43
MI'JU*KJ Q5""P.J-P:U.(Z5KT8^X$5KO.Q6G,>W-XJ(3&STH2I)%6!H11UI2
MG%N'07==8C*YG^1?W)#B,97Y2:A[L7+UD..I)ZV6EQ6)WCUO797)SQT\<C+3
MTT$+SU$Q 6.-&D<JBD@WW.>&W^\19-.X0-;:06( +-#,%45\R2 !Q)( R>D=
MK')+[6SB-2Q$M305H!*A)QY "I/D,]$$_ENXC,YKYR_&REP<-3/5TW8M)EZH
M4OEUQX;!X_(9?/32F$$B-**BG,M_25N&X)]R5[KS00>WFZM<$ &'2*T^)F54
M KYZB*=!+DJ.23FFS$8J0Y)^P*Q/\NCV=GY3&YC^>KC*O$^(4L/??46+E\5M
M/\2P>P=E87-7T@>K[S'SZ_\ :KWN?<<[5%+#]W5DFXFTN&_VK3RLO_&2.A5=
MNC^Z8*</&C'YB%0?Y@] 5\X?^WLF[?\ Q-W2?_NCZW]B+D'_ *<I%_SR7G_'
MY^BKF7_IX+?\UX/^.Q=*'^=K%)'\WZ]WC=%FZLZ_EA9T95FC"YB$R1$@:E#P
MNEQ<74CZ@^TWW?B#R!0'A<S5_8AZ<]S01S+G_?*?X6Z&;Y!T=7N#^25\3<CL
ML+5;<VEVH9=]PXR 0)C:ILMW%@IJW+1B*)E7^+YB..0MQ+-7PS>L.DGLBY8D
M2U]_]ZBW#$L\!$)8UU#3;. O'_0U)'H%*XX=&>\*9O;2P>TRD<@\2F*&LJDG
MA^,_F2#\^JZ?Y?.$W/G_ )L?&6CVE]P,G2]N[2S=<U.AD9-L;>KTSF\_)9'M
M&V(Q]:DC&UE8\CZ^Y1]SKBSMN0-V>^H4:WD05_WXXT1?F'*G\N@=RA%/+S-9
M+;882JQ_TJY?]J@CHR_SVVQO#N+^:SV/M#I0SU>_,YOWJS!;5J<542TDF,W5
MM[K+8-'DLJ]?0K(],N+JL/4U-75*+P+2R2M8H?83]N+RPV/V9M;[?Q2VCAN6
MD# '5&]Q,0M#0'6& 4?BU >?1US5!=;AS[-;[::S,\00@THRQ1U-1PTD$D^5
M">KWOECD<AWW\=_DY\;^D.R<+GOE!UKU[L*D[JAP6'I\7EM_X],7_%\YM>@D
MA:0K_$X5K:?[:&6=::6L_A\S1"I<^\<^3(HN6^9]HYJYAM6CVBZFF-L78LL1
M#:5D/^D.DU(&H+K .D=2KOS/NNT7VS;7,K7L4:"4* "X(J5'^F%1\B:&E>M,
M=T:-F1U9'1BCHX*LC*2&5E(!!!%B#[SR!!%1D'K&P@@T/5[/S%/\&_D\_!#;
MU=%"N1R>]\7N.E8AUG7&/MGM6M41"6%#H>/<]*TA! N$*ZU(;WCGR'2?WQYC
MN8R=*1.A]-7BVX]?5#_L=2MS+V>WFU1MQ+HWY>'*?^?AU1)[R-ZBGKWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K:Y_D)?]DS=N_\ B=:[_P!X#8OO#3[Q_P#RMUE_SQK_ -7INIZ]JO\ DA3_
M /-=O^K<?5Y_O'KJ3NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NM.[^=M_V6]6_P#B*NO_ /Y->\X?N_?\J!_U$S?X$ZQZ]S?^
M5E'_ #13_"W51'N;^H\Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZO-^/E=_LRG\HOY$=#43+/OKXS;B_TJ;>
MQJ*E143[.DRL^_:J>FISID:1A'N>"T6HAFA')DT'';F>/^J?O;M?,DF+;=D\
M!VX 2:1!0GT%86S\_2O4J;.W[Z]O;S:4_M;,F11Q)75XN!\^\?L^SHD?4OS=
MDZ;^'?=/Q<VIUHB;C[ORM7+N3MV3>+K+3;=R%)@\/6[;AV8FV"'1\?CZRF68
MY5;')2R&,Z0AD'>_;T;]SS8<X7MW^EMZKHMA%Q=2[JYE\3^-E:FC@H%?/H+[
M?S0=MY=N=BMX.^Y)U2Z_PL I4)I_A!'Q>9/RZ(=[DCH)]'_Z7^=4W67Q"[O^
M(.Z^L4['VGVJV7K]LYR?>1P,G7>>R6.QXILC%B)-JY\9"*ER>$H,M%3+4X_]
MZ*7]P-/Y$C3?O;I=VYXV_G>SN_I9K/0)$$6OQU5C4%O$3261F0FC8IC%"+MM
MYJ-ER]<\O3P>,D^K2Q?3X98"ATZ&K1@& J,U]:]69_$;O3=?QN_E#[O[?V;1
M87*Y;;7R ^WJ,)N*B%?@\]A,[N;K_!;@P>4I]2-XJJCR,T)=&5D+!U-UL8DY
MUY=L^:_>Z+8[YF1)K2H=#1T=(I71U/J&4&GGPZ'&P;I/LOMZVXVX#-'-\+<&
M#2(K _:">@"Q'\U'H3J6CW'N[XU?!;K[J?N_=F,EH*S>T^<ILIAL$]<BRUXQ
M&,HMNXN8TC3Q1O\ 84TN+AD,:/,&\80B2;V;YEWF2*QYKYBFO-O@8$1!6#O3
M U%G8!J$C40Y%2!QKT4ISYM%@CW&S;6D%U(*%ZC2M<FE%!(KY#2#Q/#JL+J#
MOC-]:_(O9GR+W#13]@;BV[V3%V7GJ.MRO\(J]VYB3*RY?+&JS*X[)B"6KFJ)
M'><4LP5GU>-AQ[E[?.6[?=N5I^5;5A:Q20> A"ZA&H4*M%U+4  "FH?;T!MM
MW>6QWF/>IAXSK(9&!.DN2234T-*D^G3K\F?D)6?(3Y&;X^0N/V])U]7[NS6
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MW7NO>_=>Z][]U[KWOW7NO>_=>ZT[OYVW_9;U;_XBKK__ .37O.'[OW_*@?\
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M%&5,IC=9&FMI 2@DC%5%32N(O>._/'MSS#R+=:=P3Q;5C2.X0$QMYA6_@?\
MHMQH=)8"O4G\O<T[7S'#JM6T2@=T34UK\QZK\QZBM#CH[OL ="7KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/G7_-SV1TA497J;XZ#&=I]
MT"=\/7YZ"V5V)L7)ES324;244I.7RT4G[?V-,WAAENM1*98WI3//MW[*[AS"
MJ;US/JL]OIJ"GMFF7C45'8A&=1R1E10ZA'/-'/\ :[6QV_:*7%U722,HAX4-
M/B:OX1P/$UQT5GXK_P K#MGY([O3Y)_S MP[JK&W)(F9CZUR^0JZ;?&YHY&$
MM"N\JVEEIFP.-1#IAPM"L%0D;+'_ ) (_$XOYP]X-EY5L?ZJ>V<4:B+M,ZJ#
M$GKX0-?$<^<C5!.>^M01;'R-?[S<?OKFYV8OGPB2'/IK(IH'HBT(X=M*=;%V
MUMJ[9V/M_$[3V;M_#[6VQ@J.+'X;;^ QU+B<1BZ*!=,5-0X^BBABC0?T51<D
MD\DGWC!=WEW?W+WE](TTLA+,[L69B>)+&I/4O0P0VT2P6Z!$44"J   /( =!
M[\@.Y]L?'GIKL/N7=[K_  ;8>W*O+"C\T<$V9RSE*/ ;>HY)2%%1D:ZJIZ*#
M5QKG4FP!/LRY;V*\YFWVUV*Q'ZERX6M*A5XNYIY(H+'Y#I+NFXP;3M\VXW/P
M1*6IZG@JBOFQH!\SU0[_ "<>FMQ=X=S]Q?//MM1E<W+N7<>(V?55$+B&;?F[
ME;)[ZW!C8Z@.88L?096+%T*QR.BQY"HA !IUMD7[Y[[:\O;%8^V^R=D:QHTH
M!SX4?;"C4XEF4NU0#55;\1ZBWV[V^;<]QN>:]P[G9F5/36V785X  A5H>!8>
M76R'[Q9ZF'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4Z_GQ;)K\1\G>M=
M]&!%PV].G*#%4]0%"O+G-G[JW&,Q"^E!J\=+N'&$,68_N:; *M\S/NY[A%-R
MG=[=7]2"Z+D?T)8TT_SC?J!_=2V=-Y@N_P ,D.D?Z9'8G^3KU1Y[R$ZB_KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NMO;^1QL>LVQ\-LGN
M:L#!>Q^WMX;CQ9L54XC#8S;FR5M=CJ/WNV*Z["WX6WIN<(OO![A'><]K:1_\
M1+:*-O\ 3,SS?\=D7K(3VRM6@Y;,S?Z-*[C[ %C_ ,*'JY+W!G4B=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4+)8W'9G'UV(S%!197$Y2D
MJ,?D\9DJ6"NQ^1H*R)Z>KHJZBJHY8YH98Y&22.165E8A@0;>W(I98)%FA8HZ
M$%64D$$9!!&01Y$=5=%D4HX#*10@Y!!X@CK7R^8O\HW<6S=QM\AO@7D\IL_>
M& KY=S/U9B,Q/B*Z@KH]4LV0ZESQJ87IW]3G^#5$HC*NT5)(J>*B;);D?WKM
MKZU_JQ[CHMQ;R@1_4,H8$>0N$H=7E^H!6M"P)JXB?F'D"6WG_?'*C&*5"6\(
M&F?6(^7^E.*8%!@KOX,_S=*/=>4H^B?F-'#UQVKCJQMNTO8>6HO[LX'-Y>CD
M-))B=_XZK2E7!9821E))72&DDD#*RTCZ8Y"[W"]E)+*$\Q<C$W=DXUF%3XCH
MISJA85\1/2E6 _B%2%7+'/ZW$@VKF$>!<*=.LC2K,,4<&FAOY$^AH.KW5975
M71E='4,CJ0RLK"ZLK"X((-P1[QV(I@]2AUR]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]TE-\;ZV=UIM3-[YW_N7#[1VCMRBDK\UN#.UL5!CJ"F2P!DFE8:G=F6.&% T
MDLC+'&K.RJ5FW[??;K>1[?ML33SRG2B("68_(#]I/ #)QTQ<W-O:0-<W3B.-
M!5F8T 'V]:V/R4_F#_(3YZ[^D^,'P6V[NK&[*S'W%'G-ST,;X?=F\,*D@ILA
MD\WF)7B3;>W/WD$IEEIYYPZQ3R+YS1-E3RK[9\L^W.VCF[W%EC>=*%(CW1QO
MQ"JH_M9?2@*KD@&FL0YO'-N[<U7?[DY51EC:NIQVLR\"2?P)^PG Q72;)/@?
M_*VZM^)U/BM_[Z_AG9_?@@65MT34SR;8V)43)^_1]?8VNB1A*NHQ-F:F-:J1
M0?"E''++"T5^XON]O'.COMMAJM-MK_9@]\H' S,/+ST Z1BNH@-T,>5N1[#8
M%6ZN:3W=/CIVI7B(P?V:CD_($CJU7W#W0YZ][]U[K6Z_G)]W[D[F[>ZE^!_4
M;29?,3;AVYE]Z8^AF8+7[[W9HH-@[7KWA>Z1T-'DWRE8)4:,#(4LQ*M3$C*;
MV+V"TV'9+WW'WOLC5'6(D<(H\S2+7B69="T-:JR_BZA[W%W*?<;^WY4V[N=F
M5G _C;$:FGD =1J*4*GRZO:^.?2.V_CETGUWTQM81OCMC[>IL?5Y!8EADSF>
MJ&>OW)N&H0?22OKZJHJF7G3Y0@]*@#'?F??[OFC?[K?KWX[ARP%:Z$&$0?)5
M 4?9U*&T[;!M&VP[;;_#$H%?4\68_,DDG[>AK]D/1CU[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U5Q_-I^*F2^2OQGGS&SL8V3[+Z6KJS?FUZ*FIVJ,EG,
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUO/YDO\I+-93-[C[^^*6
M_B3Y:HJ<WOWI?%1*M?\ Q*IEDJ<GN'KBE!595F9VEGPB6<.6-") Z4L>4WM5
M[U006\7+7.4FD( D-TW *!14G/E3@).%*:Z4+=0]SGR!)-*^[;$M68ZI(1Q)
M.2T?^$K_ +SZ=:XV1QV0Q%?68O+4-9B\GCJF:CR&.R-+/15]#64\C15%)64=
M2D4D4L;*5>-U5E(((!]Y31317$2SP,'1P"K*05(/ @C!!]1U#3H\3F.0%64T
M((H01Q!!ZA^W.J]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO="-U9U'V9W;O#'[!ZGV5G=
M];MR1O3XC!4AG:& .B25^2K)6AIZ.EC,B^:KJY8((P09)%'/LJWG?-HY?L6W
M+>KA+:%>+.:5/HH%2S'R502?(=+;#;K[=+@6NWQ-+(?)1P'J3P ^9('6WW_+
MD_ER;>^'&WIMZ[UFQFZ^_-UXQ:/.9RC5I\1LG$3LD\VT]IS3I&SZVCC-?7F.
M-IVC5$5(4_<PA]T?=&ZYZNA8V(:';86JB'#2L,"20"OJ=*U(4'S)ZR%Y/Y/@
MY<@,\Y$EU(*,PX*..A*^7J?/[.K1_<1=#;KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HOGR3^,/47RKZ\K>NN
MVMO1Y*C825& W#1"*EW3L_+E-,6:VSEVBE:"52!Y(F#PSH/'/%)&2OL2\J\V
M[WR=N:[ILLNAAAT.8Y5\TD7S'H>(.5(.>BK>-EV_?;,V6X)J4\&&&0^3*?(_
MR/ @C'6N#(GR[_DP=N^2(U':/QCWMG; ,:R+96[$ )\<A JO[M[LCI(/2P#I
M4+!>U=30,L64H/)/OQLM&I9[Q;I\O%C_ ,'BPDG[5K^ MW0\?W_[;[ABMQ82
MM\]+?] 24_)@/,#&R!\;?DWU'\J^NJ+L?J7<,>3HF$5/G]OUAAIMT;.S#JYD
MPFZ,0DTS4\P,;&*0%X9T'EIY)8B'.+7-/*>]\G;HVU;U%H891Q4QRK_'&U!4
M>OFIPP!QU,.S[U8;[9B]V]]2G# X9&_A8>1_D>()&>C ^PUT:]>]^Z]U[W[K
MW7O?NO= :GR5Z*D[QD^-J=DX)^[XL4,S)U^J9$Y-*,XDY_Q&N%#]E]T* ??F
MA^Y^Y%,14&(0D.1 >5>81R^.:3:/^[RVCQL::ZM'"NJFKMU4TZNVM<=%@WG:
MSN?[G$R_4@5\/-:4U>E*TS2M:9I3H<O8?Z,^O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NJX/GE_,;ZR^&F!FV_1?8[[[TR^/:;;?7D%43386.HCO2;BW]4TKAZ
M.A&L/#2ADJ:RVF'QQ^2IAE+VY]KMWY[N1</6WVY&I).1EJ<4A!^)O4_"GXJF
MBD'\T\WV/+</AXEN6';&#P]&?T'\SY>9%37Q<^!W>O\ ,+W^ORN^;.>W+2=>
M9R6EK]O[>J#487-[\P<<AGQ^*VSC8S"<#M?0Q\,T"Q3522--2F\QKC,W-_N+
MR[[9;;_4SV_CC:YCJ))!1UB?@S.V?$F]0:JI&EN&@ /9.5MSYNN_W_S.S"%J
M%4RI=?(*/P1^E,MQ''4=F':.S]K;!VUAMG;)V_B=K;5V]0PXW"8#!T,&.Q>-
MHH%TQP4M)3HBK^69K$LQ+,2Q).*-[>W>XW4E]?RM--*2SNY+,Q/F2>IG@@AM
MH5M[= B(**JB@ 'D .E'[2].]>]^Z]U[W[KW0:=P]2[)[UZTW;U+V+CY<ILS
M>E!#C\W1T]0U)5-'2U])E*.HI*M%8Q305%##/#(HNKQJPY'LUV3>;_E[=8=Y
MVM]$]NVI"149!4@CS!!((\P>D=_8VVYV<EA>+JCD%&'#SJ*'U!%0?7KW4/3_
M %ST/U_@>KNJ=M4VT]D[;2J&,Q%/4UU<XEKZN>OKZRLR.3J:VIJ9YYJEY))I
MYI&):UPH51[>][W3F+<I-WWF4S7$M-3$ <   %4       #KVW[?9[7:)8V*
M".). %3Q-2234DDGB>A+]E72SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[HLO>GPW^,OR2O/W'U!M;=.8\*4Z;J@CK-N;RCAA(:FA_
MO?MFKP^1>*(K=():F2+E@8RK,&%?+W//-G*IIL5])"E:^'4/$2>)\*0,E3ZT
MK\\#HFW3E[9=YSN-NDC<-65>GIK4AORK3JOS-_R*_AKE:^2LH=T=][:IW%EQ
M6$WKLZ>@A.IVU1R;CZYS]439@OKJ6X4?FY,F6WWA^>X(A'+%9S'^)XI Q_YQ
MS(O\N@E-[7\N2OJ1YXQZ*ZD?\;C8_P ^FG_AAGXA?\_'^2/_ *%_6/\ ]I_V
M_P#\$;SO_P HMC_SBN/^VGIK_6KY>_W]<?[W%_UIZ]_PPS\0O^?C_)'_ -"_
MK'_[3_OW_!&\[_\ *+8_\XKC_MIZ]_K5\O?[^N/][B_ZT]>_X89^(7_/Q_DC
M_P"A?UC_ /:?]^_X(WG?_E%L?^<5Q_VT]>_UJ^7O]_7'^]Q?]:>O?\,,_$+_
M )^/\D?_ $+^L?\ [3_OW_!&\[_\HMC_ ,XKC_MIZ]_K5\O?[^N/][B_ZT]>
M_P"&&?B%_P _'^2/_H7]8_\ VG_?O^"-YW_Y1;'_ )Q7'_;3U[_6KY>_W]<?
M[W%_UIZ]_P ,,_$+_GX_R1_]"_K'_P"T_P"_?\$;SO\ \HMC_P XKC_MIZ]_
MK5\O?[^N/][B_P"M/7O^&&?B%_S\?Y(_^A?UC_\ :?\ ?O\ @C>=_P#E%L?^
M<5Q_VT]>_P!:OE[_ ']<?[W%_P!:>O?\,,_$+_GX_P D?_0OZQ_^T_[]_P $
M;SO_ ,HMC_SBN/\ MIZ]_K5\O?[^N/\ >XO^M/7O^&&?B%_S\?Y(_P#H7]8_
M_:?]^_X(WG?_ )1;'_G%<?\ ;3U[_6KY>_W]<?[W%_UIZ]_PPS\0O^?C_)'_
M -"_K'_[3_OW_!&\[_\ *+8_\XKC_MIZ]_K5\O?[^N/][B_ZT]>_X89^(7_/
MQ_DC_P"A?UC_ /:?]^_X(WG?_E%L?^<5Q_VT]>_UJ^7O]_7'^]Q?]:>O?\,,
M_$+_ )^/\D?_ $+^L?\ [3_OW_!&\[_\HMC_ ,XKC_MIZ]_K5\O?[^N/][B_
MZT]>_P"&&?B%_P _'^2/_H7]8_\ VG_?O^"-YW_Y1;'_ )Q7'_;3U[_6KY>_
MW]<?[W%_UIZ]_P ,,_$+_GX_R1_]"_K'_P"T_P"_?\$;SO\ \HMC_P XKC_M
MIZ]_K5\O?[^N/][B_P"M/7O^&&?B%_S\?Y(_^A?UC_\ :?\ ?O\ @C>=_P#E
M%L?^<5Q_VT]>_P!:OE[_ ']<?[W%_P!:>O?\,,_$+_GX_P D?_0OZQ_^T_[]
M_P $;SO_ ,HMC_SBN/\ MIZ]_K5\O?[^N/\ >XO^M/7O^&&?B%_S\?Y(_P#H
M7]8__:?]^_X(WG?_ )1;'_G%<?\ ;3U[_6KY>_W]<?[W%_UIZ]_PPS\0O^?C
M_)'_ -"_K'_[3_OW_!&\[_\ *+8_\XKC_MIZ]_K5\O?[^N/][B_ZT]>_X89^
M(7_/Q_DC_P"A?UC_ /:?]^_X(WG?_E%L?^<5Q_VT]>_UJ^7O]_7'^]Q?]:>O
M?\,,_$+_ )^/\D?_ $+^L?\ [3_OW_!&\[_\HMC_ ,XKC_MIZ]_K5\O?[^N/
M][B_ZT]>_P"&&?B%_P _'^2/_H7]8_\ VG_?O^"-YW_Y1;'_ )Q7'_;3U[_6
MKY>_W]<?[W%_UIZ]_P ,,_$+_GX_R1_]"_K'_P"T_P"_?\$;SO\ \HMC_P X
MKC_MIZ]_K5\O?[^N/][B_P"M/7O^&&?B%_S\?Y(_^A?UC_\ :?\ ?O\ @C>=
M_P#E%L?^<5Q_VT]>_P!:OE[_ ']<?[W%_P!:>O?\,,_$+_GX_P D?_0OZQ_^
MT_[]_P $;SO_ ,HMC_SBN/\ MIZ]_K5\O?[^N/\ >XO^M/7O^&&?B%_S\?Y(
M_P#H7]8__:?]^_X(WG?_ )1;'_G%<?\ ;3U[_6KY>_W]<?[W%_UIZ]_PPS\0
MO^?C_)'_ -"_K'_[3_OW_!&\[_\ *+8_\XKC_MIZ]_K5\O?[^N/][B_ZT]>_
MX89^(7_/Q_DC_P"A?UC_ /:?]^_X(WG?_E%L?^<5Q_VT]>_UJ^7O]_7'^]Q?
M]:>O?\,,_$+_ )^/\D?_ $+^L?\ [3_OW_!&\[_\HMC_ ,XKC_MIZ]_K5\O?
M[^N/][B_ZT]>_P"&&?B%_P _'^2/_H7]8_\ VG_?O^"-YW_Y1;'_ )Q7'_;3
MU[_6KY>_W]<?[W%_UIZ]_P ,,_$+_GX_R1_]"_K'_P"T_P"_?\$;SO\ \HMC
M_P XKC_MIZ]_K5\O?[^N/][B_P"M/7O^&&?B%_S\?Y(_^A?UC_\ :?\ ?O\
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MF6HFS>PR75LAD-HT*13_ ,1V[,C2#)8:H6<00EUT3T#/%293\@>Z.U<X;?\
MU']QE20R@)'-)0++_")6J-,HQHD%*FF0^6ASF7DZ]V2Z_K#RJ630=31KQ3U*
M#S0_B0UI\UP+&_Y>_P#,BV/\QMOP[1W4N,V3W_@L;Y]P;2B=J?"[MIJ<Z)]R
M[":LJ:B62&Q5ZK'R2//2ECZIX0)S%_N9[6;CR+=&]M-5QMLC427BT9/".:@
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M;9IOI]VM9;9_X98V0_EJ KT,;6^LKZ/Q;*5)E]48,/Y$]"#[+>E75+_\R?\
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M;[FV+OBA,]UQN^<9E]AY>"E>^E(ZK%+O*EJ9$) 9G-$&%V"@V0RSLWWC]EF
M3?K"6W:GQ0LLRD_8WA$#_>O\O0*O_:F^0ZMMN4D%>$@*$#[5U@G\AUL(_%+J
MO=?2'QQZ=ZDWOF:#/;JV!LG&;<S&2Q,U148IIZ+R^&CQ=15T.-EDIJ6)XZ6"
M22")F2%2R@D^\9N<=XL]_P":+[>K"-HX;F9I%5J!J-YL 6 ).2 2 3QZEO8[
M&?;=HMK"Y8,\,:J2.%0/*H&!P&!CHP?L-=&O7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW43(9"@Q-#5Y
M/*5U'C<;04\M779#(5,-'0T5+ ADGJ:NKJ'CCCC15+.[LH %R;>[QQR32"*)
M2S,0  "22>  '$]:9E12S&@&23P'5:G;O\W?X0]35E7BX.P\IVIEZ%M%11=1
M8,[IHRVD,OVFZLC6X#!U(-_U4N4F /#$'W*VR>RGN#O2+*;5;-&X-<OX9_.,
M!Y!^:#H&;AS_ ,L;>2GCF=AY1#7^QL(?]ZZ+.?Y]OQEN=/4?>Q%S8F@Z_!(_
M!(&^VM_K7/L6?\#AS=_RFV?^]3?]:>B7_75V+_?$_P#O,?\ ULZZ_P"'[?C-
M_P ^B[U_\X=@?_9U[]_P.'-W_*;9_P"]3?\ 6GKW^NKL7^^)_P#>8_\ K9U[
M_A^WXS?\^B[U_P#.'8'_ -G7OW_ X<W?\IMG_O4W_6GKW^NKL7^^)_\ >8_^
MMG7O^'[?C-_SZ+O7_P X=@?_ &=>_?\  X<W?\IMG_O4W_6GKW^NKL7^^)_]
MYC_ZV=>_X?M^,W_/HN]?_.'8'_V=>_?\#AS=_P IMG_O4W_6GKW^NKL7^^)_
M]YC_ .MG7O\ A^WXS?\ /HN]?_.'8'_V=>_?\#AS=_RFV?\ O4W_ %IZ]_KJ
M[%_OB?\ WF/_ *V=>_X?M^,W_/HN]?\ SAV!_P#9U[]_P.'-W_*;9_[U-_UI
MZ]_KJ[%_OB?_ 'F/_K9U[_A^WXS?\^B[U_\ .'8'_P!G7OW_  .'-W_*;9_[
MU-_UIZ]_KJ[%_OB?_>8_^MG7O^'[?C-_SZ+O7_SAV!_]G7OW_ X<W?\ *;9_
M[U-_UIZ]_KJ[%_OB?_>8_P#K9U[_ (?M^,W_ #Z+O7_SAV!_]G7OW_ X<W?\
MIMG_ +U-_P!:>O?ZZNQ?[XG_ -YC_P"MG7O^'[?C-_SZ+O7_ ,X=@?\ V=>_
M?\#AS=_RFV?^]3?]:>O?ZZNQ?[XG_P!YC_ZV=>_X?M^,W_/HN]?_ #AV!_\
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M7O\ A^WXS?\ /HN]?_.'8'_V=>_?\#AS=_RFV?\ O4W_ %IZ]_KJ[%_OB?\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@M[8[MZDZ*VZ=U]O\
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M?\#AS=_RFV?^]3?]:>O?ZZNQ?[XG_P!YC_ZV=>_X?M^,W_/HN]?_ #AV!_\
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M7O\ A^WXS?\ /HN]?_.'8'_V=>_?\#AS=_RFV?\ O4W_ %IZ]_KJ[%_OB?\
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MYH:W9^[:F81K*\&+P^XZ?'G(,JM=CC6K%%C=O2UHUYC]N><N5$,^\63K"/\
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MOO+>&=^,NTLOLCIVL3"#;>W\UY4JH*J#!X^#.U,5+49+,200S5L<\L4+U4Q
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MG\^;_LD+KC_Q9':'_OL>X/<_?=R_Y7>Z_P">&7_M(MNHT]U/^5>A_P">A/\
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M)).0YKF]E+:+J:K.Q-%$<).23@9/1?[E0*.9(X;= -4*4"@"I+R#@//HU'R
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MO2[5[16V^W[%Q;6]Q*Q9NYO#EF(74:Y- HXYH!TQS18&]YXEVVV&DRR1(*#
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M=1) TBI'F.@!)L&Y6UK%?7\9@AED$89Q0YJ2VDT-  <F@/EU>?\ .WN'M_\
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M/(5*QZW]/N+;?WYY GNUMF>>)&-!,\)$7VX9FIGS7'G0=#&7VVYECA,JB)V
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MWEZVY;?E6VMD2T>,QD:5))*T\1C3+_BU'-<BG0%??]TEW9=ZFE9IE8,#4@
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M[\3252P\:J>;L?((!<A0VD&P'N#/8E9MMO\ F/EG7K@L+I53)(J7N(V85]1
MO4B>X[1W=MM6[:=,ES"Q;%#2D3J#]AD/0J?S6.[NR]D?&#X4]3[1W+7;<VAV
M7TQC,IOF'#SU-!D-QQ[9VCU_2XK"Y&OIIXV?'@YV>6:C(T2R"-I-0C4 E]F>
M7MIW'FS?=YOHA+-:7)6'4 RH9))BSA2/B[  WD*TX]&7/^Z7MIL^WV%LY2.>
M*KTJ"VE8Z*2/+N-1Y]!W_+EW=F]Z_P OO^99U;N2NJ\KM/KWIW)[TVK0UM3)
M518?)Y[KOM/(U,6/BJ?*((15==T54(X]*^5I) %=F8FWNE86UA[F<J;Q:J$F
MNKI8I" !J"3VX!8CB:3,*GRH. Z0<G74MSRCO-C,2R0PLZ@FM"T<I(%> K&#
M]I/5$GO(OJ*^O>_=>Z$O8G_'K=T?^(TQ7_OXNI_9/N?^YNW?\]#?]HMSTOL_
M]Q[K_FD/^K\/0:>SCI!U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U;C_,WZ.ZEZ=ZU^#E?UEL3![.KM^]*U&9
MWG68F.<56Y<M!@.M9H\CEYZB>H:6;7E:ES(QN3,Q))/N$?:'F'>M]W3F!-WN
M7G6WN@L08XC4O/55   ':,#&!U(G/6U[?MMIMAL8EB,D1+D#+$+%0L?,Y.?G
MT73L[8GPMQ7Q ZDWCUSV=NC-?*C,9>AC[(V+5FIFP^*H)(=P_P ;O32[:Q45
M,E-+2T*TLJ5M4TJR_ID5S+$*-GW+G^;GF]L=UM(X]G16\"44#,:IHH0[%BP+
M:@5%/E2A)[^TY9CY<M[FRG9KYB/$2I('Q:JC2* &E#4U^=:]$9]R-T$^O>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z%WH/#=4[A[EZYPG>.X<CM3J7
M)[FHJ7?6X<49$KL7A)!)Y)XI8L9F613((TDD%-+H1F>PMJ!%S-<;U:[!=7'+
ML2S7J1DPHW!FQY:EKBI J*F@SPZ,MGBV^;<X8MU<QV[, [#B!]M#3-*FF!Z<
M>E7\JMN]![4[RWA@OC+NW+[WZ=HTPAVWN#->5ZJ>JGP>/GSM-%55&-P\D\,-
M;)/%%,]+"2%L/(JB61'R9=<RWO+L%QS;"MO?-KUHM *!B$) + $K0D5/Y< H
MY@AVFWW62+9)#);C3I)SF@U &@J ?.G^<EW]BGHEZ][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KZ)G5G_,L>N/_  P]H?\ O/X[WR^W7_DJ7/\ S5D_X^>LP+3_
M '%B_P!(O^ =+SV@Z4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW5)G\^;_LD+KC_Q9':'_OL>X/<_?=R_Y7>Z_P">&7_M(MNHT]U/
M^5>A_P">A/\ JU-UJ5>\TNH"Z][]U[JX[^5=V?UKUYUK\[Z#?_8>QMC5V[^D
MJ/$[2H]X;MP&V:O=&47 =G0MC=NT^:R%$];4!Z^!##3"5[SQBUW6\$^\NT;M
MNFY\O2;9:S7"P73-(8HWD$:Z[<ZG**=([3DT&#Z=23R!?6-G:[FMY,D1DB4*
M'=5U&DN%U$5.1P]1UU_)O[0ZTZO[,[^K>R^P]C]>46:Z0K,7AZW?.Z\%M.CR
MN4_C^-E&,QU7GZ_'QS5!0%Q!&S.54D*0"1[WUV?=MWVO;$VFUFNFCNM3"&-Y
M"JZ#W,$#$#YG'6O;B_L;&[NVO9DA#1  NZH":\ 6(J?EU3E[G;J-^K?OYT7:
M77?:'RJZ]W1U3V'L[L'"XWH/:6+FW#L#=>&W3C*#.4G8O:62DQTN5V]7UT45
M7%#D::=H3(LB+-&Q #*3"'L-L^Y[1R==6>\VLMM(]Y(P2:-HV9#!;KJTN 2I
M*D5I0T(ZD+W(O[2]WZ&>PF255@0:HW# ,))32JDY%0?7(Z-UWCAOCW_->ZPZ
M=[7P/R$ZNZ0^16PMK0[1['V?VCFJ'#+54[2I65L"&IFH*B6EIJ^IJ:O&9"B@
MJ8)(\B\,ZP5 9(@+R_<\S>S&[WVS76V3[AMES)XD,L"LV>"G 8 E0 Z,0P*@
M@E<D2[E#M'/]E;WT-W';7<2Z9$D(X<2,T) -2K#!J0:'@Z]0;@^$_P :?B-\
MU_CML+Y';-["[.S_ $+V'7[KWQ6;AP>W]I[\WGG.M]X[=VYL/I^&NRH_C#4C
M*01CVKGDDR$?[KF188&MZMN?^;.=]AYHW+:I;6TCO(%CB".\D,23Q.\MR0O9
M6O%M(HIP*$FUA+RSLO+NY;/:7J33-!(6<LJK([1NJI%4]U*<%J<\?($__DW]
MH=:=7]F=_5O9?8>Q^O*+-=(5F+P];OG=>"VG1Y7*?Q_&RC&8ZKS]?CXYJ@H"
MX@C9G*J2%(!(''OKL^[;OM>V)M-K-=-'=:F$,;R%5T'N8(&('S..@][<7]C8
MW=VU[,D(:( %W5 37@"Q%3\ND9_*Y^4W5/3.=[EZ/^0-5+CNE?DKLY-H;@ST
MKSR8W;N2BQ^X,+_N4@B28P4>2H=TUE+55D<;F.2*E,J^!7DA7^\')^\[[;6/
M,/+2ZK_:I/$1 !J=24?M.*LC1@JOF"U.Z@*7D7?;#;I;C:]V-+:\722?A4T8
M9'D&#$$_(5QD"I-_+)^,.RMP3[V[)_F!=)OT#2U9R5')M+-X')]E[EP,BRUU
M#B,;1T65RT!K9J:.ZS4-/E"^EGCI"/2I,ONYS=N%L-NVKEJZ_>1&D^(KB"-Q
M169JJIT@^3,M, MT8GD;8[67ZN]W6+Z2M1I*^(R\0 =1%2/, U\ATX?RW.Z?
MCO@8OFK\<J[L0])XOY#8[*X/IKMG=%72XBHQV&6DWSMW T.X,]+-0)35U-3[
MGIJRG66IACED-2B2Q2F/R->ZFP<TW)V#FE;7]X/MA5KJVC!8%ZQ2.40!JJQ0
MJU :#22"*TOR9N6S1?O/9O&^F6[U"&5CI.FCJH+&E" P(J<DG@>*W^*'QB^/
M7PE^1/7O:_?GS*Z,S^?Q^XZO&=:;1ZIW;0YBCF.YJ/);53>79VX,PN,APN+I
M*7)5,\ZR%(_+$ E;,8S!.7\Y\X<S^X'+%SLW+6Q7<<3H&GEGC*D>&5D\*!%U
M%W)4 >=#E!74JG8=AVCEC>(K_=MQA9U8B-(V%.X,NN1FII !/RK^(\#6Y\J>
MQMNCYY=L]J;6RF)WCMJA[]J=Y8?*[?R='E<-N''XG<=+DXIL5EZ":>">&<4E
MHYHI&1@=2L1S[E3D[:;IO;:SV6\1K>9[,Q,KJ59"Z,O<I ((KP(KT#=_OH!S
M;-N$#"6-9PX*D$,%(.",'AU:K_,"Z0Z"^8N:E^8G7?S"Z/V[M:EZ=IUS&T]P
M9NA.\:K-[6ILS7XO$TF%?.TD\5?7"OI,=_#:B"":.< JLS2JGN'/;3F+F3D6
M#^H^Y;'=2SM<DK(BD1A9-"LQ;005727U@D$>@%>AWS9M.U<QR?UBM=QACC6$
M J2"U5U$"FH4)J%TD5!]:TZ++M'M#K2G_DS=H]6U'8>QZ?LVN[OQ^4H>NI]U
MX*'?5=BTWEUW6/DZ+:4M>E?-3B*CFD,\=.R!89"6LC6%UYL^[-[\6F\+:S&T
M6U*F<1N80W@S#29*:0:D"A-:D>O1'#?V(]MIK S()S*"(]:ZR/%0U"5K2F:T
MZS?R\/D/T1F>@N\?@E\GMV1[!V#W#52[@V/V!EI1_ ]M[JGI\*&@KJRI0P4'
MVM9M?&YB@EJY(J1IX)UF>-Y4\NO=#ECF.WYEV_W%Y1@-S<V("2PJ.]T!;( R
M^I9&C8+5@I6@(!I[D_>-JEVFYY6WR3PHK@EDD8]JL0,5.%H5#*3BM:T/%<]=
M_P NOXX=&=@8#MSO?YS_ !ZW#U-L3.8[=D&#VAF:+(;FW[_ ZA,Q183^#4F:
MR<VFI%(#-3XU<I/)'JCB +"12S=/=+FKF/;9=CY=Y>O(KRY1HR\BL$AUC06U
M%%&*X+Z #D^G2VSY-V?:+M-RW3<X6@B8. I&IRO<!34>-."ZB> ]>B6?+[Y7
MT7RO^9%)W%!3RX+8F'S.R]K;+AR_CIJVBV1MC,BK7(YHK-+''+4U-?6U\J!B
ML*U BU-XR[#[DKDN7DWD)]C8^)<R)-)+IR#+(E-*8J0 JK\R*^=.@SOV_IOO
M,Z;B.V%&C5*X(16K5OM))^0-.AI_G*=C=>]H?+3#;DZTWYLSL3;L736SL7+G
MMB[HPF[<+'DZ7<6]IZG'293 5V0@$\:5<3O"9-:K(A( 87)/8G:]SVCDN2UW
M:VEM93=2L$FC>-M)CB ;2X4T)!S2F#TO]Q[RSOM^2:RE29!"@U(RN*AGJ*J2
M*YX=//3G9O6^+_DX?*_J[)[_ -E8[LS<??\ MO,[>Z\KMT82DWQG</#G/C9-
M-E<-M2>NCKJJF1-OU[//# Z**.8EAXGLQONT[K-[Y[-O$5M*UI%9NKS"-S$C
M%+X!6D T@]ZX)KW#U'5]NO;-/;J_L7E03O.I6,LH=AJM\A:U([3D#R/IU4)[
MF[J/NK#/CY\->I/DAU!39O ?+'J?J[O2AS>X*+-]6=RY2':F)K\53_;38#*X
M'/DFH96B,AJOMZ+)@$\F$Q,KQ=S/S[OG*F^M;W6RW%WMK*A2XME,C*QJ'5T^
M&M?A!9/SK4#+9^6MNWK;A+!?QPW8+!HI2%! ^$J>/#C0-^5*='3[PW=UE\3_
M .7'N_X7Y+Y#;+^1?;_9&]L1FZ+$]?Y>7=>T.IL%29S96Y:ZAI,RKN(($DVQ
M)-3PS&CEEJ<L\R48C6H=P#R[9;MSI[IP<^0[7+M=C:Q,I:9?#DN'*2QABM!4
MG6 Q&H!4H7J5'0EW6>RY?Y.DY;DO$O+F9@0J'4L0#(Q%:X TU%:$EJA:5ZD8
M+=/Q\_F-_$;I#I3L?O#:_0GR6^->-CVIM'*]DY*EH-J[WV_-18G! )DLI4T(
MJ)*VBVQCC4)#4&JBJZ77X9H9036YM.9_:OG;<-_VO;Y-QVG=6,DBP*2\3U9\
MA0VG2TC4J-)4TJ",;BGV?G/E^UVV\NEM;VS 53(11Q0+Q)%=045H:AAP(XE@
M["_EY=5],[#WSO#LSYS?'BMSF$VCNC+['Z^ZPR8WUN??FXZ3'Y'^Z6"$"5^/
MGHHJVLCIH:BK%%5Q0AY SA$,X%^U>Z&\[_N5O8[1R]>+')+&LLTX\*.%"R^*
M]=)#%5U$#4I-!BIT]$E[R;8;9:RW%]ND!=4<I'&=32, = XU%32IH0,Y\^A%
M_DW]H=:=7]F=_5O9?8>Q^O*+-=(5F+P];OG=>"VG1Y7*?Q_&RC&8ZKS]?CXY
MJ@H"X@C9G*J2%(!(*_?79]VW?:]L3:;6:Z:.ZU,(8WD*KH/<P0,0/F<=*_;B
M_L;&[NVO9DA#1  NZH":\ 6(J?ET6S^6]\L<1\0?DCCM][NCKY>O-U;=R6P]
M^G')-556-P^4K,;E*/<%-C8@QJ'HJW#T[O&JF0P/.L5W8*PL]U>3)^=^56V^
MQT_50.LT.J@#,H92A8\-2L<\-06N,@DY,W^+E[>1<W-?!D4H]*F@)!#4'&A'
MVT)IT:_?W\L?I'>NY\QO;H'YR_&&GZ?S.1J\MC*3?._,=C\_M#%3PR5TV(K!
M0S3)*U&SK&!5+CI!"0TJJZV<$[;[N\P;=:1[=S+R]?&^C4*QBB8K*P- P#"H
MU<<:@3PP<"*[Y&VR[G>[VG<[<6S$D!F%4'$BH-,?.F./#))>P<3L+X:_)#J3
M/=&]X;>^1E1UM/L?L;.[KVK22X/:C;VP^\,ED:S8N.KZ;(YM*NC-!C*%:BL@
MJ)XY172H54J\*2%MDVY<^<J7UMS#M[[6+L2P)'(=<@B:)5$S*52C:V8A2 1I
M!]"0M>1VG+6]6\NUW2WG@Z)&=.U2X<DH""U1I J:FM3]G5JGR6^/_P 8OYD&
M[<5\G^D/E5U/U7N?=6!V[0=J;![:RV/P>=QN4Q.+IL3C*RHQYR,-1%514>/2
M@D 2>DJ/L5DIJHKK)AKE3F?F[VJLGY2YAV>XO(87<V\UNK,A5F+, VD@J6;4
M.#+J(9:TZ'N\[-LG.DZ[WM=]' [JHE22@8$"@)%00:"GF#04/54?R]ZH^-72
M]?U[L3H7N9^^-S4.%RU5V_O[%"C_ +AS9ZJJZ/\ @6+V2U ]7$T,$$4YJ&CK
M<@"9$/GU:H89GY'WGFW?DNMQYDL/W="S*+:%J^,$ ;6TNJAJ32E57@>VF2 >
M8K#9-M,-KM-S]5( QFD%-%332$I4>OF?M\A;WW]U[T1_,>Z7^+W8VV?E9TKT
MYG.JNLH]K=G;=[(W!C\?DL&QQ>WY<DDN.K,WC)HC05&&KO%)+&L-7%*LB5"K
M'ZH.Y9W/F+VJW[=]JN]FNKY+R?7 \*,5>C.%((1@=8=:@&JD4*U.)$W>RVOG
M3;;*]@OHK<V\=)%<BJU"UJ"PII*GC@C-<=%9_E!]C=6=0]O_ "/'8':&P]GX
M>NZ?R^!V[G]Y;HP>SL;N6LI]ST/V\6(GW!D:-)9IHH_,E/'(\FBY (4GV,O>
M[:]YWS9=I.VV<T\BW >1(HWE:,&/.K0IH <5( KT1>WMYM^VW]\MW<1QJ8]*
ML[*@>C'AJ(X\:=!Q_*[^5?5G2.Y.W.F/D#4/2='?)#:*;0W/E9UJZK%X')1T
M6<P\;Y6EHX*F2*BR-%N>LHJRJB4^-A3O,/!&TD1M[O\ )N\<P6MEO_+(U;AM
M4AD110,ZU1^TDBK(T895\ZL!W$ H.1=^L=LFN-MW8TM;Q=+$U*J:%<C.&#$$
M^6*XR!;'\K3X_8W<J[IS'\P?X\/T/%5KDFS--NC;7]]JS;[5 >#&PT\>Y)J
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MKPM,\<;NL2^-9G5(R@A11&-6H**?0],<G7MG:['O<-S*D;RP41695+GPYQ1
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M+Q.37-2<D*6(V3=N<+9;&V,=M*ZZHF-16A+ 9/;7@.'E0#'37\W.L]A;!_F
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M6XH&98@9,)7@0(7)H0S'2H*YJ7\K;7M$6R7?-&\Q^.ENVA(JD O1?BIQJ9%
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5X_\X+_F57\N[_Q
M5;_[SG4WO'CV,_Y*W,W_ #UK_P ?N>I3]Q_]P]I_YHM_QV+KWRU_[<\?!'_Q
M(,W_ +KNVO?N2/\ I^/,?_-$_P#'[?KW,?\ T[S:O].O_')>E!_-.P>4[#^'
M_P#+U[PVI!6Y7K_#]4P;;SU9%&9H=N9C<VT.MGQ<.3-*]3%#))-M>OHJABX5
M9Z1(M3,RCVF]G+B':N=N9>7;TA+E[@N@X:UBEG#::T)Q(K#'PDG%.G>?8I+W
ME_:MUMP3"L=&_HETC*UI4#X2#\Z#JD3&[$WIF-J;DWWB]K9ZOV7L^?%TNZ-U
MTV,JY-O8&LS=5'18>BR>76+P13U,L@6"%GUOR0I4$C(*;<]O@O8MMFF1;B<,
M8XRPUN$!+%5XD #)X=1@EG=2VSWD<;&*.@9Z'2I8@ $\*FO#CULP?*WY2;OZ
MH^&WPA[EZQZ1Z-[DZ_S?5V&V[NK+]P];U^_4Z_S5/M395'B,71U>(W-AHJ U
M-3C\I1UBR%U:?'1QJVJP.)G)G)VW[USSO^P;Q?W5C=1SL\:VTRP^,OB2EV(>
M-BU 49:4[6)X=3;O^_7>W\O;=N>WVT,\+Q@.98R_ADJFD=K "I!!^8 ZKDPW
M\W_OO$09VDV'\>?B-LNOSF"R>-R.3V'T_NO"YD8D4DU56R&:A['=7CIT@:I(
MGCEB3Q:W4JI]RI/['<LS-&^X;GN,RQNI42W,3+J)  S!Q)-,$$UH.@9'[B[P
MH9;:TM4+*02D3@TI4\)/("N<8KT*W\C7_F:OR1_\0%6?^]'C/9+]X;_DD[3_
M ,]?_/AZ,/:[_<R]_P":(_X]U1Q[R'ZBSJ[G^>[35%9\QNL:2D@FJJNJ^.FR
MZ:EI::)YZBIJ)^TNWXH8((8E9G=V8*JJ"22 !?WC_P#=U=(^1;N20A56]E))
M-  +>V)))\NI,]TE9^8X$0$DVZ  9))EEH .D#TG_,\WAA-O8CX[_,7I[;GR
M1ZIPT])M*IH-Y;?A?M/:U-CITQAIXGRL$D==6T'VZK"E5%2UWEA4&O1P&5?S
M![16-Q</S1R+?/M5Y(#*#$_^+R%AJKVD%5:N2I9*'"4Z8VSGBYCB79N8[9;R
M!2$(=?U5H:9!'<13%:-4?%7H:>Q/BYUS\5/YM/Q5VIU1]W1;'WQGNN.Q,7MK
M(5M575FTY,EN?<6!K,*D^2DEK&IO)MTU%.U6SR@3-$S,8M1(-MYOW7G'V5WF
M\WFC7%NLT+2  "0*D;AB%HNKOH=., ^?1G<['9;%[@6$-AB*4K(%)J4)+J1G
M-.VHK\QY=%1_F%_]O/>T/_$H=5?^\EU_[&?MI_TZ"U_YY[G_ *N3]$/-?_*^
M2_\ -6'_ (['T+_\\[_LL[!?^(,V1_[T^_?9-]WG_E1)?^>N7_JW#TM]T?\
ME8T_YH)_Q^3I^Z-_[<;?,G_Q9':__O0?%7VGYA_\2$V+_GAD_P".;ATYM?\
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MZ][]U[KWOW7NO>_=>Z][]U[JDS^?-_V2%UQ_XLCM#_WV/<'N?ONY?\KO=?\
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MC_Q9':'_ +['N#W/WW<O^5WNO^>&7_M(MNHT]U/^5>A_YZ$_ZM3=:E7O-+J
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$O8G_'K=T?\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO="7L3_CUNZ/_ !&F*_\
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MMX878.<W+VO\@>I.HM[?PO=VX=B]6[KJ(X=T[QVWMA:XT^7JH*K,8R>A^^%
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M546!(Z6*>6;VDW39?<SW3F@VWF2S39]KBD$DE'#2R%12@&HDFC'35549)+$
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M<'P8C0*I]99>WA^%#Y]0QSW=3;_S!;<JV)PC#61D:W%22,? E3Q\V'EU8O\
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M)WL]M'[X]PMO1AV6[&X;Y>"I=/\ C>@?GT$N>;[Z'EBZ8?%(HB'_ #<.EO\
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MK:!D*O&8^:;&8F,ZD_<K*D0TD0U+=YE%Q>_LWV#:)]_WNTV6W^.ZE2.OH&8
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M>GJJ6HA<%721)&1U((()!]WCD>)UEC)5E(((P01D$'K3*K*585!P1ZCK6(^
ME?5?!S^9GVY\4=P5,U)LSLK(9#9NWYJMW*U4]#]QO3I?,U<\J0EY:K%92;'V
M17!J<II#%5+>\M/<F-/<'VFL><[8:I[0+)(!Y:J172@"N ZAO]*M>H5Y49N6
M.=;G8)<13DJOY5>$DFG%21_ICUM ^\2.IKZ][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+5\R
M]N-NWXE?);;\<:35-=T;V>]#%)XPCY*BV=E\AC%9Y2%7_**6+UDC3^K\>Q5R
M-="RYSVJZ8T5+NWU?Z4RJ&X?(GHGYAA-QL-["HJ6@E ^W0:?SZK'_D*[B:M^
M,_;&V))FD; ]W5F5B1W9S3TNXMC[/A2*,-,P6,RX"9PJH@UN[78L=,M?>.MA
M'S;9W0%/$M%4_,I-+\N-& ^RG0)]JY2VQSQ$UTSD_8&1/\H/5YOO'OJ3NM7*
M<M_,&_G#QQIJR_4_1>9$;/ZI*,[*Z3KGDD/^?=9*;,[KK2BE/&6I\D&*W5KY
M=*/];3V-)/9>[DOY^)=#[,%(!YUHR_/J$S_R*_<6@[H+,_\ &83_ ,_2'_>3
MUM&^\1>ILZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[K70_G>]-YW9F[.C_F9U^U3CL[MK+XC9>X<M00.TF(SFWLC4
M[PZSW-(R*Z*R315M,\\H4:HZ.*[%E490?=_WRWO[/<>0]SHT4Z-*BD_$KJ(I
MX_7(*D >6L^O40^YFW2VTUKS)9U#Q,J,0.!4EXV_(U%3_1'IU>5\>>X\'\@N
MDNL^Y-OF%:'?VU,;FJBDA<NN)S?C-)N/!.Q9[O09"FJ:-S=KM 2"18G'OF78
M[CEK?[O8KKXK:1DK_$O%''R92&'R/4G;5N$6Z[;#N,/PRH&IZ'\2_:#4'[.A
ME]D?1AU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=,VXL1%N#;^=P,Q AS>&R>(E)+J!%DJ*>BD):,A
MAQ,>5(/]/;UO,;>XCN%XHRM_O)!_R=4D021M&># C]HIUKI_R!\Q6XS,_*K8
M.2#P5$"]89A:"32'HZW&5>_\+FP0D378M44B->2R^(:5.IB,H?O(PQ30[-N4
M.0WU"ZO52(73_GX\//J(/:EY(WO[.3!4Q&GH1XBM_@'5POSR[_7XU?%;MCLR
MDK%I-T?P)]J["MI,S[XW:3A<#4T\;E0YH34R9.5"1>*BD^IL#!WMURV>:^<;
M+:'75"7\2;_FE'WN"?+4!I'S8=2%S1NW[EV.XOE-'"Z4_P!.W:O[":GY ]5X
M?R,>@7V;T=O7O_.TDBY[N;<)P^W)Z@%G&P]D5%51M60M)&C*:[,5%>LPNRNN
M/IW!^H]R?]X7F07_ #%!RW;-^E8)J<#_ ']* :8_A0+3T+,.@E[8;2;7:I-U
ME'?=-1?^::5 /YL6^T =7G^\>NI-Z3&\MZ;2Z\VSE]Y[ZW)A=H[4P-(];F-P
M;@R%-B\5CZ9+#745=5)&H+,0D: EG9@B!F8 J[&QO-RNTL=OB:::0T5$4LS'
MY =,W%Q!:PM<7+B.-!4LQ  'S)ZUX?DW_-?[<^0&\4^/G\OC;.Z*NMS52^./
M8]#@Y)M[;A2-PM3+LO$5D3IA\<$NTV6R*1SI&?):@*>1LFN4_9K9.6K#^LWN
M=-&J1BO@%Z1)Z"5ER[>B(2"<=]:=1)O7/>X;M<_NCE!&9FQX@7N/KH!^%?5F
MI3^CQZNW^)>U^\]G] ;!PGR3W6F\NZ(J?+56\LQ'5TM>D;UV=R57A<2:ZBHJ
M"*:2BQTM)35$L:,K312%9)EM*\!<YW?+U[S)<W'*L)@L"5$2$$'"*&:A9B S
M!F )P",#@)*V*'=+?:HHMYD$MR =;"E,L2!@#@* XXCSX]&.]A?HWZ][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z ?Y.='8?Y(="]G=+YDT\2[VVQ
M64>'R%3&98\+NFC*9/:>=*+ZB*/)45-4.JE2Z1LEP&/L1<I\P7'*W,=IOUO4
MFWD!91C5&>V1/]LA(^5:]%>];9'O&US[;+PE4@'T;BK?DP!ZI._DD][Y?9^X
M>W?A1V09\5N/;&=SNZ]GXK('3/C\QA:P8#L_:%W_ $R03TE/710+^172?@WG
MSW^Y=@O;:QY_VJCQ3HD<K#@RLNNWD_,$J3_I!U&_MKNDMO)<<LWO;)$S,@/D
M0=,J?D:'\VZV*?>,/4N=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:SO\K]SU]_-$^8'6C!:
M:BFA[SQ%+3,(HFDJ]I]U8-L6T T4H9/LC5.HBB%U8.%" VRN]VU7<?:'8MV'
M<P^D)/'$EJVJO'.H#B?EQZAGDEC:\\;E9<%/C8_TLPT_R)ZF?SCNQMP=_?(W
MH?X0=;2O7Y"BS.$R6X*.!7GICO\ [#>'%;8CR<<(D9%Q&'J9:Z672JI!EY'<
MV0E:>QNUVW+7*^Y>X6ZC2I1U0G!\&'NDTUQWN H'FR #CFWN'=S;MO%IRO9&
MIU*S 9&M\+6G\*DL?DU>MAGJSKK;_476VQ>K]J0F';NP-J8/:>(#"TLM)A,?
M!0K5U)+.6FG,)FG<EBTDC,222?>,N[[G<[UNEQN]X:RW,CR-]KL6('R%:#T'
M4MV5I#86D5E;BB1*J+]BBG13OF)_,)Z'^'6)GH]TY0;P[1J:$U.!ZHVS5T\F
MX*@RBU)6;CJCYHL10LQO]Q5 R2(KFF@J&1D SY']L^8^>9P]DG@6@-'N) 0@
MIQ"#B[?)< TU%0:]$/,/-FU<NQTN6US$56)2-1]"W\(^9^= 3CJC?;?6OSI_
MG [SH=X]DY>HZM^->.RTL^+E6BK:+8F,BI]=.\>PMJS54$VXLK:22*7+5<S1
MQEIH_NH0J49R"NMU]O/9"Q:QVE!>[LR@-D&4DY_6D (B3S"**GM.D_'U&4-E
MS1[A7 N;UC;V(-1@A/\ :+Q=OZ1P,T(^'K88^,'Q!Z/^(^SQM;J3;"TU?604
MZ;GWOF6AR.]=WU, %JC.9D00 1AKM'1TL=-2Q$DQPJS,S8S<V\[<P<ZWWUN]
MS:E4GPXE[8H@?)%J?S8DL?,GJ6MDV#;-@MOI]O2A--3G+N1YL?\ (* >0Z,]
M["71UU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:S
M/\TWKC=/P^^7G47SRZCI!34FZ-QT,NYH8PT./_TBX"@:FRN*R+H3XZ;=.WTG
M@F6)-;-39"9F$DJGWEA[/[I9\\<DWWMQO35:)#X9XGP7:JLOJ89:$5-.Y!2@
MZAGGFTGY>Y@MN;+ 8=@''EK44(/RD2HP/)CQ/6Q#U'VAM7NKK+8_:^R:L5NU
M]^[<QVXL5)J1IJ=*V$&JQM:(RP2IHYUEI*J+ZQS0NAY4^\8MZVF\V'=KC9MP
M73-;.R,/(T.&'R84(/F"#U+=C>P;C9Q7UL:QRJ&'V'R/S' CR/0B^RSI7U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=:M_]_L#\:/YV'<6ZMT5)QFSX*/LK=&ZZE?+K3$93X\S]KR&
M*GCDJ#-)+4TT*QQW]3NI55;2@RZ_=ESS5[ V-I:#7/JA2,8RPO?IAG%*!CGT
M'Y]0E]9%L_N9<S3&D>EV<^B_3^*<>>1TY_RML._>WRD^0O\ ,%[NKL=@]N[$
MJMQ9BGS>X\K#38' [MWU'6K(@S&1>FB6DV]MYI*)/*(UC2LI&724 #?O!.O+
MG*&U^V>P*TDMP$4HBDN\<1%.U:G5++W8K4JWKU?D:,[KOEYS=N1")&6(+$:5
M9^/<:81,9\B.A6^6/\W?>/8^Y4Z"^ 6 S>Y]RYZLFP3=G4NW:K*9O+3R!XG@
MZOVO-3R.H !9LOD(/2@=HJ>,*E6";DSV4L=KM#S+[E2+!#& _P!.7"JH];B0
M'_JFAJ30%N*]+M^Y_N+R?]T\I(9)&.GQ M2?^:2_\_,*#R%.[I7?#K^3K$F5
M@[K^;^4J>R.PLK6+GVZQK,S/G\7#DY9#4M7=F[G>KJI,Y6,^EI:.*8TEU99Y
M:Y)"B(N>/?%FA.P>WZ"TM4&CQPH1BO"D$8 $:^C4U\" A&7^7O;Q1(-SYF;Q
MYF.KPR=2@^LC5.L_+X?74.K[J"@H<714F-QE'28['8^FAHZ#'T%/#245%1TT
M:PT]+24M.D<<<<:(%1$554    >\<I)))9&EE8LS$DDDDDG)))XD]2HJJBA5
M% , #@.I?NG6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7N@"^3_ $!MGY/=&[^Z8W04IX-UXEOX+F#$)IMM[JQ[K7;9W#3J
M+,?M:N")IHT9#+"982P61O8CY2YDN^4N8+;?K/)A;N7@'C.)$/\ IE) /D:'
MB.BO>MJ@WK;)=MN,"08/\+#*L/L('V\.J*_Y2WR+W/\ '/N+?7P#[_>7;E8^
M[<E%U]%E9S]OA.PXGT9K:-+5SRB,T>=CCBKL0T06.6HU&+R29!#[R&]Z.6+3
MFG8[;W*Y:'BKX:^/I&6A_!(0,ZHS59*Y I6@0]1AR#NT^S[C+RENW8P8^'7@
M'_$@)\F'<OD37B6'6RC[Q6ZF/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT[_ .=GM\[?^<%?E8@T
M+[SZIV%N!Y$+HTPBBS>S)"S"**X9-L>-K-("!8M]47.'V N?J?;\0MD07,R#
MY?!+\_-Z^7^7K'KW,B\+F;6,>)"C?S9/^?>D%\2?BW\N_FIL;;G4&U<ED.O_
M (O;9W!D\YF]T9&DGQ^R,CNC(5J_Q/-/C:63'R[JS<*4L=)3(9'CHXJ6.)IJ
M36SS&/.O-_)'(.Y3;Y=H+K>)D54C4AI5C5>U=1U"&,U+'%7+$T;@$VP;'S%S
M+9Q[="QAL$))8BB,Q.304,C#@/)0*5!X[1WQ.^$'0_P\VXV/ZSV\:[=V2I(X
M-T=E;C$%?O3<1'B>6G^^$4:45"7B5DQU"D,-T5Y!+,&F;$/G/W YCYXNO&W>
M73"AK' E5B3CG37N;/Q-5O($# F[8>6MKY>A\.Q2KM\4C9=OS\A\A0?GGHW_
M +!/0@Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z('\B?Y=?2GR)[OZY^0.8K]P[2["V%E-L5]?/MD
M8M,=OJ':6;QV7PM-NVGJJ&65Y(8Z)J-*JGG@E\$BHS.L$*I(_+/N=O\ RQR_
M=\LP*DUK=+(H$FHM#XB,KF(A@!6NH@@BHK05-0MNW*6V;MND&[REDFA*GMI1
M]#!E#@@\*4J"#3[!0_GN..A3U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%#^0/P7^-?R?WWLOL7N3
M8\^Y-R;(QZX:BD@SF6Q-)F,%#D9\O1X/<5-C:FG^ZI8*FMJ9HHPT9O53*Q9'
M*^QKRU[A<U\I;=/M>Q7/@Q7!U'L5BKE0I="P.EB  3\AYCH@W7EG9=ZNH[O<
M8?$>(4&2*BM0K $5 ))I\SZ]&GP>"PFV,-C-N[;Q&,P& PE#38S#83"T%+B\
M3BL=1Q+!24&.QU%%##!#$B!8XHT55    ]A"XN)[N=[FZ=I))"69V)9F8Y)9
MC4DGS)Z/(XXX8UBA4*B@     #@ !P'3K[9ZOU[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]T3;OOY_?$WXW5E3A>R^V\,-V4I>.;9.U(*S>6ZZ>H0M>ER>-V]!7
M+CI/0;#)RT0/%CR+CGEOVWYSYJ03[19.83_HLA$49'JK.1J_VFKH/;KS5L.S
M-X=]<*'_ (%J[_F%!I^=.J]\W_/L^-=+++'M_J/NW,1I.(XY\E3;&PB30!&U
MSJD.[\TP]8 1&4$J=3%&]'N3(/NX\VNH-Q>VB$C@#,U#Z?V2_P"KUX]!*3W4
MV-21%!.V?,(/S^,],/\ P_MTA_SXGM7_ ,^^T?\ ZM]J/^!NYC_Z.%M^R7_H
M'IK_ %UMI_Y1IO\ C'_077O^']ND/^?$]J_^??:/_P!6^_?\#=S'_P!'"V_9
M+_T#U[_76VG_ )1IO^,?]!=>_P"']ND/^?$]J_\ GWVC_P#5OOW_  -W,?\
MT<+;]DO_ $#U[_76VG_E&F_XQ_T%U[_A_;I#_GQ/:O\ Y]]H_P#U;[]_P-W,
M?_1PMOV2_P#0/7O]=;:?^4:;_C'_ $%U[_A_;I#_ )\3VK_Y]]H__5OOW_ W
M<Q_]'"V_9+_T#U[_ %UMI_Y1IO\ C'_077O^']ND/^?$]J_^??:/_P!6^_?\
M#=S'_P!'"V_9+_T#U[_76VG_ )1IO^,?]!=>_P"']ND/^?$]J_\ GWVC_P#5
MOOW_  -W,?\ T<+;]DO_ $#U[_76VG_E&F_XQ_T%U[_A_;I#_GQ/:O\ Y]]H
M_P#U;[]_P-W,?_1PMOV2_P#0/7O]=;:?^4:;_C'_ $%U[_A_;I#_ )\3VK_Y
M]]H__5OOW_ W<Q_]'"V_9+_T#U[_ %UMI_Y1IO\ C'_077O^']ND/^?$]J_^
M??:/_P!6^_?\#=S'_P!'"V_9+_T#U[_76VG_ )1IO^,?]!=>_P"']ND/^?$]
MJ_\ GWVC_P#5OOW_  -W,?\ T<+;]DO_ $#U[_76VG_E&F_XQ_T%U[_A_;I#
M_GQ/:O\ Y]]H_P#U;[]_P-W,?_1PMOV2_P#0/7O]=;:?^4:;_C'_ $%U[_A_
M;I#_ )\3VK_Y]]H__5OOW_ W<Q_]'"V_9+_T#U[_ %UMI_Y1IO\ C'_077O^
M']ND/^?$]J_^??:/_P!6^_?\#=S'_P!'"V_9+_T#U[_76VG_ )1IO^,?]!=>
M_P"']ND/^?$]J_\ GWVC_P#5OOW_  -W,?\ T<+;]DO_ $#U[_76VG_E&F_X
MQ_T%U[_A_;I#_GQ/:O\ Y]]H_P#U;[]_P-W,?_1PMOV2_P#0/7O]=;:?^4:;
M_C'_ $%U[_A_;I#_ )\3VK_Y]]H__5OOW_ W<Q_]'"V_9+_T#U[_ %UMI_Y1
MIO\ C'_077O^']ND/^?$]J_^??:/_P!6^_?\#=S'_P!'"V_9+_T#U[_76VG_
M )1IO^,?]!=>_P"']ND/^?$]J_\ GWVC_P#5OOW_  -W,?\ T<+;]DO_ $#U
M[_76VG_E&F_XQ_T%U[_A_;I#_GQ/:O\ Y]]H_P#U;[]_P-W,?_1PMOV2_P#0
M/7O]=;:?^4:;_C'_ $%U[_A_;I#_ )\3VK_Y]]H__5OOW_ W<Q_]'"V_9+_T
M#U[_ %UMI_Y1IO\ C'_077O^']ND/^?$]J_^??:/_P!6^_?\#=S'_P!'"V_9
M+_T#U[_76VG_ )1IO^,?]!=>_P"']ND/^?$]J_\ GWVC_P#5OOW_  -W,?\
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M,W_/HN]?_.'8'_V=>_?\#AS=_P IMG_O4W_6GKW^NKL7^^)_]YC_ .MG7O\
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M_.'8'_V=>_?\#AS=_P IMG_O4W_6GKW^NKL7^^)_]YC_ .MG7O\ A^WXS?\
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M_P"]3?\ 6GKW^NKL7^^)_P#>8_\ K9U[_A^WXS?\^B[U_P#.'8'_ -G7OW_
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M[]U[KWOW7NM+#^<%O/(;L^>G:]!5R2/0[&Q&P-F82.6P:GQ\6RL+N2LC4!W
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M/]-J&G^?5U/\Y5<>/Y@_21HA *ENKNI6RQB $C9#_2OV$L9JK?5_M5I@+_V
MGN O8TR?ZV&Y:ZT\>YT_9]-#P_.OYUZDOW"T_P!<;/3Q\.&OV^-)Q_*G23_G
MKYW,UGRVV;M^JR=9/@\'TKMNLQ&)DG<T&.K,WNC>'\8K*6EOH66I&,IEGD U
M.M/$K$K&@5?]W:VMX^2[BZ1 ))+IPS4[F"1Q:03Z#4U!Y5/J>DONE+(V_10L
MQ*+"I \@6=ZD#YT%?L'0=_R<N[*3KGY4?Z+MR21R;&^1.V:_KG,4%6JOCI]Q
MP05.4VC)5H9$),S"LQ,8M("<L05 .M#/WUY?;=.3OWQ;#_&-KD$RD<?#8A9
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M%O$6H;36C@4&,]##E4\DP\P00[5]5+<5;1(^@)_9MJJ!I-*5XK6IZ(1\E?\
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MB75J+/<9-9\8=T7<Q6H*-\'B$ J3J'%:T'0ODYGY3WS;;9.9(9?'M5TC1P?
M!H0P^+2,&E#P-*GHJWPD^=VWOC'4]K]9]@=<U/9/QD[J.0I]U[ 2II'S>&@J
MZ>HQ1K<8<A)##6M/CI5HJVEGJJ7R>*&5*F)X2)1G[@>W%WS:EENVVW0M=WL
MNB:A".00U&TU*T>K*0II4@J0<$'+/-<&R/<65U"9K&Y)U1X+*"",5P:K0$$C
M@#7&3)[4[^_E%= [II>Y.HNF?D!O[LC;]4F:V%M+>V0HZ;:>V=QTP:KQ==+7
M5FX:]T^VF1!'42QYN2)PLL<3NHD 3O.6O>[F6T;8M\O[2VM)!IFDB%9)$.&
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M#)((-@W^SV*WE?Z..XNF(T2295%H0:+ZU]""0<G'5POPQ^0U5_,MKNQ?C_\
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M/BK[3\P_^)";%_SPR?\ '-PZ<VO_ *=AN/\ ST+_ ,>M>G3^79_V[P_F9_\
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MZ!N[?\E6Y_YJR?\ 'SU;O_/*_P"9J_&[_P 0%1_^]'D_<)?=Y_Y).[?\]?\
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M'$^6.C3?R^_^RV/C%_XE_:7_ +FCV#/<[_IW^[?\\[_Y.A!R=_RL]E_S4'^
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MN7=WL]FW1V26]U%#0>&H7BTCD@*!Z^0J33I/MW+VY;K8S[A9J&2WIJ%>XD\
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MKWOW7NMTK^3K_P!D!=1_]KSL_P#]^5NGW@5[X_\ 3RK[_2V__:/'UDG[>_\
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MO=>]^Z]U[W[KW7O?NO=*;:^]=Y;(JY:_9>[=S;0KIUB6:MVOGLK@*N98)1-
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M):\:5CC%:8Z-O_.KW[F=C;TZ8^)FR*JNVUTMU]TSM7,P;0QTOV&)RN3?,Y_
MXJ3)4M&8HZI*"CVK3"E\J62:6=U4,VH@KV"VRWW"QO\ G3< )K^XNI$\1NYE
M&A';23D%FD.JG$ #H_\ <N\EM;BVV"U)CMHH5;0, G4RK4#B%""GS)Z>/Y)^
M\\IV1D?D+\2M[561W#U-O+IO,[B3;N2D-=@\'(^<QFT=Q18RFJ6=:=LC%OI9
M94B"J[T8D-G744_O]M\.UQ[9SIMX6*]AN50NN'?L,D98CCH,- 3D!J<.G?;.
M[>\:[V"Z)>!XBP4Y5>X(X%>&K7PX8KT^?RE>QLQU#\.OGWVEMZFHJO/]?X2A
MW;@Z?)1O+CWS&#V/O"OQAK88V1GB6:%&=%9"P!4,M[A-[T[7#O?/?+FSW)*Q
MW+>$Y7XM+S1JU/G0]/<@7DFW\M;I?1 %H:N >%5C)%?S'5&>[^TNR-_9'<>5
MWGOK=>Y:W=^8.?W,^6SF0JH,UF/)++'7UU&T_A9XS,PA_; B4Z8PJ@#WD/8[
M+M&V1Q16%M%$(%T1Z44%%\P&I7/GG/$U/46W.XW]XSO<S.YD.IJL:$^I'#[/
M3RZ0?LSZ1]7Z?S%LSF>@O@%\!_CYL6MEP>V.QMAUVZ]_-A)GQ:;DRF(VSL3.
M92FR$-,D9FIJ_*=FUE?/'*Y#20Q-('8 KC7[6V]OS-[D<Q\T;BOB2VLP2$.-
M6@/)*JD$\"B0*HIP!-*=2USE++L_*NU[-:G2DJ$R%<:BJH6! \F:0L?F,UZ6
M_P#(9[;[%R>\.W.GLINO*Y3KG";'H=WX';61J&K:/;^<.XJ#%5$V#:H,CTL4
M\-:WGIX66)W59"FL%B@^\;LNUPVECOD,*I=2RM&[J*%UT%AKIQ((P3FF*TZ4
M^U>X7DLMSM\DA:%$5E4FH4DT.FO 'TX>?2)_DO[+I*/KOYF]T4.XMH;,W[MS
M8%%LS978&^9*>AVMUT<IA-UYS);GW#E*@VBH$JL7BZFL.J("*@<,UGNB_P!^
MMPDDW78M@DBEGMY93++#%4R3T>-%C11Q>A<+QR_#&4WMM:JEEN.YJZ1RJFA)
M'^&/M9BS&H[:Z2>&%X]!IUM\-:/KKN#:O=%#_,[^%DN\MO[RQ^[ZS.R=\8ZJ
MS68JHLE'799<E75>49ZDUR&6*J%0["99762X8^S3=N>9MUV&;8'Y0W,02Q-&
MJ"T8(@TT4JH2@TFA%.%,=(['EV&RW*/<UWVT,B.')\9:MFK DOFO UX^?33_
M #!._.N=A_S)-D_([X^;MVAOF' 8_K'>.Y<QU_N#"9[!YW<6%K,AB-P827-8
M.2LIGDJ\+CJ6CJR))&"SF[ \*I]M.6MTW+VJN>5>989;<RM/'&LR.C(C*K(X
M1Z&BR$L/*HZ:YLW>SM.<X=YVF1)0@C9S&RL&(+*RZEJ*E  ?MZ4?\V[H)]V_
M*CI3L[JNFI\EAOF/MS8L.V*Z".:.AR^^G?![9HW,L$=0@6KQV9P,]XP7=I)7
M*,UV=)[*<RBRY.W#:=X)5]C>5G4TU+#1Y"*&F5=)!G P*^CWN!M!N-]M;VQ
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MKWOW7NMTK^3K_P!D!=1_]KSL_P#]^5NGW@5[X_\ 3RK[_2V__:/'UDG[>_\
M*I6WVR_]77ZL^]Q)T->O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MM.[^=M_V6]6_^(JZ_P#_ )->\X?N_?\ *@?]1,W^!.L>O<W_ )64?\T4_P +
M=5$>YOZCSKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[HT?5GQ([-[=Z)[F^0VV<GLVDV-T:L;;MHLUE,M2[DKS)20UNC;U!
M18'(T\Q$<ZD_<U5(+\ GV#MYYXVC8^8[#E>[25KC</[,HJF-:L5[R74C(\E;
MH^L.7;[<=JN=X@9!%:_&&+!C05[0%(\_,CHO&V8,%5;DV]2[IK:K&[9J<YB8
M-QY&AC,M;C\%-7T\>7K:.)::L+2Q4[221J(9;LH&AOTD47C726<KV2AY@C&-
M6P&<*= )J,$T!R/M'1/;K"UPBW!*QEE#$<0M1J(P<@?(_9T:[YM[+^)6QNS<
M!B_A_P!@Y[L/8D^S**KW)D<W+45BT&[6RF5AFHJ'(U6#VZ\JM20TLTB"G94>
M0Z96U&.(%^WVX<Z[CM,LW/%LEM<"4B,* I:/2IJ5#/3-0#6I'EYD0<TVO+]K
M>I'R]*98B@+$FH#5/ D#RI7T]?($U]CWH,]>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M;:O\AG_LD+L?_P 61W?_ .^QZ?\ >%OWC?\ E=[7_GAB_P"TBYZGWVK_ .5>
MF_YZ'_ZM0]79^X!ZDOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NM'W^:G_V7[\BO^UYL_P#]]KLOWT#]G/\ IVNU
M_P"EE_[2)>L9N??^5MO/MC_ZM)U7S[DWH(=>]^Z]U[W[KW7O?NO='%_E^[GV
MULSYF?'W=&\-PX/:FV<+OE*O,;BW+EJ#!8+$T@Q&4B^ZR>7RE12T\$>J15UR
MR(+L!>Y'L">YUG=W_(>Y6=A$\\TD0"I&K.['6AHJJ"2<>0Z$G*$\%MS):3W+
MK&BN268A5':W$F@'2C_F-[XVYO'YQ]Y[XZ[W;A]SX"MW'M6KV_N[9^;I,OB:
MR3&[&VG2/68;/8>IGAD\-31.@E@E:SQFQN/:;VMVZZL?;S;]NW2!HI%20/%*
MA5@&FD-'1@"*@\".!Z=YRNH;CFBYN[*0.I9"KHP(Q&@JK*?(CR\^K/NYJ3XW
M?S8=@=2]FT'R$ZUZ"^3FQ=GIM#L#:'9];1X:DSE/%-)D98*&HK*K$O-24]=6
M5E;05F.CK46+(O#4Q13"T<0;%)S7[+[E>[3+MD^Y;3<2>)#+ "VD_"":!@&*
MA596TFJ@J2O$=;A'LO/]I;WD=W':WL2Z722@J.) J5) ))4BHH2" >":V7FO
MC]_*JZ<[CJMN=];$^0?RQ[>VVNS]N8_K.HILQMOKND2"KDAKLOD:+(5@CACF
MKX:^=:MZ6>J:GIHH*=8Q-4!5?P<S>\N^V*W6VR[9LMD_B.TX*O-4@$*"HJ2%
M*C2"JU8LU:#IJVDVCD';KDPW:7=_<+I41T(2@-":$T&:FI!. !Y] 7\#NT.M
M-H?!3^8=L[=O8>Q]K;MWIL66EV;MC<>Z\%@]P;MJGV-N^C6EVQA\G7TM1D)?
M-/'%XZ2.9M<B+:[*"(_<;9]VOO<?EF_LK6::""53+(D;ND8$T9K(R@A13-6(
MQ7HIY5O[&WY3W:VN)DCDD1M"LZJSUC8=JD@G.,=4Y>YVZC?KWOW7NM@K;N9Z
M _F/_"3I;I3=W=NR>C_DG\:J"DV_@)NR<I1X_&;DP.,Q%-MY9*6NR4^.-72Y
M+'X:@EK#1O-54E7C[RPO R23XR7<',OM5[@7_,%E82[AM6ZL7?P%)*,S%Z$*
M&TLC,P74 K*V"#4++T$FT\Z<M6VV3W*6U[9@*/$([@HTUS2H8 $TR",U'$=/
MY?E#\)_@IV/N79>X?E5UKOKNG>FU:P[OWO2;HP> Z8V/@]N9.DECV70;KR^5
MIZ6KR];4U:R/%YI)K4+*8:70PJ [[E2\_P#N+MD.X6VS3V]A;R#PHC&[W,K2
M*?U3&JDA% H#0+W#+5P:<J)RSRK=26DM_'+<R+WOJ58D"GX Q--1)X5)QP'G
M6/\ RROE)UATOG^XNE>_*FKH.C_DSLK^X>Z\Y"T\D.V<A+1YO!0UU9%%#4F*
MDJJ+==;35=4D;F(B"1U,4;E9<]V^3]XWZVL>8.6P&W#:9?%C3%76J/0$TJRM
M&I5?.K 9(J".2-]L=MEN-LW8TMKU-#-Y*:%<C- 0Q!/EBN. BYO^5?UQ_$:K
M/[:_F ?$]NIY):JLH-SYW?6)ASM/AFJXTH?O,?0Y22AEG$;NDQ6O@!EC"JBZ
MR(RFW]Y=U\,6MWRUN'UHH#&D3:2].ZA*:@*\.TX/'&5TO(-EJ,\&[6WTYJ0[
M,*A:XK1J'YY&?+.*T>^-D=>];]K[KV1U9V;2]R;(V\V%H\9V508B3!X_=%=)
MMW$56XY\?C):JN*4]/DZBLHX'6>H22.G65)9$=7:6^6]PW/==EAW#>+0V-Q+
MK+0%M31KK81AFH,E K' ()H0"*= ?=K6SLMPDM;"<7,2:0) *!CI!:@J<!J@
M9.!Q/'K89_E]?(_XR=@?&#HJE^2/:W7VR=_?#7LC.Y79M!O3=^V-L9C<&%I-
MG[BHMJ3XG'9;(TT]?34]/NX01Q4:&4U>"I@RFZ^7&'W,Y4YLVSF[<7Y6LIKB
MVWR!!*8HI)%1C*C2!F52%):*N331(?RE_E+>MEN]CM5WBXCBFVZ0E [JI8!&
M"$ FI #TQG4H_/7J[T[@SW=O=W9'=.3FJZ3+;YWOE]TT:^8+586BEKF.W<5!
M44^@C^'4<--20NIU::=3J+<G)WEW8K;E_EZUV",!DMXEC;&':GZC$'^-B6(^
M?40[KN4NY[K-N;$AI7+#U45[1C^$ #\NKLNX:/XZ_P UW974_:%'\ANNN@_D
M]LK9U'L/?^R^U<M187$9ZCQ[UF:J)\%)53T,TT,=;EZRJI*FC%6/%5/%4112
M1ZAC]L<O-/LQ?WNT2[9-N6T7$AEAEMU+,A-$&J@8 E54,K4-5!4D',G;A'LW
M/UM;WJ7<=K>QIH=)"!4#N-*D$@$D@BN"00#P('WO\(.J_CWU/NC=6Y/F7TAV
M!VS2+MV#:73W456-XU.9JLGG<-!F*G+9Z*OAEH*>CQLU=61M4XV%9C#&HE1W
M6-Y+Y;]PMYYHWJ&SM-BNK:R;69+JX'AA0J.5"KIHQ9PJFCFE3@@5 2W;E:PV
M?;Y)Y]QAEN!ITPQ=Q)++4DUJ %J<J*T&?+H=O@=VAUIM#X*?S#MG;M[#V/M;
M=N]-BRTNS=L;CW7@L'N#=M4^QMWT:TNV,/DZ^EJ,A+YIXXO'21S-KD1;7900
MY[C;/NU][C\LW]E:S3002J99$C=TC FC-9&4$**9JQ&*]&O*M_8V_*>[6UQ,
MD<DB-H5G56>L;#M4D$YQCK-_+P^0_1&9Z"[Q^"7R>W9'L'8/<-5+N#8_8&6E
M'\#VWNJ>GPH:"NK*E#!0?:UFU\;F*"6KDBI&G@G69XWE3RZ]T.6.8[?F7;_<
M7E& W-S8@)+"H[W0%L@#+ZED:-@M6"E: @&GN3]XVJ7:;GE;?)/"BN"621CV
MJQ Q4X6A4,I.*UK0\5SUW_+K^.'1G8& [<[W^<_QZW#U-L3.8[=D&#VAF:+(
M;FW[_ ZA,Q183^#4F:R<VFI%(#-3XU<I/)'JCB +"12S=/=+FKF/;9=CY=Y>
MO(KRY1HR\BL$AUC06U%%&*X+Z #D^G2VSY-V?:+M-RW3<X6@B8. I&IRO<!3
M4>-."ZB> ]>B:?+/Y2Q_+WYHXOM7&4%5B]GT>X=B[,V!09"-(\I%M# 9U)J:
MJRB1S3(L]75Y*LKGC5B(A4B*[F,NP\Y-Y/;DCV_EV>9@\[1S2S$97Q'2A"X&
M%556OG0GSIT&]\WT<P\TQWT8(B5XTC!XZ%:M3\R23\JTZNG_ )E_QO\ C9\G
M.]<;M?(=\[:Z$^3.W.N\!5T7^DJJ6AV!V-L"ORFY9,71TV0JZZFC@R&/JJ2O
M9C3EI6BF&NGG0+)! OM3S7S7RAR\]Y%MK[EM,L[AO!%98)@L>HD!22K K\6*
MC# U#21SELFR[[N:P/=+:WJ1J1K^"2,EJ 5(R"&X9IQ!P04/MO=G0GP$^#/8
MWQ4ZQ[GVEWMWY\@<FW^D+/;(J(*_;^V-NY&EH*+*4\TV+R>1A@CBQM&U%1T\
M]3]U--D9:QX4IP($&VR67,GN5[AVO.6[6$FW;;MJCP5E!#R.I8K34JDDN=3$
M+I"J$J6R0_N,^U<H\KS;!97*W5W=DZRE"%5@ U:$T[10 FI)U4I@!!M'M#K2
MG_DS=H]6U'8>QZ?LVN[OQ^4H>NI]UX*'?5=BTWEUW6/DZ+:4M>E?-3B*CFD,
M\=.R!89"6LC6/+S9]V;WXM-X6UF-HMJ5,XC<PAO!F&DR4T@U(%":U(]>BZ&_
ML1[;36!F03F4$1ZUUD>*AJ$K6E,UIT&W\H/L#8?6GS%QVY^Q][;1Z_VTG7.^
M:%]P[VW)AMJ8-*VKAQHI*-LMG:V@IQ+*4;QQF34UC8&WLV]\-LW+=N1S:;5;
MRW,OU$3:(HVD>@#U.E 305R:=(?;R[M++F'Q[V5(4\)QJ=@BU)6@JQ KT0'N
M&NHLGVWVEDL;64N0QV0[&WO74%?0U$5715U%5[FR=12UE'54[R1RQ2QR*\<B
M,RLK @D'W)/+\4D.PV4,RE'2WA5E8$$$1J""#D$'!!X=!/<W23<KB2,AE:60
M@@U!!<D$$=6E_P XCMCKKLCM'X]9?JKLC9N^XMO=*8ZCR&4V#NW#;ECP>:BW
M%D:J.BK*[;]?6"EJT&F3PNR2J"K%1<'W#_L9LNZ;7M.Z0;S:2V_BW)(6:)X]
M:Z "0'457RKPZ'?N+N-G>7EG)M\Z2Z(LF-PVDZJBI4FA_GT8+N&C^.O\UW97
M4_:%'\ANNN@_D]LK9U'L/?\ LOM7+46%Q&>H\>]9FJB?!254]#--#'6Y>LJJ
M2IHQ5CQ53Q5$44D>H!C8Y>:?9B_O=HEVR;<MHN)#+#+;J69":(-5 P!*JH96
MH:J"I(.3?<(]FY^MK>]2[CM;V--#I(0*@=QI4@D DD$5P2" >! ^]_A!U7\>
M^I]T;JW)\R^D.P.V:1=NP;2Z>ZBJQO&IS-5D\[AH,Q4Y;/15\,M!3T>-FKJR
M-JG&PK,88U$J.ZQO)?+?N%O/-&]0V=IL5U;63:S)=7 \,*%1RH5=-&+.%4T<
MTJ<$"H"6[<K6&S[?)//N,,MP-.F&+N))9:DFM0 M3E16@SY=#M\#NT.M-H?!
M3^8=L[=O8>Q]K;MWIL66EV;MC<>Z\%@]P;MJGV-N^C6EVQA\G7TM1D)?-/'%
MXZ2.9M<B+:[*"'/<;9]VOO<?EF_LK6::""53+(D;ND8$T9K(R@A13-6(Q7HU
MY5O[&WY3W:VN)DCDD1M"LZJSUC8=JD@G.,=5X?%#-8?;?RE^->XMQ97'8+;^
M [^Z<S6<SF8K:;&XC#8?%=B;<KLGE<ID:R2&&GIJ>"!YIYY71$1&9B%!/N4N
M<[>>[Y/W6UM4:262SND1%!9F9H'"JJBI))- !DG'0-V&2.'?+*:9@B)/"68D
M  "1222>  XGHU'\POM;9V2_F0=A=N;$W%MWL+:.-W5TIN+%YW:&=QFX=OYT
M;3ZUZT7(4^-SF(JJNFFT5.(FI9#'*P22-T:S*0 9[:;+?)[56VQ[C$]K.\5W
M&R2HR.GBSSZ2R, 1A@PJ,@@]'W-FX6S<YR[C:NLT:O P9&#*VB..H# D<01]
MO5@/\P+I#H+YBYJ7YB==_,+H_;NUJ7IVG7,;3W!FZ$[QJLWM:FS-?B\3285\
M[23Q5]<*^DQW\-J(()HYP"JS-*J>XR]M.8N9.18/ZC[EL=U+.UR2LB*1&%DT
M*S%M!!5=)?6"01Z 5Z&'-FT[5S')_6*UW&&.-80"I(+5740*:A0FH7214'UK
M3K78]Y2=0WU[W[KW7O?NO=>]^Z]U[W[KW6Z5_)U_[("ZC_[7G9__ +\K=/O
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MY$U([26=E&?#ULK/,9&+*@95 )=GH"%H!FE >B58]SYOYDHRA)YV&O2"%C"
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M>JI)5S=+.L@EJI)(3-55 3R-<.6+>XV3V,VYA]->;QN,UL*TA,P"TQ@]K#@
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M"$"L>G2I8H6GFG=@RQ=NGL=R[<[A)N.S7=SMAF)+I X$9KGM6@*C)[:E<T
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UH^_S4_P#LOWY%?]KS9_\
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MWBK<::NII9:A2"HH\SLW<$!)4>N;2VEP%..GM K<L<\<P<BRX5'\:('!T*U
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M.'C+J=(4@5"D=H P64J:5!S7T+A_(U_YFK\D?_$!5G_O1XSV*?O#?\DG:?\
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M:2VG,6^^T.^%KK;XHV>-7+*1$6C% 58%0ZS(U%( 8$K34:G7-<Z2[5MW/&W
M0W3L%8J 06TN<@@@E2C#(X8/ 4,E\HOFQ\G.NOY<WQ&[XV;V9_!^U^S\UA*3
M?.ZO[F=?9#^.4]7M7>.2J(_X'E=J5V-IM4V*IWO1T=.1X[ A68$*\G<@\I[K
M[H[WRY?VGB6=HLAAC\69=!66-1WK('.&([F/'HXW[F3>K+D[;]UMIM-Q.4#M
MHC.JJ.3VE2HR!P ZUDMW;KS^_-V;GWQNO('+;IWGN+-;KW+E334=&<GG]Q9*
MIR^9R!H\?3TE/$9JBLDD\<$44:ZM*(J@ 9;6-E;;;90[=9+HA@1(XUJ3I1%"
MJM6))H !4DD^9ZA*XN)KNXDNK@ZI)69V- *LQ))H  *D^0ITGO:KIGKWOW7N
MMTK^3K_V0%U'_P!KSL__ -^5NGW@5[X_]/*OO]+;_P#:/'UDG[>_\JE;?;+_
M -77ZL^]Q)T->O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM.[^=M
M_P!EO5O_ (BKK_\ ^37O.'[OW_*@?]1,W^!.L>O<W_E91_S13_"W51'N;^H\
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NCG47Q!EI_A1E?F1N[L&':M)7=B4_7G5W7S[:_B%9V55I5I39?)0;C.XJ!
M:**E%#EF""AK&?\ @\X/C#(Q 4G/ ;G].1+&U,S+"9KB;Q-(@%*JI30VJM4S
MJ4#Q!QST)5Y=(Y9;F.XF\,&31%'IJ9,T)#:A2E&\C\)Z1/1_PZ^2OR0P68W-
MTGU7EM]X' 99<%ELG1Y;;.*IJ7+M1P9#[ '<&;Q)D<0U44C>(.%$BZB-0N8<
MP\]<I\JW*6>_WBV\LBZU4K(Q*U*U[$:F01GTZ2[7RYO6\PM/MD!E1#I)#(*&
M@-.YAY$=*+L[X%_,+IW;]9NOL+H'?6(VWC8!593.8^#&[IQN)I/W=59EJK:6
M1SBTL*^(ZY:@QHEUU,-::DNT^Y/(V^72V6V[E$\KFBJVJ,L?1?$5*GT J3Y<
M.G[WE/F/;X3<7=HZHN211P!ZG06H/F>DS\2_C7G?EGW;M_I7;NY,1M*OSF,W
M%E6SN:I:RMHZ2GV_AJO*R(*.A >1Y33K&HUQ@!BQ)TA65\[<V6_)7+\F_7,+
M3JC(NA2%)+L%XG@!QX'T^88Y>V27F#<UVV)Q&2K-J()H%%> _P!CH'NQMFU/
M7/86_.O:RM@R59L3>>Z-FU61IHY(::OJ=L9NNPD];3PRDLB2M0F1%8D@, >?
M9[M5^NZ[7;;FBE!<Q1RA2:E1(@< GY5IT6WML;*\FLV.HQ.R$^NEBM?SITC/
M:_I-U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3[MG:^Y=ZY[%[5V?
MM_,[IW-FZD4>'V_M[&5F8S.4JBCR?;T&,Q\-1-*^F-F*HC6523P"?::\O+3;
M[9[V_E2&&,59W8*JCA4L2 .G8+>>ZF6WMD:1V- J@DD_(#H]3?RJ_G\N%.>/
MQUS?V*TYJC N\NLVS7C"ZM(VVN]3D3);_=(I3)?C3?W'8]Y/;4S_ $_[T756
ME?"N-/\ O?A:?SK3H4_U#YL\/Q/HS3_3Q5_WG77^71",MB,K@,ID,)G<9D,+
MFL16U..RN(RU%4X[*8S(4<K05=!D,?61PRPS1.C))%(BLK A@"/<D03P7,*W
M%LZR1N RLI#*RG(*L*@@^1'04DCDAD,4RE64T(((((X@@Y!Z.'\K?A[+\<=I
M=#]E;;[!7M?J[O[8D&[ML[QAVE/M%L;D_MJ"OKMKY3&/G=RB.>*GRU.ZM)4Q
M2.RU$9@1J=[@7DSGH<U7NX[3=VOT5YMLOAR1&42ZEJRAU;1'454@T! [3J.H
M="/?^7#LMO:WL$WU$%VFI7T%*&@.DC4WD13(/'&.B6>Q_P!!GKWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZVU?Y#/\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UH^_S4_\ LOWY%?\
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M5=?D<C7U<DLL\\\LKRS32NSN[%F)))]KH88;>%;>W4)&@"JJ@*JJHH%4"@
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MMVM]>V+,UE,\)84)1V0D>ATD5'2)1VC971F1T8.CH2K(RD%65@0001<$>UY
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UMJ_R&?\
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MBP+#?&_^41M7,TN]]Q?-O>6_=DT$U)EHNNZ38NX*#<>;I[Q34^#RM;0;12J
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M>]^Z]U[W[KW7O?NO=>]^Z]UPEEB@BDFFDCAAAC>6665UCBBBC4O)))(Y 55
M)))  'O8!8A5%2>O$TR>JA?E;_.-^.W17WVV.J'A[^[#A\T#IM?)QT_7F$JD
M**#EM\)!61UC#7J6'$1UJL8VCEGIVL?<V<F^QO-',>F[W<';;4T-9%K,X_HP
MU!'VN5XU ;J/]^]P]GVJL%E_C<P\D/8I_I/FOV+7T)'5:N'Z*_F2_P T_(XO
M=/<VXJCJ3HBIDCRF'7+XNLVWLI**=8Y::JV3UA!605^<<@+)2Y'+U)1D=O'D
M;6C,JS<Q>U/L]&]IL,0OMR7M8JP>6HP1+<$%8_0K&M:C,?GT#DVOG/GEEFW-
M_IK0Y (*K3R*15U-Z@N?/#>75V?Q5_EQ_&CXGQX_,;4VL=X]E4T""H[0WPL&
M6W&E25/FDV[1^-:/$(2[*GV,*3&,A)JB>VHP%SC[H\U\YEH;Z;P;4G%O%58Z
M>6L_$Y_TQ(KD <.I)V+E#9=@ DMH]<WG*^6_VODOY ?,GH^GN.NA1U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:/O\
MU/\ [+]^17_:\V?_ .^UV7[Z!^SG_3M=K_TLO_:1+UC-S[_RMMY]L?\ U:3J
MOGW)O00Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>ZV/OD+U#_ "_/BUU;\:>^>R.HJ7>6Z<_TMM>+:G0VW*V3
M;V,[+WO-@<!FLYV#V+FS/62_9T?W<4#$T]0C25G[E-5Z@L6*?*V]>YG.&[[K
MR[M5\T$*7+F6[<:V@B#NJPP+@:FH30$&BX9,DS5O6W\H[#9VFZ7EL)',0"0+
MVB1Z*2\AS@<,@C/!C2F3;?2W\OSY[_&S)_(B'K^G^'+='[GJ7[GAZ^:DJ:=]
MJ8?%4^9R6/HX*?$T-'5?Q&DJ4_AM:F)6KCJXWA\-2MDGW=[_ .Y?MOS6O+#7
M1WS]X1CZ7QJU\1V**QJQ9=+ ZEUE2I!JO%:P[;RES9LIW<0C;_IF/C>'3X5
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MZ][]U[KWOW7NO>_=>ZW2OY.O_9 74?\ VO.S_P#WY6Z?>!7OC_T\J^_TMO\
M]H\?62?M[_RJ5M]LO_5U^K/O<2=#7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K3N_G;?]EO5O\ XBKK_P#^37O.'[OW_*@?]1,W^!.L>O<W_E91
M_P T4_PMU41[F_J/.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZVU?Y#/\ V2%V/_XLCN__ -]CT_[PM^\;_P KO:_\\,7_ &D7/4^^U?\
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MP%KGVE^[GI_<FYZ#J'U0H3Q(\,4/3WNI7ZZSJ*'PCC_;=0?YP7_,JOY=W_B
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MT=R=3][]Z[\A1)I),[M;K:3K[!5BJ9%.&V%5=C+'7LK$1F;+U-2I $L=-!(
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MO]8[W*_Y05_[*+?_ *V=7_UPN4O^4D_\XI?^@.O?\/%? +_G[F<_]%AV5_\
M8M[]_K'>Y7_*"O\ V46__6SKW^N%RE_RDG_G%+_T!U[_ (>*^ 7_ #]S.?\
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M^*.!_P!FN)J?ETQ+R-RI-0/9J*?PM(O_ !UQ7IF_X:+_ )>?_>/G_L5^[_\
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M_P"HO?OWMM7_ "DQ?\Y$_P _7OH+[_?,G^\-_FZ]_H^W[_SQ&[__ $&LS_\
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MW[KW7O?NO=>]^Z]U77\X/Y;_ $_\S:-=PU,[=>=QXV@6BP_9.'H(JO\ B-+
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HOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
